PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Haynes, BF				Haynes, BF			HIV vaccines: Where we are and where we are going	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELLS; ENVELOPE PROTEIN; NATURAL-HISTORY; ATTENUATED SIV; INFECTION; EPITOPES; IDENTIFICATION; SUPPRESSION; IMMUNOGEN	As the HIV-1 epidemic continues to spread world wide, the need for an effective vaccine remains urgent. Efforts to develop such a vaccine have been hampered by three main factors: (a) the extraordinary ability of the virus to mutate; (b) inability of most known specificities of anti-HIV antibodies to neutralise HIV primary isolates consistently; and (c) lack of understanding of the correlates of protective immunity to HIV infection. In view of the complex biology of HIV-host interactions, the most fruitful avenue may be development of multivalent HIV immunogens tailored to HIV isolates in specific geographical locations.			Haynes, BF (corresponding author), DUKE UNIV,MED CTR,AIDS CTR,BOX 3258,DURHAM,NC 27710, USA.				NIAID NIH HHS [AI35351] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; BARROW P, 1994, J VIROL, V68, P6103; Berzofsky J A, 1991, Semin Immunol, V3, P203; BERZOFSKY JA, 1991, FASEB J, V5, P2412, DOI 10.1096/fasebj.5.10.1712327; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CEASE KB, 1994, ANNU REV IMMUNOL, V12, P923, DOI 10.1146/annurev.iy.12.040194.004423; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; HAYNES BF, 1993, T ASSOC AM PHYSICIAN, V106, P33; HAYNES BF, 1993, SCIENCE, V260, P1279, DOI 10.1126/science.8493572; HAYNES BF, 1995, AIDS RES HUM RETROV, V11, P211, DOI 10.1089/aid.1995.11.211; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HO DD, 1995, NATURE, V373, P102; HOGERVORST E, 1995, J INFECT DIS, V171, P811, DOI 10.1093/infdis/171.4.811; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; KORBER B, 1995, HIV MOL IMMUNOLOGY D; LEE TH, 1994, J ACQ IMMUN DEF SYND, V7, P381; MARKHAM RB, 1994, LANCET, V343, P1364; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MILLICH DR, 1987, NATURE, V329, P547; MOORE JP, 1995, NATURE, V376, P115, DOI 10.1038/376115a0; MYERS G, 1995, HUMAN RETROVIRUSES A; NIXON DF, 1992, IMMUNOLOGY, V76, P515; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; PALKER TJ, 1989, J IMMUNOL, V142, P3612; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PHAIR JP, 1994, AIDS RES HUM RETROV, V10, P883, DOI 10.1089/aid.1994.10.883; PINCUS SH, 1994, J CLIN INVEST, V93, P2505, DOI 10.1172/JCI117260; ROBERTSON DL, 1995, J MOL EVOL, V40, P249, DOI 10.1007/BF00163230; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; SHIRAMIZU B, 1994, CANCER RES, V54, P2069; STAATS HF, IN PRESS J IMMUNOL; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936; Tsuji K, 1992, P 11 INT HIST WORKSH; Wain-Hobson Simon, 1994, P185; WALFIELD AM, 1992, VACCINES 92 : MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P211; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WARD F, 1995, ALAMOS DATABASE 1995; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993	47	67	78	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					933	937		10.1016/S0140-6736(96)09339-7	http://dx.doi.org/10.1016/S0140-6736(96)09339-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843815				2022-12-28	WOS:A1996VL09700015
J	Just, MA; Carpenter, PA; Keller, TA; Eddy, WF; Thulborn, KR				Just, MA; Carpenter, PA; Keller, TA; Eddy, WF; Thulborn, KR			Brain activation modulated by sentence comprehension	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; WORKING-MEMORY; INDIVIDUAL-DIFFERENCES; RIGHT-HEMISPHERE; CORTEX	The comprehension of visually presented sentences produces brain activation that increases with the linguistic complexity of the sentence. The volume of neural tissue activated (number of voxels) during sentence comprehension was measured with echo-planar functional magnetic resonance imaging. The modulation of the volume of activation by sentence complexity was observed In a network of lour areas: the classical left-hemisphere language areas (the left laterosuperior temporal cortex, or Wernicke's area, and the left inferior frontal gyrus, or Broca's area) and their homologous right-hemisphere areas, although the right areas had much smaller volumes of activation than did the left areas. These findings generally indicate that the amount of neural activity that a given cognitive process engenders is dependent on the computational demand that the task imposes.	CARNEGIE MELLON UNIV,DEPT STAT,PITTSBURGH,PA 15213; UNIV PITTSBURGH,MED CTR,DEPT RADIOL,PITTSBURGH,PA 15213	Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Just, MA (corresponding author), CARNEGIE MELLON UNIV,DEPT PSYCHOL,PITTSBURGH,PA 15213, USA.		Thulborn, Keith Raymond/D-9183-2015	Thulborn, Keith Raymond/0000-0001-6197-4296; Just, Marcel/0000-0003-1245-3050	NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019102, R01MH029617] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-29617, MH-00662, MH-19102] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Baker SC, 1996, NEUROPSYCHOLOGIA, V34, P515, DOI 10.1016/0028-3932(95)00133-6; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BINDER JR, 1994, ANN NEUROL, V35, P662, DOI 10.1002/ana.410350606; BOTTINI G, 1994, BRAIN, V117, P1241, DOI 10.1093/brain/117.6.1241; Braver T. S., 1995, Society for Neuroscience Abstracts, V21, P274; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; EDDY WF, P COMPUTATIONAL STAT; FORD M, 1983, J VERB LEARN VERB BE, V22, P203, DOI 10.1016/S0022-5371(83)90156-1; GRASBY PM, 1994, BRAIN, V117, P1271, DOI 10.1093/brain/117.6.1271; HAARMANN HH, IN PRESS BRAIN LANG; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; JUST MA, 1992, PSYCHOL REV, V99, P122, DOI 10.1037/0033-295X.99.1.122; JUST MA, 1993, CAN J EXP PSYCHOL, V47, P310, DOI 10.1037/h0078820; KARBE H, 1989, NEUROLOGY, V39, P1083, DOI 10.1212/WNL.39.8.1083; KEMPLER D, 1991, J NEUROLINGUIST, V6, P301; KING J, 1991, J MEM LANG, V30, P580, DOI 10.1016/0749-596X(91)90027-H; MAZOYER BM, 1993, J COGNITIVE NEUROSCI, V5, P467, DOI 10.1162/jocn.1993.5.4.467; METTER EJ, 1990, ARCH NEUROL-CHICAGO, V47, P1235, DOI 10.1001/archneur.1990.00530110097024; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Rueckert L, 1994, J Neuroimaging, V4, P67; SERGENT J, 1994, TRENDS NEUROSCI, V17, P221, DOI 10.1016/0166-2236(94)90002-7; STOIZ WA, 1967, J VERB LEARN VERB BE, V6, P867; Stromswold K, 1996, BRAIN LANG, V52, P452, DOI 10.1006/brln.1996.0024; TOMPKINS CA, 1985, BRAIN LANG, V24, P185, DOI 10.1016/0093-934X(85)90130-0; WEISSKOFF RM, 1994, MAGNET RESON MED, V31, P601, DOI 10.1002/mrm.1910310605	26	797	817	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					114	116		10.1126/science.274.5284.114	http://dx.doi.org/10.1126/science.274.5284.114			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VK748	8810246				2022-12-28	WOS:A1996VK74800060
J	Shachar, I; Flavell, RA				Shachar, I; Flavell, RA			Requirement for invariant chain in B cell maturation and function	SCIENCE			English	Article							CLASS-II MOLECULES; MICE LACKING; TRANSPORT; EXPRESSION	Previously the role of invariant chain (ii) had been described only as a chaperone that facilitates folding and transport of major histocompatability complex class II molecules; here it is shown that Ii is required for B cell development. B cells from mice lacking Ii were found to have a low response to T-independent type II antigen and could not proliferate after the mice were injected with antigen. Study of cell surface markers revealed a developmental arrest that prevented immature virgin B cells from becoming mature B cells in the periphery. This block was independent of major histocompatability complex class II expression and was an intrinsic feature of B cells that correlated with the amount of Ii. Thus, Ii participates by an unknown mechanism in B cell maturation.	YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University								BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; Chan S H, 1994, Semin Immunol, V6, P241, DOI 10.1006/smim.1994.1031; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; MARKOWITZ JS, 1993, J IMMUNOL, V150, P1223; NAUJOKAS MF, 1995, IMMUNITY, V3, P359, DOI 10.1016/1074-7613(95)90120-5; SHACHAR I, 1995, IMMUNITY, V3, P373, DOI 10.1016/1074-7613(95)90121-3; van Meerwijk J P, 1994, Semin Immunol, V6, P231, DOI 10.1006/smim.1994.1030; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z	11	104	110	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					106	108		10.1126/science.274.5284.106	http://dx.doi.org/10.1126/science.274.5284.106			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810244				2022-12-28	WOS:A1996VK74800058
J	Cao, ZD; Xiong, J; Takeuchi, M; Kurama, T; Goeddel, DV				Cao, ZD; Xiong, J; Takeuchi, M; Kurama, T; Goeddel, DV			TARF6 is a signal transducer for interleukin-1	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; RING FINGER PROTEIN; FACTOR RECEPTOR; CYTOPLASMIC DOMAIN; CD40; ACTIVATION; FAMILY; INVOLVEMENT; EXPRESSION	MANY cytokines signal through different cell-surface receptors to activate the transcription factor NF-kappa B (ref. 1). Members of the TRAF protein family have been implicated in the activation of NF-kappa B by the tumour-necrosis factor (TNF)-receptor superfamily(2-5). Here we report the identification of a new TRAF family member, designated TRAF6. When overexpressed in human 293 cells, TRAF6 activates NF-kappa B. A dominant-negative mutant of TRAF6 inhibits NF-kappa B activation signalled by interleukin-1 (IL-1) but not by TNF. IL-1 treatment of 293 cells induces the association of TRAF6 with IRAK, a serine/threonine kinase that is rapidly recruited to the IL-1 receptor after IL-1 induction(6). These findings indicate that TRAF proteins may function as signal transducers for distinct receptor families and that TRAF6 participates in IL-1 signalling.	TULARIK INC,S SAN FRANCISCO,CA 94080; YAMANOUCHI PHARMACEUT CO LTD,TSUKUBA,IBARAKI 305,JAPAN	Astellas Pharmaceuticals								AUSUBEL FM, 1994, CURR PROT MOL BIOL, V1; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BERBERICH I, 1994, J IMMUNOL, V153, P4357; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; MCDONALD PP, 1995, EUR J IMMUNOL, V25, P2870, DOI 10.1002/eji.1830251024; MESSER G, 1990, Cytokine, V2, P389, DOI 10.1016/1043-4666(90)90046-V; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SONG HY, 1995, BIOCHEM J, V309, P825, DOI 10.1042/bj3090825; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253	28	1078	1131	4	48	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					443	446		10.1038/383443a0	http://dx.doi.org/10.1038/383443a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837778				2022-12-28	WOS:A1996VL46300064
J	Griffiths, TD; Rees, A; Witton, C; Shakir, RA; Henning, GB; Green, GGR				Griffiths, TD; Rees, A; Witton, C; Shakir, RA; Henning, GB; Green, GGR			Evidence for a sound movement area in the human cerebral cortex	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; AUDITORY-CORTEX; FREQUENCY; BRAIN; LOCATION; SIGNALS; MOTION	HUMAN listeners can localize sounds by the difference in both arrival time (phase) and loudness between the two ears(1). Movement of the sound source modulates these cues, and responses to moving sounds have been detected in animals in primary auditory cortex(2,3) and in humans in other cortical areas(4). Here we show that detection of changes in the interaural phase or amplitude difference occurs through a mechanism distinct from that used to detect changes in one ear alone, Moreover, a patient with a right hemisphere stroke is unable to detect sound movement, regardless of whether it is defined by phase or by loudness cues. We propose that this deficit reflects damage to a distinct cortical area, outside the classical auditory areas, that is specialized for the detection of sound motion, The deficit is analagous to cerebral akinotopsia (motion blindness) in the visual system, and so the auditory system may, like the visual system(5), show localization of specialized functions to different cortical regions.	UNIV NEWCASTLE,SCH MED,DEPT CLIN NEUROSCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; INST NEUROL,WELLCOME DEPT COGNIT NEUROL,LONDON WC1N 3BG,ENGLAND; CHARING CROSS HOSP,REG NEUROSCI CTR,LONDON W6 8RF,ENGLAND; UNIV OXFORD,DEPT EXPT PSYCHOL,OXFORD OX1 3UD,ENGLAND	Newcastle University - UK; University of London; University College London; Imperial College London; University of Oxford	Griffiths, TD (corresponding author), UNIV NEWCASTLE,SCH MED,DEPT PHYSIOL SCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.		Rees, Adrian/H-2200-2012; Green, Gary GR/D-3543-2009	Rees, Adrian/0000-0003-3313-8375; Green, Gary GR/0000-0003-1977-7509; Griffiths, Timothy/0000-0001-8066-4381; Witton, Caroline/0000-0002-5610-4234	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHISSAR M, 1992, J NEUROPHYSIOL, V67, P203, DOI 10.1152/jn.1992.67.1.203; ALTMAN JA, 1986, HEARING RES, V24, P243, DOI 10.1016/0378-5955(86)90023-7; ANDERSEN RA, 1995, CEREB CORTEX, V5, P457, DOI 10.1093/cercor/5.5.457; Blauert J., 1983, SPATIAL HEARING; BNIFFITHS TD, 1994, CURR BIOL, V4, P892; GRANTHAM DW, 1979, PERCEPT PSYCHOPHYS, V26, P403, DOI 10.3758/BF03204166; JEFFRESS LA, 1948, J COMP PHYSIOL PSYCH, V41, P35, DOI 10.1037/h0061495; KAY RH, 1972, J PHYSIOL-LONDON, V225, P657, DOI 10.1113/jphysiol.1972.sp009962; LAUTER JL, 1985, HEARING RES, V20, P199, DOI 10.1016/0378-5955(85)90024-3; LAVIKAINEN J, 1994, NEUROREPORT, V6, P182, DOI 10.1097/00001756-199412300-00046; Macmillan N. A., 1991, DETECTION THEORY USE; MOORE BCJ, 1991, Q J EXP PSYCHOL-A, V43, P327, DOI 10.1080/14640749108400976; Pardo Patricia J., 1994, Society for Neuroscience Abstracts, V20, P325; PERROTT DR, 1988, J ACOUST SOC AM, V83, P1522, DOI 10.1121/1.395908; PINEK B, 1992, BRAIN COGNITION, V11, P1; RIZZO M, 1995, BRAIN, V118, P1105, DOI 10.1093/brain/118.5.1105; Strutt J., 1907, PHILOS MAG, V13, P214, DOI [DOI 10.1080/14786440709463595, 10.1080/14786440709463595]; STRYBEL TZ, 1989, PERCEPT PSYCHOPHYS, V45, P371, DOI 10.3758/BF03204951; STUMPF E, 1992, EXP BRAIN RES, V88, P158, DOI 10.1007/BF02259137; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; WHITFIEL.IC, 1965, J NEUROPHYSIOL, V28, P655, DOI 10.1152/jn.1965.28.4.655; ZIHL J, 1983, BRAIN, V106, P313, DOI 10.1093/brain/106.2.313	22	101	103	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					425	427		10.1038/383425a0	http://dx.doi.org/10.1038/383425a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837772				2022-12-28	WOS:A1996VL46300058
J	Knudsen, EI; Knudsen, PF				Knudsen, EI; Knudsen, PF			Disruption of auditory spatial working memory by inactivation of the forebrain archistriatum in barn owls	NATURE			English	Article							LESIONS; SPACE	BARN owls only localize auditory stimuli with great accuracy, they also remember the locations of auditory stimuli and can use (his remembered spatial information to guide their flight and strike(1). Although the mechanisms of sound localization have been studied extensively(2,3), the neurobiological basis auditory spatial memory has not. Here we show that the ability of barn owls to orient their gaze towards and fly to the remembered location of auditory targets is lost during pharmacological inactivation of a small region in the forebrain, the anterior archistriatum. In contrast, archistriatal inactivation has no effect on stimulus-guided responses to auditory targets. The memory-dependent deficit is evident only for acoustic events that occur in the hemifield contralateral to the side that is inactivated, The data demonstrate that in the avian archistriatum, as in the mammalian frontal cortex, there exists a region that is essential for the expression of spatial working memory and that, in the barn owl, this region encodes auditory spatial memory.			Knudsen, EI (corresponding author), STANFORD UNIV,SCH MED,DEPT NEUROBIOL,FAIRCHILD SCI BLDG,STANFORD,CA 94305, USA.							Baddeley A.D., 1986, WORKING MEMORY THOUG; Clarey JC, 1992, MAMMALIAN AUDITORY P, P232, DOI [10.1007/978-1-4612-2838-7_5, DOI 10.1007/978-1-4612-2838-7_5]; Deng S.-Y., 1986, ADAPTIVE PROCESSES V, P201; Dias EC, 1995, J NEUROPHYSIOL, V74, P2744, DOI 10.1152/jn.1995.74.6.2744; FUNAHASHI S, 1993, J NEUROSCI, V13, P1479; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1986, PREFRONTAL CORTEX; GOLDMAN-RAKIC P S, 1992, Scientific American, V267, P110; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; HIKOSAKA O, 1985, J NEUROPHYSIOL, V53, P266, DOI 10.1152/jn.1985.53.1.266; KING AJ, 1993, EXP PHYSIOL, V78, P559, DOI 10.1113/expphysiol.1993.sp003708; KNUDSEN EI, 1995, J NEUROSCI, V15, P5139; KNUDSEN EI, 1993, J NEUROSCI, V13, P2837; Knudsen EI, 1996, EXP BRAIN RES, V108, P23; KONISHI M, 1973, AM SCI, V61, P414; Neter J, 1990, APPL LINEAR STAT MOD; ZEIER H, 1971, BRAIN RES, V31, P327, DOI 10.1016/0006-8993(71)90186-7	17	51	51	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					428	431		10.1038/383428a0	http://dx.doi.org/10.1038/383428a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837773				2022-12-28	WOS:A1996VL46300059
J	Natowicz, MR; Short, MP; Wang, Y; Dickersin, GR; Gebhardt, MC; Rosenthal, DI; Sims, KB; Rosenberg, AE				Natowicz, MR; Short, MP; Wang, Y; Dickersin, GR; Gebhardt, MC; Rosenthal, DI; Sims, KB; Rosenberg, AE			Clinical and biochemical manifestations of hyaluronidase deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THIN-LAYER CHROMATOGRAPHY; DISEASE; RECEPTOR; OLIGOSACCHARIDES; INTERNALIZATION; FIBROBLASTS; DEGRADATION; DIAGNOSIS; BINDING		MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT RADIOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT ORTHOPED SURG,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Natowicz, MR (corresponding author), EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC,DIV MED GENET,200 TRAPELO RD,WALTHAM,MA 02254, USA.							Barrett AJ, 1977, LYSOSOMES LABORATORY, P19; BERTOLAMI CN, 1992, MATRIX, V12, P11, DOI 10.1016/S0934-8832(11)80100-9; BEUTLER E, 1992, SCIENCE, V256, P794, DOI 10.1126/science.1589760; Cook HC, 1990, THEORY PRACTICE HIST, P177; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; GREEN SJ, 1988, EXP CELL RES, V178, P224, DOI 10.1016/0014-4827(88)90393-X; HOLMES EW, 1979, ANAL BIOCHEM, V93, P167, DOI 10.1016/S0003-2697(79)80060-3; HUA Q, 1993, J CELL SCI, V106, P365; HUMBEL R, 1975, CLIN CHIM ACTA, V60, P143, DOI 10.1016/0009-8981(75)90119-9; HUMBEL R, 1969, HELV PAEDIATR ACTA, V24, P648; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT UBG, 1992, MATRIX, V12, P130, DOI 10.1016/S0934-8832(11)80054-5; Meyer K., 1971, ENZYMES, V5, P307; NATHANSON MA, 1990, CLIN ORTHOP RELAT R, V251, P275; Natowicz MR, 1996, CLIN CHIM ACTA, V245, P1, DOI 10.1016/0009-8981(95)06182-7; NATOWICZ MR, 1995, CLIN PEDIATR, V34, P190, DOI 10.1177/000992289503400404; NIELSEN GP, 1995, AM J SURG PATHOL, V19, P748, DOI 10.1097/00000478-199507000-00002; NOGAMI H, 1979, CLIN ORTHOPAEDICS, V143, P251; PRENCE EM, 1992, CLIN CHEM, V38, P501; REED RK, 1990, AM J PHYSIOL, V259, pH532, DOI 10.1152/ajpheart.1990.259.2.H532; Rimoin D. L, 1976, CLIN ORTHOP RELAT R, V114, P137; Roden L, 1989, CIBA F SYMP, P76; ROODMAN GD, 1993, CALCIFIED TISSUE INT, V53, pS94, DOI 10.1007/BF01673412; TAMMI R, 1991, J INVEST DERMATOL, V97, P126, DOI 10.1111/1523-1747.ep12478553; THOMPSON SW, 1966, SELECTED HISTOCHEMIC, P370; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; TRIGGSRAINE B, 1995, AM J HUM GENET, V56, P870; UCHIYAMA H, 1990, J BIOL CHEM, V265, P7753; WENGER DA, 1991, TECHNIQUES DIAGNOSTI, P587	31	116	123	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1029	1033		10.1056/NEJM199610033351405	http://dx.doi.org/10.1056/NEJM199610033351405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8793927	Bronze			2022-12-28	WOS:A1996VL45900005
J	Palmer, K; Coggon, D				Palmer, K; Coggon, D			ABC of work related disorders - Investigating suspected occupational illness and evaluating the workplace	BRITISH MEDICAL JOURNAL			English	Article											Palmer, K (corresponding author), SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON,HANTS,ENGLAND.							OLSEN J, 1991, SEARCHING CAUSES WOR; PITTOM A, 1987, TXB OCCUPATIONAL MED, P91	2	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					809	811						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842081				2022-12-28	WOS:A1996VK56600036
J	McAvoy, BR; Kaner, EFS				McAvoy, BR; Kaner, EFS			General practice postal surveys: A questionnaire too far?	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE RESEARCH; RESPONSE RATES; PRACTITIONERS; CONTRACT; PARTICIPANTS; RECRUITMENT; STRESS; VIEWS	A primary care led NHS, driven by evidence based practice, needs to build on a firm foundation of research in primary care. As researchers are making increasing use of questionnaire surveys to assess general practitioners' views and attitudes, so response rates to questionnaire surveys among general practitioners are dropping. The reasons include lack of perceived relevance of the research and lack of information and feedback about it, and researchers need to be more aware of the realities of everyday practice. Approaches that might reverse this trend include monitoring all research activities going on in an area to ensure that practices are not overused, giving general practitioners incentives to participate, and improving the relevance of research and the quality of questionnaires.	UNIV NEWCASTLE UPON TYNE,SCH MED,SCH HLTH SCI,DEPT PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK			Kaner, Eileen/ABF-2444-2020	Kaner, Eileen/0000-0002-7169-9344				BAKER R, 1993, BR J GEN PRACT, V43, P30; BICHARD A, 1991, BRIT J GEN PRACT, V41, P4; BORGIEL AEM, 1989, FAM PRACT, V6, P168, DOI 10.1093/fampra/6.3.168; BOWLING A, 1991, BRIT MED J, V303, P292, DOI 10.1136/bmj.303.6797.292; CARTWRIGHT A, 1978, BRIT MED J, V2, P1419, DOI 10.1136/bmj.2.6149.1419; Cartwright A, 1976, J R Coll Gen Pract, V26, P894; COCKBURN J, 1988, FAM PRACT, V5, P18, DOI 10.1093/fampra/5.1.18; HANNAY D, 1992, BRIT MED J, V304, P615, DOI 10.1136/bmj.304.6827.615; HEYWOOD A, 1995, FAM PRACT, V12, P227, DOI 10.1093/fampra/12.2.227; HOOPER PD, 1991, BRIT J GEN PRACT, V41, P170; HOWIE J, 1988, WORKING GROUP RES HL; HUNGIN P, 1995, RES NETWORKS PRIMARY; KOCKEN RJJ, 1993, BRIT J GEN PRACT, V43, P305; MACDONALD P, 1993, BR J GEN PRACT, V43, P484; MACPHERSON I, 1995, FAM PRACT, V12, P335, DOI 10.1093/fampra/12.3.335; MAYER CS, 1966, PUBLIC OPIN QUART, V30, P637, DOI 10.1086/267461; MURPHY E, 1992, BRIT J GEN PRACT, V42, P162; MYERSON S, 1993, FAM PRACT, V10, P342, DOI 10.1093/fampra/10.3.342; Olsen NDL, 1996, BRIT MED J, V312, P525, DOI 10.1136/bmj.312.7030.525; PETO V, 1993, FAM PRACT, V10, P207, DOI 10.1093/fampra/10.2.207; PITTS J, 1991, BRIT J GEN PRACT, V41, P34; SILAGY CA, 1989, FAM PRACT, V6, P173, DOI 10.1093/fampra/6.3.173; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545; WARD J, 1994, FAM PRACT, V11, P418, DOI 10.1093/fampra/11.4.418; WRIGHT AF, 1991, BRIT J GEN PRACT, V41, P178	25	223	225	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					732	733						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819446				2022-12-28	WOS:A1996VJ44100027
J	Stockler, S; Hanefeld, F; Frahm, J				Stockler, S; Hanefeld, F; Frahm, J			Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism	LANCET			English	Article							BRAIN; TRANSPORT; SPECTRA; CELLS; RAT	Background The creatine/creatine-phosphate system is essential for the storage and transmission of phosphate-bound energy in muscle and brain. In infants, inefficiency or failure of this metabolic pathway can impair the development of motor control and mentation. Methods We studied and treated an infant with extrapyramidal signs who was shown-by assay for urinary creatinine and by analysis of brain metabolites with use of nuclear magnetic resonance spectra-to have depletion of body and brain creatine, due to inborn deficiency of guanidinoacetate methyltransferase (GAMT). Findings Long-term oral administration of creatine-monohydrate (4-8 g per day) to this index patient resulted in substantial clinical improvement, disappearance of magnetic resonance (MRI) signal abnormalities in the globus pallidus, and normalisation of slow background activity on the electroencephalogram (EEG). During the 25-month treatment period, both brain and total body creatine concentrations became normal. Interpretation Oral creatine replacement has proved to be effective in one child with an inborn error of GAMT. It may well be effective in the treatment of other disorders of creatine synthesis.	UNIV GOTTINGEN, CHILDRENS HOSP, DEPT PAEDIAT NEUROL, GOTTINGEN, GERMANY; MAX PLANCK INST BIOPHYS CHEM, BIOMED NMR FORSCH GMBH, D-37077 GOTTINGEN, GERMANY	University of Gottingen; Max Planck Society								APPLEGARTH DA, 1968, CLIN CHIM ACTA, V22, P131, DOI 10.1016/0009-8981(68)90348-3; GREENHAFF PL, 1993, CLIN SCI, V84, P565, DOI 10.1042/cs0840565; LOIKE JD, 1988, P NATL ACAD SCI USA, V85, P807, DOI 10.1073/pnas.85.3.807; MICHAELIS T, 1993, RADIOLOGY, V187, P219, DOI 10.1148/radiology.187.1.8451417; MOLLER A, 1989, J NEUROCHEM, V52, P544, DOI 10.1111/j.1471-4159.1989.tb09154.x; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; STOCKLER S, 1994, PEDIATR RES, V36, P409; Stockler S, 1996, AM J HUM GENET, V58, P914; Walker J B, 1979, Adv Enzymol Relat Areas Mol Biol, V50, P177; WHITTINGHAM TS, 1981, J NEUROCHEM, V37, P1618, DOI 10.1111/j.1471-4159.1981.tb06337.x; Wilken B., 1996, European Journal of Pediatrics, V155, P153	11	175	180	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					789	790		10.1016/S0140-6736(96)04116-5	http://dx.doi.org/10.1016/S0140-6736(96)04116-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813986				2022-12-28	WOS:A1996VH98900012
J	Tappero, JW; Reporter, R; Wenger, JD; Ward, BA; Reeves, MW; Missbach, TS; Plikaytis, BD; Mascola, L; Schuchat, A				Tappero, JW; Reporter, R; Wenger, JD; Ward, BA; Reeves, MW; Missbach, TS; Plikaytis, BD; Mascola, L; Schuchat, A			Meningococcal disease in Los Angeles County, California, and among men in the county jails	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTILOCUS ENZYME ELECTROPHORESIS; NEISSERIA-MENINGITIDIS; SEROGROUP-C; RISK-FACTORS; CARRIAGE; EPIDEMIC; TUBERCULOSIS; POPULATION; INFECTION; INFLUENZA	Background From January through March 1993, there were 54 cases of meningococcal disease in Los Angeles County, California, of which 9 occurred among men incarcerated in the county's jail system, which was 40 percent above capacity at the time. Several of the 45 patients from the community had had contact with men recently released from a county jail. Methods We interviewed patients from the community (n = 42) and neighborhood controls matched with the patients for age, race, and ethnic group (n = 84) about potential exposures. We collected and cultured pharyngeal swabs for Neisseria meningitidis from men entering the central jail (n = 162), men leaving the central jail (n = 379), members of the jail staff (n = 121), and patients at a community health center (n = 214). Meningococcal isolates were identified by serogrouping and multilocus enzyme electrophoresis. Results The presence of community-acquired meningococcal disease was strongly associated with exposure to a person who had been in or worked at one of the county jails (multivariate matched odds ratio, 18.5; 95 percent confidence interval, 3.8 to 90.8; P<0.001). Pharyngeal carriage of meningococcus was significantly more frequent among men released from jail (19 percent) or entering jail (17 percent) than among workers at the jails (3 percent) or community residents seen at the clinic (1 percent). Among men entering jail, those who had previously been incarcerated were more often carriers than those who had not (21 percent vs. 7 percent, P = 0.03). Of the isolates from nine community residents with serogroup C meningococcal disease, eight were the same strain as that isolated from the eight inmates with serogroup C disease. Conclusions In this outbreak of meningococcal disease in Los Angeles County, nearly half of community residents with the disease had contact with persons who had been in a county jail. The high rates of carriage among recidivists and released inmates suggest that the men became meningococcal carriers while in jail. (C) 1996, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT,CHILDHOOD & RESP DIS BRANCH,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,BIOSTAT & INFORMAT BRANCH,NATL CTR INFECT DIS,ATLANTA,GA 30333; LOS ANGELES CTY DEPT HLTH SERV,PUBL HLTH PROGRAMS & SERV,LOS ANGELES,CA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								AYCOCK WL, 1950, BACTERIOL REV, V14, P115, DOI 10.1128/MMBR.14.2.115-160.1950; BROOME CV, 1986, J ANTIMICROB CHEMOTH, V18, P25, DOI 10.1093/jac/18.Supplement_A.25; CARTWRIGHT KAV, 1991, LANCET, V338, P554, DOI 10.1016/0140-6736(91)91112-8; CAUGANT DA, 1987, J BACTERIOL, V169, P2781, DOI 10.1128/jb.169.6.2781-2792.1987; CAUGANT DA, 1994, J CLIN MICROBIOL, V32, P323, DOI 10.1128/JCM.32.2.323-330.1994; DEWALS P, 1981, J INFECTION, V3, P53, DOI 10.1016/S0163-4453(81)80009-6; FRASER PK, 1973, LANCET, V1, P1235; GLASER JB, 1993, ANN INTERN MED, V118, P139, DOI 10.7326/0003-4819-118-2-199301150-00010; GOLD R, 1978, J INFECT DIS, V137, P112, DOI 10.1093/infdis/137.2.112; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; GREENFIELD S, 1971, J INFECT DIS, V123, P67, DOI 10.1093/infdis/123.1.67; HANEBERG B, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P169; HARRISON LH, 1991, ARCH INTERN MED, V151, P1005, DOI 10.1001/archinte.151.5.1005; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; HOSPEDALES CJ, 1994, EP INT SERV 43 ANN C; Imrey PB, 1996, AM J EPIDEMIOL, V143, P624, DOI 10.1093/oxfordjournals.aje.a008792; IMREY PB, 1995, J CLIN MICROBIOL, V33, P3133, DOI 10.1128/JCM.33.12.3133-3137.1995; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; JACOBS D, 1990, 15TH P ANN SAS US GR, P1413; Jones D M, 1994, Commun Dis Rep CDR Rev, V4, pR97; KING L, 1977, JAMA-J AM MED ASSOC, V237, P791, DOI 10.1001/jama.237.8.791; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; KREMASTINOU J, 1994, SCAND J INFECT DIS, V26, P719, DOI 10.3109/00365549409008641; Le Saux N, 1992, Can J Infect Dis, V3, P60; MARKS MI, 1979, AM J EPIDEMIOL, V109, P563, DOI 10.1093/oxfordjournals.aje.a112714; Mitchell LA, 1996, J INFECT DIS, V173, P1009, DOI 10.1093/infdis/173.4.1009; MOORE PS, 1990, JAMA-J AM MED ASSOC, V264, P1271, DOI 10.1001/jama.264.10.1271; MORROW HW, 1990, PEDIATR INFECT DIS J, V9, P394, DOI 10.1097/00006454-199006000-00005; MUNFORD RS, 1974, LANCET, V1, P1275; OLSEN SF, 1991, EPIDEMIOL INFECT, V106, P445, DOI 10.1017/S0950268800067492; REEVES MW, 1995, EMERG INFECT DIS, V1, P53, DOI 10.3201/eid0102.950203; *SAS I, 1994, MICR WIND ENV CHANG; SCHOLTEN RJPM, 1994, J INFECT DIS, V169, P673, DOI 10.1093/infdis/169.3.673; SCHWARTZ B, 1991, REV INFECT DIS, V13, pS170; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315, DOI 10.1017/S0950268800057733; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; STUART JM, 1988, COMMUNITY MED, V10, P139; STUART JM, 1989, LANCET, V2, P723, DOI 10.1016/S0140-6736(89)90781-2; THOMAS JC, 1991, AM J EPIDEMIOL, V133, P286, DOI 10.1093/oxfordjournals.aje.a115873; THOMAS JC, 1993, AM J PUBLIC HEALTH, V83, P1790, DOI 10.2105/AJPH.83.12.1790; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; WHALEN CM, 1995, JAMA-J AM MED ASSOC, V273, P390, DOI 10.1001/jama.273.5.390; WOODS TC, 1992, J CLIN MICROBIOL, V30, P132, DOI 10.1128/JCM.30.1.132-137.1992; YOUNG LS, 1972, NEW ENGL J MED, V287, P5, DOI 10.1056/NEJM197207062870102; 1989, MMWR-MORBID MORTAL W, V38, P635; 1989, MMWR-MORBID MORTAL W, V34, P615; 1976, JAMA-J AM MED ASSOC, V235, P261; 1995, MMWR-MORBID MORTAL W, V44, P121; 1985, MMWR-MORBID MORTAL W, V34, P255; 1992, MMWR-MORBID MORTAL W, V41, P927; 1992, MMWR-MORBID MORTAL W, V41, P507; 1989, MMWR-MORBID MORTAL W, V38, P641	53	47	52	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1996	335	12					833	840		10.1056/NEJM199609193351201	http://dx.doi.org/10.1056/NEJM199609193351201			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG869	8778600				2022-12-28	WOS:A1996VG86900001
J	vandenHazel, SJ; Speelman, P; Dankert, J; Huibregtse, K; Tytgat, GNJ; vanLeeuwen, DJ				vandenHazel, SJ; Speelman, P; Dankert, J; Huibregtse, K; Tytgat, GNJ; vanLeeuwen, DJ			Piperacillin to prevent cholangitis after endoscopic retrograde cholangiopancreatography - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							COMPLICATIONS; ERCP; SPHINCTEROTOMY; PROPHYLAXIS; SEPTICEMIA; BACTERIA; BILE	Background: Cholangitis does not often occur after endoscopic retrograde cholangiopancreatography (ERCP), but it can be a serious complication of this procedure. Antibiotic prophylaxis is therefore frequently used in patients having ERCP, but existing data are insufficient to allow evaluation of the effectiveness of this practice. Objective: To determine the efficacy of single-dose antibiotic prophylaxis with piperacillin for ERCP-induced cholangitis. Design: Randomized, double-blind, placebo-controlled clinical trial. Setting: Tertiary referral center for ERCP. Patients: Patients who had ERCP for suspected biliary tract stones or distal common bile duct stricture were eligible. Major exclusion criteria were previous ERCP within 7 days, biliary endoprosthesis in situ, and use of antimicrobial agents or presence of fever within 7 days before the procedure. Intervention: Piperacillin, 4 g, or placebo was given intravenously approximately 30 minutes before ERCP. Measurements: Duration of follow-up was 1 week. Acute cholangitis was diagnosed if a patient had a body temperature greater than 38 degrees C, a clinically apparent need for antibiotic treatment, and no symptoms indicating infection outside of the biliary tree. Results: 551 consecutive patients were enrolled. During ERCP, stones were found in 147 patients, malignant distal strictures were found in 203 patients, other pathologic findings were seen in 88 patients, and normal biliary tracts were seen in 113 patients. Seventeen of the 281 patients who received placebo (6.0%) and 12 of the 270 patients who received piperacillin (4.4%) developed acute cholangitis (relative risk, 0.73 [95% CI, 0.36 to 1.51]). The absolute risk reduction was 1.6% (CI, -5.3% to 2.1%). All cases of cholangitis (with the exception of one case seen in a patient in the piperacillin group) were mild or moderate in severity. Conclusion: Single-dose prophylaxis with piperacillin is not associated with a clinically significant reduction in the incidence of acute cholangitis after ERCP in patients suspected of having biliary tract stones or distal common bile duct stricture.	Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, Meibergdreef 9, NL-1105 AZ Amsterdam, NETHERLANDS; Univ Alabama, Div Gastroenterol & Hepatol, Birmingham, AL 35294 USA	University of Amsterdam; University of Alabama System; University of Alabama Birmingham	vandenHazel, SJ (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, Meibergdreef 9, NL-1105 AZ Amsterdam, NETHERLANDS.		van leeuwen, dirk/S-1659-2019	van leeuwen, dirk/0000-0002-3820-5066				ALVEYN CG, 1991, J HOSP INFECT, V19, P65, DOI 10.1016/0195-6701(91)90169-9; BILBAO MK, 1976, GASTROENTEROLOGY, V70, P314; BLENKHARN JI, 1985, ANTIMICROB AGENTS CH, V28, P778, DOI 10.1128/AAC.28.6.778; BRANDES JW, 1981, ENDOSCOPY, V13, P27, DOI 10.1055/s-2007-1021637; BYL B, 1995, CLIN INFECT DIS, V20, P1236, DOI 10.1093/clinids/20.5.1236; CHAMBERLAND S, 1992, CLIN INFECT DIS, V15, P615, DOI 10.1093/clind/15.4.615; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2; DEVIERE J, 1990, ENDOSCOPY, V22, P72, DOI 10.1055/s-2007-1012796; HUIBREGTSE K, 1988, ENDOSCOPIC BILIARY P, P121; KEIGHLEY MRB, 1976, GUT, V17, P495, DOI 10.1136/gut.17.7.495; LOBO A J, 1992, Gastroenterology, V102, pA320; MALUENDA F, 1989, HEPATO-GASTROENTEROL, V36, P132; MOTTE S, 1991, GASTROENTEROLOGY, V101, P1374, DOI 10.1016/0016-5085(91)90091-X; NIEDERAU C, 1994, GASTROINTEST ENDOSC, V40, P533, DOI 10.1016/S0016-5107(94)70247-0; PITT HA, 1982, ARCH SURG-CHICAGO, V117, P445; SAUTER G, 1990, ENDOSCOPY, V22, P164, DOI 10.1055/s-2007-1012830; TAYLOR EW, 1983, J INT MED RES, V11, P28, DOI 10.1177/030006058301100106; VAIRA D, 1989, LANCET, V2, P431	18	40	40	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					442	447		10.7326/0003-4819-125-6-199609150-00002	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779455				2022-12-28	WOS:A1996VF88200004
J	Grunfeld, E; Mant, D; Yudkin, P; AdewuyiDalton, R; Cole, D; Stewart, J; Fitzpatrick, R; Vessey, M				Grunfeld, E; Mant, D; Yudkin, P; AdewuyiDalton, R; Cole, D; Stewart, J; Fitzpatrick, R; Vessey, M			Routine follow up of breast cancer in primary care: Randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SURVEILLANCE; ONCOLOGISTS; CARCINOMA	Objective-To assess the effect on time to diagnosis of recurrence and on quality of life of transferring primary responsibility for follow up of women with breast cancer in remission from hospital to general practice. Design-Randomised controlled trial with 18 month follow up in which women received routine follow up either in hospital or in general practice. Subjects and setting-296 women with breast cancer in remission receiving regular follow up care at district general hospitals in England. Main outcome measures-Time between first presentation of symptoms to confirmation of recurrence; quality of life measured by specific dimensions of the SF-36 schedule, the EORTC symptom scale, and hospital anxiety and depression scale. Results-Most recurrences (18/26, 69%) presented as interval events, and almost half (7/16, 44%) of the recurrences in the hospital group presented first to general practice. The median time to hospital confirmation of recurrence was 21 days in the hospital group (range 1-376 days) and 22 days in the general practice group (range 4-64). The differences between groups in the change in SF-36 mean scores from baseline were small: -1.8 (95% confidence interval -7.2 to 3.5) for social functioning, 0.5 (-4.1 to 5.1) for mental health, and 0.6 (-3.6 to 4.8) for general health perception. The change from baseline in the mean depression score was higher in the general practice group at the mid-trial assessment (difference 0.6, 0.1 to 1.2) but there was no significant difference between groups in the anxiety score or the EORTC scales. Conclusion-General practice follow up of women with breast cancer in remission is not associated with increase in time to diagnosis, increase in anxiety, or deterioration in health related quality of life. Most recurrences are detected by women as interval events and present to the general practitioner, irrespective of continuing hospital follow up.	UNIV OXFORD, RADCLIFFE INFIRM, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX2 6HE, ENGLAND; NORTHAMPTON GEN HOSP, NORTHAMPTONSHIRE CTR ONCOL, NORTHAMPTON NN1 5BD, ENGLAND; PRINCESS MARGARET HOSP, SWINDON SN1 4JU, WILTS, ENGLAND	Radcliffe Infirmary; University of Oxford			Mant, David CA/C-7763-2009					AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; ABE O, 1992, LANCET, V339, P71; ALTMAN D, 1991, STAT PRACTICE; [Anonymous], 1992, Lancet, V339, P1; BROYN T, 1982, ACTA CHIR SCAND, V148, P401; DELTURCO MR, 1994, JAMA-J AM MED ASSOC, V271, P1593, DOI 10.1001/jama.1994.03510440053032; DEWAR J, 1995, BMJ-BRIT MED J, V310, P685, DOI 10.1136/bmj.310.6981.685; DEWAR JA, 1985, BRIT MED J, V291, P1464, DOI 10.1136/bmj.291.6507.1464; GARDNER SB, 1991, CIA; GRUNFELD E, 1995, FAM PRACT, V12, P60, DOI 10.1093/fampra/12.1.60; HOLLEN PJ, 1995, SUPPORT CARE CANCER, V3, P40, DOI 10.1007/BF00343920; James N D, 1994, Clin Oncol (R Coll Radiol), V6, P283, DOI 10.1016/S0936-6555(05)80267-5; LOOMER L, 1991, CANCER, V67, P55, DOI 10.1002/1097-0142(19910101)67:1<55::AID-CNCR2820670111>3.0.CO;2-N; LOPRINZI CL, 1994, J CLIN ONCOL, V12, P881, DOI 10.1200/JCO.1994.12.5.881; PANDYA KJ, 1985, CANCER, V55, P202, DOI 10.1002/1097-0142(19850101)55:1<202::AID-CNCR2820550132>3.0.CO;2-X; RICHERTBOE KE, 1995, CANCER-AM CANCER SOC, V75, P2605, DOI 10.1002/1097-0142(19950515)75:10<2605::AID-CNCR2820751031>3.0.CO;2-#; SCANLON EF, 1980, CANCER, V46, P977, DOI 10.1002/1097-0142(19800815)46:4+<977::AID-CNCR2820461320>3.0.CO;2-0; SCHAPIRA DV, 1991, JAMA-J AM MED ASSOC, V265, P380, DOI 10.1001/jama.265.3.380; TOMIAK E, 1993, ANN ONCOL, V4, P199, DOI 10.1093/oxfordjournals.annonc.a058456; Ware JE, 1993, SF36 HLTH SURVEY MAN; WERTHEIMER MD, 1991, JAMA-J AM MED ASSOC, V265, P396, DOI 10.1001/jama.265.3.396; WINCHESTER DP, 1979, CANCER, V43, P956, DOI 10.1002/1097-0142(197903)43:3<956::AID-CNCR2820430326>3.0.CO;2-L; Worster A, 1996, CAN FAM PHYSICIAN, V42, P263; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZWAVELING A, 1987, J SURG ONCOL, V34, P194, DOI 10.1002/jso.2930340314; 1994, JAMA-J AM MED ASSOC, V271, P1587	26	294	299	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	1996	313	7058					665	669						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8811760				2022-12-28	WOS:A1996VH16500023
J	Haddad, E; Fournet, JC; Brousse, N; Blanche, S				Haddad, E; Fournet, JC; Brousse, N; Blanche, S			A child who was feverish for 2 years	LANCET			English	Article							CASTLEMANS DISEASE; INTERLEUKIN-6; DIFFERENTIATION		HOP NECKER ENFANTS MALAD,SERV ANAT PATHOL,F-75743 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Haddad, E (corresponding author), HOP NECKER ENFANTS MALAD,DEPT PEDIAT,UNITE IMMUNOL HEMATOL & RHUMATOL PEDIAT,F-75743 PARIS 15,FRANCE.		Haddad, Elie/AAQ-4971-2020	Haddad, Elie/0000-0003-2446-6879				BRANDT SJ, 1990, J CLIN INVEST, V86, P592, DOI 10.1172/JCI114749; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; HIRANO T, 1987, P NATL ACAD SCI USA, V84, P228, DOI 10.1073/pnas.84.1.228; KLEIN B, 1989, BLOOD, V73, P517; YOSHIZAKI K, 1989, BLOOD, V74, P1360	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					724	724		10.1016/S0140-6736(96)05200-2	http://dx.doi.org/10.1016/S0140-6736(96)05200-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806293				2022-12-28	WOS:A1996VG37400013
J	ChapmanSheath, P; Wilcox, D; Mok, Q; Drake, D				ChapmanSheath, P; Wilcox, D; Mok, Q; Drake, D			Iatrogenic ileal obstruction: A complication of umbilical cord clamping	BRITISH MEDICAL JOURNAL			English	Article									GREAT ORMOND ST HOSP CHILDREN NHS TRUST,NEONATAL INTENS CARE UNIT,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust			Mok, Quen/AAA-2648-2019	Mok, Quen/0000-0003-4807-9275				ECKSTEIN HB, 1963, BRIT J SURG, V50, P405, DOI 10.1002/bjs.18005022210; LANDOR JH, 1963, SOUTHERN MED J, V56, P1236, DOI 10.1097/00007611-196311000-00008; SANDBORN WILLIAM D., 1967, J PEDIAT SURG, V2, P461, DOI 10.1016/S0022-3468(67)80089-7; SINGLETON AO, 1951, SURGERY, V29, P278; VASSEY LE, 1975, J PEDIATR SURG, V5, P797	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					613	614						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806257				2022-12-28	WOS:A1996VG10800026
J	McCormick, J				McCormick, J			Death of the personal doctor	LANCET			English	Editorial Material											McCormick, J (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT COMMUNITY HLTH & GEN PRACTICE,199 PEARSE ST,DUBLIN 2,IRELAND.							FOX T, 1965, LANCET, V2, P801; FOX TF, 1960, LANCET, V2, P743; MCCORMICK J, 1979, DOCTOR FATHER FIGURE; MCCORMICK JS, 1994, FAM DOCTOR WONCA, V4, P14	4	40	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					667	668		10.1016/S0140-6736(96)03512-X	http://dx.doi.org/10.1016/S0140-6736(96)03512-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782760				2022-12-28	WOS:A1996VF60900015
J	Chitty, LS; Barnes, CA; Berry, C				Chitty, LS; Barnes, CA; Berry, C			Continuing with pregnancy after a diagnosis of lethal abnormality: Experience of five couples and recommendations for management	BRITISH MEDICAL JOURNAL			English	Article							LOW-RISK POPULATION; ROUTINE; ULTRASOUND				Chitty, LS (corresponding author), UCL HOSP, OBSTET HOSP, FETAL MED UNIT, LONDON WC1E 6AU, ENGLAND.			chitty, lyn/0000-0002-4857-7138				CHITTY LS, 1991, BRIT MED J, V303, P1165, DOI 10.1136/bmj.303.6811.1165; HUNFELD JAM, 1993, PRENATAL DIAG, V13, P603, DOI 10.1002/pd.1970130711; LILFORD RJ, 1994, BRIT J OBSTET GYNAEC, V101, P291, DOI 10.1111/j.1471-0528.1994.tb13612.x; MARTEAU T, 1994, J MED GENET, V31, P864, DOI 10.1136/jmg.31.11.864; SHIRLEY IM, 1992, BRIT J RADIOL, V65, P564, DOI 10.1259/0007-1285-65-775-564; WATKINS D, 1989, PRACTITIONER, V233, P990	6	54	55	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					478	480						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776321				2022-12-28	WOS:A1996VE08000028
J	Travers, AF				Travers, AF			Caring for older people .7. Carers	BRITISH MEDICAL JOURNAL			English	Article								Caring by families and friends is the backbone of community care. Carers face physical, emotional, social, and financial problems. They need recognition, information, and support from the health professionals with whom they and the person they care for come in contact. Much information is available to assist carers and to enable their doctors to help them in their caring role.			Travers, AF (corresponding author), BRADFORD HLTH AUTHOR,SHIPLEY BD18 3LD,W YORKSHIRE,ENGLAND.							*CAR NAT ASS, 1996, WHO CAR PERC CAR CAR; *DEP HLTH, 1993, EMPL CAR; *DEP HLTH SOC SERV, 1981, GROW OLD; GOLDBERG DP, 1978, MANUAL GENERAL HLTH; *HC SOC SERV COMM, 1990, 5 HC SOC SERV COMM; WARNER N, 1995, BETTER TOMORROWS REP	6	16	16	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					482	486						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776323				2022-12-28	WOS:A1996VE08000030
J	Murad, F				Murad, F			Signal transduction using nitric oxide and cyclic guanosine monophosphate	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOLUBLE GUANYLATE-CYCLASE; VASCULAR SMOOTH-MUSCLE; SODIUM AZIDE; ENDOGENOUS ACTIVATOR; TISSUE PREPARATIONS; RAT-LIVER; GMP; RELAXATION; CELLS; NITROPRUSSIDE	Understanding of the formation and biological actions of nitric oxide (NO) has grown extensively during the past 2 decades. Through our discoveries of the biological effects of NO and nitrovasodilators on cyclic guanosine monophosphate (GMP) and our discoveries of the biochemical mechanisms of NO and regulation of NO synthase in numerous cell types and tissues, the complexity of the signal transduction cascade and the extensive function-regulating interactions of the NO molecule have been increasingly demonstrated. Although the diverse roles of this unique molecule continue to unfold, NO can be recognized as an intracellular second messenger, a local substance for regulation of neighboring cells, a neurotransmitter in central and peripheral neurons, and perhaps a hormone that can act at distant sites and has been shown to have beneficial or deleterious biological effects, depending on its concentration, the system, and the cellular environment.										ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BRAUGHLER JM, 1979, J BIOL CHEM, V254, P2450; BRAUGHLER JM, 1979, P NATL ACAD SCI USA, V76, P219, DOI 10.1073/pnas.76.1.219; CRAVEN PA, 1978, J BIOL CHEM, V253, P8433; DEGUCHI T, 1982, J BIOL CHEM, V257, P147; DIAMOND J, 1975, CAN J PHYSIOL PHARM, V53, P1099, DOI 10.1139/y75-153; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GERZER R, 1981, FEBS LETT, V132, P171; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIRATA M, 1990, J BIOL CHEM, V265, P1268; Ignarro L. J., 1995, ADV PHARMACOL, V34, P1; IGNARRO LJ, 1984, ADV CYCLIC NUCL PROT, V17, P267; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; ISHII K, 1989, J APPL CARDIOL, V4, P505; ISHII K, 1991, AM J PHYSIOL, V261, pH598, DOI 10.1152/ajpheart.1991.261.2.H598; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P239; KATSUKI S, 1977, MOL PHARMACOL, V13, P330; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KIMURA H, 1975, J BIOL CHEM, V250, P8016; KIMURA H, 1975, NATURE, V257, P700, DOI 10.1038/257700a0; Murad F, 1994, Adv Pharmacol, V26, P1, DOI 10.1016/S1054-3589(08)60047-2; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; Murad F, 1978, Adv Cyclic Nucleotide Res, V9, P145; MURAD F, 1994, RECENT PROG HORM RES, V49, P239; MURAD F, 1993, ADV SEC MESS PHOSPH, V28, P101; MURAD F, 1978, ADV PHARMACOL THER, V3, P123; Murad F., 1978, MOL BIOL PHARM CYCLI, P33; RAPOPORT RM, 1983, CIRC RES, V52, P352, DOI 10.1161/01.RES.52.3.352; RAPOPORT RM, 1983, J CYCLIC NUCL PROT, V9, P281; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; WALDMAN SA, 1987, PHARMACOL REV, V39, P163	32	114	120	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1189	1192		10.1001/jama.276.14.1189	http://dx.doi.org/10.1001/jama.276.14.1189			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827977				2022-12-28	WOS:A1996VL33200034
J	deGroen, PC; Lubbe, DF; Hirsch, LJ; Daifotis, A; Stephenson, W; Freedholm, D; PryorTillotson, S; Seleznick, MJ; Pinkas, H; Wang, KK				deGroen, PC; Lubbe, DF; Hirsch, LJ; Daifotis, A; Stephenson, W; Freedholm, D; PryorTillotson, S; Seleznick, MJ; Pinkas, H; Wang, KK			Esophagitis associated with the use of alendronate	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ORAL ALENDRONATE; BONE; OSTEOPOROSIS; TABLETS; TRANSIT	Background Alendronate, an aminobisphosphonate and a selective inhibitor of osteoclast-mediated bone resorption, is used to treat osteoporosis in postmenopausal women and Paget's disease of bone. Aminobisphosphonates can irritate the upper gastrointestinal mucosa. Methods We describe three patients who had severe esophagitis shortly after starting to take alendronate and also analyze adverse esophageal effects reported to Merck, the manufacturer, through postmarketing surveillance. Results As of March 5, 1996, alendronate had been prescribed for an estimated 475,000 patients worldwide, and 1213 reports of adverse effects had been received. A total of 199 patients had adverse effects related to the esophagus; in 51 of these patients (26 percent), including the 3 we describe in case reports, adverse effects were categorized as serious or severe. Thirty-two patients (16 percent) were hospitalized, and two were temporarily disabled. Endoscopic findings generally indicated chemical esophagitis, with erosions or ulcerations and exudative inflammation accompanied by thickening of the esophageal wall. Bleeding was rare, and stomach or duodenal involvement unusual. In patients for whom adequate information was available, esophagitis seemed to be associated with swallowing alendronate with little or no water, lying down during or after ingestion of the tablet, continuing to take alendronate after the onset of symptoms, and having preexisting esophageal disorders. Conclusions Alendronate can cause chemical esophagitis, including severe ulcerations, in some patients. Recommendations to reduce the risk of esophagitis include swallowing alendronate with 180 to 240 ml (6 to 8 oz) of water on arising in the morning, remaining upright for at least 30 minutes after swallowing the tablet and until the first food of the day has been ingested, and discontinuing the drug promptly if esophageal symptoms develop. (C) 1996, Massachusetts Medical Society.	MAYO CLIN & MAYO FDN, DEPT MED, ROCHESTER, MN 55905 USA; MERCK RES LABS, RAHWAY, NJ USA; UNIV S FLORIDA, DIV GEN INTERNAL MED, TAMPA, FL USA; UNIV S FLORIDA, DIV GASTROENTEROL, TAMPA, FL USA	Mayo Clinic; Merck & Company; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	deGroen, PC (corresponding author), MAYO CLIN & MAYO FDN, DIV GASTROENTEROL, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							ADAMI S, 1994, BONE, V15, P415, DOI 10.1016/8756-3282(94)90818-4; ADAMI S, 1995, BONE, V17, P383, DOI 10.1016/S8756-3282(95)00262-6; Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018-199614030-00003; BOZYMSKI EM, 1995, TXB GASTROENTEROLOGY, V1, P1283; CHANNER KS, 1986, J CLIN PHARMACOL, V26, P141, DOI 10.1002/j.1552-4604.1986.tb02922.x; CHESTNUT CH, 1995, AM J MED, V99, P144, DOI 10.1016/S0002-9343(99)80134-X; GERTZ BJ, 1995, CLIN PHARMACOL THER, V58, P288, DOI 10.1016/0009-9236(95)90245-7; HEY H, 1982, BRIT MED J, V285, P1717, DOI 10.1136/bmj.285.6356.1717; INMAN WHW, 1980, MONITORING DRUG SAFE, P9; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Liberman UA, 1996, NEW ENGL J MED, V335, P1069, DOI 10.1056/NEJM199610033351416; LUFKIN EG, 1994, OSTEOPOROSIS INT, V4, P320, DOI 10.1007/BF01622190; MACONI G, 1995, AM J GASTROENTEROL, V90, P1889; MARVOLA M, 1983, J PHARM SCI, V72, P1034, DOI 10.1002/jps.2600720917; *MERCK, 1995, FOS AL SOD TABL; *MERCK, 1996, FOS AL SOD TABL; Siris E, 1996, J CLIN ENDOCR METAB, V81, P961, DOI 10.1210/jc.81.3.961	17	572	589	3	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1016	1021		10.1056/NEJM199610033351403	http://dx.doi.org/10.1056/NEJM199610033351403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8793925				2022-12-28	WOS:A1996VL45900003
J	Jabs, T; Dietrich, RA; Dangl, JL				Jabs, T; Dietrich, RA; Dangl, JL			Initiation of runaway cell death in an Arabidopsis mutant by extracellular superoxide	SCIENCE			English	Article							DISEASE RESISTANCE RESPONSE; SALICYLIC-ACID; ACTIVE OXYGEN; HYPERSENSITIVE RESPONSE; PHYTOPHTHORA-INFESTANS; PLANT DEFENSE; GENERATION; PATHOGENESIS; TOBACCO; H2O2	Reactive oxygen intermediates (ROIs) regulate apoptosis during normal development and disease in animals. ROIs are also implicated in hypersensitive resistance responses of plants against pathogens. Arabidopsis Isd1 mutants exhibited impaired control of cell death in the absence of pathogen and could not control the spread of cell death once it was initiated. Superoxide was necessary and sufficient to initiate lesion formation; it accumulated before the onset of cell death and subsequently in live cells adjacent to spreading Isd1 lesions, Thus, runaway cell death seen in Isd1 plants reflected abnormal accumulation of superoxide and lack of responsiveness to signals derived from it.	UNIV N CAROLINA,CURRICULA GENET & MOL BIOL,CHAPEL HILL,NC 27599; MAX DELBRUCK LAB,D-50829 COLOGNE,GERMANY	University of North Carolina; University of North Carolina Chapel Hill	Jabs, T (corresponding author), UNIV N CAROLINA,DEPT BIOL,COKER HALL 108,CB 3280,CHAPEL HILL,NC 27599, USA.							AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; AUH CK, 1995, PLANT PHYSIOL, V107, P1241, DOI 10.1104/pp.107.4.1241; BAKER CJ, 1995, ANNU REV PHYTOPATHOL, V33, P299, DOI 10.1146/annurev.py.33.090195.001503; BAKER CJ, 1991, PHYTOPATHOLOGY, V81, P1504, DOI 10.1094/Phyto-81-1504; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CHEN ZX, 1993, SCIENCE, V262, P1883, DOI 10.1126/science.8266079; DANGL JL, IN PRESS PLANT CELL; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DOKE N, 1983, PHYSIOL PLANT PATHOL, V23, P345, DOI 10.1016/0048-4059(83)90019-X; DOKE N, 1985, PHYSIOL PLANT PATHOL, V27, P311, DOI 10.1016/0048-4059(85)90044-X; DROOG FNJ, 1995, PLANT PHYSIOL, V107, P1139, DOI 10.1104/pp.107.4.1139; DWYER SC, 1995, BIOCHIM BIOPHYS ACTA, V1289, P231; ENYEDI AJ, 1992, P NATL ACAD SCI USA, V89, P2480, DOI 10.1073/pnas.89.6.2480; ENYEDI AJ, 1992, CELL, V70, P879, DOI 10.1016/0092-8674(92)90239-9; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HANCOCK JT, 1987, BIOCHEM J, V242, P103, DOI 10.1042/bj2420103; Inze Dirk, 1995, Current Opinion in Biotechnology, V6, P153, DOI 10.1016/0958-1669(95)80024-7; JABS T, UNPUB; JOHAL GS, 1995, BIOESSAYS, V17, P685, DOI 10.1002/bies.950170805; Jones AM, 1996, TRENDS PLANT SCI, V1, P114, DOI 10.1016/S1360-1385(96)90005-9; KAUSS H, 1992, PLANT J, V2, P655, DOI 10.1111/j.1365-313X.1992.tb00134.x; KAUSS H, 1995, PLANT PHYSIOL, V108, P1171, DOI 10.1104/pp.108.3.1171; KIEDROWSKI S, 1992, EMBO J, V11, P4677, DOI 10.1002/j.1460-2075.1992.tb05572.x; LANGFORD AN, 1948, CAN J RES C, V26, P35, DOI 10.1139/cjr48c-006; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; May MJ, 1996, PLANT PHYSIOL, V110, P1367, DOI 10.1104/pp.110.4.1367; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; Montalbini P., 1994, Rivista di Patologia Vegetale, V4, P81; MONTALBINI P, 1992, J PHYTOPATHOL, V134, P218, DOI 10.1111/j.1439-0434.1992.tb01230.x; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; Mur LAJ, 1996, PLANT J, V9, P559, DOI 10.1046/j.1365-313X.1996.09040559.x; NEUENSCHWANDER U, UNPUB; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; RYALS J, 1994, PLANT PHYSIOL, V104, P1019; SANCHEZCASAS P, 1994, PLANT PHYSIOL, V106, P1675, DOI 10.1104/pp.106.4.1675; SCANDALIOS JG, 1993, PLANT PHYSIOL, V101, P7, DOI 10.1104/pp.101.1.7; STRELLER S, 1994, PLANTA, V192, P195, DOI 10.1007/BF01089035; UKNES S, 1993, PLANT CELL, V5, P159, DOI 10.1105/tpc.5.2.159; VERAESTRELLA R, 1993, PHYSIOL MOL PLANT P, V42, P9, DOI 10.1006/pmpp.1993.1002; WALBOT V, 1983, GENETIC ENG PLANTS, V3, P431; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; Weymann K, 1995, PLANT CELL, V7, P2013, DOI 10.1105/tpc.7.12.2013; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; WONG PC, 1995, NEURON, V14, P1106; WU GS, 1995, PLANT CELL, V7, P1357, DOI 10.1105/tpc.7.9.1357	51	662	724	3	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1853	1856		10.1126/science.273.5283.1853	http://dx.doi.org/10.1126/science.273.5283.1853			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791589				2022-12-28	WOS:A1996VJ71300043
J	Cate, JH; Gooding, AR; Podell, E; Zhou, KH; Golden, BL; Kundrot, CE; Cech, TR; Doudna, JA				Cate, JH; Gooding, AR; Podell, E; Zhou, KH; Golden, BL; Kundrot, CE; Cech, TR; Doudna, JA			Crystal structure of a group I ribozyme domain: Principles of RNA packing	SCIENCE			English	Article							PHENYLALANINE TRANSFER-RNA; RIBONUCLEASE-P REACTION; METAL-ION REQUIREMENTS; REV RESPONSIVE ELEMENT; GUANOSINE-BINDING-SITE; TETRAHYMENA RIBOZYME; TERTIARY STRUCTURE; CATALYTIC RNA; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE	Group I self-splicing introns catalyze their own excision from precursor RNAs by way of a two-step transesterification reaction. The catalytic core of these ribozymes is formed by two structural domains. The 2.8-angstrom crystal structure of one of these, the P4-P6 domain of the Tetrahymena thermophila intron, is described. In the 160-nucleolide domain, a sharp bend allows stacked helices of the conserved core to pack alongside helices of an adjacent region. Two specific long-range interactions clamp the two halves of the domain together. a two-Mg2+-coordinated adenosine-rich corkscrew plugs into the minor groove of a helix, and a GAAA hairpin loop binds to a conserved 11-nucleotide internal loop. Metal- and ribose-mediated backbone contacts further stabilize the close side-by-side helical packing, The structure indicates the extent of RNA packing required for the function of large ribozymes, the spliceosome, and the ribosome.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; YALE UNIV, DEPT MOL BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA; UNIV COLORADO, HOWARD HUGHES MED INST, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder; Yale University; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder				Golden, Barbara/0000-0002-9741-882X	NIGMS NIH HHS [5T32GM08283-07, GM22778-21] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008283] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; BREAKER RR, 1995, CHEM BIOL, V2, P655, DOI 10.1016/1074-5521(95)90028-4; Brunger A. T, 1993, XPLOR MANUAL VERSION; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CATE JH, IN PRESS STRUCTURE; CATE JH, UNPUB; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1993, GENE, V135, P33, DOI 10.1016/0378-1119(93)90046-6; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; COLLINS RA, 1988, NUCLEIC ACIDS RES, V16, P2705; COSTA M, 1995, EMBO J, V14, P1276, DOI 10.1002/j.1460-2075.1995.tb07111.x; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; CUENOUD B, 1995, NATURE, V375, P611, DOI 10.1038/375611a0; DOUDNA JA, 1993, P NATL ACAD SCI USA, V90, P7829, DOI 10.1073/pnas.90.16.7829; DOUDNA JA, 1995, RNA, V1, P36; Downs WD, 1996, RNA, V2, P718; FLOR PJ, 1989, EMBO J, V8, P3391, DOI 10.1002/j.1460-2075.1989.tb08503.x; GOLDEN BL, UNPUB; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HOLBROOK SR, 1977, NUCLEIC ACIDS RES, V4, P2811, DOI 10.1093/nar/4.8.2811; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; KALLENBACH NR, 1977, Q REV BIOPHYS, V10, P138, DOI 10.1017/S0033583500000202; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LAY PA, 1989, INORG CHEM, V28, P3001, DOI 10.1021/ic00314a026; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MOHR G, 1994, NATURE, V370, P147, DOI 10.1038/370147a0; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; MURPHY FL, 1994, SCIENCE, V265, P1709, DOI 10.1126/science.8085157; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SCHEVITZ RW, 1979, NATURE, V278, P188, DOI 10.1038/278188a0; SCHINDELIN H, 1995, J MOL BIOL, V249, P595, DOI 10.1006/jmbi.1995.0321; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SHEN LX, 1995, FASEB J, V9, P1023, DOI 10.1096/fasebj.9.11.7544309; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; SMITH D, 1992, J BIOL CHEM, V267, P2429; Strobel SA, 1996, BIOCHEMISTRY-US, V35, P1201, DOI 10.1021/bi952244f; VANDERHORST G, 1991, P NATL ACAD SCI USA, V88, P184, DOI 10.1073/pnas.88.1.184; WANG JF, 1992, SCIENCE, V256, P526, DOI 10.1126/science.1315076; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WANG YH, 1994, J MOL BIOL, V236, P64, DOI 10.1006/jmbi.1994.1118; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; WOO NH, 1980, NATURE, V286, P346, DOI 10.1038/286346a0; Wyatt J. R., 1993, RNA WORLD, P465; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848	70	1251	1278	4	167	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1996	273	5282					1678	1685		10.1126/science.273.5282.1678	http://dx.doi.org/10.1126/science.273.5282.1678			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781224				2022-12-28	WOS:A1996VH40800031
J	Parmet, WE; Daynard, RA; Gottlieb, MA				Parmet, WE; Daynard, RA; Gottlieb, MA			The physician's role in helping smoke-sensitive patients to use the Americans With Disabilities Act to secure smoke-free workplaces and public spaces	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL TOBACCO-SMOKE	Many persons suffer from a variety of conditions that render them particularly vulnerable to injuries caused by environmental tobacco smoke. Fortunately, the Americans With Disabilities Act may provide such patients with a legal right to a smoke-free environment. We examine herein how the act can be used by these patients, how the act works, and how physicians, who often advise such patients to seek smoke-free environments, can help their patients obtain the clean air to which they are entitled under law.	TOBACCO CONTROL RESOURCE CTR,BOSTON,MA 02115; NORTHEASTERN UNIV,SCH LAW,BOSTON,MA 02115	Northeastern University			Gottlieb, Mark A./ABI-1826-2020	Gottlieb, Mark A./0000-0001-8679-307X				*AM HOSP ASS, 1996, HOSP STAT 1995, P2; *AM LUNG ASS, 1995, LUNG DIS DAT 1994, P6; BORLAND R, 1995, PREV MED, V24, P56, DOI 10.1006/pmed.1995.1008; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Criteria Committee of the New York Heart Association, 1994, NOMENCLATURE CRITERI, V9th, P253; DiFranza JR, 1996, PEDIATRICS, V97, P560; FONTHAM ETH, 1994, JAMA-J AM MED ASSOC, V271, P1752, DOI 10.1001/jama.271.22.1752; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; Goldberg R J, 1993, J Cancer Educ, V8, P133; GOTTLIEB MA, 1994, ST LOUIS PUB L REV, V13, P635; Jinot J., 1992, RESP HLTH EFFECTS PA; Parmet W E, 1990, Law Med Health Care, V18, P331; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; *SOC SEC ADM, 1979, DHEW PUBL; *US DEP HHS, 1988, HLTH CONS SMOK NIC A; *US DEP HHS, 1986, 878398 CDC PHS DHHS; 1994, FED REGISTER, V59, P47570; 1993, AM REV RESPIR DIS, V147, P1056; 1995, MMWR MORB MORTAL WKL, V44	19	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					909	913						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782641				2022-12-28	WOS:A1996VF78700035
J	Dubrey, S; Mendes, L; Skinner, M; Falk, RH				Dubrey, S; Mendes, L; Skinner, M; Falk, RH			Resolution of heart failure in patients with AL amyloidosis	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY SYSTEMIC AMYLOIDOSIS; NEPHROTIC SYNDROME; PREDNISONE; MELPHALAN	Background: Patients with AL amyloidosis and congestive heart failure have a very poor prognosis. To date, the recovery of these patients has not been described in detail. Objective: To determine the frequency and characteristics of regression of disease in patients with congestive heart failure due to AL amyloidosis. Design: Review of patients with systemic AL amyloidosis. Setting: An international referral center for amyloidosis in the United States. Patients: 140 patients with congestive heart failure due to AL amyloidosis who were seen between 1983 and 1994. Measurements: Functional status, Doppler echocardiography, and objective measurements of disease activity. Results: 3 of 140 patients (2.1%) had marked resolution of congestive heart failure and evidence for remission of disease activity. All 3 had been treated with melphalan. Conclusions: Melphalan appears to have had a favorable effect in 3 patients with AL amyloidosis and heart failure. The abolition of light chains that was seen in these 3 patients suggests that light-chain toxicity may play a role in the genesis of heart failure in patients with AL amyloidosis.	BOSTON UNIV, SCH MED, BOSTON, MA 02118 USA	Boston University								BRADSTOCK K, 1978, AUST NZ J MED, V8, P176, DOI 10.1111/j.1445-5994.1978.tb04507.x; BROWN MP, 1990, MED J AUSTRALIA, V152, P95, DOI 10.5694/j.1326-5377.1990.tb124466.x; BUXBAUM JN, 1979, AM J MED, V67, P867, DOI 10.1016/0002-9343(79)90747-2; CARROLL JD, 1982, AM J CARDIOL, V49, P9, DOI 10.1016/0002-9149(82)90270-3; FRITZ DA, 1989, AM J MED, V86, P245, DOI 10.1016/0002-9343(89)90280-5; GERTZ MA, 1986, MAYO CLIN PROC, V61, P218, DOI 10.1016/S0025-6196(12)61853-9; GERTZ MA, 1991, BLOOD, V77, P257; KAUFMAN BM, 1976, P ROY SOC MED, V69, P707, DOI 10.1177/003591577606900926; KIPROV DD, 1984, LANCET, V2, P1183; KYLE RA, 1995, SEMIN HEMATOL, V32, P45; KYLE RA, 1985, AM J MED, V79, P708, DOI 10.1016/0002-9343(85)90521-2; KYLE RA, 1978, BLOOD, V52, P818; KYLE RA, 1982, ARCH INTERN MED, V142, P1445, DOI 10.1001/archinte.142.8.1445; LEDINGHAM JGG, 1990, AM J NEPHROL, V10, P52, DOI 10.1159/000168194; LOWENSTEIN J, 1970, NEW ENGL J MED, V282, P128, DOI 10.1056/NEJM197001152820304; PRADO MJ, 1996, BRAZ J MED BIOL RES, V26, P633; Skinner M, 1996, AM J MED, V100, P290, DOI 10.1016/S0002-9343(97)89487-9; SKINNER M, 1994, AMYLOID AMYLOIDOSIS, P232	18	43	45	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					481	484		10.7326/0003-4819-125-6-199609150-00009	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779461				2022-12-28	WOS:A1996VF88200010
J	vanBalen, FAM; deMelker, RA; TouwOtten, FWMM				vanBalen, FAM; deMelker, RA; TouwOtten, FWMM			Double-blind randomised trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice	LANCET			English	Article							SECRETORY OTITIS; DECONGESTANT-ANTIHISTAMINE; ANTIMICROBIAL THERAPY; CHILDREN; EFFICACY; ANTIBIOTICS; MANAGEMENT; PATHOGENS; STEROIDS; EAR	Background The treatment of persistent otitis media with effusion (OME) remains controversial, but this condition is the commonest reason for children to require ear, nose, and throat (ENT) surgery, Trials of antibiotics are inconclusive, are often weak methodologically, and have not been done in general practice. Our aim was a trial of an antibiotic for OME in such a population. Methods 433 children, aged 6 months to 6 years, with OME from 57 general practices entered a 3-month watchful waiting period. Of 223 (52%) with persistent bilateral OME, 162 were randomised double-blind to receive co-amoxiclav suspension (20 mg/kg amoxicillin, 5 mg/kg clavulanate potassium) or matching placebo, orally three times a day for 14 days. All cases also received xylometazoline 0.25% decongestant nosedrops thrice daily. Of the 61 not randomised, 13 children were referred to an ENT surgeon and parents refused consent in 48 cases. The main outcome measures were persistent OME in both ears and in one or both ears, as assessed clinically and by tympanometry. Analysis was by intention-to-treat. Findings 79 children in the treatment group and 70 in the placebo group were analysed for efficacy. 3 withdrew in the co-amoxiclav group (2 lost to follow-up, 1 due to side-effects); 6 withdrew in the placebo group (5 and 1, respectively). In addition, 4 tympanograms were uninterpretable in the controls. Compliance was over 90% in both groups, Persistent OME in both ears and in one or both ears were found at significantly lower rates in the co-amoxiclav group than in the controls at the 2-week followup: 53 vs 84% and 77 vs 93%, respectively, Odds ratios adjusted for sex, history of adenoidectomy, and upper respiratory tract infection at follow-up were 0.25 (95% CI 0.11, 0.58, p=0.001) and 0.30 (0.10, 0.89, p=0.03), respectively. Parents of children in the co-amoxiclav group reported significantly more side-effects than those of control children (44 vs 22%, p=0.03). Side-effects were mostly gastrointestinal and mild. Interpretation Our study in a general-practice setting confirmed the positive short-term effect of antibiotic treatment for persistent middle-ear infection. Before referral to an ENT surgeon, children with persistent OME presenting to general practitioners could be considered for such treatment, depending on the individual child and possible adverse sequelae.			vanBalen, FAM (corresponding author), UNIV UTRECHT,DEPT GEN PRACTICE,NL-3584 CG UTRECHT,NETHERLANDS.							BERMAN S, 1994, PEDIATRICS, V93, P353; BLUESTONE CD, 1992, CLIN INFECT DIS, V14, pS197, DOI 10.1093/clinids/14.Supplement_2.S197; CANTEKIN EI, 1980, ANN OTO RHINOL LARYN, V89, P190, DOI 10.1177/00034894800890S344; CANTEKIN EI, 1991, JAMA-J AM MED ASSOC, V266, P3309; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; CORWIN MJ, 1986, INT J PEDIATR OTORHI, V11, P109, DOI 10.1016/S0165-5876(86)80005-2; DEMELKER RA, 1993, BRIT MED J, V306, P5, DOI 10.1136/bmj.306.6869.5; DIAMOND C, 1989, J LARYNGOL OTOL, V103, P369, DOI 10.1017/S0022215100108989; FADEN H, 1994, PEDIATR INFECT DIS J, V13, P609, DOI 10.1097/00006454-199407000-00005; FIELLAU-NIKOLAJSEN M, 1979, Scandinavian Audiology, V8, P181, DOI 10.3109/01050397909076319; FIELLAUNIKOLAJSEN M, 1983, ANN OTO RHINOL LARYN, V92, P172, DOI 10.1177/000348948309200215; GIEBINK GS, 1990, PEDIATR INFECT DIS J, V9, P33, DOI 10.1097/00006454-199001000-00008; HEALY GB, 1984, INT J PEDIATR OTORHI, V8, P13, DOI 10.1016/S0165-5876(84)80021-X; JERGER J, 1970, ARCHIV OTOLARYNGOL, V92, P311; KARMA P, 1988, ACTA OTOLARYNGOL STO, V449, P47; MAKININ ML, 1985, PEDIATRICS, V75, P329; MANDEL EM, 1987, NEW ENGL J MED, V316, P432, DOI 10.1056/NEJM198702193160803; MOLLER P, 1990, J LARYNGOL OTOL, V104, P200, DOI 10.1017/S0022215100112277; PODOSHIN L, 1990, ARCH OTOLARYNGOL, V116, P1404; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; ROSENFELD RM, 1991, ARCH OTOLARYNGOL, V117, P984; ROSENFELD RM, 1992, OTOLARYNG HEAD NECK, V106, P378, DOI 10.1177/019459989210600411; SCHWARTZ RH, 1982, PEDIAT INFECT DIS, V5, P333; STOOL SE, 1994, AHCPR PUBLICATION; THOMSEN J, 1989, ARCH OTOLARYNGOL, V115, P447; TOS M, 1979, ARCH OTOLARYNGOL, V105, P582; *U LEEDS, 1992, U LEEDS B, V4; VANBALEN FAM, 1994, INT J PEDIATR OTORHI, V29, P219, DOI 10.1016/0165-5876(94)90168-6; VANDELISDONK EH, 1991, HUISARTS WET, V34, P426; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344; ZIELHUIS G, 1989, LANCET, V11, P311; ZIELHUIS GA, 1990, INT J EPIDEMIOL, V19, P1037, DOI 10.1093/ije/19.4.1037	32	39	40	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					713	716		10.1016/S0140-6736(96)02511-1	http://dx.doi.org/10.1016/S0140-6736(96)02511-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806290				2022-12-28	WOS:A1996VG37400010
J	Bonnar, J; Sheppard, BL				Bonnar, J; Sheppard, BL			Treatment of menorrhagia during menstruation: Randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-LOSS; NORETHISTERONE; INHIBITORS	Objective-To compare the efficacy and acceptability of ethamsylate, mefenamic acid, and tranexamic acid for treating menorrhagia. Design-Randomised controlled trial. Setting-A university department of obstetrics and gynaecology. Subjects-76 women with dysfunctional uterine bleeding. Interventions-Treatment for five days from day 1 of menses during three consecutive menstrual periods. 27 patients were randomised to take ethamsylate 500 mg six hourly, 23 patients to take mefenamic acid 500 mg eight hourly, and 26 patients to take tranexamic acid 1 g six hourly. Main outcome measures-Menstrual loss measured by the alkaline haematin method in three control menstrual periods and three menstrual periods during treatment; duration of bleeding; patient's estimation of blood loss: sanitary towel usage; the occurrence of dysmenorrhoea; and unwanted events. Results-Ethamsylate did not reduce mean menstrual blood loss whereas mefenamic acid reduced blood loss by 20% (mean blood loss 186 ml before treatment, 148 ml during treatment) and tranexamic acid reduced blood loss by 54% (mean blood loss 164 ml before treatment, 75 ml during treatment). Sanitary towel usage was significantly reduced in patients treated with mefenamic acid and tranexamic acid. Conclusions-Tranexamic acid given during menstruation is a safe and highly effective treatment for excessive bleeding. Patients with dysfunctional uterine bleeding should be offered medical treatment with tranexamic acid before a decision is made about surgery.	COOMBE WOMENS HOSP,DUBLIN,IRELAND	Trinity College Dublin	Bonnar, J (corresponding author), ST JAMES HOSP,TRINITY CTR HLTH SCI,TRINITY COLL,DEPT OBSTET & GYNAECOL,DUBLIN 8,IRELAND.							ANDERSON ABM, 1976, LANCET, V1, P774; Bonnar J, 1980, J Clin Pathol Suppl (R Coll Pathol), V14, P55, DOI 10.1136/jcp.33.Suppl_14.55; Bonnar J, 1983, RES CLIN FORUMS, V5, P27; CAMERON IT, 1990, OBSTET GYNECOL, V76, P85; CAMERON IT, 1988, PROSTAGLANDINS, V34, P99; CHAMBERLAIN G, 1991, BRIT J OBSTET GYNAEC, V98, P707, DOI 10.1111/j.1471-0528.1991.tb13460.x; DOCKERAY CJ, 1989, BRIT J OBSTET GYNAEC, V96, P840, DOI 10.1111/j.1471-0528.1989.tb03325.x; FRASER IS, 1981, OBSTET GYNECOL, V58, P543; HALL P, 1987, BRIT J OBSTET GYNAEC, V94, P554, DOI 10.1111/j.1471-0528.1987.tb03150.x; HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455; HALLBERG L, 1964, SCAND J CLIN LAB INV, V16, P244, DOI 10.3109/00365516409060511; HARRISON RF, 1976, LANCET, V1, P283; Haynes P J, 1980, Int J Gynaecol Obstet, V17, P567; HAYNES PJ, 1977, BRIT J OBSTET GYNAEC, V84, P763, DOI 10.1111/j.1471-0528.1977.tb12490.x; HAYNES PJ, 1979, RES CLIN FORUMS, V1, P73; *INT MED STAT LTD, 1994, UK IREL; JAFFE G, 1973, J INT MED RES, V1, P127; NILSSON L, 1967, ACTA OBSTET GYN SCAN, V46, P572, DOI 10.3109/00016346709158657; PRESTON JT, 1995, BRIT J OBSTET GYNAEC, V102, P401, DOI 10.1111/j.1471-0528.1995.tb11293.x; *ROY COLL GEN PRAC, 1986, MORB STAT GEN PRACT; RYBO G, 1991, CLIN UPDATE SAFETY T, V4, P1; SHEPPARD BL, 1984, CLIN OBSTET GYNAECOL, V11, P227; SHEPPARD BL, 1992, ADV GYNAECOLOGICAL P, P191; SMITH G, 1983, J REPROD IMMUNOL, V5, P39, DOI 10.1016/0165-0378(83)90019-0; Smith SK, 1994, DYSFUNCTIONAL UTERIN, P107	25	173	190	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					579	582						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806245				2022-12-28	WOS:A1996VG10800014
J	Pezzotti, P; Phillips, AN; Dorrucci, M; Lepri, AC; Galai, N; Vlahov, D; Rezza, G; Alliegro, B; Petrucci, A; Sinicco, A; Tarantini, G; Angarano, G; Lazzarin, A; Aiuti, F; Zaccarelli, M; Salassa, B; Castelli, F; Viale, P; Canessa, A; Barbanera, M; Ricchi, E; Ortona, L; Pristera, R; Gafa, S; Tirelli, U				Pezzotti, P; Phillips, AN; Dorrucci, M; Lepri, AC; Galai, N; Vlahov, D; Rezza, G; Alliegro, B; Petrucci, A; Sinicco, A; Tarantini, G; Angarano, G; Lazzarin, A; Aiuti, F; Zaccarelli, M; Salassa, B; Castelli, F; Viale, P; Canessa, A; Barbanera, M; Ricchi, E; Ortona, L; Pristera, R; Gafa, S; Tirelli, U			Category of exposure to HIV and age in the progression to AIDS: Longitudinal study of 1199 people with known dates of seroconversion	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED HOMOSEXUAL MEN; INTRAVENOUS-DRUG-USERS; DISEASE PROGRESSION; TRANSMISSION CATEGORY; LYMPHOCYTES; INCUBATION; RISK; SEX; SURVIVAL	Objectives-To determine whether rate of development of AIDS is affected by category of exposure to HIV and whether the more rapid development found in older subjects persists for each exposure category. Design-Longitudinal study of people with known date of seroconversion to HIV. Setting-16 HIV treatment centres throughout Italy. Subjects-1199 people infected with HIV through use of injected drugs, homosexual sex, or heterosexual sex. Main outcome measures-AIDS as defined by 1987 definition of Centers for Disease Control (including and excluding neoplasms) and by 1993 European definition. Results-225 subjects (18.8%) progressed to AIDS (Centers for Disease Control 1987 definition) during median follow up of 5.8 years. Univariate analyses showed more rapid progression to AIDS for older subjects compared with younger subjects and for homosexual men compared with other exposure categories. The age effect was of similar size in each exposure category and in men and women. In a bivariate model with age and exposure categories simultaneously included as covariates, differences by exposure category disappeared for use of injected drugs and heterosexual sex compared with homosexual sex (relative hazards 1.02 (95% confidence interval 0.71 to 1.45) and 1.07 (0.70 to 1.64) respectively), while the age effect remained (relative hazard 1.55 (1.32 to 1.83) for 10 year increase in age). Analyses using the other definitions for AIDS did not appreciably change these results. Conclusions-There was no evidence of differences in rate of development of AIDS by exposure category, while there was a strong tendency for more rapid development in older subjects for all three groups. This supports the view that external cofactors do not play major role in AIDS pathogenesis but that age is of fundamental importance.	ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON,ENGLAND; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,IL-91010 JERUSALEM,ISRAEL; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Hebrew University of Jerusalem; Johns Hopkins University	Pezzotti, P (corresponding author), IST SUPER SANITA,CTR OPERAT AIDS,EPIDEMIOL & BIOSTAT LAB,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.		Zaccarelli, Mauro/GYV-1093-2022; Galai, Noya/HII-8086-2022; rezza, giovanni/D-4393-2016; PEZZOTTI, PATRIZIO/C-6480-2016; DORRUCCI, MARIA/C-6485-2016; Castelli, Francesco/E-7045-2010; Phillips, Andrew N/B-4427-2008	rezza, giovanni/0000-0003-0268-6790; PEZZOTTI, PATRIZIO/0000-0002-0805-2927; DORRUCCI, MARIA/0000-0002-8543-6430; Phillips, Andrew N/0000-0003-2384-4807				ANCELLEPARK R, 1993, LANCET, V341, P441, DOI 10.1016/0140-6736(93)93040-8; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; BROWN SM, 1974, ARCH INTERN MED, V134, P1001, DOI 10.1001/archinte.134.6.1001; CARRE N, 1994, AIDS, V8, P797, DOI 10.1097/00002030-199406000-00012; CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; DONAHOE RM, 1986, CLIN IMMUNOL IMMUNOP, V41, P254, DOI 10.1016/0090-1229(86)90109-1; ESKILD A, 1994, SCAND J SOC MED, V4, P309; GALAI N, 1995, J ACQ IMMUN DEF SYND, V8, P66; GIESECKE J, 1988, BRIT MED J, V297, P99, DOI 10.1136/bmj.297.6641.99; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JASON J, 1989, JAMA-J AM MED ASSOC, V261, P725, DOI 10.1001/jama.261.5.725; KEET IPM, 1994, AIDS, V8, P1577, DOI 10.1097/00002030-199411000-00009; Lee E.T., 1992, STATISTICAL METHODS; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MARGOLICK JB, 1994, ARCH INTERN MED, V154, P869, DOI 10.1001/archinte.154.8.869; MARIOTTO AB, 1992, AM J EPIDEMIOL, V135, P428, DOI 10.1093/oxfordjournals.aje.a116303; MIENTJES GH, 1991, AIDS, V5, P35, DOI 10.1097/00002030-199101000-00005; OPERSKALSKI EA, 1995, J INFECT DIS, V172, P648, DOI 10.1093/infdis/172.3.648; PETERSON PK, 1990, AIDS, V4, P869, DOI 10.1097/00002030-199009000-00006; PEZZOTTI P, 1992, J ACQ IMMUN DEF SYND, V5, P745; REZZA G, 1994, HIV EPIDEMIOLOGY, P279; REZZA G, 1989, AIDS, V3, P87, DOI 10.1097/00002030-198902000-00006; ROSENBERG PS, 1994, AIDS, V8, P803, DOI 10.1097/00002030-199406000-00013; VELLA S, 1995, AIDS, V9, P51, DOI 10.1097/00002030-199501000-00007; VEUGELERS PJ, 1994, AIDS, V8, P1471, DOI 10.1097/00002030-199410000-00015; VONOVERBECK J, 1994, AIDS, V8, P1307, DOI 10.1097/00002030-199409000-00014; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WEINBERG K, 1995, NEW ENGL J MED, V332, P182, DOI 10.1056/NEJM199501193320310; 1992, AIDS, V6, P421; 1987, MMWR-MORBID MORTAL W, V36, pS1; 1994, AIDS, V8, P911	32	91	92	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					583	586						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806246				2022-12-28	WOS:A1996VG10800015
J	Stirland, H; Husain, OAN; Butler, EB; Cater, S; Russell, KS				Stirland, H; Husain, OAN; Butler, EB; Cater, S; Russell, KS			Cervical screening in the inner cities: Is the opportunistic approach still worthwhile?	BRITISH MEDICAL JOURNAL			English	Article									WOMENS NATIONWIDE CANC CONTROL CAMPAIGN,LONDON EC2A 3AR,ENGLAND; WILSON HOSP,MERTON SUTTON & WANDSWORTH HLTH AUTHOR,MITCHAM CR4 4TP,SURREY,ENGLAND									*CANC RES CAMP, 1995, FACT SHEET 1O MARCH; HUSAIN OAN, 1990, J ROY SOC MED, V83, P319, DOI 10.1177/014107689008300515; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; *NAT COORD NETW, 1994, REP 1 5 YEARS NHS CE, P4; THORNTON J, 1989, COMMUNITY MED, V11, P290	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					600	600						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806251				2022-12-28	WOS:A1996VG10800020
J	Robbins, TW				Robbins, TW			Refining the taxonomy of memory	SCIENCE			English	Editorial Material							PARKINSONS-DISEASE				Robbins, TW (corresponding author), UNIV CAMBRIDGE,DEPT EXPT PSYCHOL,DOWNING ST,CAMBRIDGE CB2 3EB,ENGLAND.		Robbins, Trevor W/A-7551-2008	Robbins, Trevor/0000-0003-0642-5977				Estes W.K., 1994, CLASSIFICATION COGNI; GAFLAN D, 1992, BEHAV NEUROSCI, V106, P30; Graybiel AM, 1995, CURR OPIN NEUROBIOL, V5, P733, DOI 10.1016/0959-4388(95)80100-6; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; LANGE KW, 1992, PSYCHOPHARMACOLOGY, V107, P394, DOI 10.1007/BF02245167; OWEN AM, 1995, NEUROPSYCHOLOGIA, V33, P1, DOI 10.1016/0028-3932(94)00098-A; OWEN AM, 1992, BRAIN, V115, P1727, DOI 10.1093/brain/115.6.1727; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; Suzuki WA, 1996, SEMIN NEUROSCI, V8, P3, DOI 10.1006/smns.1996.0002; [No title captured]	10	24	24	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1996	273	5280					1353	1354		10.1126/science.273.5280.1353	http://dx.doi.org/10.1126/science.273.5280.1353			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF610	8801630				2022-12-28	WOS:A1996VF61000031
J	Barr, H; Shepherd, NA; Dix, A; Roberts, DJH; Tan, WC; Krasner, N				Barr, H; Shepherd, NA; Dix, A; Roberts, DJH; Tan, WC; Krasner, N			Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX	LANCET			English	Article							ESOPHAGUS; ADENOCARCINOMA; PHOTOSENSITIZATION; ABLATION; MUCOSA; CANCER; ACID	Background High-grade dysplasia in columnar-lined (Barrett's) oesophagus presents a difficult therapeutic dilemma. Choices for management are endoscopic surveillance to detect a cancer or oesophagectomy. One carries the risk of missing invasive cancer, the other carries worrying morbidity and mortality. We have used endoscopic photodynamic therapy to eradicate high-grade dysplasia. Methods After the oral administration of 5-aminolaevulinic acid, the accumulation of the endogenously generated photosensitiser protoporphyrin IX was measured with quantitative fluorescence microscopy. Five patients with histologically confirmed high-grade dysplasia were treated with endoscopic photodynamic therapy with 630 nm laser light to activate the photosensitiser. Findings Protoporphyrin IX accumulated in the dysplastic epithelium rather than the adjacent stroma. Selective necrosis of the dysplastic epithelium in columnar-lined oesophagus occurred after light activation. High-grade dysplasia was eradicated in all patients and squamous regeneration occurred after acid suppression with a proton-pump inhibitor. There were no complications or recurrence of dysplasia after 26-44 months' endoscopic and histological follow-up. In two cases we saw non-dysplastic Barrett's epithelium underneath regenerative squamous mucosa. Interpretation High-grade dysplasia in columnar-lined oesophagus can be eradicated by endoscopic photodynamic therapy with endogenously generated PpIX. Remaining non-dysplastic Barrett's epithelium will require surveillance, but overall the technique has interrupted or delayed the worsening of the dysplasia through to carcinoma. This technique may prevent the need for surgical excision in these patients.	UNIV LEEDS,CTR PHOTOBIOL & PHOTODYNAM THERAPY,LEEDS,W YORKSHIRE,ENGLAND; AINTREE HOSP,DEPT GASTROENTEROL,LIVERPOOL,MERSEYSIDE,ENGLAND	University of Leeds; Aintree University Hospitals NHS Foundation Trust	Barr, H (corresponding author), GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTERSHIRE ROYAL & CRANFIELD UNIV INST MED SCI,GLOUCESTER GL1 3NN,ENGLAND.		Shepherd, Neil A/AAV-3565-2021					ALTORKI NK, 1991, AM J SURG, V161, P97, DOI 10.1016/0002-9610(91)90367-M; BERENSON MM, 1993, GASTROENTEROLOGY, V104, P1686, DOI 10.1016/0016-5085(93)90646-T; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; GORE S, 1993, ALIMENT PHARM THERAP, V7, P923; GRANT WE, 1993, LANCET, V342, P147, DOI 10.1016/0140-6736(93)91347-O; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; LAUKKA MA, 1995, GASTROINTEST ENDOSC, V42, P59, DOI 10.1016/S0016-5107(95)70245-8; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; Loh CS, 1996, GUT, V38, P71, DOI 10.1136/gut.38.1.71; MCFARLANE GJ, 1994, J R SOC MED, V78, P334; OVERHOLT BF, 1995, GASTROINTEST ENDOSC, V42, P64, DOI 10.1016/S0016-5107(95)70246-6; REGULA J, 1995, GUT, V36, P67, DOI 10.1136/gut.36.1.67	12	280	285	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					584	585		10.1016/S0140-6736(96)03054-1	http://dx.doi.org/10.1016/S0140-6736(96)03054-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774572				2022-12-28	WOS:A1996VF18600013
J	MacDonagh, SE; Masters, J; Helps, BA; Tookey, PA; Ades, AE; Gibb, DM				MacDonagh, SE; Masters, J; Helps, BA; Tookey, PA; Ades, AE; Gibb, DM			Descriptive survey of antenatal HIV testing in London: Policy, uptake, and detection	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSMISSION				MacDonagh, SE (corresponding author), INST CHILD HLTH,EPIDEMIOL & BIOSTAT UNIT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.		Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387; Gibb, Diana/0000-0002-9738-5490				CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1994, GUID OFF VOL NAM HIV; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Holland F J, 1994, J Med Screen, V1, P176	4	20	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					532	533						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789982				2022-12-28	WOS:A1996VF29400022
J	Merlo, J; Ranstam, J; Liedholm, H; Hedblad, B; Lindberg, G; Lindblad, U; Isacsson, SO; Melander, A; Rastam, L				Merlo, J; Ranstam, J; Liedholm, H; Hedblad, B; Lindberg, G; Lindblad, U; Isacsson, SO; Melander, A; Rastam, L			Incidence of myocardial infarction in elderly men being treated with antihypertensive drugs: Population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; HYPERTENSION; SWEDEN; MALMO; BORN; MORTALITY	Objective-To analyse the association between use of antihypertensive treatment, diastolic blood pressure, and long term incidence of ischaemic cardiac events in elderly men. Design-Population based cohort study. Baseline examination in 1982-3 and follow up for up to 10 years. Setting-Malmo, Sweden. Subjects-484 randomly selected men born in 1914 and living in Malmo during 1982. Main outcome measures-Observational comparisons of incidence rates and rate and hazard ratios of ischaemic cardiac events (myocardial infarction or death due to chronic ischaemic cardiac disease). Results-The crude incidence rate of ischaemic cardiac events was higher in those subjects who were taking antihypertensive drugs than in those who were not (rate ratio 2.6 (95% confidence interval 1.7 to 3.9)). After adjustment for potential confounders (differences in baseline smoking habits, blood pressure, time since diagnosis of hypertension, ischaemic or other cardiovascular disease, hypercholesterolaemia, hypertriglyceridaemia, diabetes mellitus, obesity, and raised serum creatinine concentration) this rate was reduced but still raised (hazard ratio 1.9 (1.0 to 3.7)). In men with diastolic blood pressure >90 mm Hg, antihypertensive treatment was associated with a twofold increase in the incidence of ischaemic cardiac events (rate ratio 2.0 (1.1 to 3.6)), which vanished after adjustment for potential confounders (hazard ratio 1.1 (0.5 to 2.6)). In those subjects with diastolic blood pressure less than or equal to 90 mm Hg, antihypertensive treatment was associated with fourfold increase in incidence (rate ratio 3.9 (2.1 to 7.1)), which remained after adjustment for potential confounders (hazard ratio 3.8 (1.3 to 11.0)). Conclusion-Antihypertensive treatment may increase the risk of myocardial infarction in elderly men with treated diastolic blood pressures less than or equal to 90 mm Hg.	NEPI FDN,STOCKHOLM,SWEDEN; NEPI FDN,MALMO,SWEDEN; SKARABORG INST,SKOVDE,SWEDEN		Merlo, J (corresponding author), LUND UNIV,MALMO UNIV HOSP,DEPT COMMUNITY MED,S-20502 MALMO,SWEDEN.		Merlo, Juan/E-2136-2011; Ranstam, Jonas/A-4386-2009	Merlo, Juan/0000-0001-8379-9708; Ranstam, Jonas/0000-0002-8287-7273				CLAUSEN J, 1992, J HUM HYPERTENS, V6, P53; COLLINS R, 1994, TXB HYPERTENSION, P1156; CRUICKSHANK JM, 1987, LANCET, V1, P581; CUSHMAN WC, 1995, DRUG AGING, V7, P88, DOI 10.2165/00002512-199507020-00003; CUTLER JA, 1989, HYPERTENSION S1, V13, P136; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; HANSON BS, 1987, SOC SCI MED, V25, P849, DOI 10.1016/0277-9536(87)90043-8; HEDBLAD B, 1992, HYPERTENSION, V20, P32, DOI 10.1161/01.HYP.20.1.32; ISACSSON S, 1972, ACTA MED SCAND, P537; JANZON L, 1986, J EPIDEMIOL COMMUN H, V40, P174, DOI 10.1136/jech.40.2.174; KAPLAN NM, 1990, LANCET, V335, P1093; LANGER RD, 1993, HYPERTENSION, V22, P551, DOI 10.1161/01.HYP.22.4.551; LINDBLAD U, 1994, BRIT MED J, V308, P681, DOI 10.1136/bmj.308.6930.681; Rose G, 1968, CARDIOVASCULAR SURVE; THURMER HL, 1994, J HYPERTENS, V12, P481; Waaler H T, 1988, Acta Med Scand Suppl, V723, P17; YANO K, 1983, J CHRON DIS, V36, P569, DOI 10.1016/0021-9681(83)90145-5; Zanchetti A, 1993, Blood Press, V2, P86, DOI 10.3109/08037059309077535; 1995, INFORMATION MED PROD, V3, P178	19	44	44	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					457	461						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776312				2022-12-28	WOS:A1996VE08000019
J	Greaves, MW; Wall, PD				Greaves, MW; Wall, PD			Pathophysiology of itching	LANCET			English	Review							HUMAN-SKIN; TOPICAL CAPSAICIN; ATOPIC-DERMATITIS; ARACHIDONIC-ACID; HISTAMINE; PRURITUS; INTERLEUKIN-2; INFLAMMATION; MECHANISM; EPIDERMIS	Itching is the predominant symptom of skin disease but it is ill-understood and a challenge for future research. Even the major nerve pathways for itch, and its relationship to pain are debatable. In inflamed skin, histamine plays a major role and its mode of release from mast cells in, for example, chronic urticaria is now better appreciated. Tachykinins including substance P and cytokines including interleukin-2 are evidently important peripherally. Opioid mu-receptor-dependent processes activate inhibitory circuits in the central nervous system and regulate the extent of intensity and quality of perceived itch. It is proposed that stimulation of large areas of skin such as by scratching, generates inhibitory activity which suppresses itch excitation. Therapeutic intervention based upon understanding these regulatory processes is a real prospect.	UNIV MED & DENT NEW JERSEY,ST THOMAS HOSP,SHERRINGTON DEPT PHYSIOL,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Greaves, MW (corresponding author), UNIV MED & DENT NEW JERSEY,ST THOMAS HOSP,ST JOHNS INST DERMATOL,LONDON SE1 7EH,ENGLAND.							ARRANG JM, 1987, NATURE, V327, P117, DOI 10.1038/327117a0; BLACK AK, 1985, BRIT J CLIN PHARMACO, V20, P185, DOI 10.1111/j.1365-2125.1985.tb05059.x; BRANDES LJ, 1993, ADV BIOSCI, V89, P31; BRENEMAN DL, 1992, J AM ACAD DERMATOL, V26, P91, DOI 10.1016/0190-9622(92)70013-6; CHURCH MK, 1991, INT ARCH ALLER A IMM, V94, P310, DOI 10.1159/000235393; COOK J, 1980, BRIT J PHARMACOL, V69, P579, DOI 10.1111/j.1476-5381.1980.tb07907.x; DAVIES MG, 1980, BRIT J CLIN PHARMACO, V9, P461; DOWD P M, 1988, Skin Pharmacology, V1, P30; Fiebiger E, 1995, J CLIN INVEST, V96, P2606, DOI 10.1172/JCI118325; GASPARI AA, 1987, JAMA-J AM MED ASSOC, V258, P1624, DOI 10.1001/jama.258.12.1624; GREAVES MV, 1973, BMJ-BRIT MED J, V2, P608; GREAVES MW, 1971, BMJ-BRIT MED J, V2, P258, DOI 10.1136/bmj.2.5756.258; GREAVES MW, 1981, BRIT MED J, V282, P2008, DOI 10.1136/bmj.282.6281.2008; HAGERMARK O, 1980, J INVEST DERMATOL, V74, P459; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; HEBRA FV, 1868, DIS SKIN, V2, P257; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; JONES EA, 1992, JAMA-J AM MED ASSOC, V268, P3359, DOI 10.1001/jama.268.23.3359; JORIZZO JL, 1983, EUR J PHARMACOL, V87, P67, DOI 10.1016/0014-2999(83)90051-1; KRAUSE L, 1983, BRIT MED J, V287, P1199, DOI 10.1136/bmj.287.6400.1199; Lewis T., 1927, HEART, V14, P139; LYNN B, 1992, SKIN PHARMACOL, V5, P9; MARKS R, 1977, BRIT J CLIN PHARMACO, V4, P367, DOI 10.1111/j.1365-2125.1977.tb00725.x; ROBERTSON I, 1978, BRIT J CLIN PHARMACO, V5, P319, DOI 10.1111/j.1365-2125.1978.tb01714.x; SCHWORER H, 1993, LANCET, V341, P1277, DOI 10.1016/0140-6736(93)91178-O; TSAI JC, 1994, ARCH DERMATOL RES, V286, P242, DOI 10.1007/BF00387595; WAHLGREN CF, 1990, ACTA DERM-VENEREOL, V70, P323; WAHLGREN CF, 1995, ARCH DERMATOL RES, V287, P572, DOI 10.1007/BF00374079; Wall PD, 1995, TXB PAIN; WALLENGREN J, 1991, J AM ACAD DERMATOL, V24, P286, DOI 10.1016/S0190-9622(08)80609-3	30	142	148	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					938	940		10.1016/S0140-6736(96)04328-0	http://dx.doi.org/10.1016/S0140-6736(96)04328-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843816				2022-12-28	WOS:A1996VL09700016
J	Borst, JGG; Sakmann, B				Borst, JGG; Sakmann, B			Calcium influx and transmitter release in a fast CNS synapse	NATURE			English	Article							SQUID GIANT SYNAPSE; RAT MEDIAL NUCLEUS; NERVE-TERMINALS; TRAPEZOID BODY; ION-BINDING; CURRENTS; CHANNELS; FACILITATION; HIPPOCAMPUS; EXOCYTOSIS	CALCIUM entry through presynaptic calcium channels controls the release of neurotransmitter(1). It is not known whether the putative calcium sensor that triggers this rapid neurotransmitter release is close enough to be activated by the large increase in the Ca2+ concentration (calcium 'domain') reached within nanometres of a single calcium channel or whether many channels have to open(2), We tested this in a calyx-type synapse in the rat medial nucleus of the trapezoid body, We compared the quantal content of postsynaptic currents with the presynaptic calcium current that flows during an action potential, and the results suggest that more than 60 calcium channels open for each vesicle that is released, In addition, we dialysed terminals with the slow calcium buffer EGTA, which reduced phasic transmitter release at concentrations as low as 1 mM. These results indicate that the distance that calcium ions must diffuse to reach the calcium sensor is relatively long, and that therefore Ca2+ entry through multiple calcium channels is needed to release a vesicle.			Borst, JGG (corresponding author), MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, JAHNSTR 29, D-69120 HEIDELBERG, GERMANY.							ADLER EM, 1991, J NEUROSCI, V11, P1496; Borst JGG, 1995, J PHYSIOL-LONDON, V489, P825, DOI 10.1113/jphysiol.1995.sp021095; CASEY MA, 1988, NEUROSCIENCE, V24, P189, DOI 10.1016/0306-4522(88)90322-3; COOPER RL, 1995, J NEUROSCI METH, V61, P67, DOI 10.1016/0165-0270(95)00024-O; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P574, DOI 10.1113/jphysiol.1954.sp005130; DIAMOND JS, 1995, NEURON, V15, P1097, DOI 10.1016/0896-6273(95)90098-5; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; FORSYTHE ID, 1993, P ROY SOC B-BIOL SCI, V251, P151, DOI 10.1098/rspb.1993.0022; GOLLASCH M, 1992, AM J PHYSIOL, V263, pC948, DOI 10.1152/ajpcell.1992.263.5.C948; HAYDON PG, 1994, NEURON, V13, P1275, DOI 10.1016/0896-6273(94)90414-6; HERRINGTON J, 1994, PULSE CONTROL V4 0 I; HOCHNER B, 1991, NEUROSCI LETT, V125, P215, DOI 10.1016/0304-3940(91)90032-O; ISAACSON JS, 1995, NEURON, V15, P875, DOI 10.1016/0896-6273(95)90178-7; JACKSON MB, 1991, P NATL ACAD SCI USA, V88, P380, DOI 10.1073/pnas.88.2.380; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P483, DOI 10.1098/rspb.1965.0016; Katz B., 1969, RELEASE NEURAL TRANS; KORN H, 1994, ADV SEC MESS PHOSPH, V29, P301; LIM NF, 1990, NATURE, V344, P449, DOI 10.1038/344449a0; LLINAS R, 1982, P NATL ACAD SCI-BIOL, V79, P2415, DOI 10.1073/pnas.79.7.2415; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MARTIN AR, 1964, J PHYSIOL-LONDON, V175, P1; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Neher E., 1986, EXPT BRAIN RES SERIE, P80; SCHWEIZER FE, 1995, NEURON, V14, P689, DOI 10.1016/0896-6273(95)90213-9; SMITH PD, 1984, ANAL BIOCHEM, V143, P188, DOI 10.1016/0003-2697(84)90575-X; STANLEY EF, 1993, NEURON, V11, P1007, DOI 10.1016/0896-6273(93)90214-C; WU LG, 1995, J NEUROPHYSIOL, V73, P1965, DOI 10.1152/jn.1995.73.5.1965	30	476	483	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	1996	383	6599					431	434		10.1038/383431a0	http://dx.doi.org/10.1038/383431a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837774				2022-12-28	WOS:A1996VL46300060
J	Chiang, C; Ying, LTT; Lee, E; Young, KE; Corden, JL; Westphal, H; Beachy, PA				Chiang, C; Ying, LTT; Lee, E; Young, KE; Corden, JL; Westphal, H; Beachy, PA			Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function	NATURE			English	Article							MOTOR-NEURON INDUCTION; TERMINAL CLEAVAGE PRODUCT; FLOOR PLATE; MOUSE EMBRYO; NOTOCHORD DEVELOPMENT; SCLEROTOME INDUCTION; POLARIZING ACTIVITY; XENOPUS-LAEVIS; EXPRESSION; DROSOPHILA	Targeted gene disruption in the mouse shows that the Sonic hedgehog (Shh) gene plays a critical role in patterning of vertebrate embryonic tissues, including the brain and spinal cord, the axial skeleton and the limbs. Early defects are observed in the establishment or maintenance of midline structures, such as the notochord and the floorplate, and later defects include absence of distal limb structures, cyclopia, absence of ventral cell types within the neural tube, and absence of the spinal column and most of the ribs. Defects in all tissues extend beyond the normal sites of Shh transcription, confirming the proposed role of Shh proteins as an extracellular signal required for the tissue-organizing properties of several vertebrate patterning centres.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOL BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	Chiang, C (corresponding author), NIH, LAB MAMMALIAN GENET & DEV, BETHESDA, MD 20892 USA.							Adelmann HB, 1936, Q REV BIOL, V11, P284, DOI 10.1086/394509; Adelmann HB, 1936, Q REV BIOL, V11, P161, DOI 10.1086/394504; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; BONCINELLI E, 1993, J NEUROBIOL, V24, P1356, DOI 10.1002/neu.480241008; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Cohn MJ, 1996, TRENDS GENET, V12, P253, DOI 10.1016/0168-9525(96)10030-5; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, DEVELOPMENT, V121, P2337; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Fitz C R, 1994, Neuroimaging Clin N Am, V4, P263; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; HINCHLIFFE JR, 1981, J EMBRYOL EXP MORPH, V62, P63; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAI CJ, 1995, DEVELOPMENT, V121, P2349; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LOPEZMARTINEZ A, 1995, CURR BIOL, V5, P791, DOI 10.1016/S0960-9822(95)00156-4; Macdonald R, 1996, CURR OPIN NEUROBIOL, V6, P49, DOI 10.1016/S0959-4388(96)80008-0; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MANSOURI A, 1994, J CELL SCI, P35; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; PONG TM, 1992, DEVELOPMENT, V115, P657; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; Sordino P, 1996, TRENDS ECOL EVOL, V11, P114, DOI 10.1016/0169-5347(96)81089-5; TALBOT WS, 1995, NATURE, V378, P150, DOI 10.1038/378150a0; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	51	2413	2494	2	175	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	1996	383	6599					407	413		10.1038/383407a0	http://dx.doi.org/10.1038/383407a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837770				2022-12-28	WOS:A1996VL46300053
J	Ware, JE; Bayliss, MS; Rogers, WH; Kosinski, M; Tarlov, AR				Ware, JE; Bayliss, MS; Rogers, WH; Kosinski, M; Tarlov, AR			Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service systems - Results from the medical outcomes study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGED CARE; PREPAID; SPECIALTIES; PERFORMANCE; SF-36; TRIAL	Objective.-To compare physical and mental health outcomes of chronically ill adults, including elderly and poor subgroups, treated in health maintenance organization (HMO) and fee-for-service (FFS) systems. Study Design.-A 4-year observational study of 2235 patients (18 to 97 years of age) with hypertension, non-insulin-dependent diabetes mellitus (NIDDM), recent acute myocardial infarction, congestive heart failure, and depressive disorder sampled from HMO and FFS systems in 1986 and followed up through 1990. Those aged 65 years and older covered under Medicare and low-income patients (200% of poverty) were analyzed separately. Setting and Participants.-Offices of physicians practicing family medicine, internal medicine, endocrinology, cardiology, and psychiatry, in HMO and FFS systems of care. Types of practices included both prepaid group (72% of patients) and independent practice association (28%) types of HMOs, large multispecialty groups, and solo or small, single-specialty practices in Boston, Mass, Chicago, Ill, and Los Angeles, Calif. Outcome Measures.-Differences between initial and 4-year follow-up scores of summary physical and mental health scales from the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) for all patients and practice settings. Results.-On average, physical health declined and mental health remained stable during the 4-year follow-up period, with physical declines larger for the elderly than for the nonelderly (P<.001). In comparisons between HMO and FFS systems, physical and mental health outcomes did not differ for the average patient; however, they did differ for subgroups of the population differing in age and poverty status. For elderly patients (those aged 65 years and older) treated under Medicare, declines in physical health were more common in HMOs than in FFS plans (54% vs 28%; P<.001). In 1 site, mental health outcomes were better (P<.05) for elderly patients in HMOs relative to FFS but not in 2 other sites. For patients differing in poverty status, opposite patterns of physical health (P<.05) and for mental health (P<.001) outcomes were observed across systems; outcomes favored FFS over HMOs for the poverty group and favored HMOs over FFS for the nonpoverty group. Conclusions.-During the study period, elderly and poor chronically ill patients had worse physical health outcomes in HMOs than in FFS systems; mental health outcomes varied by study site and patient characteristics. Current health care plans should carefully monitor the health outcomes of these vulnerable subgroups.	TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Tufts University; Harvard University; Harvard T.H. Chan School of Public Health	Ware, JE (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, HLTH INST, BOX 345, 750 WASHINGTON ST, BOSTON, MA 02111 USA.							BEATON DE, 1994, QUAL LIFE RES, V3, P50; BERRY S, 1992, MEASURING FUNCTIONIN, P48; Beusterien KM, 1996, J GERIATR PSYCH NEUR, V9, P13, DOI 10.1177/089198879600900103; Beusterien KM, 1996, J AM SOC NEPHROL, V7, P763; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V271, P1487, DOI 10.1001/jama.271.19.1487; Cook T.D., 1976, HDB IND ORG PSYCHOL, P223; DAVIES AR, 1993, HLTH CARE OUTCOMES I; DIEHR P, 1994, MED CARE S4, V32, pAS164; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; *GROUP HLTH ASS AM, 1995, PATT HMO ENR; HAWKER G, 1995, J RHEUMATOL, V22, P1193; KANTZ ME, 1992, MED CARE, V30, pMS240, DOI 10.1097/00005650-199205001-00024; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; Krumholz HM, 1996, MED CARE, V34, P754, DOI 10.1097/00005650-199608000-00003; LURIE N, 1992, JAMA-J AM MED ASSOC, V267, P3300, DOI 10.1001/jama.267.24.3300; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Okamoto LJ, 1996, ANN ALLERG ASTHMA IM, V76, P455, DOI 10.1016/S1081-1206(10)63463-1; Phillips R C, 1992, J Heart Valve Dis, V1, P42; RAMPAL P, 1994, SCAND J GASTROENTERO, V29, P44, DOI 10.3109/00365529409091421; RETCHIN SM, 1992, HEALTH SERV RES, V27, P651; ROGERS WH, 1993, ARCH GEN PSYCHIAT, V50, P517; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; SAFRAN DG, 1994, JAMA-J AM MED ASSOC, V271, P1579, DOI 10.1001/jama.271.20.1579; SHIELY JC, IN PRESS SF 36 HLTH; *STAT CORP, 1993, STAT REF MAN REL 3 1, V3, P3; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Stewart AL, 1992, MEASURING FUNCTIONIN; Stucki G, 1995, Arthritis Care Res, V8, P174, DOI 10.1002/art.1790080310; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; TEMPLE PC, 1995, J AM COLL SURGEONS, V181, P17; Ware J.E, 1994, PHYS MENTAL HLTH SUM; WARE JE, 1986, LANCET, V1, P1017; WARE JE, 1995, MED CARE, V33, pAS264, DOI 10.1097/00005650-199501001-00005; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P3298, DOI 10.1001/jama.262.23.3298	38	448	451	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1996	276	13					1039	1047		10.1001/jama.1996.03540130037027	http://dx.doi.org/10.1001/jama.1996.03540130037027			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK035	8847764				2022-12-28	WOS:A1996VK03500024
J	Rossing, P; Hougaard, P; BorchJohnsen, K; Parving, HH				Rossing, P; Hougaard, P; BorchJohnsen, K; Parving, HH			Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL PROTEINURIA; IMPROVED SURVIVAL; MICROALBUMINURIA; NEPHROPATHY; MELLITUS; PROGNOSIS; ONSET; COMPLICATIONS; CAPTOPRIL; DEATH	Objective-To evaluate the prognostic significance of microalbuminuria and overt diabetic nephropathy and other putative risk factors for cardiovascular and all cause mortality in insulin dependent diabetes. Design-Ten year observational follow up study. Setting-Outpatient diabetic clinic in a tertiary referral centre. Subjects-All 939 adults with insulin dependent diabetes (duration of diabetes five years or more) attending the clinic in 1984; 593 had normal urinary albumin excretion (less than or equal to 30 mg/24 h), 181 persistent microalbuminuria (31-299 mg/24 h), and 165 overt nephropathy (greater than or equal to 300 mg/24 h). Main outcome measure-All cause and cardiovascular mortality. Results-Fifteen per cent of patients (90/593) with normoalbuminuria, 25% (45/181) with microalbuminuria, and 44% (72/165) with overt nephropathy at baseline died during follow up. Cox multiple regression analysis identified the following significant predictors of all cause mortality: male sex (relative risk 2.03; 95% confidence interval 1.37 to 3.02), age (1.07; 1.06 to 1.08), height (0.96; 0.94 to 0.98), smoking (1.51; 1.09 to 2.08), social class V versus social class IV (1.70; 1.25 to 2.31), log(10) urinary albumin excretion (1.45; 1.18 to 1.77), hypertension (1.63; 1.18 to 2.25), log(10) serum creatinine concentration (8.96; 3.34 to 24.08), and haemoglobin A(1c) concentration (1.11; 1.03 to 1.20). Age, smoking, microalbuminuria, overt nephropathy, and hypertension were significant predictors of cardiovascular mortality. Mortality in patients with microalbuminuria was only slightly increased compared with that in patients with normoalbuminuria. Median survival time after the onset of overt diabetic nephropathy was 13.9 years (95% confidence interval 11.8 to 17.2 years). Conclusions-Abnormally increased urinary albumin excretion and other potentially modifiable risk factors such as hypertension, smoking, poor glycaemic control, and social class predict increased mortality in insulin dependent diabetes. Microalbuminuria by itself confers only a small increase in mortality. The prognosis of patients with overt diabetic nephropathy has improved, probably owing to effective antihypertensive treatment.	NOVO NORDISK AS,STAT HRT CNS GH,HLTH CARE DEV,DK-2880 BAGSVAERD,DENMARK; GLOSTRUP UNIV HOSP,DEPT MED C,CTR PREVENT MED,GLOSTRUP,DENMARK	Novo Nordisk; University of Copenhagen	Rossing, P (corresponding author), STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK.		rossing, peter/AAZ-3415-2021; rossing, peter/AAH-7879-2021	rossing, peter/0000-0002-1531-4294; 				ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; ANDERSEN PK, 1993, SPRINGER SERIES STAT, P152; BORCHJOHNSEN K, 1993, BRIT MED J, V306, P1722, DOI 10.1136/bmj.306.6894.1722; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; COX DR, 1972, J R STAT SOC B, V34, P187; DECKERT T, 1978, DIABETOLOGIA, V14, P363, DOI 10.1007/BF01228130; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; FORSBLOM CM, 1992, BRIT MED J, V305, P1051, DOI 10.1136/bmj.305.6861.1051; GALL MA, 1995, DIABETOLOGIA, V38, pA215; GALL MA, 1995, DIABETES, V44, P1303, DOI 10.2337/diabetes.44.11.1303; GOULD MM, 1993, BMJ-BRIT MED J, V306, P240, DOI 10.1136/bmj.306.6872.240; HANSEN EJ, 1982, DISTRIBUTION LIVING, P1; Herbert PR, 1993, CIRCULATION, V88, P1437; Jarrett R J, 1984, Diabet Med, V1, P17; Knowles H C Jr, 1971, Trans Assoc Am Physicians, V84, P95; KROLEWSKI AS, 1987, AM J CARDIOL, V59, P750, DOI 10.1016/0002-9149(87)91086-1; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; MARMOT MG, 1984, LANCET, V1, P1003; MATHIESEN ER, 1989, DIABETOLOGIA, V32, P884, DOI 10.1007/BF00297455; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MESSENT JWC, 1992, KIDNEY INT, V41, P836, DOI 10.1038/ki.1992.128; MOGENSEN CE, 1985, UREMIA INVEST, V9, P85, DOI 10.3109/08860228509088195; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; PARVING HH, 1989, BRIT MED J, V299, P230, DOI 10.1136/bmj.299.6693.230; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P550, DOI 10.1530/acta.0.1000550; PARVING HH, 1988, BMJ-BRIT MED J, V296, P156, DOI 10.1136/bmj.296.6616.156; Parving HH, 1996, KIDNEY INT, V49, P1778, DOI 10.1038/ki.1996.266; PARVING HH, 1996, KIDNEY, P1864; PEDERSEN MM, 1992, DIABETOLOGIA, V35, pA60; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; ROSSING P, 1995, BRIT MED J, V310, P296, DOI 10.1136/bmj.310.6975.296; SAWICKI PT, 1995, J HYPERTENS, V13, P933, DOI 10.1097/00004872-199508000-00015; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; VIBERTI GC, 1982, LANCET, V1, P1430; 1995, BRIT MED J, V311, P973; 1993, NEW ENGL J MED, V329, P977	39	359	367	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					779	784						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842069				2022-12-28	WOS:A1996VK56600021
J	Lemaitre, B; Nicolas, E; Michaut, L; Reichhart, JM; Hoffmann, JA				Lemaitre, B; Nicolas, E; Michaut, L; Reichhart, JM; Hoffmann, JA			The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults	CELL			English	Article							DORSAL-VENTRAL PATTERN; NF-KAPPA-B; SIGNAL-TRANSDUCTION PATHWAY; INSECT IMMUNITY; INNATE IMMUNITY; SERINE PROTEASE; EMBRYONIC POLARITY; IL-1 RECEPTOR; HOST-DEFENSE; TOLL GENE	The cytokine-induced activation cascade of NF-KB in mammals and the activation of the morphogen dorsal in Drosophila embryos show striking structural and functional similarities (Toll/IL-1, Cactus/1-kappa B, and dorsal/NF-kappa B). Here we demonstrate that these parallels extend to the immune response of Drosophila. In particular, the intracellular components of the dorsoventral signaling pathway (except for dorsal) and the extracellular Toll ligand, spatzle, control expression of the antifungal peptide gene drosomycin in adults. We also show that mutations in the Toll signaling pathway dramatically reduce survival after fungal infection. Antibacterial genes are induced either by a distinct pathway involving the immune deficiency gene (imd) or by combined activation of both imd and dorsoventral pathways.			Lemaitre, B (corresponding author), INST BIOL MOL & CELLULAIRE,UPR 9022 CNRS,15 RUE RENE DESCARTES,F-67084 STRASBOURG,FRANCE.		Lemaitre, Bruno/T-8146-2019	Lemaitre, Bruno/0000-0001-7970-1667				ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; ASLING B, 1995, INSECT BIOCHEM MOLEC, V25, P511, DOI 10.1016/0965-1748(94)00091-C; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; BULET P, 1993, J BIOL CHEM, V268, P14893; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; DELOTTO R, 1986, NATURE, V323, P688, DOI 10.1038/323688a0; DIMARCQ JL, 1994, EUR J BIOCHEM, V221, P201, DOI 10.1111/j.1432-1033.1994.tb18730.x; DINESHKUMAR SP, 1995, P NATL ACAD SCI USA, V92, P4175, DOI 10.1073/pnas.92.10.4175; ENGSTROM Y, 1993, J MOL BIOL, V232, P327, DOI 10.1006/jmbi.1993.1392; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; FLYG C, 1988, GENET RES, V52, P51, DOI 10.1017/S0016672300027300; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GERTTULA S, 1988, GENETICS, V119, P123; Gross I, 1996, NUCLEIC ACIDS RES, V24, P1238, DOI 10.1093/nar/24.7.1238; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HECHT PM, 1993, GENETICS, V135, P405; Heguy A., 1992, J BIOL CHEM, V267, P2604; Hetru C., 1994, PERSPECTIVES IMMUNIT, P167; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; Ip T.Y., 1993, CELL, V75, P753; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; KAPPLER C, 1993, EMBO J, V12, P1561, DOI 10.1002/j.1460-2075.1993.tb05800.x; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PETERSEN UM, 1995, EMBO J, V14, P3146, DOI 10.1002/j.1460-2075.1995.tb07317.x; Reichhart J.M., 1993, CR HEBD ACAD SCI, V316, P1207; ROSETTO M, 1995, BIOCHEM BIOPH RES CO, V209, P111, DOI 10.1006/bbrc.1995.1477; ROTH S, 1991, DEVELOPMENT, V112, P371; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH C, 1994, GENETICS, V136, P1355; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SUN SC, 1991, EUR J BIOCHEM, V196, P247, DOI 10.1111/j.1432-1033.1991.tb15811.x; TATEI K, 1995, MOL CELL BIOL, V15, P3627; TRYSELIUS Y, 1992, EUR J BIOCHEM, V204, P395, DOI 10.1111/j.1432-1033.1992.tb16648.x; Vey A., 1986, P89; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; WICKER C, 1990, J BIOL CHEM, V265, P22493	55	2749	2970	15	312	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					973	983		10.1016/S0092-8674(00)80172-5	http://dx.doi.org/10.1016/S0092-8674(00)80172-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808632	Green Published, Bronze			2022-12-28	WOS:A1996VJ44300015
J	Qiu, XY; Culp, JS; DiLella, AG; Hellmig, B; Hoog, SS; Janson, CA; Smith, WW; AbdelMeguid, SS				Qiu, XY; Culp, JS; DiLella, AG; Hellmig, B; Hoog, SS; Janson, CA; Smith, WW; AbdelMeguid, SS			Unique fold and active site in cytomegalovirus protease	NATURE			English	Article							SIMPLEX VIRUS TYPE-1; CLEAVAGE SITES; PROTEINASE; SUBSTRATE; IDENTIFICATION; EXPRESSION; DOMAIN; SERINE; GENE	HUMAN herpesviruses are responsible for a variety of diseases. They are divided into three subfamilies: alpha includes herpes simplex viruses (HSV-1 and HSV-2) and varicella-zoster virus (VZV); beta includes cytomegalovirus (CMV) and human herpes-virus-6 (HHV-6); and gamma includes Epstein-Barr virus (EBV). Each virus encodes a serine protease that is essential for its replication(1-14) and is a potential target for therapeutic intervention. Human CMV is a ubiquitous opportunistic pathogen that can result in life-threatening infections in congenitally infected infants, immunocompromised individuals and immunosuppressed cancer or transplant patients(15). Here we report the crystal structure of human CMV protease at 2.5 Angstrom resolution. The structure reveals a fold that has not been reported for any other serine protease, and an active site consisting of a novel catalytic triad in which the third member is a histidine instead of an aspartic acid, or possibly a catalytic tetrad consisting of a serine, two histidines and an aspartic acid. An unusual dimer interface that is important to the protease activity has also been identified.	SMITHKLINE BEECHAM PHARMACEUT,DEPT MACROMOL SCI,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT PROT BIOCHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOL GENET,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline								ALFORD CA, 1990, VIROLOGY, P1981; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAUM EZ, 1993, J VIROL, V67, P497, DOI 10.1128/JVI.67.1.497-506.1993; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURCK PJ, 1994, J VIROL, V68, P2937, DOI 10.1128/JVI.68.5.2937-2946.1994; CHOTHIA C, 1982, BIOCHEMISTRY-US, V21, P3955, DOI 10.1021/bi00260a009; COX GA, 1995, J VIROL, V69, P4524, DOI 10.1128/JVI.69.7.4524-4528.1995; Darke PL, 1996, J BIOL CHEM, V271, P7445, DOI 10.1074/jbc.271.13.7445; DILANNI CL, 1993, J BIOL CHEM, V268, P25449; GAO M, 1994, J VIROL, V68, P3702, DOI 10.1128/JVI.68.6.3702-3712.1994; HOLWERDA BC, 1994, J BIOL CHEM, V269, P25911; HOWARD AJ, 1994, J APPL CRYSTALLOGR A, V47, P110; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LIU FY, 1993, J VIROL, V67, P1300, DOI 10.1128/JVI.67.3.1300-1309.1993; LIU FY, 1992, P NATL ACAD SCI USA, V89, P2076, DOI 10.1073/pnas.89.6.2076; Margosiak SA, 1996, BIOCHEMISTRY-US, V35, P5300, DOI 10.1021/bi952842u; MCKEE DE, 1993, PRACTICAL PROTEIN CR; OBOYLE IL, 1993, J BIOL CHEM, V270, P4753; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PERONA JJ, 1995, PROTEIN SCI, V4, P337; STEVENS JT, 1994, EUR J BIOCHEM, V226, P361, DOI 10.1111/j.1432-1033.1994.tb20060.x; WEINHEIMER SP, 1993, J VIROL, V67, P5813, DOI 10.1128/JVI.67.10.5813-5822.1993; WELCH AR, 1995, J VIROL, V69, P341, DOI 10.1128/JVI.69.1.341-347.1995; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993	27	147	153	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					275	279		10.1038/383275a0	http://dx.doi.org/10.1038/383275a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805707				2022-12-28	WOS:A1996VH31500059
J	Forrest, AP; Stewart, HJ; Everington, D; Prescott, RJ; McArdle, CS; Harnett, AN; Smith, DC; George, WD				Forrest, AP; Stewart, HJ; Everington, D; Prescott, RJ; McArdle, CS; Harnett, AN; Smith, DC; George, WD			Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial	LANCET			English	Article							AXILLARY DISSECTION; RADIOTHERAPY; LUMPECTOMY; QUADRANTECTOMY; MASTECTOMY; SURGERY	Background To determine whether, when primary breast cancer is treated by local excision supported by systemic therapy appropriate to the oestrogen receptor status (ER) of the tumour, local radiotherapy can be avoided. Methods We carried out a randomised controlled trial in 585 patients aged less than 70 years with primary breast cancers of 4 cm or less in size in four specialist units and seven other hospitals in Scotland. After local excision of the tumour (1 cm margin) and an axillary lymph-node clearance or sample, all patients received systemic therapy with oral tamoxifen 20 mg daily or six 3-weekly intravenous bolus injections of cyclophosphamide 600 mg, methotrexate 50 mg, and fluorouracil 600 mg per m(2), depending upon the ER concentration in the primary tumour. Patients were then randomly allocated to postoperative radical radiotherapy (50 Gy to breast with boost to the tumour bed) or to no further local treatment, The median follow-up of living patients was 5.7 years. The primary analysis was by intention to treat but since some patients did not receive systemic therapy appropriate to their ER status, a subsidiary analysis was restricted to 464 patients in whom all details of the protocol had been observed. Findings In the primary analysis survival was equal in the radiotherapy and non-radiotherapy groups (hazard ratio [HR] 0.98, 95% CI 0.67-1.44). Event-free survival showed an advantage in the irradiated patients (HR 0.54, 95% CI 0.39-0.74), largely due to fewer loco-regional relapses (HR 0.20, 95% CI 0.12-0.33). The relapse rate in the ipsilateral breast was 24.5% in the non-irradiated group and 5.8% following breast irradiation. The subsidiary analysis confirmed these findings and indicated the advantage of radiotherapy irrespective of ER concentration. There was a non-significant trend towards fewer distant metastases in the irradiated group. Interpretation After local excision of a primary breast cancer, we conclude that radiotherapy to the residual breast tissue is advisable even when selective adjuvant systemic therapy is given.	UNIV EDINBURGH,WESTERN GEN HOSP,MED STAT UNIT,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,WESTERN GEN HOSP,DEPT SURG,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; BEATSON ONCOL CTR,DEPT RADIOTHERAPY,GLASGOW,LANARK,SCOTLAND; VICTORIA INFIRM,DEPT SURG,GLASGOW G42 9TY,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT SURG,GLASGOW,LANARK,SCOTLAND	University of Edinburgh; University of Edinburgh; Beatson Oncology Centre; University of Glasgow	Forrest, AP (corresponding author), UNIV EDINBURGH,SCH MED,SCOTTISH CANC TRIALS OFF,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							CLARK RM, 1992, JNCI-J NATL CANCER I, V84, P683, DOI 10.1093/jnci/84.9.683; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; Hawkins R A, 1981, Breast Cancer Res Treat, V1, P245, DOI 10.1007/BF01806264; Hayward JL, 1983, CONSERVATIVE MANAGEM, P77; Leake R, 1987, STEROID HORMONES PRA, P67; LILJEGREN G, 1994, JNCI-J NATL CANCER I, V86, P717, DOI 10.1093/jnci/86.9.717; MACMILLAN RD, 1994, BRIT J SURG, V81, P56, DOI 10.1002/bjs.1800810119; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; SARRAZIN D, 1984, CANCER, V53, P1209, DOI 10.1002/1097-0142(19840301)53:5<1209::AID-CNCR2820530531>3.0.CO;2-Y; STEWART HJ, 1989, LANCET, V2, P168; STEWART HJ, 1984, LANCET, V2, P1096; VANDALEN R, 1995, BREAST, V4, P231; VERONESI U, 1995, J NATL CANCER I, V87, P19, DOI 10.1093/jnci/87.1.19; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; VERONESI U, 1990, EUR J CANCER, V26, P671, DOI 10.1016/0277-5379(90)90114-9; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; 1987, LANCET, V2, P171; 1990, ANN ONCOL, V1, P30; 1993, LANCET, V341, P1293	21	307	317	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					708	713		10.1016/S0140-6736(96)02133-2	http://dx.doi.org/10.1016/S0140-6736(96)02133-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806289				2022-12-28	WOS:A1996VG37400009
J	[Anonymous]				[Anonymous]			Child protection: Medical responsibilities	BRITISH MEDICAL JOURNAL			English	Article																		*DEP HLTH, 1988, WORK TOG; *DEP HLTH, 1995, CHILD PROT MED RESP	2	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1996	313	7058					671	672						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8811762				2022-12-28	WOS:A1996VH16500026
J	Luo, ZJ; Tzivion, G; Belshaw, PJ; Vavvas, D; Marshall, M; Avruch, J				Luo, ZJ; Tzivion, G; Belshaw, PJ; Vavvas, D; Marshall, M; Avruch, J			Oligomerization activates c-Raf-1 through a Ras-dependent mechanism	NATURE			English	Article							SIGNAL-TRANSDUCTION; 14-3-3 PROTEIN; KINASE RAF; BINDING; DOMAIN	THE c-Raf-1 proto-oncoprotein is a Ras-GTP-regulated protein kinase(1) that associates in situ with 14-3-3 proteins(2,3), which are naturally dimeric(4,5). In COS cells, recombinant Raf is found in oligomeric assemblies. To examine whether induced oligomerization can alter Raf kinase activity, sequences encoding the FK506-binding protein FKBP12 were fused to the amino terminus of c-Raf-1, introducing a binding site for FK506. Oligomerization of recombinant FKBP-Raf in situ, induced by the addition of the dimeric FK506 derivative FK1012A, activated Raf kinase activity at least half as well as epidermal growth factor (EGF). As with EGF, activation of FKBP-Raf by FK1012A is entirely Ras-GTP dependent. Thus oligomerization of Raf per se promotes Raf activation through a Ras-dependent mechanism.	MASSACHUSETTS GEN HOSP, MED SERV, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, DEPT CHEM & CHEM BIOL, CAMBRIDGE, MA 02138 USA; INDIANA UNIV, DEPT MED, DIV HEMATOL & ONCOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute; Harvard University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Luo, ZJ (corresponding author), MASSACHUSETTS GEN HOSP, DIABET UNIT, BOSTON, MA 02129 USA.		Luo, Zhijun/AAE-9302-2019; Tzivion, Guri/D-8954-2011	Luo, Zhijun/0000-0001-8105-5289; Vavvas, Demetrios/0000-0002-8622-6478				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BETSHAW PJ, 1996, P NATL ACAD SCI USA, V93, P4604; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; JOHNSON LN, 1996, J CELL, V85, P149; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Okada T, 1996, J BIOL CHEM, V271, P4671; Pruschy M N, 1994, Chem Biol, V1, P163, DOI 10.1016/1074-5521(94)90006-X; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	22	200	217	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1996	383	6596					181	185		10.1038/383181a0	http://dx.doi.org/10.1038/383181a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774885				2022-12-28	WOS:A1996VG14800056
J	Ratcliffe, PJ; Dudley, CRK; Higgins, RM; Firth, JD; Smith, B; Morris, PJ				Ratcliffe, PJ; Dudley, CRK; Higgins, RM; Firth, JD; Smith, B; Morris, PJ			Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression	LANCET			English	Article							ALLOGRAFT RECIPIENTS; CYCLOSPORINE MONOTHERAPY; BLOOD-PRESSURE; THERAPY; KIDNEY; HYPERLIPIDEMIA; AZATHIOPRINE; POSTTRANSPLANTATION; HYPERTENSION; PREDNISONE	Background The combination of cyclosporin, azathioprine, and prednisolone (triple immunosuppression) is the most commonly used immunosuppressive regimen early after renal transplantation, but the risks and benefits of maintaining the steroid component of this regimen in the long term are uncertain. Methods A randomised controlled trial of steroid withdrawal was conducted among renal transplant patients receiving triple immunosuppression. Between one and six years after transplantation, 100 such patients were randomised either to reduce prednisolone treatment to zero over about four months or to maintain their triple immunosuppression unchanged. Outcome was analysed according to ''intention-to-treat''. Findings In 42 (86%) of 49 patients allocated to steroid withdrawal, complete steroid withdrawal was achieved. Although these patients did not experience defined acute rejection episodes, insidious increases in plasma creatinine were observed more frequently in this group than in the controls. In 97 patients surviving one year after trial entry, plasma creatinine exceeded the baseline by more than 25% at some time in the first year in 25 (53%) of 47 in the steroid withdrawal group compared with 9 (18%) of 50 in the control group (p<0.001, chi-square test). In some cases these increases were transient. However, when corrected for the baseline (entry) value significant differences between groups were apparent in both mean plasma creatinine and mean creatinine clearance; mean (SD) plasma creatinine values at entry, immediately after withdrawal, and at one year were 138 (27), 151 (36), and 150 (36) mu mol/L in the steroid withdrawal group versus 138 (34), 140 (51), and 139 (47) mu mol/L in the control group (p=0.017, analysis of covariance). Steroid withdrawal patients showed a further rise in mean plasma creatinine to 160 (44) and 161 (65) mu mol/L at two and three years from trial entry. Changes in several clinical and metabolic indices were also observed in association with steroid withdrawal. Blood pressure declined but the reduction was incompletely sustained, being more evident immediately after steroid withdrawal than at one year. Total cholesterol declined about 1 mmol/L in the steroid withdrawal group. Other changes associated with steroid withdrawal were reductions in white cell count and haemoglobin and increases in plasma phosphate and alkaline phosphatase. Interpretation Late steroid withdrawal is feasible in most patients with stable graft function on triple immunosuppression and has potentially beneficial metabolic effects. However, a substantial proportion of patients show a reduction in graft function, indicating a need for caution in considering the longterm outcome.			Ratcliffe, PJ (corresponding author), CHURCHILL HOSP,OXFORD TRANSPLANT CTR,OXFORD OX3 7LJ,ENGLAND.			Ratcliffe, Peter/0000-0002-2853-806X				BITTAR AE, 1990, TRANSPLANTATION, V50, P987, DOI 10.1097/00007890-199012000-00018; CAINE RY, 1978, LANCET, V2, P1323; FABREGA AJ, 1994, SURGERY, V116, P792; GRIFFIN PJA, 1987, TRANSPLANTATION, V43, P505, DOI 10.1097/00007890-198704000-00010; HRICIK DE, 1994, TRANSPLANTATION, V57, P979, DOI 10.1097/00007890-199404150-00001; HRICIK DE, 1992, TRANSPLANTATION, V53, P1232, DOI 10.1097/00007890-199206000-00012; HRICIK DE, 1992, TRANSPLANTATION, V54, P868, DOI 10.1097/00007890-199211000-00019; HRICIK DE, 1993, J AM SOC NEPHROL, V4, P1300; HRICIK DE, 1992, TRANSPLANTATION, V53, P41, DOI 10.1097/00007890-199201000-00007; HRICIK DE, 1993, KIDNEY INT, V44, pS26; INGULLI E, 1993, TRANSPLANTATION, V55, P1029, DOI 10.1097/00007890-199305000-00015; INGULLI E, 1993, KIDNEY INT, V44, pS36; JOHNSON RWG, 1989, TRANSPLANT P, V21, P1581; KASISKE BL, 1987, MEDICINE, V66, P309, DOI 10.1097/00005792-198707000-00003; KUPIN W, 1988, TRANSPLANTATION, V45, P53, DOI 10.1097/00007890-198801000-00012; LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003-4819-112-5-352; MAIORCA R, 1988, TRANSPLANT P, V20, P121; OCONNELL PJ, 1988, CLIN TRANSPLANT, V2, P102; OPELZ G, 1994, TRANSPLANTATION, V58, P443, DOI 10.1097/00007890-199408270-00009; PIRSCH JD, 1991, TRANSPLANT P, V23, P1363; REISMAN L, 1990, TRANSPLANTATION, V49, P76, DOI 10.1097/00007890-199001000-00017; RESTIFO AC, 1989, TRANSPLANT P, V21, P1604; SCHULAK JA, 1990, TRANSPLANTATION, V49, P327, DOI 10.1097/00007890-199002000-00020; SINCLAIR NRS, 1992, CAN MED ASSOC J, V147, P645; SOLEZ K, 1993, KIDNEY INT, V44, P411, DOI 10.1038/ki.1993.259; STRATTA RJ, 1988, TRANSPLANTATION, V45, P323, DOI 10.1097/00007890-198802000-00015; TAMM M, 1991, TRANSPLANT P, V23, P997; TARANTINO A, 1991, TRANSPLANTATION, V52, P53, DOI 10.1097/00007890-199107000-00011; VANBUREN CT, 1993, TRANSPL P, V25, P30; 1982, LANCET, V2, P57	30	152	152	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					643	648		10.1016/S0140-6736(96)02510-X	http://dx.doi.org/10.1016/S0140-6736(96)02510-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782754				2022-12-28	WOS:A1996VF60900009
J	Chen, CMA; Kraut, N; Groudine, M; Weintraub, H				Chen, CMA; Kraut, N; Groudine, M; Weintraub, H			I-mf, a novel myogenic repressor, interacts with members of the MyoD family	CELL			English	Article							LOOP-HELIX PROTEINS; TRANSCRIPTION FACTOR; XENOPUS-EMBRYOS; KAPPA-B; MUSCLE DIFFERENTIATION; NUCLEAR-LOCALIZATION; SKELETAL-MUSCLE; CELL LINEAGE; DNA-BINDING; NEURAL-TUBE	During embryogenesis, cells from the ventral and dorsal parts of the somites give rise to sclerotome and dermomyotome, respectively. Dermomyotome contains skeletal muscle precursors that are determined by the MyoD family of myogenic factors. We have isolated a novel myogenic repressor, I-mf (Inhibitor of MyoD family), which is highly expressed in the sclerotome. In contrast, MyoD family members are concentrated in the dermomyotome. We demonstrate that I-mf inhibits the transactivation activity of the MyoD family and represses myogenesis. I-mf associates with MyoD family members and retains them in the cytoplasm by masking their nuclear localization signals. I-mf can also interfere with the DNA binding activity of MyoD family members. We postulate that I-mf plays an important role in the patterning of the somite early in development.	FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104; UNIV WASHINGTON,FRED HUTCHINSON CANC RES CTR,PROGRAM MOL & CELLULAR BIOL,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle								AOYAMA H, 1988, DEVELOPMENT, V104, P15; BANROQUES J, 1986, CELL, V46, P837, DOI 10.1016/0092-8674(86)90065-6; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; BUCKINGHAM M, 1994, CURR BIOL, V4, P61, DOI 10.1016/S0960-9822(00)00014-2; BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; CHEN CMA, 1996, THESIS U WASHINGTON; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; GOULDING M, 1994, DEVELOPMENT, V120, P957; HARVEY RP, 1991, P NATL ACAD SCI USA, V88, P9198, DOI 10.1073/pnas.88.20.9198; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KOPAN R, 1994, DEVELOPMENT, V120, P2385; LEE JE, 1995, SCIENCE, V268, P835; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MINER JH, 1992, DEVELOPMENT, V114, P853; MUNSTERBERG AE, 1995, DEVELOPMENT, V121, P651; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTT MO, 1991, DEVELOPMENT, V111, P1097; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; RONG PM, 1992, DEVELOPMENT, V115, P657; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SMITH TH, 1994, J CELL BIOL, V127, P95, DOI 10.1083/jcb.127.1.95; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; STERN CD, 1988, DEVELOPMENT, V104, P231; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUN XH, 1991, CELL, V66, P423, DOI 10.1016/0092-8674(81)90003-9; TAM PPL, 1994, ANAT EMBRYOL, V189, P275; TRAWICK JD, 1989, J BIOL CHEM, V264, P7005; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG YQ, 1992, DEV DYNAM, V194, P222, DOI 10.1002/aja.1001940307; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WHITESIDE ST, 1993, J CELL SCI, V104, P949; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	53	114	126	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					731	741		10.1016/S0092-8674(00)80148-8	http://dx.doi.org/10.1016/S0092-8674(00)80148-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797820	Bronze			2022-12-28	WOS:A1996VG37200007
J	DiazMeco, MT; Municio, MM; Frutos, S; Sanchez, P; Lozano, J; Sanz, L; Moscat, J				DiazMeco, MT; Municio, MM; Frutos, S; Sanchez, P; Lozano, J; Sanz, L; Moscat, J			The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C	CELL			English	Article							NF-KAPPA-B; ZETA-SUBSPECIES BLOCKS; XENOPUS-LAEVIS OOCYTES; TUMOR-NECROSIS-FACTOR; SPHINGOMYELIN PATHWAY; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; INTRACELLULAR RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; PHORBOL ESTERS	The atypical PKCs are involved in a number of important cellular functions, including cell proliferation. We report here that the product of the par-4 gene specifically interacts with the regulatory domains of zeta PKC and lambda/iota PKC, which dramatically inhibits their enzymatic activity. This is particularly challenging, because expression of par-4 has been shown to correlate with growth inhibition and apoptosis. Results are shown here demonstrating that the expression of par-4 in NIH-3T3 cells induces morphological changes typical of apoptosis, which are abrogated by cotransfection of either wild-type zeta PKC or lambda/iota PKC, but not by their respective kinase-inactive mutants. These findings support a role for the atypical PKC subspecies in the control of cell growth and survival.	UNIV AUTONOMA MADRID,CONSEJO SUPER INVEST CIENT,CTR BIOL MOL,MADRID 28049,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Sánchez-Gómez, Pilar/K-8256-2014; Moscat, Jorge/A-7011-2009; Lozano, José/C-2760-2014	Sánchez-Gómez, Pilar/0000-0002-0709-4973; Lozano, José/0000-0002-8187-2833; Diaz-Meco, Maria/0000-0003-0147-0998				AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Folgueira L, 1996, J VIROL, V70, P223, DOI 10.1128/JVI.70.1.223-231.1996; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MORYA S, 1996, P NATL ACAD SCI USA, V93, P151; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO Y, 1989, P NATL ACAD SCI USA, V86, P3099; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; TOKER A, 1994, J BIOL CHEM, V269, P32358; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WAYS DK, 1992, J BIOL CHEM, V267, P4799; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YANG ZH, 1993, J BIOL CHEM, V268, P20520; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHANG YH, 1995, ENDOCRINOLOGY, V136, P4157, DOI 10.1210/en.136.10.4157	49	325	341	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					777	786		10.1016/S0092-8674(00)80152-X	http://dx.doi.org/10.1016/S0092-8674(00)80152-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797824	Bronze			2022-12-28	WOS:A1996VG37200011
J	Sijbers, AM; deLaat, WL; Ariza, RR; Biggerstaff, M; Wei, YF; Moggs, JG; Carter, KC; Shell, BK; Evans, E; deJong, MC; Rademakers, S; deRooij, J; Jaspers, NGJ; Hoeijmakers, JHJ; Wood, RD				Sijbers, AM; deLaat, WL; Ariza, RR; Biggerstaff, M; Wei, YF; Moggs, JG; Carter, KC; Shell, BK; Evans, E; deJong, MC; Rademakers, S; deRooij, J; Jaspers, NGJ; Hoeijmakers, JHJ; Wood, RD			Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease	CELL			English	Article							NUCLEOTIDE-EXCISION-REPAIR; COMPLEMENTATION GROUP-F; SACCHAROMYCES-CEREVISIAE; PROTEINS RAD1; GENE ERCC-1; FUNCTIONAL DOMAINS; GROUP-A; RECOMBINATION; COMPLEX; PURIFICATION	Nucleotide excision repair, which is defective in xeroderma pigmentosum (XP), involves incision of a DNA strand on each side of a lesion, We isolated a human gene homologous to yeast Rad1 and found that it corrects the repair defects of XP group F as well as rodent groups 4 and 11. Causative mutations and strongly reduced levels of encoded protein were identified in XP-F patients. The XPF protein was purified from mammalian cells in a tight complex with ERCC1. This complex is a structure-specific endonuclease responsible for the 5' incision during repair. These results demonstrate that the XPF, ERCC4, and ERCC11 genes are equivalent, complete the isolation of the XP genes that form the core nucleotide excision repair system, and solve the catalytic function of the XPF-containing complex.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND; ERASMUS UNIV ROTTERDAM,DEPT CELL BIOL & GENET,CTR MED GENET,NL-3000 DR ROTTERDAM,NETHERLANDS; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	Erasmus University Rotterdam; GlaxoSmithKline; Human Genome Sciences Inc			Hoeijmakers, Jan/AAX-6972-2021; de rooij, johan/C-1325-2019; Wood, Richard D/M-6319-2018; Sijbers, Anneke/G-6661-2016	Wood, Richard D/0000-0002-9495-6892; Rodriguez Ariza, Rafael/0000-0002-0338-7306; de Laat, Wouter/0000-0002-6393-595X				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BUSCH D, 1989, MUTAGENESIS, V4, P349, DOI 10.1093/mutage/4.5.349; BUSCH D, 1994, MUTAGENESIS, V9, P301, DOI 10.1093/mutage/9.4.301; CARR AM, 1994, MOL CELL BIOL, V14, P2029, DOI 10.1128/MCB.14.3.2029; DAVIES AA, 1995, J BIOL CHEM, V270, P24638, DOI 10.1074/jbc.270.42.24638; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FRIEDBERG EC, 1995, DNA REPAIR; HABRAKEN Y, 1995, J BIOL CHEM, V270, P30194; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HATA H, 1991, CANCER RES, V51, P195; HOBOHM U, 1995, J MOL BIOL, V251, P390, DOI 10.1006/jmbi.1995.0442; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEHMANN AR, 1994, MUTAT RES, V315, P41, DOI 10.1016/0921-8777(94)90026-4; LIU P, 1993, MUTAGENESIS, V8, P199, DOI 10.1093/mutage/8.3.199; LIU Q, 1995, BIOTECHNIQUES, V18, P470; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; NORRIS PG, 1988, J AM ACAD DERMATOL, V18, P1185, DOI 10.1016/S0190-9622(88)70121-8; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; REARDON JT, 1993, COLD SPRING HARB SYM, V58, P605, DOI 10.1101/SQB.1993.058.01.067; REYNOLDS P, 1987, MOL CELL BIOL, V7, P1012, DOI 10.1128/MCB.7.3.1012; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER R, 1991, FEBS LETT, V283, P203, DOI 10.1016/0014-5793(91)80588-T; SEKELSKY JJ, 1995, GENETICS, V141, P619; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SUNG P, 1993, J BIOL CHEM, V268, P26391; THOMPSON LH, 1994, P NATL ACAD SCI USA, V91, P6855, DOI 10.1073/pnas.91.15.6855; TOMKINSON AE, 1994, BIOCHEMISTRY-US, V33, P5305, DOI 10.1021/bi00183a038; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; TROELSTRA C, 1992, GENOMICS, V12, P745, DOI 10.1016/0888-7543(92)90304-B; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANDUIN M, 1989, MUTAT RES, V217, P83, DOI 10.1016/0921-8777(89)90059-1; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VANVUUREN AJ, 1995, MUTAT RES-DNA REPAIR, V337, P25, DOI 10.1016/0921-8777(95)00009-9; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; WOOD RD, 1982, MUTAT RES, V95, P505, DOI 10.1016/0027-5107(82)90281-0; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; YAMAMURA K, 1989, BRIT J DERMATOL, V121, P471, DOI 10.1111/j.1365-2133.1989.tb15514.x; ZELLE B, 1980, MUTAT RES, V73, P157, DOI 10.1016/0027-5107(80)90144-X	55	421	440	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					811	822		10.1016/S0092-8674(00)80155-5	http://dx.doi.org/10.1016/S0092-8674(00)80155-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797827	Green Published, Bronze			2022-12-28	WOS:A1996VG37200014
J	Parry, RG; Crowe, A; Stevens, JM; Mason, JC; Roderick, P				Parry, RG; Crowe, A; Stevens, JM; Mason, JC; Roderick, P			Referral of elderly patients with severe renal failure: Questionnaire survey of physicians	BRITISH MEDICAL JOURNAL			English	Article							REPLACEMENT THERAPY		ST MARYS HOSP,WESSEX RENAL & TRANSPLANT UNIT,PORTSMOUTH PO3 6AD,HANTS,ENGLAND; SOUTHAMPTON GEN HOSP,WESSEX INST PUBL HLTH MED,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton								CHALLAH S, 1984, BRIT MED J, V288, P1119, DOI 10.1136/bmj.288.6424.1119; KHAN IH, 1994, Q J MED, V87, P559; MIGNON F, 1993, KIDNEY INT, V43, pS18; PONTICELLI C, 1989, Q J MED, V72, P667; WILLIAMS AJ, 1989, Q J MED, V72, P749	5	41	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					466	466						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776315				2022-12-28	WOS:A1996VE08000022
J	Berwick, DM				Berwick, DM			Payment by capitation and the quality of care .5.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-MAINTENANCE-ORGANIZATIONS; FEE-FOR-SERVICE; TRADITIONAL MEDICAID PLANS; MANAGED-CARE; FINANCIAL INCENTIVES; RANDOMIZED TRIAL; ELDERLY PATIENTS; PHYSICIANS; OUTCOMES; PREPAID				Berwick, DM (corresponding author), INST HEALTHCARE IMPROVEMENT, BOSTON, MA 02215 USA.							BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; CAREY T, 1990, J CLIN EPIDEMIOL, V43, P1213, DOI 10.1016/0895-4356(90)90022-H; CAREY TS, 1991, HEALTH SERV RES, V26, P165; CAREY TS, 1990, ARCH INTERN MED, V150, P2369, DOI 10.1001/archinte.150.11.2369; CARLISLE DM, 1992, AM J PUBLIC HEALTH, V82, P1626, DOI 10.2105/AJPH.82.12.1626; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V271, P1487, DOI 10.1001/jama.271.19.1487; CLEMENT DG, 1994, JAMA-J AM MED ASSOC, V272, P276; EMANUEL EJ, 1995, JAMA-J AM MED ASSOC, V273, P323, DOI 10.1001/jama.273.4.323; Freund D A, 1989, Health Care Financ Rev, V11, P81; *GEN ACC OFF, 1996, GAOHEHS9663; *GEN ACC OFF, 1988, GAOHRD8929; *GEN ACC OFF, 1993, GAOHRD9346; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; GOLDFARB S, 1995, ANN INTERN MED, V123, P546, DOI 10.7326/0003-4819-123-7-199510010-00010; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HILLMAN AL, 1992, MED CARE, V30, P136, DOI 10.1097/00005650-199202000-00005; HILLMAN AL, 1991, HEALTH AFFAIR, V10, P138, DOI 10.1377/hlthaff.10.4.138; HILLMAN AL, 1991, HEALTH AFFAIR, V10, P205, DOI 10.1377/hlthaff.10.4.207; HOHLEN MM, 1990, MED CARE, V28, P59, DOI 10.1097/00005650-199001000-00007; Lahdensuo A, 1996, BRIT MED J, V312, P748; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; LURIE N, 1994, ANN INTERN MED, V120, P506, DOI 10.7326/0003-4819-120-6-199403150-00010; LURIE N, 1992, JAMA-J AM MED ASSOC, V267, P3300, DOI 10.1001/jama.267.24.3300; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MURRAY JP, 1992, MED CARE, V30, P252, DOI 10.1097/00005650-199203000-00007; RETCHIN SM, 1990, AM J PUBLIC HEALTH, V80, P411, DOI 10.2105/AJPH.80.4.411; RETCHIN SM, 1990, J GEN INTERN MED, V5, P110, DOI 10.1007/BF02600509; RETCHIN SM, 1992, HEALTH SERV RES, V27, P651; RETCHIN SM, 1991, AM J MED, V90, P236; ROESSNER J, 1993, QUAL CONNECTIONS, V2, P10; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; Selker HP, 1996, ANN INTERN MED, V124, P449, DOI 10.7326/0003-4819-124-4-199602150-00010; 1995, JAMA-J AM MED ASSOC, V273, P330	35	131	131	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1227	1231		10.1056/NEJM199610173351611	http://dx.doi.org/10.1056/NEJM199610173351611			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VN401	8815948				2022-12-28	WOS:A1996VN40100011
J	Michelson, D; Stratakis, C; Hill, L; Reynolds, J; Galliven, E; Chrousos, G; Gold, P				Michelson, D; Stratakis, C; Hill, L; Reynolds, J; Galliven, E; Chrousos, G; Gold, P			Bone mineral density in women with depression	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORTICOTROPIN-RELEASING HORMONE; BIOCHEMICAL MANIFESTATIONS; THERAPEUTIC IMPLICATIONS; TYROSINE-HYDROXYLASE; CUSHINGS-SYNDROME; RAT-BRAIN; NEUROBIOLOGY; OSTEOPOROSIS; POLYMORPHISM; DISORDERS	Background Depression is associated with alterations in behavior and neuroendocrine systems that are risk factors for decreased bone mineral density. This study was undertaken to determine whether women with past or current major depression have demonstrable decreases in bone density. Methods We measured bone mineral density at the hip, spine, and radius in 24 women with past or current major depression and 24 normal women matched for age, body-mass index, menopausal status, and race, using dual-energy x-ray absorptiometry. We also evaluated cortisol and growth hormone secretion, bone metabolism, and vitamin D-receptor alleles. Results AS compared with the normal women, the mean (+/- SD) bone density in the women with past or current depression was 6.5 percent lower at the spine (1.00 +/- 0.15 vs. 1.07 +/- 0.09 g per square centimeter, P=0.02), 13.6 percent lower at the femoral neck (0.76 +/- 0.11 vs, 0.88 +/- 0.11 g per square centimeter, P<0.001), 13.6 percent lower at Ward's triangle (0.70 +/- 0.14 vs. 0.81 +/- 0.13 g per square centimeter, P<0.001), and 10.8 percent lower at the trochanter (0.66+/-0.11 vs. 0.74+/-0.08 g per square centimeter, P<0.001), In addition, women with past or current depression had higher urinary cortisol excretion (71 +/- 29 vs. 51 +/- 19 mu g per day [196 +/- 80 vs. 141 +/- 52 nmol per day], P=0.006), lower serum osteocalcin concentrations (P=0.04), and lower urinary excretion of deoxypyridinoline (P=0.02). Conclusions Past or current depression in women is associated with decreased bone mineral density (C) 1996, Massachusetts Medical Society.	NIMH,CLIN NEUROENDOCRINOL BRANCH,BETHESDA,MD 20892; NICHHD,DEV ENDOCRINOL BRANCH,BETHESDA,MD 20892; GEORGETOWN UNIV,CHILDRENS MED CTR,DIV GENET,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Georgetown University	Michelson, D (corresponding author), NIH,DEPT NUCL MED,WARREN G MAGNUSON CLIN CTR,ROOM 2D 46,MSC 1284,BETHESDA,MD 20892, USA.		Stratakis, Constantine/AAP-4745-2020					ABRAHAM G, 1995, BIOL PSYCHIAT, V38, P131, DOI 10.1016/0006-3223(95)00062-L; ALEKEL L, 1995, MED SCI SPORT EXER, V27, P1477; BRADY LS, 1992, BRAIN RES, V572, P117, DOI 10.1016/0006-8993(92)90459-M; BRADY LS, 1991, J CLIN INVEST, V87, P831, DOI 10.1172/JCI115086; FLEISS JL, 1971, BRIT J MATH STAT PSY, V24, P117, DOI 10.1111/j.2044-8317.1971.tb00454.x; GOLD PW, 1986, NEW ENGL J MED, V314, P1329, DOI 10.1056/NEJM198605223142101; GOLD PW, 1988, NEW ENGL J MED, V319, P348, DOI 10.1056/NEJM198808113190606; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; Gold PW, 1988, NEW ENGL J MED, V319, P1428; HALBREICH U, 1995, PSYCHOSOM MED, V57, P485, DOI 10.1097/00006842-199509000-00011; HERMUS AR, 1995, J CLIN ENDOCR METAB, V80, P2859, DOI 10.1210/jc.80.10.2859; HERZOG W, 1993, J BONE MINER RES, V8, P597; HUSTMYER FG, 1994, J CLIN INVEST, V94, P2130, DOI 10.1172/JCI117568; JONES G, 1994, DRUG SAFETY, V10, P480, DOI 10.2165/00002018-199410060-00006; KEEN RW, 1995, LANCET, V345, P990, DOI 10.1016/S0140-6736(95)90740-8; Kelly TL., 1990, J BONE MIN RES, V5, pS249; KLEEREKOPPER M, 1995, J CLIN ENDOCR METAB, V80, P2856, DOI 10.1210/jc.80.10.2856; LEONG GM, 1995, 77 ANN M END SOC WAS, P438; MANNING PJ, 1992, CLIN ENDOCRINOL, V36, P229, DOI 10.1111/j.1365-2265.1992.tb01437.x; MAZESS RB, 1988, J BONE MINER RES, V3, P13; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; MICHELSON D, 1995, 77 ANN M END SOC WAS, P484; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; NIELSEN HK, 1992, J CLIN ENDOCR METAB, V74, P1410, DOI 10.1210/jc.74.6.1410; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; SCHWEIGER U, 1994, AM J PSYCHIAT, V151, P1691; SPECTOR TD, 1995, BRIT MED J, V310, P1357, DOI 10.1136/bmj.310.6991.1357; VANDERWIEL HE, 1994, J BONE JOINT SURG AM, V76A, P230, DOI 10.2106/00004623-199402000-00009; Waller K, 1996, J CLIN ENDOCR METAB, V81, P663, DOI 10.1210/jc.81.2.663; ZELISSEN PMJ, 1994, ANN INTERN MED, V120, P207, DOI 10.7326/0003-4819-120-3-199402010-00005	30	354	364	1	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1176	1181		10.1056/NEJM199610173351602	http://dx.doi.org/10.1056/NEJM199610173351602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VN401	8815939				2022-12-28	WOS:A1996VN40100002
J	Liberman, UA; Hirsch, LJ				Liberman, UA; Hirsch, LJ			Esophagitis and alendronate	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									MERCK RES LABS,RAHWAY,NJ 07065	Merck & Company	Liberman, UA (corresponding author), BEILINSON MED CTR,IL-49100 PETAH TIQWA,ISRAEL.							deGroen PC, 1996, NEW ENGL J MED, V335, P1016, DOI 10.1056/NEJM199610033351403; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; *MERCK, 1996, FOS AL SOD; *MERCK, 1995, FOS AL SOD; TUKEY JW, 1985, BIOMETRICS, V41, P295, DOI 10.2307/2530666	5	32	35	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1069	1070		10.1056/NEJM199610033351416	http://dx.doi.org/10.1056/NEJM199610033351416			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8801453				2022-12-28	WOS:A1996VL45900023
J	Nattinger, AB; Hoffmann, RG; Shapiro, R; Gottlieb, MS; Goodwin, JS				Nattinger, AB; Hoffmann, RG; Shapiro, R; Gottlieb, MS; Goodwin, JS			The effect of legislative requirements on the use of breast-conserving surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GEOGRAPHIC-VARIATION; PRACTICE GUIDELINES; CANCER-TREATMENT; MASTECTOMY; CONSENSUS; RADIOTHERAPY; PHYSICIANS; REGRESSION; RADIATION; WOMEN	Background We studied the effect of state legislation requiring the disclosure of options for the treatment of breast cancer on the use of breast-conserving surgery in clinical practice. Methods The National Cancer Institute's Surveillance, Epidemiology, and End Results registry provided data on women from 30 through 79 years of age who underwent breast-conserving surgery or mastectomy for local or regional breast cancer from 1983 through 1990. We examined the trend over time in the use of breast-conserving surgery among patients in four sites (Connecticut, Iowa, Seattle, and Utah) where there were no state laws specifically requiring the disclosure of options for the treatment of breast cancer by physicians. For four additional sites (Detroit, Atlanta, New Mexico, and Hawaii) that had such legislation, we determined whether the rate of breast-conserving surgery after the legislation was different from the expected rate. Results An attorney rated the legislation as giving most direction to physicians in Michigan, followed by Hawaii, Georgia, and New Mexico. The rate of breast-conserving surgery was up to 8.7 percent higher than expected in Detroit for six months after the passage of the Michigan law (P<0.01). The rate was up to 13.2 percent higher than expected in Hawaii for 12 months after that state's law was passed (P<0.05) and up to 6.0 percent higher than expected in Atlanta for 3 months after the passage of the Georgia law (P<0.01). After these transient increases, the surgery rates reverted to the expected levels, No significant effect was detected in New Mexico, where only a resolution without legal force was passed. Conclusions Legislation requiring physicians to disclose options for the treatment of breast cancer appeared to have only a slight and transient effect on the rate of use of breast-conserving surgery, (C) 1996, Massachusetts Medical Society.	MED COLL WISCONSIN,DEPT BIOSTAT,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT BIOETH,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT FAMILY & COMMUNITY MED,MILWAUKEE,WI 53226; UNIV TEXAS,MED BRANCH,DEPT MED,GALVESTON,TX 77550	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; University of Texas System; University of Texas Medical Branch Galveston	Nattinger, AB (corresponding author), MED COLL WISCONSIN,DEPT MED,DIV GEN INTERNAL MED,ADM OFF FMLH E,9200 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.			Nattinger, Ann/0000-0002-8189-3300	NATIONAL CANCER INSTITUTE [R01CA054676] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA54676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAY LA, 1993, EVALUATING MED CARE, P49; ANNAS GJ, 1980, HASTINGS CENT REP, V10, P27, DOI 10.2307/3561276; *BUR HLTH PROF, 1992, AR RES FILE ARF SYST; DIXON DO, 1987, STAT MED, V6, P591, DOI 10.1002/sim.4780060508; FARROW DC, 1992, NEW ENGL J MED, V326, P1097, DOI 10.1056/NEJM199204233261701; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GREER AL, 1987, JAMA-J AM MED ASSOC, V258, P2739, DOI 10.1001/jama.258.19.2739; HARRIS JR, 1985, NEW ENGL J MED, V313, P1365, DOI 10.1056/NEJM198511213132128; JENKINS GM, 1979, PRACTICAL EXPERIENCE, P104; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LANDWEHR JM, 1984, J AM STAT ASSOC, V79, P61, DOI 10.2307/2288334; LAZOVICH D, 1991, JAMA-J AM MED ASSOC, V266, P3433, DOI 10.1001/jama.266.24.3433; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MANN BA, 1988, JAMA-J AM MED ASSOC, V259, P3413; Michalski T. A., 1995, JGIM, V10, P124; MOR V, 1989, CANCER ELDERLY APPRO, P127; *NAT CANC I, 1993, SURV PROGR CANC STAT; Nattinger AB, 1996, MED CARE, V34, P479, DOI 10.1097/00005650-199605000-00009; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; NAYFIELD SG, 1994, J NATL CANCER I, V86, P1202, DOI 10.1093/jnci/86.16.1202; PIERCE PF, 1993, NURS RES, V42, P22; SARRAZIN D, 1984, CANCER, V53, P1209, DOI 10.1002/1097-0142(19840301)53:5<1209::AID-CNCR2820530531>3.0.CO;2-Y; STUDNICKI J, 1993, CANCER, V72, P2986, DOI 10.1002/1097-0142(19931115)72:10<2986::AID-CNCR2820721021>3.0.CO;2-1; SUGARMAN J, 1991, JAMA-J AM MED ASSOC, V266, P3323, DOI 10.1001/jama.266.23.3323; TARBOX BB, 1992, AM J SURG, V164, P417, DOI 10.1016/S0002-9610(05)81172-9; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; WARD S, 1989, CANCER NURS, V12, P344	28	50	51	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1035	1040		10.1056/NEJM199610033351407	http://dx.doi.org/10.1056/NEJM199610033351407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8793929				2022-12-28	WOS:A1996VL45900007
J	Velazquez, FR; Matson, DO; Calva, JJ; Guerrero, ML; Morrow, AL; CarterCampbell, S; Glass, RI; Estes, MK; Pickering, LK; RuizPalacios, GM				Velazquez, FR; Matson, DO; Calva, JJ; Guerrero, ML; Morrow, AL; CarterCampbell, S; Glass, RI; Estes, MK; Pickering, LK; RuizPalacios, GM			Rotavirus infection in infants as protection against subsequent infections	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							YOUNG-CHILDREN; ESCHERICHIA-COLI; RURAL BANGLADESH; MEXICAN CHILDREN; DIARRHEA; GASTROENTERITIS; COHORT; AGE; EPIDEMIOLOGY; SEVERITY	Background Rotavirus is the leading cause of severe diarrhea in infants. To provide a base line for assessing the efficacy of rotavirus vaccines, we evaluated the protection that is conferred by natural rotavirus infection. Methods We monitored 200 Mexican infants from birth to two years of age by weekly home visits and stool collections. A physician assessed the severity of any episodes of diarrhea and collected additional stool specimens for testing by enzyme immunoassay and typing of strains. Serum collected during the first week of life and every four months thereafter was tested for antirotavirus IgA and IgG. Results A total of 316 rotavirus infections were detected on the basis of the fecal excretion of virus (56 percent) or a serologic response (77 percent), of which 52 percent were first and 48 percent repeated infections. Children with one, two, or three previous infections had progressively lower risks of both subsequent rotavirus infection (adjusted relative risk, 0.82, 0.40, and 0.34, respectively) and diarrhea (adjusted relative risk, 0.23, 0.17, and 0.08) than children who had no previous infections. No child had moderate-to-severe diarrhea after two infections, whether symptomatic or asymptomatic. Subsequent infections were significantly less severe than first infections (P=0.024), and second infections were more likely to be caused by another G type (P=0.054). Conclusions In infants, natural rotavirus infection confers protection against subsequent infection. This protection increases with each new infection and reduces the severity of the diarrhea. (C) 1996, Massachusetts Medical Society.	INST NACL NUTR SALVADOR ZUBIRAN,DEPT INFECT DIS,MEXICO CITY 14000,DF,MEXICO; EASTERN VIRGINIA MED SCH,CHILDRENS HOSP KINGS DAUGHTERS,CTR PEDIAT RES,NORFOLK,VA 23501; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; CTR DIS CONTROL & PREVENT,VIRAL GASTROENTERITIS UNIT,ATLANTA,GA 30341; BAYLOR COLL MED,DIV MOL VIROL,HOUSTON,TX 77030	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Eastern Virginia Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Centers for Disease Control & Prevention - USA; Baylor College of Medicine			Morrow, Ardythe/GQO-8482-2022; Ruiz-Palacios, Guillermo/GYQ-5462-2022		NICHD NIH HHS [HD-13201] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTLETT AV, 1987, ANNU REV MED, V38, P399, DOI 10.1146/annurev.med.38.1.399; BERNSTEIN DI, 1995, JAMA-J AM MED ASSOC, V273, P1191, DOI 10.1001/jama.273.15.1191; BERNSTEIN DI, 1991, J INFECT DIS, V164, P277, DOI 10.1093/infdis/164.2.277; BHAN MK, 1993, J INFECT DIS, V168, P282, DOI 10.1093/infdis/168.2.282; BISHOP RF, 1983, NEW ENGL J MED, V309, P72, DOI 10.1056/NEJM198307143090203; BLACK RE, 1982, AM J EPIDEMIOL, V115, P315, DOI 10.1093/oxfordjournals.aje.a113308; BLACK RE, 1981, LANCET, V1, P141; BRANDT CD, 1983, J CLIN MICROBIOL, V18, P71, DOI 10.1128/JCM.18.1.71-78.1983; CALVA JJ, 1988, LANCET, V1, P503; CARTERCAMPBELL S, 1993, THESIS HARVARD SCH P; CLAYTON D, 1985, J R STAT SOC A STAT, V148, P82, DOI 10.2307/2981943; Conner M E, 1994, Curr Top Microbiol Immunol, V185, P285; COULSON BS, 1990, J CLIN MICROBIOL, V28, P1367, DOI 10.1128/JCM.28.6.1367-1374.1990; Dean AG, 1994, EPIINFO VERSION 6 WO; DEZOYSA I, 1985, B WORLD HEALTH ORGAN, V63, P569; ESTES MK, 1989, MICROBIOL REV, V53, P410, DOI 10.1128/MMBR.53.4.410-449.1989; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; FONTEYNE J, 1978, LANCET, V1, P983; FRIEDMAN MG, 1988, J INFECT DIS, V158, P814, DOI 10.1093/infdis/158.4.814; GEORGESCOURBOT MC, 1988, ANN INST PASTEUR VIR, V139, P421, DOI 10.1016/S0769-2617(88)80077-7; GORZIGLIA M, 1990, P NATL ACAD SCI USA, V87, P7155, DOI 10.1073/pnas.87.18.7155; GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276, DOI 10.1128/JCM.28.2.276-282.1990; GRINSTEIN S, 1989, AM J EPIDEMIOL, V130, P300, DOI 10.1093/oxfordjournals.aje.a115336; GURWITH M, 1981, J INFECT DIS, V144, P218, DOI 10.1093/infdis/144.3.218; HO MS, 1988, J INFECT DIS, V158, P1112, DOI 10.1093/infdis/158.5.1112; Kapikian AZ, 1990, VIROLOGY, P1353; LINHARES AC, 1989, EPIDEMIOL INFECT, V102, P129, DOI 10.1017/S0950268800029769; LOPEZVIDA Y, 1990, J INFECT DIS, V162, P442, DOI 10.1093/infdis/162.2.442; MATA L, 1983, J INFECT DIS, V148, P452, DOI 10.1093/infdis/148.3.452; MATSON DO, 1990, J INFECT DIS, V162, P598, DOI 10.1093/infdis/162.3.598; MATSON DO, 1990, J INFECT DIS, V162, P305; Mehta C R, 1994, Stat Methods Med Res, V3, P135, DOI 10.1177/096228029400300203; ORYAN ML, 1994, J INFECT DIS, V169, P504, DOI 10.1093/infdis/169.3.504; PICKERING LK, 1988, J PEDIATR-US, V112, P361, DOI 10.1016/S0022-3476(88)80313-5; PICKERING LK, 1978, J PEDIATR-US, V93, P383, DOI 10.1016/S0022-3476(78)81142-1; PRENTICE RL, 1981, BIOMETRIKA, V68, P373, DOI 10.1093/biomet/68.2.373; REVES RR, 1989, AM J EPIDEMIOL, V130, P981, DOI 10.1093/oxfordjournals.aje.a115431; RODRIGUEZ WJ, 1978, LANCET, V2, P37; RUUSKA T, 1990, SCAND J INFECT DIS, V22, P259, DOI 10.3109/00365549009027046; VELAZQUEZ FR, 1993, PEDIATR INFECT DIS J, V12, P54, DOI 10.1097/00006454-199301000-00013; WARD RL, 1994, J INFECT DIS, V169, P900, DOI 10.1093/infdis/169.4.900; WOODS PA, 1992, J CLIN MICROBIOL, V30, P781, DOI 10.1128/JCM.30.4.781-785.1992; 1995, S PLUS WINDOWS USERS, P1; 1986, NEW VACCINE DEV ESTA, V2, P308	44	628	666	1	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1022	1028		10.1056/NEJM199610033351404	http://dx.doi.org/10.1056/NEJM199610033351404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8793926				2022-12-28	WOS:A1996VL45900004
J	Townes, JM; Cieslak, PR; Hatheway, CL; Solomon, HM; Holloway, JT; Baker, MP; Keller, CF; McCroskey, LM; Griffin, PM				Townes, JM; Cieslak, PR; Hatheway, CL; Solomon, HM; Holloway, JT; Baker, MP; Keller, CF; McCroskey, LM; Griffin, PM			An outbreak of type a botulism associated with a commercial cheese sauce	ANNALS OF INTERNAL MEDICINE			English	Article						botulism; botulinum toxins; Clostridium botulinum; cheese; diagnosis, differential	UNITED-STATES; TOXIN	Background: Although botulism is rare, recognition of a possible case of this illness represents a public health emergency. To prevent more cases, prompt investigation must be done to determine whether illness is linked to a commercial product or restaurant, Botulism can masquerade as other illnesses, and seemingly unlikely foods can harbor botulinum toxin. Objective: To confirm the diagnosis and determine the cause and extent of an outbreak of botulism associated with food served at a delicatessen. Design: Retrospective cohort study of patrons of the delicatessen; laboratory analysis of food, serum samples, and stool samples; and traceback of implicated food. Setting: Community in Georgia. Participants: Patrons of the delicatessen. Main Outcome Measures: Botulinum toxin in food, serum, or stool and Clostridium botulinum in food and stools. Results: 8 of 52 patrons (15%) met the case definition for botulism. In 4 of the 8 patrons, an illness other than botulism was initially diagnosed. Five of the 8 were hospitalized, and 1 died. Stool cultures from 4 patrons yielded type A C. botulinum, and two serum samples contained botulinum toxin. All ill persons ate food from the delicatessen on 1 October 1993. Of the 22 persons who ate at the delicatessen that day, all 8 ill persons but none of the 14 well persons ate a potato stuffed with meat and cheese sauce. An open can of cheese sauce contained type A botulinum toxin and yielded C. botulinum on culture. Cheese sauce experimentally inoculated with C. botulinum spores became toxic after 8 days at a temperature of 22 degrees C (room temperature). Conclusions: A commercial, canned cheese caused a botulism outbreak. This product readily becomes toxic when contaminated by C. botulinum spores and left at room temperature. Mild botulism caused by unusual vehicles may be misdiagnosed. Botulism should be included in the differential diagnosis of persons with signs or symptoms of acute cranial nerve dysfunction.	GEORGIA DEPT HUMAN RESOURCES, ATLANTA, GA USA; SE HLTH UNIT, WAYCROSS, GA 31501 USA; US FDA, WASHINGTON, DC 20204 USA	US Food & Drug Administration (FDA)	Townes, JM (corresponding author), CTR DIS CONTROL & PREVENT, FOODBORNE & DIARRHEAL DIS BRANCH, MAILSTOP A-38, ATLANTA, GA 30333 USA.							ANGULO F, 1995, P EP INT SERV 44 ANN; BRIOZZO J, 1983, APPL ENVIRON MICROB, V45, P1150, DOI 10.1128/AEM.45.3.1150-1152.1983; CHERINGTON M, 1982, MUSCLE NERVE, V5, pS28; Collins-Thompson D. L., 1992, CLOSTRIDIUM BOTULINU, P261; *CTR DIS CONTR, 1979, HDB EP CLIN LAB WORK, P1; DONADIO J A, 1971, Journal of Infectious Diseases, V124, P108; GRECZ N, 1965, APPL MICROBIOL, V13, P1014, DOI 10.1128/AEM.13.6.1014-1022.1965; GRECZ N, 1963, J FOOD SCI, V28, P276, DOI 10.1111/j.1365-2621.1963.tb00196.x; Hatheway C.L., 1988, LAB DIAGNOSIS INFECT, P111; KAUTTER DA, 1979, J FOOD PROTECT, V42, P784, DOI 10.4315/0362-028X-42.10.784; KAUTTER DA, 1992, BACTERIOLOGICAL ANAL, P215; MANN JM, 1982, AM J EPIDEMIOL, V115, P598, DOI 10.1093/oxfordjournals.aje.a113341; MEYER KF, 1951, Z HYG INFEKTIONSKR, V133, P255, DOI 10.1007/BF02149050; SEALS JE, 1981, AM J EPIDEMIOL, V113, P436, DOI 10.1093/oxfordjournals.aje.a113111; SMITH LD, 1978, HEALTH LAB SCI, V15, P74; SMITH LD, 1988, BOTULISM ORGANISM IT, P11; SUGIYAMA H, 1981, J FOOD PROTECT, V44, P896, DOI 10.4315/0362-028X-44.12.896; TANAKA N, 1986, J FOOD PROTECT, V49, P526, DOI 10.4315/0362-028X-49.7.526; WAGENAAR RO, 1958, J DAIRY SCI, V41, P1182, DOI 10.3168/jds.S0022-0302(58)91072-5; WOODRUFF BA, 1992, J INFECT DIS, V166, P1281, DOI 10.1093/infdis/166.6.1281	20	70	70	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1996	125	7					558	+		10.7326/0003-4819-125-7-199610010-00004	http://dx.doi.org/10.7326/0003-4819-125-7-199610010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ653	8815754				2022-12-28	WOS:A1996VJ65300004
J	Calman, KC				Calman, KC			Cancer: Science and society and the communication of risk	BRITISH MEDICAL JOURNAL			English	Article							LUNG-CANCER; CAROTENE				Calman, KC (corresponding author), DEPT HLTH,LONDON SW1A 2NS,ENGLAND.		Calman, Kenneth C/C-9855-2010					*CHIEF MED OFF, 1995, STAT PUBL HLTH ENGL; Glanz K, 1996, JAMA-J AM MED ASSOC, V275, P253, DOI 10.1001/jama.275.3.253; HARRIS RWC, 1991, NUTR CANCER, V15, P63, DOI 10.1080/01635589109514113; ISSELBACHER KJ, 1975, HARRISONS PRINCIPLES, P793; KVALE G, 1983, INT J CANCER, V31, P397, DOI 10.1002/ijc.2910310402; Marmot M, 1996, AM J PUBLIC HEALTH, V86, P921, DOI 10.2105/AJPH.86.7.921; NEU HC, 1993, J CHEMOTHERAPY, V5, P67; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; Selby P, 1996, LANCET, V348, P313, DOI 10.1016/S0140-6736(96)02482-8; WALD NJ, 1988, BRIT J CANCER, V57, P428, DOI 10.1038/bjc.1988.97; 1992, IMMUNISATION INFECT; 1990, BMA GUIDE LIVING RIS	12	115	115	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					799	802						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842078				2022-12-28	WOS:A1996VK56600032
J	Pauletto, P; Puato, M; Caroli, MG; Casiglia, E; Munhambo, AE; Cazzolato, G; Bon, GB; Angeli, MT; Galli, C; Pessina, AC				Pauletto, P; Puato, M; Caroli, MG; Casiglia, E; Munhambo, AE; Cazzolato, G; Bon, GB; Angeli, MT; Galli, C; Pessina, AC			Blood pressure and atherogenic lipoprotein profiles of fish-diet and vegetarian villagers in Tanzania: The Lugalawa study	LANCET			English	Article							CORONARY HEART-DISEASE; N-3 FATTY-ACIDS; CONSUMPTION; MORTALITY; LIPIDS; RISK; OILS; FOOD	Background There is evidence that populations with a high intake of fish, and specifically fish oils, are at reduced risk of cardiovascular disease. To explore the effect of fish intake, we compared two groups of Bantu villagers in Tanzania; one group live on the shores of Lake Nyasa and their diet includes large amounts of freshwater fish; the other group live in the nearby hills and have a vegetarian diet. Methods We carried out a cross-sectional study of 622 fish-consuming villagers and 686 vegetarian villagers. 618 (99.4%) and 645 (94.0%), respectively, agreed to take part. Anthropometric and self-reported medical history data were collected by one local physician and a medical assistant, who also measured blood pressure and took blood samples for measurement of plasma lipids. A dietary questionnaire was administered to 25 families (about 15% of the study population) in each village. Findings After adjustment for age, sex, and alcohol intake the fish-consuming group had lower mean blood pressure than the vegetarian group (123/72 vs 133/76 mm Hg, p<0.001). The frequencies of definite and borderline hypertension (by WHO criteria) were lower in the fish-consuming than in the vegetarian group (2.8 vs 16.4%; 9.7 vs 22.3%, respectively). Plasma concentrations of total cholesterol (mean 3.53 [SD 1.04] vs 4.10 [1.04] mmol/L), triglycerides (0.92 [0.64] vs 1.31 [0.64] mmol/L), and lipoprotein(a) (201 [213] vs 321 [212] mg/L), were all lower (p<0.0001) in the fish-consuming group than in the vegetarian group. The proportions of n-3 polyunsaturated fatty acids in plasma lipids were higher (p<0.0001) in the fish-consuming group than in the vegetarian group (eicosapentaenoic acid 2.3 [1.3] vs 0.7 [0.2]%; docosapentaenoic acid 1.1 [0.4] vs 0.6 [0.3]%; docosahexaenoic acid 5.7 [1.6] vs 1.5 [1.1]%). Interpretation In these villagers, consumption of freshwater fish (300-600 g daily) was associated with raised plasma concentrations of n-3 polyunsaturated fatty acids, lower blood pressure, and lower plasma lipid concentrations.	UNIV PADUA, DIPARTIMENTO MED CLIN & SPERIMENTALE, I-35126 PADUA, ITALY; UNIV DAR ES SALAAM, MUHIMBILI MED CTR, DAR ES SALAAM, TANZANIA; CTR REG ATEROSCLEROSI, VENICE, ITALY; UNIV MILAN, IST SCI FARMACOL, MILAN, ITALY	University of Padua; University of Dar es Salaam; University of Milan				Puato, Massimo/0000-0001-6589-4824				ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BANG HO, 1971, LANCET, V1, P1143, DOI 10.1016/S0140-6736(71)91658-8; BANG HO, 1980, AM J CLIN NUTR, V33, P2657, DOI 10.1093/ajcn/33.12.2657; CHILDS MT, 1988, FASEB J, V2, pA424; ELSAS LJ, 1988, MODERN NUTRITION HLT, P1337; HAGLUND O, 1994, AM J CARDIOL, V74, P189, DOI 10.1016/0002-9149(94)90100-7; HARRIS WS, 1989, J LIPID RES, V30, P785; KAGAWA Y, 1982, J NUTR SCI VITAMINOL, V28, P441, DOI 10.3177/jnsv.28.441; KOSTNER GM, 1990, CLIN CHIM ACTA, V188, P187, DOI 10.1016/0009-8981(90)90200-C; KROMHOUT D, 1989, AM J CLIN NUTR, V49, P889, DOI 10.1093/ajcn/49.5.889; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; MORRIS MC, 1993, CIRCULATION, V88, P523, DOI 10.1161/01.CIR.88.2.523; MTABAJI JP, 1990, J CARDIOVASC PHARM, V16, pS3, DOI 10.1097/00005344-199000168-00004; NESTEL P, 1992, J LIPID RES, V33, P1029; PAULETTO P, 1994, EUR J EPIDEMIOL, V10, P159, DOI 10.1007/BF01730365; RATNAYAKE WN, 1979, LIPIDS, V14, P795, DOI 10.1007/BF02533518; SANDHOLZER C, 1991, HUM GENET, V86, P607; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; SWAI ABM, 1993, INT J EPIDEMIOL, V22, P651, DOI 10.1093/ije/22.4.651; TREMOLI E, 1995, AM J CLIN NUTR, V61, P607, DOI 10.1093/ajcn/61.3.607; VISWANATHANNAIR PG, 1978, J FOOD SCI, V43, P1162, DOI 10.1111/j.1365-2621.1978.tb15260.x	22	91	95	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	1996	348	9030					784	788		10.1016/S0140-6736(96)01391-8	http://dx.doi.org/10.1016/S0140-6736(96)01391-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813985				2022-12-28	WOS:A1996VH98900011
J	Zheng, N; Gierasch, LM				Zheng, N; Gierasch, LM			Signal sequences: The same yet different	CELL			English	Review							ENDOPLASMIC-RETICULUM MEMBRANE; RECOGNITION PARTICLE; SACCHAROMYCES-CEREVISIAE; PROTEIN TRANSLOCATION; PEPTIDES; YEAST				Zheng, N (corresponding author), UNIV MASSACHUSETTS,DEPT CHEM,AMHERST,MA 01003, USA.		Gierasch, Lila M/D-1494-2009					BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BIRD P, 1990, J BIOL CHEM, V265, P8420; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; FELDHEIM D, 1994, J CELL BIOL, V126, P935, DOI 10.1083/jcb.126.4.935; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10155, DOI 10.1021/bi00106a012; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; LURINK J, 1992, NATURE, V359, P741; Marshall G.R, 1992, CURR OPINION STRUCT, V2, P904; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; RAPOPORT TA, 1987, J MOL BIOL, V195, P621, DOI 10.1016/0022-2836(87)90186-0; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; ZIMMERMANN R, 1990, J BIOENERG BIOMEMBR, V22, P711	21	85	89	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					849	852		10.1016/S0092-8674(00)80159-2	http://dx.doi.org/10.1016/S0092-8674(00)80159-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808619	Bronze			2022-12-28	WOS:A1996VJ44300002
J	Connors, AF; Speroff, T; Dawson, NV; Thomas, C; Harrell, FE; Wagner, D; Desbiens, N; Goldman, L; Wu, AW; Califf, RM; Fulkerson, WJ; Vidaillet, H; Broste, S; Bellamy, P; Lynn, J; Knaus, WA				Connors, AF; Speroff, T; Dawson, NV; Thomas, C; Harrell, FE; Wagner, D; Desbiens, N; Goldman, L; Wu, AW; Califf, RM; Fulkerson, WJ; Vidaillet, H; Broste, S; Bellamy, P; Lynn, J; Knaus, WA			The effectiveness of right heart catheterization in the initial care of critically ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PULMONARY-ARTERY CATHETERIZATION; ACUTE MYOCARDIAL-INFARCTION; BLOOD-STREAM INFECTIONS; HOSPITALIZED ADULTS; REGRESSION-MODELS; PROPENSITY SCORE; INTENSIVE-CARE; MORTALITY; THERAPY; COMPLICATIONS	Objective.-To examine the association between the use of right heart catheterization (RHC) during the first 24 hours of care in the intensive care unit (ICU) and subsequent survival, length of stay, intensity of care, and cost of care. Design.-Prospective cohort study. Setting.-Five US teaching hospitals between 1989 and 1994. Subjects.-A total of 5735 critically ill adult patients receiving care in an ICU for 1 of 9 prespecified disease categories. Main Outcome Measures.-Survival time, cost of care, intensity of care, and length of stay in the ICU and hospital, determined from the clinical record and from the National Death Index, A propensity score for RHC was constructed using multivariable logistic regression, Case-matching and multivariable regression modeling techniques were used to estimate the association of RHC with specific outcomes after adjusting for treatment selection using the propensity score. Sensitivity analysis was used to estimate the potential effect of an unidentified or missing covariate on the results. Results.-By case-matching analysis, patients with RHC had an increased 30-day mortality (odds ratio, 1.24; 95% confidence interval, 1.03-1.49). The mean cost (25th, 50th, 75th percentiles) per hospital stay was $49 300 ($17 000, $30 500, $56 600) with RHC and $35 700 ($11 300, $20 600, $39 200) without RHC. Mean length of stay in the ICU was 14.8 (5, 9, 17) days with RHC and 13.0 (4, 7, 14) days without RHC. These findings were all confirmed by multivariable modeling techniques. Subgroup analysis did not reveal any patient group or site for which RHC was associated with improved outcomes. Patients with higher baseline probability of surviving 2 months had the highest relative risk of death following RHC. Sensitivity analysis suggested that a missing covariate would have to increase the risk of death 6-fold and the risk of RHC 8-fold for a true beneficial effect of RHC to be misrepresented as harmful. Conclusion.-In this observational study of critically ill patients, after adjustment for treatment selection bias, RHC was associated with increased mortality and increased utilization of resources. The cause of this apparent lack of benefit is unclear. The results of this analysis should be confirmed in other observational studies. These findings justify reconsideration of a randomized controlled trial of RHC and may guide patient selection for such a study.	METROHLTH MED CTR,CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH; METROHLTH MED CTR,CASE WESTERN RESERVE UNIV,DEPT EPIDEMIOL & BIOSTAT,CLEVELAND,OH; DUKE UNIV,MED CTR,DURHAM,NC; MARSHFIELD MED RES FDN,MARSCHFIELD CLIN,BOSTON,MA; BETH ISRAEL HOSP,BOSTON,MA 02215; JOHNS HOPKINS UNIV,MED CTR,BALTIMORE,MD 21218; UNIV CALIF LOS ANGELES,MED CTR,LOS ANGELES,CA 90024; GEORGE WASHINGTON UNIV,CTR IMPROVE CARE DYING,WASHINGTON,DC	Case Western Reserve University; MetroHealth System; Case Western Reserve University; MetroHealth System; Duke University; Harvard University; Beth Israel Deaconess Medical Center; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; George Washington University	Connors, AF (corresponding author), UNIV VIRGINIA,SCH MED,HLTH SCI CTR,DEPT HLTH EVALUAT SCI,DIV HLTH SERV & OUTCOMES RE,BOX 600,CHARLOTTESVILLE,VA 22908, USA.		Knaus, William/AAX-2138-2020; Wu, Albert/AAJ-4780-2021	Connors, Alfred F./0000-0001-7123-3360				Blumberg M S, 1994, Health Care Financ Rev, V15, P91; CHASTRE J, 1982, NEW ENGL J MED, V306, P278, DOI 10.1056/NEJM198202043060506; CONNORS AF, 1990, CHEST, V98, P1200, DOI 10.1378/chest.98.5.1200; CONNORS AF, 1983, NEW ENGL J MED, V308, P263, DOI 10.1056/NEJM198302033080508; CONNORS AF, 1985, CHEST, V88, P567, DOI 10.1378/chest.88.4.567; COOK EF, 1988, AM J EPIDEMIOL, V127, P626, DOI 10.1093/oxfordjournals.aje.a114838; COX DR, 1972, J R STAT SOC B, V34, P187; EISENBERG PR, 1984, CRIT CARE MED, V12, P549, DOI 10.1097/00003246-198407000-00001; FLEMING A, 1992, ARCH SURG-CHICAGO, V127, P1175; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; GORE JM, 1987, CHEST, V92, P721, DOI 10.1378/chest.92.4.721; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; GREENLAND S, 1980, INT J EPIDEMIOL, V9, P361, DOI 10.1093/ije/9.4.361; Guyatt G, 1991, J Intensive Care Med, V6, P91; HALEY RW, 1981, AM J MED, V70, P51, DOI 10.1016/0002-9343(81)90411-3; HASTIE TJ, 1989, STAT MED, V8, P785, DOI 10.1002/sim.4780080703; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; HUMPHREY H, 1990, CHEST, V97, P1176, DOI 10.1378/chest.97.5.1176; IBERTI TJ, 1990, JAMA-J AM MED ASSOC, V264, P2928, DOI 10.1001/jama.264.22.2928; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1981, JAMA-J AM MED ASSOC, V246, P2711, DOI 10.1001/jama.246.23.2711; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MERMEL LA, 1991, AM J MED, V91, pS197, DOI 10.1016/0002-9343(91)90369-9; MERMEL LA, 1994, AM J RESP CRIT CARE, V149, P1020, DOI 10.1164/ajrccm.149.4.8143037; MIETTINEN OS, 1976, AM J EPIDEMIOL, V104, P609, DOI 10.1093/oxfordjournals.aje.a112339; MIMOZ O, 1994, CRIT CARE MED, V22, P573, DOI 10.1097/00003246-199404000-00011; MITCHELL JP, 1992, AM REV RESPIR DIS, V145, P990, DOI 10.1164/ajrccm/145.5.990; MURPHY DJ, 1990, J CLIN EPIDEMIOL S, V43, pS1; ROBINS JM, 1992, BIOMETRICS, V48, P479, DOI 10.2307/2532304; ROSE R, 1977, SOUTHERN MED J, V70, P1267, DOI 10.1097/00007611-197711000-00005; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; ROSENBAUM PR, 1983, J ROY STAT SOC B MET, V45, P212; SHOEMAKER WC, 1990, CRIT CARE MED, V18, P1294; SHOEMAKER WC, 1990, ARCH SURG-CHICAGO, V125, P1332; SNAPINN SM, 1986, BIOMETRICS, V42, P583, DOI 10.2307/2531208; SPENGLER RF, 1978, JAMA-J AM MED ASSOC, V240, P2455, DOI 10.1001/jama.240.22.2455; SWAN HJC, 1974, AM J CARDIOL, V34, P119, DOI 10.1016/0002-9149(74)90108-8; TUMAN KJ, 1989, ANESTHESIOLOGY, V70, P199, DOI 10.1097/00000542-198902000-00004; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; WENZEL RP, 1988, INT J EPIDEMIOL, V17, P225, DOI 10.1093/ije/17.1.225; WRIGHT SP, 1992, BIOMETRICS, V48, P1005, DOI 10.2307/2532694; WU AW, 1990, J AM GERIATR SOC, V38, P621, DOI 10.1111/j.1532-5415.1990.tb01419.x; YARZEBSKI J, 1994, CHEST, V105, P1003, DOI 10.1378/chest.105.4.1003; ZION MM, 1990, CHEST, V98, P1331, DOI 10.1378/chest.98.6.1331; 1992, CRIT CARE MED, V20, P1057; 1996, JAMA-J AM MED ASSOC, V275, P1232; 1993, ANESTHESIOLOGY, V78, P380; 1995, JAMA-J AM MED ASSOC, V274, P1591; 1991, INTENS CARE MED, V17, pR1	53	1548	1612	2	87	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					889	897		10.1001/jama.276.11.889	http://dx.doi.org/10.1001/jama.276.11.889			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782638				2022-12-28	WOS:A1996VF78700032
J	Grassi, MA				Grassi, MA			The gift	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					854	854						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782618				2022-12-28	WOS:A1996VF78700002
J	King, LR				King, LR			Undescended testis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CRYPTORCHIDISM				King, LR (corresponding author), DUKE UNIV,MED CTR,SECT PEDIAT UROL,DURHAM,NC 27710, USA.							GIBBONS MD, 1979, J UROLOGY, V122, P76, DOI 10.1016/S0022-5347(17)56263-1; GIWERCMAN A, 1987, J UROLOGY, V138, P1214, DOI 10.1016/S0022-5347(17)43553-1; HREBINKO RL, 1993, J UROLOGY, V150, P458, DOI 10.1016/S0022-5347(17)35510-6; HUFF DS, 1989, J UROLOGY, V142, P546, DOI 10.1016/S0022-5347(17)38811-0; KOGAN SJ, 1990, J UROLOGY, V144, P508, DOI 10.1016/S0022-5347(17)39505-8	5	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					856	856		10.1001/jama.276.11.856	http://dx.doi.org/10.1001/jama.276.11.856			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782621				2022-12-28	WOS:A1996VF78700005
J	Stampfer, MJ; Krauss, RM; Ma, J; Blanche, PJ; Holl, LG; Sacks, FM; Hennekens, CH				Stampfer, MJ; Krauss, RM; Ma, J; Blanche, PJ; Holl, LG; Sacks, FM; Hennekens, CH			A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; LDL SUBCLASS PHENOTYPES; HEART-DISEASE; PLASMA TRIGLYCERIDE; APOLIPOPROTEIN-B; CHOLESTEROL; MEN; ATHEROSCLEROSIS; SUBFRACTIONS; WOMEN	Objective.-To test whether a predominance of small, dense low-density lipoprotein (LDL) particles and elevated triglyceride levels are independent risk factors for myocardial infarction (MI). Design.-Nested case-control study with prospectively collected samples. Setting.-Prospective cohort study. Participants.-Blood samples were collected at baseline (85% nonfasting samples) from 14 916 men aged 40 to 84 years in the Physicians' Health Study. Main Outcome Measurements.-Myocardial infarction diagnosed during 7 years of follow-up. Results.-Cases (n=266) had a significantly smaller LDL diameter (mean [SD], 25.6 [0.9] nm) than did controls (n=308) matched on age and smoking (mean [SD], 25.9 [8] nm; P<.001). Cases also had higher median triglyceride levels (1.90 vs 1.49 mmol/L [168 vs 132 mg/dL]; P<.001), The LDL diameter had a high inverse correlation with triglyceride level (r=-0.71), and a high direct correlation with high-density lipoprotein cholesterol (HDL-C) level (r=0.60). We observed a significant multiplicative interaction between triglyceride and total cholesterol (TC) levels (P=.01). After simultaneous adjustment for lipids and a variety of coronary risk factors, LDL particle diameter was no longer a statistically significant risk indicator, with a relative risk (RR) of 1.09 (95% confidence interval [CI], 0.85-1.40) per 0.8-nm decrease. However, triglyceride level remained significant with an RR of 1.40 (95% CI, 1.10-1.77) per 1.13 mmol/L (100-mg/dL) increase. The association between triglyceride level and MI risk appeared linear across the distribution; men in the highest quintile had a risk about 2.5 times that of those in the lowest quintile, The TC level, but not HDL-C level, also remained significant, with an RR of 1.80 (95% CI, 1.44-2.26) per 1.03-mmol/L (40-mg/dL) increase, Conclusions.-These findings indicate that nonfasting triglyceride levels appear to be a strong and independent predictor of future risk of MI, particularly when the total cholesterol level is also elevated, In contrast, LDL particle diameter is associated with risk of MI, but not after adjustment for triglyceride level. Increased triglyceride level, small LDL particle diameter, and decreased HDL-C levels appear to reflect underlying metabolic perturbations with adverse consequences for risk of MI; elevated triglyceride levels may help identify high-risk individuals.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV PREVENT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; LAWRENCE BERKELEY NATL LAB,DEPT MOL & NUCL MED,DIV LIFE SCI,BERKELEY,CA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Stampfer, MJ (corresponding author), BRIGHAM & WOMENS HOSP,CHANNING LAB,181 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R01CA042182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42182] Funding Source: Medline; NHLBI NIH HHS [HL 34595, HL 26490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; AUSTIN MA, 1995, JAMA-J AM MED ASSOC, V273, P115, DOI 10.1001/jama.1995.03520260035025; AUSTIN MA, 1993, ARTERIOSCLER THROMB, V13, P687, DOI 10.1161/01.ATV.13.5.687; AUSTIN MA, 1988, AM J HUM GENET, V43, P838; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; BAINTON D, 1992, BRIT HEART J, V68, P60; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P187, DOI 10.1161/01.ATV.12.2.187; CASTRO GR, 1985, J CLIN INVEST, V75, P874, DOI 10.1172/JCI111786; CORESH J, 1993, J LIPID RES, V34, P1687; CRIQUI MH, 1993, NEW ENGL J MED, V328, P1220, DOI 10.1056/NEJM199304293281702; CROUSE JR, 1985, J LIPID RES, V26, P566; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; DREXEL H, 1994, CIRCULATION, V90, P2230, DOI 10.1161/01.CIR.90.5.2230; FEINGOLD KR, 1992, ARTERIOSCLER THROMB, V12, P1496, DOI 10.1161/01.ATV.12.12.1496; FISHER WR, 1983, METABOLISM, V32, P283, DOI 10.1016/0026-0495(83)90194-4; GEORGOPOULOS A, 1994, METABOLISM, V43, P1063, DOI 10.1016/0026-0495(94)90046-9; HOKANSON JE, 1993, CIRCULATION, V88, P510; KRAUSS RM, 1982, J LIPID RES, V23, P97; KRAUSS RM, 1991, AM J MED, V90, pS36, DOI 10.1016/0002-9343(91)90035-V; LAMONFAVA S, 1989, J CLIN ENDOCR METAB, V68, P191; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SACKS FM, 1995, CURR OPIN LIPIDOL, V6, P161, DOI 10.1097/00041433-199506000-00008; *SAS I INC, 1982, SAS US GUID BAS 1982; *SAS I INC, 1985, SAS US GUID STAT; SCHAEFER EJ, 1987, CIRCULATION, V76, P531; SHARRETT AR, 1994, ARTERIOSCLER THROMB, V14, P1098, DOI 10.1161/01.ATV.14.7.1098; SLYPER AH, 1994, JAMA-J AM MED ASSOC, V272, P305, DOI 10.1001/jama.272.4.305; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1985, STAT MED, V4, P111, DOI 10.1002/sim.4780040202; STORER BE, 1983, APPL STAT-J ROY ST C, V32, P172; TALL A, 1986, J CLIN INVEST, V77, P1163, DOI 10.1172/JCI112417; TORNVALL P, 1991, ATHEROSCLEROSIS, V90, P67, DOI 10.1016/0021-9150(91)90245-X; TRIBBLE DL, 1992, ATHEROSCLEROSIS, V93, P189, DOI 10.1016/0021-9150(92)90255-F; TYROLER HA, 1987, CIRCULATION, V76, P515, DOI 10.1161/01.CIR.76.3.515; WILLIAMS PT, 1986, METABOLISM, V35, P45, DOI 10.1016/0026-0495(86)90094-6; World Health Organization, 1971, IHD REG REP 5 WORK G; YUDKIN JS, 1993, LANCET, V342, P781; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473; 1989, NEW ENGL J MED, V329, P129; 1993, JAMA-J AM MED ASSOC, V269, P505	44	761	831	1	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					882	888		10.1001/jama.276.11.882	http://dx.doi.org/10.1001/jama.276.11.882			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782637				2022-12-28	WOS:A1996VF78700031
J	Walker, SS; Reese, JC; Apone, LM; Green, MR				Walker, SS; Reese, JC; Apone, LM; Green, MR			Transcription activation in cells lacking TAF(II)s	NATURE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; BINDING PROTEIN; CYCLE; GENE; COMPLEX	THE general transcription factor TFIID is composed of the TATA-box-binding protein (TBP) and a set of TBP-associated factors (TAF(II)s) (ref. 1). In vitro, TAF(II)s are required for activated transcription, and have been proposed to be obligatory targets of transcriptional activator proteins (activators)(2). The function of TAF(II)s has not been investigated systematically in vivo. A Saccharomyces cerevisiae TAF(II) complex (yTAF(II) complex) has been identified that shares functional and structural similarities with higher eukaryotic TFIID. In particular, most yTAF(II)s are the homologue of a higher eukaryotic TAF (refs 3, 4). Here we report that inactivation or depletion of six different yTAF(II)s, including the core yTAF(II) that contacts TBP, does not compromise transcriptional activation. We conclude that in vivo, activated transcription of many genes can occur in the absence of functional yTAF(II)s, and that in these instances another transcription component(s) must be the target of the activator.	UNIV MASSACHUSETTS, SCH MED, HOWARD HUGHES MED INST, PROGRAM MOL MED, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								BIENZ M, 1987, ADV GENET, V24, P31, DOI 10.1016/S0065-2660(08)60006-1; BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; BUTT TR, 1984, P NATL ACAD SCI-BIOL, V81, P3332, DOI 10.1073/pnas.81.11.3332; CAPLEAUX E, 1989, J BIOL CHEM, V264, P7437; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; FURST P, 1988, CELL, V55, P705, DOI 10.1016/0092-8674(88)90229-2; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; Guthrie C, 1991, GUIDE YEAST GENETICS; HAMIL KG, 1988, MOL CELL BIOL, V8, P4328, DOI 10.1128/MCB.8.10.4328; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, pCH5; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; LEW DJ, 1992, CELL, V69, P317, DOI 10.1016/0092-8674(92)90412-6; LEWIN B, 1990, GENES, V4; MORTIMER RK, 1980, MICROBIOL REV, V44, P519, DOI 10.1128/MMBR.44.4.519-571.1980; NISHIMOTO T, 1982, SOMAT CELL GENET, V8, P811, DOI 10.1007/BF01543021; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WELCH MD, 1993, GENETICS, V135, P265; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	27	215	217	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1996	383	6596					185	188		10.1038/383185a0	http://dx.doi.org/10.1038/383185a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774886				2022-12-28	WOS:A1996VG14800057
J	Muir, J; Jones, L; Fowler, G				Muir, J; Jones, L; Fowler, G			Cost effectiveness of health checks - Effect of intervention was sustained	BRITISH MEDICAL JOURNAL			English	Letter											Muir, J (corresponding author), RADCLIFFE INFIRM,GEN PRACTICE RES GRP,OXFORD OX2 6HE,ENGLAND.							Langham S, 1996, BRIT MED J, V312, P1265, DOI 10.1136/bmj.312.7041.1265; Wonderling D, 1996, BRIT MED J, V312, P1274, DOI 10.1136/bmj.312.7041.1274; 1995, BRIT MED J, V310, P1099; 1993, BRIT MED J, V308, P308	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					624	624						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806264				2022-12-28	WOS:A1996VG10800050
J	Nakamoto, M; Cheng, HJ; Friedman, GC; McLaughlin, T; Hansen, MJ; Yoon, CH; OLeary, DDM; Flanagan, JG				Nakamoto, M; Cheng, HJ; Friedman, GC; McLaughlin, T; Hansen, MJ; Yoon, CH; OLeary, DDM; Flanagan, JG			Topographically specific effects of ELF-1 on retinal axon guidance in vitro and retinal axon mapping in vivo	CELL			English	Article							RECEPTOR TYROSINE KINASES; GROWTH CONE GUIDANCE; RETINOTECTAL PROJECTION; MOLECULES; LIGAND; RECOGNITION; EXPRESSION; MECHANISMS; COLLAPSE; CLONING	Topographic maps, which maintain the spatial order of neurons in the order of their axonal connections, are found throughout the nervous system. In the visual retinotectal projection, ELF-1, a ligand in the tectum, and its receptors in the retina show complementary gradients in expression and binding, indicating they may be positional labels for map development. Here we show that ELF-1 acts as a repellent axon guidance factor in vitro. In vivo, when the tectal ELF-1 pattern is modified by retroviral overexpression, retinal axons avoid ectopic ELF-1 patches and map to abnormally anterior positions. All these effects were seen on axons from temporal but not nasal retina, indicating that ELF-1 could determine nasal versus temporal retinotectal specificity, and providing a direct demonstration of a cell recognition molecule with topographically specific effects on neural map development.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; SALK INST BIOL STUDIES,MOL NEUROBIOL LAB,LA JOLLA,CA 92037	Harvard University; Harvard Medical School; Salk Institute			Cheng, Hwai-Jong/AAY-5067-2021; Flanagan, John/AAM-2995-2020	Cheng, Hwai-Jong/0000-0003-0647-0567; Nakamoto, Masaru/0000-0001-9356-1189	NEI NIH HHS [F32 EY06550, R01 EY07025] Funding Source: Medline; NICHD NIH HHS [R01 HD29417] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029417] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007025, F32EY006550] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BOXBERG YV, 1993, NEURON, V10, P345; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; COX EC, 1990, NEURON, V2, P31; Davenport RW, 1996, J NEUROSCI, V16, P2074; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FEKETE DM, 1993, P NATL ACAD SCI USA, V90, P2350, DOI 10.1073/pnas.90.6.2350; FRIEDMAN CG, 1996, CURR OPIN NEUROBIOL, V6, P127; FRIEDMAN GC, 1996, J NEUROSCI, V17, P5498; GARRITY PA, 1995, CELL, V83, P177, DOI 10.1016/0092-8674(95)90159-0; GIERER A, 1987, DEVELOPMENT, V101, P479; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HARIS WA, 1995, NEURON, V15, P241; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNT RK, 1990, BRAIN CIRCUITS FUNCT, P19; Itasaki N, 1996, NEURON, V16, P55, DOI 10.1016/S0896-6273(00)80023-9; Kenny D, 1995, DEV BIOL, V172, P708, DOI 10.1006/dbio.1995.8083; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROSKIES A, 1995, PERSPECT DEV NEUROBI, V3, P63; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1990, TRENDS NEUROSCI, V13, P447, DOI 10.1016/0166-2236(90)90097-T; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1995, DEVELOPMENT, V121, P4005	37	368	377	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					755	766		10.1016/S0092-8674(00)80150-6	http://dx.doi.org/10.1016/S0092-8674(00)80150-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797822	Bronze, Green Published			2022-12-28	WOS:A1996VG37200009
J	Vanderpump, MPJ; Ahlquist, JAO; Franklyn, JA; Clayton, RN				Vanderpump, MPJ; Ahlquist, JAO; Franklyn, JA; Clayton, RN			Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POSTPARTUM THYROID-DYSFUNCTION; ATRIAL-FIBRILLATION; GRAVES-DISEASE; THYROXINE TREATMENT; FOLLOW-UP; THYROTOXICOSIS; THERAPY; DRUGS	Thyroid disease is common and may present to a wide range of doctors. With the widespread availability of function testing in recent years increasing numbers of patients with symptoms which might be attributable to hypothyroidism and hyperthyroidism are being tested. Many aspects of the management of thyroid disease have not been subjected to controlled clinical trials yet there are established practices which have never been questioned. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the college, and the Society for Endocrinology set up a working group to produce a consensus statement for good practice with associated audit measures which could be used to ensure that purchasers of health care are obtaining an acceptable standard of care for patients with thyroid disease. The working group focused on patient management rather than presenting symptoms and signs, which were detailed in a similar report by the American Thyroid Association.(1) This report summarises the consensus views reached by members of the working group.	CITY GEN HOSP, DEPT ENDOCRINOL & DIABET, STOKE ON TRENT ST4 6QG, STAFFS, ENGLAND; SOUTHEND HOSP, WESTCLIFF ON SEA SS0 0RY, ENGLAND; QUEEN ELIZABETH HOSP, DEPT MED, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND	University of Birmingham								ALVAREZMARFANY M, 1994, J CLIN ENDOCR METAB, V79, P10, DOI 10.1210/jc.79.1.10; BURROW GN, 1993, ENDOCR REV, V14, P194, DOI 10.1210/er.14.2.194; CUSICK EL, 1987, BRIT J SURG, V74, P780, DOI 10.1002/bjs.1800740909; FABER J, 1994, EUR J ENDOCRINOL, V130, P350, DOI 10.1530/eje.0.1300350; FALK SA, 1990, OTOLARYNG CLIN N AM, V23, P361; FRANKLYN JA, 1991, CLIN ENDOCRINOL, V34, P71, DOI 10.1111/j.1365-2265.1991.tb01738.x; FRANKLYN JA, 1992, LANCET, V340, P9, DOI 10.1016/0140-6736(92)92423-D; FUNG HYM, 1988, BRIT MED J, V296, P241, DOI 10.1136/bmj.296.6617.241; HOLLINGSWORTH DR, 1985, PEDIATRIC THYROIDOLO, V14, P210; JONES SJ, 1982, LANCET, V1, P1229; KAPLAN MM, 1992, THYROID, V2, P147, DOI 10.1089/thy.1992.2.147; Lazarus JH, 1995, J ROY COLL PHYS LOND, V29, P464; MARTINEZFRIAS ML, 1992, LANCET, V339, P742, DOI 10.1016/0140-6736(92)90640-O; MCKENZIE JM, 1989, J CLIN ENDOCR METAB, V69, P1093, DOI 10.1210/jcem-69-6-1093; MOMOTANI N, 1989, CLIN ENDOCRINOL, V31, P591, DOI 10.1111/j.1365-2265.1989.tb01283.x; NAKAZAWA HK, 1982, AM J MED, V72, P903, DOI 10.1016/0002-9343(82)90850-6; NEIS C, 1994, BRIT J SURG, V81, P1757; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; REINWEIN D, 1993, J CLIN ENDOCR METAB, V76, P1516; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SCOTT GR, 1984, BRIT MED J, V289, P399, DOI 10.1136/bmj.289.6442.399; SINGER PA, 1995, JAMA-J AM MED ASSOC, V273, P808, DOI 10.1001/jama.273.10.808; SUGRUE D, 1980, Q J MED, V49, P51; SURKS MI, 1995, NEW ENGL J MED, V333, P1688, DOI 10.1056/NEJM199512213332507; THJODLEIFSSON B, 1977, CLIN ENDOCRINOL, V7, P367, DOI 10.1111/j.1365-2265.1977.tb03345.x; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; WEETMAN AP, 1994, Q J MED, V87, P337; WHITE HD, 1994, LANCET, V343, P683, DOI 10.1016/S0140-6736(94)91573-3	29	156	165	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 31	1996	313	7056					539	544						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789985				2022-12-28	WOS:A1996VF29400026
J	Brazas, R; Ganem, D				Brazas, R; Ganem, D			A cellular homolog of hepatitis delta antigen: Implications for viral replication and evolution	SCIENCE			English	Article							VIRUS-RNA; SELF-CLEAVAGE; NONRADIOACTIVE NORTHERN; NUCLEAR TRANSPORT; LEUCINE ZIPPER; GENOME; SEQUENCES; BINDING; CLONING; COMPLEX	Hepatitis delta virus (HDV) is a pathogenic human virus whose RNA genome and replication cycle resemble those of plant viroids. However, viroid genomes contain no open reading frames, whereas HDV RNA encodes a single protein, hepatitis delta antigen (HDAg), which is required for viral replication. A cellular gene whose product interacts with HDAg has now been identified, and this interaction was found to affect viral genomic replication in intact cells. DNA sequence analysis revealed that this protein, termed delta-interacting protein A (DIPA), is a cellular homolog of HDAg. These observations demonstrate that a host gene product can modulate HDV replication and suggest that HDV may have evolved from a primitive viroidlike RNA through capture of a cellular transcript.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APTE AN, 1993, BIOTECHNIQUES, V15, P890; AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BRANCH AD, 1989, SCIENCE, V243, P649, DOI 10.1126/science.2492676; BRANCH AD, 1984, SCIENCE, V223, P450, DOI 10.1126/science.6197756; CHANG MF, 1992, J VIROL, V66, P6019, DOI 10.1128/JVI.66.10.6019-6027.1992; CHAO M, 1991, J VIROL, V65, P4057, DOI 10.1128/JVI.65.8.4057-4062.1991; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PJ, 1992, J VIROL, V66, P2853, DOI 10.1128/JVI.66.5.2853-2859.1992; CHEN PJ, 1986, P NATL ACAD SCI USA, V83, P8774, DOI 10.1073/pnas.83.22.8774; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DESHAZER D, 1994, BIOTECHNIQUES, V17, P288; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ENGLERBLUM G, 1993, ANAL BIOCHEM, V210, P235, DOI 10.1006/abio.1993.1189; FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X; FU TB, 1993, J VIROL, V67, P6965, DOI 10.1128/JVI.67.12.6965-6972.1993; GLENN JS, 1990, J VIROL, V64, P3104, DOI 10.1128/JVI.64.6.3104-3107.1990; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; HWANG SB, 1992, VIROLOGY, V190, P413, DOI 10.1016/0042-6822(92)91227-L; KOS A, 1986, NATURE, V323, P558, DOI 10.1038/323558a0; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; LAZINSKI DW, 1993, J VIROL, V67, P2672, DOI 10.1128/JVI.67.5.2672-2680.1993; LEE CZ, 1993, J VIROL, V67, P2221, DOI 10.1128/JVI.67.4.2221-2227.1993; LIN JH, 1990, J VIROL, V64, P4051, DOI 10.1128/JVI.64.9.4051-4058.1990; LOW R, 1994, BIOTECHNIQUES, V17, P1026; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MACNAUGHTON TB, 1991, VIROLOGY, V184, P387, DOI 10.1016/0042-6822(91)90855-6; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; POLO JM, 1995, J VIROL, V69, P4880, DOI 10.1128/JVI.69.8.4880-4887.1995; PRODY GA, 1986, SCIENCE, V231, P1577, DOI 10.1126/science.231.4745.1577; RIZZETTO M, 1983, HEPATOLOGY, V3, P729; RIZZETTO M, 1980, P NATL ACAD SCI-BIOL, V77, P6124, DOI 10.1073/pnas.77.10.6124; SHARMEEN L, 1988, J VIROL, V62, P2674, DOI 10.1128/JVI.62.8.2674-2679.1988; SHARMEEN L, 1989, J VIROL, V63, P1428, DOI 10.1128/JVI.63.3.1428-1430.1989; Smedile A, 1994, Prog Liver Dis, V12, P157; SYMONS RH, 1990, SEMIN VIROL, V1, P75; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; WU HN, 1990, MOL CELL BIOL, V10, P5575, DOI 10.1128/MCB.10.10.5575; WU HN, 1989, SCIENCE, V243, P652, DOI 10.1126/science.2492677; XIA YP, 1992, J VIROL, V66, P6641, DOI 10.1128/JVI.66.11.6641-6648.1992; XIA YP, 1992, J VIROL, V66, P914, DOI 10.1128/JVI.66.2.914-921.1992	45	102	109	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	1996	274	5284					90	94		10.1126/science.274.5284.90	http://dx.doi.org/10.1126/science.274.5284.90			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810253				2022-12-28	WOS:A1996VK74800053
J	Hsiao, K; Chapman, P; Nilsen, S; Eckman, C; Harigaya, Y; Younkin, S; Yang, FS; Cole, G				Hsiao, K; Chapman, P; Nilsen, S; Eckman, C; Harigaya, Y; Younkin, S; Yang, FS; Cole, G			Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice	SCIENCE			English	Article							PRECURSOR PROTEIN GENE; FAMILIAL ALZHEIMERS-DISEASE; SENILE PLAQUES; MUTATION; ANTIBODIES; TERMINUS; PEPTIDE; BRAIN	Transgenic mice overexpressing the 695-amino acid isoform of human Alzheimer beta-amyloid (A beta) precursor protein containing a Lys(670) --> Asn, Met(671)--> Leu mutation had normal learning and memory in spatial reference and alternation tasks at 3 months of age but showed impairment by 9 to 10 months of age. A fivefold increase in A beta(1-40) and a 14-fold increase in A beta(1-42/43) accompanied the appearance of these behavioral deficits, Numerous A beta plaques that stained with Congo red dye were present in cortical and limbic structures of mice with elevated amounts of A beta. The correlative appearance of behavioral, biochemical, and pathological abnormalities reminiscent of Alzheimer's disease in these transgenic mice suggests new opportunities for exploring the pathophysiology and neurobiology of this disease.	UNIV WALES COLL CARDIFF,PHYSIOL UNIT,CARDIFF CF1 3US,S GLAM,WALES; MAYO CLIN JACKSONVILLE,JACKSONVILLE,FL 32224; VET ADM MED CTR,GRECC,SEPULVEDA,CA 91343; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 91343; UNIV CALIF LOS ANGELES,DEPT NEUROL,LOS ANGELES,CA 91343	Cardiff University; Mayo Clinic; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Hsiao, K (corresponding author), UNIV MINNESOTA,DEPT NEUROL,UMHC BOX 295,420 DELAWARE ST,MINNEAPOLIS,MN 55455, USA.				NIA NIH HHS [AG06656, AG9009] Funding Source: Medline; NINDS NIH HHS [NS33249] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006656, R01AG009009] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DOUGLAS RJ, 1990, SPONTANEOUS ALTERNAT, P73; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HIGGINS LS, 1994, ANN NEUROL, V35, P598, DOI 10.1002/ana.410350514; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KOO EH, 1990, NEURON, V2, P97; MAK K, 1994, BRAIN RES, V667, P138, DOI 10.1016/0006-8993(94)91725-6; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MORAN PM, 1995, P NATL ACAD SCI USA, V92, P5341, DOI 10.1073/pnas.92.12.5341; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; SAIDO TC, 1994, J BIOL CHEM, V269, P15253; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; YANG FS, 1994, NEUROREPORT, V5, P2117, DOI 10.1097/00001756-199410270-00032	28	3547	3798	5	380	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					99	102		10.1126/science.274.5284.99	http://dx.doi.org/10.1126/science.274.5284.99			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810256				2022-12-28	WOS:A1996VK74800056
J	Tarn, WY; Steitz, JA				Tarn, WY; Steitz, JA			Highly diverged U4 and U6 small nuclear RNAs required for splicing rare AT-AC introns	SCIENCE			English	Article							PRE-MESSENGER-RNA; BASE-PAIRING INTERACTION; PREMESSENGER RNA; CAP STRUCTURE; ACTIVE-SITE; SPLICEOSOME; SNRNA; RIBONUCLEOPROTEIN; U2; YEAST	Removal of a rare class of metazoan precursor messenger RNA introns With AU-AC at their termini is catalyzed by a spliceosome that contains U11, U12, and U5 small nuclear ribonucleoproteins. Two previously unidentified, low-abundance human small nuclear RNAs (snRNAs), U4atac and U6atac, were characterized as associated with the AT-AC spliceosome and necessary for AT-AC intron splicing. The excision of AT-AC introns therefore requires four snRNAs not found in the major spliceosome. With the use of psoralen crosslinking, a U6atac interaction with U12 was identified that is similar to a U6-U2 helix believed to contribute to the spliceosomal active center. The conservation of only limited U6atac sequences in the neighborhood of this interaction and the potential of U6atac to base pair with the 5' splice site consensus for AT-AC introns provide support for current models of the core of the spliceosome.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06536	Howard Hughes Medical Institute; Yale University			Tarn, Woan-Yuh/N-8464-2018		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026154, R37GM026154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baserga S., 1993, RNA WORLD, P359; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BLACK DL, 1989, MOL CELL BIOL, V9, P3350, DOI 10.1128/MCB.9.8.3350; BRINGMANN P, 1984, EMBO J, V3, P1357, DOI 10.1002/j.1460-2075.1984.tb01977.x; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; CHENG SC, 1987, GENE DEV, V1, P1047; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FABRIZIO P, 1992, NUCLEIC ACIDS RES, V20, P3659, DOI 10.1093/nar/20.14.3659; Field DJ, 1996, GENE DEV, V10, P489, DOI 10.1101/gad.10.4.489; FORTNER DM, 1994, GENE DEV, V8, P221, DOI 10.1101/gad.8.2.221; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; Gu J, 1996, NUCLEIC ACIDS RES, V24, P73, DOI 10.1093/nar/24.1.73; GUPTA S, 1990, J BIOL CHEM, V265, P19137; GUPTA S, 1990, NUCLEIC ACIDS RES, V18, P2231; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; HASHIMOTO C, 1984, NUCLEIC ACIDS RES, V12, P3283, DOI 10.1093/nar/12.7.3283; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; LIU MH, 1992, NUCLEIC ACIDS RES, V20, P4299, DOI 10.1093/nar/20.16.4299; MADHANI HD, 1994, GENE DEV, V8, P1071, DOI 10.1101/gad.8.9.1071; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MONTZKA KA, 1988, P NATL ACAD SCI USA, V85, P8885, DOI 10.1073/pnas.85.23.8885; Moore M., 1993, RNA WORLD, P303; Mount SM, 1996, SCIENCE, V271, P1690, DOI 10.1126/science.271.5256.1690; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; REDDY R, 1988, NUCLEIC ACIDS RES, V16, P71; REDDY R, COMMUNICATOIN; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SILLICIANO PG, 1987, CELL, V50, P585; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; SUN JS, 1995, GENE DEV, V9, P843, DOI 10.1101/gad.9.7.843; TAKAHASHI Y, 1993, MOL CELL BIOL, V13, P5613, DOI 10.1128/MCB.13.9.5613; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; TANI T, 1992, NUCLEIC ACIDS RES, V20, P2991, DOI 10.1093/nar/20.12.2991; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; TARN WY, 1995, RNA, V1, P644; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; TARN WY, UNPUB; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432; WASSARMAN DA, 1993, P NATL ACAD SCI USA, V90, P7139, DOI 10.1073/pnas.90.15.7139; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377; WOLFF T, 1994, P NATL ACAD SCI USA, V91, P903, DOI 10.1073/pnas.91.3.903; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; Yan D, 1996, MOL CELL BIOL, V16, P818; YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571; YU YT, 1995, RNA, V1, P46	54	156	157	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1824	1832		10.1126/science.273.5283.1824	http://dx.doi.org/10.1126/science.273.5283.1824			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791582				2022-12-28	WOS:A1996VJ71300036
J	Yu, AC; Margoliash, D				Yu, AC; Margoliash, D			Temporal hierarchical control of singing in birds	SCIENCE			English	Article							ZEBRA FINCH; CORTICAL-NEURONS; LEARNED SONG; NUCLEUS; VOCALIZATION; PLASTICITY; BEHAVIOR; MIDBRAIN; SPARROW; NETWORK	Songs of birds comprise hierarchical sets of vocal gestures. In zebra finches, songs Include notes and syllables (groups of notes) delivered in fixed sequences. During singing, premotor neurons in the forebrain nucleus HVc exhibited reliable changes In activity rates whose patterns were uniquely associated with syllable identity. Neurons in the forebrain nucleus robustus archistriatalis, which receives input from the HVc, exhibited precisely rimed and structured bursts of activity that were uniquely associated with note identity. Hence, units of vocal behavior are represented hierarchically in the avian forebrain. The representation of temporal sequences at each level of the hierarchy may be established by means of a decoding process involving Interactions of higher level input with intrinsic local circuitry. Behavior is apparently represented by precise temporal patterning of spike trains at lower levels of the hierarchy.	UNIV CHICAGO,DEPT ORGANISMAL BIOL & ANAT,CHICAGO,IL 60637; UNIV CHICAGO,COMM NEUROBIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago					NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH010151] Funding Source: NIH RePORTER; NIMH NIH HHS [1 F31 MH10151] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELES M, 1995, P NATL ACAD SCI USA, V92, P8616, DOI 10.1073/pnas.92.19.8616; AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; Anderson SE, 1996, J ACOUST SOC AM, V100, P1209, DOI 10.1121/1.415968; BAIR W, 1996, NEURAL COMPUT, V8, P1184; BERGLAND GD, 1969, IEEE SPECTRUM, V7, P41; CARR CE, 1988, P NATL ACAD SCI USA, V85, P8311, DOI 10.1073/pnas.85.21.8311; CARR CE, 1986, J NEUROSCI, V6, P107; deCharms RC, 1996, NATURE, V381, P610, DOI 10.1038/381610a0; Fetz EE, 1994, MOVEMENT CONTROL, P77; GERHARDT HC, 1978, J EXP BIOL, V74, P59; GOLLER F, 1995, NATURE, V373, P63, DOI 10.1038/373063a0; HOY RR, 1973, SCIENCE, V180, P82, DOI 10.1126/science.180.4081.82; Immelmann K., 1969, P61; KONISHI M, 1978, HDB SENSORY PHYSL, V8, P289; Lashley K., 1951, CEREBRAL MECH BEHAV, P112, DOI DOI 10.1093/RFS/HHQ153; LEWICKI MS, 1994, NEURAL COMPUT, V6, P1005, DOI 10.1162/neco.1994.6.5.1005; LLINAS R, 1990, COLD SPRING HARB SYM, V55, P933; MARLER P, 1977, SCIENCE, V198, P519, DOI 10.1126/science.198.4316.519; MARLER P, 1984, ANIM BEHAV, V32, P673, DOI 10.1016/S0003-3472(84)80143-8; MCCASLAND JS, 1981, P NATL ACAD SCI-BIOL, V78, P7815, DOI 10.1073/pnas.78.12.7815; MIDDLEBROOKS JC, 1994, SCIENCE, V264, P842, DOI 10.1126/science.8171339; MOONEY R, 1992, J NEUROSCI, V12, P2464; NOWICKI S, 1986, SCIENCE, V231, P1297, DOI 10.1126/science.3945824; PLOOG D, 1981, BRAIN RES REV, V3, P35, DOI 10.1016/0165-0173(81)90011-4; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; SELLER TJ, 1981, TRENDS NEUROSCI, V4, P301, DOI 10.1016/0166-2236(81)90094-1; SOSSINKA R, 1980, Z TIERPSYCHOL, V53, P123; SUTTER ML, 1994, J NEUROPHYSIOL, V72, P2105, DOI 10.1152/jn.1994.72.5.2105; Tinbergen, 1951, STUDY INSTINCT; TINBERGEN N, 1950, SYM SOC EXP BIOL, V4, P305; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; VICARIO DS, 1991, J NEUROBIOL, V22, P63, DOI 10.1002/neu.480220107; VU ET, 1994, J NEUROSCI, V14, P6924; WESTNEAT MW, 1993, J EXP BIOL, V182, P147; WILLIAMS H, 1993, J NEUROBIOL, V24, P903, DOI 10.1002/neu.480240704; ZANN R, 1996, ZEBRA FINCH	36	469	477	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1871	1875		10.1126/science.273.5283.1871	http://dx.doi.org/10.1126/science.273.5283.1871			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791594				2022-12-28	WOS:A1996VJ71300048
J	Molmenti, EP				Molmenti, EP			Gallstone ileus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Molmenti, EP (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1996	335	13					942	942		10.1056/NEJM199609263351306	http://dx.doi.org/10.1056/NEJM199609263351306			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK148	8786778				2022-12-28	WOS:A1996VK14800006
J	Andrulis, DP				Andrulis, DP			Averting traumatic injury to trauma care in Los Angeles - A near miss with lessons for all	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Andrulis, DP (corresponding author), NATL PUBL HLTH & HOSP INST,1212 NEW YORK AVE,SUITE 800,WASHINGTON,DC 20006, USA.							Cornwell EE, 1996, JAMA-J AM MED ASSOC, V276, P940, DOI 10.1001/jama.276.12.940; GOLDSTEIN A, 1995, WASHINGTON POST 0326, pB1; HACKEY IL, 1995, J TRAUMA, V39, P1045	3	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1996	276	12					946	947		10.1001/jama.276.12.946	http://dx.doi.org/10.1001/jama.276.12.946			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH990	8805719				2022-12-28	WOS:A1996VH99000017
J	Mitchell, DN				Mitchell, DN			Mycobacteria and sarcoidosis	LANCET			English	Editorial Material							CROHNS-DISEASE				Mitchell, DN (corresponding author), ROYAL BROMPTON HOSP,LONDON SW3 6NP,ENGLAND.							Almenoff PL, 1996, THORAX, V51, P530, DOI 10.1136/thx.51.5.530; BURNET FM, 1959, CLONAL SELECTION THE, P160; Graham D, 1988, SARCOIDOSIS OTHER GR, P161; GRONHAGENRISKA C, 1983, LANCET, V1, P1287; MANGIAPAN G, 1995, SARCOIDOSIS, V12, P20; MITCHELL DN, 1983, 9TH INT C SARC OTH G, P132; Moscovic E A, 1978, Pathol Annu, V13 Pt 2, P69; MOSS MT, 1992, GUT, V33, P1209, DOI 10.1136/gut.33.9.1209; RIOZ MP, 1995, J CLIN MICROBIOL, V3, P1389; SCADDING JG, 1971, 5TH INT C SARC PRAG, P89; Taub R N, 1974, Trans Assoc Am Physicians, V87, P219	11	24	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					768	769		10.1016/S0140-6736(05)65205-1	http://dx.doi.org/10.1016/S0140-6736(05)65205-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813979				2022-12-28	WOS:A1996VH98900005
J	vanderPlas, RN; Benninga, MA; Buller, HA; Bossuyt, PM; Akkermans, LMA; Redekop, WK; Taminiau, JA				vanderPlas, RN; Benninga, MA; Buller, HA; Bossuyt, PM; Akkermans, LMA; Redekop, WK; Taminiau, JA			Biofeedback training in treatment of childhood constipation: A randomised controlled study	LANCET			English	Article							PELVIC FLOOR SYNDROME; FECAL INCONTINENCE; BEHAVIORAL MEDICINE; CHILDREN; ENCOPRESIS; DEFECATION; THERAPY; TRIAL	Background Because abnormal defaecation dynamics, which can be modified by biofeedback, are considered to be the underlying problem in constipation, biofeedback training may be a useful treatment for constipation. This treatment has mainly been studied in uncontrolled trials. We evaluated defaecation dynamics and clinical outcome in chronically constipated children in a randomised study comparing conventional treatment and conventional treatment with biofeedback training. Methods Patients, 5 to 16 years old, were referred to the Academic Medical Center in Amsterdam by general practitioners, school doctors, paediatricians, and psychiatrists. They had to fulfil at least two of four criteria for paediatric constipation and were included if they had been treated medically for at least one month before randomisation. Patients had a medical history, abdominal and rectal examination, and anorectal manometry at the start and end of the 6-week intervention period. The conventional group received laxative treatment with additional dietary advice, toilet training, and maintenance of a diary of bowel habits, The biofeedback group received the same conventional treatment acid additionally five biofeedback training sessions. During the first 3 weeks, patients visited the outpatient clinic weekly; two subsequent visits were twice monthly. Findings 94 patients were randomised to conventional treatment (CT) and 98 to conventional treatment with additional biofeedback training (CT+BF). Normal defaecation dynamics increased in the CT group from 41% to 52% (not significant) and in the CT+BF group from 38% to 86% (p=0.001). At 6 weeks, more patients in the CT+BF group showed normal defaecation dynamics, compared to the CT group (p<0.001). This result was unaltered by controlling for baseline status in a logistic regression model. At 1 year, successful treatment (defaecation frequency greater than or equal to/week, soiling and/or encopresis <2/month, and no laxatives) was accomplished in 59% of the CT and 50% of the CT+BF group (p=0.24). The results were maintained after 11/2 years follow-up. No association was found between achievement of normal defaecation dynamics and clinical outcome. Interpretation Additional biofeedback training compared to conventional therapy did not result in higher success rates in chronically constipated children. Furthermore, achievement of normal defaecation dynamics was not associated with success: abnormal defaecation dynamics seem not to play a crucial role in the pathogenesis of childhood constipation, Intensive conventional laxative treatment should remain the first choice in chronically constipated children.	UNIV AMSTERDAM, ACAD MED CTR, DEPT CLIN EPIDEMIOL & BIOSTAT, NL-1105 A2 AMSTERDAM, NETHERLANDS; UNIV HOSP, DEPT SURG, UTRECHT, NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	vanderPlas, RN (corresponding author), UNIV AMSTERDAM, ACAD MED CTR, DEPT PAEDIAT GASTROENTEROL & NUTR, G8 245, NL-1105 A2 AMSTERDAM, NETHERLANDS.		Bossuyt, Patrick M/AAR-1183-2021; Redekop, Ken/AAA-2423-2020; Bossuyt, Patrick M./B-4557-2016	Bossuyt, Patrick M/0000-0003-4427-0128; Bossuyt, Patrick M./0000-0003-4427-0128; Redekop, Ken/0000-0001-9538-4083				ABRAHAMIAN FP, 1984, J PEDIATR GASTR NUTR, V3, P460, DOI 10.1097/00005176-198406000-00027; ARNDORFER RC, 1977, GASTROENTEROLOGY, V73, P23; BASSOTTI G, 1994, AM J GASTROENTEROL, V89, P158; BELLMAN M, 1966, ACTA PAEDIATR SC   S, V170, P1; BENNINGA MA, 1993, ARCH DIS CHILD, V68, P126, DOI 10.1136/adc.68.1.126; Berquist W E, 1995, Semin Pediatr Surg, V4, P48; BLEIJENBERG G, 1994, AM J GASTROENTEROL, V89, P1021; BLEIJENBERG G, 1987, DIS COLON RECTUM, V30, P108, DOI 10.1007/BF02554946; CAMMA C, 1993, DIGEST DIS SCI, V38, P916, DOI 10.1007/BF01295920; COX DJ, 1994, BIOFEEDBACK SELF-REG, V19, P41, DOI 10.1007/BF01720669; DAHL J, 1991, DIS COLON RECTUM, V34, P769, DOI 10.1007/BF02051068; ENGEL BT, 1974, NEW ENGL J MED, V290, P646, DOI 10.1056/NEJM197403212901202; KEREN S, 1988, AM J GASTROENTEROL, V83, P827; KOUTSOMANIS D, 1995, GUT, V37, P95, DOI 10.1136/gut.37.1.95; KUIJPERS HC, 1985, DIS COLON RECTUM, V28, P669, DOI 10.1007/BF02553449; LINKENHOKER D, 1983, J DEV BEHAV PEDIATR, V4, P16, DOI 10.1097/00004703-198303000-00004; LoeningBaucke V, 1996, DIGEST DIS SCI, V41, P65, DOI 10.1007/BF02208585; LOENINGBAUCKE V, 1989, GUT, V30, P999, DOI 10.1136/gut.30.7.999; LOENINGBAUCKE V, 1990, J PEDIATR-US, V116, P214, DOI 10.1016/S0022-3476(05)82877-X; LOENINGBAUCKE V, 1995, PEDIATRICS, V96, P105; LOENINGBAUCKE V, 1993, GASTROENTEROLOGY, V105, P1557, DOI 10.1016/0016-5085(93)90166-A; LOENINGBAUCKE V, 1991, DIGEST DIS SCI, V36, P153, DOI 10.1007/BF01300749; LOENINGBAUCKE VA, 1982, J PEDIATR-US, V100, P213, DOI 10.1016/S0022-3476(82)80637-9; LOENINGBAUCKE VA, 1984, GASTROENTEROLOGY, V87, P1299; MERCER RD, 1967, PEDIATR CLIN N AM, V14, P175; MEUNIER P, 1979, GASTROENTEROLOGY, V77, P330; NOLAN T, 1991, LANCET, V338, P523, DOI 10.1016/0140-6736(91)91097-E; OLNESS K, 1980, J PEDIATR-US, V96, P505, DOI 10.1016/S0022-3476(80)80711-6; PAPACHRYSOSTOMOU M, 1994, GUT, V35, P252, DOI 10.1136/gut.35.2.252; SHEPHERD K, 1989, AUST PAEDIATR J, V25, P351; STAIANO A, 1994, DIGEST DIS SCI, V39, P561, DOI 10.1007/BF02088343; WALD A, 1981, ANN INTERN MED, V95, P146, DOI 10.7326/0003-4819-95-2-146; WALD A, 1987, J PEDIATR GASTR NUTR, V6, P554, DOI 10.1097/00005176-198707000-00011; WALD A, 1986, J PEDIATR GASTR NUTR, V5, P346, DOI 10.1097/00005176-198605000-00002; WEBER J, 1987, DIS COLON RECTUM, V30, P844, DOI 10.1007/BF02555421	35	127	129	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	1996	348	9030					776	780		10.1016/S0140-6736(96)03206-0	http://dx.doi.org/10.1016/S0140-6736(96)03206-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813983				2022-12-28	WOS:A1996VH98900009
J	Ono, M; Bolland, S; Tempst, P; Ravetch, JV				Ono, M; Bolland, S; Tempst, P; Ravetch, JV			Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc gamma RIIB	NATURE			English	Article							CYTOPLASMIC DOMAIN; CELL ACTIVATION; GENERATION; RELEASE; MOTIF; PTP1C	IMMUNE complexes are potent activators of inflammatory cells, triggering effector responses through the crosslinking of Fc receptors (FcRs) such as Fc epsilon RI or Fc gamma RIII (ref, 1). On B cells and mast cells, immune complexes are also negative regulators of activation triggered by antigen and Fc receptors, a consequence of coligation of the B-cell antigen receptor or Fc epsilon RI, respectively, and the inhibitory receptor Fc gamma RIIB. Here we show that inhibitory signalling by Fc gamma RIIB does not require the SH2-domain-containing protein tyrosine phosphatase, SHP-1, in mast cells and results in the recruitment of the SH2-domain-containing inositol polyphosphate 5-phosphatase, SHIP, to the tyrosine-phosphorylated 13-amino-acid inhibitory motif of Fc gamma RIIB in both B cells and mast cells. SHIP, by hydrolysing the 5-phosphate of phosphatidylinositol(3,4,5)P-3 and inositol(1,3,4,5) P-4, suggests a mechanism by which Fc gamma RIIB can inhibit calcium influx and downstream responses triggered by immune receptors.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center			Troshina, Olga/V-8941-2018; Tamagnini, Paula/AGF-3206-2022; Ravetch, Jeffrey/Z-1596-2019; Lindblad, Peter/ABC-4091-2020; Tamagnini, Paula/A-6613-2010	Troshina, Olga/0000-0003-3319-043X; Tamagnini, Paula/0000-0003-4396-2122; Ravetch, Jeffrey/0000-0003-2024-9041; Lindblad, Peter/0000-0001-7256-0275; Tamagnini, Paula/0000-0003-4396-2122				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; DAERON M, 1992, J IMMUNOL, V149, P1365; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; Galandrini R, 1996, J EXP MED, V183, P179, DOI 10.1084/jem.183.1.179; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KATZ HR, 1992, J IMMUNOL, V148, P868; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; TOKER A, 1994, J BIOL CHEM, V269, P32358	19	632	656	2	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					263	266		10.1038/383263a0	http://dx.doi.org/10.1038/383263a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805703				2022-12-28	WOS:A1996VH31500055
J	FaberLangendoen, K				FaberLangendoen, K			Weight gain in women receiving adjuvant chemotherapy for breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FaberLangendoen, K (corresponding author), UNIV MINNESOTA,DIV MED ONCOL,MINNEAPOLIS,MN 55455, USA.							CHELBOWSKI RT, 1994, CANCER, V74, P2734; CHELBOWSKI RT, 1991, BREAST CANC RES TREA, V20, P73; DEMARKWAHNEFRIED W, 1993, J CLIN ONCOL, V11, P1418, DOI 10.1200/JCO.1993.11.7.1418; HOSKIN PJ, 1992, BREAST CANCER RES TR, V22, P129, DOI 10.1007/BF01833342	4	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					855	856						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782620				2022-12-28	WOS:A1996VF78700004
J	McKnight, A; Cupples, M				McKnight, A; Cupples, M			Secondary prevention of coronary heart disease in primary care is cost effective	BRITISH MEDICAL JOURNAL			English	Letter											McKnight, A (corresponding author), QUEENS UNIV BELFAST,DEPT GEN PRACTICE,DUNLUCE HLTH CTR,BELFAST BT9 7HR,ANTRIM,NORTH IRELAND.							CUPPLES ME, 1994, BRIT MED J, V309, P993, DOI 10.1136/bmj.309.6960.993; Cupples ME, 1996, HLTH ED J, V55, P75; Langham S, 1996, BRIT MED J, V312, P1265, DOI 10.1136/bmj.312.7041.1265; ONEILL C, IN PRESS J EPIDEMIOL; Wonderling D, 1996, BRIT MED J, V312, P1269, DOI 10.1136/bmj.312.7041.1269	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					563	563						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8790013				2022-12-28	WOS:A1996VF29400073
J	Saillour, F; Dabis, F; Dupon, M; Lacoste, D; Trimoulet, P; Rispal, P; Monlun, E; Ragnaud, JM; Morlat, P; Pellegrin, JL; Fleury, H; Couzigou, P				Saillour, F; Dabis, F; Dupon, M; Lacoste, D; Trimoulet, P; Rispal, P; Monlun, E; Ragnaud, JM; Morlat, P; Pellegrin, JL; Fleury, H; Couzigou, P			Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK; SEROPREVALENCE	Objective-To evaluate the prevalence of antibodies to hepatitis C virus and serological markers for hepatitis B virus infection in patients with HIV. Design-Cross sectional survey. Setting-Aquitaine, southwestern France, 1991-94. Subjects-1935 HIV positive patients seen at least once since June 1991. Main outcome measures-Presence of antibodies to hepatitis C virus were detected by second or third generation enzyme linked immunosorbent assay (ELISA) and recombinant immunoblot assay (RIBA) and markers for hepatitis B virus detected by ELISA. Results-The prevalence was 42.5% (823) for antibodies to hepatitis C virus, 56.4 (507) for antibodies to hepatitis B core antigen, 6.9% (133) for hepatitis B surface antigen, 30.2% (584) for antibodies to hepatitis B core and surface antigen with no detectable surface antigen, 26.2% (507) for antibodies to core antigen only, and 4.8% (92) for antibodies to surface antigen only. The prevalence of antibodies to hepatitis C virus was 86.1% (726/843) in subjects who had bloodborne HIV infection and 7.3% (66/899) in those with sexually acquired infection. The prevalence of markers for hepatitis B was higher among homosexuals than in the other groups of patients, except for antibodies to surface antigen alone. The relation between markers for hepatitis B and hepatitis C virus was negative among men but positive among women. Conclusions-The results favour the hypothesis that hepatitis C virus is sexually transmitted much less commonly than either HIV or hepatitis B virus.	UNIV BORDEAUX 2,INSERM,U330,F-33076 BORDEAUX,FRANCE; CHU BORDEAUX,CTR INFORMAT & SOINS IMMUNODEFICIENCE HUMAINE,BORDEAUX,FRANCE; CHU BORDEAUX,MED VIROL LAB,BORDEAUX,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux; CHU Bordeaux			DABIS, FRANCOIS/S-9298-2019	DABIS, FRANCOIS/0000-0002-1614-8857				AOKI SK, 1993, BLOOD, V82, P100; BAATH L, 1992, J VIROL METHODS, V40, P287, DOI 10.1016/0166-0934(92)90087-T; BRICE L, 1994, SOLIDARITE SANTE, V3, P47; DABIS F, 1991, AIDS, V5, P774; DIETZMAN DE, 1977, JAMA-J AM MED ASSOC, V238, P2625, DOI 10.1001/jama.238.24.2625; ESTEBAN JI, 1989, LANCET, V2, P294; FLOMENBERG P, 1995, AIDS, V9, P97; FONG TL, 1991, HEPATOLOGY, V14, P64, DOI 10.1002/hep.1840140111; IWARSON S, 1995, CLIN INFECT DIS, V20, P1361, DOI 10.1093/clinids/20.5.1361; KLEINMAN S, 1992, TRANSFUSION, V32, P805, DOI 10.1046/j.1537-2995.1992.32993110750.x; KWO G, 1989, SCIENCE, V244, P362; LADNER J, 1992, PRESSE MED, V21, P219; LEBOVICS E, 1988, AM J GASTROENTEROL, V83, P1; LEVINE OS, 1994, EPIDEMIOL REV, V16, P418, DOI 10.1093/oxfordjournals.epirev.a036161; NUBLING CM, 1994, J MED VIROL, V44, P49, DOI 10.1002/jmv.1890440110; PILLONEL J, 1992, BEH, V39, P185; QUAN CM, 1993, CLIN INFECT DIS, V17, P117, DOI 10.1093/clinids/17.1.117; *RES NAT SANT PUBL, 1995, GROUP ACT CONC HEP C; SHEEN IS, 1992, J INFECT DIS, V165, P831, DOI 10.1093/infdis/165.5.831; SHERMAN KE, 1991, J INFECT DIS, V163, P414, DOI 10.1093/infdis/163.2.414; WRIGHT TL, 1994, HEPATOLOGY, V20, P1152	21	52	59	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					461	464						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776313	Green Published			2022-12-28	WOS:A1996VE08000020
J	White, IR				White, IR			ABC of work related disorders - Occupational dermatitis	BRITISH MEDICAL JOURNAL			English	Article											White, IR (corresponding author), ST THOMAS HOSP,ST JOHNS INST DERMATOL,LONDON,ENGLAND.							Medical Devices Agency, 1996, LAT SENS HLTH CAR SE	1	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					487	489						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776325				2022-12-28	WOS:A1996VE08000032
J	Denissenko, MF; Pao, A; Tang, MS; Pfeifer, GP				Denissenko, MF; Pao, A; Tang, MS; Pfeifer, GP			Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53	SCIENCE			English	Article							DIPLOID HUMAN FIBROBLASTS; EXCISION REPAIR; DNA ADDUCTS; HPRT GENE; DAMAGE; STRAND; CLUES; CELLS	Cigarette smoke carcinogens such as benzo[a]pyrene are implicated in the development of lung cancer. The distribution of benzo[a]pyrene diol epoxide (BPDE) adducts along exons of the P53 gene in BPDE-treated HeLa cells and bronchial epithelial cells was mapped at nucleotide resolution. Strong and selective adduct formation occurred at guanine positions in codons 157, 248, and 273. These same positions are the major mutational hotspots in human lung cancers. Thus, targeted adduct formation rather than phenotypic selection appears to shape the P53 mutational spectrum in lung cancer. These results provide a direct etiological link between a defined chemical carcinogen and human cancer.	UNIV TEXAS, MD ANDERSON CANC CTR, SMITHVILLE, TX 78957 USA; BECKMAN RES INST CITY HOPE, DEPT BIOL, DUARTE, CA 91010 USA	University of Texas System; UTMD Anderson Cancer Center; City of Hope; Beckman Research Institute of City of Hope					NATIONAL CANCER INSTITUTE [R01CA065652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003124] Funding Source: NIH RePORTER; NCI NIH HHS [CA65652] Funding Source: Medline; NIEHS NIH HHS [ES03124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CHEN RH, 1990, P NATL ACAD SCI USA, V87, P8680, DOI 10.1073/pnas.87.21.8680; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DENISSENKO MF, UNPUB; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HECHT SS, 1993, J CELL BIOCHEM, P27; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PUISIEUX A, 1991, CANCER RES, V51, P6185; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RUGGERI B, 1993, P NATL ACAD SCI USA, V90, P1013, DOI 10.1073/pnas.90.3.1013; SANCAR A, 1993, PHOTOCHEM PHOTOBIOL, V57, P905, DOI 10.1111/j.1751-1097.1993.tb09233.x; Singer B., 1983, MOL BIOL MUTAGENS CA; TANG MS, 1992, BIOCHEMISTRY-US, V31, P8429, DOI 10.1021/bi00151a006; TANG MS, 1996, TECHNOLOGIES DETECTI, P39; TOMALETTI S, 1993, ONCOGENE, V8, P2051; TORNALETTI S, 1995, ONCOGENE, V10, P1493; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VENKATACHALAM S, 1995, CARCINOGENESIS, V16, P2029, DOI 10.1093/carcin/16.9.2029	26	1368	1415	3	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	1996	274	5286					430	432		10.1126/science.274.5286.430	http://dx.doi.org/10.1126/science.274.5286.430			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832894				2022-12-28	WOS:A1996VN17300057
J	Rep, M; vanDijl, JM; Suda, K; Schatz, G; Grivell, LA; Suzuki, CK				Rep, M; vanDijl, JM; Suda, K; Schatz, G; Grivell, LA; Suzuki, CK			Promotion of mitochondrial membrane complex assembly by a proteolytically inactive yeast Lon	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PUTATIVE ATPASES; PROTEIN FAMILY; GENE; MEMBER; ENCODES; CHAPERONE; SEQUENCE; BINDING; OXIDASE	Afg3p and Rca1p are adenosine triphosphate (ATP)-dependent metalloproteases in yeast mitochondria. Cells lacking both proteins exhibit defects in respiration-dependent growth, degradation of mitochondrially synthesized proteins, and assembly of inner-membrane complexes. Defects in growth and protein assembly, but not in degradation, were suppressed by overproduction of yeast mitochondrial Lon, an ATP-dependent serine protease. Suppression by Lon was enhanced by inactivation of the proteolytic site and was prevented by mutation of the ATP-binding site. It is suggested that the mitochondrial proteases Lon, Afg3p, and Rca1p can also serve a chaperone-like function in the assembly of mitochondrial protein complexes.	UNIV BASEL,BIOZENTRUM,BIOCHEM ABT,CH-4056 BASEL,SWITZERLAND; UNIV AMSTERDAM,DEPT MOL CELL BIOL,MOL BIOL SECT,NL-1098 SM AMSTERDAM,NETHERLANDS	University of Basel; University of Amsterdam			van Dijl, Jan Maarten/G-1205-2013	Rep, Martijn/0000-0003-3608-6283				Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; AMERIK AY, 1991, FEBS LETT, V287, P211, DOI 10.1016/0014-5793(91)80053-6; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Guelin E, 1996, FEBS LETT, V381, P42, DOI 10.1016/0014-5793(96)00074-9; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; Langer T, 1995, METHOD ENZYMOL, V260, P495, DOI 10.1016/0076-6879(95)60161-9; LEONHARDT SA, 1993, MOL CELL BIOL, V13, P6304, DOI 10.1128/MCB.13.10.6304; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; MASON TL, 1973, J BIOL CHEM, V248, P1346; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; PAUL MF, 1995, FEBS LETT, V373, P66, DOI 10.1016/0014-5793(95)00979-J; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; Rep M, 1996, FEBS LETT, V388, P185, DOI 10.1016/0014-5793(96)00543-1; Rep M, 1996, CURR GENET, V30, P206, DOI 10.1007/s002940050122; ROSPERT S, 1993, FEBS LETT, V335, P358, DOI 10.1016/0014-5793(93)80419-U; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SUZUKI CK, 1994, SCIENCE, V264, P891, DOI 10.1126/science.8178144; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; TOMOYASU T, 1993, J BACTERIOL, V175, P1344, DOI 10.1128/JB.175.5.1344-1351.1993; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; VANDYCK L, 1994, J BIOL CHEM, V269, P238; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218	30	135	138	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					103	106		10.1126/science.274.5284.103	http://dx.doi.org/10.1126/science.274.5284.103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810243	Green Submitted			2022-12-28	WOS:A1996VK74800057
J	Pushpangadan, M; Burns, E				Pushpangadan, M; Burns, E			Caring for older people: Community services: Health	BRITISH MEDICAL JOURNAL			English	Article								Many frail or disabled elderly people are now being maintained in the community, partially at least as a consequence of the Community Care Act 1993. This paper details the work of the major health professionals who are involved in caring for older people in the community and describes how to access nursing, palliative care, continence, mental health, Hospital at Home, physiotherapy, occupational therapy equipment, and optical, dental, and dietetic services. in many areas, services are evolving to meet needs and some examples of innovative practice are included.			Pushpangadan, M (corresponding author), LEEDS GEN INFIRM,DEPT MED ELDERLY,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.							BARODAWALA S, 1996, BRIT MED J, V313, P741; CORLETT A, IN PRESS BMJ; MULLEY GP, 1991, MORE EVERYDAY AIDS A; MULLEY GP, 1989, EVERYDAY AIDS APPL; *OPCS, 1994, LIVING BRITAIN RE SA; Wattis J, 1996, BRIT MED J, V313, P101, DOI 10.1136/bmj.313.7049.101	6	10	10	2	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					805	808						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842079				2022-12-28	WOS:A1996VK56600034
J	Zerr, I; Bodemer, M; Otto, A; Poser, S; Windl, O; Kretzschmar, HA; Gefeller, O; Weber, T				Zerr, I; Bodemer, M; Otto, A; Poser, S; Windl, O; Kretzschmar, HA; Gefeller, O; Weber, T			Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid	LANCET			English	Article							NEURON-SPECIFIC ENOLASE; EARLY STAGE; PROTEINS	Background The diagnosis of Creutzfeldt-Jakob disease (CJD) is based on clinical and electroencephalographic criteria which do not allow a reliable diagnosis to be made during life. Methods Serum and cerebrospinal fluid (CSF) samples were obtained after informed consent from relatives of suspected cases of CJD referred to the German CJD surveillance unit. CSF samples from 58 definite (neuropathologically verified), 46 probable, and 34 possible CJD cases, and from 44 patients without CJD were analysed by two-dimensional gel electrophoresis (2-DE). Two investigators blinded to clinical findings recorded the presence of two proteins, p130/131. The kappa value for the level of agreement between these investigators was calculated. Results obtained were compared with the determination of neuron-specific enolase (NSE) in CSF. NSE concentrations of more than 35 ng/mL were considered indicative of CJD. Findings p130/131 was detected in 81% of definite (47/58), 80% of probable (37/46), 68% of possible (23/34) CJD cases, and in none of the other 44 cases, NSE concentrations of more than 35 ng/mL were seen in 79% of definite (46/58), 80% of probable (37/46), 59% of possible (20/34) CJD cases, and 9% of other cases (4/43). The positive predictive value for 2-DE of CSF is 100% and the negative predictive value is 69%. The level of agreement for the detection of p130/131 by two evaluators in a subset of 141 2-DE gels was a kappa of 0.93 (95% Cl 0.86-0.99). Of 13 cases initially classified as possible and later reclassified as definite, ten cases were identified correctly by the 2-DE analysis, indicating a better diagnostic accuracy of this test compared with the current clinical classification. None of nine cases classified as other by neuropathology had p130/131 in 2-DE. Interpretation 2-DE for p130/131 is a specific test for the diagnosis of CJD. These data suggest including detection of p130/131 as a criterion for the diagnosis of probable CJD in addition to the currently accepted criteria of a rapidly progressive dementia of less than 2 years duration, typical neurological signs, and periodic sharp-wave complexes in the EEG.	MARIEN HOSP,NEUROL KLIN,D-22087 HAMBURG,GERMANY; UNIV GOTTINGEN,NEUROL KLIN & POLIKLIN,D-3400 GOTTINGEN,GERMANY; UNIV GOTTINGEN,INST NEUROPATHOL,D-3400 GOTTINGEN,GERMANY; UNIV GOTTINGEN,ABT MED STAT,D-3400 GOTTINGEN,GERMANY	St. Marien Hospital; University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen; University of Gottingen			Otto, Markus/F-4304-2015; Gefeller, Olaf/W-9604-2019; Windl, Otto/C-6760-2011	Otto, Markus/0000-0003-4273-4267; Gefeller, Olaf/0000-0002-8985-7582; Weber, Thomas/0000-0002-3833-6197				ALPEROVITCH A, 1994, LANCET, V343, P918, DOI 10.1016/S0140-6736(94)90037-X; BLISARD KS, 1990, J NEUROL SCI, V99, P75, DOI 10.1016/0022-510X(90)90201-W; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BUDKA H, 1995, BRAIN PATHOL, V5, P319, DOI 10.1111/j.1750-3639.1995.tb00609.x; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; ESMONDE TFG, 1992, ANN NEUROL, V31, P230, DOI 10.1002/ana.410310218; Finkenstaedt M, 1996, RADIOLOGY, V199, P793, DOI 10.1148/radiology.199.3.8638007; HARRINGTON MG, 1986, NEW ENGL J MED, V315, P279, DOI 10.1056/NEJM198607313150502; HAYASHI R, 1992, ACTA NEUROL SCAND, V85, P161; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; JIMI T, 1992, CLIN CHIM ACTA, V211, P37, DOI 10.1016/0009-8981(92)90103-W; KOVANEN J, 1985, J COMPUT ASSIST TOMO, V9, P125, DOI 10.1097/00004728-198501000-00023; KRETZSCHMAR HA, 1996, IN PRESS ARCH NEUROL, V53; LEE LKH, 1996, LANCET, V348, P887; LEVY SR, 1986, J CLIN NEUROPHYSIOL, V3, P1, DOI 10.1097/00004691-198601000-00001; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MASULLO C, 1988, EUR J EPIDEMIOL, V4, P482, DOI 10.1007/BF00146403; MOKUNO K, 1983, J NEUROL SCI, V60, P443, DOI 10.1016/0022-510X(83)90155-7; PERRY RT, 1995, AM J MED GENET, V60, P12, DOI 10.1002/ajmg.1320600104; Steinhoff BJ, 1996, ARCH NEUROL-CHICAGO, V53, P162, DOI 10.1001/archneur.1996.00550020074017; TARTARO A, 1993, EUR J RADIOL, V17, P155, DOI 10.1016/0720-048X(93)90095-5; WAKAYAMA Y, 1987, KLIN WOCHENSCHR, V65, P798, DOI 10.1007/BF01743256; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204; YAMAMOTO K, 1992, ANN NEUROL, V32, P114, DOI 10.1002/ana.410320124; ZERR I, 1995, LANCET, V345, P1609, DOI 10.1016/S0140-6736(95)90118-3	27	92	96	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1996	348	9031					846	849		10.1016/S0140-6736(96)08077-4	http://dx.doi.org/10.1016/S0140-6736(96)08077-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826809				2022-12-28	WOS:A1996VK03700009
J	Cavallini, G; Tittobello, A; Frulloni, L; Masci, E; Mariani, A; DiFrancesco, V; Angelini, GP; Casarini, MB; Bedogni, G; Conigliaro, R; Bonardi, L; Khajekini, MTA; Cipolletta, L; Bianco, MA; Costamagna, G; Perri, V; Dobrilla, G; DePretis, G; Familiari, L; Giacobbe, G; Fratton, A; Carone, N; Loriga, P; Muscas, A; Mazzeo, F; Gaeta, L; Miglioli, M; Pezzilli, R; Morelli, A; Santucci, L; Naccarato, R; DelFavero, G; Orlandi, F; Macarri, GP; Russo, A; Virgilio, C; Uomo, G; Manes, G				Cavallini, G; Tittobello, A; Frulloni, L; Masci, E; Mariani, A; DiFrancesco, V; Angelini, GP; Casarini, MB; Bedogni, G; Conigliaro, R; Bonardi, L; Khajekini, MTA; Cipolletta, L; Bianco, MA; Costamagna, G; Perri, V; Dobrilla, G; DePretis, G; Familiari, L; Giacobbe, G; Fratton, A; Carone, N; Loriga, P; Muscas, A; Mazzeo, F; Gaeta, L; Miglioli, M; Pezzilli, R; Morelli, A; Santucci, L; Naccarato, R; DelFavero, G; Orlandi, F; Macarri, GP; Russo, A; Virgilio, C; Uomo, G; Manes, G			Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SPHINCTEROTOMY-INDUCED PANCREATITIS; SOMATOSTATIN ANALOG OCTREOTIDE; ERCP-INDUCED PANCREATITIS; DUCT OBSTRUCTION; MESILATE; MULTICENTER; INHIBITORS; ESTERASE; TRIAL	Background Endoscopic retrograde cholangiopancreatography (ERCP) is associated with elevated levels of pancreatic enzymes and pancreatitis. Gabexate, a protease inhibitor, has been used to prevent pancreatic damage related to ERCP. Methods We conducted a multicenter, double-blind comparison of gabexate (1 g given by intravenous infusion starting 30 to 90 minutes before endoscopy and continuing for 12 hours afterward) with placebo (mannitol and sodium chloride, administered in the same fashion). A total of 435 adults scheduled to undergo ERCP and, when indicated, endoscopic sphincterotomy underwent randomization; 17 were excluded from the final analysis for various reasons. The remaining 418 patients (mean age, 60.4 years) - 208 in the gabexate group and 210 in the placebo group - were analyzed. Acute pancreatitis was considered to be present if serum amylase or lipase levels (or both) were five times greater than the upper limits of normal in association with the onset of pancreatic pain, Results After the procedures, 276 patients (66 percent) had elevated pancreatic-enzyme levels; the frequency was similar in the two groups. Mean serum amylase values were higher in the placebo group than in the gabexate group through 24 hours of observation (P=0.03). Twelve patients in the gabexate group and 29 in the placebo group had abdominal pain (6 percent vs. 14 percent, P=0.009). Sixteen patients in the placebo group and five in the gabexate group had acute pancreatitis (8 percent vs. 2 percent, P=0.03). Two patients treated with gabexate and six given placebo had adverse events, all of which resolved, Two patients given placebo died of acute pancreatitis; one was excluded from the evaluation because pancreatitis was present before endoscopy. One patient in the gabexate group died, from a myocardial infarction. Conclusions Prophylactic treatment with gabexate reduced pancreatic damage related to ERCP, as reflected by reductions in the extent but not the frequency of elevated enzyme levels and in the frequency of pancreatic pain and acute pancreatitis.	UNIV VERONA,CATTEDRA GASTROENTEROL,I-37100 VERONA,ITALY; OSPED SAN RAFFAELE,SERV GASTROENTEROL & ENDOSCPIA DIGEST,MILAN,ITALY; OSPED SANTA MARIA NUOVA,REGGIO EMILIA,ITALY; PRESIDIO SANIT GRADENIGO,TURIN,ITALY; OSPED TORRE GRECO,NAPLES,ITALY; POLICLIN GEMELLI,ROME,ITALY; OSPED GEN REG,BOLZANO,ITALY; POLICLIN UNIV,MESSINA,ITALY; OSPED BORGO TRENTO,VERONA,ITALY; OSPED S MARIA TRINITA,CAGLIARI,ITALY; POLICLIN 2,NAPLES,ITALY; POLICLIN S ORSOLA,BOLOGNA,ITALY; MONTELUCE POLICLIN,PERUGIA,ITALY; OSPED CIVILE,PADUA,ITALY; UNIV ANCONA,ANCONA,ITALY; DIAGNOST & CHIRURG ENDOSCOP,CATANIA,ITALY; OSPED CARDERELLI,NAPLES,ITALY	University of Verona; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS Arcispedale S. Maria Nuova; Humanitas Hospital Gradenigo; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; AOU Policlinico Gaetano Martino; University of Messina; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Marche Polytechnic University			Di Francesco, Vincenzo/AAA-4813-2020; Frulloni, Luca/E-5244-2012; Masci, Enzo/AAC-1746-2020; Pezzilli, Raffaele/H-8280-2019	Frulloni, Luca/0000-0001-7417-2655; Masci, Enzo/0000-0001-9150-4498; Pezzilli, Raffaele/0000-0001-9827-7451				ARCIDIACONO R, 1994, ENDOSCOPY, V26, P715, DOI 10.1055/s-2007-1009081; BENINI I, 1985, DIGESTION, V32, P165; BINMOELLER KF, 1992, GUT, V33, P1129, DOI 10.1136/gut.33.8.1129; Blackwood W D, 1973, Gastrointest Endosc, V20, P56, DOI 10.1016/S0016-5107(73)73873-6; BORDAS JM, 1988, HORM RES, V29, P106, DOI 10.1159/000180981; BORSCH G, 1984, MED WELT, V35, P109; BUCHLER M, 1993, GASTROENTEROLOGY, V104, P1165; CHEN YK, 1994, AM J GASTROENTEROL, V89, P327; INADA Y, 1980, GENDAI IRYO, V12, P1493; KOCH H, 1975, ENDOSCOPY, V7, P221, DOI 10.1055/s-0028-1098577; KUNO N, 1978, GENDAI IRYO, V10, P571; LaFerla G, 1986, Pancreas, V1, P160, DOI 10.1097/00006676-198603000-00009; MATSUNAGA E, 1979, GENDAI IRYO, V11, P1213; NIEDERAU C, 1986, J CLIN INVEST, V78, P1056, DOI 10.1172/JCI112661; NISHIJIMA MK, 1983, THROMB RES, V31, P279, DOI 10.1016/0049-3848(83)90330-4; ODES HS, 1977, DIGESTION, V16, P180, DOI 10.1159/000198070; OHSHIO G, 1989, GASTROENTEROLOGY, V96, P853; OHSHIO G, 1991, GASTROENTEROLOGY, V100, P196, DOI 10.1016/0016-5085(91)90601-G; PEDERZOLI P, 1993, INT J PANCREATOL, V14, P117; SAARI A, 1988, SURG RES COMMUN, V24, P271; SALOMON V, 1982, PROT INH FOY WORKSH, P132; SALUJA A, 1989, J CLIN INVEST, V84, P1260, DOI 10.1172/JCI114293; SAND J, 1993, DIGESTION, V54, P105, DOI 10.1159/000201021; SHERMAN S, 1994, GASTROINTEST ENDOSC, V40, P422, DOI 10.1016/S0016-5107(94)70204-7; SHERMAN S, 1991, PANCREAS, V6, P350, DOI 10.1097/00006676-199105000-00013; SHERMAN S, 1994, AM J GASTROENTEROL, V89, P303; SHERMAN S, 1992, PANCREAS, V7, P402; SILVIS SE, 1975, GASTROINTEST ENDOSC, V21, P162, DOI 10.1016/S0016-5107(75)73837-3; SKUDE G, 1976, GUT, V17, P127, DOI 10.1136/gut.17.2.127; STERNLIEB JM, 1992, AM J GASTROENTEROL, V87, P1561; TAMURA Y, 1977, BIOCHIM BIOPHYS ACTA, V484, P417, DOI 10.1016/0005-2744(77)90097-3; TESTONI PA, 1988, ITAL J GASTROENTEROL, V20, P70; TSUNASSHIMA T, 1979, GENDAI IRYO, V11, P543; VAIRA D, 1989, LANCET, V2, P431; WAKAYAMA T, 1989, AM J GASTROENTEROL, V84, P272; WISNER JR, 1987, PANCREAS, V2, P181, DOI 10.1097/00006676-198703000-00010	36	311	322	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1996	335	13					919	923		10.1056/NEJM199609263351302	http://dx.doi.org/10.1056/NEJM199609263351302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK148	8786777	Bronze			2022-12-28	WOS:A1996VK14800002
J	Iglehart, JK				Iglehart, JK			The National Committee for Quality Assurance	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE											*AM ASS HLTH PLANS, 1996, GUID ACCR; ANDERS G, 1996, WALL STREET J   0716, pA4; ANDERS G, 1996, WALL STREET J   0716, pA3; AUERBACH S, 1996, WASH POST HLTH  0625, P12; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; FREUDENHEIM M, 1996, NY TIMES        0130, pD1; FREUDENHEIM M, 1996, NY TIMES        0716, pD5; GOTTLIEB M, 1996, NY TIMES        0114, pF1; Greenfield Lee, 1996, EVALUATING QUALITY H; Iglehart JK, 1996, NEW ENGL J MED, V334, P131, DOI 10.1056/NEJM199601113340221; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; MAHAR M, 1996, BARRONS         0304, P29; MARKSON LE, 1995, ACCOUNTABILITY QUALI; *NCQA, 1996, M COMM PERF MEAS JUN; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; ROPER WL, 1996, LOOKING BACK LOOKING, P39; SEGAL D, 1996, WASHINGTON POST 0119, pF1; SPRAGINS E, 1996, NEWSWEEK        0624, P56	22	86	86	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1996	335	13					995	999		10.1056/NEJM199609263351322	http://dx.doi.org/10.1056/NEJM199609263351322			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK148	8786789				2022-12-28	WOS:A1996VK14800036
J	Hoeg, JM				Hoeg, JM			Can genes prevent atherosclerosis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; APOLIPOPROTEIN-A-I; ULTRAFAST COMPUTED-TOMOGRAPHY; FAMILIAL HYPERCHOLESTEROLEMIA; CHOLESTEROL LEVELS; TRANSGENIC MICE; FRAMINGHAM; MORTALITY; ATHEROGENESIS				Hoeg, JM (corresponding author), NHLBI, MOL DIS BRANCH, NIH, BLDG 10, ROOM 7N115, BETHESDA, MD 20892 USA.							Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; BADIMON JJ, 1990, J CLIN INVEST, V85, P1234, DOI 10.1172/JCI114558; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; Berg K, 1981, Prog Clin Biol Res, V69 Pt C, P117; BRUCE C, 1995, CURR OPIN LIPIDOL, V6, P306, DOI 10.1097/00041433-199510000-00010; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CHEUNG MC, 1989, J LIPID RES, V30, P499; CHEUNG MC, 1991, J LIPID RES, V32, P383; DUVERGER N, 1991, ADV EXP MED BIOL, V285, P93; ETTINGER WH, 1989, MED CLIN N AM, V73, P1525, DOI 10.1016/S0025-7125(16)30614-9; FLEISHER LN, 1982, J BIOL CHEM, V257, P6653; GLOMSET JA, 1968, J LIPID RES, V9, P155; GLUECK CJ, 1975, METABOLISM, V24, P1243, DOI 10.1016/0026-0495(75)90063-3; GOFMAN JW, 1966, CIRCULATION, V34, P679, DOI 10.1161/01.CIR.34.4.679; GOLDBOURT U, 1990, ARTERIOSCLEROSIS, V10, P512, DOI 10.1161/01.ATV.10.4.512; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HOEG JM, 1994, ARTERIOSCLER THROMB, V14, P1066, DOI 10.1161/01.ATV.14.7.1066; HOEG JM, 1994, JAMA-J AM MED ASSOC, V271, P543, DOI 10.1001/jama.271.7.543; HOEG JM, 1994, GENETIC FACTORS CORO, P351; IKEWAKI K, 1993, J CLIN INVEST, V92, P1650, DOI 10.1172/JCI116750; KANNEL WB, 1986, AM HEART J, V112, P825, DOI 10.1016/0002-8703(86)90481-3; KARATHANASIS SK, 1987, P NATL ACAD SCI USA, V84, P7198, DOI 10.1073/pnas.84.20.7198; LEAF A, 1988, NUTR REV, V46, P40, DOI 10.1111/j.1753-4887.1988.tb05385.x; LUSIS AJ, 1988, J LIPID RES, V29, P397; MATSUNAGA T, 1991, P NATL ACAD SCI USA, V88, P2793, DOI 10.1073/pnas.88.7.2793; MILLER GJ, 1975, LANCET, V1, P16; ORDOVAS JM, 1989, J BIOL CHEM, V264, P16339; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PATSCH JR, 1983, P NATL ACAD SCI-BIOL, V80, P1449, DOI 10.1073/pnas.80.5.1449; POMERANTZ KB, 1985, J LIPID RES, V26, P1269; RADER DJ, 1993, METABOLISM, V42, P1429, DOI 10.1016/0026-0495(93)90194-S; RENAUD S, 1989, J INTERN MED, V225, P39, DOI 10.1111/j.1365-2796.1989.tb01434.x; RIFKIND BM, 1983, JAMA-J AM MED ASSOC, V250, P1869, DOI 10.1001/jama.250.14.1869; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SCHAEFER EJ, 1989, METABOLISM, V38, P293, DOI 10.1016/0026-0495(89)90113-3; SHEKELLE RB, 1989, LANCET, V1, P1177; Shih DM, 1996, J CLIN INVEST, V97, P1630, DOI 10.1172/JCI118589; SPARKS CE, 1981, J LIPID RES, V22, P519; TSELEPIS AD, 1995, ARTERIOSCL THROM VAS, V15, P1764, DOI 10.1161/01.ATV.15.10.1764; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	48	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1996	276	12					989	992						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH990	8805735				2022-12-28	WOS:A1996VH99000041
J	Foulkes, WD; Brunet, JS; Sieh, W; Black, MJ; Shenouda, G; Narod, SA				Foulkes, WD; Brunet, JS; Sieh, W; Black, MJ; Shenouda, G; Narod, SA			Familial risks of squamous cell carcinoma of the head and neck: Retrospective case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UPPER AERODIGESTIVE TRACT; 2ND PRIMARY TUMORS; LUNG-CANCER RISK; MUTAGEN SENSITIVITY; PHARYNGEAL CANCER; ESOPHAGEAL CANCER; MAJOR CANCERS; ORAL-CANCER; HISTORY; SMOKING	Objective-To determine the contribution of inheritance to the incidence of squamous cell carcinoma of the head and neck. Design-Historical cohort study. First degree relatives of cases with squamous cell carcinoma of the head and neck made up the exposed cohort and first degree relatives of spouses of cases made up the comparison unexposed cohort. Setting-Ear, nose, and throat clinic in a large metropolitan teaching hospital. Subjects-1429 first degree relatives of 242 index cases of squamous cell carcinoma of the head and neck; as controls, 934 first degree relatives of the spouses of 156 index cases. Main outcome measures-Relative risk of developing squamous cell carcinoma in first degree relatives of cases compared with risk in first degree relatives of spouses. Results-The adjusted relative risk for developing head and neck cancer if the index case had squamous cell carcinoma of the head and neck was 3.79 (95% confidence interval 1.11 to 13.0). There were no significantly increased risks associated with a family history of cancer at other sites. The adjusted relative risk for squamous cell carcinoma of the head and neck was 7.89 (1.50 to 41.6) in first degree relatives of patients with multiple primary head and neck tumours. Conclusions-These data suggest that genetic factors are important in the aetiology of head and neck cancer, in particular for patients with multiple primary cancers. Given the prolonged exposure of these subjects to carcinogens, these genetic factors may have a role in modifying carcinogen activity or in host resistance to carcinogens. Inherited factors may be important in persons with environmentally induced cancers.	MCGILL UNIV, SIR MORTIMER B DAVIS JEWISH GEN HOSP, MONTREAL, PQ H3T 1E2, CANADA	McGill University	Foulkes, WD (corresponding author), MCGILL UNIV, MONTREAL GEN HOSP,DEPT MED,DIV MED GENET, ROOM L10-116, 1650 CEDAR AVE, MONTREAL, PQ H3G 1A4, CANADA.		Foulkes, William D./AAR-9586-2021; Narod, Steven A/AAA-6112-2022	Foulkes, William D./0000-0001-7427-4651; 				AITKEN J, 1995, AM J EPIDEMIOL, V141, P863, DOI 10.1093/oxfordjournals.aje.a117522; BLOT WJ, 1988, CANCER RES, V48, P3282; BONDY ML, 1993, CANCER EPIDEM BIOMAR, V2, P103; BRAUN MM, 1994, LANCET, V344, P440, DOI 10.1016/S0140-6736(94)91770-1; Califano J, 1996, CANCER RES, V56, P2488; COPPER MP, 1995, ARCH OTOLARYNGOL, V121, P157; DAY GL, 1993, JNCI-J NATL CANCER I, V85, P465, DOI 10.1093/jnci/85.6.465; DAY GL, 1992, CANCER, V70, P14, DOI 10.1002/1097-0142(19920701)70:1<14::AID-CNCR2820700103>3.0.CO;2-S; ELWOOD JM, 1984, INT J CANCER, V34, P603, DOI 10.1002/ijc.2910340504; Foulkes WD, 1995, INT J CANCER, V63, P769, DOI 10.1002/ijc.2910630603; FRANCO EL, 1989, INT J CANCER, V43, P992, DOI 10.1002/ijc.2910430607; GHADIRIAN P, 1985, CANCER-AM CANCER SOC, V56, P2112, DOI 10.1002/1097-0142(19851015)56:8<2112::AID-CNCR2820560838>3.0.CO;2-3; GOLDGAR DE, 1994, J NATL CANCER I, V86, P1600, DOI 10.1093/jnci/86.21.1600; HERRMANN N, 1985, AM J EPIDEMIOL, V121, P937, DOI 10.1093/oxfordjournals.aje.a114064; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; LI JY, 1989, INT J CANCER, V43, P755, DOI 10.1002/ijc.2910430502; LONDON SJ, 1995, J NATL CANCER I, V87, P1246, DOI 10.1093/jnci/87.16.1246; LOVE RR, 1985, J CHRON DIS, V38, P289, DOI 10.1016/0021-9681(85)90074-8; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; MORITA M, 1994, INT J CANCER, V58, P207, DOI 10.1002/ijc.2910580211; OOI WL, 1986, J NATL CANCER I, V76, P217; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PINTOS J, 1994, EPIDEMIOLOGY, V5, P583, DOI 10.1097/00001648-199411000-00005; SAMET JM, 1986, AM REV RESPIR DIS, V134, P466; SAS, 1988, SAS STAT US GUID REL; SELLERS TA, 1987, AM J EPIDEMIOL, V126, P237, DOI 10.1093/aje/126.2.237; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SPITZ MR, 1994, J NATL CANCER I, V86, P1681, DOI 10.1093/jnci/86.22.1681; *STAT CAN, 1990 CANC CAN, P28; TOKUHATA GEORGE K., 1963, JOUR NATL CANCER INST, V30, P289; TRIZNA Z, 1992, OTOLARYNG CLIN N AM, V25, P1089; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; Wu AH, 1996, AM J EPIDEMIOL, V143, P535; WYNDER EL, 1957, CANCER, V10, P1300, DOI 10.1002/1097-0142(195711/12)10:6&lt;1300::AID-CNCR2820100628&gt;3.0.CO;2-2; WYNDER EL, 1977, CANCER RES, V37, P4608	37	105	105	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	1996	313	7059					716	721						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819440	Green Published			2022-12-28	WOS:A1996VJ44100021
J	Gaillard, PHL; Martini, EMD; Kaufman, PD; Stillman, B; Moustacchi, E; Almouzni, G				Gaillard, PHL; Martini, EMD; Kaufman, PD; Stillman, B; Moustacchi, E; Almouzni, G			Chromatin assembly coupled to DNA repair: A new role for chromatin assembly factor I	CELL			English	Article							NUCLEOTIDE EXCISION-REPAIR; XENOPUS-LAEVIS OOCYTES; HUMAN CELL-EXTRACTS; SIMIAN VIRUS-40 DNA; REPLICATION INVITRO; FREE SYSTEM; DROSOPHILA EMBRYOS; HISTONE COMPLEXES; BINDING-PROTEIN; TRANSCRIPTION	DNA repair in the eukaryotic cell disrupts local chromatin organization. To investigate whether the resetting of nucleosomal arrays can be linked to the repair process, we developed model systems, with both Xenopus egg extract and human cell extracts, to follow repair and chromatin assembly in parallel on circular DNA templates. Both systems were able to carry out nucleotide excision repair of DNA lesions. We observed that UV-dependent DNA synthesis occurs simultaneously with chromatin assembly, strongly indicating a mechanistic coupling between the two processes. A complementation assay established that chromatin assembly factor I (CAF1) is necessary for this repair-associated chromatin formation.	INST CURIE,RES SECT,UMR218 CNRS,F-75231 PARIS 05,FRANCE; INST CURIE,RES SECT,LRC 1 CEA,F-75231 PARIS 05,FRANCE; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Cold Spring Harbor Laboratory	Gaillard, PHL (corresponding author), INST CURIE,RES SECT,UMR144 CNRS,26 RUE ULM,F-75231 PARIS 05,FRANCE.		Almouzni, Genevieve/ABG-1029-2021; gaillard, pierre-henri/AAC-6004-2020	Almouzni, Genevieve/0000-0001-5570-0723; gaillard, pierre-henri/0000-0003-0781-0826; Stillman, Bruce/0000-0002-9453-4091; Kaufman, Paul/0000-0003-3089-313X				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ALMOUZNI G, 1988, EMBO J, V7, P665, DOI 10.1002/j.1460-2075.1988.tb02861.x; ALMOUZNI G, 1993, EXP CELL RES, V205, P1, DOI 10.1006/excr.1993.1051; ALMOUZNI G, 1988, EMBO J, V7, P4355, DOI 10.1002/j.1460-2075.1988.tb03334.x; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; BANERJEE S, 1990, MOL CELL BIOL, V10, P2863, DOI 10.1128/MCB.10.6.2863; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULGER M, 1995, P NATL ACAD SCI USA, V92, P11726, DOI 10.1073/pnas.92.25.11726; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; FRIEDBERG EC, 1995, DNA REPAIR; GERMOND JE, 1979, P NATL ACAD SCI USA, V76, P3779, DOI 10.1073/pnas.76.8.3779; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; GRUSS C, 1993, EMBO J, V12, P4533, DOI 10.1002/j.1460-2075.1993.tb06142.x; GURDON JB, 1986, METHOD CELL BIOL, V15, P270; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1991, J BIOL CHEM, V266, P7025; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kamakaka RT, 1996, MOL CELL BIOL, V16, P810; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LASKEY RA, 1993, PHILOS T ROY SOC B, V339, P263, DOI 10.1098/rstb.1993.0024; LEGERSKI RJ, 1987, MOL CELL BIOL, V7, P4317, DOI 10.1128/MCB.7.12.4317; LI JJ, 1985, MOL CELL BIOL, V5, P12038; MATSUMOTO H, 1995, PHOTOCHEM PHOTOBIOL, V61, P459, DOI 10.1111/j.1751-1097.1995.tb02345.x; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; NELSON T, 1979, P NATL ACAD SCI USA, V76, P5510, DOI 10.1073/pnas.76.11.5510; NELSON T, 1981, BIOCHEMISTRY-US, V20, P2594, DOI 10.1021/bi00512a035; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; RYOJI M, 1989, NUCLEIC ACIDS RES, V17, P10243, DOI 10.1093/nar/17.24.10243; SAXENA JK, 1990, NUCLEIC ACIDS RES, V18, P7425, DOI 10.1093/nar/18.24.7425; SEALY L, 1986, BIOCHEMISTRY-US, V25, P3064, DOI 10.1021/bi00358a049; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SMERDON M, 1992, DNA REPAIR MECH THEI; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SMITH S, 1991, J BIOL CHEM, V266, P12041; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; SUGASAWA K, 1993, J BIOL CHEM, V268, P9098; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; TRAVERS AA, 1994, BIOESSAYS, V16, P657, DOI 10.1002/bies.950160911; TURNER BM, 1995, BIOESSAYS, V17, P1013, DOI 10.1002/bies.950171204; WANG ZG, 1991, J BIOL CHEM, V266, P22472; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WOLFFE AP, 1994, CURR OPIN GENET DEV, V4, P245, DOI 10.1016/S0959-437X(05)80051-6; WOLFFE AP, 1994, DEV GENET, V15, P463, DOI 10.1002/dvg.1020150604; WOOD RD, 1993, COLD SPRING HARB SYM, V58, P625, DOI 10.1101/SQB.1993.058.01.069; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022	64	275	281	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					887	896		10.1016/S0092-8674(00)80164-6	http://dx.doi.org/10.1016/S0092-8674(00)80164-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808624	Bronze			2022-12-28	WOS:A1996VJ44300007
J	Kohler, M; Hirschberg, B; Bond, CT; Kinzie, JM; Marrion, NV; Maylie, J; Adelman, JP				Kohler, M; Hirschberg, B; Bond, CT; Kinzie, JM; Marrion, NV; Maylie, J; Adelman, JP			Small-conductance, calcium-activated potassium channels from mammalian brain	SCIENCE			English	Article							RAT HIPPOCAMPAL-NEURONS; ACTION-POTENTIAL REPOLARIZATION; VAGAL MOTONEURONS; AFTER-HYPERPOLARIZATION; PYRAMIDAL CELLS; ION CHANNELS; K+ CHANNELS; AFTERHYPERPOLARIZATION; CURRENTS; CA2+	Members of a previously unidentified family of potassium channel subunits were cloned from rat and human brain. The messenger RNAs encoding these subunits were widely expressed in brain with distinct yet overlapping patterns, as well as in several peripheral tissues. Expression of the messenger RNAs in Xenopus oocytes resulted in calcium-activated, voltage-independent potassium channels. The channels that formed from the various subunits displayed differential sensitivity to apamin and tubocurare. The distribution, function, and pharmacology of these channels are consistent with the SK class of small-conductance, calcium-activated potassium channels, which contribute to the afterhyperpolarization in central neurons and other cell types.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT OBSTET & GYNECOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University								ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; ARTALEJO AR, 1993, PFLUG ARCH EUR J PHY, V423, P97, DOI 10.1007/BF00374966; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dawson R. M. C., 1991, DATA BIOCH RES, V3rd, P363; DUN NJ, 1986, J PHYSIOL-LONDON, V375, P499, DOI 10.1113/jphysiol.1986.sp016130; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GELHERT DR, 1993, NEUROSCIENCE, V52, P191; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; GRISSMER S, 1992, J GEN PHYSIOL, V99, P63, DOI 10.1085/jgp.99.1.63; GUSTAFSSON B, 1981, BRAIN RES, V206, P462, DOI 10.1016/0006-8993(81)90548-5; HOTSON JR, 1980, J NEUROPHYSIOL, V43, P409, DOI 10.1152/jn.1980.43.2.409; HOUAMED KM, 1991, SCIENCE, V349, P760; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; LANCASTER B, 1994, J PHYSIOL-LONDON, V475, P229, DOI 10.1113/jphysiol.1994.sp020064; LANCASTER B, 1991, J NEUROSCI, V11, P23; LANCASTER B, 1986, J NEUROPHYSIOL, V55, P1268, DOI 10.1152/jn.1986.55.6.1268; LANCASTER B, 1987, J PHYSIOL-LONDON, V389, P187, DOI 10.1113/jphysiol.1987.sp016653; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PARK Y, 1994, J PHYSIOL-LONDON, V481, P555, DOI 10.1113/jphysiol.1994.sp020463; Pedarzani P, 1996, PFLUG ARCH EUR J PHY, V431, P723, DOI 10.1007/s004240050057; SAH P, 1995, J NEUROPHYSIOL, V74, P1772, DOI 10.1152/jn.1995.74.4.1772; SAH PAJ, 1992, J NEUROPHYSIOL, V68, P1834, DOI 10.1152/jn.1992.68.5.1834; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; VIANA F, 1993, J NEUROPHYSIOL, V69, P2150, DOI 10.1152/jn.1993.69.6.2150; YAROM Y, 1985, NEUROSCIENCE, V16, P719, DOI 10.1016/0306-4522(85)90090-9; ZHANG L, 1995, J PHYSIOL-LONDON, V488, P861	32	768	792	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1996	273	5282					1709	1714		10.1126/science.273.5282.1709	http://dx.doi.org/10.1126/science.273.5282.1709			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781233				2022-12-28	WOS:A1996VH40800040
J	Knight, RT				Knight, RT			Contribution of human hippocampal region to novelty detection	NATURE			English	Article							INTRACEREBRAL POTENTIALS; RECOGNITION MEMORY; PREFRONTAL CORTEX; VISUAL-STIMULI; RHESUS-MONKEY; RARE TARGET; LESIONS; WORKING; LOBE; P300	THE ability to respond to unexpected stimuli (the 'orienting response') is a fundamental characteristic of mammalian behaviour(1), but the brain mechanisms by which novelty is detected remain poorly defined. Electrophysiological recordings of scalp and intracranial event-related potentials (ERPs) have shown that novel stimuli activate a distributed network involving prefrontal and posterior association cortex(2-6). In addition, ERP(7,8) and single-neuron(9,10) recordings, as well as neuroimaging(11) and modelling(12) studies, have suggested that temporal cortical regions, including the hippocampus, are also involved. To examine further the role of the medial temporal lobe in novelty processing, I measured physiological responses to novel auditory and tactile stimuli in patients with damage to the posterior hippocampal region. In normal control subjects, unexpected novel stimuli produce a characteristic ERP signal, accompanied by an autonomic skin response. Both responses are reduced in hippocampal lesion patients, whereas the response to expected control stimuli is unaffected. Thus the hippocampal region, in addition to its known role in memory formation, is an essential component of the distributed limbic-cortical network that detects and responds to novel stimuli.			Knight, RT (corresponding author), UNIV CALIF DAVIS,CTR VET MED,CTR NEUROSCI,DEPT NEUROL,150 MUIR RD,MARTINEZ,CA 94553, USA.							BAUDENA P, 1995, ELECTROEN CLIN NEURO, V94, P251, DOI 10.1016/0013-4694(95)98476-O; COURCHESNE E, 1975, ELECTROEN CLIN NEURO, V39, P131, DOI 10.1016/0013-4694(75)90003-6; DERENZI E, 1987, BRAIN, V110, P1099, DOI 10.1093/brain/110.5.1099; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; FRIEDMAN HR, 1994, J NEUROSCI, V14, P2775; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; GUTRECHT JA, 1994, J CLIN NEUROPHYSIOL, V11, P519, DOI 10.1097/00004691-199409000-00006; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P191, DOI 10.1016/0013-4694(94)00259-N; Halgren Eric, 1995, P1137; KARIS D, 1984, COGNITIVE PSYCHOL, V16, P177, DOI 10.1016/0010-0285(84)90007-0; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; KNIGHT RT, 1989, BRAIN RES, V502, P109, DOI 10.1016/0006-8993(89)90466-6; METCALFE J, 1993, PSYCHOL REV, V100, P3, DOI 10.1037/0033-295X.100.1.3; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; ONOFRJ M, 1992, NEUROLOGY, V42, P1762, DOI 10.1212/WNL.42.9.1762; POLICH J, 1993, ELECTROEN CLIN NEURO, V86, P408, DOI 10.1016/0013-4694(93)90136-J; RENAULT B, 1982, SCIENCE, V215, P1413, DOI 10.1126/science.7063853; RICHARDSON B C, 1992, Neurology, V42, P170; Risold PY, 1996, SCIENCE, V272, P1484, DOI 10.1126/science.272.5267.1484; ROLLS ET, 1993, EXP BRAIN RES, V93, P299; Scabini D., 1993, Society for Neuroscience Abstracts, V19, P564; SOKOLOV EN, 1963, ANNU REV PHYSIOL, V25, P545, DOI 10.1146/annurev.ph.25.030163.002553; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; Tulving E, 1996, CEREB CORTEX, V6, P71, DOI 10.1093/cercor/6.1.71; Van Hoesen GW, 1996, NEUROPSYCHIATRY, P113; von Restorff H, 1933, PSYCHOL FORSCH, V18, P299, DOI 10.1007/BF02409636; VONCRAMON DY, 1988, BRAIN, V111, P1061, DOI 10.1093/brain/111.5.1061; WOODS DL, 1993, COGNITIVE BRAIN RES, V1, P227, DOI 10.1016/0926-6410(93)90007-R; YAMAGUCHI S, 1991, J NEUROSCI, V11, P2039	30	644	693	2	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					256	259		10.1038/383256a0	http://dx.doi.org/10.1038/383256a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805701				2022-12-28	WOS:A1996VH31500053
J	Shieh, HS; Kurumbail, RG; Stevens, AM; Stegeman, RA; Sturman, EJ; Pak, JY; Wittwer, AJ; Palmier, MO; Wiegand, RC; Holwerda, BC; Stallings, WC				Shieh, HS; Kurumbail, RG; Stevens, AM; Stegeman, RA; Sturman, EJ; Pak, JY; Wittwer, AJ; Palmier, MO; Wiegand, RC; Holwerda, BC; Stallings, WC			Three dimensional structure of human cytomegalovirus protease	NATURE			English	Article							HERPES-SIMPLEX VIRUS; MATURATIONAL PROTEINASE; INTERFACE PEPTIDES; CLEAVAGE SITES; IDENTIFICATION; RESOLUTION; GENE; REFINEMENT; EXPRESSION; SUBSTRATE	HERPESVIRUSES encode a serine protease(1,2) that specifically cleaves assembly protein(3). This protease is critical for replication(4), and represents a new target for antiviral drug design(5). Here we report the three-dimensional structure of the protease from human cytomegalovirus (hCMV) at 2.27 Angstrom resolution. The structure reveals a unique fold and new catalytic strategy for cleavage. The monomer fold of the enzyme, a seven-stranded beta-barrel encircled by a chain of helices that form the carboxy terminus of the molecule, is unrelated to those observed in classic serine proteases such as chymotrypsin and subtilisin. The serine nucleophile at position 132 is activated by two juxtaposed histidine residues at positions 63 and 157. Dimerization, which seems to be necessary for activity(6,7), is observed in the crystals. Correlations of the structure with the sequences of herpesvirus proteases(1,5,8) suggest that dimerization may confer specificity and recognition in substrate binding.	MONSANTO SEARLE,SEARLE DISCOVERY RES,DEPT INFECT DIS,ST LOUIS,MO 63198; MONSANTO SEARLE,SEARLE DISCOVERY RES,DEPT BIOL SCI,ST LOUIS,MO 63198	Monsanto; Monsanto	Shieh, HS (corresponding author), MONSANTO SEARLE,SEARLE DISCOVERY RES,DEPT MED & STRUCT CHEM,700 CHESTERFIELD PKWY N,ST LOUIS,MO 63198, USA.							BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003; BAUM EZ, 1993, J VIROL, V67, P497, DOI 10.1128/JVI.67.1.497-506.1993; BODE W, 1987, EUR J BIOCHEM, V166, P673, DOI 10.1111/j.1432-1033.1987.tb13566.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURCK PJ, 1994, J VIROL, V68, P2937, DOI 10.1128/JVI.68.5.2937-2946.1994; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COX GA, 1995, J VIROL, V69, P4524, DOI 10.1128/JVI.69.7.4524-4528.1995; Darke PL, 1996, J BIOL CHEM, V271, P7445, DOI 10.1074/jbc.271.13.7445; DILANNI CL, 1993, J BIOL CHEM, V268, P25449; DILANNI CL, 1994, J BIOL CHEM, V269, P12672; DIVITA G, 1995, J BIOL CHEM, V270, P28642, DOI 10.1074/jbc.270.48.28642; FUREY W, IN PRESS METHODS ENZ; GIBSON W, 1972, J VIROL, V10, P1044, DOI 10.1128/JVI.10.5.1044-1052.1972; Gibson W., 1995, PERSPECT DRUG DISCOV, V2, P413; HOLWERDA BC, 1994, J BIOL CHEM, V269, P25911; HUBER R, 1974, J MOL BIOL, V89, P73, DOI 10.1016/0022-2836(74)90163-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TR, 1994, J VIROL, V68, P3742, DOI 10.1128/JVI.68.6.3742-3752.1994; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LOUTSCH JM, 1994, BIOCHEM BIOPH RES CO, V203, P472, DOI 10.1006/bbrc.1994.2206; Margosiak SA, 1996, BIOCHEMISTRY-US, V35, P5300, DOI 10.1021/bi952842u; MURZIN AG, 1994, J MOL BIOL, V236, P1382, DOI 10.1016/0022-2836(94)90065-5; OTINOWSKI Z, 1993, P CCP4 STUD WEEK DAT; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; WELCH AR, 1991, P NATL ACAD SCI USA, V88, P10792, DOI 10.1073/pnas.88.23.10792; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993	30	154	160	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					279	282		10.1038/383279a0	http://dx.doi.org/10.1038/383279a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805708				2022-12-28	WOS:A1996VH31500060
J	Rodowski, MF				Rodowski, MF			Doctor's orders	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Rodowski, MF (corresponding author), JEFFERSON MED COLL, 210 HAYSTACK LANE, GREENVILLE, DE 19807 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					512	512		10.7326/0003-4819-125-6-199609150-00015	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00015			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779467				2022-12-28	WOS:A1996VF88200016
J	Shen, WK; Hayes, DL; Hammill, SC; Bailey, KR; Ballard, DJ; Gersh, BJ				Shen, WK; Hayes, DL; Hammill, SC; Bailey, KR; Ballard, DJ; Gersh, BJ			Survival and functional independence after implantation of a permanent pacemaker in octogenarians and nonagenarians - A population-based study	ANNALS OF INTERNAL MEDICINE			English	Article							SICK SINUS SYNDROME; LONG-TERM SURVIVAL; ATRIOVENTRICULAR-BLOCK; HEART-BLOCK; FOLLOW-UP; PROGNOSIS; MODE; AGE	Background: The number of very elderly persons who are candidates for implantation of a permanent pacemaker is increasing, but the effect of cardiac pacing on long-term survival and functional variables has not been determined. Objective: To determine long-term survival after implantation of a permanent pacemaker in octogenarians and nonagenarians and to assess functional independence after such implantation. Design: Retrospective, population-based cohort study. Setting: Epidemiologic setting from an unselected population. Patients: 157 octogenarians and nonagenarians who initially received a pacemaker between 1962 and 1988 and were followed through 1992. Main Outcome Measures: Overall mortality rate, functional capabilities, and placement in a nursing home. Results: Observed survival in patients with heart disease was significantly worse than that in age- and sex-matched controls (P < 0.001). Observed survival in community residents without heart disease was similar to that in controls (P > 0.2). Multivariable analysis identified congestive heart failure, chronic obstructive pulmonary disease, old age, syncope, cancer, and atrioventricular block as independent predictors of increased mortality. Symptoms decreased in 118 patients (75%) after pacemaker implantation. After implantation, 70 patients (45%) were permanently placed in nursing homes; this number is similar to the estimated probability of lifetime use of nursing homes from the National Mortality Followback Survey. Dementia developed or worsened in 51 patients (32%), and orthopedic disability occurred in 41 patients (26%). Conclusions: Normal relative survival in octogenarians and nonagenarians without heart disease is reassuring; the poor prognosis in patients with heart disease warrants careful evaluation of the methods and indications for cardiac pacing. Permanent pacing alleviates bradycardia-related symptoms. Placement in a nursing home and development or worsening of cardiac, neurologic, or orthopedic disabilities frequently occur after implantation of a permanent pacemaker in the very elderly.	MAYO CLIN & MAYO FDN, DEPT HLTH SCI, ROCHESTER, MN 55905 USA	Mayo Clinic	Shen, WK (corresponding author), MAYO CLIN & MAYO FDN, DIV CARDIOVASC DIS & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA.		Ballard, David J/H-1062-2018					ALPERT MA, 1982, J CHRON DIS, V35, P341, DOI 10.1016/0021-9681(82)90005-4; ALPERT MA, 1987, AM HEART J, V113, P958, DOI 10.1016/0002-8703(87)90057-3; [Anonymous], 1964, DIS HEART BLOOD VESS; BERGSTRALH EJ, 1988, CONDITIONAL PROBABIL, P1; BREIVIK K, 1984, ACTA MED SCAND, V216, P119; CALLAHAN D, 1989, JAMA-J AM MED ASSOC, V261, P905, DOI 10.1001/jama.261.6.905; COX DR, 1972, J R STAT SOC B, V34, P187; EDHAG O, 1976, ACTA MED SCAND, V200, P457; ELIZABETH JE, 1991, POSTGRAD MED J, V67, P663, DOI 10.1136/pgmj.67.789.663; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; GINKS W, 1979, BRIT HEART J, V41, P633; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; LINDEEDELSTAM C, 1992, PACE, V15, P304, DOI 10.1111/j.1540-8159.1992.tb06500.x; ROSENQVIST M, 1988, AM HEART J, V116, P16, DOI 10.1016/0002-8703(88)90244-X; SGARBOSSA EB, 1993, CIRCULATION, V88, P1045, DOI 10.1161/01.CIR.88.3.1045; SHEN WK, 1994, AM J CARDIOL, V74, P560, DOI 10.1016/0002-9149(94)90744-7; STRAUSS HD, 1978, PACE, V1, P458, DOI 10.1111/j.1540-8159.1978.tb03507.x; TUNG RT, 1994, AM J CARDIOL, V74, P1016, DOI 10.1016/0002-9149(94)90851-6; VANHEMEL NM, 1981, PACE, V4, P8	20	38	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					476	480		10.7326/0003-4819-125-6-199609150-00008	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779460				2022-12-28	WOS:A1996VF88200009
J	Majeed, FA; Martin, D; Crayford, T				Majeed, FA; Martin, D; Crayford, T			Deprivation payments to general practitioners: Limitations of census data	BRITISH MEDICAL JOURNAL			English	Article								The census data from which deprivation payments have been calculated since June 1995 suffer from limitations including underenumeration; under counting of homeless people and refugees, and artefactual errors because of the way in which the 1991 census data were tabulated. These limitations reduced the fairness of the changes that many practices experienced in their deprivation payments, The validity of the current system of deprivation payments would be improved if these limitations were borne in mind when allocating payments to practices and if enumeration districts were used as the basis of payments rather than electoral wards.	UNIV SOUTHAMPTON,DEPT GEOG,SOUTHAMPTON SO17 1BJ,HANTS,ENGLAND; UNIV LONDON KINGS COLL,SCH MED,DEPT PUBL HLTH MED,LONDON SE5 9PJ,ENGLAND	University of Southampton; University of London; King's College London	Majeed, FA (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Martin, David/J-7192-2012	Martin, David/0000-0003-0397-0769				BALARAJAN R, 1994, BRIT MED J, V309, P287; CRAYFORD T, 1995, BRIT MED J, V311, P787, DOI 10.1136/bmj.311.7008.787; Hastings A, 1996, BRIT MED J, V312, P183; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; MAJEED FA, 1995, BRIT MED J, V311, P1674	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1996	313	7058					669	670						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8811761				2022-12-28	WOS:A1996VH16500024
J	Frade, JM; RodriguezTebar, A; Barde, YA				Frade, JM; RodriguezTebar, A; Barde, YA			Induction of cell death by endogenous nerve growth factor through its p75 receptor	NATURE			English	Article							NEUROTROPHIN RECEPTORS; CHICK-EMBRYOS; APOPTOSIS; NGF; EXPRESSION; NEURONS; RETINA; BRAIN	DURING development, neuronal survival is regulated by the limited availability of neurotrophins, which are proteins of the nerve growth factor (NGF) family. Activation of specific trk tyrosine kinase receptors by the neurotrophins blocks programmed cell death. The trkA-specific ligand NGF has also been shown to activate the non-tyrosine kinase receptor p75, a member of the tumour necrosis factor (TNF) receptor and Fas (APO-1/CD95) family. Here we report that, early in development, endogenous NGF causes the death of retinal neurons that express p75 but not trkA. These results indicate that, as with cells of the immune system, the death of neurons in the central nervous system can also be induced by ligands, and that the effect of NGF on cell fate depends on the type of receptor expressed by developing neurons.	MAX PLANCK INST PSYCHIAT,DEPT NEUROBIOCHEM,D-82152 PLANEGG,GERMANY; CSIC,INST CAJAL,E-28002 MADRID,SPAIN	Max Planck Society; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)			Barde, Yves/F-6019-2011; Frade, Jose M/E-7913-2013	Frade, Jose M/0000-0001-7067-2505; Barde, Yves/0000-0002-7627-461X				ALLENDOERFER KL, 1994, J NEUROSCI, V14, P1795; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; Bovolenta P, 1996, J NEUROSCI, V16, P4402; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CUADROS MA, 1988, ANAT EMBRYOL, V178, P543, DOI 10.1007/BF00305042; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EBENDAL T, 1986, EMBO J, V5, P1483, DOI 10.1002/j.1460-2075.1986.tb04386.x; EMFORS P, 1989, NEURON, V2, P1605; GAESE F, 1994, DEVELOPMENT, V120, P1613; GHOSH A, 1992, SCIENCE, V255, P1441, DOI 10.1126/science.1542795; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; LEIST M, 1994, J IMMUNOL, V153, P1778; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; OPPHENHEIM RW, 1991, ANN REV NEUROSCI, V14, P453; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; ROHRER H, 1988, DEVELOPMENT, V103, P545; Schropel A, 1995, MOL CELL NEUROSCI, V6, P544, DOI 10.1006/mcne.1995.0006; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; VONBARTHELD CS, 1991, J COMP NEUROL, V310, P103, DOI 10.1002/cne.903100110; VONBARTHELD CS, 1994, NEURON, V12, P639, DOI 10.1016/0896-6273(94)90219-4; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A	25	641	662	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					166	168						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774880				2022-12-28	WOS:A1996VG14800051
J	Hunt, TW; Fields, TA; Casey, PJ; Peralta, EG				Hunt, TW; Fields, TA; Casey, PJ; Peralta, EG			RCS10 is a selective activator of G alpha(i) GTPase activity	NATURE			English	Article							BETA-GAMMA-SUBUNITS; G-PROTEIN; ALPHA; PATHWAY	POLYPEPTIDES that define a protein family termed RGS (for regulators of G-protein signalling) are encoded by the SST2 gene of the yeast Saccharomyces cerevisiae, the EGL-10 gene of the nematode Caenorhabdatis elegans, and several related mammalian genes. Genetic studies in invertebrates and mammalian cell-transfection experiments indicate that RGS proteins negatively regulate signalling pathways involving seven transmembrane receptors and heterotrimeric G proteins(1-3). However, the biochemical mechanism by which RGS proteins control these pathways is unknown. Here we report the characterization of human RGS10, a member of this protein family. Co-immunoprecipitation studies demonstrate that RGS10 associates specifically with the activated forms of two related G-protein subunits, G alpha(i3), and G alpha(z) but fails to interact with the structurally and functionally distinct G alpha(s) subunit. In vitro assays with purified proteins indicate that RGS10 increases potently and selectively the GTP hydrolytic activity of several members of the G alpha(i) family, including G alpha(i3), G alpha z and G alpha(o). These results demonstrate that RGS proteins can attenuate signalling pathways involving heterotrimeric G proteins by serving as GTPase-activating proteins for specific types of G alpha subunits.	DUKE UNIV, SCH MED, DEPT MOL CANC BIOL, DURHAM, NC 27710 USA; DUKE UNIV, SCH MED, DEPT BIOCHEM, DURHAM, NC 27710 USA; HARVARD UNIV, DEPT MOL & CELLULAR BIOL, CAMBRIDGE, MA 02138 USA	Duke University; Duke University; Harvard University				Casey, Patrick/0000-0002-7366-9309				ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; AUSUBEL F, 1995, CURRENT PROTOCOLS MO, P1314; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HONG JX, 1993, J IMMUNOL, V150, P3895; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LINDER ME, 1990, J BIOL CHEM, V265, P8243; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0	23	306	314	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1996	383	6596					175	177		10.1038/383175a0	http://dx.doi.org/10.1038/383175a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774883				2022-12-28	WOS:A1996VG14800054
J	Kraut, R; Chia, W; Jan, LY; Jan, YN; Knoblich, JA				Kraut, R; Chia, W; Jan, LY; Jan, YN; Knoblich, JA			Role of inscuteable in orienting asymmetric cell divisions in Drosophila	NATURE			English	Article							C-ELEGANS EMBRYOS; CAENORHABDITIS-ELEGANS; CONFOCAL MICROSCOPY; SPINDLE ORIENTATION; GENETIC-CONTROL; NERVOUS-SYSTEM; PROSPERO; PROTEIN; NUMB; POLARITY	Drosophila neuroblasts and epithelial cells in the procephalic neurogenic region divide perpendicular to the surface, and segregate the proteins Numb and Prospero into the basal daughter cell. We demonstrate here that orientation of the mitotic spindle and correct localization of Numb and Prospero in these cells require the inscuteable gone. Moreover, ectopic expression of inscuteable in other epithelial cells leads to spindle reorientation. the Inscuteable protein localizes to the apical cell cortex before mitosis, suggesting that Inscuteable functions in establishing polarity for asymmetric cell division.	NATL UNIV SINGAPORE, INST MOL & CELL BIOL, SINGAPORE 119260, SINGAPORE; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT BIOCHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT BIOPHYS, SAN FRANCISCO, CA 94143 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco			Knoblich, Juergen A/C-2974-2015	Knoblich, Juergen A/0000-0002-6751-3404; Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498				ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chant J, 1996, CELL, V84, P187, DOI 10.1016/S0092-8674(00)80972-1; CHENG NN, 1995, GENETICS, V139, P549; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; FOE VE, 1989, DEVELOPMENT, V107, P1; HARTENSTEIN V, 1994, DEV BIOL, V165, P480, DOI 10.1006/dbio.1994.1269; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; LLOYD C, 1995, CURR BIOL, V5, P1085, DOI 10.1016/S0960-9822(95)00216-8; LUNDELL MJ, 1994, BIOTECHNIQUES, V16, P434; ORSULIC S, 1994, BIOTECHNIQUES, V16, P441; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; PRADLING A, 1986, DROSOPHILA PRACTICAL, P175; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; TORRESRUIZ RA, 1994, DEVELOPMENT, V120, P2967; TRAAS J, 1995, NATURE, V375, P676, DOI 10.1038/375676a0; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; WADDLE JA, 1994, DEVELOPMENT, V120, P2317; White J, 1996, CELL, V84, P195, DOI 10.1016/S0092-8674(00)80974-5; WHITFIELD WGF, 1988, J CELL SCI, V89, P467	34	329	336	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 5	1996	383	6595					50	55		10.1038/383050a0	http://dx.doi.org/10.1038/383050a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779714				2022-12-28	WOS:A1996VF29500041
J	Barrett, PJ; Emmins, PD; Clarke, PD; Bradley, DJ				Barrett, PJ; Emmins, PD; Clarke, PD; Bradley, DJ			Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: Postal and telephone survey of travellers	BRITISH MEDICAL JOURNAL			English	Article							MALARIA	Objective-To compare the frequency of adverse events, particularly neuropsychiatric effects, from mefloquine and from chloroquine plus proguanil as used for malaria chemoprophylaxis. Design-Retrospective questionnaire to travellers taking either regimen between November 1993 and February 1995; telephone interview with those reporting pronounced side effects. Setting-Travellers from Britain who consulted an advisory helpline. Subjects-1214 adults taking mefloquine and 1181 taking chloroquine plus proguanil. Main outcome Measures-Reported presence of and degree of disability from 12 neuropsychiatric and other symptoms, as assessed by the subjects and by referees and on the basis of behaviour change. Results-There were equal rates of any side effects (40%) and of stopping or changing medication. Overall, neuropsychiatric adverse events were significantly more common in travellers taking mefloquine. In all, 333 neuropsychiatric adverse events were reported by 1214 travellers taking mefloquine, compared with 189 such events in 1181 travellers taking proguanil plus chloroquine (P<0.001). In all, 0.7% of travellers taking mefloquine had disabling neuropsychiatric adverse effects, compared with 0.09% of those taking proguanil plus chloroquine (P=0.021). Two travellers taking mefloquine (1 in 607) were admitted to hospital as a result of the adverse event, compared with 1 in 1181 travellers taking proguanil plus chloroquine. Conclusion-There is a significant excess of adverse neuropsychiatric events of intermediate degrees of severity associated with the use of mefloquine compared with proguanil plus chloroquine. This finding may also explain the discrepant findings between earlier studies and clinical experience.	UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Barrett, PJ (corresponding author), MED ADVISORY SERV TRAVELLERS ABROAD,LONDON WC1E 7HT,ENGLAND.							BRADLEY DJ, 1995, BRIT MED J, V310, P709, DOI 10.1136/bmj.310.6981.709; Council for International Organizations of Medical Sciences, 1987, INT REP ADV DRUG REA; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W	3	153	156	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					525	528						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789977	Green Published			2022-12-28	WOS:A1996VF29400017
J	Duery, L				Duery, L			Santiago - Bad news travels fast in Chile?	LANCET			English	News Item																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					605	605		10.1016/S0140-6736(05)64811-8	http://dx.doi.org/10.1016/S0140-6736(05)64811-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774580				2022-12-28	WOS:A1996VF18600030
J	Schulz, TF; Boshoff, CH; Weiss, RA				Schulz, TF; Boshoff, CH; Weiss, RA			HIV infection and neoplasia	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN PAPILLOMAVIRUS INFECTION; KAPOSIS-SARCOMA; DNA-SEQUENCES; INTRAEPITHELIAL NEOPLASIA; CANCER INCIDENCE; CELL-LINE; HIGH-RISK; AIDS	HIV infection predisposes to several neoplastic conditions, especially non-Hodgkin lymphoma (NHL) and Kaposi's sarcoma (HS), and also intraepithelial cervical neoplasia (GIN) and anal neoplasia (AIN) (but not cervical or anal invasive cancer) and possibly seminoma. For neoplasias associated with oncogenic human viruses (ie, some NHL, GIN, AIN, and probably KS) the role of HIV is most probably linked to its immunosuppressive effect and interference with immune-mediated tumour surveillance. HIV-1, through its regulatory protein fat, might also have a direct promoting effect on KS lesions but it is not essential for their development. The increased frequency of Burkitt's lymphoma and Epstein-Barr-virus-negative large-cell lymphoma in AIDS patients, but not in immunosuppressed transplant patients, and the increased rate of testicular tumours in HIV-infected individuals remain unexplained and may indicate either a direct role for HIV or other cofactors.	INST CANC RES,VIROL LAB,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Schulz, TF (corresponding author), UNIV LIVERPOOL,DEPT MED MICROBIOL & GENITOURINARY MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.		Schulz, Thomas/AAA-1634-2019	Schulz, Thomas/0000-0001-8792-5345				AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; ATEENYIAGABA C, 1995, LANCET, V345, P695, DOI 10.1016/S0140-6736(95)90870-6; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2; Bigoni B, 1996, J INFECT DIS, V173, P542, DOI 10.1093/infdis/173.3.542; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; BOSHOFF C, 1995, LANCET, V345, P1043; BREESE PL, 1995, SEX TRANSM DIS, V22, P7, DOI 10.1097/00007435-199501000-00002; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COLLANDRE H, 1995, LANCET, V345, P1043, DOI 10.1016/S0140-6736(95)90779-3; CORBEIL J, 1994, J CLIN INVEST, V93, P1981, DOI 10.1172/JCI117190; COSTAGLIOLA D, 1995, LANCET, V346, P578, DOI 10.1016/S0140-6736(95)91417-X; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; GOEDERT JJ, 1995, LANCET, V346, P257, DOI 10.1016/S0140-6736(95)91309-2; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; HERNDIER BG, 1994, AIDS, V8, P1025, DOI 10.1097/00002030-199408000-00003; HUANG YQ, 1992, LANCET, V339, P515, DOI 10.1016/0140-6736(92)90338-4; JONES JL, 1995, SCIENCE, V267, P1078, DOI 10.1126/science.7855583; KEDES DH, IN PRESS NATURE MED; KEMPF W, 1995, HUM PATHOL, V26, P914, DOI 10.1016/0046-8177(95)90016-0; KIEFF E, 1995, VIROLOGY, P2343; LEBBE C, 1995, LANCET, V345, P1180, DOI 10.1016/S0140-6736(95)91011-5; LUNARDIISKANDAR Y, 1995, NATURE, V375, P64, DOI 10.1038/375064a0; LYTER D, 1994, P ASCO, V13, P50; MAGGWA BN, 1993, AIDS, V7, P733, DOI 10.1097/00002030-199305000-00019; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; Moore PS, 1996, AIDS, V10, P175, DOI 10.1097/00002030-199602000-00007; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MORI S, 1994, VIRCHOWS ARCH, V424, P397; Moyle G, 1991, Int J STD AIDS, V2, P293; MULLER JR, 1995, P NATL ACAD SCI USA, V92, P6577, DOI 10.1073/pnas.92.14.6577; Newton R, 1996, LANCET, V347, P1450, DOI 10.1016/S0140-6736(96)91685-2; PALEFSKY JM, 1990, JAMA-J AM MED ASSOC, V263, P2911, DOI 10.1001/jama.263.21.2911; QUNIBI W, 1988, AM J MED, V84, P225, DOI 10.1016/0002-9343(88)90418-4; RABKIN CS, 1993, INT J CANCER, V55, P208, DOI 10.1002/ijc.2910550207; RABKIN CS, 1994, J NATL CANCER I, V86, P1711, DOI 10.1093/jnci/86.22.1711; RICKINSON AB, 1992, CANCER SURV, V13, P53; ROTH WK, 1992, AIDS, V6, P895, DOI 10.1097/00002030-199209000-00001; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; SHIRAMIZU B, 1994, CANCER RES, V54, P2069; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; TAYLOR JF, 1972, BRIT J CANCER, V26, P483, DOI 10.1038/bjc.1972.66; VANDENBERG F, 1989, J CLIN PATHOL, V42, P128, DOI 10.1136/jcp.42.2.128; VERMUND SH, 1991, AM J OBSTET GYNECOL, V165, P392, DOI 10.1016/0002-9378(91)90101-V; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WANG RYH, 1993, CLIN INFECT DIS, V17, P724, DOI 10.1093/clinids/17.4.724; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9	50	93	94	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					587	591		10.1016/S0140-6736(95)11033-X	http://dx.doi.org/10.1016/S0140-6736(95)11033-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774574				2022-12-28	WOS:A1996VF18600015
J	Altman, DG; Matthews, JNS				Altman, DG; Matthews, JNS			Statistics notes .24. Heterogeneity of effects	BRITISH MEDICAL JOURNAL			English	Article							EXPOSURE		MED SCH NEWCASTLE UPON TYNE,DEPT MED STAT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK	Altman, DG (corresponding author), IMPERIAL CANC RES FUND,MED STAT GRP,CTR STAT MED,INST HLTH SCI,POB 777,OXFORD OX3 7LF,ENGLAND.		Matthews, John N S/H-7502-2013	Matthews, John N S/0000-0003-2559-037X				BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; HELGASON T, 1981, LANCET, V2, P716; PENTTINEN J, 1994, BRIT MED J, V309, P1267, DOI 10.1136/bmj.309.6964.1267; POCOCK SJ, 1987, INT J EPIDEMIOL, V16, P57, DOI 10.1093/ije/16.1.57; RAFFN E, 1988, SCAND J WORK ENV HEA, V14, P378, DOI 10.5271/sjweh.1903; 1981, AM J OBSTET GYNECOL, V141, P276	7	63	59	1	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					486	486						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776324				2022-12-28	WOS:A1996VE08000031
J	Oelkers, W				Oelkers, W			Adrenal insufficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORTICOTROPIN-RELEASING HORMONE; TUBERCULOUS ADDISONS-DISEASE; PLASMA ADRENOCORTICOTROPIN; METYRAPONE TEST; ACTH; CORTISOL; DEFICIENCY; THERAPY; AXIS; HYPOPITUITARISM				Oelkers, W (corresponding author), FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,DEPT MED,DIV ENDOCRINOL,HINDENBURGDAMM 30,D-12200 BERLIN,GERMANY.							AMBERSON JB, 1989, ADRENAL DISORDERS, P13; ASHERSON RA, 1991, J RHEUMATOL, V18, P1; AUBOURG P, 1994, CURR OPIN GENET DEV, V4, P407, DOI 10.1016/0959-437X(94)90029-9; BLEVINS LS, 1994, J CLIN ENDOCR METAB, V78, P261, DOI 10.1210/jc.78.2.261; BORST GC, 1982, NEW ENGL J MED, V306, P1462, DOI 10.1056/NEJM198206173062405; BROIDE J, 1995, J CLIN ENDOCR METAB, V80, P1243, DOI 10.1210/jc.80.4.1243; BURKE CW, 1985, CLIN ENDOCRINOL META, V14, P947, DOI 10.1016/S0300-595X(85)80084-0; Chen S, 1996, J CLIN ENDOCR METAB, V81, P1871, DOI 10.1210/jc.81.5.1871; FALORNI A, 1995, J CLIN ENDOCR METAB, V80, P2752, DOI 10.1210/jc.80.9.2752; FIAD TM, 1994, CLIN ENDOCRINOL, V40, P603, DOI 10.1111/j.1365-2265.1994.tb03011.x; FREDA PU, 1994, J CLIN ENDOCR METAB, V79, P1540, DOI 10.1210/jc.79.6.1540; GRINSPOON SK, 1994, J CLIN ENDOCR METAB, V79, P923, DOI 10.1210/jc.79.4.923; Keljo DJ, 1996, NEW ENGL J MED, V334, P46, DOI 10.1056/NEJM199601043340111; KULKARNI MV, 1988, AM J NEURORADIOL, V9, P5; MAY ME, 1989, ADRENAL DISORDERS, P171; MOORE PSJ, 1991, CLIN ENDOCRINOL, V34, P107, DOI 10.1111/j.1365-2265.1991.tb00279.x; NEWRICK PG, 1990, LANCET, V335, P212, DOI 10.1016/0140-6736(90)90289-H; OELKERS W, 1989, NEW ENGL J MED, V321, P492, DOI 10.1056/NEJM198908243210802; OELKERS W, 1992, J CLIN ENDOCR METAB, V75, P259, DOI 10.1210/jc.75.1.259; Oelkers W, 1996, EUR J ENDOCRINOL, V135, P27, DOI 10.1530/eje.0.1350027; OELKERS W, 1976, KLIN WOCHENSCHR, V54, P607, DOI 10.1007/BF01469025; OELKERS W, 1988, J CLIN ENDOCR METAB, V66, P181, DOI 10.1210/jcem-66-1-181; OELKERS W, 1994, ADV T ADDISONS DIS, V1, P69; ORTH DN, 1992, ENDOCR REV, V13, P164, DOI 10.1210/er.13.2.164; PAVORD SR, 1992, CLIN ENDOCRINOL, V36, P135, DOI 10.1111/j.1365-2265.1992.tb00947.x; PENRICE J, 1992, POSTGRAD MED J, V68, P204, DOI 10.1136/pgmj.68.797.204; SCHLAGHECKE R, 1992, NEW ENGL J MED, V326, P226, DOI 10.1056/NEJM199201233260403; STEINER H, 1994, EXP CLIN ENDOCRINOL, V102, P33, DOI 10.1055/s-0029-1211262; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; THODOU E, 1995, J CLIN ENDOCR METAB, V80, P2302, DOI 10.1210/jc.80.8.2302; TOBIN MV, 1989, AM J GASTROENTEROL, V84, P1302; TOBIN MV, 1988, POSTGRAD MED J, V64, P953, DOI 10.1136/pgmj.64.758.953; TORDJMAN K, 1995, J CLIN ENDOCR METAB, V80, P1301, DOI 10.1210/jc.80.4.1301; TRAINER PJ, 1995, J CLIN ENDOCR METAB, V80, P412, DOI 10.1210/jc.80.2.412; TSATSOULIS A, 1988, CLIN ENDOCRINOL, V28, P225, DOI 10.1111/j.1365-2265.1988.tb03659.x; TSIGOS C, 1995, J CLIN ENDOCR METAB, V80, P2186, DOI 10.1210/jc.80.7.2186; VANCE ML, 1994, NEW ENGL J MED, V331, P487; VANCE ML, 1994, NEW ENGL J MED, V330, P1651, DOI 10.1056/NEJM199406093302306; VELARDO A, 1992, J ENDOCRINOL INVEST, V15, P53, DOI 10.1007/BF03348660; VERMES I, 1995, J CLIN ENDOCR METAB, V80, P1238, DOI 10.1210/jc.80.4.1238; VILLABONA CM, 1993, EUR J RADIOL, V17, P210, DOI 10.1016/0720-048X(93)90106-W; WALKER BR, 1992, CLIN SCI, V83, P171, DOI 10.1042/cs0830171; WERBEL SS, 1993, ENDOCRIN METAB CLIN, V22, P303, DOI 10.1016/S0889-8529(18)30168-3; ZELISSEN PMJ, 1994, ANN INTERN MED, V120, P207, DOI 10.7326/0003-4819-120-3-199402010-00005	44	561	583	2	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1206	1212		10.1056/NEJM199610173351607	http://dx.doi.org/10.1056/NEJM199610173351607			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN401	8815944				2022-12-28	WOS:A1996VN40100007
J	Bartley, M				Bartley, M			Unemployment and health selection	LANCET			English	Editorial Material											Bartley, M (corresponding author), CITY UNIV LONDON,SOCIAL STAT RES UNIT,LONDON EC1N 0HB,ENGLAND.							[Anonymous], 2017, REDUNDANCY EXPERIENC, V20, P15; Bartley M, 1996, BRIT MED J, V313, P445; GREGG P, 1995, OXFORD REV ECON POL, V11, P73, DOI 10.1093/oxrep/11.1.73; MONTGOMERY S, 1996, J EPIDEMIOL COMMUNIT, V50, P5; MONTGOMERY S, 1995, J EPIDEMIOL COMMUNIT, V49, P552; MOSER K, 1990, LONGITUDINAL STUDY M	6	21	21	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					904	904		10.1016/S0140-6736(05)65331-7	http://dx.doi.org/10.1016/S0140-6736(05)65331-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VL097	8843802				2022-12-28	WOS:A1996VL09700002
J	Cavallo, MG; Fava, D; Monetini, L; Barone, F; Pozzilli, P				Cavallo, MG; Fava, D; Monetini, L; Barone, F; Pozzilli, P			Cell-mediated immune response to beta casein in recent-onset insulin-dependent diabetes: Implications for disease pathogenesis	LANCET			English	Article							COWS MILK; MELLITUS; PEPTIDES; ALBUMIN	Background The cows' milk hypothesis for the cause of insulin-dependent diabetes (IDDM) is based on the concept that early consumption of cows' milk may expose the immune system to a foreign protein possessing immunological cross-reactivity with an antigen present on pancreatic beta-cells. Methods We measured in-vitro peripheral lymphocyte response to beta casein, a protein in cows' milk, in 47 patients with recent-onset IDDM, in 36 healthy people and, to lest disease specificity, in 10 patients with autoimmune thyroid disease. Other antigens tested for were bovine serum albumin, purified protein derivative, human serum albumin, and phytohaemagglutinin. Results Specific proliferation of T lymphocytes with bovine beta casein was seen in patients with IDDM (mean [SD] age 18.7 [9]) with a significant difference in mean stimulation index (SI) versus healthy people (p<0.00001) or patients with autoimmune thyroid disease (p<0.002). 24 of 47 (51.1%) patients with IDDM versus 0/10 patients with thyroid disease and 1/36 (2.7%) healthy people had a positive response to beta casein defined as a SI above the mean value +2 SD of healthy people (p<0.00001). No significant differences were observed between the groups of subjects with respect to other antigens tested. Interpretation The association between IDDM and early consumption of cows' milk may be explained by the generation of a specific immune response to beta casein. Exposure to cows' milk triggers a cellular and humoral anti-beta casein immune response which may cross-react with beta-cell antigen. it is of interest that sequence homologies exist between beta casein and several beta-cell molecules.	ST BARTHOLOMEWS HOSP,DEPT DIABET & METAB,LONDON EC1A 7BE,ENGLAND; UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,IST CLIN MED 2,CATTEDRA ENDOCRINOL 1,ROME,ITALY	University of London; Queen Mary University London; Sapienza University Rome; University Hospital Sapienza Rome			Pozzilli, Paolo/A-5235-2010	cavallo, maria gisella/0000-0001-6630-8049				ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; ATKINSON MA, 1993, NEW ENGL J MED, V329, P1853, DOI 10.1056/NEJM199312163292505; BECKER F, 1995, AUTOIMMUNITY, V21, pA342; BORCHJOHNSEN K, 1984, LANCET, V2, P1083; DAHLQUIST G, 1992, DIABETOLOGIA, V35, P980, DOI 10.1007/BF00401429; DAMOTO M, 1994, TISSUE ANTIGENS, V43, P295; ELLIOTT RB, 1988, DIABETOLOGIA, V31, P62; Ellis TM, 1996, LANCET, V347, P1464, DOI 10.1016/S0140-6736(96)91690-6; FAVA D, 1994, DIABETES CARE, V17, P1488, DOI 10.2337/diacare.17.12.1488; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; INMAN LR, 1993, P NATL ACAD SCI USA, V90, P1281, DOI 10.1073/pnas.90.4.1281; JAKOBSSON I, 1986, GUT, V27, P1029, DOI 10.1136/gut.27.9.1029; JAZIRI M, 1992, BIOCHIM BIOPHYS ACTA, V1160, P251, DOI 10.1016/0167-4838(92)90085-R; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; MIYAZAKI I, 1995, J IMMUNOL, V154, P1461; PIETROPAOLO M, 1993, J CLIN INVEST, V92, P359, DOI 10.1172/JCI116574; REDDY S, 1995, DIABETES RES CLIN PR, V29, P83, DOI 10.1016/0168-8227(95)01109-9; SVEDBERG J, 1985, PEPTIDES, V6, P825, DOI 10.1016/0196-9781(85)90308-0; VAARALA U, 1996, DIABETES, V45, P178; WASMUTH HE, 1995, AUTOIMMUNITY, V21, pA328; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	21	91	95	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					926	928		10.1016/S0140-6736(95)12065-3	http://dx.doi.org/10.1016/S0140-6736(95)12065-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843812				2022-12-28	WOS:A1996VL09700012
J	Bueno, MJG; Herraez, J				Bueno, MJG; Herraez, J			Visceral leishmaniasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Bueno, MJG (corresponding author), HOSP CAMPO ARANUELO, NAVALMORAL 10300, SPAIN.								0	1	1	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1034	1034		10.1056/NEJM199610033351406	http://dx.doi.org/10.1056/NEJM199610033351406			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8801447				2022-12-28	WOS:A1996VL45900006
J	Phibbs, CS; Bronstein, JM; Buxton, E; Phibbs, RH				Phibbs, CS; Bronstein, JM; Buxton, E; Phibbs, RH			The effects of patient volume and level of care at the hospital of birth on neonatal mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONGITUDINAL DATA-ANALYSIS; WEIGHT INFANTS; PERINATAL-MORTALITY; INTENSIVE-CARE; COMPETITION; CALIFORNIA; DELIVERY; PROGRAM	Objective.-To examine the effects of neonatal intensive care unit (NICU) patient volume and the level of NICU care available at the hospital of birth on neonatal mortality. Design.-Birth certificate data linked to infant death certificates and to infant discharge abstracts were used in a logistic regression model to control for differences in each patient's clinical and demographic risks. Hospitals were classified by the level of NICU care available (no NICU: level I; intermediate NICU: level II; expanded intermediate NICU: level II+: tertiary NICU: level III) and by the average patient census in the NICU. Setting.-All nonfederal hospitals in California with maternity services. Patients.-All births in nonfederal hospitals in California in 1990 (N=594 104), 473 209 (singletons only) of which were successfully linked with discharge abstracts. Of these infants, 53 229 were classified as likely NICU admissions. Main Outcome Measures.-Death within the first 28 days of life, or within the first year of life, if continuously hospitalized. Results.-Patient volume and level of NICU care at the hospital of birth both had significant effects on mortality. Compared with hospitals without an NICU, infants born in a hospital with a level III NICU with an average NICU census of at least 15 patients per day had significantly lower risk-adjusted neonatal mortality (odds ratio, 0.62; 95% confidence interval, 0.47-0.82; P=.002). Risk-adjusted neonatal mortality for infants born in smaller level III NICUs, and in level II+ and level II NICUs, regardless of size, was not significantly different from hospitals without an NICU, and was significantly higher than hospitals with large level III NICUs. Conclusions.-Risk-adjusted neonatal mortality was significantly lower for births that occurred in hospitals with large (average census, >15 patients per day) level III NICUs. Despite the differences in outcomes, costs for the birth of infants born at hospitals with large level III NICUs were not more than those for infants born at other hospitals with NICUs, Concentration of high-risk deliveries in urban areas in a smaller number of hospitals that could provide level III NICU care has the potential to decrease neonatal mortality without increasing costs.	VET AFFAIRS PALO ALTO CALIF HLTH CARE SYST, HLTH SERV RES & DEV CTR HLTH CARE EVALUAT, PALO ALTO, CA USA; STANFORD UNIV, DEPT HLTH RES & POLICY, STANFORD, CA 94305 USA; UNIV ALABAMA, DEPT HLTH CARE ORG, BIRMINGHAM, AL USA; UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; University of Alabama System; University of Alabama Birmingham; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Phibbs, Ciaran/0000-0002-4353-3507	AHRQ HHS [HS-282-0039, HS-290-92-0055] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BATT DR, 1996, 1996 US NEONATALOGIS; BINKIN N J, 1985, Journal of the American Medical Association, V253, P372, DOI 10.1001/jama.253.3.372; BOWMAN MA, 1983, JAMA-J AM MED ASSOC, V250, P2623, DOI 10.1001/jama.250.19.2623; BRONSTEIN JM, 1991, J HEALTH POLIT POLIC, V16, P87, DOI 10.1215/03616878-16-1-87; BRONSTEIN JM, 1995, AM J PUBLIC HEALTH, V85, P357, DOI 10.2105/AJPH.85.3.357; BUTTERFIELD LJ, 1977, SEMIN PERINATOL, V1, P217; *CAL CHILDR SERV, 1988, MAN PROC STAND NEON; GAGNON D, 1988, PEDIATR ANN, V17, P447, DOI 10.3928/0090-4481-19880701-06; GAGNON DE, 1993, HIGH RISK PREGNANCY; GORTMAKER SL, 1987, HEALTH SERV RES, V22, P91; HANDLER A, 1991, Journal of Public Health Policy, V12, P184, DOI 10.2307/3342503; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; HOSMER DW, 1989, APPL LOGISTIC REGRES; KEELER E, 1995, MANAGEMENT OUTCOMES; KOLLEE LAA, 1988, OBSTET GYNECOL, V72, P729; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; KRAKAUER H, 1992, HEALTH SERV RES, V27, P317; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1990, HOSPITAL VOLUME PHYS; *MARCH DIM BIRTH D, 1993, IMPR OUTC PREGN 90S; *MARCH DIM BIRTH D, 1977, IMPR OUTC PREGN REC; MAYFIELD JA, 1990, AM J PUBLIC HEALTH, V80, P819, DOI 10.2105/AJPH.80.7.819; MCCORMICK M C, 1985, Journal of the American Medical Association, V253, P799, DOI 10.1001/jama.253.6.799; MELNICK GA, 1995, AM J PUBLIC HEALTH, V85, P1391, DOI 10.2105/AJPH.85.10.1391; MELNICK GA, 1988, JAMA-J AM MED ASSOC, V260, P2669, DOI 10.1001/jama.260.18.2669; OZMINKOWSKI RJ, 1988, STAT MED, V7, P1207, DOI 10.1002/sim.4780071202; PANETH N, 1982, NEW ENGL J MED, V307, P149, DOI 10.1056/NEJM198207153070303; PANETH N, 1984, PEDIATRICS, V73, P854; Phibbs CS, 1995, MED CARE RES REV, V52, P532, DOI 10.1177/107755879505200406; PHIBBS CS, 1993, HEALTH SERV RES, V28, P201; POWELL SL, 1995, AM J OBSTET GYNECOL, V173, P1585, DOI 10.1016/0002-9378(95)90653-3; POWERS WF, 1987, AM J PERINAT, V4, P24, DOI 10.1055/s-2007-999732; RICHARDSON DK, 1993, PEDIATRICS, V91, P969; ROBINSON JC, 1988, JAMA-J AM MED ASSOC, V260, P2676, DOI 10.1001/jama.260.18.2676; SAS Institute, 1990, SAS STAT US GUID VER, V2; Shah BV, 1997, SOFTWARE STAT ANAL C; Welsch R, 1980, REGRESSION DIAGNOSTI; WILLIAMS RL, 1979, MED CARE, V17, P95, DOI 10.1097/00005650-197902000-00001; WILLIAMS RL, 1982, NEW ENGL J MED, V306, P207, DOI 10.1056/NEJM198201283060404; WILLIAMS RL, 1983, 1978 1981 MATERNAL C; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	43	276	277	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1996	276	13					1054	1059		10.1001/jama.276.13.1054	http://dx.doi.org/10.1001/jama.276.13.1054			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VK035	8847767				2022-12-28	WOS:A1996VK03500026
J	Arribas, JR; Storch, GA; Clifford, DB; Tselis, AC				Arribas, JR; Storch, GA; Clifford, DB; Tselis, AC			Cytomegalovirus encephalitis	ANNALS OF INTERNAL MEDICINE			English	Review							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; IMMUNE-DEFICIENCY-SYNDROME; CENTRAL-NERVOUS-SYSTEM; BONE-MARROW TRANSPLANTATION; HERPES-SIMPLEX VIRUS; MULTINUCLEATED GIANT-CELLS; AIDS DEMENTIA COMPLEX; HIV-INFECTED PATIENTS; CEREBROSPINAL-FLUID; AUTOPSY FINDINGS	Purpose: To review the pathologic and clinical features of and establish the frequency of cytomegalovirus encephalitis in adults and to review the methods available for diagnosis and treatment. Data Source: MEDLINE search of all English-language articles from January 1965 to August 1995. Study Selection: Articles dealing with cytomegalovirus infection of the brain in adults. We also reviewed all unselected autopsies of these populations to establish the frequency of cytomegalovirus encephalitis in recipients of organ transplants and in patients infected with tl-ie human immunodeficiency virus (HIV). Data Extraction: Epidemiologic and pathologic characteristics, clinical manifestations, diagnostic methods, pathogenetic mechanisms, and use of anticytomegalovirus treatments. Data Synthesis: Of 676 patients receiving a diagnosis of cytomegalovirus encephalitis, 574 (85%) were infected with HIV, 81 (12%) had other causes of immunosuppression, and 21 (3%) were otherwise healthy. Cytomegalovirus encephalitis was confirmed during autopsy in 12% of HIV-infected patients and 2% of transplant recipients. The most common lesion was microglial nodule encephalitis, but the clinical findings corresponding to this pathologic entity are not well defined. In contrast, the pathologic entity of cytomegalovirus ventriculoencephalitis, found almost exclusively in patients with advanced HIV infection, has distinct clinical features that allow recognition even in patients with HIV encephalopathy. Polymerase chain reaction has been shown to be useful for diagnosis of cytomegalovirus encephalitis. Conclusions: Cytomegalovirus encephalitis is an important opportunistic infection in HIV-infected patients but is rarely recognized in other groups. Cytomegalovirus ventriculoencephalitis has emerged as a unique entity in patients with advanced HIV infection. Recent developments in diagnostic techniques allow early recognition and may make more aggressive approaches to therapy possible.	WASHINGTON UNIV, SCH MED, DEPT PEDIAT, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA; HOSP UNIV PENN, PHILADELPHIA, PA 19104 USA	Washington University (WUSTL); Washington University (WUSTL); University of Pennsylvania; Pennsylvania Medicine	Arribas, JR (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MED, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.		Arribas, Jose/A-1595-2015	Arribas, Jose/0000-0002-7410-9450	NIAID NIH HHS [AI25903] Funding Source: Medline; NINDS NIH HHS [T32-NS-01780] Funding Source: Medline; PHS HHS [P01-N53728-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001780] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHIM CL, 1994, J NEUROPATH EXP NEUR, V53, P284, DOI 10.1097/00005072-199405000-00010; ACHIM CL, 1994, J INFECT DIS, V169, P623, DOI 10.1093/infdis/169.3.623; AFESSA B, 1992, J ACQ IMMUN DEF SYND, V5, P132; ANDERS K, 1986, CLIN NEUROPATHOL, V5, P1; ANDERS KH, 1986, AM J PATHOL, V124, P537; ANG LC, 1989, CAN J NEUROL SCI, V16, P291, DOI 10.1017/S0317167100029115; ARRIBAS JR, 1995, J INFECT DIS, V172, P527, DOI 10.1093/infdis/172.2.527; BACK E, 1977, SCAND J INFECT DIS, V9, P141, DOI 10.3109/inf.1977.9.issue-2.17; BAMBORSCHKE S, 1992, J NEUROL, V239, P205, DOI 10.1007/BF00839141; BEHAR R, 1987, NEUROLOGY, V37, P557, DOI 10.1212/WNL.37.4.557; BELEC L, 1990, ACTA NEUROPATHOL, V81, P99, DOI 10.1007/BF00662645; BERMAN SM, 1994, AM J MED, V96, P415, DOI 10.1016/0002-9343(94)90167-8; BUFFET R, 1991, AIDS, V5, P1419, DOI 10.1097/00002030-199112000-00002; BYLSMA SS, 1995, ARCH OPHTHALMOL-CHIC, V113, P89, DOI 10.1001/archopht.1995.01100010091026; CAUSEY JQ, 1976, SOUTHERN MED J, V69, P1384, DOI 10.1097/00007611-197610000-00039; CHIN W, 1973, JAMA-J AM MED ASSOC, V225, P740, DOI 10.1001/jama.225.7.740; CHOU SW, 1995, J INFECT DIS, V171, P576, DOI 10.1093/infdis/171.3.576; CINQUE P, 1992, J INFECT DIS, V166, P1408, DOI 10.1093/infdis/166.6.1408; CINQUE P, 1995, J INFECT DIS, V171, P1603, DOI 10.1093/infdis/171.6.1603; COHEN BA, 1993, NEUROLOGY, V43, P493, DOI 10.1212/WNL.43.3_Part_1.493; CORDONNIER C, 1983, SCAND J HAEMATOL, V31, P248; CORNFORD ME, 1992, CAN J NEUROL SCI, V19, P442, DOI 10.1017/S0317167100041627; CORNFORD ME, 1991, MODERN PATHOL, V4, P232; DEGANS J, 1990, J ACQ IMMUN DEF SYND, V3, P1155; DIETERICH DT, 1993, J INFECT DIS, V167, P1184, DOI 10.1093/infdis/167.5.1184; DIX RD, 1985, ANN NEUROL, V18, P611, DOI 10.1002/ana.410180516; DORFMAN LJ, 1973, NEUROLOGY, V23, P136, DOI 10.1212/WNL.23.2.136; DUCHOWNY M, 1979, ANN NEUROL, V5, P458, DOI 10.1002/ana.410050510; DYER JR, 1995, J INFECTION, V30, P147, DOI 10.1016/S0163-4453(95)80010-7; EDWARDS RH, 1985, NEUROLOGY, V35, P560, DOI 10.1212/WNL.35.4.560; EVANS DJ, 1968, J CLIN PATHOL, V21, P311, DOI 10.1136/jcp.21.3.311; FABER DW, 1992, INVEST OPHTH VIS SCI, V33, P2345; FERRIRO JA, 1992, ACTA NEUROPATHOL, V84, P1, DOI 10.1007/BF00427209; FIALA M, 1993, J NEUROL, V240, P223, DOI 10.1007/BF00818709; FILLET AM, 1993, AIDS, V7, P1016, DOI 10.1097/00002030-199307000-00018; FLETCHER C, 1986, CLIN PHARMACOL THER, V40, P281, DOI 10.1038/clpt.1986.177; FULLER GN, 1989, J NEUROL NEUROSUR PS, V52, P975, DOI 10.1136/jnnp.52.8.975; FULLER GN, 1992, J ACQ IMMUN DEF SYND, V5, pS33; GIAMPALMO A, 1989, CLIN NEUROPATHOL, V8, P120; GOZLAN J, 1995, AIDS, V9, P253, DOI 10.1097/00002030-199509030-00006; GOZLAN J, 1992, J INFECT DIS, V166, P1416, DOI 10.1093/infdis/166.6.1416; GUARDA LA, 1984, AM J CLIN PATHOL, V81, P549, DOI 10.1093/ajcp/81.5.549; HAWLEY DA, 1983, AM J CLIN PATHOL, V80, P874, DOI 10.1093/ajcp/80.6.874; HAYMAKER W, 1954, J NEUROPATH EXP NEUR, V13, P562, DOI 10.1093/jnen/13.4.562; HENGGE UR, 1993, ANTIMICROB AGENTS CH, V37, P1010, DOI 10.1128/AAC.37.5.1010; HOLLAND NR, 1994, NEUROLOGY, V44, P507, DOI 10.1212/WNL.44.3_Part_1.507; HOTSON JR, 1976, BRAIN, V99, P673, DOI 10.1093/brain/99.4.673; HUI AN, 1984, HUM PATHOL, V15, P670; JENSEN OA, 1989, APMIS, V97, P325, DOI 10.1111/j.1699-0463.1989.tb00795.x; KALAYJIAN RC, 1993, MEDICINE, V72, P67, DOI 10.1097/00005792-199303000-00001; KATO T, 1987, ACTA NEUROPATHOL, V73, P287, DOI 10.1007/BF00686624; KAUFFMAN CA, 1979, AM J MED, V67, P724, DOI 10.1016/0002-9343(79)90274-2; KAY E, 1991, IRISH J MED SCI, V160, P393, DOI 10.1007/BF02957798; KIEBURTZ KD, 1993, ARCH NEUROL-CHICAGO, V50, P430, DOI 10.1001/archneur.1993.00540040082019; KIM YS, 1993, CLIN INFECT DIS, V17, P32, DOI 10.1093/clinids/17.1.32; KLATT EC, 1994, ARCH PATHOL LAB MED, V118, P884; KLEMOLA E, 1967, ACTA MED SCAND, V181, P603; KOEPPEN AH, 1981, J NEUROL SCI, V51, P395, DOI 10.1016/0022-510X(81)90117-9; KURE K, 1991, HUM PATHOL, V22, P700, DOI 10.1016/0046-8177(91)90293-X; LANG W, 1989, ACTA NEUROPATHOL, V77, P379, DOI 10.1007/BF00687372; LASKIN OL, 1987, ARCH NEUROL-CHICAGO, V44, P843, DOI 10.1001/archneur.1987.00520200047017; LEVY RM, 1984, J NEUROSURG, V61, P9, DOI 10.3171/jns.1984.61.1.0009; LINNEMANN CC, 1978, ARCH INTERN MED, V138, P1247, DOI 10.1001/archinte.138.8.1247; MAHIEUX F, 1989, J NEUROL NEUROSUR PS, V52, P270, DOI 10.1136/jnnp.52.2.270; MANISCHEWITZ JF, 1990, ANTIMICROB AGENTS CH, V34, P373, DOI 10.1128/AAC.34.2.373; MARKIN RS, 1989, MODERN PATHOL, V2, P339; MARMADUKE DP, 1991, ARCH PATHOL LAB MED, V115, P1154; MARTINEZ AJ, 1988, TRANSPLANT P, V20, P806; MCCUTCHAN JA, 1995, CLIN INFECT DIS, V20, P747, DOI 10.1093/clinids/20.4.747; MCKENZIE R, 1991, MEDICINE, V70, P326, DOI 10.1097/00005792-199109000-00004; Mobley K, 1985, Pathol Annu, V20 Pt 1, P45; MOHRMANN RL, 1990, HUM PATHOL, V21, P630, DOI 10.1016/S0046-8177(96)90010-6; MOIR DH, 1982, PATHOLOGY, V14, P197, DOI 10.3109/00313028209061294; MONFORTE AD, 1992, AIDS, V6, P1159, DOI 10.1097/00002030-199210000-00015; MONTERO CG, 1986, NEUROLOGY, V36, P1149, DOI 10.1212/WNL.36.9.1149; MORGELLO S, 1987, HUM PATHOL, V18, P289, DOI 10.1016/S0046-8177(87)80012-6; MOSKOWITZ LB, 1984, ARCH PATHOL LAB MED, V108, P873; MOSKOWITZ LB, 1984, ARCH PATHOL LAB MED, V108, P867; MUSIANI M, 1994, J CLIN PATHOL, V47, P886, DOI 10.1136/jcp.47.10.886; NAGAYAMA M, 1994, NEUROLOGY, V44, P1518, DOI 10.1212/WNL.44.8.1518; NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603; NIEDT GW, 1985, ARCH PATHOL LAB MED, V109, P727; NIELSEN SL, 1984, AM J CLIN PATHOL, V82, P678, DOI 10.1093/ajcp/82.6.678; PANTONI L, 1991, ACTA NEUROL SCAND, V84, P56, DOI 10.1111/j.1600-0404.1991.tb04903.x; PATCHELL RA, 1985, NEUROLOGY, V35, P300, DOI 10.1212/WNL.35.3.300; PEPOSE JS, 1984, OPHTHALMOLOGY, V91, P1669; PERHAM TGM, 1971, BRIT MED J, V2, P50, DOI 10.1136/bmj.2.5752.50; PETITO CK, 1986, J NEUROPATH EXP NEUR, V45, P635, DOI 10.1097/00005072-198611000-00003; PHILLIPS CA, 1977, JAMA-J AM MED ASSOC, V238, P2299, DOI 10.1001/jama.238.21.2299; PILLAY D, 1993, AIDS, V7, P969, DOI 10.1097/00002030-199307000-00010; POWER C, 1990, CAN J NEUROL SCI, V17, P378, DOI 10.1017/S0317167100030912; PRAYSON RA, 1995, ARCH PATHOL LAB MED, V119, P59; RAFFI F, 1993, ANTIMICROB AGENTS CH, V37, P1777, DOI 10.1128/AAC.37.9.1777; REIBER H, 1991, CLIN CHEM, V37, P1153; REICHERT CM, 1983, AM J PATHOL, V112, P357; REIS J, 1985, PRESSE MED, V14, P1779; REIS MA, 1995, J ROY SOC MED, V88, P24; REVELLO MG, 1994, J INFECT DIS, V170, P1275, DOI 10.1093/infdis/170.5.1275; REYES MG, 1988, ANN NEUROL, V24, P98, DOI 10.1002/ana.410240119; RICHERT JR, 1987, NEUROLOGY, V37, P149, DOI 10.1212/WNL.37.1.149; ROUSSEAU F, 1993, EUR J CLIN MICROBIOL, V12, P938, DOI 10.1007/BF01992168; SAID G, 1991, ANN NEUROL, V29, P139, DOI 10.1002/ana.410290205; SALAZAR A, 1995, SCAND J INFECT DIS, V27, P165, DOI 10.3109/00365549509019000; SCHMIDBAUER M, 1989, ACTA NEUROPATHOL, V79, P286, DOI 10.1007/BF00294663; SCHNECK SA, 1965, J NEUROPATH EXP NEUR, V24, P415, DOI 10.1097/00005072-196507000-00004; SCHOBER R, 1973, LANCET, V1, P962; SCHWARZ TF, 1990, INFECTION, V18, P289, DOI 10.1007/BF01647008; SCROGGS MW, 1987, ARCH PATHOL LAB MED, V111, P983; SHARER LR, 1985, ACTA NEUROPATHOL, V66, P188, DOI 10.1007/BF00688583; SHEPP DH, 1985, ANN INTERN MED, V103, P368, DOI 10.7326/0003-4819-103-3-368; SIEGMANIGRA Y, 1984, ISRAEL J MED SCI, V20, P163; SINGH BM, 1986, ACTA NEUROL SCAND, V73, P590, DOI 10.1111/j.1600-0404.1986.tb04605.x; SINGH N, 1993, CLIN INFECT DIS, V17, P283, DOI 10.1093/clinids/17.2.283; SJOVALL J, 1989, ANTIMICROB AGENTS CH, V33, P1023, DOI 10.1128/AAC.33.7.1023; SMEE DF, 1983, ANTIMICROB AGENTS CH, V23, P676, DOI 10.1128/AAC.23.5.676; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; STERNER G, 1970, Scandinavian Journal of Infectious Diseases, V2, P95, DOI 10.3109/inf.1970.2.issue-2.04; STUDAHL M, 1992, LANCET, V340, P1045, DOI 10.1016/0140-6736(92)93068-X; STUDAHL M, 1994, ACTA NEUROL SCAND, V89, P451; SUZUMIYA J, 1991, ACTA PATHOL JAPON, V41, P291; TUCKER T, 1985, ANN NEUROL, V18, P74, DOI 10.1002/ana.410180113; VINTERS HV, 1989, BRAIN, V112, P245, DOI 10.1093/brain/112.1.245; VITAL C, 1985, ARCH PATHOL LAB MED, V109, P105; VITAL C, 1995, ACTA NEUROPATHOL, V89, P105, DOI 10.1007/BF00294267; WAHREN B, 1980, INTERVIROLOGY, V14, P7, DOI 10.1159/000149156; WELCH K, 1984, JAMA-J AM MED ASSOC, V252, P1152, DOI 10.1001/jama.252.9.1152; WILEY CA, 1986, J NEUROPATH EXP NEUR, V45, P127, DOI 10.1097/00005072-198603000-00003; WILEY CA, 1988, AM J PATHOL, V133, P73; WILKES MS, 1988, LANCET, V2, P85; WOLF DG, 1992, J INFECT DIS, V166, P1412, DOI 10.1093/infdis/166.6.1412; WOLF DG, 1995, J CLIN INVEST, V95, P257, DOI 10.1172/JCI117648; YANAGISAWA N, 1975, ACTA NEUROPATHOL, V33, P153, DOI 10.1007/BF00687541	132	162	175	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1996	125	7					577	587		10.7326/0003-4819-125-7-199610010-00008	http://dx.doi.org/10.7326/0003-4819-125-7-199610010-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ653	8815757				2022-12-28	WOS:A1996VJ65300008
J	Benson, J; Britten, N				Benson, J; Britten, N			Respecting the autonomy of cancer patients when talking with their families: Qualitative analysis of semistructured interviews with patients	BRITISH MEDICAL JOURNAL			English	Article							ETHICAL DECISION-MAKING; MEDICAL-ETHICS; GENERAL-PRACTITIONERS; CONFIDENTIALITY; PHYSICIANS; NETHERLANDS; RECORDS; ACCESS	Objectives-To discover cancer patients) views about disclosure of information to their family, their family's influence over the information given them, and their preferences for doctors' behaviour if they and their family disagree, as a complement to applied ethical theory. Design-Semistructured interviews followed by qualitative content analysis. Setting-Mainly urban British general practice. Subjects-30 patients in whom cancer, excluding basal and squamous cell skin carcinomas, was diagnosed 1-7 years earlier. Results-All subjects wished doctors to respect their views rather than those of their family, should they differ. With their consent, subjects favoured close family receiving information about their illness, all but one mentioning advantage to their family. Without such consent, six unconditionally favoured disclosure of information to their family while seven unconditionally opposed disclosure. Seventeen participants restricted their approval for such disclosure to specific circumstances. Only two participants approved of their family influencing the information that they received about their illness; all but seven wished to receive full information, the exceptions relating to information about bad prognosis. Conclusions-Subjects favoured openness with their family but most rejected unconditional disclosure of information without their consent and their family influencing what information they would be given. They valued respect for their autonomy more highly than beneficence and considered that their own needs took priority over those of their family.	UNITED MED & DENT SCH,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	University of London; King's College London								BRITTEN N, 1991, J ROY SOC MED, V84, P284, DOI 10.1177/014107689108400513; CHRISTIE RJ, 1987, CAN MED ASSOC J, V137, P891; CHRISTIE RJ, 1989, J ROY COLL GEN PRACT, V39, P448; CHRISTIE RJ, 1983, J FAM PRACTICE, V16, P1133; DAYRINGER R, 1983, J FAM PRACTICE, V17, P267; DUNN JWM, 1983, J ROY COLL GEN PRACT, V33, P763; FISHER B, 1993, BRIT J GEN PRACT, V43, P52; Gillion R, 1995, J MED ETHICS, V21, P323, DOI 10.1136/jme.21.6.323; GILLON R, 1994, BRIT MED J, V309, P184, DOI 10.1136/bmj.309.6948.184; *GMC, 1995, CONF GUID GEN MED CO; HOFFMASTER B, 1992, SOC SCI MED, V35, P1421, DOI 10.1016/0277-9536(92)90045-R; HOFFMASTER B, 1994, SOC SCI MED, V39, P1155, DOI 10.1016/0277-9536(94)90348-4; Hoffmaster C B, 1992, Fam Med, V24, P433; Holm S, 1995, J MED ETHICS, V21, P332, DOI 10.1136/jme.21.6.332; LAKO CJ, 1990, J FAM PRACTICE, V31, P167; LAKO CJ, 1990, FAM PRACT, V7, P34, DOI 10.1093/fampra/7.1.34; LAKO CJ, 1991, SOC SCI MED, V32, P153, DOI 10.1016/0277-9536(91)90055-H; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; Ritchie J, 2002, ANAL QUALITATIVE DAT, P187; WEISS BD, 1982, JAMA-J AM MED ASSOC, V247, P2695, DOI 10.1001/jama.247.19.2695; 1984, HDB MED ETHICS; 1990, ACCESS HLTH RECORDS	22	68	68	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					729	731		10.1136/bmj.313.7059.729	http://dx.doi.org/10.1136/bmj.313.7059.729			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VJ441	8819445	Green Published			2022-12-28	WOS:A1996VJ44100026
J	Avins, AL; Browner, WS				Avins, AL; Browner, WS			Lowering risk without lowering cholesterol: Implications national cholesterol policy	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							UNITED-STATES ADULTS; PRIMARY PREVENTION; POSTMENOPAUSAL WOMEN; BLOOD CHOLESTEROL; SERUM-CHOLESTEROL; CORONARY RISK; ASPIRIN USE; HEALTH; DISEASE; CANCER	Current recommendations for the treatment of hypercholesterolemia include drug therapy for persons at sufficiently elevated risk for coronary heart disease. However, no guidelines incorporate the effects of alternative interventions that decrease risk for coronary heart disease but are not used specifically to alter blood lipids. We did a simulation study to estimate the number of hypercholesterolemic adults who would continue to exceed a high-risk threshold after receiving aspirin, antihypertensive medication, and estrogen-replacement therapy. We found that of all persons who are currently candidates for hypolipidemic medication because they are at high risk for coronary heart disease, 6 to 8 million would no longer have this therapy recommended if the abilities of alternative interventions to reduce risk were considered. Pharmaceutical cost savings associated with alternative interventions range from $3 to $4 billion per year. Current guidelines should be revised to account for this effect.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	Avins, AL (corresponding author), VET AFFAIRS MED CTR, GEN INTERNAL MED SECT, 111A1, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046297, R29HL051024] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51024, HL46297] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CURB JD, 1985, JAMA-J AM MED ASSOC, V253, P3263, DOI 10.1001/jama.253.22.3263; DAVEYSMITH G, 1994, BRIT MED J, V308, P72; GIBBONS LW, 1995, AM J MED, V99, P378, DOI 10.1016/S0002-9343(99)80185-5; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HENNEKENS CH, 1988, NEW ENGL J MED, V318, P923; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MCDOWELL A, 1981, DHHS PUBLICATION; MCISAAC WJ, 1991, J GEN INTERN MED, V6, P518, DOI 10.1007/BF02598220; *MED EC CO, 1995, DRUG TOP RED BOOK; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; *NAT CTR HLTH STAT, 1964, CYCL 1 HLTH EX SURV; NEIL HAW, 1995, BMJ-BRIT MED J, V310, P569, DOI 10.1136/bmj.310.6979.569; Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55; PEDERSEN TR, 1994, LANCET, V344, P1767; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; Schectman G, 1996, AM J MED, V100, P197, DOI 10.1016/S0002-9343(97)89459-4; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; STAMLER J, 1993, CIRCULATION, V88, P1954, DOI 10.1161/01.CIR.88.4.1954; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; *US BUR CENS, 1994, US POP EST AG SEX RA; Wassertheilsmoller S, 1991, ANN INTERN MED, V114, P613, DOI 10.7326/0003-4819-114-8-613	35	12	14	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					502	506		10.7326/0003-4819-125-6-199609150-00012	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779464				2022-12-28	WOS:A1996VF88200013
J	Slaughter, S; Hayden, MK; Nathan, C; Hu, TC; Rice, T; VanVoorhis, J; Matushek, M; Franklin, C; Weinstein, RA				Slaughter, S; Hayden, MK; Nathan, C; Hu, TC; Rice, T; VanVoorhis, J; Matushek, M; Franklin, C; Weinstein, RA			A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit	ANNALS OF INTERNAL MEDICINE			English	Article							NOSOCOMIAL INFECTION; ISOLATION PRECAUTIONS; FAECIUM; EPIDEMIOLOGY; OUTBREAK; COLONIZATION; PREVENTION; FAECALIS; PATTERNS	Objective: To determine the efficacy of the use of gloves and gowns compared with that of the use of gloves alone for the prevention of nosocomial transmission of vancomycin-resistant enterococci. Design: Epidemiologic study and controlled, nonrandomized clinical trial. Setting: University-affiliated, 900-bed, urban teaching hospital in which vancomycin-resistant enterococci are endemic. Patients: 181 consecutive patients admitted to the medical intensive care unit for 48 hours or more. Intervention: It was determined that all hospital employees would always use gloves and gowns when attending 8 particular beds in the medical intensive care unit and would always use gloves alone when attending 8 others. Compliance with precautions was monitored weekly. Rectal surveillance cultures were taken from patients daily. Cultures of environmental surfaces, such as those of bed rails, bedside tables, and other frequently touched objects in patient rooms and common areas, were taken monthly. Pulsed-field gel electrophoresis was used for molecular epidemiologic typing of vancomycin-resistant enterococci. Measurements: The number of patients becoming colonized by vancomycin-resistant enterococci; the number of days to acquisition of vancomycin-resistant enterococci; and other measurements, including nosocomial infections, length of hospital stay, and mortality rates. Results: The 93 patients in glove-and-gown rooms and the 88 patients in glove-only rooms had similar demographic and clinical characteristics. Fifteen (16.1%) patients in the glove-and-gown group and 13 (14.8%) in the glove-only group had vancomycin-resistant enterococci on admission to the medical intensive care unit. Twenty-four (25.8%) patients in the glove-and-gown group and 21 (23.9%) in the glove-only group acquired vancomycin-resistant enterococci in the medical intensive care unit. The mean times to colonization among the patients who became colonized were 8.0 days in the glove-and-gown group and 7.1 days in the glove-only group. None of these comparisons were statistically significant. Risk factors for acquisition of vancomycin-resistant enterococci included length of stay in the medical intensive care unit, use of enteral feeding, and use of sucralfate. Compliance with precautions was 79% in glove-and-gown rooms and 62% in glove-only rooms (P < 0.001). Only 25 of 397 (6.3%) environmental cultures were positive for vancomycin-resistant enterococci. Nineteen types of vancomycin-resistant enterococci were documented by pulsed-field gel electrophoresis during the study period. Conclusions: Universal use of gloves and gowns was no better than universal use of gloves only in preventing rectal colonization by vancomycin-resistant enterococci in a medical intensive care unit of a hospital in which vancomycin-resistant enterococci are endemic. Because the use of gowns and gloves together may be associated with better compliance and may help prevent transmission of other infectious agents, this finding may not be applicable to outbreaks caused by single strains or hospitals in which the prevalence of vancomycin-resistant enterococci is low.	COOK CTY HOSP, DIV INFECT DIS, CHICAGO, IL 60612 USA; COOK CTY HOSP, DEPT MED, CHICAGO, IL 60612 USA; COOK CTY HOSP, MED INTENS CARE UNIT, CHICAGO, IL 60612 USA; RUSH MED COLL, CHICAGO, IL 60612 USA	John H Stroger Junior Hospital Cook County; John H Stroger Junior Hospital Cook County; John H Stroger Junior Hospital Cook County; Rush University				Hayden, Mary/0000-0002-4603-8501				ALBERT RK, 1981, NEW ENGL J MED, V304, P1465, DOI 10.1056/NEJM198106113042404; BONTEN MJM, 1994, CRIT CARE MED, V22, P939, DOI 10.1097/00003246-199406000-00010; BOYCE JM, 1994, J CLIN MICROBIOL, V32, P1148, DOI 10.1128/JCM.32.5.1148-1153.1994; BOYLE JF, 1993, J CLIN MICROBIOL, V31, P1280, DOI 10.1128/JCM.31.5.1280-1285.1993; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P597; DASSEY DE, 1995, 35 INT C ANT AG CHEM, pJ40; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; DUTKAMALEN S, 1995, J CLIN MICROBIOL, V33, P1434, DOI 10.1128/JCM.33.5.1434-1434.1995; EDMOND MB, 1995, CLIN INFECT DIS, V20, P1126, DOI 10.1093/clinids/20.5.1126; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; EVERS S, 1993, GENE, V124, P143, DOI 10.1016/0378-1119(93)90779-3; FACKLAM RR, 1989, J CLIN MICROBIOL, V27, P731, DOI 10.1128/JCM.27.4.731-734.1989; GOERING RV, 1993, INFECT CONT HOSP EP, V14, P595; HANDWERGER S, 1993, CLIN INFECT DIS, V16, P750, DOI 10.1093/clind/16.6.750; HARIHARAN R, 1993, 33 INT C ANT AG CHEM, P849; JONES RN, 1993, PERFORMANCE STANDARD; KARANFIL LV, 1992, INFECT CONT HOSP EP, V13, P195, DOI 10.1086/646509; KLEIN BS, 1989, NEW ENGL J MED, V320, P1714, DOI 10.1056/NEJM198906293202603; LARSON E, 1983, AM J INFECT CONTROL, V11, P221, DOI 10.1016/0196-6553(83)90004-4; LECLAIR JM, 1987, NEW ENGL J MED, V317, P329, DOI 10.1056/NEJM198708063170601; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; LUND S, 1994, AM J INFECT CONTROL, V22, P352, DOI 10.1016/0196-6553(94)90034-5; MONTECALVO MA, 1994, ANTIMICROB AGENTS CH, V38, P1363, DOI 10.1128/AAC.38.6.1363; MORRIS JG, 1995, ANN INTERN MED, V123, P250, DOI 10.7326/0003-4819-123-4-199508150-00002; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; National Committee for Clinical Laboratory Standards, 1993, METH DIL ANT SUSC TE; PETTINGER A, 1991, INFECT CONT HOSP EP, V12, P303; PRESTON GA, 1981, AM J MED, V70, P641, DOI 10.1016/0002-9343(81)90588-X; RHINEHART E, 1990, NEW ENGL J MED, V323, P1814, DOI 10.1056/NEJM199012273232606; RUBIN LG, 1992, INFECT CONT HOSP EP, V13, P700; SCHABERG DR, 1991, AM J MED, V91, pS72, DOI 10.1016/0002-9343(91)90346-Y; SHAY DK, 1995, J INFECT DIS, V172, P993, DOI 10.1093/infdis/172.4.993; SIMMONS B, 1990, INFECT CONT HOSP EP, V11, P589; STRINGER B, 1991, AM J INFECT CONTROL, V19, P233, DOI 10.1016/S0196-6553(05)80254-8; SWENSON JM, 1993, 33 INT C ANT AG CHEM, P263; VanHorn KG, 1996, J CLIN MICROBIOL, V34, P924, DOI 10.1128/JCM.34.4.924-927.1996; Weinstein JW, 1996, J CLIN MICROBIOL, V34, P210, DOI 10.1128/JCM.34.1.210-212.1996; WEINSTEIN RA, 1980, J INFECT DIS, V141, P338, DOI 10.1093/infdis/141.3.338; 1995, INFECT CONT HOSP EP, V16, P105	40	223	234	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					448	456		10.7326/0003-4819-125-6-199609150-00004	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779456				2022-12-28	WOS:A1996VF88200005
J	Collins, R; MacMahon, S; Flather, M; Baigent, C; Remvig, L; Mortensen, S; Appleby, P; Godwin, J; Yusuf, S; Peto, R				Collins, R; MacMahon, S; Flather, M; Baigent, C; Remvig, L; Mortensen, S; Appleby, P; Godwin, J; Yusuf, S; Peto, R			Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: Systematic overview of randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; EARLY INTRAVENOUS HEPARIN; LEFT-VENTRICULAR THROMBI; DEEP-VEIN-THROMBOSIS; LOW-DOSE HEPARIN; SUBCUTANEOUS HEPARIN; VENOUS THROMBOSIS; CORONARY-ARTERY; GUSTO TRIAL; THROMBOLYSIS	Objectives-Most randomised trials of anticoagulant therapy for suspected acute myocardial infarction have been small and, in some, aspirin and fibrinolytic therapy were not used routinely. A systematic overview (meta-analysis) of their results is needed, in particular to assess the clinical effects of adding heparin to aspirin. Design-Computer aided searches, scrutiny of reference lists, and inquiry of investigators and companies were used to identify potentially eligible studies. On central review, 26 studies were found to involve unconfounded randomised comparisons of anticoagulant therapy versus control in suspected acute myocardial infarction. Additional information on study design and outcome was sought by correspondence with study investigators. Subjects-Patients with suspected acute myocardial infarction. Interventions-No routine aspirin was used among about 5000 patients in 21 trials (including half of one small trial) that assessed heparin alone or heparin plus oral anticoagulants, and aspirin was used routinely among 68 000 patients in six trials (including the other half of one small trial) that assessed the addition of intravenous or high dose subcutaneous heparin. Main outcome measurements-Death, reinfarction, stroke, pulmonary embolism, and major bleeds (average follow up of about 10 days). Results-In the absence of aspirin, anticoagulant therapy reduced mortality by 25% (SD 8%; 95% confidence interval 10% to 38%; 2P = 0.002), representing 35 (11) fewer deaths per 1000. There were also 10 (4) fewer strokes per 1000 (2P = 0.01), 19 (5) fewer pulmonary emboli per 1000 (2P<0.001), and non-significantly fewer reinfarctions, with about 13 (5) extra major bleeds per 1000 (2P = 0.01). Similar sized effects were seen with the different anticoagulant regimens studied. in the presence of aspirin, however, heparin reduced mortality by only 6% (SD 3%; 0% to 10%; 2P = 0.03), representing just 5 (2) fewer deaths per 1000. There were 3 (1.3) fewer reinfarctions per 1000 (2P = 0.04) and 1 (0.5) fewer pulmonary emboli per 1000 (2P = 0.01), but there was a small non-significant excess of stroke and a definite excess of 3 (1) major bleeds per 1000 (2P<0.0001). Conclusions-The clinical evidence from randomised trials does not justify the routine addition of either intravenous or subcutaneous heparin to aspirin in the treatment of acute myocardial infarction (irrespective of whether any type of fibrinolytic therapy is used).	UNIV OXFORD, BHF, MRC, ICRF, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND; UNIV AUCKLAND, CLIN TRIALS RES UNIT, AUCKLAND, NEW ZEALAND; ROYAL BROMPTON HOSP, CLIN TRIALS & EVALUAT UNIT, LONDON SW3 6NP, ENGLAND; RIGSHOSP, DEPT MED B, COPENHAGEN, DENMARK; HAMILTON GEN HOSP, MCMASTER CLIN, HAMILTON, ON, CANADA	University of Oxford; University of Auckland; Royal Brompton Hospital; Rigshospitalet; University of Copenhagen; McMaster University				Yusuf, Salim/0000-0003-4776-5601				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1994, Circulation, V90, P1631; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1969, Br Med J, V1, P335; [Anonymous], 1994, BMJ, V308, P235; [Anonymous], 1990, Lancet, V336, P65; ANTMAN EM, 1994, CIRCULATION, V90, P1624, DOI 10.1161/01.CIR.90.4.1624; ARNOUT J, 1992, J AM COLL CARDIOL, V20, P513, DOI 10.1016/0735-1097(92)90001-4; ARVAN S, 1987, AM HEART J, V113, P688, DOI 10.1016/0002-8703(87)90708-3; BJERKELUND CJ, 1957, ACTA MED SCAND  S330, V158, P5; BLEICH SD, 1990, AM J CARDIOL, V66, P1412, DOI 10.1016/0002-9149(90)90525-6; BORCHGREVINK CF, 1960, ACTA MED SCAND S359, V168, P5; BROWN KWG, 1964, CAN MED ASSOC J, V90, P1345; CADE JF, 1982, AUST NZ J MED, V12, P501, DOI 10.1111/j.1445-5994.1982.tb03831.x; CARLETON RA, 1960, NEW ENGL J MED, V263, P1002, DOI 10.1056/NEJM196011172632006; CHALMERS TC, 1977, NEW ENGL J MED, V297, P1091, DOI 10.1056/NEJM197711172972004; COL J, 1992, CIRCULATION, V86, P259; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; COLLINS R, 1987, EUR HEART J, V8, P634; COLLINS R, 1996, IN PRESS N ENGL J ME; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; DAVIS MJE, 1986, AM J CARDIOL, V57, P1244, DOI 10.1016/0002-9149(86)90196-7; DEBONO DP, 1992, BRIT HEART J, V67, P122; DIAZ RA, 1988, REV MED CHILE, V116, P13; DRAPKIN A, 1972, J AMER MED ASSOC, V222, P541, DOI 10.1001/jama.222.5.541; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; EMERSON PA, 1977, BRIT MED J, V1, P18, DOI 10.1136/bmj.1.6052.18; GALLUS AS, 1973, NEW ENGL J MED, V288, P545, DOI 10.1056/NEJM197303152881103; GRANGER CB, 1992, CIRCULATION, V86, P258; GUERET P, 1986, J AM COLL CARDIOL, V8, P419, DOI 10.1016/S0735-1097(86)80061-4; HABERSBERGER PG, 1973, BRIT HEART J, V35, P538; HANDLEY AJ, 1972, LANCET, V2, P623; HANDLEY AJ, 1972, BRIT MED J, V2, P436, DOI 10.1136/bmj.2.5811.436; HARVALD B, 1962, LANCET, V2, P626; HENNEKENS CH, 1995, EUR HEART J, V16, P2, DOI 10.1093/eurheartj/16.suppl_D.2; HIRSH J, 1994, CIRCULATION, V89, P1449, DOI 10.1161/01.CIR.89.3.1449; HSIA J, 1992, J AM COLL CARDIOL, V20, P31, DOI 10.1016/0735-1097(92)90133-8; HSIA J, 1990, NEW ENGL J MED, V323, P1433, DOI 10.1056/NEJM199011223232101; HUNT D, 1992, LANCET, V339, P753; LOELIGER EA, 1967, ACTA MED SCAND, V182, P549; LOVELL RRH, 1967, MED J AUSTRALIA, V54, P97; MACMAHON S, 1992, CIRCULATION, V86, P259; MACMAHON S, 1988, CIRCULATION S2, V78, P98; MACMILLAN R L, 1960, Can Med Assoc J, V83, P567; Mahaffey KW, 1996, AM J CARDIOL, V77, P551, DOI 10.1016/S0002-9149(97)89305-8; NEUHAUS KL, 1994, CIRCULATION, V90, P1638, DOI 10.1161/01.CIR.90.4.1638; NORDREHAUG JE, 1985, AM J CARDIOL, V55, P1491, DOI 10.1016/0002-9149(85)90959-2; OCONNOR CM, 1994, J AM COLL CARDIOL, V23, P11, DOI 10.1016/0735-1097(94)90496-0; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PITT A, 1980, AM HEART J, V99, P574, DOI 10.1016/0002-8703(80)90729-2; Prandoni P, 1986, Minerva Cardioangiol, V34, P653; Remvig L, 1983, Ugeskr Laeger, V145, P1053; RIDKER PM, 1993, LANCET, V341, P1574, DOI 10.1016/0140-6736(93)90707-N; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; RUGGIERO HA, 1987, CLIN CARDIOL, V10, P598, DOI 10.1002/clc.4960101018; SORENSEN OH, 1969, ACTA MED SCAND, V185, P65; STEFFENSEN KA, 1969, ACTA MED SCAND, V186, P519; TAVAZZI L, 1989, LANCET, V2, P182; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; VAKIL RJ, 1964, AM J CARDIOL, V14, P55, DOI 10.1016/0002-9149(64)90106-7; VANDEWERF F, 1990, LANCET, V336, P71; VANDEWERF F, 1995, JAMA-J AM MED ASSOC, V273, P1586, DOI 10.1001/jama.273.20.1586; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WARLOW C, 1973, LANCET, V2, P934; WASSERMAN AJ, 1966, AM HEART J, V71, P43, DOI 10.1016/0002-8703(66)90655-7; WRAY R, 1973, NEW ENGL J MED, V288, P815, DOI 10.1056/NEJM197304192881604; ZAWILSKA K, 1989, COR VASA, V31, P179; 1973, JAMA-J AM MED ASSOC, V225, P724	72	145	152	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	1996	313	7058					652	659						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8811758				2022-12-28	WOS:A1996VH16500020
J	Trouillas, P; Xie, J; Adeleine, P				Trouillas, P; Xie, J; Adeleine, P			Treatment of cerebellar ataxia with buspirone: A double-blind study	LANCET			English	Letter									HOP NEUROL,UNITE CEREBROVASC,F-69003 LYON,FRANCE; UNIV LYON 1,BIOSTAT UNIT,F-69365 LYON,FRANCE	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Trouillas, P (corresponding author), HOP NEUROL,CTR RECH ATAXIE,F-69003 LYON,FRANCE.							CHANPALAY V, 1979, J COMP NEUROL, V176, P467; LOU JS, 1995, ARCH NEUROL-CHICAGO, V52, P462; TROUILLAS P, 1988, ARCH NEUROL-CHICAGO, V45, P1217, DOI 10.1001/archneur.1988.00520350055016; TROUILLAS P, 1995, REV NEUROL, V12, P708; Trouillas Paul, 1993, P323	5	18	18	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					759	759		10.1016/S0140-6736(05)65674-7	http://dx.doi.org/10.1016/S0140-6736(05)65674-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806320				2022-12-28	WOS:A1996VG37400066
J	Croft, P; Pope, D; Silman, A				Croft, P; Pope, D; Silman, A			The clinical course of shoulder pain: Prospective cohort study in primary care	BRITISH MEDICAL JOURNAL			English	Article							DISORDERS		UNIV MANCHESTER,ARC,EPIDEMIOL RES UNIT,MANCHESTER M13 9PT,LANCS,ENGLAND	University of Manchester	Croft, P (corresponding author), UNIV KEELE,POSTGRAD MED SCH,IND & COMMUNITY HLTH RES CTR,STOKE ON TRENT ST4 7QB,STAFFS,ENGLAND.		Pope, Daniel P/C-3054-2014	Pope, Daniel/0000-0003-2694-5478				BADLEY EM, 1992, ANN RHEUM DIS, V51, P366, DOI 10.1136/ard.51.3.366; CHARD MD, 1991, ARTHRITIS RHEUM-US, V34, P766, DOI 10.1002/art.1780340619; CROFT P, 1994, ANN RHEUM DIS, V53, P525, DOI 10.1136/ard.53.8.525; HART FD, 1984, PRACTICAL PROBLEMS R; PATRICK DL, 1981, HLTH CARE PHYSICALLY	5	183	185	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					601	602						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806252				2022-12-28	WOS:A1996VG10800021
J	Mulcahy, HE; Croke, DT; Farthing, MJG				Mulcahy, HE; Croke, DT; Farthing, MJG			Cancer and mutant DNA in blood plasma	LANCET			English	Editorial Material									ROYAL COLL SURGEONS IRELAND,DEPT BIOCHEM,DUBLIN 2,IRELAND	Royal College of Surgeons - Ireland	Mulcahy, HE (corresponding author), ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT,DEPT GASTROENTEROL,LONDON EC1M 6BQ,ENGLAND.			Croke, David/0000-0003-2718-3583; mulcahy, hugh/0000-0002-7087-6177				ANKER P, 1975, CANCER RES, V35, P2375; Chen XQ, 1996, NAT MED, V2, P1033; FOURNIE GJ, 1995, CANC LETT, P221; LEON SA, 1977, CANCER RES, V37, P646; Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035; STROUN M, 1987, EUR J CANCER CLIN ON, V23, P707, DOI 10.1016/0277-5379(87)90266-5; STROUN M, 1989, ONCOLOGY, V46, P318	7	21	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					628	628		10.1016/S0140-6736(05)65067-2	http://dx.doi.org/10.1016/S0140-6736(05)65067-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782747				2022-12-28	WOS:A1996VF60900002
J	Chen, P; Tsuge, H; Almassy, RJ; Gribskov, CL; Katoh, S; Vanderpool, DL; Margosiak, SA; Pinko, C; Matthews, DA; Kan, CC				Chen, P; Tsuge, H; Almassy, RJ; Gribskov, CL; Katoh, S; Vanderpool, DL; Margosiak, SA; Pinko, C; Matthews, DA; Kan, CC			Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad	CELL			English	Article							ASSEMBLY PROTEIN; CLEAVAGE SITES; SUBSTRATE; IDENTIFICATION; PRECURSOR; RELEASE	Proteolytic processing of capsid assembly protein precursors by herpesvirus proteases is essential for virion maturation. A 2.5 Angstrom crystal structure of the human cytomegalovirus protease catalytic domain has been determined by X-ray diffraction. The structure defines a new class of serine protease with respect to global-fold topology and has a catalytic triad consisting of Ser-132, His-63, and His-157 in contrast with the Ser-His-Asp triads found in other serine proteases. However, catalytic machinery for activating the serine nucleophile and stabilizing a tetrahedral transition state is oriented similarly to that for members of the trypsin-like and subtilisin-like serine protease families. Formation of the active dimer is mediated primarily by burying a helix of one protomer into a deep cleft in the protein surface of the other.	JAPAN TOBACCO INC,CENT PHARMACEUT RES INST,TAKATSUKI,OSAKA 569,JAPAN	Japan Tobacco Inc.	Chen, P (corresponding author), AGOURON PHARMACEUT,3565 GEN ATOM COURT,SAN DIEGO,CA 92121, USA.		Tsuge, Hideaki/ABF-6424-2021	Tsuge, Hideaki/0000-0003-0166-9163				Baum EZ, 1996, BIOCHEMISTRY-US, V35, P5838, DOI 10.1021/bi952996+; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURCK PJ, 1994, J VIROL, V68, P2937, DOI 10.1128/JVI.68.5.2937-2946.1994; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; COX GA, 1995, J VIROL, V69, P4524, DOI 10.1128/JVI.69.7.4524-4528.1995; Darke PL, 1996, J BIOL CHEM, V271, P7445, DOI 10.1074/jbc.271.13.7445; DILANNI CL, 1994, J BIOL CHEM, V269, P12672; EFIMOV AV, 1992, FEBS LETT, V298, P261, DOI 10.1016/0014-5793(92)80072-O; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GARAVITO RM, 1977, BIOCHEMISTRY-US, V16, P5065, DOI 10.1021/bi00642a019; GIBSON W, 1990, J VIROL, V64, P1241, DOI 10.1128/JVI.64.3.1241-1249.1990; Gibson W., 1995, PERSPECT DRUG DISCOV, V2, P413; Gold E, 1982, VIRAL INFECT HUMANS, P167; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TR, 1994, J VIROL, V68, P3742, DOI 10.1128/JVI.68.6.3742-3752.1994; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; Margosiak SA, 1996, BIOCHEMISTRY-US, V35, P5300, DOI 10.1021/bi952842u; MATUSICKKUMAR L, 1995, J VIROL, V69, P7113, DOI 10.1128/JVI.69.11.7113-7121.1995; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PINKO C, 1995, J BIOL CHEM, V270, P23634, DOI 10.1074/jbc.270.40.23634; PRESTON VG, 1983, J VIROL, V45, P1056, DOI 10.1128/JVI.45.3.1056-1064.1983; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; VINOD VS, 1994, J BIOL CHEM, V269, P14337; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WELCH AR, 1991, J VIROL, V65, P4091, DOI 10.1128/JVI.65.8.4091-4100.1991; WELCH AR, 1993, J VIROL, V67, P7360, DOI 10.1128/JVI.67.12.7360-7372.1993	28	149	156	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					835	843		10.1016/S0092-8674(00)80157-9	http://dx.doi.org/10.1016/S0092-8674(00)80157-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797829	Bronze			2022-12-28	WOS:A1996VG37200016
J	Hollfelder, F; Kirby, AJ; Tawfik, DS				Hollfelder, F; Kirby, AJ; Tawfik, DS			Off-the-shelf proteins that rival tailor-made antibodies as catalysts	NATURE			English	Article							GENERAL ACID CATALYSIS; ENOL ETHER HYDROLYSIS; HUMAN-SERUM ALBUMIN; PROTON-TRANSFER; ACETAL HYDROLYSIS; ENZYME; CARBON	MIMICKING the efficiency of enzyme catalysis Is a daunting challenge, An enzyme selectively binds and stabilizes the transition state(s) for a particular reaction(1,2). Artificial host systems can bind ground states just as efficiently(3), and rate enhancements comparable to those in enzymatic reactions can be achieved by bringing catalytic and substrate groups together in intramolecular reactions, But the combination of selective binding and efficient catalysis remains elusive, The best enzyme mimics currently known are catalytic antibodies(5,6), They bind transition-state analogues with high affinity, but their catalytic efficiency generally falls far short of that of enzymes(4,8), Thorn et al.(9) recently described an antibody that catalyses the eliminative ring-opening of a benzisoxazole ''exceptionally efficiently'' using carboxylate as the general base, raising the intriguing possibility that this high efficiency derives from precise positioning of catalytic and substrate groups(10). Here we show that familiar 'off-the-shelf' proteins-serum albumins-catalyse the same reaction at similar rates, using a lysine side-chain amino group as the catalytic general base, Comparisons suggest that formal general base catalysis is of only modest efficiency in both systems, and that the antibody catalysis Is boosted by a non-specific medium effect.	UNIV CAMBRIDGE,CHEM LAB,CAMBRIDGE CB2 1EW,ENGLAND	University of Cambridge				Hollfelder, Florian/0000-0002-1367-6312				BEHR JP, 1994, LOCK KEY PRINCIPLE; BENKOVIC SJ, 1992, ANNU REV BIOCHEM, V61, P29; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CASEY ML, 1973, J ORG CHEM, V38, P2294, DOI 10.1021/jo00953a006; DEMPSEY WB, 1962, J BIOL CHEM, V237, P1113; EISENTHAL R, 1993, ENZYME ASSAYS; Fersht A., 1985, ENZYME STRUCTURE MEC; HO XM, 1992, NATURE, V358, P209; KEMP DS, 1995, NATURE, V373, P196, DOI 10.1038/373196a0; KEMP DS, 1975, J AM CHEM SOC, V97, P7312, DOI 10.1021/ja00858a018; Kirby A.J., 1980, ADV PHYS ORG CHEM, V17, P183; Kirby AJ, 1996, ACTA CHEM SCAND, V50, P203, DOI 10.3891/acta.chem.scand.50-0203; Kirby AJ, 1996, ANGEW CHEM INT EDIT, V35, P707; KIRBY AJ, 1994, J CHEM SOC PERK T 2, P649, DOI 10.1039/p29940000649; KIRBY AJ, 1989, J CHEM SOC PERK T 2, P907, DOI 10.1039/p29890000907; KIRBY AJ, 1994, J CHEM SOC CHEM COMM, P707, DOI 10.1039/c39940000707; KIRBY AJ, 1994, J CHEM SOC PERK T 2, P643, DOI 10.1039/p29940000643; MEANS GE, 1975, BIOCHEMISTRY-US, V14, P4989, DOI 10.1021/bi00693a031; MENGER FM, 1987, J AM CHEM SOC, V109, P3145, DOI 10.1021/ja00244a047; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SERGEEVA MV, IN PRESS ISR J CHEM; SUDLOW G, 1975, MOL PHARMACOL, V11, P824; Tawfik Dan S., 1994, Molecular Biotechnology, V1, P87, DOI 10.1007/BF02821512; TAYLOR RP, 1973, J AM CHEM SOC, V95, P5819, DOI 10.1021/ja00798a093; TAYLOR RP, 1975, J AM CHEM SOC, V97, P1943, DOI 10.1021/ja00840a056; TAYLOR RP, 1975, J AM CHEM SOC, V97, P1934, DOI 10.1021/ja00840a055; THOM SN, 1995, NATURE, V273, P228	29	149	149	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					60	63		10.1038/383060a0	http://dx.doi.org/10.1038/383060a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779715				2022-12-28	WOS:A1996VF29500044
J	Katzenstein, DA; Hammer, SM; Hughes, MD; Gundacker, H; Jackson, JB; Fiscus, S; Rasheed, S; Elbeik, T; Reichman, R; Japour, A; Merigan, TC; Hirsch, MS				Katzenstein, DA; Hammer, SM; Hughes, MD; Gundacker, H; Jackson, JB; Fiscus, S; Rasheed, S; Elbeik, T; Reichman, R; Japour, A; Merigan, TC; Hirsch, MS			The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; DISEASE PROGRESSION; BIOLOGICAL PHENOTYPE; TYPE-1 RNA; ZIDOVUDINE; PLASMA; QUANTITATION; VIREMIA; AIDS	Background We studied measures of human immunodeficiency virus (HIV) replication, the viral phenotype, and immune function (CD4 cell counts) and the relation of changes in these indicators to clinical outcomes in a subgroup of patients in a controlled trial of early antiretroviral treatment for HIV, the AIDS Clinical Trials Group Study 175. Methods The 391 subjects, each of whom entered the study with a single screening CD4 cell count of 200 to 500 per cubic millimeter, were randomly assigned to receive zidovudine alone, didanosine alone, zidovudine plus didanosine, or zidovudine plus zalcitabine. Plasma concentrations of HIV RNA were assessed in 366 subjects, and viral isolates from 332 subjects were assayed for the presence of the syncytium-inducing phenotype. Results After eight weeks, the mean (+/-SE) decrease from base line in the concentration of HIV RNA, expressed as the change in the base 10 log of the number of copies per milliliter, was 0.26+/-0.06 for patients treated with zidovudine alone, 0.65+/-0.07 for didanosine alone, 0.93+/-0.10 for zidovudine plus didanosine, and 0.89+/-0.06 for zidovudine plus zalcitabine (P<0.001 for each of the pairwise comparisons with zidovudine alone). Multivariate proportional-hazards models showed that higher base-line concentrations of plasma HIV RNA, less suppression of plasma HIV RNA by treatment, and the presence of the syncytium-inducing phenotype were significantly associated with an increased risk of progression to the acquired immunodeficiency syndrome and death. After adjustment for these measures of viral replication and for the viral phenotype, CD4 cell counts were not significant predictors of clinical outcome. Conclusions Both the risk of the progression of HIV disease and the efficacy of antiretroviral therapy are strongly associated with the plasma level of HIV RNA and with the viral phenotype. The changes in the plasma concentration of HIV RNA predict the changes in CD4 cell counts and survival after treatment with reverse-transcriptase inhibitors.	HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; UNIV SO CALIF, LOS ANGELES, CA USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; UNIV ROCHESTER, ROCHESTER, NY USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Case Western Reserve University; University of North Carolina; University of North Carolina Chapel Hill; University of Southern California; University of California System; University of California San Francisco; University of Rochester	Katzenstein, DA (corresponding author), STANFORD UNIV, MED CTR, DIV INFECT DIS, S-156, STANFORD, CA 94305 USA.		Merigan, Thomas/AGQ-7464-2022	katzenstein, david/0000-0002-8593-4560; Elbeik, Tarek/0000-0001-5983-0867; jackson, brooks/0000-0001-9458-135X				Armitage P., 1971, STAT METHODS MED RES, V1; BOUCHER CAB, 1992, AIDS, V6, P1259, DOI 10.1097/00002030-199211000-00003; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; GULICK R, 1996, 3 NAT RETR OTH OPP I; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HENRARD DR, 1995, JAMA-J AM MED ASSOC, V274, P554, DOI 10.1001/jama.274.7.554; Hills, 1993, STAT MODELS EPIDEMIO; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLODNIY M, 1991, J CLIN INVEST, V88, P1755, DOI 10.1172/JCI115494; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KOZAL MJ, 1994, J ACQ IMMUN DEF SYND, V7, P832; LIN HJ, 1994, J INFECT DIS, V170, P553, DOI 10.1093/infdis/170.3.553; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; SANDE MA, 1993, JAMA-J AM MED ASSOC, V270, P2583, DOI 10.1001/jama.270.21.2583; Schooley RT, 1996, J INFECT DIS, V173, P1354, DOI 10.1093/infdis/173.6.1354; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SELIGMANN M, 1994, LANCET, V343, P871; SEMPLE M, 1991, J MED VIROL, V35, P38, DOI 10.1002/jmv.1890350109; TERSMETTE M, 1989, LANCET, V1, P983; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	27	412	418	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1996	335	15					1091	1098		10.1056/NEJM199610103351502	http://dx.doi.org/10.1056/NEJM199610103351502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN399	8813039				2022-12-28	WOS:A1996VN39900002
J	Robbins, JB; Schneerson, R; Anderson, P; Smith, DH				Robbins, JB; Schneerson, R; Anderson, P; Smith, DH			Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b - Impact on public health and implications for other polysaccharide-based vaccines	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TETANUS TOXOID CONJUGATE; HEMOPHILUS-INFLUENZAE; CAPSULAR POLYSACCHARIDE; ANTIBODY-RESPONSES; NEISSERIA-MENINGITIDIS; IMMUNOLOGICAL RESPONSES; MECKLENBURG COUNTY; MEMBRANE-PROTEIN; NORTH-CAROLINA; INFANTS	The development of Haemophilus influenzae type b (Hib) conjugate vaccines has led to the virtual elimination of systemic infections caused by that patnogen, has provided insights into the pathogenesis of and immunity to other capsulated bacteria, and has contributed to the development of new vaccines, Meningitis, a common and serious infection of children, and other infections caused by Hib have been virtually eliminated in countries that have achieved widespread vaccination with Hib conjugates, including the United States, Canada, the United Kingdom, Iceland, Scandinavia, France, and Germany. Hib conjugates have also been shown to be highly effective in developing countries, The principles derived from the use of these vaccines, along with studies of other capsulated pathogens, should allow the rapid inclusion of new polysaccharide-based conjugates into routine vaccination schedules of infants, and should help to realize further reductions in serious systemic infectious diseases.	UNIV ROCHESTER,ROCHESTER,NY 14627; DAVID HAMILTON SMITH FDN,NEW YORK,NY	University of Rochester	Robbins, JB (corresponding author), NICHHD,DEV & MOL IMMUN LAB,NIH,BLDG 6,ROOM 424,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; Alexander Hattie E., 1944, YALE JOUR BIOL AND MED, V16, P425; ANDERSON P, 1985, J PEDIATR-US, V107, P346, DOI 10.1016/S0022-3476(85)80504-7; ANDERSON P, 1985, J CLIN INVEST, V76, P52, DOI 10.1172/JCI111976; ANDERSON P, 1983, INFECT IMMUN, V39, P233, DOI 10.1128/IAI.39.1.233-238.1983; ANDERSON P, 1972, J CLIN INVEST, V51, P39, DOI 10.1172/JCI106794; ANDERSON PW, 1986, J IMMUNOL, V137, P1181; [Anonymous], 1991, WHO TECHN REP SER, V814, P4; Avery O.T., 1929, J EXP MED, V50, P521; BARINGTON T, 1994, INFECT IMMUN, V62, P9, DOI 10.1128/IAI.62.1.9-14.1994; CHU CY, 1983, INFECT IMMUN, V40, P245, DOI 10.1128/IAI.40.1.245-256.1983; CLAESSON BA, 1989, J PEDIATR-US, V114, P97, DOI 10.1016/S0022-3476(89)80611-0; CLAESSON BA, 1988, J PEDIATR-US, V112, P695, DOI 10.1016/S0022-3476(88)80684-X; Claesson BA, 1996, PEDIATR INFECT DIS J, V15, P170, DOI 10.1097/00006454-199602000-00016; COHEN D, IN PRESS LANCET; CRISEL RM, 1975, J BIOL CHEM, V250, P4926; EGAN WM, 1980, MAGNETIC RESONANCE B, P198; EINHORN MS, 1986, LANCET, V2, P299; Fothergill LD, 1933, J IMMUNOL, V24, P273; GLODE MP, 1976, J PEDIATR-US, V88, P36, DOI 10.1016/S0022-3476(76)80723-8; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; GRANOFF DM, 1994, JAMA-J AM MED ASSOC, V272, P1116, DOI 10.1001/jama.272.14.1116; GREENBERG DP, 1995, J PEDIATR-US, V126, P206, DOI 10.1016/S0022-3476(95)70546-5; INSEL RA, 1986, J EXP MED, V163, P262, DOI 10.1084/jem.163.2.262; INSEL RA, 1985, J INFECT DIS, V152, P407, DOI 10.1093/infdis/152.2.407; INSEL RA, 1985, J IMMUNOL, V135, P2810; JANEWAY CA, 1967, GAMMA GLOBULINS; KROLL JS, 1988, CELL, V53, P347, DOI 10.1016/0092-8674(88)90155-9; KUO JSC, 1985, J BACTERIOL, V163, P769, DOI 10.1128/JB.163.2.769-773.1985; MARBURG S, 1986, J AM CHEM SOC, V108, P5282, DOI 10.1021/ja00277a037; PARKE JC, 1977, J INFECT DIS, V136, pS51, DOI 10.1093/infdis/136.Supplement.S51; PARKE JC, 1972, J PEDIATR-US, V81, P765, DOI 10.1016/S0022-3476(72)80099-4; PARKE JC, 1991, J PEDIATR-US, V118, P184, DOI 10.1016/S0022-3476(05)80480-9; PEETERS CCAM, 1992, INFECT IMMUN, V60, P1826, DOI 10.1128/IAI.60.5.1826-1833.1992; PELTOLA H, 1977, PEDIATRICS, V60, P730; PITTMAN M, 1931, J EXP MED, V58, P683; PITTMAN MARGARET, 1931, JOUR EXP MED, V53, P471, DOI 10.1084/jem.53.4.471; REDMOND SR, 1984, JAMA-J AM MED ASSOC, V252, P2581, DOI 10.1001/jama.252.18.2581; Robbins J. B., 1980, MOL BASIS MICROBIAL, P115; ROBBINS JB, 1990, J INFECT DIS, V161, P821, DOI 10.1093/infdis/161.5.821; ROBBINS JB, 1973, PEDIATR RES, V7, P103, DOI 10.1203/00006450-197303000-00001; ROBBINS JB, 1990, NEW ENGL J MED, V323, P1415, DOI 10.1056/NEJM199011153232010; ROBBINS JB, 1995, J INFECT DIS, V171, P1387, DOI 10.1093/infdis/171.6.1387; ROBBINS JB, 1992, CLIN INFECT DIS, V15, P346, DOI 10.1093/clinids/15.2.346; RODRIGUES LP, 1971, J IMMUNOL, V107, P1071; ROTHSTEIN EP, 1991, J PEDIATR-US, V119, P655, DOI 10.1016/S0022-3476(05)82423-0; SCHLESINGER Y, 1992, JAMA-J AM MED ASSOC, V267, P1489, DOI 10.1001/jama.267.11.1489; SCHNEERSON R, 1971, J IMMUNOL, V107, P1081; SCHNEERSON R, 1992, INFECT IMMUN, V60, P3528, DOI 10.1128/IAI.60.9.3528-3532.1992; SCHNEERSON R, 1980, J EXP MED, V152, P361, DOI 10.1084/jem.152.2.361; SCHNEERSON R, 1975, NEW ENGL J MED, V292, P1093, DOI 10.1056/NEJM197505222922103; SCHNEERSON R, 1986, INFECT IMMUN, V52, P519, DOI 10.1128/IAI.52.2.519-528.1986; SCHNEERSON R, 1984, INFECT IMMUN, V45, P582, DOI 10.1128/IAI.45.3.582-591.1984; SCOTT MG, 1992, INT REV IMMUNOL, V9, P43; SELL SHW, 1972, PEDIATRICS, V49, P206; SHACKELFORD PG, 1987, J IMMUNOL, V138, P587; SMITH DH, 1973, PEDIATRICS, V52, P637; SUTTON A, 1982, INFECT IMMUN, V35, P95, DOI 10.1128/IAI.35.1.95-104.1982; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; TROLLFORS B, 1992, J INFECT DIS, V166, P1335, DOI 10.1093/infdis/166.6.1335; 1990, MMWR-MORBID MORTAL W, V39, P698	62	130	136	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1181	1185		10.1001/jama.276.14.1181	http://dx.doi.org/10.1001/jama.276.14.1181			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827975				2022-12-28	WOS:A1996VL33200032
J	Preston, FE; Rosendaal, FR; Walker, ID; Briet, E; Berntorp, E; Conard, J; Fontcuberta, J; Makris, M; Mariani, G; Noteboom, W; Pabinger, I; Legnani, C; Scharrer, I; Schulman, S; vanderMeer, FJM				Preston, FE; Rosendaal, FR; Walker, ID; Briet, E; Berntorp, E; Conard, J; Fontcuberta, J; Makris, M; Mariani, G; Noteboom, W; Pabinger, I; Legnani, C; Scharrer, I; Schulman, S; vanderMeer, FJM			Increased fetal loss in women with heritable thrombophilia	LANCET			English	Article							ACTIVATED PROTEIN-C; POOR ANTICOAGULANT RESPONSE; FACTOR-V LEIDEN; THROMBOSIS; RESISTANCE; ANTIBODIES; COFACTOR; RISK	Background A successful outcome of pregnancy requires an efficient uteroplacental vascular system. Since this system may be compromised by disorders of haemostasis associated with a prothrombotic state, we postulated that maternal thrombophilia might be a risk factor for fetal loss, We studied the relation between heritable thrombophilic defects and fetal loss in a cohort of women with factor V Leiden or deficiency of antithrombin, protein C, or protein S. Methods We studied 1384 women enrolled in the European Prospective Cohort on Thrombophilia (EPCOT). Of 843 women with thrombophilia 571 had 1524 pregnancies; of 541 control women 395 had 1019 pregnancies. The controls were partners of male members of the EPCOT cohort or acquaintances of cases. We analysed the frequencies of miscarriage (fetal loss at or before 28 weeks of gestation) and stillbirth (fetal loss after 28 weeks of gestation) jointly and separately. Findings The risk of fetal loss was increased in women with thrombophilia (168/571 vs 93/395; odds ratio 1.35 [95% CI 1.01-1.82]). The odds ratio was higher for stillbirth than for miscarriage (3.6 [1.4-9.4] vs 1.27 [0.94-1.71]). The highest odds ratio for stillbirth was in women with combined defects (14.3 [2.4-86.0]) compared with 5.2 (1.5-18.1) in antithrombin deficiency, 2.3 (0.6-8.3) in protein-C deficiency, 3.3 (1.0-11.3) in protein-S deficiency, and 2.0 (0.5-7.7) with factor V Leiden. The corresponding odds ratios for miscarriage in these subgroups were 0.8 (0.2-3.6), 1.7 (1.0-2.8), 1.4 (0.9-2.2), 1.2 (0.7-1.9), and 0.9 (0.5-1.5). Significantly more pregnancy terminations had been done in women with thrombophilia than in controls (odds ratio 2.9 [1.8-4.8]); this discrepancy was apparent in nine of 11 participating centres and for all thrombophilia subgroups. Interpretation Women with familial thrombophilia, especially those with combined defects or antithrombin deficiency, have an increased risk of fetal loss, particularly stillbirth. Our findings have important implications for therapy and provide a rationale for clinical trials of thromboprophylaxis for affected women with recurrent fetal loss.	UNIV LEIDEN HOSP,DEPT CLIN EPIDEMIOL & HAEMATOL,NL-2300 RC LEIDEN,NETHERLANDS; GLASGOW ROYAL INFIRM,GLASGOW G4 0SF,LANARK,SCOTLAND; UNIV AMSTERDAM,ACAD MED CTR,NL-1105 AZ AMSTERDAM,NETHERLANDS; LUND UNIV,MALMO,SWEDEN; HOP HOTEL DIEU,PARIS,FRANCE; HOSP SANTA CRUZ & SAN PABLO,E-08025 BARCELONA,SPAIN; UNIV ROMA LA SAPIENZA,ROME,ITALY; ALLGEMEINES KRANKENHAUS STADT WIEN,VIENNA,AUSTRIA; UNIV HOSP ST ORSOLA,BOLOGNA,ITALY; UNIV FRANKFURT KLINIKUM,D-6000 FRANKFURT,GERMANY; NATL HAEMOPHILIA CTR,TEL HASHOMER,ISRAEL; ROYAL HALLAMSHIRE HOSP,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	Leiden University; Leiden University Medical Center (LUMC); University of Glasgow; University of Amsterdam; Academic Medical Center Amsterdam; Lund University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Sapienza University Rome; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Sheffield			Scharrer, Inge/N-2999-2013; Makris, Mike/A-2772-2011; Schulman, Sam/I-7559-2019; Rosendaal, Frits/Q-3842-2017	Makris, Mike/0000-0001-7622-7939; Schulman, Sam/0000-0002-8512-9043; Rosendaal, Frits/0000-0003-2558-7496; LEGNANI, CRISTINA/0000-0003-1999-7800				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; HEALY AM, 1995, P NATL ACAD SCI USA, V92, P850, DOI 10.1073/pnas.92.3.850; INFANTERIVARD C, 1991, NEW ENGL J MED, V325, P1063, DOI 10.1056/NEJM199110103251503; KOELEMAN BPC, 1994, BLOOD, V84, P1031; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; MALIA RG, 1990, BRIT J HAEMATOL, V76, P101, DOI 10.1111/j.1365-2141.1990.tb07843.x; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; STIRRAT GM, 1990, LANCET, V336, P673, DOI 10.1016/0140-6736(90)92159-F	10	528	548	1	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					913	916		10.1016/S0140-6736(96)04125-6	http://dx.doi.org/10.1016/S0140-6736(96)04125-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843809				2022-12-28	WOS:A1996VL09700009
J	Chassin, MR				Chassin, MR			Improving the quality of care .3.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADVERSE DRUG EVENTS; NEW-YORK-STATE; APPROPRIATENESS; METAANALYSES; PERFORMANCE; GUIDELINES; SURGERY		MT SINAI SCH MED, NEW YORK, NY USA	Icahn School of Medicine at Mount Sinai								BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; BORZAK S, 1995, ANN INTERN MED, V123, P873, DOI 10.7326/0003-4819-123-11-199512010-00010; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; CHASE M, 1996, WALL STREET J   0311, pB1; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Field MJ., 1992, GUIDELINES CLIN PRAC; Field MJ, 1990, CLIN PRACTICE GUIDEL; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; James B C, 1993, Front Health Serv Manage, V10, P3; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LOEB JM, 1995, JAMA-J AM MED ASSOC, V273, P1405, DOI 10.1001/jama.273.18.1405; MAHAR M, 1996, BARRONS         0304, P29; MEIER B, 1996, NY TIMES        0402, pD8; MESSERLI FH, 1995, ANN INTERN MED, V123, P888, DOI 10.7326/0003-4819-123-11-199512010-00015; MOORE WS, 1991, STROKE, V22, P1353, DOI 10.1161/01.STR.22.11.1353; NOBLE HB, 1995, NY TIMES        1030, pA14; NOBLE HB, 1995, NY TIMES        0703, pA1; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; OXMAN AD, 1995, JAMA-J AM MED ASSOC, V274, P845, DOI 10.1001/jama.274.10.845; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Pine M, 1996, Qual Manag Health Care, V4, P14; *PREV SERV TASK FO, 1989, GUID CLIN PREV SERV; QUINT M, 1995, NY TIMES        0224, pD1; STOOL SE, 1994, AHCPR PUBLICATION; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; 1995, NY TIMES        0710, pA12; 1995, US NEWS WORLD R 0724, P61	34	171	173	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1060	1063		10.1056/NEJM199610033351413	http://dx.doi.org/10.1056/NEJM199610033351413			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8793935				2022-12-28	WOS:A1996VL45900013
J	Stefansson, S; Lawrence, DA				Stefansson, S; Lawrence, DA			The serpin PAI-1 inhibits cell migration by blocking integrin alpha(v)beta(3) binding to vitronectin	NATURE			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; EXTRACELLULAR-MATRIX; RECEPTOR; DOMAIN; LOCALIZATION; PURIFICATION; MEMBRANE; FORMS	DURING wound healing, migrating cells increase expression of both the vitronectin receptor (VNR) integrins(1) and plasminogen activators(2,3). Here we report that vitronectin significantly enhances the migration of smooth muscle cells (SMCs), and that the specific VNR alpha(v) beta(3) is required for cell motility, We also show that the alpha(v) beta(3) attachment site on vitronectin overlaps with the binding site for plasminogen activator inhibitor (PAI)-1, and that the active conformation of PAI-I blocks SMC migration, This effect requires high-affinity binding to vitronectin, and is not dependent on the ability of PAI-1 to inhibit plasminogen activators. Formation of a complex between PAI-1 and plasminogen activators results in loss of PAI-1 affinity for vitronectin and restores cell migration. These data demonstrate a direct link between plasminogen activators and integrin-mediated cell migration, and show that PAI-1 can control cell-matrix interactions by regulating the accessibility of specific cell-attachment sites. This indicates that the localization of plasminogen activators at sites of focal contact does not initiate a proteolytic cascade leading to generalized matrix destruction, but instead is required to expose cryptic cell-attachment sites necessary for SMC migration.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOCHEM,ROCKVILLE,MD 20855	American Red Cross				Lawrence, Daniel/0000-0003-3126-1935				BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN SL, 1994, CARDIOVASC RES, V28, P1815, DOI 10.1093/cvr/28.12.1815; CARMELIET P, 1996, FIBRINOLYSIS, V10, P194; CIAMBRONE GJ, 1992, J BIOL CHEM, V267, P13617; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark RAF, 1996, AM J PATHOL, V148, P1407; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; ENRLICH HJ, 1990, J BIOL CHEM, V265, P13029; GRADAHLHANSEN J, 1988, J INVEST DERMATOL, V90, P790; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; KIM JP, 1994, J BIOL CHEM, V269, P26926; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; MIMURO J, 1987, BLOOD, V70, P721; MORE RS, 1995, CARDIOVASC RES, V29, P22, DOI 10.1016/0008-6363(96)88541-5; NASKI MC, 1993, J BIOL CHEM, V268, P12367; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PINTUCCI G, 1993, J LAB CLIN MED, V122, P69; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; SMITH JW, 1988, J BIOL CHEM, V263, P18726; Stefansson S, 1996, J BIOL CHEM, V271, P8215, DOI 10.1074/jbc.271.14.8215; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0	30	591	601	1	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					441	443		10.1038/383441a0	http://dx.doi.org/10.1038/383441a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837777				2022-12-28	WOS:A1996VL46300063
J	Derbyshire, SWG; Furedi, A				Derbyshire, SWG; Furedi, A			For debate: Do fetuses feel pain? ''Fetal pain'' is a misnomer	BRITISH MEDICAL JOURNAL			English	Article									UNIV MANCHESTER,HOPE HOSP,CTR RHEUMAT DIS,SALFORD M6 8HD,LANCS,ENGLAND; BIRTH CONTROL TRUST,LONDON W1N 7RD,ENGLAND	University of Manchester				Derbyshire, Stuart/0000-0002-2766-3424				FITZGERALD M, 1994, TXB PAIN, P153; Fitzgerald M., 1995, FOETAL PAIN UPDATE C; GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; LEVENTHAL H, 1984, ADV EXP SOC PSYCHOL, V17, P117, DOI 10.1016/S0065-2601(08)60119-7; MRZLJAK L, 1988, J COMP NEUROL, V271, P355, DOI 10.1002/cne.902710306; *OFF NAT STAT, 1995, SERIES AB, V21, P19	6	34	35	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					795	795						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842074				2022-12-28	WOS:A1996VK56600026
J	Hole, DJ; Watt, GCM; DaveySmith, G; Hart, CL; Gillis, CR; Hawthorne, VM				Hole, DJ; Watt, GCM; DaveySmith, G; Hart, CL; Gillis, CR; Hawthorne, VM			Impaired lung function and mortality risk in men and women: Findings from the Renfrew and Paisley prospective population study	BRITISH MEDICAL JOURNAL			English	Article							FORCED EXPIRATORY VOLUME; CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; PULMONARY-FUNCTION; RESPIRATORY SYMPTOMS; PLASMA-CHOLESTEROL; CANCER; INTERVENTION; DEATH; BREATHLESSNESS	Objective-To assess the relation between forced expiratory volume in one second (FEV(1)) and subsequent mortality. Design-Prospective general population study. Setting-Renfrew and Paisley, Scotland. Subjects-7058 men and 8353 women aged 45-64 years at baseline screening in 1972-6. Main outcome measure-Mortality from all causes, ischaemic heart disease, cancer, lung and other cancers, stroke, respiratory disease, and other causes of death after 15 years of follow up. Results-2545 men and 1894 women died during the follow up period. Significant trends of increasing risk with diminishing FEV(1) are apparent for both sexes for all the causes of death examined after adjustment for age, cigarette smoking, diastolic blood pressure, cholesterol concentration, body mass index, and social class. The relative hazard ratios for all cause mortality for subjects in the lowest fifth of the FEV(1) distribution were 1.92 (95% confidence interval 1.68 to 2.20) for men and 1.89 (1.63 to 2.20) for women. Corresponding relative hazard ratios were 1.56 (1.26 to 1.92) and 1.88 (1.44 to 2.47) for ischaemic heart disease, 2.53 (1.69 to 3.79) and 4.37 (1.84 to 10.42) for lung cancer, and 1.66 (1.07 to 2.59) and 1.65 (1.09 to 2.49) for stroke. Reduced FEV(1) was also associated with an increased risk for each cause of death examined except cancer for lifelong nonsmokers. Conclusions-Impaired lung function is major clinical indicator of mortality risk in men and women for a wide range of diseases. The use of FEV(1) as part of any health assessment of middle aged patients should be considered. Smokers with reduced FEV(1) should form a priority group for targeted advice to stop smoking.	UNIV GLASGOW,DEPT GEN PRACTICE,GLASGOW,LANARK,SCOTLAND; UNIV BRISTOL,DEPT SOCIAL MED,BRISTOL,AVON,ENGLAND; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109	University of Glasgow; University of Bristol; University of Michigan System; University of Michigan	Hole, DJ (corresponding author), RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; BROWNER WS, 1992, WESTERN J MED, V157, P534; COOK DG, 1988, EUR HEART J, V9, P1215, DOI 10.1093/oxfordjournals.eurheartj.a062432; COX DR, 1972, J R STAT SOC B, V34, P187; EBIKRYSTON KL, 1988, J CLIN EPIDEMIOL, V41, P251, DOI 10.1016/0895-4356(88)90129-1; EBIKRYSTON KL, 1989, INT J EPIDEMIOL, V18, P84, DOI 10.1093/ije/18.1.84; FARCHI G, 1987, AM J EPIDEMIOL, V126, P400, DOI 10.1093/oxfordjournals.aje.a114671; Fletcher CM, 1976, NATURAL HIST CHRONIC; GILLIS CR, 1988, J EPIDEMIOL COMMUN H, V42, P44, DOI 10.1136/jech.42.1.44; HAWTHORNE VM, 1974, BMJ-BRIT MED J, V3, P600, DOI 10.1136/bmj.3.5931.600; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; KANNELL WB, 1983, AM HEART J, V331, P315; KRZYZANOWSKI M, 1986, INT J EPIDEMIOL, V15, P56, DOI 10.1093/ije/15.1.56; KULLER LH, 1990, AM J EPIDEMIOL, V132, P265, DOI 10.1093/oxfordjournals.aje.a115656; KULLER LW, 1989, AM REV RESPIR DIS, V140, P576; PERSSON C, 1986, AM J EPIDEMIOL, V124, P942, DOI 10.1093/oxfordjournals.aje.a114483; PETO R, 1983, AM REV RESPIR DIS, V128, P491, DOI 10.1164/arrd.1983.128.3.491; ROSE G, 1986, BRIT MED J, V293, P306, DOI 10.1136/bmj.293.6542.306; SHAPER AG, 1989, BRIT MED J, V298, P1381, DOI 10.1136/bmj.298.6684.1381; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; STRACHAN DP, 1991, BMJ-BRIT MED J, V302, P84, DOI 10.1136/bmj.302.6768.84; TOCKMAN MS, 1989, AM REV RESPIR DIS, V140, pS56, DOI 10.1164/ajrccm/140.3_Pt_2.S56; TOCKMAN MS, 1987, ANN INTERN MED, V106, P512, DOI 10.7326/0003-4819-106-4-512; VANDENEEDEN SK, 1992, EPIDEMIOLOGY, V3, P253, DOI 10.1097/00001648-199205000-00011; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; 1985, ACTA MED SCAND, V217, P241	26	693	708	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					711	715						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819439				2022-12-28	WOS:A1996VJ44100019
J	Yuzhakov, A; Turner, J; ODonnell, M				Yuzhakov, A; Turner, J; ODonnell, M			Replisome assembly reveals the basis for asymmetric function in leading and lagging strand replication	CELL			English	Article							DNA-POLYMERASE-III; ONE HOLOENZYME PARTICLE; CELL NUCLEAR ANTIGEN; ESCHERICHIA-COLI; SLIDING CLAMPS; ACCESSORY PROTEINS; PRIMED DNA; HELICASE; PRIMASE; BACTERIOPHAGE-T7	The E. coli replicase, DNA polymerase III holoenzyme, contains two polymerases for replication of duplex DNA. The DNA strands are antiparallel requiring different modes of replicating the two strands: one is continuous (leading) while the other is discontinuous (lagging). The two polymerases within holoenzyme are generally thought to have asymmetric functions for replication of these two strands. This report finds that the two polymerases have equal properties, both are capable of replicating the more difficult lagging strand. Asymmetric action is, however, imposed by the helicase that encircles the lagging strand. The helicase contact defines the leading polymerase constraining it to a subset of actions, while leaving the other to cycle on the lagging strand. The symmetric actions of the two polymerases free holoenzyme to assemble into the replisome in either orientation without concern for a correct match to one or the other strand.	CORNELL UNIV,COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Cornell University; Howard Hughes Medical Institute	Yuzhakov, A (corresponding author), CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM 38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BURGERS PMJ, 1983, J BIOL CHEM, V258, P7669; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DONG ZM, 1993, J BIOL CHEM, V268, P11758; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; MAKI H, 1988, J BIOL CHEM, V263, P6570; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MOK M, 1987, J BIOL CHEM, V262, P16558; NAKAI H, 1986, J BIOL CHEM, V261, P5208; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4732; ROWEN L, 1978, J BIOL CHEM, V253, P758; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; SELICK HE, 1987, DNA REPLICATION RECO, V47, P183; SINHA NK, 1980, J BIOL CHEM, V263, P6561; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; TOUGU K, 1994, J BIOL CHEM, V269, P4675; TURNER J, 1994, METHOD ENZYMOL, V262, P442; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P1764, DOI 10.1073/pnas.70.6.1764; WU CA, 1992, J BIOL CHEM; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297	47	156	158	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					877	886		10.1016/S0092-8674(00)80163-4	http://dx.doi.org/10.1016/S0092-8674(00)80163-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808623	hybrid			2022-12-28	WOS:A1996VJ44300006
J	Miller, B				Miller, B			Tuberculin skin testing of hospital workers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Miller, B (corresponding author), CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,ATLANTA,GA 30341, USA.							BURWEN DE, 1994, AM J RESP CRIT CAR S, V149, pA856; *CDCP, 1996, REP TUB US 1995; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; 1994, MMWR MORB MORTAL S13, V43, P1	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					855	855						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782619				2022-12-28	WOS:A1996VF78700003
J	Gordon, SM; Carlyn, CJ; Doyle, LJ; Knapp, CC; Longworth, DL; Hall, GS; Washington, JA				Gordon, SM; Carlyn, CJ; Doyle, LJ; Knapp, CC; Longworth, DL; Hall, GS; Washington, JA			The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: Epidemiology and risk factors	ANNALS OF INTERNAL MEDICINE			English	Article							FIELD GEL-ELECTROPHORESIS; RESISTANCE; OFLOXACIN; NORFLOXACIN; CRITERIA; STRAINS	Background: Until 1992, almost all strains of Neisseria gonorrhoeae that had been tested in the United States were susceptible to fluoroquinolones, including ciprofloxacin. However, among men with urethral gonococcal infections who attended one sexually transmitted disease clinic in Cleveland, Ohio, the prevalence of gonococci with decreased susceptibility to ciprofloxacin increased from 2% in 1991 to 16% in 1994. Objective: To describe the emergence of and risk factors for gonococcal urethritis caused by gonococci with decreased susceptibility to ciprofloxacin. Resistance to ciprofloxacin was considered to be decreased if the mean inhibitory concentration was at least 0.12 mu g/mL and was less than or equal to 0.25 mu g/mL; this definition did not equate with the definition of clinical resistance. Design: Case-control study. Setting: An urban sexually transmitted disease clinic. Participants: 51 case-patients and 106 controls. Measurements: Pulsed-field gel electrophoresis was used to identify individual genotypes of ciprofloxacin-resistant and ciprofloxacin-susceptible isolates. Results: 55 of the 746 isolates of N. gonorrhoeae that were tested (7.4%) had decreased susceptibility to ciprofloxacin, and the prevalence of N. gonorrhoeae with decreased susceptibility significantly increased during the study period. Case-patients were significantly less likely to have gram-negative diplococci seen on microscopic examination of urethral discharge (P less than or equal to 0.01) and were less likely to be treated for gonococcal urethritis than were controls (P less than or equal to 0.001). Molecular typing suggested the spread of a single genotype of N. gonorrhoeae. Conclusions: Strains of gonococci with decreased susceptibility to ciprofloxacin appear to have become endemic in Cleveland, Ohio. The clinical significance of these isolates is not clear, but the potential for the emergence of clinically important resistance may preclude the use of fluoroquinolones as an alternative treatment for uncomplicated gonorrhea.	CLEVELAND CLIN FDN, DEPT PATHOL & LAB MED, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation	Gordon, SM (corresponding author), CLEVELAND CLIN FDN, DEPT INFECT DIS, 9500 EUCLID AVE, MAILSTOP S-32, CLEVELAND, OH 44195 USA.							[Anonymous], 1993, MMWR Recomm Rep, V42, P1; BIRLEY H, 1994, GENITOURIN MED, V70, P292; CARLYN CJ, 1995, ANTIMICROB AGENTS CH, V39, P1606, DOI 10.1128/AAC.39.7.1606; GORDON SM, 1993, CLIN INFECT DIS, V17, P462, DOI 10.1093/clinids/17.3.462; Gorwitz Rachel J., 1993, Morbidity and Mortality Weekly Report, V42, P29; JEPHCOTT AE, 1990, LANCET, V335, P165, DOI 10.1016/0140-6736(90)90035-4; KAM KM, 1995, GENITOURIN MED, V71, P141; KNAPP JS, 1994, ANTIMICROB AGENTS CH, V38, P2194, DOI 10.1128/AAC.38.9.2194; KNAPP JS, 1995, ANTIMICROB AGENTS CH, V39, P2442, DOI 10.1128/AAC.39.11.2442; MORELLO JA, 1991, MANUAL CLIN MICROBIO, P248; *NAT COMM CLIN LAB, 1994, M10055 NAT COMM CLIN; National Committee for Clinical Laboratory standards, 1993, M7A3 NAT COMM CLIN L; RICHARD P, 1994, CLIN INFECT DIS, V19, P54, DOI 10.1093/clinids/19.1.54; TAPSALL JW, 1992, MED J AUSTRALIA, V156, P143; TARTAGLIONE TA, 1990, SEXUALLY TRANSMITTED, P993; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; XIA MS, 1995, J INFECT DIS, V171, P455, DOI 10.1093/infdis/171.2.455; YEUNG KH, 1990, LANCET, V336, P759, DOI 10.1016/0140-6736(90)92261-F; 1994, MMWR-MORBID MORTAL W, V43, P325; 1995, MMWR-MORBID MORTAL W, V44, P761; 1987, MMWR MORTAL WKLY S5, V36, pS1	21	37	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					465	470		10.7326/0003-4819-125-6-199609150-00006	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779458				2022-12-28	WOS:A1996VF88200007
J	Blackshear, JL; Baker, VS; Rubino, F; Safford, R; Lane, G; Flipse, T; Malouf, J; Thompson, R; Webel, R; Flaker, GC; Young, L; Hess, D; Friedman, G; Burger, R; McAnulty, JH; Coull, BM; Marchant, C; Timberg, J; Janzik, C; Giraud, G; Halperin, B; Kron, J; Wynn, M; Raitt, M; Anderson, DC; Asinger, RW; Newburg, SM; Fifield, J; Bundlie, SR; Koller, RL; Tarrel, RD; Dick, C; Haugland, JM; Jorgensen, CR; Leonard, AD; Kanter, MC; Solomon, DH; Zabalgoitia, M; Mego, D; Carter, JE; Boyd, SY; Boop, BS; LaLonde, D; Modlin, R; Logan, WR; Green, BJ; Hamilton, WP; Mezei, L; Riggio, S; Feldman, G; Hayward, A; Strauss, R; Anderson, W; Grover, J; McKenzie, M; HartMcArthur, P; Gramberg, M; Houston, H; Halperin, JL; Rothauf, EB; Weinberger, JM; Goldman, ME; Laupacis, A; Chan, KL; Bourque, P; Biggs, J; Ives, A; Feinberg, WM; Kern, KB; Pennock, GD; Fenster, PE; Huerta, BJ; Ohm, J; Dittrich, HC; Kerridge, C; Keen, W; Swenson, M; Kopecky, SL; Litin, SC; Wiebers, DO; Holland, AE; Brown, RD; Khandheria, BK; Meissner, I; Tucker, KR; Rothbart, R; Torelli, J; Schmidt, J; Murray, D; Ruzich, RS; Loutfi, H; Appleton, C; Ingall, T; Carlson, L; Wilson, D; Dunn, M; Nolte, B; Edwards, C; Dick, A; Price, LA; Janosik, DL; Bjerregaard, P; Quattromani, A; Schiller, L; Labovitz, A; Burch, C; Parks, BJ; Thompson, D; Berarducci, L; Carey, S; Vigil, A; Falk, R; Battinelli, N; McNeil, M; Davidoff, R; Bernard, S; Bergethon, P; Fiori, L; Albers, G; Atwood, E; Clark, J; Tong, D; Yenari, M; Froelicker, V; Lutsep, H; Hock, NH; Quaglietti, S; Kemp, S; Alpert, MA; Rothrock, JF; Hupp, CH; Massey, CV; Hamilton, WJ; Miller, VT; Fox, J				Blackshear, JL; Baker, VS; Rubino, F; Safford, R; Lane, G; Flipse, T; Malouf, J; Thompson, R; Webel, R; Flaker, GC; Young, L; Hess, D; Friedman, G; Burger, R; McAnulty, JH; Coull, BM; Marchant, C; Timberg, J; Janzik, C; Giraud, G; Halperin, B; Kron, J; Wynn, M; Raitt, M; Anderson, DC; Asinger, RW; Newburg, SM; Fifield, J; Bundlie, SR; Koller, RL; Tarrel, RD; Dick, C; Haugland, JM; Jorgensen, CR; Leonard, AD; Kanter, MC; Solomon, DH; Zabalgoitia, M; Mego, D; Carter, JE; Boyd, SY; Boop, BS; LaLonde, D; Modlin, R; Logan, WR; Green, BJ; Hamilton, WP; Mezei, L; Riggio, S; Feldman, G; Hayward, A; Strauss, R; Anderson, W; Grover, J; McKenzie, M; HartMcArthur, P; Gramberg, M; Houston, H; Halperin, JL; Rothauf, EB; Weinberger, JM; Goldman, ME; Laupacis, A; Chan, KL; Bourque, P; Biggs, J; Ives, A; Feinberg, WM; Kern, KB; Pennock, GD; Fenster, PE; Huerta, BJ; Ohm, J; Dittrich, HC; Kerridge, C; Keen, W; Swenson, M; Kopecky, SL; Litin, SC; Wiebers, DO; Holland, AE; Brown, RD; Khandheria, BK; Meissner, I; Tucker, KR; Rothbart, R; Torelli, J; Schmidt, J; Murray, D; Ruzich, RS; Loutfi, H; Appleton, C; Ingall, T; Carlson, L; Wilson, D; Dunn, M; Nolte, B; Edwards, C; Dick, A; Price, LA; Janosik, DL; Bjerregaard, P; Quattromani, A; Schiller, L; Labovitz, A; Burch, C; Parks, BJ; Thompson, D; Berarducci, L; Carey, S; Vigil, A; Falk, R; Battinelli, N; McNeil, M; Davidoff, R; Bernard, S; Bergethon, P; Fiori, L; Albers, G; Atwood, E; Clark, J; Tong, D; Yenari, M; Froelicker, V; Lutsep, H; Hock, NH; Quaglietti, S; Kemp, S; Alpert, MA; Rothrock, JF; Hupp, CH; Massey, CV; Hamilton, WJ; Miller, VT; Fox, J			Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation III randomised clinical trial	LANCET			English	Article							ORAL ANTICOAGULANTS; STOPPING RULES; COMPLICATIONS; THERAPY	Background Adjusted-dose warfarin is highly efficacious for prevention of ischaemic stroke in patients with atrial fibrillation (AF). However, this treatment carries a risk of bleeding and the need for frequent medical monitoring. We sought an alternative that would be safer and easier to administer to patients with AF who are at high-risk of thromboembolism. Methods 1044 patients with AF and with at least one thromboembolic risk factor (congestive heart failure or left ventricular fractional shortening less than or equal to 25%, previous thromboembolism, systolic blood pressure of more than 160 mm Hg at study enrolment, or being a woman aged over 75 years) were randomly assigned either a combination of low-intensity, fixed-dose warfarin (international normalised ratio [INR] 1.2-1.5 for initial dose adjustment) and aspirin (325 mg/day) or adjusted-dose warfarin (INR 2.0-3.0). Drugs were given open-labelled. Findings The mean INR during follow-up of patients taking combination therapy (n=521) was 1.3, compared with 2.4 for those taking adjusted-dose warfarin (n=523). During followup, 54% of INRs in patients taking combination therapy were 1.2-1.5 and 34% were less than 1.2. The trial was stopped after a mean follow-up of 1.1 years when the rate of ischaemic stroke and systemic embolism (primary events) in patients given combination therapy (7.9% per year) was significantly higher than in those given adjusted-dose warfarin (1.9% per year) at an interim analysis (p<0.0001), an absolute reduction of 6.0% per year (95% CI 3.4, 8.6) by adjusted-dose warfarin. The annual rates of disabling stroke (5.6% vs 1.7%, p=0.0007) and of primary event or vascular death (11.8% vs 6.4%, p=0.002), were also higher with combination therapy. The rates of major bleeding were similar in both treatment groups. Interpretation Low-intensity, fixed-dose warfarin plus aspirin in this regimen is insufficient for stroke prevention in patients with non-valvular AF at high-risk for thromboembolism; adjusted-dose warfarin (target INR 2.0-3.0) importantly reduces stroke for high-risk patients.	MAYO CLIN JACKSONVILLE, JACKSONVILLE, FL 32224 USA; UNIV MISSOURI, COLUMBIA, MO USA; OREGON HLTH SCI UNIV, PORTLAND, OR 97201 USA; HENNEPIN CTY MED CTR, ABBOTT NW HOSP, MINNEAPOLIS, MN USA; PARK NICOLLET MED CTR, MINNEAPOLIS, MN USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX USA; AUDIE L MURPHY MEM VET ADM MED CTR, SAN ANTONIO, TX 78284 USA; ST JOHNS MERCY MED CTR, ST LOUIS, MO 63141 USA; KAISER PERMANENTE, PORTLAND, OR USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA; UNIV OTTAWA, OTTAWA CIVIC HOSP, OTTAWA, ON, CANADA; UNIV ARIZONA, COLL MED, TUCSON, AZ 85721 USA; UNIV CALIF SAN DIEGO, SAN DIEGO MED CTR, LA JOLLA, CA 92093 USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; LEBAUER CARDIOL ASSOCIATES, GREENSBORO, NC USA; MAYO CLIN SCOTTSDALE, SCOTTSDALE, AZ USA; UNIV KANSAS, MED CTR, KANSAS CITY, KS 66103 USA; ST LOUIS UNIV, MED CTR, ST LOUIS, MO USA; BOSTON CITY HOSP, BOSTON, MA 02118 USA; STANFORD UNIV, STROKE CTR, PALO ALTO, CA 94304 USA; VET AFFAIRS MED CTR, PALO ALTO, CA 94304 USA; UNIV S ALABAMA, COLL MED, MOBILE, AL 36688 USA; MARSHFIELD CLIN FDN MED RES & EDUC, CHIPPEWA FALLS, WI USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA; STATE & EPIDEMIOL RES CORP, SEATTLE, WA USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX USA; UNIV VERMONT, BURLINGTON, VT USA; UNIV PITTSBURGH, PITTSBURGH, PA USA; KNOLL PHARMACEUT CO, WHIPPANY, NJ 07981 USA; WAYNE STATE UNIV, DETROIT, MI USA; HENRY FORD HOSP, DETROIT, MI 48202 USA	Mayo Clinic; University of Missouri System; University of Missouri Columbia; Oregon Health & Science University; Hennepin County Medical Center; Park Nicollet Clinic; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Saint Johns Mercy Medical Center; Kaiser Permanente; Icahn School of Medicine at Mount Sinai; University of Ottawa; Ottawa Hospital Research Institute; University of Arizona; University of California System; University of California San Diego; Mayo Clinic; LeBauer-Brodie Center for Cardiovascular Research & Education; Mayo Clinic; Mayo Clinic Phoenix; University of Kansas; University of Kansas Medical Center; Saint Louis University; Boston Medical Center; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of South Alabama; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Health San Antonio; University of Vermont; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wayne State University; Henry Ford Health System; Henry Ford Hospital	Blackshear, JL (corresponding author), STAT & EPIDEMIOL RES CORP, SPAF STAT CTR, 1107 NE 45TH ST, SUITE 520, SEATTLE, WA 98105 USA.		Modlin, Robert L/M-7941-2014; Halperin, Jonathan/AAJ-4721-2020; Thompson, David/E-2431-2018	Modlin, Robert L/0000-0003-4720-031X; Halperin, Jonathan/0000-0002-8318-5471; Thompson, David/0000-0001-8518-6307; Albers, Gregory/0000-0003-0263-4632; McNeil, Michael/0000-0003-0713-8312; Anderson, David/0000-0001-9874-5649	NINDS NIH HHS [R01 NS 24224] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024224] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1995, J STROKE CEREBROVASC, V5, P147, DOI [DOI 10.1016/S1052-3057(10)80166-1, 10.1016/S10523057(10)80166-1]; [Anonymous], 1994, ARCH INTERN MED, V154, P1449; [Anonymous], 1996, ARCH INTERN MED, V156, P409; [Anonymous], 1994, LANCET, V343, P687; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; Breslow N. E., 1987, STATISTICAL METHODS, VII; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; GITTER MJ, 1995, MAYO CLIN PROC, V70, P725, DOI 10.4065/70.8.725; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; HART RG, 1995, STROKE, V26, P1471, DOI 10.1161/01.STR.26.8.1471; HUGHES MD, 1988, STAT MED, V7, P1231, DOI 10.1002/sim.4780071204; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LANDEFELD CS, 1989, J CLIN EPIDEMIOL, V42, P711, DOI 10.1016/0895-4356(89)90066-8; Miller VT, 1996, NEUROLOGY, V46, P238, DOI 10.1212/WNL.46.1.238; MILLER VT, 1993, NEUROLOGY, V43, P32, DOI 10.1212/WNL.43.1_Part_1.32; PETERSEN P, 1989, LANCET, V1, P175; POCOCK SJ, 1989, CONTROL CLIN TRIALS, V10, pS209; SHORR RI, 1993, ARCH INTERN MED, V153, P1665, DOI 10.1001/archinte.153.14.1665; SINGER DE, 1993, CLIN RES, V41, P482; TAKANO K, 1994, AM J CARDIOL, V74, P935, DOI 10.1016/0002-9149(94)90590-8; 1995, NEW ENGL J MED, V333, P5; 1991, CIRCULATION, V84, P527; 1993, LANCET, V342, P1255; 1992, NEW ENGL J MED, V327, P1406; IN PRESS J STROKE CE	28	863	878	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 7	1996	348	9028					633	638						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782752				2022-12-28	WOS:A1996VF60900007
J	Warren, JB; Higenbottam, T				Warren, JB; Higenbottam, T			Caution with use of inhaled nitric oxide	LANCET			English	Editorial Material									UNIV SHEFFIELD,DEPT MED & PHARMACOL,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND	University of Sheffield	Warren, JB (corresponding author), ST THOMAS HOSP,DEPT PHARMACOL,LONDON,ENGLAND.							Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BEBERA JA, 1996, LANCET, V347, P436; BIHARI D, 1987, NEW ENGL J MED, V317, P394; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; JAI L, 1996, NATURE, V380, P221; KINSELLA JP, 1992, LANCET, V340, P436; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROSSIANT R, 1993, NEW ENGL J MED, V328, P299; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; YOSHIDA K, 1983, INT ARCH OCC ENV HEA, V52, P103, DOI 10.1007/BF00405415; 1996, CURR PROBL PHARMACOV, V22, P8	11	43	46	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					629	630		10.1016/S0140-6736(05)65068-4	http://dx.doi.org/10.1016/S0140-6736(05)65068-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782748				2022-12-28	WOS:A1996VF60900003
J	Scadding, JG				Scadding, JG			Essentialism and nominalism in medicine: Logic of diagnosis in disease terminology	LANCET			English	Article							CHRONIC FATIGUE SYNDROME		UNIV LONDON,NATL HEART & LUNG INST,LONDON SW3 6LY,ENGLAND	Imperial College London; University of London								CAMPBELL EJM, 1979, BMJ-BRIT MED J, V2, P757, DOI 10.1136/bmj.2.6193.757; COSTA DC, 1995, QJM-INT J MED, V88, P767; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; Popper K., 1959, LOGIC SCI DISCOVERY; POPPER KR, 1945, OPEN SOC ITS ENEMIES, V1, P32; POPPER KR, 1945, OPEN SOC ITS ENEMIES, V2, P14; SAISCH SGN, 1994, Q J MED, V87, P63; SCADDING JG, 1990, PSYCHOL MED, V20, P243, DOI 10.1017/S0033291700017566; SCADDING JG, 1967, LANCET, V2, P877; SCADDING JG, 1988, J MED ETHICS, V14, P118, DOI 10.1136/jme.14.3.118; SCADDING JG, 1959, LANCET, V1, P323; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22	12	72	74	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					594	596		10.1016/S0140-6736(96)02049-1	http://dx.doi.org/10.1016/S0140-6736(96)02049-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774576				2022-12-28	WOS:A1996VF18600018
J	Nightingale, SL				Nightingale, SL			Plan for distribution of prescription drug information for patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1996, JAMA-J AM MED ASSOC, V276, P935; 1996, RED REG, V61, P43769; 1995, JAMA-J AM MED ASSOC, V274, P1109	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1128	1128						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827954				2022-12-28	WOS:A1996VL33200004
J	McNamee, D				McNamee, D			Speaking about pharmacovigilance	LANCET			English	Editorial Material																			0	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					908	908		10.1016/S0140-6736(05)65336-6	http://dx.doi.org/10.1016/S0140-6736(05)65336-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843807				2022-12-28	WOS:A1996VL09700007
J	Claret, FX; Hibi, M; Dhut, S; Toda, T; Karin, M				Claret, FX; Hibi, M; Dhut, S; Toda, T; Karin, M			A new group of conserved coactivators that increase the specificity of AP-1 transcription factors	NATURE			English	Article							DNA-BINDING SPECIFICITY; PROTEIN-KINASE; MDR1 GENE; YEAST; JUN; FOS; TRANSFORMATION; EXTRADENTICLE; ACTIVATION; EXPRESSION	THE Jun proteins are nuclear proteins that combine with Fos proteins to form a gene-regulatory protein, AP-1. They have highly conserved DNA-binding and dimerization domains, resulting in almost identical sequence-recognition properties(1-3). Nevertheless, there are many indications that each Jun protein activates a distinct and only partially overlapping set of AP-1 target genes(4-6). Using the more variable activation domain of c-Jun as a bait, we identified a protein, JAB1, that interacts with c-Jun and JunD, but not with JunB or v-Jun. As a result, JAB1 selectively potentiates transactivation by only c-Jun or JunD, In vitro, JAB1 specifically stabilizes complexes of c-Jun or JunD with AP-1 sites and does not affect binding of either JunB or v-Jun. The amino-terminal half of JAB1 is very similar to the amino terminal region of Pad1 from fission yeast, which was identified genetically as a coactivator of a subset of AP-1 target genes(7). JAB1 and Pad1 are also functionally interchangeable. They define a new group of coactivators that increase the specificity of target gene activation by AP-1 proteins.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA; IMPERIAL CANC RES FUND, LAB CELL REGULAT, LONDON WC2A 3PX, ENGLAND	University of California System; University of California San Diego; Cancer Research UK			Claret, Francois X/R-2104-2016; Hibi, Masahiko/I-6215-2014	Claret, Francois X/0000-0003-4629-6495; Hibi, Masahiko/0000-0002-9142-4444				ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bartel P. L., 1993, CELLULAR INTERACTION, P153; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Claret FX, 1996, MOL CELL BIOL, V16, P219; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kumada K, 1996, MOL GEN GENET, V250, P59, DOI 10.1007/s004380050051; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; SHIMANUKI M, 1995, J CELL SCI, V108, P569; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; UCHIUMI T, 1993, FEBS LETT, V326, P11, DOI 10.1016/0014-5793(93)81750-T; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	30	402	424	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	1996	383	6599					453	457		10.1038/383453a0	http://dx.doi.org/10.1038/383453a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837781				2022-12-28	WOS:A1996VL46300067
J	LloydThomas, AR; Fitzgerald, M				LloydThomas, AR; Fitzgerald, M			For debate - Do fetuses feel pain? Reflex responses do not necessarily signify pain	BRITISH MEDICAL JOURNAL			English	Article							HUMAN SPINAL-CORD; PREMATURE; MATURATION; CHILDREN; PRETERM; INFANTS		UCL, DEPT ANAT & DEV BIOL, LONDON WC1E 6BT, ENGLAND	University of London; University College London	LloydThomas, AR (corresponding author), GREAT ORMOND ST HOSP CHILDREN NHS TRUST, DEPT ANAESTHESIA, LONDON WC1N 3JH, ENGLAND.		Fitzgerald, Maria/C-5760-2008					ANDREWS K, 1994, PAIN, V56, P95, DOI 10.1016/0304-3959(94)90154-6; CRAIG KD, 1993, PAIN, V52, P287, DOI 10.1016/0304-3959(93)90162-I; deLima J, 1996, BRIT MED J, V313, P787; FITZGERALD M, 1986, DEV BRAIN RES, V24, P261, DOI 10.1016/0165-3806(86)90194-X; Fitzgerald M., 1993, PAIN INFANTS CHILDRE, P11; FITZGERALD M, 1994, TXB PAIN, P46; FLAKE AW, 1995, ANNU REV MED, V46, P67; GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; GRUNAU RVE, 1994, PAIN, V56, P353, DOI 10.1016/0304-3959(94)90174-0; GRUNAU RVE, 1994, PAIN, V58, P341, DOI 10.1016/0304-3959(94)90128-7; HACK M, 1994, NEW ENGL J MED, V331, P753, DOI 10.1056/NEJM199409223311201; KAR S, 1995, J COMP NEUROL, V354, P253, DOI 10.1002/cne.903540208; KLIMACH VJ, 1988, DEV MED CHILD NEUROL, V30, P208; KONSTANTINIDOU AD, 1995, J COMP NEUROL, V354, P1, DOI 10.1002/cne.903540102; MRZLJAK L, 1988, J COMP NEUROL, V271, P355, DOI 10.1002/cne.902710306; STEVENS BJ, 1994, PAIN, V59, P101, DOI 10.1016/0304-3959(94)90053-1; STEVENSON J, 1995, P PSYCHOL SOC, V3, P59; TADDIO A, 1994, LANCET, V344, P291; TOHYAMA T, 1991, J COMP NEUROL, V310, P285, DOI 10.1002/cne.903100302; VISSER GHA, 1985, EARLY HUM DEV, V12, P173, DOI 10.1016/0378-3782(85)90180-X; WOLF AR, 1993, LANCET, V342, P319, DOI 10.1016/0140-6736(93)91468-2	21	28	28	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					797	798						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842077				2022-12-28	WOS:A1996VK56600030
J	Dean, M; Carrington, M; Winkler, C; Huttley, GA; Smith, MW; Allikmets, R; Goedert, JJ; Buchbinder, SP; Vittinghoff, E; Gomperts, E; Donfield, S; Vlahov, D; Kaslow, R; Saah, A; Rinaldo, C; Detels, R; OBrien, SJ				Dean, M; Carrington, M; Winkler, C; Huttley, GA; Smith, MW; Allikmets, R; Goedert, JJ; Buchbinder, SP; Vittinghoff, E; Gomperts, E; Donfield, S; Vlahov, D; Kaslow, R; Saah, A; Rinaldo, C; Detels, R; OBrien, SJ			Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MOLECULAR-CLONING; RECEPTOR; DNA; POLYMORPHISMS; LOCALIZATION; POPULATIONS; HEMOPHILIA; EVOLUTION; COHORT	The chemokine receptor 5 (CKR5) protein serves as a secondary receptor on CD4(+) T lymphocytes for certain strains of human immunodeficiency virus-type 1 (HIV-1). The CKR5 structural gene was mapped to human chromosome 3p21, and a 32-base pair deletion allele (CKR5 Delta 32) was identified that is present at a frequency of similar to 0.10 in the Caucasian population of the United States. An examination of 1955 patients included among six well-characterized acquired immunodeficiency syndrome (AIDS) cohort studies revealed that 17 deletion homozygotes occurred exclusively among 612 exposed HIV-1 antibody-negative individuals (2.8 percent) and not at all in 1343 HIV-1-infected individuals. The frequency of CKR5 deletion heterozygotes was significantly elevated in groups of individuals that had survived HIV-1 infection for more than 10 years, and, in some risk groups, twice as frequent as their occurrence in rapid progressors to AIDS. Survival analysis clearly shows that disease progression is slower in CKR5 deletion heterozygotes than in individuals homozygous for the normal CKR5 gene. The CKR5 Delta 32 deletion may act as a recessive restriction gene against HIV-1 infection and may exert a dominant phenotype of delaying progression to AIDS among infected individuals.	NCI,LAB GENOM DIVERS,FREDERICK,MD 21702; NCI,INTRAMURAL RES SUPPORT PROGRAM,SCI APPLICAT INT CORP FREDERICK,FREDERICK,MD 21702; NCI,VIRAL EPIDEMIOL BRANCH,BETHESDA,MD 20892; SAN FRANCISCO CITY CLIN,DEPT PUBL HLTH,SAN FRANCISCO,CA 94102; CHILDRENS HOSP LOS ANGELES,LOS ANGELES,CA 90027; NEW ENGLAND RES INST INC,WATERTOWN,MA 02172; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; UNIV ALABAMA,DEPT EPIDEMIOL,BIRMINGHAM,AL 35294; UNIV PITTSBURGH,SCH PUBL HLTH,PITTSBURGH,PA 15213; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA 90025; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90025	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Children's Hospital Los Angeles; HealthCore, Inc; Johns Hopkins University; University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Dean, Michael C/G-8172-2012; OBRIEN, STEPHEN/ABD-1346-2020; Smith, Michael/B-5341-2012; Allikmets, Rando/ABD-4533-2021; Dean, Michael/R-7501-2019; Huttley, Gavin A/G-5169-2015	Dean, Michael C/0000-0003-2234-0631; Huttley, Gavin A/0000-0001-7224-2074; OBRIEN, STEPHEN/0000-0001-7857-0757	NCRR NIH HHS [MO1-RR06020] Funding Source: Medline; NICHD NIH HHS [N01-HD-4-3200] Funding Source: Medline; NIDA NIH HHS [DA04334] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD043200] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA004334, R01DA004334] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; BUCHBINDER SP, 1994, AIDS, V8, P1123, DOI 10.1097/00002030-199408000-00014; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CHAKRABORTY R, 1988, P NATL ACAD SCI USA, V85, P3071, DOI 10.1073/pnas.85.9.3071; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; DEAN M, 1994, AM J HUM GENET, V55, P788; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DETELS R, 1994, J ACQ IMMUN DEF SYND, V7, P1263; Detels R, 1996, AIDS, V10, P102, DOI 10.1097/00002030-199601000-00016; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; GOEDERT JJ, 1985, AM J EPIDEMIOL, V121, P629, DOI 10.1093/aje/121.5.629; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; HERZOG H, 1993, DNA CELL BIOL, V12, P465, DOI 10.1089/dna.1993.12.465; HILGARTNER MW, 1993, AM J PEDIAT HEMATOL, V15, P208; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MAY R, 1995, INFECT DIS HUMANS; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Morse Stephen S., 1993, EMERGING VIRUSES; MOTULSKY AG, 1981, HUMAN GENETICS PATTE; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; O'BRIEN S J, 1991, Current Biology, V1, P209, DOI 10.1016/0960-9822(91)90058-5; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; RAVNIKGLAVAC M, 1994, HUM MOL GENET, V3, P801, DOI 10.1093/hmg/3.5.801; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Sokal R. R, 1981, BIOMETRY; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; STEPHENS JC, 1994, AM J HUM GENET, V55, P809; VLAHOV D, 1990, AM J EPIDEMIOL, V132, P847, DOI 10.1093/oxfordjournals.aje.a115727; VLAHOV D, 1991, NIDA RES MONOGRAPH S, V103; WAINHOBSON S, 1993, CURR OPIN GENET DEV, V3, P878, DOI 10.1016/0959-437X(93)90008-D; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; Weir B.S., 1996, GENETIC DATA ANAL; WHITE MB, 1992, GENOMICS, V12, P301, DOI 10.1016/0888-7543(92)90377-5; Zar, 1984, BIOSTAT ANAL, P71; 1987, MORB MORTAL WKLY S1, V36; 1992, MORB MORTAL WKLY S1, V41	55	2085	2176	1	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1856	1862		10.1126/science.273.5283.1856	http://dx.doi.org/10.1126/science.273.5283.1856			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791590	Green Submitted			2022-12-28	WOS:A1996VJ71300044
J	Nilsen, TW				Nilsen, TW			Update - A parallel spliceosome	SCIENCE			English	Editorial Material							RNA-RNA INTERACTIONS				Nilsen, TW (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106, USA.							Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; Kreivi JP, 1996, CURR BIOL, V6, P802, DOI 10.1016/S0960-9822(02)00599-7; MADHANI HD, 1994, ANNU REV GENET, V28, P1; Mount SM, 1996, SCIENCE, V271, P1690, DOI 10.1126/science.271.5256.1690; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; TARN WY, 1996, SCIENCE, V2732, P1824	7	12	12	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1813	1813		10.1126/science.273.5283.1813	http://dx.doi.org/10.1126/science.273.5283.1813			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8815545				2022-12-28	WOS:A1996VJ71300033
J	Paz, R; Jortner, R; Tunick, PA; Sclarovsky, S; Eilat, B; Perez, JL; Kronzon, I				Paz, R; Jortner, R; Tunick, PA; Sclarovsky, S; Eilat, B; Perez, JL; Kronzon, I			The effect of the ingestion of ethanol on obstruction of the left ventricular outflow tract in hypertrophic cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background Ethanol causes vasodilatation, which might have an adverse effect, due to increased obstruction of the left ventricular outflow tract, in patients with hypertrophic obstructive cardiomyopathy. We assessed the hemodynamic effects of the ingestion of ethanol, in an amount commonly consumed socially, in patients with hypertrophic cardiomyopathy. Methods We performed echocardiography in 36 patients before and several times after the ingestion of either 50 ml of 40 percent ethanol or an isocaloric placebo with the aroma of rum. Each patient received both ethanol and placebo, on different days. The patients, but not the physicians, were blinded to the content of the drink. We measured the sizes of the left atrium and left ventricle, the left-ventricular-wall thickness, blood pressure, heart rate, the degree of systolic anterior motion of the mitral valve, and the pressure gradient across the left ventricular outflow tract. Results The ingestion of ethanol resulted in a significant drop in the mean (+/-SD) systolic blood pressure (from 130.5+/-18.6 to 122.5+/-20.3 mm Hg, P<0.001), a significant increase in systolic anterior motion of the mitral valve (from a grade of 2.1 to a grade of 2.5, P<0.001), and a 63 percent increase in the mean gradient across the left ventricular outflow tract (from 38.1+/-26.5 to 62.2+/-42.4 mm Hg, P<0.001). These changes, which were not associated with symptoms, did not occur after the ingestion of placebo. Conclusions The ingestion of a small amount of ethanol caused an increase in the gradient across the left ventricular outflow tract in patients with hypertrophic obstructive cardiomyopathy, which could have an adverse clinical effect.	BEILINSON MED CTR,PETAH TIQWA,ISRAEL; NYU,MED CTR,NEW YORK,NY 10016	Rabin Medical Center; New York University								AHMED S S, 1980, Clinical Cardiology, V3, P335; BORGGREFE M, 1993, CIRCULATION, V88, P210; BRAUNWALD E, 1992, HEART DISEASE TXB CA, P1; COOK EN, 1932, P STAFF M MAYO CLIN, V7, P449; GOULD L, 1973, CHEST, V63, P943, DOI 10.1378/chest.63.6.943; GOULD L, 1971, J AMER MED ASSOC, V218, P1799, DOI 10.1001/jama.218.12.1799; GOULD L, 1972, Q J STUD ALCOHOL, V33, P451; JUCHEMS R, 1969, AM HEART J, V78, P133, DOI 10.1016/0002-8703(69)90270-1; KELBAEK H, 1990, PROG CARDIOVASC DIS, V32, P347, DOI 10.1016/0033-0620(90)90021-S; KUPARI M, 1983, BRIT HEART J, V49, P174, DOI 10.1136/hrt.49.2.174; MCAREAVEY D, 1994, CIRCULATION, V90, P443; RIFF DP, 1969, AM HEART J, V78, P592, DOI 10.1016/0002-8703(69)90510-9; WIGLE ED, 1995, CIRCULATION, V92, P680	13	37	39	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1996	335	13					938	941		10.1056/NEJM199609263351305	http://dx.doi.org/10.1056/NEJM199609263351305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK148	8782501	Bronze			2022-12-28	WOS:A1996VK14800005
J	AdamKlages, S; Adam, D; Wiegmann, K; Struve, S; Kolanus, W; SchneiderMergener, J; Kronke, M				AdamKlages, S; Adam, D; Wiegmann, K; Struve, S; Kolanus, W; SchneiderMergener, J; Kronke, M			FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase	CELL			English	Article							TUMOR-NECROSIS-FACTOR; CELL-FREE SYSTEM; PHOSPHOLIPASE-C; DEATH DOMAIN; FACTOR-ALPHA; KAPPA-B; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; FAS/APO-1 CD95; BETA-SUBUNIT	The initiation of intracellular signaling events through the 55 kDa tumor necrosis factor-receptor (TNF-R55) appears to depend on protein intermediates that interact with specific cytoplasmic domains of TNF-R55. By combined use of the yeast interaction trap system and a peptide scanning library, the novel WD-repeat protein FAN has been identified, which specifically binds to a cytoplasmic nine amino acid binding motif of TNF-R55. This region has been previously recognized as a distinct functional domain that is both required and sufficient for the activation of neutral sphingomyelinase (N-SMase). Overexpression of full-length FAN enhanced N-SMase activity in TNF-treated cells, while truncated mutants of FAN produced dominant negative effects. The data suggest that FAN regulates ceramide production by N-SMase, which is a crucial step in TNF signaling.	UNIV MUNICH,GENZENTRUM,MOL BIOL LAB,D-81375 MUNICH,GERMANY; UNIV KLINIKUM CHARITE,INST MED IMMUNOL,D-10117 BERLIN,GERMANY	University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	AdamKlages, S (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL,INST IMMUNOL,D-24105 KIEL,GERMANY.		Adam, Dieter/E-9763-2010; Adam-Klages, Sabine/E-9761-2010	Adam, Dieter/0000-0002-5668-5032; 				Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; BARBARA JAJ, 1994, EMBO J, V13, P843, DOI 10.1002/j.1460-2075.1994.tb06327.x; Bazzoni F, 1995, J INFLAMM, V45, P221; BELKA K, 1995, EMBO J, V14, P1156; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FEUCHTER AE, 1992, GENOMICS, V13, P1237, DOI 10.1016/0888-7543(92)90041-P; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GEHR G, 1992, J IMMUNOL, V149, P911; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GRELL M, 1994, J IMMUNOL, V153, P1963; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; Kronke M, 1992, Immunol Ser, V56, P189; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU J, 1994, J BIOL CHEM, V269, P3047; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MURAKAWA K, 1994, GENOMICS, V23, P379, DOI 10.1006/geno.1994.1514; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; REDDY SAG, 1994, J BIOL CHEM, V269, P25369; REINEKE U, 1996, IN PRESS MOL DIVERSI; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VIETOR I, 1993, J BIOL CHEM, V268, P18994; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WEIHERGRABER O, 1996, FEBS LETT, V379, P122; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	63	337	349	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					937	947		10.1016/S0092-8674(00)80169-5	http://dx.doi.org/10.1016/S0092-8674(00)80169-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808629	Bronze			2022-12-28	WOS:A1996VJ44300012
J	Kim, TK; Maniatis, T				Kim, TK; Maniatis, T			Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway	SCIENCE			English	Article							KAPPA-B-ALPHA; INDUCED PHOSPHORYLATION; DEGRADATION; PROTEIN; PROTEOLYSIS; SIGNAL; TYROSINE; TRANSCRIPTION; END	STAT proteins (signal transducers and activators of transcription) are latent cytoplasmic transcription factors that are phosphorylated by Janus kinases in response to cytokines. Phosphorylated STAT proteins translocate to the nucleus, where they transiently turn on specific sets of cytokine-inducible genes. The mechanism that controls the amounts of activated STAT proteins is not understood. STAT1 proteins activated by interferon-gamma treatment in HeLa cells were shown to be stabilized by a proteasome inhibitor and ubiquitinated in vivo. Thus, the amount of activated STAT1 may be negatively regulated by the ubiquitin-proteasome pathway.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020642, R01AI020642] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20642] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; HASPEL RL, IN PRESS EMBO J; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; JENTSCH S, 1992, ANNU REV GENET, V26, P177; Kim T. J., UNPUB; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SALMA SR, 1994, MOL CELL BIOL, V14, P7953; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	28	346	361	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1996	273	5282					1717	1719		10.1126/science.273.5282.1717	http://dx.doi.org/10.1126/science.273.5282.1717			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781235				2022-12-28	WOS:A1996VH40800042
J	Peters, LL; Shivdasani, RA; Liu, SC; Hanspal, M; John, KM; Gonzalez, JM; Brugnara, C; Gwynn, B; Mohandas, N; Alper, SL; Orkin, SH; Lux, SE				Peters, LL; Shivdasani, RA; Liu, SC; Hanspal, M; John, KM; Gonzalez, JM; Brugnara, C; Gwynn, B; Mohandas, N; Alper, SL; Orkin, SH; Lux, SE			Anion exchanger 1 (band 3) is required to prevent erythrocyte membrane surface loss but not to form the membrane skeleton	CELL			English	Article							REFLECT SPECTRIN DEFICIENCIES; RED-BLOOD-CELL; HEREDITARY SPHEROCYTOSIS; CYTOPLASMIC DOMAIN; HEMOLYTIC-ANEMIA; PROTEIN BAND-3; KIDNEY BAND-3; BETA-SPECTRIN; GENE FAMILY; ANKYRIN	The red blood cell (RBC) membrane protein AE1 provides high affinity binding sites for the membrane skeleton, a structure critical to RBC integrity. AE1 biosynthesis is postulated to be required for terminal erythropoiesis and membrane skeleton assembly. We used targeted mutagenesis to assess AE1 function in vivo. RBCs lacking AE1 spontaneously shed membrane vesicles and tubules, leading to severe spherocytosis and hemolysis, but the levels of the major skeleton components, the synthesis of spectrin in mutant erythroblasts, and skeletal architecture are normal or nearly normal. The results indicate that AE1 does not regulate RBC membrane skeleton assembly in vivo but is essential for membrane stability. We postulate that stabilization is achieved through AE1-lipid interactions and that loss of these interactions is a key pathogenic event in hereditary spherocytosis.	CHILDRENS HOSP, DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DEPT PEDIAT ONCOL, BOSTON, MA 02115 USA; ST ELIZABETHS MED CTR, DEPT BIOMED RES, BOSTON, MA 02115 USA; CHILDRENS HOSP, DEPT LAB MED, BOSTON, MA 02115 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, BERKELEY, CA 94720 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, MOL MED UNIT, BOSTON, MA 02115 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT MED, RENAL UNIT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; St. Elizabeth's Medical Center; Harvard University; Boston Children's Hospital; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Peters, LL (corresponding author), JACKSON LAB, 600 MAIN ST, BAR HARBOR, ME 04609 USA.		Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713; Peters, Luanne/0000-0002-0784-0534	NHLBI NIH HHS [HL37462, R01 HL055321, HL32262] Funding Source: Medline; NIDDK NIH HHS [DK34083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262, P01HL037462, R01HL055321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034083, R01DK034083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPER SL, 1989, P NATL ACAD SCI USA, V86, P5429, DOI 10.1073/pnas.86.14.5429; ALPER SL, 1994, CELL PHYSIOL BIOCHEM, V4, P265, DOI 10.1159/000154730; BENNETT V, 1979, J BIOL CHEM, V254, P2533; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; CHASIS JA, 1988, J CLIN INVEST, V82, P617, DOI 10.1172/JCI113640; CHASIS JA, 1992, BLOOD, V80, P1869; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK MR, 1983, BLOOD, V61, P899, DOI 10.1182/blood.V61.5.899.899; COHEN AM, 1986, BLOOD, V68, P920; COX JV, 1987, J CELL BIOL, V105, P1405, DOI 10.1083/jcb.105.3.1405; DING Y, 1994, J BIOL CHEM, V269, P32201; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; GILLIGAN DM, 1993, SEMIN HEMATOL, V30, P74; GROVES JD, 1994, J MEMBRANE BIOL, V140, P81; HANSPAL M, 1991, J BIOL CHEM, V266, P15626; HANSPAL M, 1987, J CELL BIOL, V105, P1417, DOI 10.1083/jcb.105.3.1417; HANSPAL M, 1992, EUR J CELL BIOL, V58, P313; HANSPAL M, 1992, BLOOD, V80, P530; Inaba M, 1996, J CLIN INVEST, V97, P1804, DOI 10.1172/JCI118610; JAROLIM P, 1995, BLOOD, V85, P634, DOI 10.1182/blood.V85.3.634.bloodjournal853634; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KAY MMB, 1990, P NATL ACAD SCI USA, V87, P5734, DOI 10.1073/pnas.87.15.5734; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; KORSGREN C, 1988, J BIOL CHEM, V263, P10212; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1987, CELL, V51, P345, DOI 10.1016/0092-8674(87)90631-3; LEHNERT ME, 1988, J CELL BIOL, V107, P413, DOI 10.1083/jcb.107.2.413; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LIU SC, 1990, BLOOD, V76, P198; LIU SC, 1994, BLOOD, V84, pA362; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MAKSYMIW R, 1987, BIOCHEMISTRY-US, V26, P2983, DOI 10.1021/bi00385a005; NEHLS V, 1993, AM J PATHOL, V142, P1565; ORTWEIN R, 1994, BBA-BIOMEMBRANES, V1191, P317, DOI 10.1016/0005-2736(94)90182-1; PETERS LL, 1993, BLOOD, V81, P2144; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PETERS LL, 1992, BLOOD, V80, P2122; PETERS LL, 1992, P NATL ACAD SCI USA, V89, P5749, DOI 10.1073/pnas.89.13.5749; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; REID ME, 1990, BLOOD, V75, P2229; REINHART WH, 1994, BRIT J HAEMATOL, V86, P147, DOI 10.1111/j.1365-2141.1994.tb03266.x; Robertson E. J., 1987, TERATOCARCINOMAS EMB; RYBICKI AC, 1988, J CLIN INVEST, V81, P893, DOI 10.1172/JCI113400; SAVVIDES P, 1993, BLOOD, V82, P2953; SCHOFIELD AE, 1992, NATURE, V355, P836, DOI 10.1038/355836a0; SHEETZ MP, 1980, NATURE, V285, P510, DOI 10.1038/285510a0; THOMAS HA, 1989, AM J PHYSIOL, V257, pC537, DOI 10.1152/ajpcell.1989.257.3.C537; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONDENHOF A, 1994, BIOCHEMISTRY-US, V33, P4517, DOI 10.1021/bi00181a011; WANG CC, 1995, J BIOL CHEM, V270, P17892, DOI 10.1074/jbc.270.30.17892; WAUGH RE, 1988, J CLIN INVEST, V81, P133, DOI 10.1172/JCI113284; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; WOODS CM, 1986, J CELL BIOL, V103, P1789, DOI 10.1083/jcb.103.5.1789; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	58	208	209	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1996	86	6					917	927		10.1016/S0092-8674(00)80167-1	http://dx.doi.org/10.1016/S0092-8674(00)80167-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808627	Bronze			2022-12-28	WOS:A1996VJ44300010
J	Motzer, RJ; Bander, NH; Nanus, DM				Motzer, RJ; Bander, NH; Nanus, DM			Renal-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TUMOR-SUPPRESSOR GENE; VONHIPPEL-LINDAU DISEASE; NEPHRON-SPARING SURGERY; ACTIVATED KILLER-CELLS; POLYMERASE CHAIN-REACTION; GROWTH FACTOR-ALPHA; 18 MAJOR CANCERS; INTERFERON ALFA-2A; PROGNOSTIC FACTORS; FOLLOW-UP		MEM SLOAN KETTERING CANC CTR, DEPT MED, DIV SOLID TUMOR ONCOL, GENITOURINARY ONCOL SERV, NEW YORK, NY 10021 USA; NEW YORK HOSP, DEPT UROL, NEW YORK, NY 10021 USA; CORNELL UNIV MED COLL, DEPT MED, NEW YORK, NY USA; CORNELL UNIV MED COLL, DEPT UROL, NEW YORK, NY USA	Memorial Sloan Kettering Cancer Center; NewYork-Presbyterian Hospital; Cornell University; Cornell University								*ACS, 1996, CANC FACTS FIG 1996; *ACS, 1989, 12 ACS; AKHTAR M, 1995, AM J SURG PATHOL, V19, P1245, DOI 10.1097/00000478-199511000-00004; AMENDOLA MA, 1988, RADIOLOGY, V166, P637, DOI 10.1148/radiology.166.3.3277239; ANGLARD P, 1991, CANCER RES, V51, P1071; ATLAS I, 1992, CANCER RES, V52, P3335; BANDER NH, 1989, CANCER RES, V49, P6774; Beahrs OH, 1993, HDB STAGING CANC MAN; BELLDEGRUN A, 1993, J NATL CANCER I, V85, P207, DOI 10.1093/jnci/85.3.207; Berger DP, 1995, ANN ONCOL, V6, P817, DOI 10.1093/oxfordjournals.annonc.a059322; BOSNIAK MA, 1986, RADIOLOGY, V158, P1; BOSNIAK MA, 1991, RADIOLOGY, V179, P307, DOI 10.1148/radiology.179.2.2014269; BOSNIAK MA, 1991, RADIOLOGY, V181, P289; BOT FJ, 1994, INT J CANCER, V57, P634; BRAUCH H, 1994, WORLD J UROL, V12, P162; BROOKS JD, 1993, J UROLOGY, V150, P1278, DOI 10.1016/S0022-5347(17)35760-9; CAIRNS P, 1995, CANCER RES, V55, P224; CHEN F, 1995, CANCER RES, V55, P4804; CHERRIE RJ, 1982, J UROLOGY, V128, P910, DOI 10.1016/S0022-5347(17)53273-5; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; COUILLARD DR, 1993, UROL CLIN N AM, V20, P263; CRONIN RE, 1976, MEDICINE, V55, P291, DOI 10.1097/00005792-197607000-00002; CROTTY TB, 1995, J UROLOGY, V154, P964, DOI 10.1016/S0022-5347(01)66944-1; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Fidler I J, 1992, Semin Urol, V10, P3; FOSSA SD, 1989, BRIT J UROL, V64, P468, DOI 10.1111/j.1464-410X.1989.tb05278.x; FOSSA SD, 1992, ANN ONCOL, V3, P301, DOI 10.1093/oxfordjournals.annonc.a058185; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; FUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655, DOI 10.1097/00000478-198210000-00007; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; GASTL G, 1992, CANCER RES, V52, P6229; GILL IS, 1994, J UROLOGY, V152, P1082, DOI 10.1016/S0022-5347(17)32508-9; GIULIANI L, 1990, J UROLOGY, V143, P468, DOI 10.1016/S0022-5347(17)39992-5; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GOTOH A, 1993, CANCER, V71, P2803, DOI 10.1002/1097-0142(19930501)71:9<2803::AID-CNCR2820710919>3.0.CO;2-S; Hanninen EL, 1996, J UROLOGY, V155, P19, DOI 10.1016/S0022-5347(01)66527-3; HELLSTEN S, 1981, SCAND J UROL NEPHROL, V15, P269, DOI 10.3109/00365598109179615; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERR HW, 1994, CANCER, V73, P160, DOI 10.1002/1097-0142(19940101)73:1<160::AID-CNCR2820730127>3.0.CO;2-S; HERRLINGER A, 1991, J UROLOGY, V146, P1224, DOI 10.1016/S0022-5347(17)38052-7; Hoffman AD, 1996, CLIN CANCER RES, V2, P1077; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; IMAI Y, 1994, MODERN PATHOL, V7, P766; ISHIKAWA I, 1993, HISTOPATHOLOGY, V22, P135, DOI 10.1111/j.1365-2559.1993.tb00091.x; JOHNSON CD, 1987, AM J ROENTGENOL, V148, P59, DOI 10.2214/ajr.148.1.59; Kanayama H, 1994, Int J Urol, V1, P324, DOI 10.1111/j.1442-2042.1994.tb00058.x; KELLERER M, 1995, INT J CANCER, V62, P501, DOI 10.1002/ijc.2910620502; KENNEDY SM, 1990, HUM PATHOL, V21, P449, DOI 10.1016/0046-8177(90)90209-N; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KIKUCHI Y, 1994, VIRCHOWS ARCH, V424, P229; KJAER M, 1987, INT J RADIAT ONCOL, V13, P665, DOI 10.1016/0360-3016(87)90283-5; KONNAK JW, 1985, J UROLOGY, V134, P1094, DOI 10.1016/S0022-5347(17)47639-7; KOSARY CL, 1993, NIH PUBLICATION; KOVACS A, 1992, GENE CHROMOSOME CANC, V4, P267, DOI 10.1002/gcc.2870040313; KOVACS G, 1989, INT J CANCER, V43, P422, DOI 10.1002/ijc.2910430313; KOVACS G, 1989, J NATL CANCER I, V81, P527, DOI 10.1093/jnci/81.7.527; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P249, DOI 10.1002/gcc.2870030403; KROWN SE, 1987, CANCER, V59, P647, DOI 10.1002/1097-0142(19870201)59:3+<647::AID-CNCR2820591313>3.0.CO;2-#; LAMIELL JM, 1989, MEDICINE, V68, P1; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LAW TM, 1995, CANCER-AM CANCER SOC, V76, P824, DOI 10.1002/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N; LICHT MR, 1994, J UROLOGY, V152, P39, DOI 10.1016/S0022-5347(17)32810-0; LINDBLAD P, 1995, INT J CANCER, V61, P192, DOI 10.1002/ijc.2910610209; LIPPONEN P, 1995, BRIT J CANCER, V71, P863, DOI 10.1038/bjc.1995.166; MAHER ER, 1991, BRIT J CANCER, V63, P176, DOI 10.1038/bjc.1991.43; MANCILLAJIMENEZ R, 1976, CANCER, V38, P2469, DOI 10.1002/1097-0142(197612)38:6<2469::AID-CNCR2820380636>3.0.CO;2-R; MANDEL JS, 1995, INT J CANCER, V61, P601, DOI 10.1002/ijc.2910610503; MARBERGER M, 1981, BRIT J UROL, V53, P528, DOI 10.1111/j.1464-410X.1981.tb03254.x; MARSHALL FF, 1988, J UROLOGY, V139, P1166, DOI 10.1016/S0022-5347(17)42848-5; McCaffrey JA, 1996, SEMIN ONCOL, V23, pR19; MCCREDIE M, 1995, INT J CANCER, V60, P345, DOI 10.1002/ijc.2910600312; MCLAUGHLIN JK, 1984, JNCI-J NATL CANCER I, V72, P275; MELLEMGAARD A, 1995, INT J CANCER, V60, P350; MELLEMGAARD A, 1994, CANCER CAUSE CONTROL, V5, P105, DOI 10.1007/BF01830256; MINASIAN LM, 1993, J CLIN ONCOL, V11, P1368, DOI 10.1200/JCO.1993.11.7.1368; Moch H, 1996, CANCER RES, V56, P27; MOLL V, 1993, J UROLOGY, V150, P319, DOI 10.1016/S0022-5347(17)35471-X; MORGAN WR, 1990, J UROLOGY, V144, P852, DOI 10.1016/S0022-5347(17)39608-8; MORRA MN, 1993, J UROLOGY, V150, P295, DOI 10.1016/S0022-5347(17)35466-6; MOTZER RJ, 1995, J CLIN ONCOL, V13, P1958, DOI 10.1200/JCO.1995.13.8.1958; MOTZER RJ, 1995, J CLIN ONCOL, V13, P1950, DOI 10.1200/JCO.1995.13.8.1950; MYDLO JH, 1989, CANCER RES, V49, P3407; NANUS DM, 1990, CANCER RES, V50, P4190; NANUS DM, 1990, J UROLOGY, V143, P175, DOI 10.1016/S0022-5347(17)39905-6; NANUS DM, 1993, J NATL CANCER I, V85, P1597, DOI 10.1093/jnci/85.19.1597; NEIDHART JA, 1991, J CLIN ONCOL, V9, P832, DOI 10.1200/JCO.1991.9.5.832; NOVICK AC, 1995, SEMIN ONCOL, V22, P29; NOVICK AC, 1989, J UROLOGY, V141, P835, DOI 10.1016/S0022-5347(17)41026-3; NSEYO UO, 1986, UROLOGY, V28, P301, DOI 10.1016/0090-4295(86)90011-7; OKA H, 1995, CANCER RES, V55, P4182; OLIVER RTD, 1989, BRIT J UROL, V63, P128, DOI 10.1111/j.1464-410X.1989.tb05147.x; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PATHAK S, 1982, SCIENCE, V217, P939, DOI 10.1126/science.7112106; PHILLIPS E, 1993, UROLOGY, V41, P9, DOI 10.1016/0090-4295(93)90234-2; PIERCE WC, 1995, SEMIN ONCOL, V22, P74; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; PORENA M, 1992, J CLIN ULTRASOUND, V20, P395, DOI 10.1002/jcu.1870200606; PRESTI JC, 1991, CANCER RES, V51, P1544; PROVET J, 1991, J UROLOGY, V145, P472, DOI 10.1016/S0022-5347(17)38371-4; RABINOVITCH RA, 1994, J CLIN ONCOL, V12, P206, DOI 10.1200/JCO.1994.12.1.206; RACKLEY R R, 1991, Journal of Urology, V145, p422A; RITCHIE AWS, 1983, SEMIN ONCOL, V10, P390; RO JY, 1987, CANCER, V59, P516, DOI 10.1002/1097-0142(19870201)59:3<516::AID-CNCR2820590327>3.0.CO;2-W; ROBERTSON CN, 1990, J UROLOGY, V144, P614, DOI 10.1016/S0022-5347(17)39537-X; ROBSON CJ, 1969, J UROLOGY, V101, P297, DOI 10.1016/S0022-5347(17)62331-0; ROFSKY NM, 1991, RADIOLOGY, V180, P85, DOI 10.1148/radiology.180.1.2052729; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; SAGALOWSKY AI, 1994, J UROLOGY, V151, P1181, DOI 10.1016/S0022-5347(17)35208-4; SAITOH H, 1982, J UROLOGY, V127, P1092, DOI 10.1016/S0022-5347(17)54243-3; SANDOCK DS, 1995, J UROLOGY, V154, P28, DOI 10.1016/S0022-5347(01)67215-X; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; SEMELKA RC, 1993, JMRI-J MAGN RESON IM, V3, P597, DOI 10.1002/jmri.1880030408; SENE AP, 1992, BRIT J UROL, V70, P125, DOI 10.1111/j.1464-410X.1992.tb15689.x; SHALEV M, 1995, J UROLOGY, V153, P1415, DOI 10.1016/S0022-5347(01)67416-0; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SKINNER DG, 1971, CANCER-AM CANCER SOC, V28, P1165, DOI 10.1002/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G; SMITH SJ, 1989, RADIOLOGY, V170, P699, DOI 10.1148/radiology.170.3.2644658; SPEICHER MR, 1994, AM J PATHOL, V145, P356; STEINBACH F, 1995, WORLD J UROL, V13, P163; STEINBACH F, 1992, J UROLOGY, V148, P24, DOI 10.1016/S0022-5347(17)36499-6; STORKEL S, 1995, WORLD J UROL, V13, P153; STORKEL S, 1989, VIRCHOWS ARCH B, V56, P237; STUDER UE, 1990, J UROLOGY, V144, P243, DOI 10.1016/S0022-5347(17)39422-3; SUZUKI Y, 1994, VIRCHOWS ARCH, V424, P453; SUZUKI Y, 1994, VIRCHOWS ARCH, V425, P335; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; THOMPSON IM, 1988, J UROLOGY, V140, P487, DOI 10.1016/S0022-5347(17)41698-3; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; THRASHER JB, 1994, UROLOGY, V43, P160; THRASHER JB, 1993, UROL CLIN N AM, V20, P247; UCHIDA T, 1993, J UROLOGY, V150, P1298, DOI 10.1016/S0022-5347(17)35764-6; Uhlman DL, 1995, CLIN CANCER RES, V1, P913; UHLMAN DL, 1994, J NATL CANCER I, V86, P1470, DOI 10.1093/jnci/86.19.1470; vandenBerg A, 1996, GENE CHROMOSOME CANC, V15, P64, DOI 10.1002/(SICI)1098-2264(199601)15:1<64::AID-GCC9>3.0.CO;2-2; VANDENBERG E, 1993, INT J CANCER, V55, P223, DOI 10.1002/ijc.2910550210; VOGELZANG NJ, 1992, J UROLOGY, V148, P1247, DOI 10.1016/S0022-5347(17)36874-X; VOGELZANG NJ, 1993, J CLIN ONCOL, V11, P1809, DOI 10.1200/JCO.1993.11.9.1809; WALTHER MM, 1995, J UROLOGY, V153, P2050, DOI 10.1016/S0022-5347(01)67400-7; WALTHER MM, 1995, J UROLOGY, V154, P278, DOI 10.1016/S0022-5347(01)67294-X; WARSHAUER DM, 1988, RADIOLOGY, V169, P363, DOI 10.1148/radiology.169.2.3051112; WASHECKA R, 1991, UROLOGY, V37, P340, DOI 10.1016/0090-4295(91)80261-5; WEISS LM, 1995, AM J CLIN PATHOL, V103, P624; WHANG M, 1995, J UROLOGY, V154, P968, DOI 10.1016/S0022-5347(01)66945-3; Wigginton JM, 1996, JNCI-J NATL CANCER I, V88, P38, DOI 10.1093/jnci/88.1.38; WIRTH MP, 1993, UROL CLIN N AM, V20, P283; Wolk A, 1996, CANCER CAUSE CONTROL, V7, P5, DOI 10.1007/BF00115634; Wolk A, 1996, INT J CANCER, V65, P67, DOI 10.1002/(SICI)1097-0215(19960103)65:1&lt;67::AID-IJC12&gt;3.0.CO;2-F; YAGODA A, 1995, SEMIN ONCOL, V22, P42; YAO M, 1988, CANCER RES, V48, P6753; YU MC, 1986, JNCI-J NATL CANCER I, V77, P351; ZBAR B, 1994, J UROLOGY, V151, P561, DOI 10.1016/S0022-5347(17)35015-2; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	152	1385	1437	0	57	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1996	335	12					865	875		10.1056/NEJM199609193351207	http://dx.doi.org/10.1056/NEJM199609193351207			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG869	8778606				2022-12-28	WOS:A1996VG86900007
J	Wolfe, S				Wolfe, S			Drug advertisements that go straight to the hippocampus	LANCET			English	Editorial Material											Wolfe, S (corresponding author), PUBL CITIZENS HLTH RES GRP,1600 20TH ST NW,WASHINGTON,DC 20009, USA.							AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; *HLTH CAR COMM, 1989, EFF J ADV MARK SHAR; KESSLER DA, 1992, ANN INTERN MED, V116, P950, DOI 10.7326/0003-4819-116-11-950; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912	4	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					632	632		10.1016/S0140-6736(05)65071-4	http://dx.doi.org/10.1016/S0140-6736(05)65071-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782751				2022-12-28	WOS:A1996VF60900006
J	Gerstner, W; Kempter, R; vanHemmen, JL; Wagner, H				Gerstner, W; Kempter, R; vanHemmen, JL; Wagner, H			A neuronal learning rule for sub-millisecond temporal coding	NATURE			English	Article							COCHLEAR NUCLEUS; BARN OWL; BRAIN; CELLS; REPRESENTATION; INTEGRATION; HIPPOCAMPUS; CODES	A PARADOX that exists in auditory and electrosensory neural systems(1,2) is that they encode behaviourally relevant signals in the range of a few microseconds with neurons that are at least one order of magnitude slower, The importance of temporal coding in neural information processing is not clear yet(3-8), A central question is whether neuronal firing can be more precise than the time constants of the neuronal processes involved(9), Here we address this problem using the auditory system of the barn owl as an example, We present a modelling study based on computer simulations of a neuron in the laminar nucleus. Three observations explain the paradox. First, spiking of an 'integrate-and-fire' neuron driven by excitatory postsynaptic potentials with a width at half-maximum height of 250 mu s, has an accuracy of 25 mu s if the presynaptic signals arrive coherently. Second, the necessary degree of coherence in the signal arrival times can be attained during ontogenetic development by virtue of an unsupervised hebbian learning rule, Learning selects connections with matching delays from a broad distribution of axons with random delays, Third, the learning rule also selects the correct delays from two independent groups of inputs, for example, from the left and right ear.	TECH UNIV MUNICH,DEPT PHYS,D-85747 GARCHING,GERMANY; TECH UNIV MUNICH,FAK CHEM & BIOL,D-85747 GARCHING,GERMANY	Technical University of Munich; Technical University of Munich			Wagner, Hermann/G-5454-2012	Wagner, Hermann/0000-0002-8191-7595				Abeles M, 1994, MODELS NEURAL NETWOR, P121, DOI [10.1007/978-1-4612-4320-5_3, DOI 10.1007/978-1-4612-4320-5_3]; BERNANDER O, 1991, P NATL ACAD SCI USA, V88, P11569, DOI 10.1073/pnas.88.24.11569; BIALEK W, 1991, SCIENCE, V252, P1854, DOI 10.1126/science.2063199; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRAITENBERG V, 1993, NETWORK-COMP NEURAL, V4, P11, DOI 10.1088/0954-898X/4/1/002; CARR CE, 1993, ANNU REV NEUROSCI, V16, P223, DOI 10.1146/annurev.ne.16.030193.001255; CARR CE, 1990, J NEUROSCI, V10, P3227; CARR CE, 1995, ADV HEARING RES, P24; DEBANNE D, 1994, P NATL ACAD SCI USA, V91, P1148, DOI 10.1073/pnas.91.3.1148; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GOLDBERG JM, 1969, J NEUROPHYSIOL, V32, P613, DOI 10.1152/jn.1969.32.4.613; HEBB DO, 1949, ORG BEHAVIOR; Heiligenberg W., 1991, NEURAL NETS ELECT FI; HERZ AV, 1989, BIOL CYBERN, V60, P457, DOI 10.1007/BF00204701; HOPFIELD JJ, 1995, NATURE, V376, P33, DOI 10.1038/376033a0; JEFFRESS LA, 1948, J COMP PHYSIOL PSYCH, V41, P35, DOI 10.1037/h0061495; KNUDSEN EI, 1979, J COMP PHYSIOL, V133, P1, DOI 10.1007/BF00663105; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MANIS PB, 1991, J NEUROSCI, V11, P2865; Markram Henry, 1995, Society for Neuroscience Abstracts, V21, P2007; MOISEFF A, 1981, J COMP PHYSIOL, V144, P299, DOI 10.1007/BF00612561; OERTEL D, 1983, J NEUROSCI, V3, P2043; REYES AD, 1994, J NEUROSCI, V14, P5352; Reyes AD, 1996, J NEUROSCI, V16, P993; SALINAS E, 1994, J COMPUT NEUROSCI, V1, P87; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; Softky W R, 1995, Curr Opin Neurobiol, V5, P239, DOI 10.1016/0959-4388(95)80032-8; SOFTKY WR, 1993, J NEUROSCI, V13, P334; SULLIVAN WE, 1984, J NEUROSCI, V4, P1787; YIN TCT, 1990, J NEUROPHYSIOL, V64, P465, DOI 10.1152/jn.1990.64.2.465	30	745	767	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					76	78		10.1038/383076a0	http://dx.doi.org/10.1038/383076a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779718	Green Submitted			2022-12-28	WOS:A1996VF29500050
J	Maguire, CP; Kirby, M; Coen, R; Coakley, D; Lawlor, BA; ONeill, D				Maguire, CP; Kirby, M; Coen, R; Coakley, D; Lawlor, BA; ONeill, D			Family members' attitudes toward telling the patient with Alzheimer's disease their diagnosis	BRITISH MEDICAL JOURNAL			English	Article											Maguire, CP (corresponding author), ST JAMES HOSP,MERCERS INST RES AGING,DUBLIN 8,IRELAND.		O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				BAHRO M, 1995, J AM GERIATR SOC, V43, P41, DOI 10.1111/j.1532-5415.1995.tb06240.x; DRICKAMER MA, 1992, NEW ENGL J MED, V326, P947, DOI 10.1056/NEJM199204023261410; MICHON A, 1994, J NEUROL NEUROSUR PS, V57, P805, DOI 10.1136/jnnp.57.7.805; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; ROHDE K, 1995, J AM GERIATR SOC, V43, P187, DOI 10.1111/j.1532-5415.1995.tb06388.x	5	107	107	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					529	530		10.1136/bmj.313.7056.529	http://dx.doi.org/10.1136/bmj.313.7056.529			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VF294	8789979	Green Published			2022-12-28	WOS:A1996VF29400019
J	Meredith, S; Watson, JM; Citron, KM; Cockcroft, A; Darbyshire, JH				Meredith, S; Watson, JM; Citron, KM; Cockcroft, A; Darbyshire, JH			Are healthcare workers in England and Wales at increased risk of tuberculosis?	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether healthcare workers in England and Wales are at increased risk of tuberculosis and to examine the frequency of drug resistance in this population. Design-Comparison of notification rates by occupation obtained from national tuberculosis notification surveys in 1988 and 1993, with denominators from the 1991 census. Subjects-People with notified tuberculosis in professional and associate professional occupations from the two surveys. Main outcome measures-Rates of notified tuberculosis in health professionals (mainly doctors) and health associate professionals (mainly nurses) compared with rates in other professional and associate professional occupations, adjusted for ethnic group, sex, and age. Results-119 cases of tuberculosis were identified in healthcare workers, including 61 nurses and 42 doctors. The crude notification rate in healthcare workers was 11.8 per 100 000 per year (95% confidence interval 9.8 to 14.1) compared with 3.3 per 100 000 per year (2.9 to 3.6) in other professional and associate professional occupations; rate ratios were higher (range 1.7 to 3.2) in all ethnic groups. The relative risk adjusted for ethnic group, sex, and age was 2.4 (95% confidence interval 2.0 to 3.0), slightly higher for health professionals (2.7 (1.9 to 3.8)) than for associate professionals (2.0 (1.5 to 2.6)). No multiple drug resistant strains of tuberculosis were identified in healthcare workers. Conclusions-Better detection and notification of cases of tuberculosis in healthcare workers may account for some of the apparent increased risk, but these findings imply that tuberculosis remains a hazard for healthcare workers and highlight the importance of ensuring that occupational health monitoring and protection workers are not neglected.	UNIV LONDON, COLL MED, DEPT EPIDEMIOL & MED STAT, LONDON E1 4NS, ENGLAND; PUBL HLTH LAB SERV, CTR COMMUNICABLE DIS SURVEILLANCE, LONDON NW9 5EQ, ENGLAND; ROYAL BROMPTON HOSP, LONDON SW3 6NP, ENGLAND; UNIV LONDON ROYAL FREE HOSP, LONDON NW3 2QG, ENGLAND; UCL, SCH MED, MRC, HIV CLIN TRIALS CTR, LONDON WC1E 6AU, ENGLAND	University of London; Public Health England; Royal Brompton Hospital; University of London; University College London; Medical Research Council Clinical Trials Unit; University of London; University College London; UCL Medical School								ABRUZZI WA, 1953, NEW ENGL J MED, V248, P722, DOI 10.1056/NEJM195304232481705; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; CAPEWELL S, 1988, TUBERCLE, V69, P113, DOI 10.1016/0041-3879(88)90073-6; CHILDRESS WG, 1951, JAMA-J AM MED ASSOC, V146, P1188, DOI 10.1001/jama.1951.03670130010004; *COMP RES CTR, 1992, STAT REF MAN REL 3 0; DANIELS M, 1948, TUBERCULOSIS YOUNG A, V2; *EMPL DEP GROUP OF, 1990, STAND OCC CLASS; HARRINGTON JM, 1976, BRIT MED J, V1, P759, DOI 10.1136/bmj.1.6012.759; Hayward A C, 1995, Commun Dis Rep CDR Rev, V5, pR29; HEIMBECK J., 1936, Tubercle, V18, P97, DOI 10.1016/S0041-3879(36)80249-9; LOUGHREY C, 1992, American Review of Respiratory Disease, V145, pA103; LUNN JA, 1989, J SOC OCCUP MED, V39, P30; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206; MEREDITH SK, 1992, THORAX, V47, P770; MIKOL EX, 1952, AM REV TUBERC PULM, V66, P16; *OFF POP CENS SURV, 1994, 1991 CENS EC ACT GRE; REID DD, 1957, BMJ-BRIT MED J, V2, P10, DOI 10.1136/bmj.2.5035.10; SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012; SHELDON CD, 1992, THORAX, V47, P1015, DOI 10.1136/thx.47.12.1015; SKINNER C, 1994, THORAX, V49, P1193, DOI 10.1136/thx.49.12.1193; Warburton A R, 1993, Commun Dis Rep CDR Rev, V3, pR175; WATSON JM, 1995, THORAX, V50, pP442	23	43	43	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					522	525						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789976	Green Published			2022-12-28	WOS:A1996VF29400016
J	Newton, JA; Pepper, PV				Newton, JA; Pepper, PV			Relapsing fever	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									USN,MED CTR,SAN DIEGO,CA 92134	United States Department of Defense; United States Navy	Newton, JA (corresponding author), USN,MED CTR,PORTSMOUTH,VA 23708, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1197	1197		10.1056/NEJM199610173351605	http://dx.doi.org/10.1056/NEJM199610173351605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN401	8815942				2022-12-28	WOS:A1996VN40100005
J	Lefebvre, O; Chenard, MP; Masson, R; Linares, J; Dierich, A; LeMeur, M; Wendling, C; Tomasetto, C; Chambon, P; Rio, MC				Lefebvre, O; Chenard, MP; Masson, R; Linares, J; Dierich, A; LeMeur, M; Wendling, C; Tomasetto, C; Chambon, P; Rio, MC			Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein	SCIENCE			English	Article							PANCREATIC SPASMOLYTIC POLYPEPTIDE; TUMOR-SUPPRESSOR GENES; HUMAN-BREAST-CANCER; P-DOMAIN; EXPRESSION; STOMACH; FAMILY; CARCINOMA; PEPTIDES; HSP	To determine the function of the pS2 trefoil protein, which is normally expressed in the gastric mucosa, the mouse pS2 (mpS2) gene was inactivated, The antral and pyloric gastric mucosa of mpS2-null mice was dysfunctional and exhibited severe hyperplasia and dysplasia. All homozygous mutant mice developed antropyloric adenoma, and 30 percent developed multifocal intraepithelial or intramucosal carcinomas. The small intestine was characterized by enlarged villi and an abnormal infiltrate of lymphoid cells. These results indicate that mpS2 is essential for normal differentiation of the antral and pyloric gastric mucosa and may function as a gastric-specific tumor suppressor gene.	UNIV STRASBOURG 1,COLL FRANCE,CNRS,INSERM,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; CHU HAUTEPIERRE,SERV ANAT PATHOL GEN,F-67098 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg			Tomasetto, Catherine Laure/J-2783-2014; Lefebvre, Olivier/S-6436-2019; Lefebvre, Olivier/I-2388-2016; Chenard, Marie-Pierre/O-2373-2016	Tomasetto, Catherine Laure/0000-0002-1811-5848; Lefebvre, Olivier/0000-0001-9130-9174; Lefebvre, Olivier/0000-0001-9130-9174; 				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DE A, 1994, P NATL ACAD SCI USA, V91, P1084, DOI 10.1073/pnas.91.3.1084; GAJHEDE M, 1993, STRUCTURE, V1, P253, DOI 10.1016/0969-2126(93)90014-8; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HAGGITT RC, 1994, HUM PATHOL, V25, P982, DOI 10.1016/0046-8177(94)90057-4; HENRY JA, 1991, BRIT J CANCER, V64, P677, DOI 10.1038/bjc.1991.380; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEFEBVRE O, 1993, J CELL BIOL, V122, P191, DOI 10.1083/jcb.122.1.191; LEFEBVRE O, UNPUB; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUQMANI Y, 1989, INT J CANCER, V44, P806, DOI 10.1002/ijc.2910440510; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; PANJA A, 1994, J EXP MED, V179, P943, DOI 10.1084/jem.179.3.943; Playford RJ, 1996, P NATL ACAD SCI USA, V93, P2137, DOI 10.1073/pnas.93.5.2137; PONCE MR, 1992, NUCLEIC ACIDS RES, V20, P623, DOI 10.1093/nar/20.3.623; RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; RIO MC, 1990, CANCER CELL-MON REV, V2, P269; RIO MC, 1988, CR ACAD SCI III-VIE, V307, P825; ROCHA B, 1995, CURR OPIN IMMUNOL, V7, P235, DOI 10.1016/0952-7915(95)80008-5; ROSAI J, 1996, ACKERMANS SURG PATHO, V8, P632; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; THEISINGER B, 1991, EUR J CANCER, V27, P770, DOI 10.1016/0277-5379(91)90186-H; THIM L, 1994, DIGESTION, V55, P353, DOI 10.1159/000201165; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; TOMASETTO C, 1992, GENOMICS, V13, P1328, DOI 10.1016/0888-7543(92)90059-2; TOMITA M, 1995, BIOCHEM J, V311, P293, DOI 10.1042/bj3110293; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELTER C, 1992, LAB INVEST, V66, P187; WRIGHT NA, 1990, J PATHOL, V162, P279, DOI 10.1002/path.1711620402	35	434	459	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					259	262		10.1126/science.274.5285.259	http://dx.doi.org/10.1126/science.274.5285.259			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824193				2022-12-28	WOS:A1996VM67100047
J	Roeske, LC; Kennedy, PR				Roeske, LC; Kennedy, PR			Syphilitic gummas in a patient with human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Roeske, LC (corresponding author), EMORY UNIV,SCH MED,ATLANTA,GA 30322, USA.								0	9	10	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1996	335	15					1123	1123		10.1056/NEJM199610103351506	http://dx.doi.org/10.1056/NEJM199610103351506			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN399	8813043				2022-12-28	WOS:A1996VN39900006
J	Kattan, MW; Inoue, Y; Giles, FJ; Talpaz, M; Ozer, H; Guilhot, F; Zuffa, E; Huber, SL; Beck, JR				Kattan, MW; Inoue, Y; Giles, FJ; Talpaz, M; Ozer, H; Guilhot, F; Zuffa, E; Huber, SL; Beck, JR			Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia	ANNALS OF INTERNAL MEDICINE			English	Article						leukemia, chronic, myeloid; cost-benefit analysis; interferon-alpha; hydroxyurea; quality of life	BONE-MARROW TRANSPLANTATION; BREAST-CANCER; ALFA THERAPY; SURVIVAL; EFFICACY; GUIDE	Objective: To compare the cost-effectiveness of interferon-alpha with that of hydroxyurea as initial therapy for patients with chronic myelogenous leukemia (CML) in the chronic phase. Design: A decision analysis and Markov model that described the natural history of the therapeutic process. The Markov model contained two treatment arms (interferon-alpha and hydroxyurea) and eight states of health (complete hematologic remission with cytogenetic response, complete hematologic remission without cytogenetic response, partial hematologic remission, chronic phase without hematologic remission, accelerated phase, blast crisis, bone marrow transplantation, and death). Probabilities, costs, and utilities were obtained from published clinical studies and clinical investigators. Measurement: Quality-adjusted years of life saved and costs and qualities discounted at 5% per year. Setting: University medical centers in North America and Europe. Patients: Meta-analysis of results from patients studied in clinical trials. Results: The model's predictions of median survival (69 months with interferon-alpha therapy and 58 months with hydroxyurea therapy) were derived from data in the recent literature. In patients 50 years of age, interferon-alpha improved life expectancy over hydroxyurea by approximately 18 months. The marginal cost-effectiveness of interferon-alpha (incremental discounted cost of interferon-alpha compared with that of conventional therapy) was $34 800 per quality-adjusted year of life saved. The model was sensitive to the monthly cost of interferon-alpha therapy (if the cost of interferon-alpha is reduced by one third, the cost-effectiveness becomes $19 300 per quality-adjusted year of life saved) but was not particularly sensitive to the costs associated with blast crisis or bone marrow transplantation. The other significant variable was quality of life during therapy with interferon-alpha; when this measure was varied from 70% to 100% of the quality of life during hydroxyurea therapy, cost-effectiveness changed from $123 200 to $25 620 per quality-adjusted year of life saved. When the quality of life associated with interferon-alpha was less than 62% of the quality of life associated with hydroxyurea, the discounted quality-adjusted life expectancy with interferon-alpha was less than that with hydroxyurea. Conclusion: Compared with hydroxyurea, interferon-alpha is, in most clinical scenarios, a cost-effective initial therapy for patients with chronic-phase CML who can tolerate the drug.	BAYLOR COLL MED, INFORMAT TECHNOL PROGRAM, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, HOUSTON, TX 77030 USA; YAMAGUCHI UNIV, SCH MED, DEPT MED INFORMAT, YAMAGUCHI 755, JAPAN; CEDARS SINAI MED CTR, LOS ANGELES, CA 90048 USA; EMORY UNIV, SCH MED, CTR CANC, ATLANTA, GA 30322 USA; CHR UNIV MIL, F-86201 POITIERS, FRANCE; UNIV BOLOGNA, POLICLIN S ORSOLA, INST HEMATOL, I-40138 BOLOGNA, ITALY	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Yamaguchi University; Cedars Sinai Medical Center; Emory University; CHU Poitiers; Universite de Poitiers; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna			beck, robert/AAE-8384-2019; Kattan, Michael/AAF-9735-2021	Kattan, Michael/0000-0002-3840-4161; Guilhot, Francois/0000-0001-7222-487X; Talpaz, Moshe/0000-0003-3361-3981	NATIONAL LIBRARY OF MEDICINE [G08LM004905, T15LM007093] Funding Source: NIH RePORTER; NLM NIH HHS [LM07093, LM04905] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; BILHOUNABERA C, 1992, LEUKEMIA, V6, P595; BYERS T, 1992, CANCER, V70, P1288, DOI 10.1002/1097-0142(19920901)70:3+<1288::AID-CNCR2820701515>3.0.CO;2-1; DESCH CE, 1992, J CLIN ONCOL, V10, P200, DOI 10.1200/JCO.1992.10.2.200; FELDMAN S, 1993, OBSTET GYNECOL, V81, P968; GIRALT SA, 1993, J CLIN ONCOL, V11, P1055, DOI 10.1200/JCO.1993.11.6.1055; HEHLMANN R, 1993, BLOOD, V82, P398, DOI 10.1182/blood.V82.2.398.bloodjournal822398; HILLNER BE, 1992, JAMA-J AM MED ASSOC, V267, P2055, DOI 10.1001/jama.267.15.2055; Hjorth M, 1996, ANN INTERN MED, V124, P212, DOI 10.7326/0003-4819-124-2-199601150-00004; KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003; KANTARJIAN HM, 1993, BLOOD, V82, P691; KANTARJIAN HM, 1987, AM J MED, V83, P445, DOI 10.1016/0002-9343(87)90754-6; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; *NAT CTR HLTH STAT, 1991, DHHS PUBL; NORD E, 1992, SOC SCI MED, V94, P560; OZER H, 1993, BLOOD, V82, P2975; PROVENZALE D, 1994, AM J GASTROENTEROL, V89, P670; SACCHI S, 1995, J CLIN ONCOL, V13, P2401, DOI 10.1200/JCO.1995.13.9.2401; SCHOFIELD JR, 1994, ANN INTERN MED, V121, P736, DOI 10.7326/0003-4819-121-10-199411150-00002; SMITH TJ, 1993, J CLIN ONCOL, V11, P771, DOI 10.1200/JCO.1993.11.4.771; Sobocinski K A, 1994, J Hematother, V3, P95, DOI 10.1089/scd.1.1994.3.95; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; STIPP D, 1994, WALL STREET J   0706, pB1; TURA S, 1994, NEW ENGL J MED, V330, P820; TURA S, 1992, HAEMATOLOGICA, V77, P204; WONG JB, 1995, ANN INTERN MED, V122, P664, DOI 10.7326/0003-4819-122-9-199505010-00004	26	53	55	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1996	125	7					541	+		10.7326/0003-4819-125-7-199610010-00002	http://dx.doi.org/10.7326/0003-4819-125-7-199610010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ653	8815752				2022-12-28	WOS:A1996VJ65300002
J	Jensen, LS; KissmeyerNielsen, P; Wolff, B; Qvist, N				Jensen, LS; KissmeyerNielsen, P; Wolff, B; Qvist, N			Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery	LANCET			English	Article							CANCER SURGERY; INFECTIOUS COMPLICATIONS; DELAYED-HYPERSENSITIVITY; RED-CELLS; RANITIDINE; INTERLEUKIN-2; FILTER; RISK	Background Allogeneic blood transfusion is associated with an increased frequency of postoperative infection. We studied whether such events can be avoided by the intraoperative and postoperative use of leucocyte-depleted blood. Methods 589 consecutive patients scheduled for elective colorectal surgery were randomised to receive buffy-coat poor (n=299) or filtered leucocyte-depleted red-cells (n=290) when transfusion was indicated. 260 patients actually received blood transfusion. Three patients were excluded from analysis. Findings The 142 patients randomised to and transfused with buffy-coat-poor blood had a significantly higher frequency of wound infections and intra-abdominal abscesses than the 155 patients who were allocated to this group but who were not transfused. (12 vs 1%, p<0.0001) and (5 vs 0%, p=0.005), respectively. Those receiving buffy-coat-poor blood also had a significantly higher frequency of wound infections and intra-abdominal abscesses than the 118 randomised to and receiving leucocyte-depleted blood (12 vs 0%, p<0.0001) and (5 vs 0%, p=0.017), respectively. Postoperative pneumonia occurred at a significantly higher rate in patients receiving buffy-coat-poor blood: 23 versus 3% in non-transfused patients (p<0.0001), and 23 versus 3% in patients transfused with leucocyte-depleted blood (p<0.001). The mortality rate between the groups was not statistically different. Interpretation Our data suggests that the association between allogeneic blood transfusion and postoperative infection is limited to allogeneic blood products that are not adequately depleted of immunosuppressive leucocytes. This undesirable effect can be reduced by leucocyte depletion with high-efficiency filters.	ODENSE UNIV HOSP, DK-5000 ODENSE, DENMARK	University of Southern Denmark; Odense University Hospital	Jensen, LS (corresponding author), AARHUS UNIV HOSP, DEPT SURG GASTROENTEROL, DK-8000 AARHUS C, DENMARK.			Qvist, Niels/0000-0002-1113-195X				AGARWAL N, 1993, ARCH SURG-CHICAGO, V128, P171; AKIYOSHI T, 1985, CLIN EXP IMMUNOL, V59, P45; BLUMBERG N, 1994, ARCH PATHOL LAB MED, V118, P371; EDNA TH, 1992, J TRAUMA, V33, P659, DOI 10.1097/00005373-199211000-00010; FERNANDEZ LA, 1992, AM J SURG, V163, P263, DOI 10.1016/0002-9610(92)90114-7; FRIEDMAN BA, 1979, TRANSFUSION, V19, P268, DOI 10.1046/j.1537-2995.1979.19379204208.x; GAFTER U, 1992, KIDNEY INT, V41, P143, DOI 10.1038/ki.1992.19; GIANOTTI L, 1993, TRANSFUSION, V33, P458, DOI 10.1046/j.1537-2995.1993.33693296806.x; HALLISSEY MT, 1992, ANN ROY COLL SURG, V74, P59; HAMMER JH, 1992, EUR SURG RES, V24, P133, DOI 10.1159/000129199; HEISS MM, 1993, LANCET, V342, P1328, DOI 10.1016/0140-6736(93)92247-Q; HOUBIERS JGA, 1994, LANCET, V344, P573, DOI 10.1016/S0140-6736(94)91965-8; JENSEN LS, 1994, LANCET, V344, P1429; Jensen LS, 1996, BRIT J SURG, V83, P973, DOI 10.1002/bjs.1800830727; JENSEN LS, 1992, BRIT J SURG, V79, P513, DOI 10.1002/bjs.1800790613; KAPLAN J, 1984, BLOOD, V64, P308; KOMAI H, 1994, ANN THORAC SURG, V57, P134, DOI 10.1016/0003-4975(94)90381-6; MEZROW CK, 1992, TRANSFUSION, V32, P27, DOI 10.1046/j.1537-2995.1992.32192116427.x; MIHOLIC J, 1985, ANN THORAC SURG, V40, P224, DOI 10.1016/S0003-4975(10)60032-X; MURPHY P, 1991, TRANSFUSION, V31, P212, DOI 10.1046/j.1537-2995.1991.31391165169.x; NIELSEN HJ, 1991, CAN J SURG, V34, P146; NIELSEN HJ, 1989, SURGERY, V105, P711; NIELSEN HJ, 1995, BRIT J SURG, V82, P582, DOI 10.1002/bjs.1800820505; NIELSEN HJ, 1994, BRIT J SURG, V81, P1747, DOI 10.1002/bjs.1800811213; RASMUSSEN LA, 1995, J AM COLL SURGEONS, V181, P138; SIRCHIA G, 1990, TRANSFUSION, V30, P30, DOI 10.1046/j.1537-2995.1990.30190117625.x; SPROGOEJAKOBSEN U, 1995, TRANSFUSION, V35, P421, DOI 10.1046/j.1537-2995.1995.35595259153.x; TARTTER PI, 1988, BRIT J SURG, V75, P789, DOI 10.1002/bjs.1800750822; TRIULZI DJ, 1992, TRANSFUSION, V32, P517, DOI 10.1046/j.1537-2995.1992.32692367194.x; WENZ B, 1989, CONTROVERSIES LEUKOC, P27; WENZ B, 1989, ROLE LEUCOCYTE DEPLE, P83; WIDMANN FK, 1991, STANDARDS BLOOD BANK	32	314	318	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 28	1996	348	9031					841	845		10.1016/S0140-6736(96)06168-5	http://dx.doi.org/10.1016/S0140-6736(96)06168-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826808				2022-12-28	WOS:A1996VK03700008
J	Arieli, A; Sterkin, A; Grinvald, A; Aertsen, A				Arieli, A; Sterkin, A; Grinvald, A; Aertsen, A			Dynamics of ongoing activity: Explanation of the large variability in evoked cortical responses	SCIENCE			English	Article							PRIMARY VISUAL-CORTEX; ELECTRICAL-ACTIVITY; ORIENTATION DISCRIMINATION; SINGLE CELLS; NEURONS; MONKEY; BRAIN; CAT; PATTERNS; PERFORMANCE	Evoked activity in the mammalian cortex and the resulting behavioral responses exhibit a large variability to repeated presentations of the same stimulus. This study examined whether the variability can be attributed to ongoing activity, Ongoing and evoked spatiotemporal activity patterns in the cat visual cortex were measured with real-time optical imaging; local field potentials and discharges of single neurons were recorded simultaneously, by electrophysiological techniques. The evoked activity appeared deterministic, and the variability resulted from the dynamics of ongoing activity, presumably reflecting the instantaneous state of cortical networks, In spite of the large variability, evoked responses in single trials could be predicted by linear summation of the deterministic response and the preceding ongoing activity, Ongoing activity must play an important role in cortical function and cannot be ignored in exploration of cognitive processes.			Arieli, A (corresponding author), WEIZMANN INST SCI, DEPT NEUROBIOL, POB 26, IL-76100 REHOVOT, ISRAEL.							ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; ARIELI A, 1995, J NEUROPHYSIOL, V73, P2072, DOI 10.1152/jn.1995.73.5.2072; Arieli A., 1995, Society for Neuroscience Abstracts, V21, P772; ARIELI A, 1992, INFORMATION PROCESSI, P123; ARIELI A, IN PRESS SOC NEUR AB; BLAIR W, 1994, SOC NEUR ABSTR, V20, P1279; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; COOPER R, 1965, ELECTROEN CLIN NEURO, V18, P217, DOI 10.1016/0013-4694(65)90088-X; Creutzfeldt O., 1974, HDB ELECTROENCEPHALO, V2C, P5; Elul R, 1971, Int Rev Neurobiol, V15, P227; FERSTER D, 1995, SCIENCE, V270, P756, DOI 10.1126/science.270.5237.756; GEISLER WS, 1995, VISION RES, V35, P2723, DOI 10.1016/0042-6989(95)00029-Y; GERSTEIN GL, 1960, SCIENCE, V131, P1811, DOI 10.1126/science.131.3416.1811; GEVINS AS, 1980, CRC CR REV BIOM ENG, V4, P113; GRATTON G, 1995, PSYCHOPHYSIOLOGY, V32, P292, DOI 10.1111/j.1469-8986.1995.tb02958.x; GRINVALD A, 1994, J NEUROSCI, V14, P2545; GRINVALD A, 1982, J PHYSIOL-LONDON, V333, P269, DOI 10.1113/jphysiol.1982.sp014453; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; GRINVALD A, 1984, NATURE, V308, P848, DOI 10.1038/308848a0; HARTVEIT E, 1994, J NEUROPHYSIOL, V72, P1278, DOI 10.1152/jn.1994.72.3.1278; HEGGELUND P, 1978, EXP BRAIN RES, V32, P197; Holt Gary R., 1995, Society for Neuroscience Abstracts, V21, P22; JOHN ER, 1972, SCIENCE, V177, P850, DOI 10.1126/science.177.4052.850; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; Mechler F., 1995, Society for Neuroscience Abstracts, V21, P22; ORBACH HS, 1985, J NEUROSCI, V5, P1886; Regan D., 1989, HUMAN BRAIN ELECTROP; ROSENBLITH WA, 1959, PROCESSING NEUROELEC; SCHILLER PH, 1976, BRAIN RES, V105, P347, DOI 10.1016/0006-8993(76)90432-7; SCOBEY RP, 1989, EXP BRAIN RES, V77, P398, DOI 10.1007/BF00274997; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; Shadlen MN, 1996, J NEUROSCI, V16, P1486; SHAW GL, 1982, EXP NEUROL, V77, P324, DOI 10.1016/0014-4886(82)90249-7; SNOWDEN RJ, 1992, EXP BRAIN RES, V88, P389, DOI 10.1007/BF02259114; SOFTKY WR, 1993, J NEUROSCI, V13, P334; STERKIN A, UNPUB; VOGELS R, 1989, EXP BRAIN RES, V77, P432, DOI 10.1007/BF00275002; WHEAT HE, 1995, J NEUROSCI, V15, P5582	38	1235	1251	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	1996	273	5283					1868	1871		10.1126/science.273.5283.1868	http://dx.doi.org/10.1126/science.273.5283.1868			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791593				2022-12-28	WOS:A1996VJ71300047
J	Madar, J; Richmond, S				Madar, J; Richmond, S			Role of extracorporeal membrane oxygenation	LANCET			English	Letter									DIST GEN HOSP,NEONATOL UNIT,SUNDERLAND,TYNE & WEAR,ENGLAND		Madar, J (corresponding author), DERRIFORD HOSP,NEONATOL UNIT,PLYMOUTH PL6 8DH,DEVON,ENGLAND.			peek, giles/0000-0002-1313-6498				MADAR RJ, 1994, COLLABORATIVE SURVEY, P43; Skinner JR, 1996, ARCH DIS CHILD-FETAL, V74, pF26, DOI 10.1136/fn.74.1.F26; Soll RF, 1996, LANCET, V348, P70; TRACY TF, 1994, J PEDIATR SURG, V29, P265, DOI 10.1016/0022-3468(94)90330-1; 1996, LANCET, V348, P75	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					823	823		10.1016/S0140-6736(05)65239-7	http://dx.doi.org/10.1016/S0140-6736(05)65239-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8814000				2022-12-28	WOS:A1996VH98900045
J	Michel, F; Westhof, E				Michel, F; Westhof, E			Visualizing the logic behind RNA self-assembly	SCIENCE			English	Editorial Material							TERTIARY STRUCTURE; GAAA TETRALOOP; DOMAIN		CNRS, INST BIOL MOL & CELLULAIRE, F-67084 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Michel, F (corresponding author), CNRS, CTR GENET MOL, F-91190 GIF SUR YVETTE, FRANCE.							Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CATE JH, IN PRESS STRUCTURE; COSTA M, 1995, EMBO J, V14, P1276, DOI 10.1002/j.1460-2075.1995.tb07111.x; DOCKBREGEON AC, 1988, NATURE, V335, P375, DOI 10.1038/335375a0; MASSIRE C, 1994, J MOL GRAPHICS, V12, P201, DOI 10.1016/0263-7855(94)80088-X; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848	11	11	11	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1996	273	5282					1676	1677		10.1126/science.273.5282.1676	http://dx.doi.org/10.1126/science.273.5282.1676			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8830411				2022-12-28	WOS:A1996VH40800029
J	Localio, AR; Weaver, SL; Landis, JR; Lawthers, AG; Brennan, TA; Hebert, L; Sharp, TJ				Localio, AR; Weaver, SL; Landis, JR; Lawthers, AG; Brennan, TA; Hebert, L; Sharp, TJ			Identifying adverse events caused by medical care: Degree of physician agreement in a retrospective chart review	ANNALS OF INTERNAL MEDICINE			English	Article							DRUG-REACTIONS; APPROPRIATE INDICATIONS; INTEROBSERVER VARIATION; HOSPITALIZED-PATIENTS; SUBSTANDARD CARE; QUALITY; JUDGMENTS; MALPRACTICE; RELIABILITY; KAPPA	Objective: To 1) assess the degree of agreement among physicians on the cause of previously flagged adverse outcomes and 2) relate the findings to systems of quality assurance and performance assessment and proposals for no-fault compensation for medical injuries. Design: Observational study of 7533 pairs of ''structured implicit'' reviews (subjective opinions based on guidelines) of medical records done by 127 physicians working independently. Setting: Random sample of 51 inpatient facilities in New York State. Patients: Random sample of inpatient medical records from the selected facilities. Measurements: 1) Number of agreed-upon adverse events compared with the number of cases of extreme disagreement and 2) internally and indirectly standardized rates at which physician reviewers found adverse events (injuries to patients caused at least in part by medical management). Results: In 12.9% of cases (971 of 7533), the two physicians in a pair had extreme disagreement about the occurrence of an adverse event. These cases outnumbered those in which both reviewers found an adverse event (10%; n = 757). Agreement was highest for wound infections and lowest for adverse events attributed to failure to diagnose or lack of therapy. The amount of experience the physicians had in reviewing records tended to increase the level of agreement. Even after standardization to the results of the entire sample, individual physicians' rates of finding at least slight evidence of an adverse event varied widely (range, 9.9% to 43.7%) (P < 0.001). Conclusions: Structured implicit reviews produced disagreement on the causes of adverse patient outcomes. If systems of quality assurance, performance audits, or no-fault patient compensation are to succeed, methods for overcoming the common tendency toward disagreement among experts must be developed.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; RUSH UNIV, RUSH INST AGING, RUSH ALZHEIMERS DIS CTR, CHICAGO, IL 60612 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, CHICAGO, IL 60612 USA	Harvard University; Harvard T.H. Chan School of Public Health; Rush University; Rush University	Localio, AR (corresponding author), PENN STATE UNIV, COLL MED, CTR BIOSTAT & EPIDEMIOL, POB 850, HERSHEY, PA 17033 USA.		Landis, J. Richard/A-9330-2010	Landis, J Richard/0000-0001-8099-0988	AHRQ HHS [R01 HS07067-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALTMAN DG, 1991, PRACTICAL STAT MED R, P161; *AM MED ASS, 1988, PROP ALT CIV JUST SY; BADER JD, 1993, J DENT RES, V72, P891, DOI 10.1177/00220345930720051001; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BENICHOU C, 1993, J CLIN EPIDEMIOL, V46, P1331, DOI 10.1016/0895-4356(93)90102-7; BEST WR, 1994, MED CARE, V32, P390, DOI 10.1097/00005650-199404000-00007; BOVBJERG RR, 1991, JAMA-J AM MED ASSOC, V265, P2836, DOI 10.1001/jama.265.21.2836; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; BROOK RH, 1988, LANCET, V1, P750; BYRT T, 1993, J CLIN EPIDEMIOL, V46, P423, DOI 10.1016/0895-4356(93)90018-V; California Medical Association, 1977, REP MED INS FEAS STU; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; CASELLA G, 1985, AM STAT, V39, P83, DOI 10.2307/2682801; CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M; *COMM MED PROF LIA, 1979, DES COMP EV SYST FEA; DALY L, 1992, COMPUT BIOL MED, V22, P351, DOI 10.1016/0010-4825(92)90023-G; DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6; DAVIS CE, 1990, CONTROL CLIN TRIALS, V11, P37, DOI 10.1016/0197-2456(90)90030-6; DEVET HCW, 1992, J CLIN EPIDEMIOL, V45, P785, DOI 10.1016/0895-4356(92)90056-S; DIPPE SE, 1989, WESTERN J MED, V151, P93; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; ELMORE JG, 1992, J CLIN EPIDEMIOL, V45, P567, DOI 10.1016/0895-4356(92)90128-A; EPSTEIN RA, 1986, LAW CONTEMP PROBL, V49, P200, DOI 10.2307/1191422; FEINSTEIN AR, 1985, J CHRON DIS, V38, P619, DOI 10.1016/0021-9681(85)90016-5; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; FLEMING JG, 1984, LA LAW REV, V44, P1193; GEFFEN N, 1968, GUT, V9, P150, DOI 10.1136/gut.9.2.150; GOLDMAN RL, 1992, JAMA-J AM MED ASSOC, V267, P958, DOI 10.1001/jama.267.7.958; GRAHAM P, 1993, J CLIN EPIDEMIOL, V46, P1055, DOI 10.1016/0895-4356(93)90173-X; GRANT JM, 1991, LANCET, V337, P215, DOI 10.1016/0140-6736(91)92169-3; HARRIS EK, 1979, J CHRON DIS, V32, P233, DOI 10.1016/0021-9681(79)90069-9; *HARV MED PRACT ST, 1990, PAT DOCT LAW MED INJ; Havighurst C C, 1984, Health Aff (Millwood), V3, P63, DOI 10.1377/hlthaff.3.4.63; HAVIGHURST CC, 1973, MILBANK FUND Q, V51, P125, DOI 10.2307/3349578; HAYWARD RA, 1993, ANN INTERN MED, V118, P550, DOI 10.7326/0003-4819-118-7-199304010-00010; *I MED DIV LEG ETH, 1978, MALPR COMP MED INJ; JOHNSON WG, 1992, JAMA-J AM MED ASSOC, V267, P2487, DOI 10.1001/jama.267.18.2487; KAHN KL, 1992, EFFECTS DRG BASED PR, P83; KARCH FE, 1976, CLIN PHARMACOL THER, V19, P489; KOCHWESER J, 1977, EUR J CLIN PHARMACOL, V11, P75, DOI 10.1007/BF00562895; KORAN LM, 1975, NEW ENGL J MED, V293, P695, DOI 10.1056/NEJM197510022931405; KRAMER MS, 1981, BRIT J CLIN PHARMACO, V11, pS105; KRAMER MS, 1992, J CLIN EPIDEMIOL, V45, P639, DOI 10.1016/0895-4356(92)90136-B; KRAMER MS, 1979, JAMA-J AM MED ASSOC, V242, P623, DOI 10.1001/jama.242.7.623; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LEVENTHAL JM, 1979, JAMA-J AM MED ASSOC, V242, P1991, DOI 10.1001/jama.242.18.1991; Lichtenstein S., 1982, JUDGMENT UNCERTAINTY, P306, DOI [DOI 10.1017/CBO9780511809477, DOI 10.1017/CBO9780511809477.023]; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; LOCALIO AR, 1993, CLIN DECISIONMAKING; LYALL S, 1993, NY TIMES        0107, pB8; LYALL S, 1993, NY TIMES        0421, V142, pB1; MACKENZIE EJ, 1992, J TRAUMA, V33, P292, DOI 10.1097/00005373-199208000-00021; MACNEE CL, 1994, INQUIRY-J HEALTH CAR, V31, P66; MCCLELLAN M, 1992, MED CARE, V30, P565, DOI 10.1097/00005650-199207000-00001; MOORE H, 1984, LA LAW REV, V44, P1495; MUSCH DC, 1985, BRIT J IND MED, V42, P346; NARANJO CA, 1992, J CLIN PHARMACOL, V32, P897, DOI 10.1002/j.1552-4604.1992.tb04635.x; OCONNELL J, 1975, INSUR LAW J, P261; PARK RE, 1989, AM J PUBLIC HEALTH, V79, P445, DOI 10.2105/AJPH.79.4.445; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; POSES RM, 1988, MED DECIS MAKING, V8, P233, DOI 10.1177/0272989X8800800403; POSES RM, 1989, CRIT CARE MED, V17, P827, DOI 10.1097/00003246-198908000-00021; RICHARDS T, 1987, MEASURING CASE MIX Q; Richardson F M, 1972, Med Care, V10, P29, DOI 10.1097/00005650-197201000-00004; RUBENSTEIN LV, 1990, JAMA-J AM MED ASSOC, V264, P1974, DOI 10.1001/jama.264.15.1974; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P36; SCHROEDER SA, 1991, JAMA-J AM MED ASSOC, V265, P1995; STRATTON KR, 1994, ADVERSE EVENTS ASS C, P19; WADLINGTON W, 1991, JAMA-J AM MED ASSOC, V265, P2861; WILCOSKY TC, 1985, J CHRON DIS, V38, P849, DOI 10.1016/0021-9681(85)90109-2; WILSON DS, 1992, J TRAUMA, V32, P45, DOI 10.1097/00005373-199201000-00010; WOLFINGER R, 1993, J STAT COMPUT SIM, V48, P233, DOI 10.1080/00949659308811554; 1994, ANN INTERN MED, V120, P423; 1996, ANN INTERN MED, V122, P466	76	127	129	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					457	464		10.7326/0003-4819-125-6-199609150-00005	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VF882	8779457				2022-12-28	WOS:A1996VF88200006
J	Young, J				Young, J			Caring for older people - Rehabilitation and older people .10.	BRITISH MEDICAL JOURNAL			English	Article								Rehabilitation is concerned with lessening the impact of disabling conditions. These are particularly common in older people and considerable health gain can be achieved by successful rehabilitation. Hospital doctors and general practitioners should be aware of the core principles of rehabilitation, be able to recognise rehabilitation need in their patients, and have sufficient knowledge of their local rehabilitation services to trigger the referral process.			Young, J (corresponding author), ST LUKES HOSP,BRADFORD HOSP TRUST,BRADFORD BD5 0NA,W YORKSHIRE,ENGLAND.			young, john/0000-0003-4085-9306				MARTEN J, 1989, 1 OPCS; Travers AF, 1996, BRIT MED J, V313, P482	2	24	24	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1996	313	7058					677	681						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8811764				2022-12-28	WOS:A1996VH16500031
J	Farrar, MA; AlberolaIla, J; Perlmutter, RM				Farrar, MA; AlberolaIla, J; Perlmutter, RM			Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization	NATURE			English	Article							BINDS COUMARIN DRUGS; NIH 3T3 CELLS; PROTEIN-KINASE; PLASMA-MEMBRANE; DNA GYRASE; SIGNAL-TRANSDUCTION; IN-VITRO; RAS; PHOSPHORYLATION; SUBDOMAIN	THE Raf-1 serine/threonine kinase is a key component of the MAP kinase cascade(1-3), regulating both proliferation and commitment to cell fate(4,5). Raf activation is stimulated following its translocation to the plasma membrane, a process that ordinarily requires interaction with the membrane-localized GTPase, Ras-GTP(6-10). To investigate the mechanisms underlying Raf activation, we have developed a coumermycin-induced chemical dimerization method. We find that dimerization is by itself sufficient, in the absence of any membrane components, both to activate a modified Raf protein and to stimulate the MAP kinase cascade appropriately. As Ras-GTP-induced membrane localization increases the effective intracellular Ras concentration, our results indicate that homotypic oligomerization may ordinarily act to promote Raf activation in vivo.	UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM & MED MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle			Farrar, Michael A/M-7802-2013	Farrar, Michael/0000-0002-5569-0366; alberola-ila, Jose/0000-0003-2439-553X				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; GILBERT EJ, 1994, MOL MICROBIOL, V12, P365, DOI 10.1111/j.1365-2958.1994.tb01026.x; GODFREY JC, 1972, ADV APPL MICROBIOL, V15, P653; GONZALEZ AL, 1995, TRENDS GENET, V11, P216, DOI 10.1016/S0168-9525(00)89051-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; Sambrook J., 2002, MOL CLONING LAB MANU; SEGER R, 1994, J BIOL CHEM, V269, P25699; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	28	266	289	1	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					178	181		10.1038/383178a0	http://dx.doi.org/10.1038/383178a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774884				2022-12-28	WOS:A1996VG14800055
J	Stiff, GJ; Haray, PN; Foster, ME				Stiff, GJ; Haray, PN; Foster, ME			Dyschromatopsia (number 97) and rectal bleeding	BRITISH MEDICAL JOURNAL			English	Article									E GLAMORGAN NHS TRUST,DEPT SURG,PONTYPRIDD CF38 1AB,M GLAM,WALES									BIRCH J, 1993, DIAGNOSIS DEFECTIVE, P41; PEARL SS, 1978, JAMA-J AM MED ASSOC, V239, P1132, DOI 10.1001/jama.1978.03280390028009	2	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					594	594						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806249				2022-12-28	WOS:A1996VG10800018
J	Hausladen, A; Privalle, CT; Keng, T; DeAngelo, J; Stamler, JS				Hausladen, A; Privalle, CT; Keng, T; DeAngelo, J; Stamler, JS			Nitrosative stress: Activation of the transcription factor OxyR	CELL			English	Article							NITRIC-OXIDE; ESCHERICHIA-COLI; OXIDATIVE-STRESS; SERUM-ALBUMIN; SALMONELLA-TYPHIMURIUM; S-NITROSOTHIOLS; SOXR PROTEIN; GLUTATHIONE; RESISTANCE; REDUCTASE	Hydrogen peroxide (H2O2) imposes an oxidative stress to Escherichia coli that is manifested by oxidation of glutathione and related redox-sensitive targets. OxyR is a thiol-containing transcriptional activator whose oxidation controls the expression of genes involved in H2O2 detoxification. Here we report that certain S-nitrosothiols (RSNOs) impose what we term a ''nitrosative stress'' to E. coli, evidenced by lowering of intracellular thiol and the transcriptional activation of OxyR by S-nitrosylation. This cellular and genetic response determines the metabolic fate of RSNOs and thereby contributes to bacterial rescue from stasis. Our studies reveal that signaling by S-nitrosylation can extend to the level of transcription and describe a metabolic pathway that constitutes an adaptation to nitrosative stress.	DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; APEX BIOSCI INC, RES TRIANGLE PK, NC 27709 USA	Duke University; Duke University				Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HL02582, HL52529] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002582, R01HL052529] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; CASELLI A, 1994, J BIOL CHEM, V269, P24878; CASTELLANI AG, 1955, APPL MICROBIOL, V3, P154, DOI 10.1128/AEM.3.3.154-159.1955; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DEGROOTE MA, 1995, CLIN INFECT DIS, V21, pS162, DOI 10.1093/clinids/21.Supplement_2.S162; DeGroote MA, 1996, SCIENCE, V272, P414, DOI 10.1126/science.272.5260.414; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; FEELLSCH M, 1996, METHODS NITRIC OXIDE; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HAJJAR DP, 1995, J AM CHEM SOC, V117, P3340, DOI 10.1021/ja00117a004; HAN J, 1995, BIOL NITRIC OXIDE, V4, P114; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; INCZE K, 1974, APPL MICROBIOL, V27, P202, DOI 10.1128/AEM.27.1.202-205.1974; JI XB, 1989, BIOCHEM ARCH, V5, P61; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; JOHNSTON MA, 1971, CAN INST F SCI TEC J, V4, P179, DOI 10.1016/S0008-3860(71)74226-3; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KULLIK I, 1995, J BACTERIOL, V177, P1275, DOI 10.1128/jb.177.5.1275-1284.1995; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LITTLE C, 1969, EUR J BIOCHEM, V10, P533, DOI 10.1111/j.1432-1033.1969.tb00721.x; LOEWEN PC, 1984, J BACTERIOL, V157, P622, DOI 10.1128/JB.157.2.622-626.1984; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MIRNA A, 1969, FLEISCHWIRTSCHAFT, V10, P1361; Mohr S, 1996, J BIOL CHEM, V271, P4209; MORRIS SL, 1981, J BACTERIOL, V148, P465, DOI 10.1128/JB.148.2.465-471.1981; MORRIS SL, 1984, J BIOL CHEM, V259, P3590; MUKHOPADHYAY S, 1994, J BACTERIOL, V176, P2300, DOI 10.1128/JB.176.8.2300-2307.1994; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794, DOI 10.1128/IAI.63.3.794-798.1995; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PRIVALLE CT, 1988, J BIOL CHEM, V263, P4274; PRIVALLE CT, 1990, J BIOL CHEM, V265, P21966; RICHTER HE, 1981, BIOCHEM BIOPH RES CO, V100, P1039, DOI 10.1016/0006-291X(81)91928-8; ROCKETT KA, 1991, INFECT IMMUN, V59, P3280, DOI 10.1128/IAI.59.9.3280-3283.1991; ROMAN R, 1973, CAN J CHEM, V51, P588, DOI 10.1139/v73-089; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STORZ G, 1994, METHOD ENZYMOL, V234, P217; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; TARTAGLIA LA, 1989, J MOL BIOL, V210, P709, DOI 10.1016/0022-2836(89)90104-6; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; WROTHINGTON V, 1993, WORTHINGTON ENZYME M, P293; WU J, 1995, J BIOL CHEM, V270, P10323, DOI 10.1074/jbc.270.17.10323	68	296	312	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1996	86	5					719	729		10.1016/S0092-8674(00)80147-6	http://dx.doi.org/10.1016/S0092-8674(00)80147-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797819	Bronze			2022-12-28	WOS:A1996VG37200006
J	Roest, HP; vanKlaveren, J; deWit, J; vanGurp, CG; Koken, MHM; Vermey, M; vanRoijen, JH; Hoogerbrugge, JW; Vreeburg, JTM; Baarends, WM; Bootsma, D; Grootegoed, JA; Hoeijmakers, JHJ				Roest, HP; vanKlaveren, J; deWit, J; vanGurp, CG; Koken, MHM; Vermey, M; vanRoijen, JH; Hoogerbrugge, JW; Vreeburg, JTM; Baarends, WM; Bootsma, D; Grootegoed, JA; Hoeijmakers, JHJ			Inactivation of the HR6B ubiquitin-conjugating DNA repair enzyme in mice causes male sterility associated with chromatin modification	CELL			English	Article							MOUSE Y-CHROMOSOME; N-END RULE; GENE RAD6; SACCHAROMYCES-CEREVISIAE; ACTIVATING ENZYME-E1; INFERTILE MEN; PROTEIN; YEAST; SPERMATOGENESIS; DEGRADATION	The ubiquitin-conjugating yeast enzyme RAD6 and its human homologs hHR6A and hHR6B are implicated in postreplication repair and damage-induced mutagenesis, The yeast protein is also required for sporulation and may modulate chromatin structure via histone ubiquitination. We report the phenotype of the first animal mutant in the ubiquitin pathway: inactivation of the hHR6B-homologous gene in mice causes male infertility. Derailment of spermatogenesis becomes overt during the postmeiotic condensation of chromatin in spermatids. These findings provide a parallel between yeast sporulation and mammalian spermatogenesis and strongly implicate hHR6-dependent ubiquitination in chromatin remodeling. Since heterozygous male mice and even knockout female mice are completely normal and fertile and thus able to transmit the defect, similar hHR6B mutations may cause male infertility in man.	ERASMUS UNIV ROTTERDAM, FAC MED & HLTH SCI, DEPT ENDOCRINOL & REPROD, NL-3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, FAC MED & HLTH SCI, DEPT PATHOL, NL-3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam	Roest, HP (corresponding author), ERASMUS UNIV ROTTERDAM, FAC MED & HLTH SCI, MGC, DEPT CELL BIOL & GENET, NL-3000 DR ROTTERDAM, NETHERLANDS.		koken, marcel/J-8154-2012; koken, marcel/N-1349-2019; Hoeijmakers, Jan/AAX-6972-2021	koken, marcel/0000-0002-0839-0125; 				AGELL N, 1988, BIOCHEM J, V250, P883, DOI 10.1042/bj2500883; AGELL N, 1983, FEBS LETT, V155, P209, DOI 10.1016/0014-5793(82)80604-2; AITKEN RJ, 1995, HUM REPROD, V10, P248, DOI 10.1093/oxfordjournals.humrep.a135922; ALFONSO PJ, 1993, BIOL REPROD, V48, P522, DOI 10.1095/biolreprod48.3.522; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Balhorn R., 1989, P366; BROCK WA, 1980, P NATL ACAD SCI-BIOL, V77, P371, DOI 10.1073/pnas.77.1.371; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEVAILLIER P, 1987, LANCET, V2, P806; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEYEBRA L, 1993, J BIOL CHEM, V268, P10553; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DULLAART J, 1975, J REPROD FERTIL, V43, P189, DOI 10.1530/jrf.0.0430189; FORESTA C, 1992, INT J ANDROL, V15, P330, DOI 10.1111/j.1365-2605.1992.tb01132.x; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDKNOPF IL, 1980, BIOCHEM BIOPH RES CO, V96, P1724, DOI 10.1016/0006-291X(80)91373-X; GORCZYCA W, 1993, CANCER RES, V53, P1945; HENDRIKSEN PJM, 1995, DEV BIOL, V170, P730, DOI 10.1006/dbio.1995.1252; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KISTLER WS, 1989, HISTONES OTHER BASIC, P331; KOKEN M, 1991, P NATL ACAD SCI USA, V88, P3832, DOI 10.1073/pnas.88.9.3832; Koken MHM, 1996, DEV BIOL, V173, P119, DOI 10.1006/dbio.1996.0011; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; MADURA K, 1993, J BIOL CHEM, V268, P12046; Meistrich M., 1989, HISTONES OTHER BASIC, P165; MEISTRICH ML, 1992, MOL REPROD DEV, V31, P170, DOI 10.1002/mrd.1080310303; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; MONTELONE BA, 1981, MOL GEN GENET, V184, P410, DOI 10.1007/BF00352514; NICKEL BE, 1987, BIOCHEMISTRY-US, V26, P4417, DOI 10.1021/bi00388a034; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; PETERSON MW, 1992, J APPL PHYSIOL, V72, P236, DOI 10.1152/jappl.1992.72.1.236; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; RHIM JA, 1995, BIOL REPROD, V52, P20, DOI 10.1095/biolreprod52.1.20; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; ROLLER ML, 1995, MAMM GENOME, V6, P305; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THORNE AW, 1987, EMBO J, V6, P1005, DOI 10.1002/j.1460-2075.1987.tb04852.x; UNNI E, 1995, MOL REPROD DEV, V42, P210, DOI 10.1002/mrd.1080420210; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125; WONG TW, 1973, ARCH PATHOL, V95, P151; ZHOU XY, 1995, GENE DEV, V9, P2623, DOI 10.1101/gad.9.21.2623	55	326	351	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1996	86	5					799	810		10.1016/S0092-8674(00)80154-3	http://dx.doi.org/10.1016/S0092-8674(00)80154-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797826	Green Published, Bronze			2022-12-28	WOS:A1996VG37200013
J	Wetzel, R				Wetzel, R			For protein misassembly, it's the ''I'' decade	CELL			English	Review							PRION PROTEIN; MECHANISM; DISEASE; SCRAPIE						Wetzel, Ronald/G-7453-2011					BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BLAKE C, 1996, IN PRESS STRUCTURE; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; HARTL FU, 1996, SCIENCE, V381, P571; Helms LR, 1996, J MOL BIOL, V257, P77, DOI 10.1006/jmbi.1996.0148; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; LANSBURY PJ, 1995, NAT STRUCT BIOL, V23, P990; MIROY GJ, 1996, IN PRESS P NATL ACAD; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; PRUSINER SB, 1995, AMYLOID, V2, P39, DOI 10.3109/13506129509031887; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Rudolph Rainer, 1996, P283; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0; WETZEL R, 1992, STABILITY PROTEIN PH, P43; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; Wood SJ, 1996, J BIOL CHEM, V271, P4086; WOOD SJ, 1996, IN PRESS BIOCHEMISTR	20	155	159	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					699	702		10.1016/S0092-8674(00)80143-9	http://dx.doi.org/10.1016/S0092-8674(00)80143-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797816	Bronze			2022-12-28	WOS:A1996VG37200003
J	Packer, M; OConnor, CM; Ghali, JK; Pressler, ML; Carson, PE; Belkin, RN; Miller, AB; Neuberg, GW; Frid, D; Wertheimer, JH; Cropp, AB; DeMets, DL				Packer, M; OConnor, CM; Ghali, JK; Pressler, ML; Carson, PE; Belkin, RN; Miller, AB; Neuberg, GW; Frid, D; Wertheimer, JH; Cropp, AB; DeMets, DL			Effect of amlodipine on morbidity and mortality in severe chronic heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY-EDEMA; DOUBLE-BLIND; NIFEDIPINE; VERAPAMIL; FELODIPINE; DILTIAZEM	Background Previous studies have shown that calcium-channel blockers increase morbidity and mortality in patients with chronic heart failure. We studied the effect of a new calcium-channel blocker, amlodipine, in patients with severe chronic heart failure. Methods We randomly assigned 1153 patients with severe chronic heart failure and ejection fractions of less than 30 percent to double-blind treatment with either placebo (582 patients) or amlodipine (571 patients) for 6 to 33 months, while their usual therapy was continued. The randomization was stratified on the basis of whether patients had ischemic or nonischemic causes of heart failure. The primary end point of the study was death from any cause and hospitalization for major cardiovascular events. Results Primary end points were reached in 42 percent of the placebo group and 39 percent of the amlodipine group, representing a 9 percent reduction in the combined risk of fatal and nonfatal events with amlodipine (95 percent confidence interval, 24 percent reduction to 10 percent increase; P=0.31). A total of 38 percent of the patients in the placebo group died, as compared with 33 percent of those in the amlodipine group, representing a 16 percent reduction in the risk of death with amlodipine (95 percent confidence interval, 31 percent reduction to 2 percent increase; P=0.07). Among patients with ischemic heart disease, there was no difference between the amlodipine and placebo groups in the occurrence of either end point. In contrast, among patients with nonischemic cardiomyopathy, amlodipine reduced the combined risk of fatal and nonfatal events by 31 percent (P=0.04) and decreased the risk of death by 46 percent (P<0.001). Conclusion Amlodipine did not increase cardiovascular morbidity or mortality in patients with severe heart failure. The possibility that amlodipine prolongs survival in patients with nonischemic dilated cardiomyopathy requires further study.	DUKE UNIV, MED CTR, DURHAM, NC USA; LOUISIANA STATE UNIV HLTH SCI CTR, SHREVEPORT, LA 71105 USA; KRANNERT CARDIOVASC RES INST, INDIANAPOLIS, IN USA; VET AFFAIRS MED CTR, WASHINGTON, DC 20422 USA; NEW YORK MED COLL, VALHALLA, NY 10595 USA; UNIV FLORIDA, COLL MED, JACKSONVILLE, FL USA; ALBERT EINSTEIN MED CTR, PHILADELPHIA, PA 19141 USA; PFIZER INC, PFIZER CENT RES, GROTON, CT 06340 USA; UNIV WISCONSIN, MADISON, WI USA	Duke University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; US Department of Veterans Affairs; Veterans Health Administration (VHA); New York Medical College; State University System of Florida; University of Florida; Yeshiva University; Pfizer; University of Wisconsin System; University of Wisconsin Madison	Packer, M (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DIV CIRCULATORY PHYSIOL, 630 W 168TH ST, NEW YORK, NY 10032 USA.							BARJON JN, 1987, J AM COLL CARDIOL, V9, P622, DOI 10.1016/S0735-1097(87)80057-8; BATRA AK, 1985, RESPIRATION, V47, P161, DOI 10.1159/000194763; COX DR, 1972, J R STAT SOC B, V34, P187; ELKAYAM U, 1985, AM J CARDIOL, V56, P560, DOI 10.1016/0002-9149(85)91185-3; ELKAYAM U, 1990, CIRCULATION, V82, P1954, DOI 10.1161/01.CIR.82.6.1954; FERLINZ J, 1984, CIRCULATION, V70, P305; GHEORGHIADE M, 1991, Journal of the American College of Cardiology, V17, p274A; GILLMER DJ, 1980, BRIT MED J, V280, P1420, DOI 10.1136/bmj.280.6229.1420; GOLDSTEIN RE, 1991, CIRCULATION, V83, P52, DOI 10.1161/01.CIR.83.1.52; HAYWOOD GA, 1992, CIRCULATION, V86, P896, DOI 10.1161/01.CIR.86.3.896; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LECHAT P, 1994, CIRCULATION, V90, P1765, DOI 10.1161/01.CIR.90.4.1765; LITTLER WA, 1995, BRIT HEART J, V73, P428; MOHINDRA SK, 1989, JAMA-J AM MED ASSOC, V261, P994, DOI 10.1001/jama.1989.03420070044025; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PACKER M, 1993, CIRCULATION, V88, P301; PACKER M, 1987, J AM COLL CARDIOL, V10, P1303, DOI 10.1016/S0735-1097(87)80135-3; PACKER M, 1989, CIRCULATION, V80, P59; PACKER M, 1991, J AM COLL CARDIOL, V17, P740, DOI 10.1016/S0735-1097(10)80193-7; PACKER M, 1985, CIRCULATION, V72, P275; PACKER M, 1987, CIRCULATION, V75, P56; SEMIGRAN MJ, 1994, J AM COLL CARDIOL, V24, P982, DOI 10.1016/0735-1097(94)90859-1; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; SMITH WB, 1994, CIRCULATION, V90, P603; TAN LB, 1987, BRIT HEART J, V58, P122; WITCHITZ S, 1975, NOUV PRESSE MED, V4, P337; YORAN C, 1973, CHEST, V63, P843, DOI 10.1378/chest.63.5.843	29	883	918	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1996	335	15					1107	1114		10.1056/NEJM199610103351504	http://dx.doi.org/10.1056/NEJM199610103351504			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN399	8813041				2022-12-28	WOS:A1996VN39900004
J	Russell, LB; Gold, MR; Siegel, JE; Daniels, N; Weinstein, MC				Russell, LB; Gold, MR; Siegel, JE; Daniels, N; Weinstein, MC			The role of cost-effectiveness analysis in health and medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ECONOMIC-EVALUATION; STATES; CARE; PREFERENCES; QUALITY; OREGON; LIFE; GUIDELINES; POPULATION; OUTCOMES	Objective.-To develop consensus-based recommendations guiding the conduct of cost-effectiveness analysis (CEA) to improve the comparability and quality of studies. The recommendations apply to analyses intended to inform the allocation of health care resources across a broad range of conditions and interventions. This article, first in a 3-part series, discusses how this goal affects the conduct and use of analyses. The remaining articles will outline methodological and reporting recommendations, respectively. Participants.-The Panel on Cost-Effectiveness in Health and Medicine, a nonfederal panel with expertise in CEA, clinical medicine, ethics, and health outcomes measurement, was convened by the US Public Health Service (PHS). Evidence.-The panel reviewed the theoretical foundations of CEA, current practices, and alternative procedures for measuring and assigning Values to resource use and health outcomes. Consensus Process.-The panel met 11 limes during 2 1/2 years with PHS staff and methodologists from federal agencies. Working groups brought issues and preliminary recommendations to the full panel for discussion, Draft recommendations were circulated to outside experts and the federal agencies prior to finalization. Conclusions.-The panel's recommendations define a ''reference case'' cost-effectiveness analysis, a standard set of methods to serve as a point of comparison across studies, The reference case analysis is conducted from the societal perspective and accounts for benefits, harms, and costs to all parties. Although CEA does not reflect every element of importance in health care decisions, the information it provides is critical to informing decisions about the allocation of health care resources.	US PHS,OFF DIS PREVENT & HLTH PROMOT,WASHINGTON,DC 20201; RUTGERS STATE UNIV,INST HLTH HLTH CARE POLICY & AGING RES,NEW BRUNSWICK,NJ 08903; HARVARD UNIV,SCH PUBL HLTH,CAMBRIDGE,MA 02138; TUFTS UNIV,DEPT PHILOSOPHY,MEDFORD,MA 02155	United States Public Health Service; Rutgers State University New Brunswick; Harvard University; Harvard T.H. Chan School of Public Health; Tufts University								[Anonymous], 1995, ANN INTERN MED, V123, P61; BALABAN DJ, 1986, MED CARE, V24, P973, DOI 10.1097/00005650-198611000-00001; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; BOYLE MH, 1984, MED CARE, V22, P1045, DOI 10.1097/00005650-198411000-00007; BROWN LD, 1991, HLTH AFF, V10, P29; BROWN ML, 1993, BREAST CANCER RES TR, V25, P113, DOI 10.1007/BF00662136; *CAN COORD OFF HLT, 1994, GUID EC EV PHARM; DANIELS N, 1985, JUST HLTH CARE; Daniels N, 1988, AM I MY PARENTS KEEP; DANIELS SR, 1993, J HUM HYPERTENS, V7, P223; DWORKIN R, 1981, PHILOS PUBLIC AFF, V10, P283; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2135, DOI 10.1001/jama.266.15.2135; Eddy DM, 1991, JAMA-J AM MED ASSOC, V265, P2405; ELIXHAUSER A, 1993, MED CARE, V31, pJS1, DOI 10.1097/00005650-199307001-00001; EPSTEIN AM, 1989, MED CARE, V27, pS91, DOI 10.1097/00005650-198903001-00008; EVANS RG, 1995, ANN INTERN MED, V123, P59, DOI 10.7326/0003-4819-123-1-199507010-00010; FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P585, DOI 10.1016/0895-4356(89)90155-8; Gold MR, 1996, COST EFFECTIVENESS H; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HADORN DC, 1995, J CLIN EPIDEMIOL, V48, P607, DOI 10.1016/0895-4356(94)00185-S; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; Harsanyi JC, 1955, J POLIT ECON, V63, P309, DOI 10.1086/257678; Harsanyi JC, 1953, J POLIT ECON, V61, P434, DOI 10.1086/257416; Henry D, 1992, Pharmacoeconomics, V1, P54, DOI 10.2165/00019053-199201010-00010; KAPLAN RM, 1988, HEALTH SERV RES, V23, P203; KAPLAN RM, 1978, P ANN M SOC STAT SEC; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; KLEVIT HD, 1991, ARCH INTERN MED, V151, P912, DOI 10.1001/archinte.151.5.912; LLEWELLYNTHOMAS H, 1984, MED CARE, V22, P543, DOI 10.1097/00005650-198406000-00005; MENZEL PT, 1992, STRONG MED; NAJMAN JM, 1981, SOC SCI MED F-MED S, V15, P107, DOI 10.1016/0271-5392(81)90012-5; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; *OFF TECHN ASS, 1991, OFF TECHN ASS PUBL; OLDRIDGE N, 1993, AM J CARDIOL, V72, P154, DOI 10.1016/0002-9149(93)90152-3; Patrick D. L., 1993, HLTH STATUS HLTH POL; PATRICK DL, 1994, MED DECIS MAKING, V14, P9, DOI 10.1177/0272989X9401400102; PATRICK DL, 1985, AM J PUBLIC HEALTH, V75, P1402, DOI 10.2105/AJPH.75.12.1402; Rawls J., 1971, THEORY JUSTICE; Russell L., 1996, COST EFFECTIVENESS H; Russell LB., 1986, IS PREVENTION BETTER; RUSSELL LB, 1993, PROMOTING COMMUNITY; Russell Louise B., 1994, ED GUESSES MAKING PO; SACKETT DL, 1978, J CHRON DIS, V31, P697, DOI 10.1016/0021-9681(78)90072-3; SIEGEL JE, IN PRESS JAMA; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; Spilker B., 1990, QUALITY LIFE ASSESSM; TORRANCE GW, 1982, OPER RES, V30, P1043, DOI 10.1287/opre.30.6.1043; Torrance GW, 1987, METHODS EC EVALUATIO; WEINSTEIN MC, IN PRESS JAMA; WEISNTEIN MC, 1976, HYPERTENSION POLICY; 1990, HLTH POLICY, V16, P199	51	976	987	1	91	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1172	1177		10.1001/jama.276.14.1172	http://dx.doi.org/10.1001/jama.276.14.1172			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VL332	8827972				2022-12-28	WOS:A1996VL33200029
J	Gradishar, WJ; Tallman, MS; Abrams, JS				Gradishar, WJ; Tallman, MS; Abrams, JS			High-dose chemotherapy for breast cancer	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RANDOMIZED CLINICAL-TRIAL; BONE-MARROW SUPPORT; COMPARING TOTAL MASTECTOMY; ADJUVANT CHEMOTHERAPY; STAGE-II; INTENSIVE CHEMOTHERAPY; RADICAL MASTECTOMY; AUTOLOGOUS MARROW; CELL SUPPORT; HIGH-RISK	The role of high-dose chemotherapy in the management of women with breast cancer remains one of the most controversial issues in oncology. During the past decade, numerous pilot studies have shown the feasibility of administering high-dose chemotherapy followed by autologous bone marrow transplantation or peripheral blood stem-cell transplantation (referred to as high-dose chemotherapy) to women with metastatic disease. However, it appears that survival improves in few treated patients. This treatment strategy is now being evaluated in the adjuvant setting in patients who are at high risk for developing recurrent disease. The National Cancer Institute has selected two randomized, adjuvant breast cancer trials for its High-Priority Clinical Trials Program. These trials are comparing conventional-dose chemotherapy with high-dose chemotherapy in patients in the early stages of breast cancer who are at high risk for disease recurrence. This paper focuses on the rationale for the randomized studies evaluating adjuvant high-dose chemotherapy in the early stages of breast cancer and reviews the efforts to overcome physician and patient biases so that the trials can be completed.	NCI, CLIN INVEST BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gradishar, WJ (corresponding author), NORTHWESTERN UNIV, CTR CANC, 233 E ERIE, SUITE 700, CHICAGO, IL 60611 USA.				NCI NIH HHS [R21 CA 64487-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA064487] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; AYASH LJ, 1995, J CLIN ONCOL, V13, P2043, DOI 10.1200/JCO.1995.13.8.2043; AYASH LJ, 1994, J CLIN ONCOL, V12, P37, DOI 10.1200/JCO.1994.12.1.37; Basser RL, 1995, CLIN CANCER RES, V1, P715; BELANGER D, 1991, J CLIN ONCOL, V9, P7, DOI 10.1200/JCO.1991.9.1.7; BENSON AB, 1991, J CLIN ONCOL, V9, P2067, DOI 10.1200/JCO.1991.9.11.2067; BEZWODA WR, 1989, ONCOLOGY, V46, P208; BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; CANELLOS GP, 1995, BREAST DIS YB Q, V6, P19; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; Cohen MH, 1996, J CLIN ONCOL, V14, P685, DOI 10.1200/JCO.1996.14.2.685; Crump M, 1996, J CLIN ONCOL, V14, P66, DOI 10.1200/JCO.1996.14.1.66; DAVIDSON NE, 1992, J NATL CANCER I, V84, P301, DOI 10.1093/jnci/84.5.301; DEGRAAF H, 1994, EUR J CANCER, V30A, P150, DOI 10.1016/0959-8049(94)90076-0; DUNPHY FR, 1994, CANCER, V73, P2157, DOI 10.1002/1097-0142(19940415)73:8<2157::AID-CNCR2820730821>3.0.CO;2-1; DUNPHY FR, 1992, J NATL CANCER I, V84, P128, DOI 10.1093/jnci/84.2.128; EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; GELBER RD, 1993, J CLIN ONCOL, V11, P580, DOI 10.1200/JCO.1993.11.3.580; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; HENDERSON IC, 1988, J CLIN ONCOL, V6, P1501, DOI 10.1200/JCO.1988.6.9.1501; HORTOBAGYI GN, 1995, HIGH DOSE CHEMOTHERA, P341; HRYNIUK W, 1986, J CLIN ONCOL, V4, P1162, DOI 10.1200/JCO.1986.4.8.1162; Hryniuk W M, 1986, NCI Monogr, P87; HUDIS C, 1995, P AN M AM SOC CLIN, V14, P113; JONES RB, 1990, P AN M AM SOC CLIN, V9, P9; JONES SE, 1987, AM J CLIN ONCOL-CANC, V10, P387, DOI 10.1097/00000421-198710000-00005; JONES VE, 1993, EUR J CANCER, V29A, P1488, DOI 10.1016/0959-8049(93)90027-D; KENNEDY MJ, 1991, J NATL CANCER I, V83, P920, DOI 10.1093/jnci/83.13.920; KENNEDY MJ, 1995, J CLIN ONCOL, V13, P2477, DOI 10.1200/JCO.1995.13.10.2477; MATHEWS J, 1995, J NATL CANCER I, V87, P1510, DOI 10.1093/jnci/87.20.1510; MULDER NH, 1993, EUR J CANCER, V29A, P668, DOI 10.1016/S0959-8049(05)80343-0; *NAT CANC I, 1995, AM SOC CLIN ONC NAT; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M; PASSAMANI E, 1991, NEW ENGL J MED, V324, P1589, DOI 10.1056/NEJM199105303242209; PETERS WP, 1988, J CLIN ONCOL, V6, P1368, DOI 10.1200/JCO.1988.6.9.1368; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; PETERS WP, 1995, P AN M AM SOC CLIN, V14, P317; PETERS WP, 1996, BREAST CANC RES S35, V3, P11; RAHMAN Z, 1995, P AN M AM SOC CLIN, V14, P95; RAJAGOPAL S, 1994, J CLIN ONCOL, V12, P1296, DOI 10.1200/JCO.1994.12.6.1296; ROWLINGS PA, 1996, P AN M AM SOC CLIN, V14, P325; Spriridonidis CH, 1996, J CLIN ONCOL, V14, P686; TANNOCK IF, 1988, J CLIN ONCOL, V6, P1377, DOI 10.1200/JCO.1988.6.9.1377; UNG O, 1995, J CLIN ONCOL, V13, P435, DOI 10.1200/JCO.1995.13.2.435; VALAGUSSA P, 1978, CANCER, V41, P1170, DOI 10.1002/1097-0142(197803)41:3<1170::AID-CNCR2820410355>3.0.CO;2-I; WILLIAMS SF, 1989, J CLIN ONCOL, V7, P1824, DOI 10.1200/JCO.1989.7.12.1824; WOOD WC, 1994, NEW ENGL J MED, V330, P1253, DOI 10.1056/NEJM199405053301801	55	32	31	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1996	125	7					599	604		10.7326/0003-4819-125-7-199610010-00010	http://dx.doi.org/10.7326/0003-4819-125-7-199610010-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ653	8815759				2022-12-28	WOS:A1996VJ65300010
J	PerezTerzic, C; Pyle, J; Jaconi, M; StehnoBittel, L; Clapham, DE				PerezTerzic, C; Pyle, J; Jaconi, M; StehnoBittel, L; Clapham, DE			Conformational states of the nuclear pore complex induced by depletion of nuclear Ca2+ stores	SCIENCE			English	Article							CALCIUM; TRANSPORT; GLYCOPROTEIN; MICROSCOPY; DIFFUSION; ENVELOPE; CELLS	The nuclear pore complex (NPC) is essential for the transit of molecules between the cytoplasm and nucleoplasm of a cell and until recently was thought to allow intermediate-sized molecules (relative molecular mass of similar to 10,000) to diffuse freely across the nuclear envelope. However, the depletion of calcium from the nuclear envelope of Xenopus laevis oocytes was shown to regulate the passage of intermediate-sized molecules. Two distinct conformational stales of the NPC were observed by field emission scanning electronmicroscopy and atomic force microscopy. A central plug occluded the NPC channel after nuclear calcium stores had been depleted and free diffusion of intermediate-sized molecules had been blocked. Thus, the NPC conformation appears to gate molecular movement across the nuclear envelope.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic			Clapham, David/R-5974-2019; Jaconi, Marisa EE/J-4392-2013	Jaconi, Marisa/0000-0002-2004-8226; Stehno-Bittel, Lisa/0000-0002-8879-6124; Clapham, David/0000-0002-4459-9428				AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; AKEY CW, 1995, J MOL BIOL, V248, P2732; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; GOLDBERG MW, 1995, CURR OPIN CELL BIOL, V7, P301, DOI 10.1016/0955-0674(95)80083-2; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GREBER UF, 1992, J CELL BIOL, V116, P15, DOI 10.1083/jcb.116.1.15; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; HANOVER JA, 1992, FASEB J, V6, P2288, DOI 10.1096/fasebj.6.6.1312045; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MAK DOD, 1994, J BIOL CHEM, V269, P29375; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; UNWIN PNT, 1982, J CELL BIOL, V93, P63, DOI 10.1083/jcb.93.1.63	21	156	158	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1875	1877		10.1126/science.273.5283.1875	http://dx.doi.org/10.1126/science.273.5283.1875			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791595				2022-12-28	WOS:A1996VJ71300049
J	Eng, C				Eng, C			Seminars in medicine of the Beth Israel Hospital, Boston: The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MEDULLARY-THYROID CARCINOMA; TUMOR-SUPPRESSOR GENE; VONHIPPEL-LINDAU DISEASE; TYROSINE KINASE DOMAIN; MEN 2A; GERMLINE MUTATIONS; POINT MUTATION; PROTOONCOGENE MUTATIONS; MISSENSE MUTATION; FAMILIES		HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; UNIV CAMBRIDGE,CANC RES CAMPAIGN,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 1TN,ENGLAND	Harvard University; Harvard Medical School; CRUK Cambridge Institute; University of Cambridge	Eng, C (corresponding author), DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTROL,44 BINNEY ST,D920C,BOSTON,MA 02115, USA.			Eng, Charis/0000-0002-3693-5145				Amiel J, 1996, HUM MOL GENET, V5, P355, DOI 10.1093/hmg/5.3.355; ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; ANGRIST M, 1993, NAT GENET, V4, P351, DOI 10.1038/ng0893-351; ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; Auricchio A, 1996, HUM MOL GENET, V5, P351, DOI 10.1093/hmg/5.3.351; BLOCK MA, 1980, ARCH SURG-CHICAGO, V115, P142; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; BORST MJ, 1995, SURGERY, V117, P386, DOI 10.1016/S0039-6060(05)80057-1; BRANDI ML, 1987, ENDOCR REV, V8, P391, DOI 10.1210/edrv-8-4-391; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, ONCOGENE, V9, P3025; Ceccherini I, 1995, Oncogene, V10, P1257; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; CROSSEY PA, 1995, J MED GENET, V32, P885, DOI 10.1136/jmg.32.11.885; DECKER RA, 1995, SURGERY, V118, P257, DOI 10.1016/S0039-6060(05)80332-0; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EASTON DF, 1989, AM J HUM GENET, V44, P208; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Edery P, 1996, NAT GENET, V12, P442, DOI 10.1038/ng0496-442; ENG C, 1993, FASEB J, V7, P910, DOI 10.1096/fasebj.7.10.8102106; ENG C, 1995, CLIN ENDOCRINOL, V43, P123, DOI 10.1111/j.1365-2265.1995.tb01903.x; Eng C, 1996, CANCER RES, V56, P2167; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1994, HUM MOL GENET, V3, P686; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; FEWTRELL MS, 1994, J MED GENET, V31, P325, DOI 10.1136/jmg.31.4.325; FrankRaue K, 1996, J CLIN ENDOCR METAB, V81, P1780, DOI 10.1210/jc.81.5.1780; Frilling A, 1992, Henry Ford Hosp Med J, V40, P253; FUTAMI H, 1994, P JPN ACAD B-PHYS, V70, P210, DOI 10.2183/pjab.70.210; GAGEL RF, 1989, ANN INTERN MED, V111, P802, DOI 10.7326/0003-4819-111-10-802; GARDNER E, 1993, HUM MOL GENET, V2, P241, DOI 10.1093/hmg/2.3.241; GORLIN RJ, 1968, CANCER, V22, P293, DOI 10.1002/1097-0142(196808)22:2<293::AID-CNCR2820220206>3.0.CO;2-R; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; KOMMINOTH P, 1995, ENDOCR PATHOL, V6, P267, DOI 10.1007/BF02738727; KWOK JBJ, 1993, ONCOGENE, V8, P2575; Landsvater RM, 1996, HUM GENET, V97, P11, DOI 10.1007/BF00218825; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LARSSON C, 1994, ENDOCRIN METAB CLIN, V23, P67, DOI 10.1016/S0889-8529(18)30116-6; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEAROYD DL, 1995, TRENDS ENDOCRIN MET, V6, P273, DOI 10.1016/1043-2760(95)00151-4; Lips C J, 1992, Henry Ford Hosp Med J, V40, P171; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; LUO Y, 1993, HUM MOL GENET, V2, P1803, DOI 10.1093/hmg/2.11.1803; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; Marsh DJ, 1996, CANCER RES, V56, P1241; Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P213, DOI 10.1046/j.1365-2265.1996.505292.x; MARSH DJ, 1994, GENOMICS, V23, P477, DOI 10.1006/geno.1994.1526; MCMAHON R, 1994, HUM MOL GENET, V3, P643, DOI 10.1093/hmg/3.4.643; MOLE SE, 1993, HUM MOL GENET, V2, P247, DOI 10.1093/hmg/2.3.247; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MULLIGAN LM, 1995, J INTERN MED, V238, P343, DOI 10.1111/j.1365-2796.1995.tb01208.x; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MYERS SM, 1995, ONCOGENE, V11, P2039; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; NEUMANN HPH, 1995, JAMA-J AM MED ASSOC, V274, P1149; Okamoto E, 1967, J PEDIATR SURG, V2, P437; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PASSARGE E, 1967, NEW ENGL J MED, V276, P138, DOI 10.1056/NEJM196701192760303; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PONDER BAJ, 1988, LANCET, V1, P397; PONDER BAJ, 1988, Q J MED, V67, P299; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSSEL M, 1995, HUM GENET, V95, P403; SAMAAN NA, 1989, CANCER, V64, P741, DOI 10.1002/1097-0142(19890801)64:3<741::AID-CNCR2820640329>3.0.CO;2-F; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SKOGSEID B, 1994, ENDOCRIN METAB CLIN, V23, P1; THAKKER RV, 1988, BAILLIERE CLIN ENDOC, V2, P1031, DOI 10.1016/S0950-351X(88)80029-6; Toogood AA, 1995, CLIN ENDOCRINOL, V43, P759, DOI 10.1111/j.1365-2265.1995.tb00547.x; VASEN HFA, 1989, ARCH INTERN MED, V149, P2717, DOI 10.1001/archinte.149.12.2717; VERDY M, 1982, J PEDIATR GASTR NUTR, V1, P603, DOI 10.1097/00005176-198212000-00027; WELLS SA, 1994, ANN SURG, V220, P237, DOI 10.1097/00000658-199409000-00002; XUE FY, 1994, HUM MOL GENET, V3, P635, DOI 10.1093/hmg/3.4.635; Yin Luo, 1994, European Journal of Human Genetics, V2, P272; ZEDENIUS J, 1994, HUM MOL GENET, V3, P1259, DOI 10.1093/hmg/3.8.1259; ZEDENIUS J, 1995, J CLIN ENDOCR METAB, V80, P3088, DOI 10.1210/jc.80.10.3088; Zhou Songyang, 1995, Nature (London), V373, P536	91	232	243	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1996	335	13					943	951		10.1056/NEJM199609263351307	http://dx.doi.org/10.1056/NEJM199609263351307			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK148	8782503				2022-12-28	WOS:A1996VK14800007
J	Kessler, DA; Witt, AM; Barnett, PS; Zeller, MR; Natanblut, SL; Wilkenfeld, JP; Lorraine, CC; Thompson, LJ; Schultz, WB				Kessler, DA; Witt, AM; Barnett, PS; Zeller, MR; Natanblut, SL; Wilkenfeld, JP; Lorraine, CC; Thompson, LJ; Schultz, WB			The Food and Drug Administration's regulation of tobacco products	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENCE; CHILDREN				Kessler, DA (corresponding author), US FDA,OFF COMMISSIONER,5600 FISHERS LN,HF-1,ROCKVILLE,MD 20857, USA.							AFRICK J, 1986, COMMUNICATION    WIN, P2; *AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, P159; *AMA, 1993, 1993 AMA POL COMP, P35; BAVLEY A, 1966, Patent No. 3280823; Benowitz N L, 1990, NIDA Res Monogr, V99, P12; COTTLER LB, 1993, ADDICTION, V88, P689, DOI 10.1111/j.1360-0443.1993.tb02082.x; DAGNOLI J, 1990, ADVERTISING AGE 0212, P31; *DEP HHS, 1994, PREV TOB US YOUNG PE, P249; *DEP HLTH HUM SERV, 1994, PREV TOB US YOUNG PE, P80; *DEP HLTH HUM SERV, 1988, HLTH CONS SMOK NIC A, P7; *DEP HLTH HUM SERV, 1988, DHHS CDC PUBL, P13; *DEP HLTH HUM SERV, 1994, DHHS PUBL, P89; *DEP HLTH HUM SERV, 1994, SN017001004910 DEP H, P5; *DEP HLTH HUM SERV, 1994, PREV TOB US YOUNG PE; *DEP HLTH HUM SERV, 1986, PUBL DEP HLTH HUM SE, P4; *DEP HLTH HUM SERV, 1994, PREV TOB US YOUNG PE, P65; *DEP HLTH HUM SERV, 1988, DHHS PUBL, P274; DIFRANZA JR, 1990, JAMA-J AM MED ASSOC, V263, P2784, DOI 10.1001/jama.263.20.2784; DUNN WL, 1974, COMMUNICATION   0509; DUNN WL, 1972, MOTIVES INCENTIVES C, P5; ELLIS C, 1962, SMOKING HLTH POLICY, P4; ERICKSEN MP, 1995, TOBACCO MORTALITY ES; *FED REP BRAZ MIN, 1993, PUBL FED REP BRAZ MI; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; *GH GALL INT I, 1992, TEEN ATT BEH TOB REP, P17; HARSHBARGER S, 1996, PROPOSED REGULATIONS; HILTS PJ, 1994, NY TIMES        0507; *HLTH WELF CAN HLT, 1989, TOB NIC ADD COMM REP, pR5; HUGHES JR, 1987, AM J PSYCHIAT, V144, P205; *I MED, 1994, GROW TOB FREE PREV N, P215; *I MED, 1994, GROW TOB FREE PREV N, P3; *I MED, 1994, GROW TOB FREE PREV N; JOHNSTON LD, 1994, NIH PUBLICATION, P9; KESSLER DA, 1994, AGENCYS RESPONSE COA; Levin Gary, 1992, ADVERTISING AGE 0427, P12; *MED RES COUNC, 1994, MRC FIELD REV DRUG D, P11; *NAT AUT MERCH ASS, 1989, FIND STUD TEEN CIG S; *OUTD ADV ASS AM, OUTD ITS NOT MED ITS; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P61, DOI 10.1001/jama.261.1.61; SENKUS M, 1976, SOME EFFECTS SMOKING, P4; SLADE J, 1994, 9 WORLD C TOB HLTH; TEAGUE CE, 1972, COMMUNICATION   0414; TEINOWITZ I, 1993, ADVERTISING AGE 0426, P46; TEINOWITZ I, 1993, ADVERTISING AGE 0426, P3; *U MICH NEWS INF S, 1995, SMOK RAT CLIMB AM TE; WAKEHAM H, 1969, COMMUNICATION   1126, P240; *WHO, 1992, ICD 10 CLASS MENT BE, P76; WOODY GE, 1993, ADDICTION, V88, P1573, DOI 10.1111/j.1360-0443.1993.tb03144.x; YEAMAN AY, 1963, BATCO RES C JUL 17, P4; 1995, FED REGISTER, V60, P41625; 1995, FED REGISTER, V62, P41737; 1995, FED REGISTER, V60, P41453; 1994, MMWR-MORBID MORTAL W, V43, P925; 1996, FED REGISTER, V61, P44396; 1993, MMWR-MORBID MORTAL W, V42, P645; 1994, MMWR-MORBID MORTAL W, V43, P577; 1995, FED REGISTER, V60, P41314; 1996, FED REGISTER, V61, P11419; 1996, ROLLING STONE   0307, P12; 1995, FED REGISTER, V60, P41701; 1988, CHEM BIOL STUDIES NE; 1995, FED REGISTER, V60, P41723; 1996, ROLLING STONE   0307, P13	63	95	96	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1996	335	13					988	994		10.1056/NEJM199609263351321	http://dx.doi.org/10.1056/NEJM199609263351321			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VK148	8782508	Bronze			2022-12-28	WOS:A1996VK14800035
J	Wilcox, MH				Wilcox, MH			Cleaning up Clostridium difficile infection	LANCET			English	Editorial Material							DIARRHEA		GEN INFIRM,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	Leeds General Infirmary	Wilcox, MH (corresponding author), UNIV LEEDS,DEPT MICROBIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.							ANAND A, 1994, AM J GASTROENTEROL, V89, P519; BORRIELLO SP, 1986, J MED MICROBIOL, V21, P299, DOI 10.1099/00222615-21-4-299; *DEP HLTH PUBL HLT, 1994, CLOSTR DIFF INF PREV; Djuretic T, 1996, Commun Dis Rep CDR Rev, V6, pR107; IMPALLOMENI M, 1995, BRIT MED J, V311, P1345, DOI 10.1136/bmj.311.7016.1345; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; PALLARES R, 1993, INFECT CONT HOSP EP, V14, P376, DOI 10.2307/30148319; *PARL OFF SCI TECH, 1994, DIS FIGHT BACK; Samore MH, 1996, AM J MED, V100, P32, DOI 10.1016/S0002-9343(96)90008-X; Wilcox MH, 1996, J HOSP INFECT, V34, P23, DOI 10.1016/S0195-6701(96)90122-X	10	42	43	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					767	768		10.1016/S0140-6736(05)65204-X	http://dx.doi.org/10.1016/S0140-6736(05)65204-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813978				2022-12-28	WOS:A1996VH98900004
J	Greenwald, AG; Draine, SC; Abrams, RL				Greenwald, AG; Draine, SC; Abrams, RL			Three cognitive markers of unconscious semantic activation	SCIENCE			English	Article							VISUAL MASKING; SPEED-ACCURACY; PERCEPTION; MEMORY; AWARENESS; STIMULI	A ''response window'' technique is described and used to reliably demonstrate unconscious activation of meaning by subliminal (visually masked) words. Visually masked prime words were shown to influence judged meaning of following target words. This priming-effect marker was used to identify two additional markers of unconscious semantic activation: (i) the activation is very short-lived (the target word must occur within about 100 milliseconds of the subliminal prime); and (ii) unlike supraliminal prime-target pairs, a subliminal pair leaves no memory trace that can be observed in response to the next prime-target pair. Thus, unconscious semantic activation is shown to be a readily reproducible phenomenon but also very limited in the duration of its effect.			Greenwald, AG (corresponding author), UNIV WASHINGTON,DEPT PSYCHOL,BOX 351525,SEATTLE,WA 98195, USA.		Greenwald, Anthony G./AAB-2397-2020	Greenwald, Anthony G./0000-0001-6865-8552	NIMH NIH HHS [MH-41328] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH041328] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABRAMS RL, 1995, 36 ANN M PSYCH SOC L; BALOTA DA, 1983, J VERB LEARN VERB BE, V22, P88, DOI 10.1016/S0022-5371(83)80008-5; BARGH JA, 1992, J PERS SOC PSYCHOL, V62, P893, DOI 10.1037/0022-3514.62.6.893; BORNSTEIN RF, 1992, PERCEPTION AWARENESS; Broadbent D.E., 1958, PERCEPTION COMMUNICA; BUSEY TA, 1994, PSYCHOL REV, V101, P446, DOI 10.1037/0033-295X.101.3.446; CHEESMAN J, 1986, CAN J PSYCHOL, V40, P343, DOI 10.1037/h0080103; CHERRY EC, 1953, J ACOUST SOC AM, V25, P975, DOI 10.1121/1.1907229; DAGENBACH D, 1989, J MEM LANG, V28, P412, DOI 10.1016/0749-596X(89)90020-X; DEBNER JA, 1994, J EXP PSYCHOL LEARN, V20, P304, DOI 10.1037/0278-7393.20.2.304; DILOLLO V, 1988, J EXP PSYCHOL HUMAN, V14, P671, DOI 10.1037/0096-1523.14.4.671; Dixon N. F., 1981, PRECONSCIOUS PROCESS; DOSHER BA, 1981, COGNITIVE PSYCHOL, V13, P551, DOI 10.1016/0010-0285(81)90020-7; ERIKSEN CW, 1960, PSYCHOL REV, V67, P279, DOI 10.1037/h0041622; FAZIO RH, 1986, J PERS SOC PSYCHOL, V50, P229, DOI 10.1037/0022-3514.50.2.229; FOWLER CA, 1981, J EXP PSYCHOL GEN, V110, P341, DOI 10.1037/0096-3445.110.3.341; GREEN DM, 1967, SIGNAL DETECTION THE; GREENWALD AG, 1991, PSYCHOL SCI, V2, P119, DOI 10.1111/j.1467-9280.1991.tb00112.x; GREENWALD AG, 1995, J EXP PSYCHOL GEN, V124, P22, DOI 10.1037/0096-3445.124.1.22; GREENWALD AG, 1995, 36 ANN M PSYCH SOC L; GREENWALD AG, IN PRESS 25 CARN S C; HOLENDER D, 1986, BEHAV BRAIN SCI, V9, P1, DOI 10.1017/S0140525X00021269; KUNSTWILSON WR, 1980, SCIENCE, V207, P557, DOI 10.1126/science.7352271; MARCEL AJ, 1983, COGNITIVE PSYCHOL, V15, P197, DOI 10.1016/0010-0285(83)90009-9; MERIKLE PM, 1991, J EXP PSYCHOL LEARN, V17, P224, DOI 10.1037/0278-7393.17.2.224; MEYER DE, 1971, J EXP PSYCHOL, V90, P227, DOI 10.1037/h0031564; MOORE TE, 1982, J MARKETING, V46, P38, DOI 10.2307/3203339; NEELY JH, 1977, J EXP PSYCHOL GEN, V106, P226, DOI 10.1037/0096-3445.106.3.226; Neisser U., 1967, COGNITIVE PSYCHOL; NORMAN DA, 1968, PSYCHOL REV, V75, P522, DOI 10.1037/h0026699; Pierce CS., 1885, MEMOIRS NATL ACAD SC, V3, P73; POTTER MC, 1993, MEM COGNITION, V21, P156, DOI 10.3758/BF03202727; SPERLING G, 1967, ACTA PSYCHOL, V27, P285, DOI 10.1016/0001-6918(67)90070-4; Sperling G., 1960, PSYCHOL MONOGR, V74; TREISMAN AM, 1960, Q J EXP PSYCHOL, V12, P242, DOI 10.1080/17470216008416732; WICKELGREN WA, 1977, ACTA PSYCHOL, V41, P67, DOI 10.1016/0001-6918(77)90012-9	36	457	474	1	158	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1996	273	5282					1699	1702		10.1126/science.273.5282.1699	http://dx.doi.org/10.1126/science.273.5282.1699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VH408	8781230				2022-12-28	WOS:A1996VH40800037
J	Hiller, MM; Finger, A; Schweiger, M; Wolf, DH				Hiller, MM; Finger, A; Schweiger, M; Wolf, DH			ER degradation of a misfolded luminal protein by the cytosolic ubiquitin-proteasome pathway	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; DEPENDENT PROTEOLYSIS; MULTIUBIQUITIN CHAIN; YEAST PROTEASOME; CELL; LOCALIZATION; MEMBRANE; GENE; RESISTANCE	Secretion of proteins is initiated by their uptake into the endoplasmic reticulum (ER), which possesses a proteolytic system able to degrade misfolded and nonassembled proteins. The ER degradation system was studied with yeast mutants defective in the breakdown of a mutated soluble vacuolar protein, carboxypeptidase yscY (CPYstar). The ubiquitin-conjugating enzyme Ubc7p participated in the degradation process, which was mediated by the cytosolic 26S proteasome. It is likely that CPYstar entered the ER, was glycosylated, and was then transported back out of the ER lumen to the cytoplasmic side of the organelle, where it was conjugated with ubiquitin and degraded.	UNIV STUTTGART, INST BIOCHEM, D-70569 STUTTGART, GERMANY	University of Stuttgart								ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BONIFACINO JS, 1994, CELLULAR PROTEOLYTIC, V15, P137; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; EGNER R, 1995, MOL CELL BIOL, V15, P5879; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Guthrie C, 1991, METHODS ENZYMOL, V194; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HILT W, 1993, J BIOL CHEM, V268, P3479; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; PALMER A, 1994, EUR J CELL BIOL, V64, P163; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RIVETT AJ, 1993, CURR BIOL, V3, P127, DOI 10.1016/0960-9822(93)90173-L; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; ROMISCH K, 1992, P NATL ACAD SCI USA, V89, P7227, DOI 10.1073/pnas.89.15.7227; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; SCHWARTZ AL, 1988, EMBO J, V7, P2961, DOI 10.1002/j.1460-2075.1988.tb03158.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SPORMANN DO, 1992, J BIOL CHEM, V267, P8021; VALLON U, 1994, PROTOPLASMA, V182, P15, DOI 10.1007/BF01403684; VASSAL A, 1992, BIOCHIM BIOPHYS ACTA, V1132, P211, DOI 10.1016/0167-4781(92)90015-R; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5	46	595	601	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1996	273	5282					1725	1728		10.1126/science.273.5282.1725	http://dx.doi.org/10.1126/science.273.5282.1725			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781238				2022-12-28	WOS:A1996VH40800045
J	Posas, F; WurglerMurphy, SM; Maeda, T; Witten, EA; Thai, TC; Saito, H				Posas, F; WurglerMurphy, SM; Maeda, T; Witten, EA; Thai, TC; Saito, H			Yeast HOG1 MAP kinase cascade is regulated by a multistep phosphorelay mechanism in the SLN1-YPD1-SSK1 ''two-component'' osmosensor	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; 2-COMPONENT REGULATORS; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; RESPONSE PATHWAY; MAMMALIAN-CELLS; GENE	An osmosensing mechanism in the budding yeast (Saccharomyces cerevisiae) involves both a two-component signal transducer (Sln1p, Ypd1p and Ssk1p) and a MAP kinase cascade (Ssk2p/Ssk22p, Pbs2p, and Hog1p). The transmembrane protein Sln1p contains an extracellular sensor domain and cytoplasmic histidine kinase and receiver domains, whereas the cytoplasmic protein Ssk1p contains a receiver domain. Ypd1p binds to both Sln1p and Ssk1p and mediates the multistep phosphotransfer reaction (phosphorelay). This phosphorelay system is initiated by the autophosphorylation of Sln1p at His576. This phosphate is then sequentially transferred to Sln1p-Asp1144, then to Ypd1p-His64, and finally to Ssk1p-Asp554. We propose that the multistep phosphorelay mechanism is a universal signal transduction apparatus utilized both in prokaryotes and eukaryotes.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	Posas, F (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, 44 BINNEY ST, BOSTON, MA 02115 USA.		Saito, Haruo/AAF-6113-2019; Posas, Francesc/K-1364-2013	Saito, Haruo/0000-0001-7891-1689; Posas, Francesc/0000-0002-4164-7076	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050909, F32GM016154] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM16154, R01 GM50909] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alex LA, 1996, P NATL ACAD SCI USA, V93, P3416, DOI 10.1073/pnas.93.8.3416; BOGUSLAWSKI G, 1992, J GEN MICROBIOL, V138, P2425, DOI 10.1099/00221287-138-11-2425; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; BROWN JL, 1994, EMBO J, V13, P5186, DOI 10.1002/j.1460-2075.1994.tb06849.x; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FUJITAKI JM, 1984, METHOD ENZYMOL, V107, P23; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARPER JW, 1993, CELL, V75, P805; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; IUCHI S, 1993, J BIOL CHEM, V268, P23972; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIM YH, 1993, J BIOL CHEM, V268, P18513; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MAGER WH, 1993, MOL MICROBIOL, V10, P253, DOI 10.1111/j.1365-2958.1993.tb01951.x; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; TRACH KA, 1993, MOL MICROBIOL, V8, P69, DOI 10.1111/j.1365-2958.1993.tb01204.x; Tsuzuki M, 1995, MOL MICROBIOL, V18, P953, DOI 10.1111/j.1365-2958.1995.18050953.x; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; WANNER BL, 1992, J BACTERIOL, V174, P2053, DOI 10.1128/JB.174.7.2053-2058.1992; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; [No title captured]	52	725	757	0	37	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1996	86	6					865	875		10.1016/S0092-8674(00)80162-2	http://dx.doi.org/10.1016/S0092-8674(00)80162-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808622	Bronze			2022-12-28	WOS:A1996VJ44300005
J	Fried, LP; Francomano, CA; MacDonald, SM; Wagner, EM; Stokes, EJ; Carbone, KM; Bias, WB; Newman, MM; Stobo, JD				Fried, LP; Francomano, CA; MacDonald, SM; Wagner, EM; Stokes, EJ; Carbone, KM; Bias, WB; Newman, MM; Stobo, JD			Career development for women in academic medicine - Multiple interventions in a department of medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIANS; PROFESSION; PROMOTION; SCIENCE; FACULTY; MEN	Objective.-To determine the gender-based career obstacles for women in an academic department of medicine and to report the interventions to correct such obstacles (resulting from the evaluation) and the results of these interventions, Design.-Intervention study, before-after trial, with assessment of faculty concerns and perceived change through structured, self-administered questionnaires. Setting.-The Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Md. Participants.-Full-time faculty. Interventions.-Multifaceted intervention from 1990 through 1995 to correct gender-based career obstacles reported by women faculty, including problem identification, leadership, and education of faculty, and interventions to improve faculty development, mentoring, and rewards and to reduce isolation and structural career impediments. Main Outcome Measures.-Retention and promotion of deserving women faculty, salary equity, quality of mentoring, decreased isolation from information and colleagues, integration of women faculty into the scientific community, and decreased manifestations of gender bias. Results.-Junior women were retained and promoted, reversing previous experience, with a 550% increase in the number of women at the associate professor rank over 5 years (from 4 in 1990 to 26 in 1995), Interim 3-year follow-up showed a 183% increase in the proportion of women faculty who expected they would still be in academic medicine in 10 years (from 23% [7/30] in 1990 to 65% [30/46] in 1993). One half to two thirds of women faculty reported improvements in timeliness of promotions, manifestations of gender bias, access to information needed for faculty development, isolation, and salary equity, Men also reported improvements in these areas. Conclusions.-The outcomes reported here indicate that it is possible to make substantive improvements in the development of women's careers, that an institutional strategy to this end can be successful in retaining women in academic medicine, and that such interventions are likely to benefit all faculty. Long-term interventions appear essential.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; NIH,NATL CTR HUMAN GENOME RES,MED GENET BRANCH,BETHESDA,MD 20892; JOHNS HOPKINS HLTHCARE LLC,BALTIMORE,MD	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Johns Hopkins University; Johns Hopkins Medicine								ANGELL M, 1981, NEW ENGL J MED, V304, P1161, DOI 10.1056/NEJM198105073041908; Angell M, 1982, J Am Med Womens Assoc (1972), V37, P64; BARINAGA M, 1992, SCIENCE, V255, P1366, DOI 10.1126/science.1542786; BICKEL J, 1988, NEW ENGL J MED, V319, P1579, DOI 10.1056/NEJM198812153192405; BICKEL J, 1995, WESTERN J MED, V162, P165; BICKEL J, 1990, BUILDING STRONGER WO; BICKEL J, 1994, WOMEN US ACAD MED ST; BOYER JL, 1988, REPORT TASK FORCE WO; CARR P, 1992, J GEN INTERN MED, V7, P418, DOI 10.1007/BF02599159; CARR PL, 1993, ANN INTERN MED, V119, P908, DOI 10.7326/0003-4819-119-9-199311010-00008; *COMM WORK FAM, 1989, REC DEP MED; CONLEY FK, 1993, NEW ENGL J MED, V328, P351, DOI 10.1056/NEJM199302043280513; *COUNC GRAD MED ED, 1995, HLTH RES SERV ADM PU; DEANGELIS CD, 1995, JAMA-J AM MED ASSOC, V273, P1056; *DEANS OFF DEANS A, 1993, SURV FAC QUAL WORK L; EISENBERG C, 1989, NEW ENGL J MED, V321, P1542, DOI 10.1056/NEJM198911303212210; ETZKOWITZ H, 1994, SCIENCE, V266, P51, DOI 10.1126/science.7939644; FRIED LP, 1990, QUESTIONNAIRE FACULT; FRIED LP, 1991, MENTORING REPORT TAS; GRISSO JA, 1991, ANN INTERN MED, V114, P43, DOI 10.7326/0003-4819-114-1-43; GROSZ BJ, 1991, REPORT WOMEN SCI H 1; HEINS M, 1983, JAMA-J AM MED ASSOC, V249, P209, DOI 10.1001/jama.249.2.209; HIGGINS L, 1994, STANFORD MED, V11, P4; KOMAROMY M, 1993, NEW ENGL J MED, V328, P322, DOI 10.1056/NEJM199302043280507; KOSHLAND DE, 1993, SCIENCE, V260, P275, DOI 10.1126/science.8469977; Lenhart S, 1993, J Am Med Womens Assoc (1972), V48, P155; Lenhart S A, 1991, J Am Med Womens Assoc (1972), V46, P77; Lenhart S A, 1991, J Am Med Womens Assoc (1972), V46, P121; LEVINSON W, 1991, WESTERN J MED, V154, P423; LEVINSON W, 1989, NEW ENGL J MED, V321, P1511, DOI 10.1056/NEJM198911303212205; *PROV COMM STAT WO, 1989, 1 J HOPK U; RELMAN AS, 1989, NEW ENGL J MED, V321, P1540, DOI 10.1056/NEJM198911303212209; STOBO JD, 1993, ACAD MED, V68, P349, DOI 10.1097/00001888-199305000-00007; *TASK FORC STAT WO, 1990, REP DEP MED; *TASK FORC WOM AC, 1992, ANN REP DEP MED; *TASK FORC WOM AC, 1991, ANN REP DEP MED; *TASK FORC WOM AC, 1994, ANN REP DEP MED; *TASK FORC WOM AC, 1995, ANN REP DEP MED; *TASK FORC WOM AC, 1993, ANN REP DEP MED; TESCH BJ, 1995, JAMA-J AM MED ASSOC, V273, P1022, DOI 10.1001/jama.273.13.1022; 1991, ANN INTERN MED, V114, P63	41	219	219	2	36	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					898	905		10.1001/jama.276.11.898	http://dx.doi.org/10.1001/jama.276.11.898			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782639				2022-12-28	WOS:A1996VF78700033
J	Driscoll, DM; Tronic, B				Driscoll, DM; Tronic, B			Pediculosis capitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Driscoll, DM (corresponding author), LAHEY HITCHCOCK CLIN,BURLINGTON,MA 01805, USA.								0	3	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1996	335	11					790	790		10.1056/NEJM199609123351105	http://dx.doi.org/10.1056/NEJM199609123351105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF786	8778586				2022-12-28	WOS:A1996VF78600005
J	Kohda, D; Morton, CJ; Parkar, AA; Hatanaka, H; Inagaki, FM; Campbell, ID; Day, AJ				Kohda, D; Morton, CJ; Parkar, AA; Hatanaka, H; Inagaki, FM; Campbell, ID; Day, AJ			Solution structure of the link module: A hyaluronan-binding domain involved in extracellular matrix stability and cell migration	CELL			English	Article							CARTILAGE PROTEOGLYCAN CORE; NUCLEAR-MAGNETIC-RESONANCE; E-SELECTIN; TERTIARY STRUCTURE; CRYSTAL-STRUCTURE; PROTEIN; ACID; CD44; SPECTROSCOPY; RECEPTOR	Link modules are hyaluronan-binding domains found in proteins involved in the assembly of extracellular matrix, cell adhesion, and migration. The solution structure of the Link module from human TSG-6 was determined and found to consist of two alpha helices and two antiparallel beta sheets arranged around a large hydrophobic core. This defines the consensus fold for the Link module superfamily, which includes CD44, cartilage link protein, and aggrecan. The TSG-6 Link module was shown to interact with hyaluronan, and a putative binding surface was identified on the structure. A structural database search revealed close similarity between the Link module and the C-type lectin domain, with the predicted hyaluronan-binding site at an analogous position to the carbohydrate-binding pocket in E-selectin.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; UNIV OXFORD,OXFORD CTR MOL SCI,OXFORD OX1 3QU,ENGLAND; TOKYO METROPOLITAN INST MED SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Oxford; University of Oxford; Tokyo Metropolitan Institute of Medical Science			Kohda, Daisuke/I-4990-2019; Morton, Craig/GON-8638-2022; Day, Anthony/O-1658-2015	Kohda, Daisuke/0000-0001-8234-3776; Morton, Craig/0000-0001-5452-5193; Day, Anthony/0000-0002-1415-3134; Parkar, Ashfaq/0000-0003-0173-0673	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BARTON GJ, 1987, J MOL BIOL, V198, P327, DOI 10.1016/0022-2836(87)90316-0; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BORK P, 1995, TRENDS BIOCH S, V2; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P531; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHRISTNER JE, 1977, BIOCHEM J, V167, P711, DOI 10.1042/bj1670711; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; DOEGE K, 1987, J BIOL CHEM, V262, P17757; FOSANG AJ, 1990, MATRIX, V10, P306, DOI 10.1016/S0934-8832(11)80186-1; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HARDINGHAM TE, 1976, BIOCHEM J, V157, P127, DOI 10.1042/bj1570127; HARDINGHAM TE, 1973, BIOCHEM J, V135, P905, DOI 10.1042/bj1350905; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; HASCALL VC, 1974, J BIOL CHEM, V249, P4242; HATANAKA H, 1994, J MOL BIOL, V240, P155, DOI 10.1006/jmbi.1994.1429; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HAYNES BF, 1991, ARTHRITIS RHEUM, V34, P1434; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; HOLM L, 1992, PROTEIN SCI, V1, P1691, DOI 10.1002/pro.5560011217; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JUTILA MA, 1994, J IMMUNOL, V153, P3917; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KOGAN TP, 1995, J BIOL CHEM, V270, P14047, DOI 10.1074/jbc.270.23.14047; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; LYON M, 1986, BIOCHIM BIOPHYS ACTA, V881, P22, DOI 10.1016/0304-4165(86)90092-9; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; Maier R, 1996, ARTHRITIS RHEUM, V39, P552, DOI 10.1002/art.1780390403; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; MORGELIN M, 1988, BIOCHEM J, V253, P175; MORGELIN M, 1995, BIOCHEM J, V307, P595; NEAME PJ, 1993, EXPERIENTIA, V49, P393, DOI 10.1007/BF01923584; NEAME PJ, 1986, J BIOL CHEM, V261, P3519; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; POUYANI T, 1994, BIOCONJUGATE CHEM, V5, P370, DOI 10.1021/bc00028a015; RAUCH U, 1992, J BIOL CHEM, V267, P19536; SHARON N, 1993, TRENDS BIOCHEM SCI, V18, P221, DOI 10.1016/0968-0004(93)90193-Q; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; SURI AK, 1993, J MAGN RESON SER B, V101, P320, DOI 10.1006/jmrb.1993.1050; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; VARELAS JB, 1995, ARCH BIOCHEM BIOPHYS, V321, P21, DOI 10.1006/abbi.1995.1363; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; YAMADA H, 1994, J BIOL CHEM, V269, P10119; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; YU Q, 1995, BIOTECHNIQUES, V19, P122; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	66	249	262	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					767	775		10.1016/S0092-8674(00)80151-8	http://dx.doi.org/10.1016/S0092-8674(00)80151-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797823	Bronze			2022-12-28	WOS:A1996VG37200010
J	Reinbothe, S; Reinbothe, C; Apel, K; Lebedev, N				Reinbothe, S; Reinbothe, C; Apel, K; Lebedev, N			Evolution of chlorophyll biosynthesis - The challenge to survive photooxidation	CELL			English	Review							LIGHT; PLANTS; PROTEIN; DNA		RUSSIAN ACAD SCI, AN BAKH BIOCHEM INST, MOSCOW 117071, RUSSIA	Research Center of Biotechnology RAS; Russian Academy of Sciences	Reinbothe, S (corresponding author), ETH ZENTRUM, DEPT GENET, INST PLANT SCI, UNIV STR 2, CH-8092 ZURICH, SWITZERLAND.		Reinbothe, Steffen/AAW-9893-2021					ADAMSKA I, 1992, P NATL ACAD SCI USA, V89, P2610, DOI 10.1073/pnas.89.7.2610; ALLEN JF, 1995, NATURE, V376, P26, DOI 10.1038/376026a0; ARMSTRONG GA, 1995, PLANT PHYSIOL, V108, P1505, DOI 10.1104/pp.108.4.1505; BURKE DH, 1993, P NATL ACAD SCI USA, V90, P7134, DOI 10.1073/pnas.90.15.7134; FAY P, 1992, MICROBIOL REV, V56, P340, DOI 10.1128/MMBR.56.2.340-373.1992; HOLTORF H, 1995, P NATL ACAD SCI USA, V92, P3254, DOI 10.1073/pnas.92.8.3254; LARCUM AWD, 1991, CHLOROPHYLLS, P367; Lebedev N, 1995, PLANT CELL, V7, P2081, DOI 10.1105/tpc.7.12.2081; LERS A, 1991, J BIOL CHEM, V266, P13698; MEYER G, 1984, EUR J BIOCHEM, V138, P201, DOI 10.1111/j.1432-1033.1984.tb07900.x; RAUBESON LA, 1992, SCIENCE, V255, P1697, DOI 10.1126/science.255.5052.1697; RIVAS JD, 1993, BIOCHEMISTRY-US, V32, P6944, DOI 10.1021/bi00078a019; SUZUKI JY, 1995, P NATL ACAD SCI USA, V92, P3749, DOI 10.1073/pnas.92.9.3749; VON WETTSTEIN D, 1995, PLANT CELL, V7, P1039, DOI 10.1105/tpc.7.7.1039	14	103	110	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1996	86	5					703	705		10.1016/S0092-8674(00)80144-0	http://dx.doi.org/10.1016/S0092-8674(00)80144-0			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797817	Bronze			2022-12-28	WOS:A1996VG37200004
J	Laufer, TM; DeKoning, J; Markowitz, JS; Lo, D; Glimcher, LH				Laufer, TM; DeKoning, J; Markowitz, JS; Lo, D; Glimcher, LH			Unopposed positive selection and autoreactivity in mice expressing class II MHC only on thymic cortex	NATURE			English	Article							CD4+ T-CELLS; TRANSGENIC MICE; NEGATIVE SELECTION; EPITHELIAL-CELLS; CLONAL DELETION; ANTIGEN; MOLECULES; MEDULLA; DIFFERENTIATION; APOPTOSIS	THE normal development of T cells in the thymus requires both positive and negative selection. During positive selection, thymocytes mature only if their T-cell receptors react with some specificity to host major histocompatibility complex (MHC) and host peptides. During negative selection, thymocytes die if their T-cell receptors react with too high an affinity to the presenting cell, self MHC, and peptides to which they are exposed. These two processes are important for the development of the T-cell repertoire and the acquisition of self-tolerance, but their precise location and temporal relationship are not known. We have used the keratin 14 (K14) promoter to re-express a class II MHC antigen (I-A(b)) in class II-negative mice. The transgenic I-A molecule is expressed only on thymic cortical epithelium; thymic medullary epithelium and bone-marrow-derived cells are I-A negative. CD4(+) cells are positively selected in K14 mice, but clonal deletion does not occur in K14 mice or in reIB-negative mice, which lack a thymic medulla. The K14 CD4 cells are autoreactive, as they proliferate extensively to and specifically lyse I-A(b)-positive target cells. These autoreactive cells make up 5% of the peripheral CD4 T cells, providing an estimate of the minimal frequency of positively selected cells that must subsequently undergo negative selection for self-tolerance to be preserved, Thus positive and negative selection occur in anatomically distinct sites.	HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Scripps Research Institute								ANDERSON G, 1994, J EXP MED, V179, P2027, DOI 10.1084/jem.179.6.2027; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; BURKLY LC, 1993, J IMMUNOL, V151, P3954; COSGROVE D, 1992, INT IMMUNOL, V4, P707, DOI 10.1093/intimm/4.6.707; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DIGHE AS, 1995, IMMUNITY, V3, P657, DOI 10.1016/1074-7613(95)90136-1; GLIMCHER LH, 1981, J EXP MED, V154, P1652, DOI 10.1084/jem.154.5.1652; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HENGARTNER H, 1988, NATURE, V336, P388, DOI 10.1038/336388a0; HOFFMANN MW, 1995, P NATL ACAD SCI USA, V92, P9851, DOI 10.1073/pnas.92.21.9851; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; POIRIER G, 1994, IMMUNITY, V1, P385, DOI 10.1016/1074-7613(94)90069-8; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TASWELL C, 1981, J IMMUNOL, V126, P1614; VANEWIJK W, 1988, CELL, V53, P357, DOI 10.1016/0092-8674(88)90156-0; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; WIDERA G, 1987, CELL, V51, P175, DOI 10.1016/0092-8674(87)90145-0	24	325	332	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					81	85		10.1038/383081a0	http://dx.doi.org/10.1038/383081a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779719				2022-12-28	WOS:A1996VF29500052
J	Kain, KC; Gadd, E; Gushulak, B; McCarthy, A; MacPherson, D				Kain, KC; Gadd, E; Gushulak, B; McCarthy, A; MacPherson, D			Errors in treatment recommendations for severe malaria	LANCET			English	Letter											Kain, KC (corresponding author), TORONTO HOSP, 200 ELIZABETH ST, EN G-224, TORONTO, ON M5G 2C4, CANADA.			Kain, Kevin/0000-0001-6068-1272				Krogstad DJ, 1995, MANDELL DOUGLAS BENN, V2, P2415; MILLER KD, 1989, NEW ENGL J MED, V321, P65, DOI 10.1056/NEJM198907133210201; White N. J., 1996, Manson's tropical diseases., P1087; 1995, CAN COMM DIS REP S3, V21, P1; [No title captured]	5	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	1996	348	9027					621	622		10.1016/S0140-6736(05)64843-X	http://dx.doi.org/10.1016/S0140-6736(05)64843-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774603				2022-12-28	WOS:A1996VF18600063
J	Lenton, SW; Sidebotham, PD				Lenton, SW; Sidebotham, PD			Incidence of adverse reactions after administration of high dose diphtheria with tetanus vaccine to school leavers: Retrospective questionnaire study	BRITISH MEDICAL JOURNAL			English	Article							ADULTS		UNIV SOUTHAMPTON,SCH MED,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND	University of Southampton	Lenton, SW (corresponding author), BATH & W COMMUNITY NHS TRUST,DEPT CHILD HLTH,BATH BA1 3QE,AVON,ENGLAND.		Sidebotham, Peter D/E-3011-2010	Sidebotham, Peter D/0000-0003-4891-6926				*DEP HLTH, 1994, 942 PL CMO DEP HLTH; MIDDAUGH JP, 1979, AM J PUBLIC HEALTH, V69, P246, DOI 10.2105/AJPH.69.3.246; MORTIMER J, 1986, LANCET, V2, P1182; MYERS MG, 1982, JAMA-J AM MED ASSOC, V248, P2478, DOI 10.1001/jama.248.19.2478; SCHEIBEL I, 1948, ACTA PATHOL MIC SC, V25, P319	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					533	534						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VF294	8789983	Green Published			2022-12-28	WOS:A1996VF29400023
J	Wright, CM; Corbett, SS; Drewett, RF				Wright, CM; Corbett, SS; Drewett, RF			Sex differences in weight in infancy and the British 1990 national growth standards	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine if there is a sex difference in infancy in the new British national standards for weight (based on data from 1990). Design-Weight data in a birth cohort were compared with the 1990 standards and Tanner and Whitehouse (1966) standards up to age 12 months. Setting-Newcastle upon Tyne. Subjects-3418 term infants. Results-Our cohort showed a mean difference in standard deviation scores of 0.42 between boys and girls (P<0.0001) when compared with the 1990 standards. Two and a half times as many girls as boys had weights below the 3rd centile during the first year, with an equivalent excess of boys above the 97th centile (P<0.0001). Similar results were found with Tanner and Whitehouse standards. Conclusions-These differences could result in substantial sex bias in the identification of poor growth in early childhood. The standards need modification.	UNIV DURHAM, DEPT PSYCHOL, DURHAM DH1 3LE, ENGLAND	Durham University	Wright, CM (corresponding author), UNIV NEWCASTLE UPON TYNE, DEPT CHILD HLTH, GATESHEAD NE8 3EB, TYNE & WEAR, ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOYCE L, 1993, GROWTH PROGRAM VERSI; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; SAVAGE S, IN PRESS P NUTR SOC; SKUSE D, 1994, EUR J CLIN NUTR, V48, pS113; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; WRIGHT CM, 1993, ARCH DIS CHILD, V69, P420, DOI 10.1136/adc.69.4.420; WRIGHT CM, 1994, ACTA PAEDIATR, V83, P351, DOI 10.1111/j.1651-2227.1994.tb18118.x	7	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 31	1996	313	7056					513	514						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789973	Green Published			2022-12-28	WOS:A1996VF29400013
J	Power, C; Matthews, S; Manor, O				Power, C; Matthews, S; Manor, O			Inequalities in self rated health in the 1958 birth cohort: Lifetime social circumstances or social mobility?	BRITISH MEDICAL JOURNAL			English	Article							FOLLOW-UP; MORTALITY; CHILDHOOD; MEN; ADULTHOOD; FINLAND; ILLNESS	Objective-To investigate explanations for social inequalities in health with respect to health related social mobility and cumulative socioeconomic circumstances over the first three decades of life. Design-Longitudinal follow up. Setting-Great Britain. Subjects-Data from the 1958 birth cohort study (all children born in England, Wales, and Scotland during 3-9 March 1958) were used, from the original birth survey and from sweeps at 16, 23, and 33 years. Main outcome measures-Subjects' own ratings of their health; social differences in self rated health at age 33. Results-Social mobility varied by health status, with those reporting poor health at age 23 having higher odds of downward mobility than of staying in same social class. Men with poor health were also less likely to be upwardly mobile. Prevalence of poor health at age 33 increased with decreasing social class: from 8.5% in classes I and II to 17.7% in classes IV and V among men, and horn 9.4% to 18.8% among women. These social differences remained significant after adjustment for effects of social mobility. Health inequalities attenuated when adjusted for social class at birth, at age 16, or at 23 or for self rated health at age 23. When adjusted for all these variables simultaneously, social differences in self rated health at age 33 were substantially reduced and no longer significant. Conclusions-Lifetime socioeconomic circumstances accounted for inequalities in self reported health at age 33, while social mobility did not have a major effect on health inequalities.	HEBREW UNIV JERUSALEM,SCH PUBL HLTH & COMMUNITY MED,JERUSALEM,ISRAEL	Hebrew University of Jerusalem	Power, C (corresponding author), INST CHILD HLTH,DEPT BIOSTAT & EPIDEMIOL,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.			Matthews, Sharon/0000-0003-3105-7029				Agresti A., 1984, ANAL ORDINAL CATEGOR; *ALL DUNB, 1992, NAT FITN SURV; BLANE D, 1993, SOCIOLOGY HLTH ILLNE, V1, P1; Cox BD, 1993, HLTH LIFESTYLE SURVE; DAHL E, 1993, EUROPEAN J PUBLIC HL, V31, P24; DAVEYSMITH G, 1990, J EPIDEMIOL COMMUN H, V44, P265; *DEP HLTH, 1995, VAR HLTH WHAT CAN DE; ELO IT, 1992, POPUL INDEX, V58, P186, DOI 10.2307/3644718; FERRI E, 1993, LIFE 33 5 FOLLOW UP; FORSDAHL A, 1977, BRIT J PREV SOC MED, V31, P91; Giddens, 1989, SOCIOLOGY; Goldblatt P, 1990, LONGITUDINAL STUDY M; HART C, 1995, J EPIDEMIOL COMMUNIT, V49, P552; HOSMER DW, 1989, APPL LOGISTIC REGRES; IDLER EL, 1990, AM J PUBLIC HEALTH, V80, P446, DOI 10.2105/AJPH.80.4.446; KAPLAN GA, 1983, AM J EPIDEMIOL, V117, P292, DOI 10.1093/oxfordjournals.aje.a113541; LUNDBERG O, 1993, SOC SCI MED, V36, P1047, DOI 10.1016/0277-9536(93)90122-K; Lundberg O., 1991, EUR SOCIOL REV, V7, P149, DOI DOI 10.1093/oxfordjournals.esr.a036593; LYNCH JW, 1994, LANCET, V343, P524, DOI 10.1016/S0140-6736(94)91468-0; MARE RD, 1990, MEASUREMENT ANAL MOR, P362; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MILLER JE, 1994, AM J EPIDEMIOL, V140, P233, DOI 10.1093/oxfordjournals.aje.a117242; MOORE DE, 1990, DEMOGRAPHY, V27, P31, DOI 10.2307/2061551; ODONNELL O, 1991, J HEALTH ECON, V10, P1, DOI 10.1016/0167-6296(91)90014-E; PECK MN, 1994, SOC SCI MED, V39, P553; POWER C, 1986, Q J SOC AFF, V2, P397; POWER C, 1990, J R STAT SOC A STAT, V153, P17, DOI 10.2307/2983094; Power C., 1991, HLTH CLASS EARLY YEA; RAHKONEN O, 1995, SOC SCI MED, V41, P163, DOI 10.1016/0277-9536(94)00320-S; RODGERS B, 1993, J HEALTH SOC BEHAV, V34, P165, DOI 10.2307/2137242; ROSE D, 1995, REPORT PHASE 1 ESRG; WADSWORTH M, 1986, CLASS HLTH; WANNAMETHEE G, 1991, INT J EPIDEMIOL, V20, P239, DOI 10.1093/ije/20.1.239; WAX Y, 1992, STAT MED, V11, P1273, DOI 10.1002/sim.4780111003; Welsch R, 1980, REGRESSION DIAGNOSTI; WEST P, 1988, SOC SCI MED, V27, P291, DOI 10.1016/0277-9536(88)90262-6; WHITEHEAD M, 1988, INEQUALITIES HLTH	37	150	150	1	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					449	453						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VE080	8776310				2022-12-28	WOS:A1996VE08000017
J	Christen, WG; Glynn, RJ; Manson, JE; Ajani, UA; Buring, JE				Christen, WG; Glynn, RJ; Manson, JE; Ajani, UA; Buring, JE			A prospective study of cigarette smoking and risk of age-related macular degeneration in men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMOKERS; PLASMA; ANTIOXIDANTS; MACULOPATHY; THROMBOSIS; EYE	Objective.-To examine the association between cigarette smoking and the incide Design.-Prospective cohort study with average person-years of follow-up for AMD of 12.2 years. Participants.-A total of 21 157 US male physicians participating in the Physicians' Health Study who did not have a diagnosis of AMD at baseline, were followed for at least 7 years, and had known levels of baseline smoking. Based on information reported at baseline, 11% were current smokers, 39% were past smokers, and 50% were never smokers. Main Outcome Measure.-Incident AMD, defined as a self-report that was confirmed by medical record review, first diagnosed after randomization, and responsible for vision loss to 20/30 or worse. Results.-A total of 268 incident cases of AMD with vision loss were confirmed. In multivariate analysis, current smokers of 20 or more cigarettes per day, compared with never smokers, had an increased risk of AMD (relative risk [RR], 2.46; 95% confidence interval [CI], 1.60-3.79). Past smokers had a modest elevation in risk of AMD (RR, 1.30; 95% CI, 0.99-1.70). For current smokers of fewer than 20 cigarettes per day, there was a nonsignificant 26% increased risk of AMD (RR, 1.26; 95% CI, 0.61-2.59). Conclusions.-These prospective data provide support for the hypothesis that cigarette smoking increases the risk of developing AMD.	BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health					NEI NIH HHS [EY03355, EY06633] Funding Source: Medline; NHLBI NIH HHS [HL34595] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552; BOLTONSMITH C, 1991, BRIT J NUTR, V65, P337, DOI 10.1079/BJN19910094; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; CHOW CK, 1986, J AM COLL NUTR, V5, P305; CHRISTEN WG, 1992, JAMA-J AM MED ASSOC, V268, P989; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784; DUTHIE GG, 1991, AM J CLIN NUTR, V53, pS1061, DOI 10.1093/ajcn/53.4.1061S; FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912; FOULDS WS, 1990, EYE, V4, P243, DOI 10.1038/eye.1990.35; FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8; GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674; HAWKINS RI, 1972, NATURE, V236, P450, DOI 10.1038/236450a0; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629; KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429; KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LEHR HA, 1993, FREE RADICAL BIO MED, V14, P573, DOI 10.1016/0891-5849(93)90138-K; LEVINE PH, 1973, CIRCULATION, V48, P619, DOI 10.1161/01.CIR.48.3.619; MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197; MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; *NAT ADV EYE COUNC, NIH PUBL; *NAT CTR HLTH STAT, 1993, HLTH US 1992; NORDENBERG D, 1990, JAMA-J AM MED ASSOC, V264, P1556, DOI 10.1001/jama.264.12.1556; OGSTON D, 1970, ATHEROSCLEROSIS, V11, P349, DOI 10.1016/0021-9150(70)90073-0; PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67; SEDDON J, 1995, AM J EPIDEMIOL, V141, pS34; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; WEST S, 1994, ARCH OPHTHALMOL-CHIC, V112, P222, DOI 10.1001/archopht.1994.01090140098031; WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038; YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701; YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1145/1165387.275645; [No title captured]	35	226	231	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1147	1151		10.1001/jama.276.14.1147	http://dx.doi.org/10.1001/jama.276.14.1147			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827967				2022-12-28	WOS:A1996VL33200024
J	Schwarz, K; Gauss, GH; Ludwig, L; Pannicke, U; Li, Z; Lindner, D; Friedrich, W; Seger, RA; HansenHagge, TE; Desiderio, S; Lieber, MR; Bartram, CR				Schwarz, K; Gauss, GH; Ludwig, L; Pannicke, U; Li, Z; Lindner, D; Friedrich, W; Seger, RA; HansenHagge, TE; Desiderio, S; Lieber, MR; Bartram, CR			RAG mutations in human B cell-negative SCID	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; BARE LYMPHOCYTE SYNDROME; RECEPTOR GAMMA-CHAIN; CLASS-II DEFICIENCY; V(D)J RECOMBINATION; INTERLEUKIN-2; GENES; PROTEINS; SIGNAL; DEFECT	Patients with human severe combined immunodeficiency (SCID) can be divided into those with B lymphocytes (B+ SCID) and those without (B- SCID). Although several genetic causes are known for B+ SCID, the etiology of B- SCID has not been defined. Six of 14 B- SCID patients tested were found to carry a mutation of the recombinase activating gene 1 (RAG-1), RAG-2, or both. This mutation resulted in a functional inability to form antigen receptors through genetic recombination and links a defect in one of the site-specific recombination systems to a human disease.	UNIV ULM,MOL BIOL SECT,D-89070 ULM,GERMANY; UNIV ULM,DEPT PEDIAT 2,D-89070 ULM,GERMANY; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; UNIV ZURICH,CHILDRENS HOSP,ZURICH,SWITZERLAND	Ulm University; Ulm University; Washington University (WUSTL); Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; University Children's Hospital Zurich; University of Zurich			Pannicke, Ulrich/D-7348-2014	Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909				ABE T, 1994, J IMMUNOL, V152, P5504; AMAIZ VA, 1992, NEW ENGL J MED, V327, P529; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHATILA T, 1990, P NATL ACAD SCI USA, V87, P10033, DOI 10.1073/pnas.87.24.10033; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FISCHER A, 1992, Immunodeficiency Reviews, V3, P83; GAUSS GH, 1993, MOL CELL BIOL, V13, P3900, DOI 10.1128/MCB.13.7.3900; Gauss GH, 1996, MOL CELL BIOL, V16, P258; Hirschhorn R., 1993, PEDIATR RES, V33, P35; ICHIKARA Y, 1992, IMMUNOL LETT, V33, P272; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MARKERT M L, 1991, Immunodeficiency Reviews, V3, P45; MATTHEWS DJ, 1995, BLOOD, V85, P38, DOI 10.1182/blood.V85.1.38.bloodjournal85138; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; SADOFSKY MJ, 1994, NUCLEIC ACIDS RES, V22, P1805, DOI 10.1093/nar/22.10.1805; SADOFSKY MJ, 1993, NUCLEIC ACIDS RES, V21, P5644, DOI 10.1093/nar/21.24.5644; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHWARZ K, 1991, J EXP MED, V174, P1039, DOI 10.1084/jem.174.5.1039; SCHWARZ K, UNPUB; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SOUDAIS C, 1993, NAT GENET, V3, P77, DOI 10.1038/ng0193-77; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406	32	377	391	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					97	99		10.1126/science.274.5284.97	http://dx.doi.org/10.1126/science.274.5284.97			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810255				2022-12-28	WOS:A1996VK74800055
J	Bodenheimer, TS; Grumbach, K				Bodenheimer, TS; Grumbach, K			Capitation or decapitation - Keeping your head in changing times	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGED CARE; PHYSICIANS		UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Grumbach, Kevin/L-9222-2016					*ADV BOARD CO, 1994, CAP STRAT; BODENHEIMER T, 1994, JAMA-J AM MED ASSOC, V272, P971, DOI 10.1001/jama.272.12.971; BODENHEIMER TS, 1995, UNDERSTANDING HLTH P; CLANCY CM, 1995, JAMA-J AM MED ASSOC, V273, P338, DOI 10.1001/jama.273.4.338; Friedman E, 1996, JAMA-J AM MED ASSOC, V275, P957, DOI 10.1001/jama.275.12.957; GOLD M, 1995, MED CARE RES REV, V52, P307, DOI 10.1177/107755879505200301; Johnson J., 1993, AIAA SPAC PROGR TECH, P1; KONGSTVEDT PR, 1989, MANAGED CARE HDB; LIGHT D, 1993, BRITAINS HLTH SYSTEM; NEWHOUSE JP, 1994, HEALTH AFFAIR, V13, P132, DOI 10.1377/hlthaff.13.1.132; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; *US DEP HHS, 1995, HLTH US 1994; VOGEL DE, 1992, FAMILY PHYSICIANS MA; WAGNER ER, 1987, EVALUATING PHYSICIAN; WOOLHANDLER S, 1995, NEW ENGL J MED, V333, P1706, DOI 10.1056/NEJM199512213332510; 1995, INTERSTUDY COMPETI 2; 1995, INTERSTUDY COMPETI 3; 1995, JAMA-J AM MED ASSOC, V273, P330	18	41	41	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1996	276	13					1025	1031		10.1001/jama.276.13.1025	http://dx.doi.org/10.1001/jama.276.13.1025			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK035	8847754				2022-12-28	WOS:A1996VK03500008
J	Pasternak, RC; Brown, LE; Stone, PH; Silverman, DI; Gibson, CM; Sacks, FM				Pasternak, RC; Brown, LE; Stone, PH; Silverman, DI; Gibson, CM; Sacks, FM			Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and ''normal'' cholesterol levels - A randomized, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						coronary disease; cholesterol; drug therapy, combination; hyperlipidemia; anticholesterolemic agents	ACUTE-RENAL-FAILURE; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; RECIPIENT RECEIVING LOVASTATIN; HIGH-DENSITY-LIPOPROTEIN; ARTERY DISEASE; MODERATE HYPERCHOLESTEROLEMIA; NORMOCHOLESTEROLEMIC PATIENTS; COMBINED HYPERLIPIDEMIA; ANGIOGRAPHIC TRIALS; NICOTINIC-ACID	Background: Combination drug therapy has been shown to decrease cholesterol levels in hyperlipidemic patients. However, its efficacy has not been well studied in patients previously considered to be normolipidemic, many of whom are now candidates for this therapy. Objective: To determine the efficacy and tolerability of multidrug therapy designed to improve low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels. in patients with coronary heart disease and average lipid levels. Design: Randomized, placebo-controlled, 2.5-year trial comparing patients receiving usual care with patients receiving stepped-care drug therapy. Intervention: Stepped-care therapy (pravastatin, nicotinic acid, cholestyramine, and gemfibrozil) to decrease total cholesterol levels to less than 4.1 mmol/L (160 mg/dL) and the ratio of LDL cholesterol to HDL cholesterol to less than 2.0. Setting: 2 academic, urban, tertiary care hospitals. Patients: 91 patients (80 men and 11 women) with coronary heart disease, a mean age of 60 years, total cholesterol levels less than 6.4 mmol/L (250 mg/dL) at baseline, and ratios of total cholesterol to HDL cholesterol greater than 4.0 at baseline. Measurements: Easting serum lipoprotein profile, fasting apolipoprotein levels, and frequency of adverse effects. Patients were assessed every 6 weeks during drug titration and every 3 months thereafter. Results: Mean lipid levels at baseline were as follows: total cholesterol, 5.5 mmol/L (214 mg/dL); LDL cholesterol, 3.6 mmol/L (140 mg/dL); HDL cholesterol, 1.1 mmol/L (42 mg/dL); and triglycerides, 1.8 mmol/L (159 mg/dL). With pravastatin, changes in levels from baseline were -22% for total cholesterol, -32% for LDL cholesterol, +8% for HDL cholesterol, and -15% for triglycerides (P < 0.001 for all comparisons). With the addition of 1.5 g of nicotinic acid, additional changes were -6% for total cholesterol (P < 0.002), -11% for LDL cholesterol, +8% for HDL cholesterol, and -10% for triglycerides (P < 0.001 for all comparisons). With 2.25 to 3 g of nicotinic acid, these changes were - 7% for total cholesterol (P = 0.007), -14% for LDL cholesterol (P < 0.001), +6% for HDL cholesterol (P = 002), and -13% for triglycerides (P = 0.03). With cholestyramine, total cholesterol and LDL cholesterol levels were unchanged compared with the previous step; the change in HDL cholesterol level was -8% (P = 0.03); and the change in triglyceride level was +46% (P < 0.001). With gemfibrozil, total cholesterol level was unchanged; the additional change in LDL cholesterol level was +12% (P = 0.09); the change in HDL cholesterol level was +12% (P = 0.03); and the change in triglyceride level was -37% (P < 0.001). Apolipoprotein B levels decreased by 25% overall (P < 0.001); lipoprotein(a) levels did not change significantly. Adverse effects were primarily attributable to nicotinic acid or cholestyramine. In 18 of the 35 patients (50%) whose baseline LDL cholesterol levels were greater than 3.35 mmol/L (130 mg/dL), pravastatin decreased LDL cholesterol levels to 2.6 mmol/L (100 mg/dL) or less by 6 weeks; 70% of patients needed combination therapy to reach this National Cholesterol Education Program goal during the 2.5 years of the study. Adding nicotinic acid to pravastatin produced LDL cholesterol levels of 2.6 mmol/L or less in 15 more of these 35 patients, so that 94% (n = 33) of the patients receiving these two drugs reached this goal. Conclusions: To reach current goals for LDL cholesterol levels, most normolipidemic patients with coronary heart disease iri this study needed combination therapy. Pravastatin with nicotinic acid and pravastatin with gemfibrozil are well-tolerated combinations that can maintain target LDL cholesterol levels, decrease triglyceride levels, and increase HDL cholesterol levels. Adding resin to these combinations produced no further benefit.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; MASSACHUSETTS GEN HOSP, CARDIAC UNIT, BOSTON, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital			Gibson, C. Michael/AAE-8212-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034980] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR02635] Funding Source: Medline; NHLBI NIH HHS [HL34980] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGMON J, 1992, CIRCULATION, V86, P839; ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; [Anonymous], 1993, Am J Cardiol, V72, P1031; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BROWN BG, 1995, AM J CARDIOL, V76, pC93; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; DAVIGNON J, 1994, AM J CARDIOL, V73, P339, DOI 10.1016/0002-9149(94)90005-1; EAST C, 1988, ANN INTERN MED, V109, P25, DOI 10.7326/0003-4819-109-1-25; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GINSBURG GS, 1991, AM J CARDIOL, V68, P187, DOI 10.1016/0002-9149(91)90742-4; GLUECK CJ, 1992, AM J CARDIOL, V70, P1, DOI 10.1016/0002-9149(92)91380-M; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; GRUNDY SM, 1985, ANN INTERN MED, V103, P339, DOI 10.7326/0003-4819-103-3-339; HOLME I, 1995, AM J CARDIOL, V76, pC10, DOI 10.1016/S0002-9149(99)80465-2; HOOGERBRUGGE N, 1990, J INTERN MED, V228, P261, DOI 10.1111/j.1365-2796.1990.tb00229.x; HUTCHESSON ACJ, 1994, J CLIN PHARM THER, V19, P387, DOI 10.1111/j.1365-2710.1994.tb00698.x; ILLINGWORTH DR, 1989, CIRCULATION, V79, P590, DOI 10.1161/01.CIR.79.3.590; ILLINGWORTH DR, 1984, ANN INTERN MED, V101, P598, DOI 10.7326/0003-4819-101-5-598; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; LEREN TP, 1988, ATHEROSCLEROSIS, V73, P135, DOI 10.1016/0021-9150(88)90034-2; MALLOY MJ, 1987, ANN INTERN MED, V107, P616, DOI 10.7326/0003-4819-107-5-616; MARAIS GE, 1990, ANN INTERN MED, V112, P228, DOI 10.7326/0003-4819-112-3-228; MARCOVINA SM, 1994, CLIN CHEM, V40, P586; MILLER M, 1990, AM J CARDIOL, V65, P1, DOI 10.1016/0002-9149(90)90017-U; National Cholesterol Education Program, 1993, NIH PUBL; NORMAN DJ, 1988, NEW ENGL J MED, V318, P46; PAN HY, 1990, CLIN PHARMACOL THER, V48, P201, DOI 10.1038/clpt.1990.136; PEDERSEN TR, 1994, LANCET, V344, P1383; PIERCE LR, 1990, JAMA-J AM MED ASSOC, V264, P71, DOI 10.1001/jama.264.1.71; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSSOUW JE, 1995, AM J CARDIOL, V76, pC86, DOI 10.1016/S0002-9149(99)80476-7; RUBINS HB, 1995, AM J CARDIOL, V75, P1196, DOI 10.1016/S0002-9149(99)80761-9; SACKS FM, 1994, LANCET, V344, P1182, DOI 10.1016/S0140-6736(94)90506-1; SACKS FM, 1995, AM J CARDIOL, V76, pC78, DOI 10.1016/S0002-9149(99)80475-5; SHEPHERD J, 1995, AM J CARDIOL, V76, pC113, DOI 10.1016/S0002-9149(99)80480-9; STEIN E, 1990, ARCH INTERN MED, V150, P341, DOI 10.1001/archinte.150.2.341; TOBERT JA, 1988, NEW ENGL J MED, V318, P48; VACEK JL, 1995, AM J CARDIOL, V76, P182, DOI 10.1016/S0002-9149(99)80056-3; VEGA GL, 1987, JAMA-J AM MED ASSOC, V257, P33, DOI 10.1001/jama.257.1.33; WIKLUND O, 1993, AM J MED, V94, P13, DOI 10.1016/0002-9343(93)90114-5; WIREBAUGH SR, 1992, PHARMACOTHERAPY, V12, P445; YTREARNE K, 1989, J INTERN MED, V226, P285, DOI 10.1111/j.1365-2796.1989.tb01397.x	47	65	73	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1996	125	7					529	+		10.7326/0003-4819-125-7-199610010-00001	http://dx.doi.org/10.7326/0003-4819-125-7-199610010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ653	8815751				2022-12-28	WOS:A1996VJ65300001
J	Freeman, ML; Nelson, DB; Sherman, S; Haber, GB; Herman, ME; Dorsher, PJ; Moore, JP; Fennerty, MB; Ryan, ME; Shaw, MJ; Lande, JD; Pheley, AM				Freeman, ML; Nelson, DB; Sherman, S; Haber, GB; Herman, ME; Dorsher, PJ; Moore, JP; Fennerty, MB; Ryan, ME; Shaw, MJ; Lande, JD; Pheley, AM			Complications of endoscopic biliary sphincterotomy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BILE-DUCT STONES; POST-ERCP PANCREATITIS; ODDI DYSFUNCTION; RETROGRADE CHOLANGIOPANCREATOGRAPHY; PRECUT PAPILLOTOMY; CONSECUTIVE PATIENTS; RISK; MANAGEMENT; CHOLEDOCHOLITHIASIS; CHOLECYSTECTOMY	Background Endoscopic sphincterotomy is commonly used to remove bile-duct stones and to treat other problems. We prospectively investigated risk factors for complications of this procedure and their outcomes. Methods We studied complications that occurred within 30 days of endoscopic biliary sphincterotomy in consecutive patients treated at 17 institutions in the United States and Canada from 1992 through 1994. Results Of 2347 patients, 229 (9.8 percent) had a complication, including pancreatitis in 127 (5.4 percent) and hemorrhage in 48 (2.0 percent). There were 55 deaths from all causes within 30 days; death was directly or indirectly related to the procedure in 10 cases. Of five significant risk factors for complications identified in a multivariate analysis, two were characteristics of the patients (suspected dysfunction of the sphincter of Oddi as an indication for the procedure and the presence of cirrhosis) and three were related to the endoscopic technique (difficulty in cannulating the bile duct, achievement of access to the bile duct by ''precut'' sphincterotomy, and use of a combined percutaneous-endoscopic procedure). The overall risk of complications was not related to the patient's age, the number of coexisting illnesses, or the diameter of the bile duct. The rate of complications was highest when the indication for the procedure was suspected dysfunction of the sphincter of Oddi (21.7 percent) and lowest when the indication was removal of bile-duct stones within 30 days of laparoscopic cholecystectomy (4.9 percent). As compared with those who performed fewer procedures, endoscopists who performed more than one sphincterotomy per week had lower rates of complications (8.4 percent vs. 11.1 percent, P=0.03). Conclusions The rate of complications after endoscopic biliary sphincterotomy can vary widely in different circumstances and is primarily related to the indication for the procedure and to endoscopic technique, rather than to the age or general medical condition of the patient.	VET AFFAIRS MED CTR,MINNEAPOLIS,MN; INDIANA UNIV,MED CTR,INDIANAPOLIS,IN; UNIV TORONTO,WELLESLEY HOSP,TORONTO,ON M4Y 1J3,CANADA; UNIV MINNESOTA HOSP & CLIN,MINNEAPOLIS,MN 55455; ST CLOUD CLIN INTERNAL MED,ST CLOUD,MN; DULUTH CLIN,DULUTH,MN; UNIV ARIZONA,TUCSON,AZ; MARSHFIELD CLIN FDN MED RES & EDUC,MARSHFIELD,WI	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Indiana University System; Indiana University-Purdue University Indianapolis; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital; University of Arizona; Marshfield Clinic	Freeman, ML (corresponding author), HENNEPIN CTY MED CTR,DEPT MED,701 PK AVE,MINNEAPOLIS,MN 55415, USA.			Silverman, William/0000-0003-0471-6105				ALIPERTI G, 1991, ANN INTERN MED, V115, P783, DOI 10.7326/0003-4819-115-10-783; BOENDER J, 1994, ENDOSCOPY, V26, P209, DOI 10.1055/s-2007-1008945; CHEN YK, 1994, AM J GASTROENTEROL, V89, P327; CLASSEN M, 1974, DEUT MED WOCHENSCHR, V99, P496, DOI 10.1055/s-0028-1107790; Classen M, 1987, GASTROENTEROLOGIC EN, P631; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; COTTON PB, 1989, GASTROINTEST ENDOSC, V35, P578, DOI 10.1016/S0016-5107(89)72921-7; COTTON PB, 1991, GASTROINTEST ENDOSC, V37, P383, DOI 10.1016/S0016-5107(91)70740-2; COTTON PB, 1994, AM J GASTROENTEROL, V89, pS169; DOWSETT JF, 1989, GASTROENTEROLOGY, V96, P1180, DOI 10.1016/0016-5085(89)91639-9; ESCOURROU J, 1990, GASTROINTEST ENDOSC, V36, P205; FERRARI AP, 1994, GASTROINTEST ENDOSC, V40, pP20; GEENEN JE, 1981, GASTROINTEST ENDOSC, V27, P31, DOI 10.1016/S0016-5107(81)73140-7; GEENEN JE, 1989, NEW ENGL J MED, V320, P82, DOI 10.1056/NEJM198901123200203; HAMILTON I, 1983, CLIN RADIOL, V34, P543, DOI 10.1016/S0009-9260(83)80156-1; HOSMER DW, 1989, APPL LOGISTIC REGRES; HUIBREGTSE K, 1986, GASTROINTEST ENDOSC, V32, P403, DOI 10.1016/S0016-5107(86)71921-4; JOHNSON G, 1993, GASTROINTEST ENDOSC, V39, P319; KAWAI K, 1974, GASTROINTEST ENDOSC, V20, P148, DOI 10.1016/S0016-5107(74)73914-1; KOZAREK RA, 1993, GASTROINTEST ENDOSC, V3, P167; KUMAR S, 1995, GASTROINTEST ENDOSC, V41, P445, DOI 10.1016/S0016-5107(05)80001-X; LAUGIER R, 1991, DIGESTION, V50, P202, DOI 10.1159/000200762; LEESE T, 1985, BRIT J SURG, V72, P215, DOI 10.1002/bjs.1800720325; LENRIOT JP, 1993, GASTROEN CLIN BIOL, V17, P244; MARTIN DF, 1991, BRIT MED J, V302, P1466, DOI 10.1136/bmj.302.6790.1466-b; MELLINGER JD, 1991, SURG GYNECOL OBSTET, V172, P465; NELSON DB, 1994, J CLIN GASTROENTEROL, V19, P283, DOI 10.1097/00004836-199412000-00004; NEOPTOLEMOS JP, 1989, ANN SURG, V209, P157, DOI 10.1097/00000658-198902000-00004; NEOPTOLEMOS JP, 1988, BRIT J SURG, V75, P454, DOI 10.1002/bjs.1800750518; NEOPTOLEMOS JP, 1991, HEPATO-GASTROENTEROL, V38, P243; NEWCOMER MK, 1995, GASTROINTEST ENDOSC, V41, P408, DOI 10.1016/S0016-5107(05)80487-0; OSTROFF JW, 1989, ERCP DIAGNOSTIC THER, P61; PONSKY JL, 1992, SURG CLIN N AM, V72, P1099; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Remuzzi G, 1989, Adv Nephrol Necker Hosp, V18, P171; ROLNY P, 1990, GUT, V31, P821, DOI 10.1136/gut.31.7.821; SHAKOOR T, 1992, GASTROINTEST ENDOSC, V38, P623, DOI 10.1016/S0016-5107(92)70537-9; SHERMAN S, 1990, GASTROINTEST ENDOSC, V36, P462, DOI 10.1016/S0016-5107(90)71115-7; SHERMAN S, 1991, GASTROENTEROLOGY, V101, P1068, DOI 10.1016/0016-5085(91)90735-4; SHERMAN S, 1991, PANCREAS, V6, P350, DOI 10.1097/00006676-199105000-00013; SHERMAN S, 1994, AM J GASTROENTEROL, V89, P303; SHERMAN S, 1990, ADV THERAPEUTIC ENDO, P201; SHERMAN S, 1992, PANCREAS, V7, P402; SHERMAN S, 1994, GASTROINTEST ENDOS S, V40, pP124; STOLTE M, 1980, LEBER MAGEN DARM, V10, P293; STRASBERG SM, 1995, GASTROENTEROLOGY, V109, P320, DOI 10.1016/0016-5085(95)90302-X; SUGIYAMA M, 1993, ANN SURG, V218, P68, DOI 10.1097/00000658-199307000-00011; TARNASKY P, 1995, GASTROINTEST ENDOSC, V41, P430, DOI 10.1016/S0016-5107(05)80573-5; VAIRA D, 1989, LANCET, V2, P431	49	1945	2044	0	39	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1996	335	13					909	918		10.1056/NEJM199609263351301	http://dx.doi.org/10.1056/NEJM199609263351301			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK148	8782497				2022-12-28	WOS:A1996VK14800001
J	Heymann, TD; Chopra, K; Nunn, E; Coulter, L; Westaby, D; MurrayLyon, IM				Heymann, TD; Chopra, K; Nunn, E; Coulter, L; Westaby, D; MurrayLyon, IM			Bowel preparation at home: Prospective study of adverse effects in elderly people	BRITISH MEDICAL JOURNAL			English	Article									CHELSEA & WESTMINSTER HOSP,DEPT GASTROENTEROL,LONDON SW10 9NH,ENGLAND; CHARING CROSS HOSP,LONDON W6 8RF,ENGLAND	Imperial College London; Imperial College London								BORKJE B, 1991, SCAND J GASTROENTERO, V26, P162, DOI 10.3109/00365529109025026; *BRIT MED ASS, 1995, 27 BMA RPS, P48; GURWITZ JH, 1992, AM J MED, V92, P41, DOI 10.1016/0002-9343(92)90013-2; MARSHALL JB, 1993, ALIMENT PHARM THERAP, V7, P679	4	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					727	728						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819444				2022-12-28	WOS:A1996VJ44100025
J	Tong, L; Qian, CG; Massariol, MJ; Bonneau, PR; Cordingley, MG; Lagace, L				Tong, L; Qian, CG; Massariol, MJ; Bonneau, PR; Cordingley, MG; Lagace, L			A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease	NATURE			English	Article							SUBSTRATE; PROTEINS	HUMAN cytomegalovirus (hCMV), a herpesvirus, infects up to 70% of the general population in the United States and can cause morbidity and mortality in immunosuppressed individuals (organ-transplant recipients and AIDS patients) and congenitally infected newborns(1). hCMV protease is essential for the production of mature infectious virions, as it performs proteolytic processing near the carboxy terminus (M-site) of the viral assembly protein precursor (for a review, see ref. 2). hCMV protease is a serine protease(2), although it has little homology to other clans of serine proteases(2,3). Here we report the crystal structure of hCMV pretense at 2.0 Angstrom resolution, and show that it possesses a new polypeptide backbone fold. Ser 132 and His 63 are found in close proximity in the active site, confirming earlier biochemical and mutagenesis studies(2). The structure suggests that the third member of the triad is probably His 157. A dimer of the protease with an extensive interface is found in the crystal structure. This structure information will help in the design and optimization of inhibitors against herpesvirus proteases.	BIOMEGA BOEHRINGER INGELHEIM RES INC,LAVAL,PQ H7S 2G5,CANADA	Boehringer Ingelheim	Tong, L (corresponding author), BOEHRINGER INGELHEIM PHARMACEUT INC,90 E RIDGE POB 368,RIDGEFIELD,CT 06877, USA.			Tong, Liang/0000-0002-0563-6468				BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; BURCK PJ, 1994, J VIROL, V68, P2937, DOI 10.1128/JVI.68.5.2937-2946.1994; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Darke PL, 1996, J BIOL CHEM, V271, P7445, DOI 10.1074/jbc.271.13.7445; FIELDS BN, 1990, VIROLOGY, V2, pCH64; Gibson Wade, 1995, Perspectives in Drug Discovery and Design, V2, P413, DOI 10.1007/BF02172034; HALL DL, 1995, J BIOL CHEM, V270, P22697, DOI 10.1074/jbc.270.39.22697; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; Margosiak SA, 1996, BIOCHEMISTRY-US, V35, P5300, DOI 10.1021/bi952842u; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PINKO C, 1995, J BIOL CHEM, V270, P23634, DOI 10.1074/jbc.270.40.23634; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; TONG L, 1993, J APPL CRYSTALLOGR, V26, P15, DOI 10.1107/S0021889892007295; TONG L, 1993, J APPL CRYSTALLOGR, V26, P748, DOI 10.1107/S0021889893005631; YAMAMOTO A, 1992, BIOCHEMISTRY-US, V31, P11305, DOI 10.1021/bi00161a007	23	162	167	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					272	275		10.1038/383272a0	http://dx.doi.org/10.1038/383272a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805706				2022-12-28	WOS:A1996VH31500058
J	Chen, HL; Chang, MH; Ni, YH; Hsu, HY; Lee, PI; Lee, CY; Chen, DS				Chen, HL; Chang, MH; Ni, YH; Hsu, HY; Lee, PI; Lee, CY; Chen, DS			Seroepidemiology of hepatitis B virus infection in children - Ten years of mass vaccination in Taiwan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIGEN CARRIER MOTHERS; PROGRAM; INFANTS; EFFICACY; TAIPEI	Objective.-To study the seroepidemiology of hepatitis B virus (HBV) infection in children 10 years after a mass hepatitis B vaccination program was begun in Taiwan. Design.-Cross-sectional seroprevalence survey. Setting.-Cheng-Chung/Chung-Cheng District, Taipei, Taiwan, 1994. Subjects and Methods.-Serum samples from 1515 healthy children younger than 12 years were tested for HBV markers. The results were compared with a baseline seroepidemiologic study conducted just before the vaccination program was launched in 1984 and with a subsequent study in 1989 in the same area. Main Results.-Eighty-seven percent of the children had received at least 3 doses of HBV vaccine. The overall prevalence rate of hepatitis B surface antigenemia decreased from 9.8% in 1984 to 1.3% in 1994. A statistically significant decrease was observed in every age group from 1 to 10 years. The overall prevalence rate of hepatitis B core antibody was 26% in 1984, 15% in 1989, and 4.0% in 1994. This suggests that the risk of horizontal HBV infection has decreased overtime, not only because of the protective effect of the vaccine but also because the infection source has diminished. A high prevalence rate of hepatitis B surface antibody (79%) was noted in 1994 as anticipated. Conclusions.-The Taiwanese mass vaccination program has protected most children younger than 10 years from becoming carriers, reducing both perinatal and horizontal HBV transmission. Mass HBV vaccination has proved to be a successful method to control HBV infection in this hyperendemic area.	NATL TAIWAN UNIV HOSP, DEPT PEDIAT, TAIPEI 10016, TAIWAN; NATL TAIWAN UNIV HOSP, DEPT INTERNAL MED, TAIPEI 10016, TAIWAN	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital				LEE, PING-ING/0000-0002-7299-2825; Chang, Mei Hwei/0000-0002-3648-9261; Hsu, Hong-Yuan/0000-0002-5720-4835; LEE, CHIN-YUN/0000-0002-3938-377X; CHEN, DING-SHINN/0000-0001-7791-6154; Ni, Yen-Hsuan/0000-0002-1158-5249				BEASLEY RP, 1982, HEPATOLOGY, V2, pS21; BEASLEY RP, 1981, LANCET, V2, P1129; Chen D S, 1978, Taiwan Yi Xue Hui Za Zhi, V77, P263; Chen D S, 1982, Taiwan Yi Xue Hui Za Zhi, V81, P1357; Chen D-S, 1987, NEOPLASMS LIVER, P71; CHEN DS, 1987, JAMA-J AM MED ASSOC, V257, P2597; *DEP HLTH EX YUAN, 1984, HLTH STAT VIT STAT R, V2, P44; HSU HM, 1988, JAMA-J AM MED ASSOC, V260, P2231, DOI 10.1001/jama.260.15.2231; HSU HY, 1986, J MED VIROL, V18, P301, DOI 10.1002/jmv.1890180402; LEE PI, 1995, J PEDIATR-US, V126, P716, DOI 10.1016/S0022-3476(95)70398-5; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; SUNG JL, 1980, SCAND J GASTROENTERO, V15, P321, DOI 10.3109/00365528009181477; SUNG JL, 1984, CHINESE J GASTROENTE, V1, P1; TSEN YJ, 1991, J MED VIROL, V34, P96, DOI 10.1002/jmv.1890340205; WONG WCW, 1994, VACCINE, V12, P229, DOI 10.1016/0264-410X(94)90199-6	15	269	277	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					906	908		10.1001/jama.276.11.906	http://dx.doi.org/10.1001/jama.276.11.906			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782640				2022-12-28	WOS:A1996VF78700034
J	Irwin, K; Olivo, N; Schable, CA; Weber, JT; Janssen, R; Ernst, J; BekoeTabiri, S; Benjamin, F; Carniciu, S; Chavaria, C; Chiriboga, V; Disla, M; Fernandez, A; Ganea, C; Martinez, G; Parsons, R; Rosario, F; Rothman, W; Santos, W; Shulman, R; Vasquez, Y; Brown, K; Cowart, F; Daugharty, A; Edeline, M; Lewis, E; McRae, B; Raimondi, V; Wells, L; Winter, R; Minor, P				Irwin, K; Olivo, N; Schable, CA; Weber, JT; Janssen, R; Ernst, J; BekoeTabiri, S; Benjamin, F; Carniciu, S; Chavaria, C; Chiriboga, V; Disla, M; Fernandez, A; Ganea, C; Martinez, G; Parsons, R; Rosario, F; Rothman, W; Santos, W; Shulman, R; Vasquez, Y; Brown, K; Cowart, F; Daugharty, A; Edeline, M; Lewis, E; McRae, B; Raimondi, V; Wells, L; Winter, R; Minor, P			Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article							TESTS	Background: The delay between collection of blood samples and availability of test results may be as long as 3 weeks and is one barrier to the acceptance of voluntary testing for human immunodeficiency virus (HIV) infection. Serologic tests that provide results rapidly could overcome this barrier, but the accuracy and reliability of rapid tests have not been well characterized in the United States. Objective: To evaluate, in a ''real world'' setting, the performance characteristics of a rapid HIV assay that reduces the need for patients to return for counseling after the test. Design: Testing of HIV antibodies by rapid and nonrapid assays and survey about risk behaviors for HIV. Setting: A hospital in Bronx, New York, with a high prevalence of HIV-seropositive patients. Patients: 837 patients who were not known to be infected with HIV, had not been admitted for conditions related to the acquired immunodeficiency syndrome, and agreed to participate in HIV testing and an interview. Measurements: Sensitivity and specificity of a rapid HIV antibody assay based on comparisons with nonrapid assay and Western blot assay. Results: According to nonrapid assays, 5.4% of patients were infected with HIV. The rapid assay was highly accurate in this sample overall: Its sensitivity was 1.00, its specificity was 0.991, its positive predictive value was 0.865, and its negative predictive value was 1.00. The assay was also highly accurate in various subgroups. Conclusions: Accurate, rapid tests for HIV infection may enhance testing programs by preventing the need for delayed counseling of seronegative patients and by providing preliminary results to seropositive patients. These preliminary results may encourage patients to return for confirmatory test results and to adopt risk-reducing behaviors sooner.			Irwin, K (corresponding author), CTR DIS CONTROL & PREVENT, DIV HIV AIDS PREVENT, MAILSTOP E-45, 1600 CLIFTON RD, ATLANTA, GA 30333 USA.		Rosario, Fredrick Joseph/I-2835-2019		PHS HHS [U64/CCU206797] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM MED ASS, 1994, DIG HIV AIDS POL; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; *DIV HIV PREV AIDS, 1992, COMM NEED IND; Farnham PG, 1996, PUBLIC HEALTH REP, V111, P44; FERRERA C, 1993, 9 INT C AIDS BERL; FLEMING DW, 1987, JAMA-J AM MED ASSOC, V258, P785, DOI 10.1001/jama.258.6.785; HARDY LM, 1991, HIV SCREENING PREGNA; IRWIN KL, 1996, 11 INT C AIDS VANC; KASSLER WJ, 1995, J CLIN MICROBIOL, V33, P2899, DOI 10.1128/JCM.33.11.2899-2902.1995; KASSLER WJ, 1994, 10 INT C AIDS YOK; KLINE RL, 1993, 9 INT C AIDS BERL; MALONE JD, 1993, J ACQ IMMUN DEF SYND, V6, P115; MOORE JD, 1986, NEW ENGL J MED, V314, P1387; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; SAS Institute, 1990, SAS STAT US GUID VER; SCHABLE C, 1994, LANCET, V344, P1333, DOI 10.1016/S0140-6736(94)90695-5; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; WHITE LJ, 1988, ANN INTERN MED, V108, P460, DOI 10.7326/0003-4819-108-3-460; 1987, MMWR-MORBID MORTAL W, V36, P509	20	40	43	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					471	475		10.7326/0003-4819-125-6-199609150-00007	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779459				2022-12-28	WOS:A1996VF88200008
J	Tschachler, E; Bergstresser, PR; Stingl, G				Tschachler, E; Bergstresser, PR; Stingl, G			HIV-related skin diseases	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TOXIC EPIDERMAL NECROLYSIS; IMMUNE-DEFICIENCY-SYNDROME; CRYPTOCOCCUS-NEOFORMANS; BACILLARY ANGIOMATOSIS; SEBORRHEIC DERMATITIS; DRUG-REACTIONS; HERPES-ZOSTER; INFECTION; ASSOCIATION	Disorders of the skin and mucous membranes, including various infections, Kaposi's sarcoma, and miscellaneous conditions, occur throughout the course of HIV infection, affecting more than 90% of patients at some time. These lesions are often the first manifestations of symptomatic HIV disease. Clinicians need to be aware of these diagnoses and the order of their appearance since correct interpretation is essential for counselling patients about the progression of their illness and for initiating appropriate therapy.	UNIV TEXAS,SW MED CTR,DEPT DERMATOL,DALLAS,TX	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Tschachler, E (corresponding author), UNIV VIENNA,SCH MED,DEPT DERMATOL,DIV IMMUNOL ALLERGY & INFECT DIS,WAHRINGER GURTEL 18-20,A-1090 VIENNA,AUSTRIA.			Tschachler, Erwin/0000-0002-0248-1798				BELSITO DV, 1984, NEW ENGL J MED, V310, P1279, DOI 10.1056/NEJM198405173102002; BREESE PL, 1995, SEX TRANSM DIS, V22, P7, DOI 10.1097/00007435-199501000-00002; BUCHBINDER SP, 1992, J INFECT DIS, V166, P1153, DOI 10.1093/infdis/166.5.1153; CLARK RA, 1990, REV INFECT DIS, V12, P768; COCKERELL CJ, 1990, J AM ACAD DERMATOL, V22, P501, DOI 10.1016/0190-9622(90)70071-O; COHEN PR, 1989, CLIN EXP DERMATOL, V14, P273, DOI 10.1111/j.1365-2230.1989.tb01978.x; COLDIRON BM, 1989, ARCH DERMATOL, V125, P357, DOI 10.1001/archderm.125.3.357; COLEBUNDERS R, 1988, J INFECT DIS, V157, P314, DOI 10.1093/infdis/157.2.314; COOPMAN SA, 1993, NEW ENGL J MED, V328, P1670, DOI 10.1056/NEJM199306103282304; DOMPMARTIN D, 1990, INT J DERMATOL, V29, P337, DOI 10.1111/j.1365-4362.1990.tb04755.x; DURDEN FM, 1994, J AM ACAD DERMATOL, V30, P844, DOI 10.1016/S0190-9622(94)70094-X; FIVESON DP, 1988, J AM ACAD DERMATOL, V29, P912; FROMMEL D, 1994, LANCET, V344, P165, DOI 10.1016/S0140-6736(94)92760-X; GORDIN FM, 1994, J INFECT DIS, V169, P893, DOI 10.1093/infdis/169.4.893; GREGORY N, 1990, J AM ACAD DERMATOL, V22, P1061, DOI 10.1016/0190-9622(90)70153-9; GROISSER D, 1989, J AM ACAD DERMATOL, V20, P770, DOI 10.1016/S0190-9622(89)70088-8; GULICK RM, 1990, ARCH DERMATOL, V126, P1086, DOI 10.1001/archderm.126.8.1086; HILSMARSDOTTIR I, 1993, J ACQ IMMUN DEF SYND, V6, P466; HUTCHINSON CM, 1994, ANN INTERN MED, V121, P94, DOI 10.7326/0003-4819-121-2-199407150-00003; JOHNSON RA, 1993, DERMATOLOGY GEN MED, P172; JURA E, 1989, PEDIATR INFECT DIS J, V8, P586, DOI 10.1097/00006454-198909000-00003; LAIUTAUD B, 1989, ARCH DERMATOL, V125, P629; LANGHOFF E, 1991, P NATL ACAD SCI USA, V88, P7998, DOI 10.1073/pnas.88.18.7998; MATHES BM, 1985, J AM ACAD DERMATOL, V13, P947, DOI 10.1016/S0190-9622(85)70243-5; MELBYE M, 1987, LANCET, V1, P728; NICHOLS L, 1989, AM J CLIN PATHOL, V92, P787, DOI 10.1093/ajcp/92.6.787; PETRY KU, 1994, INT J CANCER, V57, P836, DOI 10.1002/ijc.2910570612; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; PORTEOUS DM, 1991, ARCH DERMATOL, V127, P740, DOI 10.1001/archderm.127.5.740; ROSENTHAL D, 1991, ARCH DERMATOL, V127, P206, DOI 10.1001/archderm.127.2.206; SAIAG P, 1992, J AM ACAD DERMATOL, V26, P567, DOI 10.1016/0190-9622(92)70082-Q; SCHWARTZ JJ, 1992, J AM ACAD DERMATOL, V27, P583, DOI 10.1016/0190-9622(92)70226-6; SKOUTELIS AT, 1990, J ACQ IMMUN DEF SYND, V3, P335; SLATER LN, 1992, ARCH INTERN MED, V152, P602, DOI 10.1001/archinte.152.3.602; SMITH KJ, 1994, ARCH DERMATOL, V130, P521, DOI 10.1001/archderm.130.4.521; SMITH KJ, 1994, J AM ACAD DERMATOL, V31, P746, DOI 10.1016/S0190-9622(94)70236-5; SOLINGER AM, 1993, J RHEUMATOL, V20, P678; STINGL G, 1993, DERMATOLOGY GENERAL, P172; STRAUS WL, 1994, ANN INTERN MED, V120, P118, DOI 10.7326/0003-4819-120-2-199401150-00004; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; TINDALL B, 1989, AIDS, V3, P747, DOI 10.1097/00002030-198911000-00010; TSCHACHLER E, 1987, J INVEST DERMATOL, V88, P233, DOI 10.1111/1523-1747.ep12525402; WIKIER JR, 1992, J AM ACAD DERMATOL, V27, P37; 1993, MMWR-MORBID MORTAL W, V41, P1; 1988, MMWR-MORBID MORTAL W, V37, P600	45	93	101	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					659	663		10.1016/S0140-6736(96)01032-X	http://dx.doi.org/10.1016/S0140-6736(96)01032-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782758	Green Published			2022-12-28	WOS:A1996VF60900013
J	Purchase, ND; McCallum, AK; Kennedy, HG				Purchase, ND; McCallum, AK; Kennedy, HG			Evaluation of a psychiatric court liaison scheme in north London	BRITISH MEDICAL JOURNAL			English	Article									ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Purchase, ND (corresponding author), ENFIELD COMMUNITY CARE TRUST,N LONDON FORENS PSYCHIAT SERV,CAMLET LODGE,LONDON EN2 8JL,ENGLAND.		Kennedy, Harry G/AAE-6401-2020	Kennedy, Harry G/0000-0003-3174-3272				CONWAY AS, 1994, BRIT MED J, V308, P627, DOI 10.1136/bmj.308.6929.627a; JAMES DV, 1992, MED SCI LAW, V32, P167, DOI 10.1177/106002809203200212; TYRER P, 1995, LANCET, V345, P756, DOI 10.1016/S0140-6736(95)90640-1	3	13	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					531	532						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VF294	8789981				2022-12-28	WOS:A1996VF29400021
J	Socie, G; Mary, JY; deGramont, A; Rio, B; Leporrier, M; Rose, C; Heudier, P; Rochant, H; Cahn, JY; Gluckman, E				Socie, G; Mary, JY; deGramont, A; Rio, B; Leporrier, M; Rose, C; Heudier, P; Rochant, H; Cahn, JY; Gluckman, E			Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; PIG-A GENE; APLASTIC-ANEMIA; HEMOGLOBINURIA PNH; SOMATIC MUTATIONS; ANCHOR	Background Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired disorder of haematopoietic stem cells. Although knowledge about the pathophysiology of the disease is increasing, no multivariate analysis of factors influencing survival has been undertaken, mainly because the disease is rare. We undertook such an investigation. Methods Data were collected on 220 patients with PNH diagnosed over a 46-year period (1950-1995) from participating French centres. Diagnosis of the disease required, at least, an unequivocally positive Ham's test. Findings The Kaplan-Meier survival estimate was 65% (SE 4) at 10 years and 48% (6) at 15 years after diagnosis. 8-year cumulative incidence rates of the main complications (pancytopenia, thrombosis, and myelodysplastic syndrome) were 15% (3), 28% (4), and 5% (2), respectively. Demographic data, presenting features, initial treatment, complications, and causes of death were similar to those previously reported, In multivariate analysis, seven factors were significantly associated with survival in patients with PNH. Poor survival was associated with the occurrence of thrombosis as a complication (relative risk 10.2 [95% CI 6-17], p<0.0001), evolution to pancytopenia (5.5 [2.8-11], p<0.0001), myelodysplastic syndrome or acute leukaemia (19.1 [7.3-50], p<0.001), age over 55 years at diagnosis (4 [2.4-6.9], p<0.0001), need for additional treatment (2.1 [1.3-3.6], p<0.003), and thrombocytopenia at diagnosis (2.2 [1.3-3.8, p<0.003). Better survival was shown for patients in whom aplastic anaemia antedated PNH (0.32 [0.14-0.72], p<0.02). Factors associated in multivariate analysis with a high risk of thrombosis during the disease course were thrombosis at diagnosis (5.1 [2.5-10.6], p=0.0002), age over 54 years (2.6 [1.5-4.6, p=0.0014), and infection at diagnosis (2.6 [1.3-5.2], p=0.0099). The risk factors for progression to pancytopenia were absence at diagnosis of anaemia (4.03 [1.3-12.2], p=0.03) and neutropenia (2.45 [1.1-5.7], p=0.03). The risk factors for development of myelodysplastic syndrome or acute leukaemia were abdominal pain crisis at presentation (10.5 [2.5-44.0], p=0.004) and year of diagnosis after 1983 (8.45 [1.8-40.7], p=0.004). Interpretation This large number of cases permitted a detailed analysis of prognostic factors for the first time, in this rare disease. Estimates of PNH prognostic factors may serve as baseline data in the assessment of current and future treatments for this disease.Interpretation This large number of cases permitted a detailed analysis of prognostic factors for the first time, in this rare disease. Estimates of PNH prognostic factors may serve as baseline data in the assessment of current and future treatments for this disease.	UNIV PARIS 07,INSERM,U444,CTR BIOINFORMAT,PARIS,FRANCE; HOP ST ANTOINE,SERV MED INTERNE ONCOL,F-75571 PARIS,FRANCE; HOP HOTEL DIEU,SERV HEMATOL,PARIS,FRANCE; CTR HOSP REG & UNIV CAEN,CAEN,FRANCE; HOP C HURIEZ,LILLE,FRANCE; HOP CIMIEZ,F-06003 NICE,FRANCE; HOP HENRI MONDOR,F-94010 CRETEIL,FRANCE; HOP J MINJOZ,BESANCON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Caen NORMANDIE; Universite de Caen Normandie; Universite de Lille - ISITE; CHU Lille; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite de Franche-Comte; CHU Besancon	Socie, G (corresponding author), HOP ST LOUIS,SERV GREFFE MOELLE,F-75475 PARIS 10,FRANCE.		eliane, Gluckman/AAA-5024-2021					ALTMAN DG, 1994, STAT MED, V13, P301, DOI 10.1002/sim.4780130402; ANTIN JH, 1985, BLOOD, V66, P1247; BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; Byar DP., 1988, CANC CLIN TRIALS MET, P423; Cox D. R., 1984, ANAL SURVIVAL DATA; DACIE JV, 1967, HAEMOLYTIC ANAEMIA 4, P1128; DACIE JV, 1972, SER HAEMATOL, V3, P3; DEGRAMONT A, 1985, REV MED INTERNE, V6, P477, DOI 10.1016/S0248-8663(85)80028-X; FORMAN K, 1984, ACTA HAEMATOL-BASEL, V71, P217, DOI 10.1159/000206591; FUJIOKA S, 1989, ACTA HAEMATOL JAPON, V52, P1386; GRISCELLIBENNACEUR A, 1995, BLOOD, V85, P1354, DOI 10.1182/blood.V85.5.1354.bloodjournal8551354; GROSBY WH, 1953, BLOOD, V8, P769; HARTMANN RC, 1972, SER HAEMATOL, V3, P42; HILLMEN P, 1995, NEW ENGL J MED, V333, P1253, DOI 10.1056/NEJM199511093331904; KAWAHARA K, 1992, AM J HEMATOL, V39, P283, DOI 10.1002/ajh.2830390409; LEWIS SM, 1967, BRIT J HAEMATOL, V13, P236, DOI 10.1111/j.1365-2141.1967.tb08736.x; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PEYTREMANN R, 1972, SER HAEMATOL, V3, P115; PRAMOONJAGO P, 1995, BLOOD, V86, P1736, DOI 10.1182/blood.V86.5.1736.bloodjournal8651736; ROSSE WF, 1995, PRINCIPLES PRACTICE, P367; ROTOLI B, 1989, SEMIN HEMATOL, V26, P201; SASO R, 1995, EXP HEMATOL, V23, P866; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SPATHSCHWALBE E, 1995, DEUT MED WOCHENSCHR, V120, P1027, DOI 10.1055/s-2008-1055440; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TICHELLI A, 1994, LEUKEMIA LYMPHOMA, V12, P167, DOI 10.3109/10428199409059587; VANKAMP H, 1995, BRIT J HAEMATOL, V89, P79, DOI 10.1111/j.1365-2141.1995.tb08907.x; WARE RE, 1991, NEW ENGL J MED, V325, P91; YEH ETH, 1994, J CLIN INVEST, V93, P2305, DOI 10.1172/JCI117234	29	351	376	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					573	577		10.1016/S0140-6736(95)12360-1	http://dx.doi.org/10.1016/S0140-6736(95)12360-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774569				2022-12-28	WOS:A1996VF18600010
J	Bartley, M; Owen, C				Bartley, M; Owen, C			Relation between socioeconomic status, employment, and health during economic change, 1973-93	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; MEN; UNEMPLOYMENT	Objective-To investigate the association between the national unemployment rate and class differences in the relation between health and employment during the period 1973-93. Design-Data from general household surveys, 1973-93. Comparison of rates of employment, unemployment, and economic inactivity among those with and without limiting longstanding illness in different socioeconomic groups and how these varied over 20 years. Subjects-All men aged 20-59 years in each survey between 1973 and 1993. Main outcome measures-Change over time in class specific rates of employment, unemployment, and economic inactivity in those with and without limiting longstanding illness. Results-Men in socioeconomic groups 1 and 2 with no longstanding illness experienced little decrease in their chances of being in paid employment as the general unemployment rate rose. Those most affected were men in manual groups with limiting longstanding illness. The likelihood of paid employment was affected far less by such illness in non-manual than in manual groups. In group 1 about 85% of men with such illness were in paid employment in 1979 and 75% by 1993; in group 4 the equivalent proportions were 70% and 40%. In men in manual groups with limiting longstanding illness there was no sign of employment rates rising again as the economy recovered. Conclusion-Socioeconomic status makes large difference to the impact of illness on the ability to remain in paid employment, and this impact increases as unemployment rises. Men with chronic illness in manual occupations were not drawn back into the labour force during the economic recovery of the late 1980s.	UNIV LONDON,INST EDUC,THOMAS CORAM RES UNIT,LONDON WC1H 0AA,ENGLAND	University of London; University College London; UCL Institute of Education	Bartley, M (corresponding author), CITY UNIV LONDON,SOCIAL STAT RES UNIT,LONDON EC1V 0HB,ENGLAND.		Owen, Charlie/C-4457-2008	Owen, Charlie/0000-0002-4560-7477				ARBER S, 1987, BRIT MED J, V294, P1069, DOI 10.1136/bmj.294.6579.1069; ATKINSON AB, 1993, AGE WORK SOCIAL SECU; BLANE D, 1986, J ROYAL STAT SOC A, V159, P77; BLANE D, 1993, MED SOCIOLOGY RES CH; CARPENTER LM, 1987, BRIT J IND MED, V44, P289; *CENTR STAT OFF, 1994, SOC TRENDS 1992; Dale A., 1988, DOING SECONDARY ANAL; DUNNELL K, 1995, POPULATION TRENDS, V82, P12; FOX AJ, 1976, BR J PREV SOC MED, V9, P80; FOX AJ, 1982, LONGITUDINAL STUDY S; GOLDBLATT P, 1990, OPCS SERIES LS, V6; Hannay D R, 1978, J R Coll Gen Pract, V28, P492; HOUSE JS, 1990, MILBANK Q, V68, P383, DOI 10.2307/3350111; IVERSEN I, 1989, BRIT MED J, V295, P879; LAST JM, 1963, LANCET, V2, P28; LAWLOR J, 1990, EMPLOYMENT GAZET DEC, P601; McMichael AJ, 1976, J OCCUP MED, V17, P126; NICKELL S, 1995, OXFORD REV ECON POL, V11, P40, DOI 10.1093/oxrep/11.1.40; PIACHAUD D, 1986, J SOC POLICY, V15, P145, DOI 10.1017/S0047279400001641; SHAPER AG, 1984, BRIT HEART J, V51, P606; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595	21	175	177	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					445	449						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VE080	8776309				2022-12-28	WOS:A1996VE08000016
J	Carlisle, R; Johnstone, S				Carlisle, R; Johnstone, S			Factors influencing the response to advertisements for general practice vacancies	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To investigate the extent of problems in recruiting general practitioners and to determine which practice characteristics affect recruitment-in particular, to see if practices with deprived patients have more recruitment problems. Design-Postal questionnaire survey in August 1995. Subjects-489 consecutive practices that had advertised for a partner in the BMJ from January to April 1995. Main outcome measures-The number of applicants, the practices' satisfaction with their quantity and quality, and whether a successful appointment was made. Results-442 (90%) practices replied. 262 practices (60%) were not very satisfied or very dissatisfied with the number of applications they received; 15 (3%) received no applications. There was a significant difference in the number of applications received by practices in different NHS regions. The 32 practices with the highest proportions of patients eligible for deprivation payments received a median of five applicants compared with 10 for practices without deprivation. Conclusion-There is a widespread problem in recruiting general practitioners. Recruitment is hardest in areas with the greatest health needs.	N NOTTINGHAMSHIRE HLTH,DIRECTORATE PUBL HLTH & CLIN PRACTICE,RAINWORTH NG21 0ER,NOTTS,ENGLAND		Carlisle, R (corresponding author), UNIV NOTTINGHAM,DEPT GEN PRACTICE,QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND.							Altman DG., 1991, PRACTICAL STAT MED R, P241; DONALD AG, 1990, BRIT MED J, V301, P1060, DOI 10.1136/bmj.301.6760.1060; *GEN MED SERV COMM, 1994, REP GMSC RECR MOR TA; GRAY DP, 1990, PRACTITIONER, V234, P1011; Harris T, 1996, BRIT MED J, V312, P97; *MED PRACT COMM, 1995, MED PRACT COMM RECR; ROWSELL R, 1995, BRIT J GEN PRACT, V45, P601	7	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					468	471						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776317				2022-12-28	WOS:A1996VE08000024
J	Klassen, A; Fitzpatrick, R; Jenkinson, C; Goodacre, T				Klassen, A; Fitzpatrick, R; Jenkinson, C; Goodacre, T			Should breast reduction surgery be rationed? A comparison of the health status of patients before and after treatment: Postal questionnaire survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SF-36	Objectives-To assess the health status of patients before and after breast reduction surgery and to make comparisons with the health status of women in the general population. Design-Postal questionnaire survey sent to patients before and six months after surgery. Setting-The three plastic surgery departments in the Oxford Regional Health Authority, during April to August 1993. Subjects-166 women (over the age of 16 years) referred for breast reduction; scores from the ''short form 36'' (SF-36) health questionnaire completed by women in the 1991-2 Oxford healthy life survey. Main outcome measures-Health status of breast reduction patients before and after surgery as assessed by the SF-36, the 28 item general health questionnaire, and Rosenberg's self esteem scale; comparisons between the health status of breast reduction patients and that of women in the general population; outcome of surgery as assessed retrospectively by patients. Results-Differences between the health status of breast reduction patients and that of women in the general population were detected by the SF-36 both before and after surgery. Breast reduction surgery produced substantial change in patients' physical, social, and psychological function. The proportion of cases of possible psychiatric morbidity according to the general health questionnaire fell from 41% (22/54) before surgery to 11% (6/54) six months after treatment. Eighty six per cent (50/58) of patients expressed great satisfaction with the surgical result postoperatively. Conclusion-The study provides empirical evidence that supports the inclusion of breast reduction surgery in NHS purchasing contracts.	UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX3 7LF, ENGLAND; UNIV OXFORD, RADCLIFFE INFIRM, DEPT PUBL HLTH & PRIMARY CARE, HLTH SERV RES UNIT, OXFORD OX2 6HE, ENGLAND; RADCLIFFE INFIRM, DEPT PLAST & RECONSTRUCT SURG, OXFORD OX2 6HE, ENGLAND	University of Oxford; Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary			Goodacre, Timothy/AAY-7888-2020; Klassen, Anne F/AAS-3211-2021	Goodacre, Timothy/0000-0001-6812-2934; Klassen, Anne F/0000-0003-4720-0096				Bardsley M J, 1992, Qual Health Care, V1, P10, DOI 10.1136/qshc.1.1.10; BOWLING A, 1993, SOC SCI MED, V37, P851, DOI 10.1016/0277-9536(93)90138-T; Cohen J., 1988, STAT POWER ANAL BEHA, DOI DOI 10.1016/B978-0-12-179060-8.50006-2; COLE RP, 1994, BRIT J PLAST SURG, V47, P117, DOI 10.1016/0007-1226(94)90170-8; *DEP HLTH, 1994, HOSP EP STAT; DEYO RA, 1995, MED CARE, V33, pAS286; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; Fitzpatrick R, 1992, Qual Health Care, V1, P89, DOI 10.1136/qshc.1.2.89; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; *HC HLTH COMM, 1995, 1341 HC HLTH COMM; JENKINSON C, 1995, QUAL LIFE RES, V4, P47, DOI 10.1007/BF00434383; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; Jenkinson C, 1993, QUALITY LIFE MEASURE; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; KLEIN R, 1992, 7 NAT ASS HOSP TRUST; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1515/9781400876136; SODERLUND N, 1995, COST WEIGHTS CASEMIX; WRIGHT L, 1992, HLTH LIFESTYLES OXFO	19	90	91	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 24	1996	313	7055					454	457						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VE080	8776311				2022-12-28	WOS:A1996VE08000018
J	Rafferty, JB; Sedelnikova, SE; Hargreaves, D; Artymiuk, PJ; Baker, PJ; Sharples, GJ; Mahdi, AA; Lloyd, RG; Rice, DW				Rafferty, JB; Sedelnikova, SE; Hargreaves, D; Artymiuk, PJ; Baker, PJ; Sharples, GJ; Mahdi, AA; Lloyd, RG; Rice, DW			Crystal structure of DNA recombination protein RuvA and a model for its binding to the Holliday junction	SCIENCE			English	Article							ESCHERICHIA-COLI; BRANCH MIGRATION; HOMOLOGOUS RECOMBINATION; HELICASE ACTIVITY; HEXAMERIC RINGS; POLYMERASE-BETA; GENE-PRODUCT; RECG PROTEIN; IN-VITRO; RESOLUTION	The Escherichia coli DNA binding protein RuvA acts in concert with the helicase RuvB to drive branch migration of Holliday intermediates during recombination and DNA repair. The atomic structure of RuvA was determined at a resolution of 1.9 angstroms. Four monomers of RuvA are related by fourfold symmetry in a manner reminiscent of a four-petaled flower. The four DNA duplex arms of a Holliday junction can be modeled in a square planar configuration and docked into grooves on the concave surface of the protein around a central pin that may facilitate strand separation during the migration reaction. The model presented reveals how a RuvAB-junction complex may also accommodate the resolvase RuvC.	UNIV SHEFFIELD, KREBS INST, DEPT MOL BIOL & BIOTECHNOL, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND; UNIV NOTTINGHAM, QUEENS MED CTR, DEPT GENET, NOTTINGHAM NG7 2UH, ENGLAND	University of Sheffield; University of Nottingham			Sharples, Gary/B-8638-2016	Sharples, Gary/0000-0003-2495-0062; Baker, Patrick/0000-0003-1995-5643; Rafferty, John/0000-0003-1183-7474	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; ARNOTT S, 1969, ACTA CRYSTALL B-STRU, VB 25, P2192, DOI 10.1107/S0567740869005450; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BENNETT RJ, 1995, P NATL ACAD SCI USA, V92, P5635, DOI 10.1073/pnas.92.12.5635; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; DUNDERDALE HJ, 1994, J BIOL CHEM, V269, P5187; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GRINDLEY HM, 1993, J MOL BIOL, V229, P707, DOI 10.1006/jmbi.1993.1074; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HYDE H, 1994, J BIOL CHEM, V269, P5202; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB, P26; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LLOYD RG, IN PRESS CELLULAR MO; LOLL PJ, 1989, PROTEINS, V5, P183, DOI 10.1002/prot.340050302; MAESHIMA K, 1995, GENE, V160, P195, DOI 10.1016/0378-1119(95)00148-Y; Mahdi AA, 1996, J MOL BIOL, V257, P561, DOI 10.1006/jmbi.1996.0185; MANDAL TN, 1993, J BACTERIOL, V175, P4325, DOI 10.1128/JB.175.14.4325-4334.1993; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Palmer T. A., UNPUB; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SEDELNIKOVA SE, IN PRESS ACTA CRYS D; SHAH R, 1994, CELL, V79, P853, DOI 10.1016/0092-8674(94)90074-4; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHARPLES GJ, 1994, EMBO J, V13, P6133, DOI 10.1002/j.1460-2075.1994.tb06960.x; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; STAHL FW, 1994, GENETICS, V138, P241; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1994, J BIOL CHEM, V269, P26552; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; West SC, 1996, J BACTERIOL, V178, P1237, DOI 10.1128/jb.178.5.1237-1241.1996; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WHITBY M, UNPUB; WHITBY MC, 1994, EMBO J, V13, P5220, DOI 10.1002/j.1460-2075.1994.tb06853.x; White MF, 1996, J MOL BIOL, V257, P330, DOI 10.1006/jmbi.1996.0166; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	71	150	151	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	1996	274	5286					415	421		10.1126/science.274.5286.415	http://dx.doi.org/10.1126/science.274.5286.415			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832889				2022-12-28	WOS:A1996VN17300052
J	Grimes, DA; Daley, J; Delbanco, TL				Grimes, DA; Daley, J; Delbanco, TL			A 17-year-old mother seeking contraception	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PELVIC INFLAMMATORY DISEASE; MEDROXYPROGESTERONE ACETATE; BONE-DENSITY; PATIENT SATISFACTION; ADOLESCENT MOTHERS; DEPO-PROVERA; WOMEN; LEVONORGESTREL; TRIAL; RISK		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco								*A GUTTM I, 1994, SEX AM TEEN; ARROYO P, 1995, INT J GYNECOL OBSTET, V48, P269, DOI 10.1016/0020-7292(94)02284-6; BERENSON AB, 1993, PEDIATRICS, V92, P257; Brown S.S., 1995, BEST INTENTIONS UNIN; CORMIA FE, 1967, JAMA-J AM MED ASSOC, V201, P141; CUNDY T, 1994, BRIT MED J, V308, P247, DOI 10.1136/bmj.308.6923.247; CUNDY T, 1991, BRIT MED J, V303, P13, DOI 10.1136/bmj.303.6793.13; Davis AJ, 1996, J REPROD MED, V41, P407; DROEGEMUELLER W, 1989, AM J OBSTET GYNECOL, V161, P1407, DOI 10.1016/0002-9378(89)90705-9; FIHN SD, 1985, JAMA-J AM MED ASSOC, V254, P240, DOI 10.1001/jama.254.2.240; FORREST JD, 1990, FAM PLANN PERSPECT, V22, P206, DOI 10.2307/2135494; FORREST JD, 1989, NEED AVAILABILITY FI, P36; Gleicher N, 1979, Obstet Gynecol Surv, V34, P721, DOI 10.1097/00006254-197910000-00001; GRAY RH, 1985, LANCET, V1, P1046; GROU F, 1994, AM J OBSTET GYNECOL, V171, P1529, DOI 10.1016/0002-9378(94)90396-4; HAREL Z, 1995, J ADOLESCENT HEALTH, V16, P379, DOI 10.1016/S1054-139X(95)00094-9; HO PC, 1993, HUM REPROD, V8, P389, DOI 10.1093/oxfordjournals.humrep.a138057; JONES EF, 1985, FAM PLANN PERSPECT, V17, P53, DOI 10.2307/2135261; JONES EF, 1992, FAM PLANN PERSPECT, V24, P12, DOI 10.2307/2135719; JONES KP, 1994, AM J OBSTET GYNECOL, V170, P1575; Kato K, 1995, Zentralbl Gynakol, V117, P260; KAUNITZ AM, 1994, AM J OBSTET GYNECOL, V170, P1548; KOOIKER CH, 1990, WESTERN J MED, V153, P279; MAINWARING R, 1995, CONTRACEPTION, V51, P149, DOI 10.1016/0010-7824(95)00011-X; MARX PA, 1996, AM SOC CLIN INV MAY; MASTROIANNI L, 1990, DEV NEW CONTRACEPTIV, P118; MCGREGOR JA, 1993, AM J OBSTET GYNECOL, V168, P2033, DOI 10.1016/S0002-9378(12)90946-1; MOORE KA, 1989, FAM PLANN PERSPECT, V21, P110, DOI 10.2307/2135660; NAESSEN T, 1995, CONTRACEPTION, V52, P35, DOI 10.1016/0010-7824(95)00121-P; PARIANI S, 1991, STUD FAMILY PLANN, V22, P384, DOI 10.2307/1966452; PETERSEN KR, 1994, AM J OBSTET GYNECOL, V171, P400, DOI 10.1016/S0002-9378(94)70041-9; POLANECZKY M, 1994, NEW ENGL J MED, V331, P1201, DOI 10.1056/NEJM199411033311806; RECKER RR, 1992, JAMA-J AM MED ASSOC, V268, P2403, DOI 10.1001/jama.268.17.2403; REUBINOFF BE, 1995, FERTIL STERIL, V68, P516; ROSSNER S, 1995, OBES RES, V3, pS267; RYDEN G, 1979, CONTRACEPTION, V20, P149, DOI 10.1016/0010-7824(79)90087-8; SALEH WA, 1993, AM J OBSTET GYNECOL, V168, P1740, DOI 10.1016/0002-9378(93)90685-C; Sawaya GF, 1996, OBSTET GYNECOL, V87, P884; SEITZ V, 1993, AM J ORTHOPSYCHIAT, V63, P572, DOI 10.1037/h0079483; SINEI SKA, 1990, BRIT J OBSTET GYNAEC, V97, P412, DOI 10.1111/j.1471-0528.1990.tb01828.x; SMITH RD, 1995, ADOLESCENT PEDIAT G, V8, P24, DOI 10.1016/S0932-8610(12)80157-5; Srinivasan SR, 1996, METABOLISM, V45, P235, DOI 10.1016/S0026-0495(96)90060-8; TRUSSELL J, 1995, AM J PUBLIC HEALTH, V85, P494, DOI 10.2105/AJPH.85.4.494; TRUSSELL J, 1990, STUD FAMILY PLANN, V21, P51, DOI 10.2307/1966591; *US PREV SERV TASK, 1995, GUID CLIN PREV SERV; Virutamasen P, 1994, Asia Oceania J Obstet Gynaecol, V20, P269; WALSH TL, 1994, CONTRACEPTION, V50, P319, DOI 10.1016/0010-7824(94)90019-1; WOODS ER, 1992, AM J OBSTET GYNECOL, V166, P901, DOI 10.1016/0002-9378(92)91359-I; ZABIN LS, 1979, FAM PLANN PERSPECT, V11, P215, DOI 10.2307/2134252	49	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1163	1170		10.1001/jama.276.14.1163	http://dx.doi.org/10.1001/jama.276.14.1163			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VL332	8827970				2022-12-28	WOS:A1996VL33200027
J	Seddon, JM; Willett, WC; Speizer, FE; Hankinson, SE				Seddon, JM; Willett, WC; Speizer, FE; Hankinson, SE			A prospective study of cigarette smoking and age-related macular degeneration in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VITAMIN-C; PLASMA; RISK; SMOKERS; HEART; EYE	Objective.-To evaluate the relationship between cigarette smoking acid incidence of age-related macular degeneration (AMD) among women. Design.-Prospective cohort study with 12 years of follow-up (1980 to 1992), in which information on smoking habits was updated every 2 years. Setting.-Eleven states throughout the United States. Participants.-A total of 31 843 registered nurses enrolled in the Nurses' Health Study who were aged 50 to 59 years in 1980 and did not report a diagnosis of cancer or AMD at the beginning of the study. Additional women entered the analytic cohort as they reached 50 years of age. Main Outcome Measure.-Incidence of AMD with visual loss. Results.-During 556 338 person-years of follow-up, 215 women were newly diagnosed as having AMD. After adjusting for other risk factors for AMD, women who currently smoked 25 or more cigarettes per day had a relative risk (RR) of AMD of 2.4 (95% confidence interval [CI], 1.4-4.0) compared with women who never smoked. Past smokers of this amount also had a 2-fold increased risk (RR=2.0; 95% CI, 1.2-3.4) relative to never smokers. Compared with current smokers, little reduction in risk was suggested even after quitting smoking for 15 or more years. Risk of AMD also increased with an increasing number of pack-years smoked (P for trend <.001); among women who smoked for 65 or more pack-years, the risk was 2.4 times the risk of never smokers (95% CI, 1.5-3.8). Analyses of dry and exudative types of AMD and other alternative definitions of AMD revealed similar results, Conclusions.-Cigarette smoking is an independent and avoidable risk factor for AMD among women. Because AMD is the most common cause of severe visual impairment among the elderly and treatment is not available or is ineffective for most patients, reducing the risk of this disease is another important reason to avoid smoking.	BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT OPHTHALMOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Seddon, JM (corresponding author), MASSACHUSETTS EYE & EAR INFIRM,DEPT OPHTHALMOL,EPIDEMIOL UNIT,243 CHARLES ST,BOSTON,MA 02114, USA.				NCI NIH HHS [CA 40356] Funding Source: Medline; NEI NIH HHS [EY 09611] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009611] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BETMAN J, 1958, ARCH OPHTHALMOL-CHIC, V59, P481; BLACKMAN BC, 1984, ANN NY ACAD SCI, V435, P385, DOI 10.1111/j.1749-6632.1984.tb13828.x; CHOW CK, 1986, J AM COLL NUTR, V5, P305; COX DR, 1972, J R STAT SOC B, V34, P187; GREENLAND S, 1984, STAT MED, V3, P131, DOI 10.1002/sim.4780030206; HANKINSON SE, 1992, JAMA-J AM MED ASSOC, V268, P994, DOI 10.1001/jama.268.8.994; HOSMER DW, 1989, APPL LOGISTIC REGRES; HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629; KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429; KLEIN R, 1992, OPHTHALMOLOGY, V99, P933; KLEIN R, 1993, AM J EPIDEMIOL, V137, P191; *NAT ADV EY COUNC, 1993, NAT I HLTH PUBL; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; U.S. Department of Health and Human Services, 1990, US DEP HLTH HUM SERV; *US DEP HHS, 1983, HLTH CONS SMOK CARD; WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038; WILLETT W, 1983, AM HEART J, V105, P417, DOI 10.1016/0002-8703(83)90358-7; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; Willett WC, 1996, JAMA-J AM MED ASSOC, V275, P458, DOI 10.1001/jama.275.6.458; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1992, ARCH OPHTHALMOL-CHIC, V110, P1701; 1993, ARCH OPHTHALMOL-CHIC, V111, P104; 1986, ARCH OPHTHALMOL-CHIC, V104, P503	25	377	383	0	33	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1141	1146		10.1001/jama.276.14.1141	http://dx.doi.org/10.1001/jama.276.14.1141			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827966				2022-12-28	WOS:A1996VL33200023
J	Irvine, WM; BockeleeMorvan, D; Lis, DC; Matthews, HE; Biver, N; Crovisier, J; Davies, JK; Dent, WRF; Gautier, D; Godfrey, PD; Keene, J; Lovell, AJ; Owen, TC; Phillips, TG; Rauer, H; Schloerb, FP; Senay, M; Young, K				Irvine, WM; BockeleeMorvan, D; Lis, DC; Matthews, HE; Biver, N; Crovisier, J; Davies, JK; Dent, WRF; Gautier, D; Godfrey, PD; Keene, J; Lovell, AJ; Owen, TC; Phillips, TG; Rauer, H; Schloerb, FP; Senay, M; Young, K			Spectroscopic evidence for interstellar ices in comet Hyakutake	NATURE			English	Article							ABSORPTION FEATURES; ABUNDANCE RATIO; HNC; HCN; CHEMISTRY; MOLECULES; CLOUDS; WATER	VOLATILE compounds in comets are the most pristine materials surviving from the time of formation of the Solar System, and thus potentially provide information about conditions that prevailed in the primitive solar nebula(1-3). Moreover, comets may have supplied a substantial fraction of the volatiles on the terrestrial planets, perhaps including organic compounds that played a role in the origin of life on Earth(4-6), Here we report the detection of hydrogen isocyanide (HNC) in comet Hyakutake. The abundance of HNC relative to hydrogen cyanide (HCN) is very similar to that observed in quiescent interstellar molecular clouds, and quite different from the equilibrium ratio expected in the outermost solar nebula, where comets are thought to form. Such a departure from equilibrium has long been considered a hallmark of gas-phase chemical processing in the interstellar medium(7), suggesting that interstellar gases have been incorporated into the comet's nucleus, perhaps as ices frozen onto interstellar grains. If this interpretation is correct, our results should provide constraints on the temperature of the solar nebula, and the subsequent chemical processes that occurred in the region where comets formed.	OBSERV PARIS, F-92195 MEUDON, FRANCE; MONASH UNIV, DEPT CHEM, CLAYTON, VIC 3168, AUSTRALIA; UNIV HAWAII, INST ASTRON, HONOLULU, HI 96822 USA; CALTECH, DOWN LAB PHYS 32047, PASADENA, CA 91125 USA; NATL RES COUNCIL CANADA, HERZBERG INST ASTROPHYS, OTTAWA, ON K1A 0R6, CANADA; JOINT ASTRON CTR, HILO, HI 96720 USA	UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Monash University; University of Hawaii System; California Institute of Technology; National Research Council Canada	Irvine, WM (corresponding author), UNIV MASSACHUSETTS, FIVE COLL RADIO ASTRON OBSERV, 619 LGRC, AMHERST, MA 01003 USA.			Lis, Dariusz/0000-0002-0500-4700				Bergin EA, 1996, ASTROPHYS J, V460, P343, DOI 10.1086/176974; BERNSTEIN MP, 1995, ASTROPHYS J, V454, P327, DOI 10.1086/176485; BOCKELEEMORVAN D, 1984, ASTRON ASTROPHYS, V141, P411; BROWN PD, 1988, MON NOT R ASTRON SOC, V231, P409, DOI 10.1093/mnras/231.2.409; BROWN RD, 1977, NATURE, V270, P39, DOI 10.1038/270039a0; BROWN RD, 1989, ASTROPHYS J, V347, P855, DOI 10.1086/168175; CRONIN JR, 1993, NATO ADV SCI INST SE, V416, P209; CROVISIER J, 1984, ASTRON ASTROPHYS, V130, P361; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; CROVISIER J, 1994, IAU SYMP, P313; DEISEMME AH, 1991, FRONTEIRS LIFE, P105; DESFORETS GP, 1990, MON NOT R ASTRON SOC, V244, P668; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; Fegley B.J., 1989, FORMATION EVOLUTION, P171; GOLDSMITH PF, 1986, ASTROPHYS J, V310, P383, DOI 10.1086/164692; GOLDSMITH PF, 1981, ASTROPHYS J, V249, P524, DOI 10.1086/159312; GREENBERG JM, 1994, IAU SYMP, P327; GREENBERG JM, 1993, NATO ADV SCI INST SE, V416, P195; GREENBERG JM, 1992, ADV SPACE RES-SERIES, V12, P169; HERZBERG G, 1966, ELECT SPECTRA ELECT, P494; Huebner W. F., 1991, COMETS POST HALLEY E, V2, P907; Irvine W. M., 1987, INTERSTELLAR PROCESS, V134, P561; IRVINE WM, 1985, PROTOSTARS PLANETS, V2, P579; Irvine WM, 1989, ORIGIN EVOLUTION PLA, P3; LACY JH, 1984, ASTROPHYS J, V276, P533, DOI 10.1086/161642; LARSON HP, 1985, ASTROPHYS J, V299, P873, DOI 10.1086/163754; LIS D, 1996, 6362 IAU; MATTHEWS HE, 1996, 6353 IAU; MILLIGAN DE, 1967, J CHEM PHYS, V47, P278, DOI 10.1063/1.1711859; Mumma M. J., 1993, PROTOSTARS PLANETS, P1177; MUMMA MJ, 1996, 6366 IAU; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; SCHILKE P, 1992, ASTRON ASTROPHYS, V256, P595; SWADE DA, 1987, COMETARY RADIO ASTRO, P79; Watson W. D., 1980, International Astronomical Union Symposium. No.87. Interstellar Molecules, P341	35	109	110	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					418	420		10.1038/383418a0	http://dx.doi.org/10.1038/383418a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837771				2022-12-28	WOS:A1996VL46300055
J	Lala, DS; Mukherjee, R; Schulman, IG; Koch, SSC; Dardashti, LJ; Nadzan, AM; Croston, GE; Evans, RM; Heyman, RA				Lala, DS; Mukherjee, R; Schulman, IG; Koch, SSC; Dardashti, LJ; Nadzan, AM; Croston, GE; Evans, RM; Heyman, RA			Activation of specific RXR heterodimers by an antagonist of RXR homodimers	NATURE			English	Article							9-CIS RETINOIC ACID; NUCLEAR HORMONE RECEPTORS; LIGAND-BINDING DOMAIN; CO-REPRESSOR; X RECEPTOR; RESPONSE PATHWAYS; CRYSTAL-STRUCTURE; TRANSACTIVATION; ALPHA; RAR	RETINOID X receptor (RXR) plays a central role in the regulation a of many intracellular receptor signalling pathways(1) and can mediate ligand-dependent transcription, acting as a homodimer or as a heterodimer(1-6). Here we identify an antagonist towards RXR homodimers which also functions as an agonist when RXR is paired as a heterodimer to specific partners, including peroxisome proliferator-activated receptor and retinoic acid receptor. This dimer-selective ligand confers differential interactions on the transcription machinery: the antagonist promotes association with TAF110) (TATA-binding protein (TBP)-associated factor 110) and the co-repressor SMRT(7), but not with TBP, and these properties are distinct from pure RXR agonists. This unique class of RXR ligands will provide a means to control distinct target genes at the level of transcription and allow the development of retinoids with a new pharmacological action.	LIGAND PHARMACEUT INC, DEPT RETINOID RES, SAN DIEGO, CA 92121 USA; LIGAND PHARMACEUT INC, DEPT CARDIOVASC RES, SAN DIEGO, CA 92121 USA; LIGAND PHARMACEUT INC, DEPT RETINOID CHEM, SAN DIEGO, CA 92121 USA; LIGAND PHARMACEUT INC, DEPT NEW LEADS, SAN DIEGO, CA 92121 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA	Ligand Pharmaceuticals; Ligand Pharmaceuticals; Ligand Pharmaceuticals; Ligand Pharmaceuticals; Salk Institute			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Koch SSC, 1996, J MED CHEM, V39, P3229, DOI 10.1021/jm960311d; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LANOTTE M, 1991, BLOOD, V77, P1080; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; ROY DY, 1995, MOL CELL BIOL, V15, P6481; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033	30	150	153	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	1996	383	6599					450	453		10.1038/383450a0	http://dx.doi.org/10.1038/383450a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837780				2022-12-28	WOS:A1996VL46300066
J	Kapp, MB				Kapp, MB			Managed care and mandatory movies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1996	276	13					1023	1023		10.1001/jama.276.13.1023	http://dx.doi.org/10.1001/jama.276.13.1023			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK035	8847753				2022-12-28	WOS:A1996VK03500007
J	Gorsche, RG; Verstraten, KL				Gorsche, RG; Verstraten, KL			A butcher with sharp pains in his arms	LANCET			English	Article																		*ALB HLTH PROV ALB, 1994, STAT REP SEX TRANSM; CAREY LA, 1995, ARCH INTERN MED, V155, P1657, DOI 10.1001/archinte.155.15.1657; ROLFS RT, 1990, JAMA-J AM MED ASSOC, V264, P825	3	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 28	1996	348	9031					862	862		10.1016/S0140-6736(96)06075-8	http://dx.doi.org/10.1016/S0140-6736(96)06075-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826813				2022-12-28	WOS:A1996VK03700013
J	Yang, YP; Wilson, JM				Yang, YP; Wilson, JM			CD40 ligand-dependent T cell activation: Requirement of B7-CD28 signaling through CD40	SCIENCE			English	Article							X-LINKED IMMUNODEFICIENCY; HYPER-IGM SYNDROME; MICE; GENE; DEFICIENT; EXPRESSION	The role of CD40 ligand (CD40L) in the primary activation of T cells is not clear. The cellular and humoral immune responses to adenoviral vectors in a murine model of liver-directed gene transfer were studied to define the mechanisms responsible for CD40L-dependent T cell priming. CD40L-deficient mice did not develop effective cytotoxic T cells to transduced hepatocytes, and T cell-dependent B cell responses were absent. Full reconstitution of cellular and humoral immunity was achieved in CD40L-deficient mice by administration of an activating antibody to CD40 that increased expression of B7.2 on spleen cells. Wild-type mice could be made nonresponsive to vector by administration of antibodies to B7. Thus, CD40L-dependent activation of T cells occurs through signaling of CD40 in the antigen-presenting cell to enhance requisite costimulatory pathways that include B7.	WISTAR INST ANAT & BIOL,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT MOL & CELLULAR ENGN,PHILADELPHIA,PA 19104	The Wistar Institute; University of Pennsylvania; University of Pennsylvania			Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ALLISON JP, 1995, SCIENCE, V270, P932, DOI 10.1126/science.270.5238.932; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; HASBOLD J, 1994, EUR J IMMUNOL, V24, P1835, DOI 10.1002/eji.1830240817; Kamanaka M, 1996, IMMUNITY, V4, P275, DOI 10.1016/S1074-7613(00)80435-5; KAY MA, 1995, NAT GENET, V11, P191, DOI 10.1038/ng1095-191; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; LI QT, 1993, HUM GENE THER, V4, P403, DOI 10.1089/hum.1993.4.4-403; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; Soong L, 1996, IMMUNITY, V4, P263, DOI 10.1016/S1074-7613(00)80434-3; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; WU Y, 1995, CURR BIOL, V5, P1303, DOI 10.1016/S0960-9822(95)00257-0; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; Yang YP, 1996, J VIROL, V70, P6370, DOI 10.1128/JVI.70.9.6370-6377.1996; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1995, NAT MED, V1, P890, DOI 10.1038/nm0995-890; YANG YP, 1994, IMMUNITY, V1, P433, DOI 10.1016/1074-7613(94)90074-4; ZSENGELLER ZK, 1995, HUM GENE THER, V6, P457, DOI 10.1089/hum.1995.6.4-457	24	351	364	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1862	1864		10.1126/science.273.5283.1862	http://dx.doi.org/10.1126/science.273.5283.1862			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791591				2022-12-28	WOS:A1996VJ71300045
J	Trunkey, D				Trunkey, D			Trauma systems at risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Trunkey, D (corresponding author), OREGON HLTH SCI UNIV,DEPT SURG,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.							*COMM APPR SUBC LA, 1996, 104 C 2 SESS JUN 20; Cornwell EE, 1996, JAMA-J AM MED ASSOC, V276, P940, DOI 10.1001/jama.276.12.940; Mitchell F L Jr, 1996, Bull Am Coll Surg, V81, P20; Violence prevention task force of the eastern association for the surgery of trauma: violence, 1995, J TRAUMA, V38, P163; 1976, B AM COLL SURG, V161, P15	5	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1996	276	12					944	945		10.1001/jama.276.12.944	http://dx.doi.org/10.1001/jama.276.12.944			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH990	8805717				2022-12-28	WOS:A1996VH99000015
J	LeDeist, F; Emile, JF; RieuxLaucat, F; Benkerrou, M; Roberts, I; Brousse, N; Fischer, A				LeDeist, F; Emile, JF; RieuxLaucat, F; Benkerrou, M; Roberts, I; Brousse, N; Fischer, A			Clinical, immunological, and pathological consequences of Fas-deficient conditions	LANCET			English	Article							LYMPHOPROLIFERATIVE SYNDROME; T-LYMPHOCYTES; DEATH DOMAIN; CELL-DEATH; APOPTOSIS; ANTIGEN; MUTATIONS; INTERACTS; PROTEIN; CD95	Background The surface molecule named Fas/CD95, which is expressed on activated lymphocytes, can trigger cell death following interaction with its ligand (Fas L). This Fas-Fas-L interaction is thought to be a major regulatory mechanism for controlling the life span of peripheral lymphocytes, and therefore autoimmunity. Methods We assessed clinical, immunological and pathological features in three children who inherited mutations of the Fas-encoding gene. One infant had a genomic homozygous deletion, while two siblings had a heterozygous mutation in the fas gene. Findings The patient with a complete lack of Fas protein expression had prenatal onset of massive lymphoproliferation, which involved the spleen, the liver, and the intrathoracic and abdominal lymph nodes. Lymphoproliferation mainly involved T cells negative for the CD4 and CD8 receptors. These cells, which had a high mitotic index, were essentially found in the T cell zones of lymphoid organs. Active cell division was indicated by a rapid rise in the lymphocyte count following a chemotherapy-induced reduction in the lymphocyte burden. Despite the total Fas protein deficiency, limited autoimmunity was found in this child at age 1 year. A lymphoproliferative syndrome with similar characteristics-but less intense than in the patient with complete Fas deficiency-also occurred from a young age in the siblings with a fas gene mutation on one allele only. One sibling developed neutropoenia, autoimmune haemolytic anaemia, and severe recurrent thrombocytopoenia. Interpretation Fas-deficiency causes non-malignant syndrome characterised by the accumulation of dividing lymphocytes. Severity of disease is probably related to the degree of functional Fas deficiency. Heterozygous fas gene mutations, like homozygous deletions, can also be expressed in various cells acid tissues and may predispose towards autoimmune disorders. Fas deficiency should be considered in children with enlarged peripheral lymphoid organs and hyperimmunoglobulinaemia, and sometimes the occurrence of autoimmune manifestations towards blood cells.	HOP NECKER ENFANTS MALAD,UNITE IMMUNOL & HEMATOL,PARIS,FRANCE; HOP NECKER ENFANTS MALAD,LAB ANATOMOPATHOL,PARIS,FRANCE; UNIV PARIS 05,PARIS,FRANCE; HAMMERSMITH HOSP,DEPT HAEMATOL,LONDON,ENGLAND	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Imperial College London	LeDeist, F (corresponding author), HOP NECKER ENFANTS MALAD,INSERM U429,149 RUE SEVRES,F-75743 PARIS 15,FRANCE.		Rieux-Laucat, Frédéric/A-7916-2017	Rieux-Laucat, Frédéric/0000-0001-7858-7866				ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; KISSCHKEL F, 1995, EMBO, V14, P5579; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; MASON DY, 1978, J CLIN PATHOL, V31, P454, DOI 10.1136/jcp.31.5.454; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; RATHMELL JC, 1994, J IMMUNOL, V153, P2831; RIEUXLAUCAT F, 1993, EUR J IMMUNOL, V23, P928, DOI 10.1002/eji.1830230425; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Roths J.B., 1987, NEW HORIZONS ANIMAL, P21; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SNELLER MC, 1992, J CLIN INVEST, V90, P334, DOI 10.1172/JCI115867; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1	20	155	158	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					719	723		10.1016/S0140-6736(96)02293-3	http://dx.doi.org/10.1016/S0140-6736(96)02293-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806292				2022-12-28	WOS:A1996VG37400012
J	Staessen, JA				Staessen, JA			Potential adverse effects of blood pressure lowering - J-curve revisited	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION				Staessen, JA (corresponding author), KATHOLIEKE UNIV LEUVEN,DEPT CARDIOL,B-3000 LOUVAIN,BELGIUM.		Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				CARLSSON A, 1993, STROKE, V24, P195, DOI 10.1161/01.STR.24.2.195; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; KANNEL WB, 1980, AM J CARDIOL, V45, P326, DOI 10.1016/0002-9149(80)90654-2; Merlo J, 1996, BRIT MED J, V313, P457; Rodgers A, 1996, BRIT MED J, V313, P147, DOI 10.1136/bmj.313.7050.147; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; WITTEMAN JCM, 1994, LANCET, V343, P504, DOI 10.1016/S0140-6736(94)91459-1	9	15	17	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					696	697		10.1016/S0140-6736(05)65599-7	http://dx.doi.org/10.1016/S0140-6736(05)65599-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806284				2022-12-28	WOS:A1996VG37400003
J	Beckwith, SVW; Sargent, AI				Beckwith, SVW; Sargent, AI			Circumstellar disks and the search for neighbouring planetary systems	NATURE			English	Review							T-TAURI STARS; MAIN-SEQUENCE STARS; YOUNG STELLAR OBJECTS; ACCRETION DISKS; BETA-PICTORIS; BROWN DWARF; HL-TAURI; UNSEEN COMPANIONS; INFRARED-SPECTRA; MOLECULAR CLOUDS	The recent discoveries of planets orbiting several 'mature' stars bring new life to the question of just how common other planetary systems might be. Observations of very young stars provide a way to address this question and suggest that a significant number of such stars harbour conditions appropriate for the formation of planetary systems like our own.	CALTECH,OWENS VALLEY RADIO OBSERV 10524,PASADENA,CA 91125	California Institute of Technology	Beckwith, SVW (corresponding author), MAX PLANCK INST ASTRON,KONIGSTUHL 17,D-69117 HEIDELBERG,GERMANY.							ADAMS FC, 1986, ASTROPHYS J, V308, P836, DOI 10.1086/164555; ADAMS FC, 1988, ASTROPHYS J, V326, P865, DOI 10.1086/166144; AGLADZE NI, 1994, NATURE, V372, P243, DOI 10.1038/372243a0; ALCOCK C, 1993, NATURE, V365, P619; ANDRE P, 1994, ASTROPHYS J, V420, P837, DOI 10.1086/173608; ANGEL JRP, 1994, NATURE, V368, P203, DOI 10.1038/368203a0; AUBOURG E, 1993, NATURE, V365, P623, DOI 10.1038/365623a0; AUMANN HH, 1984, ASTROPHYS J, V278, pL23, DOI 10.1086/184214; Backman D. E., 1993, PROTOSTARS PLANETS, P1253; BAHCALL JN, 1994, ASTROPHYS J, V435, pL51, DOI 10.1086/187592; BASRI G, IN PRESS ASTROPHYS J; BECKWITH S, 1986, ASTROPHYS J, V309, P755, DOI 10.1086/164645; BECKWITH SVW, 1990, ASTRON J, V99, P924, DOI 10.1086/115385; BECKWITH SVW, 1991, ASTROPHYS J, V381, P250, DOI 10.1086/170646; BERTOUT C, 1989, ANNU REV ASTRON ASTR, V27, P351; BODENHEIMER P, 1995, ANNU REV ASTRON ASTR, V33, P199; BOSS AP, 1993, ASTROPHYS J, V411, pL99, DOI 10.1086/186922; BOSS AP, 1988, ASTROPHYS J, V331, P370, DOI 10.1086/166563; BURROWS A, 1993, REV MOD PHYS, V65, P301, DOI 10.1103/RevModPhys.65.301; BURROWS C, IN PRESS ASTROPHYS J; Butler RP, 1996, ASTROPHYS J, V464, pL153, DOI 10.1086/310102; CAMERON AGW, 1988, ANNU REV ASTRON ASTR, V26, P441; COHEN M, 1989, ASTROPHYS J, V339, P455, DOI 10.1086/167310; DUQUENNOY A, 1991, ASTRON ASTROPHYS, V248, P485; DUTREY A, 1994, ASTRON ASTROPHYS, V286, P149; ELSASSER H, 1978, ASTRON ASTROPHYS, V70, pL3; Guillot T, 1996, ASTROPHYS J, V459, pL35, DOI 10.1086/309935; HARTMANN L, 1991, ASTRON J, V101, P1050, DOI 10.1086/115747; JENSEN ELN, 1994, ASTROPHYS J, V429, pL29, DOI 10.1086/187405; KNACKE RF, 1993, ASTROPHYS J, V418, P440, DOI 10.1086/173405; KOEMER DW, 1995, ASTRON J, V109, P2138; LADA CJ, 1993, ASTROPHYS J, V408, P471, DOI 10.1086/172605; LADD EF, 1993, ASTROPHYS J, V410, P168, DOI 10.1086/172735; LAGAGE PO, 1994, NATURE, V369, P628, DOI 10.1038/369628a0; LATHAM DW, 1989, NATURE, V339, P38, DOI 10.1038/339038a0; LAY OP, 1994, ASTROPHYS J, V434, pL75, DOI 10.1086/187578; MANNINGS V, 1994, MON NOT R ASTRON SOC, V267, P361, DOI 10.1093/mnras/267.2.361; Marcel G., 1994, BOTTOM MAIN SEQUENCE, P99; Marcy GW, 1996, ASTROPHYS J, V464, pL147, DOI 10.1086/310096; MARSH KA, 1992, ASTROPHYS J, V395, pL115, DOI 10.1086/186501; MCCAUGHREAN MJ, 1996, C R ASTRON J, V111, P1977; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MIZUNO H, 1988, ASTRON ASTROPHYS, V195, P183; MIZUNO H, 1980, PROG THEOR PHYS, V64, P544, DOI 10.1143/PTP.64.544; MUNDY LG, IN PRESS ASTROPHYS J; NAKAJIMA T, 1995, NATURE, V378, P463, DOI 10.1038/378463a0; ODELL CR, 1994, ASTROPHYS J, V436, P194, DOI 10.1086/174892; OSSENKOPF V, 1994, ASTRON ASTROPHYS, V291, P943; OSTERLOH M, 1995, ASTROPHYS J, V439, P288, DOI 10.1086/175172; PACZYNSKI B, 1986, ASTROPHYS J, V304, P1, DOI 10.1086/164140; PARRY IR, 1995, C SER ASTRON SOC PAC, V84, P124; POLLACK JB, 1994, ASTROPHYS J, V421, P615, DOI 10.1086/173677; REBOLO R, 1995, NATURE, V377, P129, DOI 10.1038/377129a0; Safronov V S., 1969, EVOLUTION PROTOPLANE; SAITO M, 1995, ASTROPHYS J, V453, P384, DOI 10.1086/176398; SARGENT AI, 1987, ASTROPHYS J, V323, P294, DOI 10.1086/165827; SARGENT AI, 1991, ASTROPHYS J, V382, pL31, DOI 10.1086/186207; SCHOPF JW, 1992, MAJOR EVENTS HIST LI, P235; SHKLOVSKIL IS, 1996, INTELLIGENT LIFE UNI; SHU F, 1993, PROTOSTARS PLANETS, V3, P3; SHU FH, 1987, ANNU REV ASTRON ASTR, V25, P23, DOI 10.1146/annurev.aa.25.090187.000323; SKRUTSKIE MF, 1990, ASTRON J, V99, P1187, DOI 10.1086/115407; SKUTSKIE MF, 1991, ASTRON J, V102, P1749; SMITH BA, 1984, SCIENCE, V226, P1421, DOI 10.1126/science.226.4681.1421; STAUFFER JR, 1994, ASTRON J, V108, P155, DOI 10.1086/117053; STAUFFER JR, 1994, ASTRON J, V108, P1375, DOI 10.1086/117159; STEVENSON DJ, 1982, PLANET SPACE SCI, V30, P755, DOI 10.1016/0032-0633(82)90108-8; STROM KM, 1989, ASTRON J, V97, P1451, DOI 10.1086/115085; STROM KM, 1995, ASTROPHYS J, V438, P813, DOI 10.1086/175125; Strom S. E., 1993, PROTOSTARS PLANETS, P837; UDALSKI A, 1994, ASTROPHYS J, V426, pL69, DOI 10.1086/187342; WALTER FM, 1988, ASTRON J, V96, P297, DOI 10.1086/114809; Weidenschilling S.J., 1993, PROTOSTARS PLANETS, P1031; WEIDENSCHILLING SJ, 1987, GERL BEITR GEOPHYS, V96, P21; WETHERILL GW, 1990, ANNU REV EARTH PL SC, V18, P205, DOI 10.1146/annurev.ea.18.050190.001225; WETHERILL GW, 1991, SCIENCE, V253, P535, DOI 10.1126/science.253.5019.535; WOLSZCZAN A, 1992, NATURE, V355, P145, DOI 10.1038/355145a0; Wood J. A., 1988, METEORITES EARLY SOL, P329; ZUCKERMAN B, 1995, NATURE, V373, P494, DOI 10.1038/373494a0; ZUCKERMAN B, 1993, ASTROPHYS J, V414, P793, DOI 10.1086/173123	82	229	231	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					139	144		10.1038/383139a0	http://dx.doi.org/10.1038/383139a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774877				2022-12-28	WOS:A1996VG14800042
J	Phillips, AN; Smith, GD; Johnson, MA				Phillips, AN; Smith, GD; Johnson, MA			Will we ever know when to treat HIV infection?	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PLACEBO-CONTROLLED TRIAL; CUBIC MILLIMETER; DOUBLE-BLIND; DEFERRED ZIDOVUDINE; CELL COUNTS; AIDS; IMMEDIATE; EFFICACY; CONCORDE	Confidence in the efficacy of using antiretroviral drugs to treat HIV infection has grown in the past year as a result of the prolonged survival of those randomly allocated to receive an additional drug in comparative controlled trials, HIV remains, however, the only serious infectious disease for which antimicrobial treatment is deliberately delayed. This is because infected subjects can often be symptomless for more than a decade in the absence of any treatment, and results from trials with the nucleoside analogue reverse transcriptase inhibitor zidovudine have failed to show any evidence for extended survival in those beginning treatment early compared with those who deferred treatment. The new confidence in currently available treatments, and in the prospects for new ones, inevitably leads to renewed questioning of the current strategy of waiting for signs of immune deficiency before electing to intervene. A new randomised controlled trial comparing strategies of early and deferred treatment is required to assess whether the time has come for intervention immediately after HIV has been diagnosed.	UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND; ROYAL FREE HOSP, DEPT THORAC MED, LONDON NW3 2QG, ENGLAND	University of Bristol; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Phillips, AN (corresponding author), ROYAL FREE HOSP, SCH MED, HIV RES UNIT, DEPT PRIMARY CARE & POPULAT SCI, LONDON NW3 2PF, ENGLAND.		Phillips, Andrew N/B-4427-2008; Davey Smith, George/A-7407-2013	Phillips, Andrew N/0000-0003-2384-4807; Davey Smith, George/0000-0002-1407-8314				BARTLETT JG, 1993, NEW ENGL J MED, V329, P351, DOI 10.1056/NEJM199307293290510; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; COREY L, 1992, NEW ENGL J MED, V326, P484, DOI 10.1056/NEJM199202133260710; EGGER M, 1994, LANCET, V343, P1355, DOI 10.1016/S0140-6736(94)92490-2; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GAZZARD BG, 1993, BRIT MED J, V306, P1016, DOI 10.1136/bmj.306.6884.1016; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; JAMES JS, 1993, AIDS TREATMENT NEWS; LENDERKING WR, 1994, NEW ENGL J MED, V330, P738, DOI 10.1056/NEJM199403173301102; MULDER JW, 1994, AIDS, V8, P313, DOI 10.1097/00002030-199403000-00004; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PEZZOTTI P, 1996, IN PRESS BMJ, V312; PHILLIPS AN, 1994, BRIT MED J, V309, P309, DOI 10.1136/bmj.309.6950.309; Pinching A J, 1991, Int J STD AIDS, V2, P157; Pinching AJ, 1996, BRIT MED J, V312, P521, DOI 10.1136/bmj.312.7030.521; SELIGMANN M, 1994, LANCET, V343, P871; SWART AM, 1990, BRIT MED J, V301, P825, DOI 10.1136/bmj.301.6756.825; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1995, NEW ENGL J MED, V333, P401, DOI 10.1056/NEJM199508173330701; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; 1990, LANCET, V335, P821	25	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					608	610						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806255				2022-12-28	WOS:A1996VG10800024
J	Veys, CA				Veys, CA			Occupational cancers	BRITISH MEDICAL JOURNAL			English	Article											Veys, CA (corresponding author), KEELE UNIV,POSTGRAD MED SCH,KEELE,STAFFS,ENGLAND.							Alderson M., 1986, OCCUPATIONAL CANC; DUFFUS JH, 1995, CANC WORKSPLACE CHEM, V17; International Agency for Research on Cancer, 1972, IARC MON EV CARC RIS, V1; 1994, HUNTERS DIS OCCUPATI, P623; 1988, BR J UROL, V61, P183	5	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					615	619						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806258				2022-12-28	WOS:A1996VG10800028
J	Barth, DS; MacDonald, KD				Barth, DS; MacDonald, KD			Thalamic modulation of high-frequency oscillating potentials in auditory cortex	NATURE			English	Article							MEDIAL GENICULATE-BODY; EVOKED-POTENTIALS; RAT; PROJECTIONS; CONNECTIONS; NEURONS; ACTIVATION; ANATOMY	PERHAPS the most widely recognized but least understood electrophysiological activity of the cerebral cortex is its characteristic electrical oscillations. Recently, there have been efforts to understand the mechanisms underlying high-frequency gamma oscillations (similar to 40 Hz) because they may coordinate sensory processing between populations of cortical cells(1,2), High-resolution cortical recordings show that gamma oscillations are constrained to sensory cortex(3-5) that they occur independently in auditory and somatosensory cortex(4), and that they are phase-locked between primary and secondary sensory cortex(5). As yet, the mechanism of their neurogenesis is unknown(2). Whereas cortical neurons can produce gamma oscillations without subcortical input(6-9), they may also be modulated by the thalamus(10) and basal forebrain(11). Here we report that the neural generator of gamma oscillations in auditory cortex seems to be intracortical, serving to synchronize interactions between the primary and secondary areas. The acoustic thalamus directly modulates these oscillations, which are inhibited by stimulation of the dorsal and ventral divisions of the medial geniculate nucleus (MGd and MGv) and evoked by stimulation of the adjacent posterior intralaminar nucleus (PIL).			Barth, DS (corresponding author), UNIV COLORADO,DEPT PSYCHOL,CAMPUS BOX 345,BOULDER,CO 80309, USA.							ARNAULT P, 1987, J COMP NEUROL, V258, P463, DOI 10.1002/cne.902580313; ARNAULT P, 1990, J COMP NEUROL, V302, P110, DOI 10.1002/cne.903020109; Basar E, 1992, INDUCED RHYTHMS BRAI; BRETT B, 1994, BRAIN RES, V647, P65, DOI 10.1016/0006-8993(94)91399-4; DI S, 1992, J NEUROPHYSIOL, V68, P425, DOI 10.1152/jn.1992.68.2.425; FRANOWICZ MN, 1995, J NEUROPHYSIOL, V74, P96, DOI 10.1152/jn.1995.74.1.96; GUTFREUND Y, 1995, J PHYSIOL-LONDON, V483, P621, DOI 10.1113/jphysiol.1995.sp020611; Kolb B, 1990, CEREBRAL CORTEX RAT, P21; LEDOUX JE, 1987, J COMP NEUROL, V264, P123, DOI 10.1002/cne.902640110; LEDOUX JE, 1985, J COMP NEUROL, V242, P182, DOI 10.1002/cne.902420204; LLINAS RR, 1991, P NATL ACAD SCI USA, V88, P897, DOI 10.1073/pnas.88.3.897; MACDONALD KD, 1995, BRAIN RES, V694, P1, DOI 10.1016/0006-8993(95)00662-A; MACDONALD KD, IN PRESS J NEUROPHYS; METHERATE R, 1992, J NEUROSCI, V12, P4701; MOREST DK, 1986, ADV ANAT EMBRYOL CEL, V97, P1; PATTERSON H, 1977, THESIS U BOSTON; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; SILVA LR, 1991, SCIENCE, V251, P432, DOI 10.1126/science.1824881; Singer W., 1994, LARGE SCALE NEURONAL, P201; STERIADE M, 1993, NEUROSCIENCE, V56, P1, DOI 10.1016/0306-4522(93)90556-U; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; Steriade M, 1996, J NEUROSCI, V16, P2788; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0	23	119	123	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					78	81		10.1038/383078a0	http://dx.doi.org/10.1038/383078a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779725				2022-12-28	WOS:A1996VF29500051
J	Peat, DS; Mathieson, PW				Peat, DS; Mathieson, PW			Lesson of the week: Cholesterol emboli may mimic systemic vasculitis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ATHEROEMBOLIC RENAL-DISEASE; GLOMERULONEPHRITIS		ADDENBROOKES HOSP, DEPT HISTOPATHOL, CAMBRIDGE, ENGLAND; ADDENBROOKES HOSP, DEPT MED, CAMBRIDGE, ENGLAND	Addenbrooke's Hospital; University of Cambridge; Addenbrooke's Hospital; University of Cambridge								ANGANGCO R, 1994, NEPHROL DIAL TRANSPL, V9, P630, DOI 10.1093/ndt/9.6.630; CLUTTERBUCK EJ, 1990, NEPHROL DIAL TRANSPL, V5, P161, DOI 10.1093/ndt/5.3.161; COSIO FG, 1985, LANCET, V2, P118; FINE MJ, 1987, ANGIOLOGY, V38, P769, DOI 10.1177/000331978703801007; GOLDMAN M, 1985, BRIT MED J, V290, P205, DOI 10.1136/bmj.290.6463.205; GROSS WL, 1993, CLIN EXP IMMUNOL, V91, P1; HYMAN BT, 1987, AM J MED, V82, P1233, DOI 10.1016/0002-9343(87)90231-2; KAPLANPAVOVCIC S, 1995, CLIN EXP IMMUNOL  S1, V101, P68; KASINATH BS, 1987, ARCH INTERN MED, V147, P1384, DOI 10.1001/archinte.147.8.1384; LYE WC, 1993, AM J NEPHROL, V13, P489, DOI 10.1159/000168669; PUSEY CD, 1991, KIDNEY INT, V40, P757, DOI 10.1038/ki.1991.272; RATTNER DW, 1991, NEW ENGL J MED, V325, P118; SMITH MC, 1981, AM J MED, V71, P174, DOI 10.1016/0002-9343(81)90290-4; Unsworth DJ, 1996, LANCET, V347, P115, DOI 10.1016/S0140-6736(96)90240-8; YOUNG DK, 1986, J RHEUMATOL, V13, P423	15	35	36	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 31	1996	313	7056					546	547						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789987				2022-12-28	WOS:A1996VF29400028
J	Bischoff, JR; Kim, DH; Williams, A; Heise, C; Horn, S; Muna, M; Ng, L; Nye, JA; SampsonJohannes, A; Fattaey, A; McCormick, F				Bischoff, JR; Kim, DH; Williams, A; Heise, C; Horn, S; Muna, M; Ng, L; Nye, JA; SampsonJohannes, A; Fattaey, A; McCormick, F			An adenovirus mutant that replicates selectively in p53-deficient human tumor cells	SCIENCE			English	Article							5 DNA; P53; TRANSFORMATION; GENES; LINES; EXPRESSION; PROTEINS	The human adenovirus E1B gene encodes a 55-kilodalton protein that inactivates the cellular tumor suppressor protein p53, Here it is shown that a mutant adenovirus that does not express this viral protein can replicate in and lyse p53-deficient human tumor cells but not cells with functional p53. Ectopic expression of the 55-kilodalton E1B protein in the latter cells rendered them sensitive to infection with the mutant virus. Injection of the mutant virus into p53-deficient human cervical carcinomas grown in nude mice caused a significant reduction in tumor size and caused complete regression of 60 percent of the tumors. These data raise the possibility that mutant adenoviruses can be used to treat certain human tumors.	ONYX PHARMACEUT,RICHMOND,CA 94806									BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BISCHOFF JL, UNPUB; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; CROOK T, 1991, ONCOGENE, V6, P873; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; DYSON N, 1992, CANCER SURV, V12, P161; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KIM D, UNPUB; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Righetti SC, 1996, CANCER RES, V56, P689; RUGGERI B, 1992, ONCOGENE, V7, P1503; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; VAN MEIR EG, 1994, CANCER RES, V54, P649; VANDEREB AJ, 1977, GENE, V2, P115, DOI 10.1016/0378-1119(77)90012-9; VANDYKE TA, 1994, SEMIN CANCER BIOL, V5, P47; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WHITE E, 1994, APOPTOSIS, V2, P111; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	24	1423	1569	1	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					373	376		10.1126/science.274.5286.373	http://dx.doi.org/10.1126/science.274.5286.373			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832876				2022-12-28	WOS:A1996VN17300039
J	Chen, RH; Waters, JC; Salmon, ED; Murray, AW				Chen, RH; Waters, JC; Salmon, ED; Murray, AW			Association of spindle assembly checkpoint component XMAD2 with unattached kinetochores	SCIENCE			English	Article							BUDDING YEAST; EXTRACTS	The spindle assembly checkpoint delays anaphase until all chromosomes are attached to a mitotic spindle. The mad (mitotic arrest-deficient) and bub (budding uninhibited by benzimidazole) mutants of budding yeast rack this checkpoint and fail to arrest the cell cycle when microtubules are depolymerized. A frog homolog of MAD2 (XMAD2) was isolated and found to play an essential role in the spindle assembly checkpoint in frog egg extracts. XMAD2 protein associated with unattached kinetochores in prometaphase and in nocodazole-treated cells and disappeared from kinetochores at metaphase in untreated cells, suggesting that XMAD2 plays a role in the activation of the checkpoint by unattached kinetochores. This study furthers understanding of the mechanism of cell cycle checkpoints in metazoa and provides a marker for studying the role of the spindle assembly checkpoint in the genetic instability of tumors.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill			Chen, Rey-Huei/AAA-5087-2021	Chen, Rey-Huei/0000-0002-6006-2137				BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; Chen R., UNPUB; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CYERT MS, 1988, DEV BIOL, V129, P209, DOI 10.1016/0012-1606(88)90175-3; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; Rieder C.L., 1990, International Review of Cytology, V122, P153, DOI 10.1016/S0074-7696(08)61208-5; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75	22	377	390	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					242	246		10.1126/science.274.5285.242	http://dx.doi.org/10.1126/science.274.5285.242			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824188				2022-12-28	WOS:A1996VM67100042
J	Saravolatz, LD; Winslow, DL; Collins, G; Hodges, JS; Pettinelli, C; Stein, DS; Markowitz, N; Reves, R; Loveless, MO; Crane, L; Thompson, M; Abrams, D				Saravolatz, LD; Winslow, DL; Collins, G; Hodges, JS; Pettinelli, C; Stein, DS; Markowitz, N; Reves, R; Loveless, MO; Crane, L; Thompson, M; Abrams, D			Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS-INFECTION; PHASE-I; THERAPY; RESISTANCE; TIME	Background We compared two combinations of nucleosides with zidovudine alone in patients with advanced human immunodeficiency virus (HIV) infection. Methods A total of 1102 patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter were randomly assigned to receive zidovudine alone or zidovudine combined with either didanosine or zalcitabine. Disease progression, survival, toxic effects, and the CD4 cell response were assessed. Results After a median follow-up of 35 months, disease progression or death occurred in 62 percent of the 363 patients assigned to zidovudine plus didanosine, 63 percent of the 367 assigned to zidovudine plus zalcitabine, and 66 percent of the 372 assigned to zidovudine alone (P=0.24). As compared with zidovudine therapy, treatment with zidovudine plus didanosine was associated with a relative risk of disease progression or death of 0.86 (95 percent confidence interval, 0.71 to 1.03), and treatment with zidovudine plus zalcitabine was associated with a relative risk of 0.92 (95 percent confidence interval, 0.76 to 1.10). Survival was similar in the three groups. In a subgroup analysis, combination therapy delayed disease progression or death in patients who had previously received zidovudine for 12 months or less. Therapy with zidovudine plus didanosine resulted in more gastrointestinal adverse effects, and treatment with zidovudine plus zalcitabine, more neuropathy. The mean increases in CD4 cell counts at two months were higher with combination therapy than with zidovudine alone. Conclusions In patients with advanced HIV infection, combination therapy with zidovudine and either didanosine or zalcitabine is not superior to zidovudine therapy alone. However, these combinations may be more effective than zidovudine monotherapy in patients with little or no previous zidovudine treatment.	ST JOHNS HOSP,DETROIT,MI; DELAWARE COMMUNITY PROGRAM CLIN RES AIDS,WILMINGTON,DE; UNIV MINNESOTA,SCH PUBL HLTH,DIV BIOSTAT,MINNEAPOLIS,MN 55455; NIAID,DIV AIDS,NIH,BETHESDA,MD 20892; ALBANY MED COLL,ALBANY,NY 12208; HENRY FORD HOSP,DETROIT,MI 48202; DENVER COMMUNITY PROGRAM CLIN RES AIDS,DETROIT,MI; RES & EDUC GRP,PORTLAND,OR; WAYNE STATE UNIV,MED CTR,DETROIT,MI 48202; AIDS RES CONSORTIUM ATLANTA,ATLANTA,GA; COMMUNITY CONSORTIUM SAN FRANCISCO,SAN FRANCISCO,CA	University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Albany Medical College; Henry Ford Health System; Henry Ford Hospital; Detroit Medical Center; Wayne State University					NIAID NIH HHS [N01-AI-45227, N01-AI-04045, N01-AI-45231] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045231, N01AI045227] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOZZETTE S, 1990, 6 INT C AIDS SAN FRA, V3, P192; COLLIER AC, 1993, ANN INTERN MED, V119, P786, DOI 10.7326/0003-4819-119-8-199310150-00003; COOLEY T, 1990, 6 INT C AIDS SAN FRA, V3, P205; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; GOTTLIEB M, 1989, 5TH P INT C AIDS MON, P212; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; JOHNSON VA, 1990, 6 INT C AIDS SAN FRA, V2, P106; LAWLESS JF, 1982, STATISTICAL MODELS M; MAYERS DL, 1994, ANTIMICROB AGENTS CH, V38, P307, DOI 10.1128/AAC.38.2.307; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MERIGAN TC, 1991, AM J MED, V90, pS8, DOI 10.1016/0002-9343(91)90405-M; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; PRICE RW, 1988, J INFECT DIS, V158, P1079, DOI 10.1093/infdis/158.5.1079; RAGNI M, 1992, 8 INT C AIDS 3 STD W, V1; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840; YARCHOAN R, 1988, LANCET, V1, P76; YARCHOAN R, 1990, REV INFECT DIS, V12, pS522; YARCHOAN R, 1989, P 5 INT C AIDS MONTR, P212; 1994, LANCET, V343, P871; 1987, MMWR MORB MORTAL S1, V36, pS3	24	139	143	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1996	335	15					1099	1106		10.1056/NEJM199610103351503	http://dx.doi.org/10.1056/NEJM199610103351503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN399	8813040				2022-12-28	WOS:A1996VN39900003
J	Harrison, LC				Harrison, LC			Cow's milk and IDDM	LANCET			English	Editorial Material							BETA-LACTOGLOBULIN; DIABETES-MELLITUS				Harrison, LC (corresponding author), WALTER & ELIZA HALL INST MED RES,BURNET CLIN RES UNIT,MELBOURNE,VIC 3050,AUSTRALIA.							DAHLQUIST G, 1992, DIABETOLOGIA, V35, P980, DOI 10.1007/BF00401429; ELITSUR Y, 1991, CLIN EXP IMMUNOL, V85, P493; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; JAKOBSSON I, 1985, ACTA PAEDIATR SCAND, V74, P342, DOI 10.1111/j.1651-2227.1985.tb10981.x; Vaarala O, 1996, DIABETES, V45, P178, DOI 10.2337/diabetes.45.2.178; Vaarala O, 1995, J ALLERGY CLIN IMMUN, V96, P917, DOI 10.1016/S0091-6749(95)70229-6	6	11	11	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					905	906		10.1016/S0140-6736(05)65333-0	http://dx.doi.org/10.1016/S0140-6736(05)65333-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843804				2022-12-28	WOS:A1996VL09700004
J	Mai, NTH; Day, NPJ; VanChuong, L; Waller, D; Phu, NH; Bethell, DB; Hien, TT; White, NJ				Mai, NTH; Day, NPJ; VanChuong, L; Waller, D; Phu, NH; Bethell, DB; Hien, TT; White, NJ			Post-malaria neurological syndrome	LANCET			English	Article							CEREBRAL MALARIA; FALCIPARUM-MALARIA; MEFLOQUINE; CHILDREN; SEQUESTRATION	Background Neurological signs and symptoms are common in malaria, but observations in Vietnam and Thailand have pointed to a discrete transient neurological syndrome after recovery from severe infections. Methods A prospective study of the post-malaria neurological syndrome (PMNS) was conducted at two centres in Vietnam over four years. Criteria for inclusion were recent symptomatic malaria infection with parasites cleared from blood (and in cases of cerebral malaria full recovery of consciousness), and development of neurological or psychiatric symptoms within two months after the acute illness. Half of the patients with severe falciparum malaria had been taking part in a randomised trial of antimalarials. Findings Of 18 124 patients with falciparum malaria treated (1176 of whom had severe infections) 19 adults and three children had subsequent PMNS; in one patient it followed uncomplicated malaria and in 21 it followed severe malaria. The overall incidence (95% confidence interval) of PMNS after falciparum malaria at the main study centre was 1.2 per 1000 (0.7 to 18 per 1000) and relative risk (95% CI) for developing PMNS after severe versus uncomplicated falciparum malaria was 299 (40 to 2223). 13 patients had an acute confusional state or psychosis, six had one or more generalised convulsions, two had generalised convulsions followed by a long period of acute confusion, and one developed a fine tremor. At the time of PMNS diagnosis all patients were aparasitaemic. The syndrome was self-limiting, median duration 60 h (range 24-240). PMNS was associated with the use of oral mefloquine. In the randomised trial 44% (10/228) of patients with severe malaria who received mefloquine after parenteral treatment developed PMNS compared with 0.5% (1/210) of those who received quinine; relative risk 9.2 (95% CI 1.2 to 71.3, p=0.012). Interpretation Mefloquine is not the only risk factor for PMNS but it is a strong one. Where an effective alternative drug is available, mefloquine should not be used after treatment of severe malaria.	CHO QUAN HOSP, CTR TROP DIS, WELLCOME TRUST CLIN RES UNIT, Ho Chi Minh City OX3 9DU, VIETNAM; JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, CTR TROP MED, OXFORD, ENGLAND	University of Oxford			White, Nicholas J/I-4629-2012; White, Nick/AAC-6527-2019; Thi, Nguyen/AAM-7074-2020	White, Nick/0000-0002-1897-1978; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; BURKE DS, 1985, AM J TROP MED HYG, V34, P1203, DOI 10.4269/ajtmh.1985.34.1203; DESILVA HJ, 1992, T ROY SOC TROP MED H, V86, P129, DOI 10.1016/0035-9203(92)90536-L; Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202; HOSMER DW, 1989, APPL LOGISTIC REGRES; LUXEMBURGER C, 1991, LANCET, V338, P1268, DOI 10.1016/0140-6736(91)92131-K; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MIETTINEN OS, 1970, BIOMETRICS, V26, P75, DOI 10.2307/2529046; MOOD AM, 1963, INTRO THEORY STATIST; PHILLIPSHOWARD PA, 1995, DRUG SAFETY, V12, P370, DOI 10.2165/00002018-199512060-00003; PONGPONRATN E, 1991, AM J TROP MED HYG, V44, P168, DOI 10.4269/ajtmh.1991.44.168; POWELL KF, 1990, LANCET, V335, P357, DOI 10.1016/0140-6736(90)90648-O; ROMAN GC, 1991, J NEUROL SCI, V101, P1, DOI 10.1016/0022-510X(91)90012-V; ROUVEIX B, 1989, ANN INTERN MED, V110, P577, DOI 10.7326/0003-4819-110-7-577; SILVA HJD, 1992, T R SOC TROP MED HYG, V86, P608; SOWUNMI A, 1993, J NATL MED ASSOC, V85, P695; SPEICH R, 1994, NEW ENGL J MED, V331, P57, DOI 10.1056/NEJM199407073310120; WARRELL DA, 1982, NEW ENGL J MED, V306, P313, DOI 10.1056/NEJM198202113060601; WATTANAGOON Y, 1994, T ROY SOC TROP MED H, V88, P426, DOI 10.1016/0035-9203(94)90415-4; WEINKE T, 1991, AM J TROP MED HYG, V45, P86, DOI 10.4269/ajtmh.1991.45.86; WHITE NJ, 1992, ADV PARASIT, V31, P83, DOI 10.1016/S0065-308X(08)60021-4; WHITE NJ, 1987, LANCET, V1, P708; 1990, T R SOC TROP MED S2, V84, P1	23	112	118	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 5	1996	348	9032					917	921		10.1016/S0140-6736(96)01409-2	http://dx.doi.org/10.1016/S0140-6736(96)01409-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843810				2022-12-28	WOS:A1996VL09700010
J	Goodman, OB; Krupnick, JG; Santini, F; Gurevich, VV; Penn, RB; Gagnon, AW; Keen, JH; Benovic, JL				Goodman, OB; Krupnick, JG; Santini, F; Gurevich, VV; Penn, RB; Gagnon, AW; Keen, JH; Benovic, JL			beta-arrestin acts as a clathrin adaptor in endocytosis of the beta(2)-adrenergic receptor	NATURE			English	Article							PLASMA-MEMBRANE; COATED VESICLES; PROTEIN; SEQUESTRATION; RESENSITIZATION; PHOSPHORYLATION; DISSOCIATION; MECHANISM; KINASES; SUBUNIT	THE ability of a system to regulate its responsiveness in the presence of a continuous stimulus, often termed desensitization, has been extensively characterized for the beta(2)-adrenergic receptor (beta(2)AR). beta(2)AR signalling is rapidly attenuated through receptor phosphorylation and subsequent binding of the protein beta-arrestin(1,2). Ultimately the receptor undergoes internalization(3,4), and although the molecular mechanism is unclear, receptor phosphorylation and beta-arrestin binding have been implicated in this process(5,6). Here we report that beta-arrestin and arrestin-3, but not visual arrestin, promote beta(2)AR internalization and bind with high affinity directly and stoichiometrically to clathrin, the major structural protein of coated pits, Moreover, beta-arrestin/arrestin chimaeras that are defective in either beta(2)AR or clathrin binding show a reduced ability to promote beta(2)AR endocytosis. Immunofluorescence microscopy of intact cells indicates an agonist-dependent colocalization of the beta(2)AR and beta-arrestin with clathrin, These results show that beta-arrestin functions as an adaptor in the receptor-mediated endocytosis pathway, and suggest a general mechanism for regulating the trafficking of G-protein-coupled receptors.	THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT BIOCHEM & MOL PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University			Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351; Goodman, Oscar/0000-0002-0882-3621				Diviani D, 1996, J BIOL CHEM, V271, P5049; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GOODMAN OB, 1995, J BIOL CHEM, V270, P2376; GUERVICH VV, 1995, J BIOL CHEM, V270, P720; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KEEN JH, 1981, J BIOL CHEM, V256, P2538; LAHSE MJ, 1990, SCIENCE, V248, P1547; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSE BMF, 1981, ANNU REV BIOCHEM, V50, P85, DOI 10.1146/annurev.bi.50.070181.000505; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Santini F, 1996, J CELL BIOL, V132, P1025, DOI 10.1083/jcb.132.6.1025; SCHMID SL, 1985, J BIOL CHEM, V260, P44; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; YU SS, 1993, J BIOL CHEM, V268, P337	28	1098	1117	1	42	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					447	450		10.1038/383447a0	http://dx.doi.org/10.1038/383447a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837779				2022-12-28	WOS:A1996VL46300065
J	Carballo, M; Simic, S; Zeric, D				Carballo, M; Simic, S; Zeric, D			Health in countries torn by conflict: Lessons from Sarajevo	LANCET			English	Editorial Material									INT CTR MIGRAT & HLTH, SARAJEVO, BOSNIA & HERCEG; KOSEVO CLIN, DEPT OBSTET & GYNAECOL, SARAJEVO, BOSNIA & HERCEG		Carballo, M (corresponding author), INT CTR MIGRAT & HLTH, CH-1206 GENEVA, SWITZERLAND.							FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; FILIPOVICHADZIO.A, 1996, HLTH SOCIAL CONSEQUE; *INT CTR MIGR HLTH, 1995, 1995 ICMH TECHN WORK; *REP COMM HLTH SOC, 1995, B SOC HLTH CONS AGGR, P179; SIMIC S, 1996, HLTH SOCIAL CONSEQUE; SMAJKIC A, 1996, HLTH SOCIAL CONSEQUE	6	20	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 28	1996	348	9031					872	874		10.1016/S0140-6736(96)05386-X	http://dx.doi.org/10.1016/S0140-6736(96)05386-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826816				2022-12-28	WOS:A1996VK03700016
J	Rennie, D				Rennie, D			The living structured auto-obituary	LANCET			English	Editorial Material											Rennie, D (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94109, USA.							Freeman AG, 1996, LANCET, V347, P545, DOI 10.1016/S0140-6736(96)91179-4; Horton R, 1996, LANCET, V347, P6, DOI 10.1016/S0140-6736(96)91552-4; LOCK S, 1995, BRIT MED J, V311, P680, DOI 10.1136/bmj.311.7006.680; Mason JM, 1996, LANCET, V347, P545, DOI 10.1016/S0140-6736(96)91180-0; McIntosh N, 1996, LANCET, V347, P544, DOI 10.1016/S0140-6736(96)91177-0; WILLIAMS JW, 1995, JAMA-J AM MED ASSOC, V273, P1015, DOI 10.1001/jama.273.13.1015	6	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1996	348	9031					875	876		10.1016/S0140-6736(96)01202-0	http://dx.doi.org/10.1016/S0140-6736(96)01202-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826817				2022-12-28	WOS:A1996VK03700017
J	Kindig, DA; Libby, DL				Kindig, DA; Libby, DL			Domestic production vs international immigration - Options for the US physician workforce	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REFORM	Objective.-To determine alternate combinations for reductions in US medical school graduates (USMGs), international medical graduate (IMG) immigration, and graduate medical education (GME) residencies, based on future physician supply targets. Design.-A demographic projection model of the physician supply was constructed and calibrated to fit observed American Medical Association Physician Masterfile data and current supply forecasts. Total annual input to GME was backcast from given future supply targets, adjusting for the portion of IMGs in GME who do not enter the US workforce. Main Outcome Measures.-The annual number of new physicians added to supply from domestic or international sources needed to reach future physician-to-population ratio targets. Results.-Because of the low rate of attrition from the physician supply, it takes up to 50 years for workforce policy to effectively stabilize the physician-to-population ratio at a target level, All target ratios considered here would require immediate reductions in the total number of GME positions. These reductions must be followed by gradual annual increases to account for population growth. The size of USMG and IMG reductions are interrelated and depend critically on the percentage of IMG trainees who remain to practice in the United States. Conclusions.-Reductions in future physician supply can come from either the IMG or USMG component of physician production, or both. The model developed here allows the estimation of multiple combinations of both GME components.			Kindig, DA (corresponding author), UNIV WISCONSIN,SCH MED,BRADLEY MEM HOSP 227,DEPT PREVENT MED,1300 UNIV AVE,MADISON,WI 53706, USA.							American Medical Association, 1995, PHYS CHAR DISTR US; ANDERSON DG, 1950, JAMA-J AM MED ASSOC, V144, P109, DOI 10.1001/jama.1950.02920020029009; COOPER RA, 1994, JAMA-J AM MED ASSOC, V272, P680, DOI 10.1001/jama.272.9.680; COOPER RA, 1995, JAMA-J AM MED ASSOC, V274, P1534, DOI 10.1001/jama.274.19.1534; *COUNC GRAD MED ED, 1995, 7 US DEP HLTH HUM SE; *COUNC GRAD MED ED, 1996, 8 US DEP HLTH HUM SE; *COUNC GRAD MED ED, 1992, IMPR ACC HLTH CAR PH; *COUNC GRAD MED ED, 1994, 4 US DEP HLTH HUM SE; DAY JC, 1963, CURRENT POPULATION R; GAMLIEL S, 1995, HEALTH AFFAIR, V14, P131, DOI 10.1377/hlthaff.14.2.131; *GRAD MED ED NAT A, 1981, MOD RES DAT TECHN PA, V2, P2; *I MED, 1996, NAT PHYS WORKF OPT B; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; KINDIG DA, 1994, JAMA-J AM MED ASSOC, V272, P37, DOI 10.1001/jama.272.1.37; MICK SS, 1984, MED CARE, V22, P1014, DOI 10.1097/00005650-198411000-00004; MULLAN F, 1995, JAMA-J AM MED ASSOC, V273, P1521, DOI 10.1001/jama.273.19.1521; *NAT RES MAT PROGR, 1995, NRMP DAT; Pew Health Professions Commission, 1995, CRIT CHALL REV HLTH; *PHYS PAYM REV COM, 1993, ANN REP C; Tarlov A R, 1986, Health Aff (Millwood), V5, P23, DOI 10.1377/hlthaff.5.1.23; TARLOV AR, 1995, JAMA-J AM MED ASSOC, V274, P1558, DOI 10.1001/jama.274.19.1558; TURNER EL, 1955, JAMA-J AM MED ASSOC, V159, P563, DOI 10.1001/jama.1955.02960230027010; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WEINER JP, 1995, ASSESSING CURRENT FU; WIGGINS WS, 1960, JAMA-J AM MED ASSOC, V174, P1423, DOI 10.1001/jama.1960.03030110051013; 1970, JAMA-J AM MED ASSOC, V214, P1483; 1965, JAMA-J AM MED ASSOC, V194, P731; 1940, JAMA-J AM MED ASSOC, V115, P685; 1993, ACAD MED, V68, P1; 1945, JAMA-J AM MED ASSOC, V129, P33	30	11	11	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1996	276	12					978	982		10.1001/jama.276.12.978	http://dx.doi.org/10.1001/jama.276.12.978			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH990	8805733				2022-12-28	WOS:A1996VH99000039
J	vonOnciul, J				vonOnciul, J			ABC of work related disorders - Stress at work	BRITISH MEDICAL JOURNAL			English	Article									IBM GERMANY,MUNICH,GERMANY	International Business Machines (IBM)	vonOnciul, J (corresponding author), LUCAS VARITY IND MANAGEMENT DEV & TRAINING IND MA,SOLIHULL,W MIDLANDS,ENGLAND.								0	33	37	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					745	748						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819451				2022-12-28	WOS:A1996VJ44100035
J	Maestri, NE; Brusilow, SW; Clissold, DB; Bassett, SS				Maestri, NE; Brusilow, SW; Clissold, DB; Bassett, SS			Long-term treatment of girls with ornithine, transcarbamylase deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UREA SYNTHESIS; INBORN-ERRORS; CHILDREN	Background Ornithine transcarbamylase is an X-linked mitochondrial enzyme that catalyzes the synthesis of citrulline from carbamoyl phosphate and ornithine. A deficiency of this enzyme leads to hyperammonemia and hyperglutaminemia. In boys the disease is often fatal when its onset occurs during the neonatal period, but it is milder when onset occurs later in childhood. Heterozygous girls may be normal or may have episodes of hyperammonemic encephalopathy and decline in cognitive function. We report here on the long-term outcome in girls with ornithine transcarbamylase deficiency enrolled in studies of treatments designed to activate new pathways of waste-nitrogen excretion. Methods We studied 32 girls (age, 1 to 17 years) with ornithine transcarbamylase deficiency who had had at least one episode of encephalopathy. The patients were assigned to treatment that consisted of sodium benzoate, alone or in combination with sodium phenylacetate or sodium phenylbutyrate, or sodium phenylbutyrate alone. Collaborating physicians provided clinical, metabolic, and developmental data at specified intervals. Results Patients treated according to these protocols had greater than 90 percent survival at five years and maintained appropriate weight for height. The frequency of hyperammonemic episodes decreased with increasing age and with sodium phenylacetate or sodium phenylbutyrate treatment. Although the mean IQ before treatment was in the low average range, 19 of the 23 girls in whom intelligence was tested longitudinally had stable test scores. Conclusions Girls with symptomatic ornithine transcarbamylase deficiency who are treated with drugs that activate new pathways of waste-nitrogen excretion have fewer hyperammonemic episodes and a reduced risk of further cognitive decline. (C) 1996, Massachusetts Medical Society.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NICHD NIH HHS [HD21358, HD11134, HD29004] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029004, R01HD011134] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BATSHAW ML, 1986, J PEDIATR-US, V108, P236, DOI 10.1016/S0022-3476(86)80989-1; BATSHAW ML, 1980, NEW ENGL J MED, V302, P482, DOI 10.1056/NEJM198002283020902; BBRUSILOW SW, 1995, PROGR LIVER DIS, V13, P293; Brusilow S W, 1996, Adv Pediatr, V43, P127; BRUSILOW SW, 1984, NEW ENGL J MED, V310, P1630, DOI 10.1056/NEJM198406213102503; BRUSILOW SW, 1993, METABOLISM, V42, P1336, DOI 10.1016/0026-0495(93)90135-B; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; FINKELSTEIN JE, 1990, J PEDIATR-US, V117, P897, DOI 10.1016/S0022-3476(05)80129-5; FINKELSTEIN JE, 1991, J PEDIATR, V118, P326; MAESTRI NE, 1995, J PEDIATR-US, V127, P929, DOI 10.1016/S0022-3476(95)70030-7; MSALL M, 1984, NEW ENGL J MED, V310, P1500, DOI 10.1056/NEJM198406073102304; ROWE PC, 1986, NEW ENGL J MED, V314, P541, DOI 10.1056/NEJM198602273140903; Sattler JM, 1992, ASSESSMENT CHILDRENS; SULLIVAN KM, 1990, ANTHRO SOFTWARE CALC; Wechsler D., 1991, WISC 3 WECHSLER INTE	15	215	243	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1996	335	12					855	859		10.1056/NEJM199609193351204	http://dx.doi.org/10.1056/NEJM199609193351204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG869	8778603				2022-12-28	WOS:A1996VG86900004
J	Kane, MA				Kane, MA			Global status of hepatitis B immunisation	LANCET			English	Editorial Material							VACCINATION				Kane, MA (corresponding author), WHO,EXPANDED PROGRAMME IMMUNISAT,CH-1211 GENEVA 27,SWITZERLAND.							ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; CHEN DS, 1996, 9 TRIENN INT S VIR H, P41; COURSAGET P, 1993, HEPATITIS B VACCINES, P209; MANGTANI P, 1995, J EPIDEMIOL COMMUN H, V49, P238, DOI 10.1136/jech.49.3.238; MARGOLIS HS, 1995, JAMA-J AM MED ASSOC, V274, P1201, DOI 10.1001/jama.274.15.1201; VANDAMME P, 1995, VACCINE, V13, pS54; WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6; *WORLD BANK, 1993, 1993 WORLD BANK, P72	8	129	135	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					696	696		10.1016/S0140-6736(05)65598-5	http://dx.doi.org/10.1016/S0140-6736(05)65598-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806283				2022-12-28	WOS:A1996VG37400002
J	Weiss, A; Keshet, I; Razin, A; Cedar, H				Weiss, A; Keshet, I; Razin, A; Cedar, H			DNA demethylation in vitro: Involvement of RNA	CELL			English	Article							MOUSE EMBRYO; NUCLEAR EXTRACTS; GENE-EXPRESSION; CPG ISLAND; ACTIN GENE; APRT GENE; METHYLATION; CELLS; 5-METHYLCYTOSINE; DIFFERENTIATION	An in vitro system for studying DNA demethylation has been established using extracts from tissue culture cells, this reaction, which is unusually resistant to proteinase K, takes place through the removal of a 5-methylcytosine nucleotide unit from the DNA substrate end its conversion to an RNase-sensitive form. It is likely that this represents the in vivo mechanism, as well, Since extracts from L8 mybolasts specifically demethylate an alpha-actin gene, while extracts from F9 teratocarcinoma cells specifically demodify the Aprt CpG island. After pretreatment with proteinase K, these extracts demethylate both genes equally, suggesting that gene specificity may be controlled by protein factors.			Weiss, A (corresponding author), HEBREW UNIV JERUSALEM,SCH MED,DEPT CELLULAR BIOCHEM,IL-91120 JERUSALEM,ISRAEL.							BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; GRIFFIN EA, 1995, CHEM BIOL, V2, P761, DOI 10.1016/1074-5521(95)90104-3; GRUENBAUM Y, 1981, FEBS LETT, V123, P67; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; Jahner D., 1984, DNA METHYLATION BIOC, P189; Jones PA, 1984, DNA METHYLATION BIOC, P165; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; KAFRI T, 1993, P NATL ACAD SCI USA, V90, P10558, DOI 10.1073/pnas.90.22.10558; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KIRILLOV A, 1996, IN PRESS NATURE GENE, V13; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; LOWY I, 1980, CELL, V22, P817, DOI 10.1016/0092-8674(80)90558-9; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MONK M, 1987, DEVELOPMENT, V99, P371; MORI M, 1992, CELL, V70, P803; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; POLLACK Y, 1980, P NATL ACAD SCI-BIOL, V77, P6463, DOI 10.1073/pnas.77.11.6463; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SALUZ HP, 1986, P NATL ACAD SCI USA, V83, P7167, DOI 10.1073/pnas.83.19.7167; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; STEIN R, 1982, P NATL ACAD SCI USA, V80, P2422; SULLIVAN CH, 1986, P NATL ACAD SCI USA, V83, P329; VAIRAPANDI M, 1993, NUCLEIC ACIDS RES, V21, P5323, DOI 10.1093/nar/21.23.5323; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x; Yeivin A, 1993, EXS, V64, P523; YISRAELI J, 1986, CELL, V46, P409, DOI 10.1016/0092-8674(86)90661-6; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6	39	171	183	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					709	718		10.1016/S0092-8674(00)80146-4	http://dx.doi.org/10.1016/S0092-8674(00)80146-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797818	Bronze			2022-12-28	WOS:A1996VG37200005
J	Egberts, TCG; Smulders, M; deKoning, FHP; Meyboom, RHB; Leufkens, HGM				Egberts, TCG; Smulders, M; deKoning, FHP; Meyboom, RHB; Leufkens, HGM			Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals	BRITISH MEDICAL JOURNAL			English	Article									NETHERLANDS PHARMACOVIGILANCE FDN LAREB,NL-5026 RH TILBURG,NETHERLANDS		Egberts, TCG (corresponding author), UNIV UTRECHT,UTRECHT INST PHARMACEUT SCI,DEPT PHARMACOEPIDEMIOL & PHARMACOTHERAPY,POB 80082,NL-3508 TB UTRECHT,NETHERLANDS.		Egberts, Toine/A-6625-2012; Egberts, Toine/K-4579-2019	Egberts, Toine/0000-0003-1758-7779; Egberts, Toine/0000-0003-1758-7779; Smulders, Maartje/0000-0002-4081-1292				HARAMBURU F, 1990, EUR J CLIN PHARMACOL, V39, P287, DOI 10.1007/BF00315112; MANN RD, 1992, PHARMACOEPIDEM DR S, V1, P269; MITCHELL AS, 1988, BRIT MED J, V297, P891, DOI 10.1136/bmj.297.6653.891; ROSSI AC, 1984, JAMA-J AM MED ASSOC, V252, P1030; VENNING GR, 1983, BRIT MED J, V286, P458, DOI 10.1136/bmj.286.6363.458	5	70	72	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					530	531						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789980				2022-12-28	WOS:A1996VF29400020
J	Hopkins, A; Solomon, JK				Hopkins, A; Solomon, JK			For debate - Can contracts drive clinical care?	BRITISH MEDICAL JOURNAL			English	Article								The instrument through which a commissioner purchases health services from a provider is, as in other walks of life, a contract, so considerable importance has been attached by the NHS Executive to the contracting mechanism. A contract should in theory influence the quality of the service provided, but they are in many cases an inappropriate vehicle for driving clinical care. Much clinical activity is related to the management of chronic diseases and the effects of aging. The implicit contract here is based not on process and outcome measures but on mutual trust between doctors and patients that the doctors will provide the best care they can within budgetary constraints.			Hopkins, A (corresponding author), ROYAL COLL PHYSICIANS,RES UNIT,LONDON NW1 4LE,ENGLAND.							HOPKINS A, 1990, BRIT MED J, V300, P919, DOI 10.1136/bmj.300.6729.919; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; *NHS EX, 1995, CLIN INV CONTR HDB G; *NHS MAN EX, 1993, 93115 EL NHS EX; *ROYAL COLL PHYS, 1994, STROK AUD PACK	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					477	478						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776320				2022-12-28	WOS:A1996VE08000027
J	Mallat, Z; Tedgui, A; Fontaliran, F; Frank, R; Durigon, M; Fontaine, G				Mallat, Z; Tedgui, A; Fontaliran, F; Frank, R; Durigon, M; Fontaine, G			Evidence of apoptosis in arrhythmogenic right ventricular dysplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL-DEATH; CARDIOMYOPATHY; IDENTIFICATION	Background Arrhythmogenic right ventricular dysplasia, a disorder that may lead to severe ventricular arrhythmias and sudden death, is characterized by the progressive replacement of myocardial cells by fat and fibrous tissue. We examined whether the loss of myocardial cells in this disease could result from cell death by apoptosis (programmed cell death). Methods Specimens obtained at autopsy from the right ventricular myocardium of eight patients with arrhythmogenic right Ventricular dysplasia and four age-matched normal subjects were analyzed. To identify individual cells undergoing apoptosis, we performed in situ end-labeling of fragmented DNA on paraffin sections using biotinylated deoxyuridine triphosphate and the enzyme terminal deoxynucleotidyl transferase, We also examined the level of expression of CPP-32, a cysteine protease required for apoptotic cell death in mammalian cells, using immunohistochemical techniques. Results Apoptosis was detected in the right ventricular myocardium of six of the eight patients with arrhythmogenic right ventricular dysplasia and was absent in the controls, High levels of expression of CPP-32 were associated with positive in situ end-labeling of fragmented DNA. Conclusions These results indicate that apoptotic myocardial cell death occurs in arrhythmogenic right ventricular dysplasia and may contribute to the loss of myocardial cells in this disorder. (C) 1996, Massachusetts Medical Society.	HOP LARIBOISIERE,INSERM,U141,F-75475 PARIS,FRANCE; HOP RAY POINCARE,SERV ANAT & CYTOL PATHOL,GARCHES,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP	Mallat, Z (corresponding author), HOP JEAN ROSTAND,CTR RYTHMOL & STIMULAT CARDIAQUE,39 RUE JEAN LE GALLEU,F-94200 IVRY,FRANCE.		Mallat, Ziad/D-4041-2012	Mallat, Ziad/0000-0003-0443-7878				CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; FONTAINE G, 1995, HEART VESSELS, V10, P227, DOI 10.1007/BF01744901; FONTALIRAN F, 1991, ARCH MAL COEUR VAISS, V84, P33; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLD R, 1994, LAB INVEST, V71, P219; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gottlieb RA, 1996, J CLIN INVEST, V97, P2391, DOI 10.1172/JCI118683; James TN, 1996, CIRCULATION, V93, P1588, DOI 10.1161/01.CIR.93.8.1588; JAMES TN, 1994, CIRCULATION, V90, P556, DOI 10.1161/01.CIR.90.1.556; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1994, CELL BIOL LAB HDB, V1, P319; MARCUS FI, 1982, CIRCULATION, V65, P384, DOI 10.1161/01.CIR.65.2.384; MCKENNA WJ, 1994, BRIT HEART J, V71, P215; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Sharov VG, 1996, AM J PATHOL, V148, P141; THIENE G, 1988, NEW ENGL J MED, V318, P129, DOI 10.1056/NEJM198801213180301; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251	20	336	355	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1190	1196		10.1056/NEJM199610173351604	http://dx.doi.org/10.1056/NEJM199610173351604			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN401	8815941	Bronze			2022-12-28	WOS:A1996VN40100004
J	Nightingale, SL				Nightingale, SL			Treatment to protect against poison ivy approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1128	1128						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827954				2022-12-28	WOS:A1996VL33200006
J	Gorlick, R; Goker, E; Trippett, T; Waltham, M; Banerjee, D; Bertino, JR				Gorlick, R; Goker, E; Trippett, T; Waltham, M; Banerjee, D; Bertino, JR			Intrinsic and acquired resistance to methotrexate in acute leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; REDUCED-FOLATE CARRIER; WILD-TYPE P53; DIHYDROFOLATE-REDUCTASE; GENE AMPLIFICATION; PHASE-II; CELLS; TRIMETREXATE; TRANSPORT; PROTEIN		MEM SLOAN KETTERING CANC CTR,DEPT MOL PHARMACOL & THERAPEUT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT PEDIAT,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Waltham, Mark/A-1728-2009	GORLICK, RICHARD/0000-0001-8995-2929				AHUJA HG, 1991, BLOOD, V78, P3259; ALLEGRA CJ, 1987, NEW ENGL J MED, V317, P978, DOI 10.1056/NEJM198710153171602; BARREDO JC, 1994, BLOOD, V84, P564; BARRUECO JR, 1992, J BIOL CHEM, V267, P15356; BERTINO JR, 1993, J CLIN ONCOL, V11, P5, DOI 10.1200/JCO.1993.11.1.5; BERTINO JR, 1993, CANC MED, V1, P698; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; Chu E., 1996, CANC CHEMOTHERAPY BI, P109; DEBOER CJ, 1995, BLOOD, V86, P2715, DOI 10.1182/blood.V86.7.2715.bloodjournal8672715; DICKER AP, 1993, P NATL ACAD SCI USA, V90, P11797, DOI 10.1073/pnas.90.24.11797; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRY DW, 1988, CANCER RES, V48, P6986; GOKER E, 1995, LEUKEMIA, V9, P274; GOKER E, 1993, LEUKEMIA, V7, P1000; GOKER E, 1995, BLOOD, V86, P677, DOI 10.1182/blood.V86.2.677.bloodjournal862677; Gorlick R., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P317; HAUSKNECHT RU, 1995, NEW ENGL J MED, V333, P537, DOI 10.1056/NEJM199508313330901; HITCHINGS GH, 1989, IN VITRO CELL DEV B, V25, P303; HOCHHAUSER D, IN PRESS J NATL CANC; HRYNIUK WM, 1969, J CLIN INVEST, V48, P2140, DOI 10.1172/JCI106181; HYDE JE, 1990, PHARMACOL THERAPEUT, V48, P45, DOI 10.1016/0163-7258(90)90017-V; Jackman AL, 1995, ANN ONCOL, V6, P871, DOI 10.1093/oxfordjournals.annonc.a059353; JACKMAN AL, 1993, ADV EXP MED BIOL, V339, P265; JOLIVET J, 1983, NEW ENGL J MED, V309, P1094, DOI 10.1056/NEJM198311033091805; JONSSON OG, 1991, CANCER INVEST, V9, P53, DOI 10.3109/07357909109032800; KAMEN BA, 1984, BIOCHEM PHARMACOL, V33, P1697, DOI 10.1016/0006-2952(84)90298-3; KHERADPOUR A, 1995, CANCER INVEST, V13, P36, DOI 10.3109/07357909509024893; KLOHS WD, 1986, CANCER LETT, V31, P253, DOI 10.1016/0304-3835(86)90145-X; KORNBLAU SM, 1994, BLOOD, V84, P256; LACERDA JF, 1995, BLOOD, V85, P2675, DOI 10.1182/blood.V85.10.2675.bloodjournal85102675; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; LI WW, 1993, CHEM BIOL PTERIDINES, V338, P635; LIN JT, 1991, LEUKEMIA RES, V15, P1191, DOI 10.1016/0145-2126(91)90189-Z; LIN JT, 1991, CANCER INVEST, V9, P159, DOI 10.3109/07357909109044227; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MATHERLY LH, 1995, BLOOD, V85, P500; MAURITZ R, 1994, BLOOD, V84, pA45; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; Melera P W, 1991, Semin Cancer Biol, V2, P245; MOSCOW JA, 1995, CANCER RES, V55, P3790; NEVINS JR, 1992, SCIENCE, V258, P424; PAPPO A, 1990, J NATL CANCER I, V82, P1641, DOI 10.1093/jnci/82.20.1641; PIZZORNO G, 1988, CANCER RES, V48, P2149; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; RHEE MS, 1993, CANCER RES, V53, P2227; RODENHUIS S, 1986, CANCER RES, V46, P6513; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; SIROTNAK FM, 1984, CANCER CHEMOTH PHARM, V12, P26; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; SYNOLD TW, 1994, J CLIN INVEST, V94, P1996, DOI 10.1172/JCI117552; TRIPPETT T, 1992, BLOOD, V80, P1158; WESTERHOF GR, 1995, CANCER RES, V55, P3795; WHITEHEAD VM, 1990, BLOOD, V76, P44; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zalcberg JR, 1996, J CLIN ONCOL, V14, P716, DOI 10.1200/JCO.1996.14.3.716	59	200	208	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1041	1048		10.1056/NEJM199610033351408	http://dx.doi.org/10.1056/NEJM199610033351408			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8793930				2022-12-28	WOS:A1996VL45900008
J	Daniels, SE; Bhattacharrya, S; James, A; Leaves, NI; Young, A; Hill, MR; Faux, JA; Ryan, GF; leSouef, PN; Lathrop, GM; Musk, AW; Cookson, WOCM				Daniels, SE; Bhattacharrya, S; James, A; Leaves, NI; Young, A; Hill, MR; Faux, JA; Ryan, GF; leSouef, PN; Lathrop, GM; Musk, AW; Cookson, WOCM			A genome-wide search for quantitative trait loci underlying asthma	NATURE			English	Article							FC-EPSILON-RI; IMMUNOGLOBULIN-E; POPULATION-SAMPLE; GENETIC-LINKAGE; IGE LEVELS; SERUM IGE; CHROMOSOME-11Q; ATOPY; POLYMORPHISM; ALLERGENS	ASTHMA now affects one child in seven in the United Kingdom(1). Most cases (95%) of childhood asthma are associated with atopy, the immunoglobulin E (IgE)-mediated familial syndrome of allergic asthma, eczema and rhinitis. Segregation analysis has consistently suggested the presence of major genes influencing atopy and IgE levels(2-4), with the expectation that these genes may be identified by positional cloning or the examination of candidate genes. Here we report the results of a genome wide search for linkage to one qualitative and four quantitative traits associated with allergic (atopic) asthma. We have identified six potential linkages (P < 0.001), five of which are to quantitative traits. Monte Carlo simulations show that 1.6 false-positive linkages at this level of significance would be expected from the data. One linkage, to chromosome 11q13, has been established previously(5). Three of the new loci show evidence of linkage to a second panel of families, in which maternal effects and pleiotropy of linked phenotypes are seen. The results demonstrate the extent and the complexity of the genetic predisposition to asthma.	UNIV OXFORD,WELLCOME TRUST CTR HUMAN GENET DIS,OXFORD OX3 7BN,ENGLAND; SIR CHARLES GAIRDNER HOSP,DEPT RESP MED,PERTH,WA,AUSTRALIA; RADCLIFFE INFIRM,CTSU,OXFORD OX2 6HE,ENGLAND; UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; PRINCESS MARGARET HOSP CHILDREN,UNIV DEPT PAEDIAT,PERTH,WA,AUSTRALIA	University of Oxford; Wellcome Centre for Human Genetics; University of Western Australia; Radcliffe Infirmary; University of Oxford; University of Oxford; University of Western Australia			Le Souef, Peter N/H-5256-2014; Cookson, William/HHC-1790-2022; Hill, Michael/C-4861-2008	Le Souef, Peter/0000-0003-0930-1654	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABERG N, 1993, CLIN EXP ALLERGY, V23, P829, DOI 10.1111/j.1365-2222.1993.tb00260.x; BORECKI I B, 1985, Genetic Epidemiology, V2, P327, DOI 10.1002/gepi.1370020402; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COLLEE JM, 1993, LANCET, V342, P936, DOI 10.1016/0140-6736(93)91988-X; COOKSON WOCM, 1988, LANCET, V1, P86; COOKSON WOCM, 1989, LANCET, V1, P1292; DIZIER MH, 1995, GENET EPIDEMIOL, V12, P93, DOI 10.1002/gepi.1370120109; EIBERG H, 1985, CYTOGENET CELL GENET, V40, P622; GERRARD JW, 1978, AM J HUM GENET, V30, P46; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; HERWERDEN L, 1995, LANCET, V346, P1262; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; HODGE S E, 1984, Genetic Epidemiology, V1, P109, DOI 10.1002/gepi.1370010203; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; KUEHR J, 1993, CLIN EXP ALLERGY, V23, P600, DOI 10.1111/j.1365-2222.1993.tb00900.x; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MOFFATT MF, 1992, CLIN EXP ALLERGY, V22, P1046, DOI 10.1111/j.1365-2222.1992.tb00128.x; MYERS DA, 1994, GENOMICS, V23, P464; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; OCONNOR GT, 1994, AM J RESP CRIT CARE, V149, pS21, DOI 10.1164/ajrccm/149.2_Pt_2.S21; PEAT JK, 1987, CLIN ALLERGY, V17, P271; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SHIRAKAWA T, 1994, CLIN GENET, V46, P125; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174, DOI 10.1136/adc.70.3.174; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YOUNG RP, 1992, J MED GENET, V29, P236, DOI 10.1136/jmg.29.4.236	30	628	652	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					247	250		10.1038/383247a0	http://dx.doi.org/10.1038/383247a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805698				2022-12-28	WOS:A1996VH31500050
J	Watson, N; Linder, ME; Druey, KM; Kehrl, JH; Blumer, KJ				Watson, N; Linder, ME; Druey, KM; Kehrl, JH; Blumer, KJ			RGS family members: GTPase-activating proteins for heterotrimeric G-protein alpha-subunits	NATURE			English	Article							LIPID MODIFICATIONS; CRYSTAL-STRUCTURE; BETA-GAMMA; MECHANISM; HYDROLYSIS; TRANSDUCIN; DEACTIVATION; DESENSITIZATION; INCREASES; AFFINITY	SIGNALLING pathways using heterotrimeric guanine-nucleotide-binding-proteins (G proteins) trigger physiological responses elicited by hormones, neurotransmitters and sensory stimuli(1,2) GTP binding activates G proteins by dissociating G alpha from G beta gamma subunits, and GTP hydrolysis by G alpha subunits deactivates G proteins by allowing heterotrimers to reform. However, deactivation of G-protein signalling pathways in vivo can occur 10- to 100-fold faster than the rate of GTP hydrolysis of G alpha subunits in vitro(3-8), suggesting that GTPase-activating proteins (GAPs) deactivate G alpha subunits. Here we report that RGS(9,10) (for regulator of G-protein signalling) proteins are GAPs for G alpha subunits. RGS1, RGS4 and GAIP (for G alpha-interacting protein(17)) bind specifically and tightly to G alpha(i) and G alpha(o) in cell membranes treated with GDP and AIF(4)(-), and are GAPs for G alpha(i), G alpha(o) and transducin alpha-subunits, but not for G alpha(s). Thus, these RGS proteins are likely to regulate a subset of the G-protein signalling pathways in mammalian cells. Our results provide insight into the mechanisms that govern the duration and specificity of physiological responses elicited by G-protein-mediated signalling pathways.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Kehrl, John/AAE-6292-2019; Blumer, Kendall J/C-5268-2012; Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712; Kehrl, John/0000-0002-6526-159X				ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; Breer H, 1992, Curr Opin Neurobiol, V2, P439, DOI 10.1016/0959-4388(92)90177-M; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DOHLMAN HG, 1996, J MOL CELL BIOL, V16, P5194; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HONG JX, 1993, J IMMUNOL, V150, P3895; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Pan JY, 1996, J BIOL CHEM, V271, P1322, DOI 10.1074/jbc.271.3.1322; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; SHUI Z, 1995, J PHYSIOL-LONDON, V487, P359, DOI 10.1113/jphysiol.1995.sp020885; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; VUONG TM, 1990, NATURE, V346, P71, DOI 10.1038/346071a0; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	30	473	477	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					172	175		10.1038/383172a0	http://dx.doi.org/10.1038/383172a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774882				2022-12-28	WOS:A1996VG14800053
J	Christiaens, GCML; Nieuwenhuis, HK				Christiaens, GCML; Nieuwenhuis, HK			Images in clinical medicine - Heparin-induced skin necrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Christiaens, GCML (corresponding author), UNIV UTRECHT HOSP,UTRECHT,NETHERLANDS.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1996	335	10					715	715		10.1056/NEJM199609053351005	http://dx.doi.org/10.1056/NEJM199609053351005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH266	8786763				2022-12-28	WOS:A1996VH26600005
J	Bradley, M				Bradley, M			Caring for older people: Elder abuse	BRITISH MEDICAL JOURNAL			English	Article								Elder abuse takes many forms and occurs in a variety of settings; it is both under-recognised and under-reported. Despite a lack of statutory guidelines or legislation, effective management is possible. More could be done to recognise abuse, and healthcare workers need to be vigilant, paying attention to both the circumstances in which abuse occurs and its warning signs.			Bradley, M (corresponding author), SEACROFT HOSP,DEPT GERIATR GEN MED,LEEDS LS14 6UH,W YORKSHIRE,ENGLAND.							*AGE CONC BRIT GER, 1990, AB ELD PEOPL GUID AC; *DEP HLTH SOC SERV, 1993, NO LONG AFR SAF OLD; *SOC SERV INSP, 1992, CONFR ELD AB	3	12	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					548	550						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VF294	8789988				2022-12-28	WOS:A1996VF29400029
J	SollnerWebb, B				SollnerWebb, B			Trypanosome RNA editing: Resolved	SCIENCE			English	Editorial Material							LIGASE; GRNA; ENDONUCLEASE; INFORMATION; MOLECULES; CLEAVAGE; CHIMERAS				SollnerWebb, B (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.							Arts GJ, 1996, BBA-GENE STRUCT EXPR, V1307, P39; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CruzReyes J, 1996, P NATL ACAD SCI USA, V93, P8901, DOI 10.1073/pnas.93.17.8901; Frech GC, 1996, MOL CELL BIOL, V16, P4584; HARRIS M, 1992, MOL CELL BIOL, V12, P2591, DOI 10.1128/MCB.12.6.2591; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; LEWIN B, 1994, GENES, V5, P963; PILLER KJ, 1995, MOL CELL BIOL, V15, P2925; RUSCHE L, UNP0UB; RUSCHE LN, 1995, MOL CELL BIOL, V15, P2933; SABATINI R, 1995, J BIOL CHEM, V270, P7233, DOI 10.1074/jbc.270.13.7233; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; Sollner-Webb B, 1991, CURR OPIN CELL BIOL, V3, P1056, DOI 10.1016/0955-0674(91)90129-M	18	14	15	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1182	1183		10.1126/science.273.5279.1182	http://dx.doi.org/10.1126/science.273.5279.1182			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8787123				2022-12-28	WOS:A1996VE47600025
J	Macarthur, C; Macarthur, A; Weeks, S				Macarthur, C; Macarthur, A; Weeks, S			Accuracy of recall of back pain after delivery	BRITISH MEDICAL JOURNAL			English	Article							LONG-TERM BACKACHE; EPIDURAL-ANESTHESIA; CHILDBIRTH		WOMENS COLL HOSP,TORONTO,ON M5S 1B2,CANADA; ROYAL VICTORIA HOSP,MONTREAL,PQ H3A 1A1,CANADA	University of Toronto; University Toronto Affiliates; Womens College Hospital; McGill University; Royal Victoria Hospital	Macarthur, C (corresponding author), HOSP SICK CHILDREN,DIV GEN PAEDIAT,PAEDIAT OUTCOMES RES TEAM,555 UNIV AVE,TORONTO,ON M5G 1X8,CANADA.		MacArthur, Christine/ABA-8601-2021	MacArthur, Christine/0000-0003-0434-2158				COUGHLIN SS, 1990, J CLIN EPIDEMIOL, V43, P87, DOI 10.1016/0895-4356(90)90060-3; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; MACARTHUR A, 1995, BRIT MED J, V311, P1336, DOI 10.1136/bmj.311.7016.1336; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; RUSSELL R, 1993, BRIT MED J, V306, P1299, DOI 10.1136/bmj.306.6888.1299	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					467	467						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776316				2022-12-28	WOS:A1996VE08000023
J	Williams, DJ; Mauk, BH; McEntire, RE; Roelof, EC; Armstrong, TP; Wilken, B; Roederer, JG; Krimigis, SM; Fritz, TA; Lanzerotti, LJ				Williams, DJ; Mauk, BH; McEntire, RE; Roelof, EC; Armstrong, TP; Wilken, B; Roederer, JG; Krimigis, SM; Fritz, TA; Lanzerotti, LJ			Electron beams and ion composition measured at Io and in its torus	SCIENCE			English	Article							JOVIAN MAGNETOSPHERE; PLASMA TORUS; HOT PLASMA; JUPITER	Intense, magnetic field-aligned, bidirectional, energetic (>15 kiloelectron volts) electron beams were discovered by the Galileo energetic particles detector during the flyby of Io. These beams can carry sufficient energy flux into Jupiter's atmosphere to produce a visible aurora at the footprint of the magnetic flux tube connecting Io to Jupiter. Composition measurements through the torus showed that the spatial distributions of protons, oxygen, and sulfur are different, with sulfur being the dominant energetic (>similar to 10 kiloelectron volts per nucleon) ion at closest approach.	UNIV KANSAS,DEPT PHYS & ASTRON,LAWRENCE,KS 66045; MAX PLANCK INST AERON,D-37189 KATLENBURG DUHM,GERMANY; UNIV ALASKA,INST GEOPHYS,FAIRBANKS,AK 99775; BOSTON UNIV,CTR SPACE PHYS,BOSTON,MA 02215; LUCENT TECHNOL,MURRAY HILL,NJ 07974	University of Kansas; Max Planck Society; University of Alaska System; University of Alaska Fairbanks; Boston University; Alcatel-Lucent; Lucent Technologies	Williams, DJ (corresponding author), JOHNS HOPKINS UNIV,APPL PHYS LAB,JOHNS HOPKINS RD,LAUREL,MD 20723, USA.		Krimigis, Stamatios/G-4591-2019; Roelof, Edmond/G-6654-2019; Mauk, Barry H/E-8420-2017	Krimigis, Stamatios/0000-0003-2781-2386; Roelof, Edmond/0000-0002-2270-0652; Mauk, Barry H/0000-0001-9789-3797; Roederer, Juan/0000-0002-8042-5150				ARMSTRONG TP, 1981, J GEOPHYS RES-SPACE, V86, P8343, DOI 10.1029/JA086iA10p08343; BAGENAL F, 1983, J GEOPHYS RES-SPACE, V88, P3013, DOI 10.1029/JA088iA04p03013; CARR TD, 1983, PHYSICS JOVIAN MAGNE, P266; Clarke JT, 1996, SCIENCE, V274, P404, DOI 10.1126/science.274.5286.404; CONNERNEY JEP, 1993, SCIENCE, V262, P1035, DOI 10.1126/science.262.5136.1035; FILLIUS RW, 1974, J GEOPHYS RES, V79, P3589, DOI 10.1029/JA079i025p03589; GOERTZ CK, 1980, J GEOPHYS RES-SPACE, V85, P2949, DOI 10.1029/JA085iA06p02949; GOLDREICH P, 1969, ASTROPHYS J, V156, P59, DOI 10.1086/149947; GOLDSTEIN ML, 1983, PHYSICS JOVIAN MAGNE, P317; GURNETT DA, 1972, ASTROPHYS J, V175, P525, DOI 10.1086/151576; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; KLUMPAR DM, 1988, GEOPHYS RES LETT, V15, P1295, DOI 10.1029/GL015i011p01295; KRIMIGIS SM, 1981, J GEOPHYS RES-SPACE, V86, P8227, DOI 10.1029/JA086iA10p08227; LANZEROTTI LJ, 1992, SCIENCE, V257, P1518, DOI 10.1126/science.257.5076.1518; NEUBAUER FM, 1980, J GEOPHYS RES-SPACE, V85, P1171, DOI 10.1029/JA085iA03p01171; Prange R, 1996, NATURE, V379, P323, DOI 10.1038/379323a0; SHAWHAN SD, 1976, J GEOPHYS RES-SPACE, V81, P3373, DOI 10.1029/JA081i019p03373; SMITH RA, 1978, J GEOPHYS RES-SPACE, V83, P2617, DOI 10.1029/JA083iA06p02617; WILLIAMS DJ, 1992, SPACE SCI REV, V60, P385, DOI 10.1007/BF00216863	19	92	92	2	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					401	403		10.1126/science.274.5286.401	http://dx.doi.org/10.1126/science.274.5286.401			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832885				2022-12-28	WOS:A1996VN17300048
J	Durr, A; Cossee, M; Agid, Y; Campuzano, V; Mignard, C; Penet, C; Mandel, JL; Brice, A; Koenig, M				Durr, A; Cossee, M; Agid, Y; Campuzano, V; Mignard, C; Penet, C; Mandel, JL; Brice, A; Koenig, M			Clinical and genetic abnormalities in patients with Friedreich's ataxia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RETAINED TENDON REFLEXES; ONSET CEREBELLAR-ATAXIA; DISEASE; CARDIOMYOPATHY; MUTATION; FEATURES; PROTEIN; LOCUS	Background Friedreich's ataxia, the most common inherited ataxia, is associated with a mutation that consists of an unstable expansion of GAA repeats in the first intron of the frataxin gene on chromosome 9, which encodes a protein of unknown function. Methods We studied 187 patients with autosomal recessive ataxia, determined the size of the GAA expansions, and analyzed the clinical manifestations in relation to the number of GAA repeats and the duration of disease. Results One hundred forty of the 187 patients, with ages at onset ranging from 2 to 51 years, were homozygous for a GAA expansion that had 120 to 1700 repeats of the trinucleotides. About one quarter of the patients, despite being homozygous, had atypical Friedreich's ataxia; they were older at presentation and had intact tendon reflexes. Larger GAA expansions correlated with earlier age at onset and shorter times to loss of ambulation. The size of the GAA expansions (and particularly that of the smaller of each pair) was associated with the frequency of cardiomyopathy and loss of reflexes in the upper limbs. The GAA repeats were unstable during transmission. Conclusions The clinical spectrum of Friedreich's ataxia is broader than previously recognized, and the direct molecular test for the GAA expansion on chromosome 9 is useful for diagnosis, determination of prognosis, and genetic counseling. (C) 1996, Massachusetts Medical Society.	HOP LA PITIE SALPETRIERE, INSERM, U289, F-75651 PARIS 13, FRANCE; HOP LA PITIE SALPETRIERE, FEDERAT NEUROL, F-75651 PARIS 13, FRANCE; INST GENET & BIOL MOL & CELLULAIRE, STRASBOURG, FRANCE; CTR HOSP GEN ST PIERRE, ST PIERRE, Reunion, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)			Campuzano, V/G-1826-2014; Brice, Alexis/A-2170-2009; Campuzano, Victoria/ABG-7429-2020; brice, alexis/AAE-8275-2019; CAMPUZANO, VICTORIA/K-7883-2019	Campuzano, V/0000-0001-8128-2641; Campuzano, Victoria/0000-0001-8128-2641; brice, alexis/0000-0002-0941-3990; 				Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BENHAMIDA C, 1993, NAT GENET, V5, P195, DOI 10.1038/ng1093-195; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHAMBERLAIN S, 1988, NATURE, V334, P248, DOI 10.1038/334248a0; DEMICHELE G, 1994, J NEUROL NEUROSUR PS, V57, P977, DOI 10.1136/jnnp.57.8.977; DEMICHELE G, 1989, J NEUROL NEUROSUR PS, V52, P1398, DOI 10.1136/jnnp.52.12.1398; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; Durr A, 1996, CURR OPIN NEUROL, V9, P290; FILLA A, 1990, J NEUROL NEUROSUR PS, V53, P667, DOI 10.1136/jnnp.53.8.667; HANAUER A, 1990, AM J HUM GENET, V46, P133; HARDING AE, 1981, BRAIN, V104, P589, DOI 10.1093/brain/104.3.589; HARDING AE, 1981, J NEUROL NEUROSUR PS, V44, P503, DOI 10.1136/jnnp.44.6.503; KLOCKGETHER T, 1991, BRAIN, V114, P1559, DOI 10.1093/brain/114.4.1559; KLOCKGETHER T, 1993, ARCH NEUROL-CHICAGO, V50, P803, DOI 10.1001/archneur.1993.00540080014006; Klockgether T, 1996, NEUROLOGY, V46, P118, DOI 10.1212/WNL.46.1.118; MORVAN D, 1992, EUR HEART J, V13, P1393, DOI 10.1093/oxfordjournals.eurheartj.a060072; PALAU F, 1995, ANN NEUROL, V37, P359, DOI 10.1002/ana.410370312; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104	20	749	764	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1169	1175		10.1056/NEJM199610173351601	http://dx.doi.org/10.1056/NEJM199610173351601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN401	8815938	Bronze			2022-12-28	WOS:A1996VN40100001
J	Schnitzer, JE; Oh, P; McIntosh, DP				Schnitzer, JE; Oh, P; McIntosh, DP			Role of GTP hydrolysis in fission of caveolae directly from plasma membranes	SCIENCE			English	Article							GPI-ANCHORED PROTEINS; FROG MESENTERIC CAPILLARIES; TRANS-GOLGI-NETWORK; CELL-SURFACE; 3-DIMENSIONAL ORGANIZATION; VESICULAR TRANSPORT; MEDIATED TRANSPORT; ENDOTHELIAL-CELLS; MODIFIED ALBUMINS; VESICLES	Caveolae are specialized invaginated cell surface microdomains of undefined function. A cell-free system that reconstituted fission of caveolae from lung endothelial plasma membranes was developed. Addition of cytosol and the hydrolysis of guanosine triphosphate (GTP) induced caveolar fission. The budded caveolae were isolated as vesicles rich in caveolin and the sialoglycolipid G(M1) but not glycosylphosphatidylinositol (GPI)-anchored proteins. These vesicles contained the molecular machinery for endocytosis and transcytosis. In permeabilized endothelial cells, GTP stimulated, whereas GTP gamma S prevented, caveolar budding and endocytosis of the cholera toxin B chain to endosomes. Thus, caveolae may bud to form discrete carrier vesicles that participate in membrane trafficking.			Schnitzer, JE (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT PATHOL,RES N,99 BROOKLINE AVE,BOSTON,MA 02215, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052766, R29HL043278] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52766, HL43278] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BUNDGAARD M, 1983, FED PROC, V42, P2425; BUNDGAARD M, 1979, P NATL ACAD SCI USA, V76, P6439, DOI 10.1073/pnas.76.12.6439; CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FRA AM, 1994, J BIOL CHEM, V269, P30745; FROKJAERJENSEN J, 1991, J ELECTRON MICR TECH, V19, P291, DOI 10.1002/jemt.1060190305; FROKJAERJENSEN J, 1980, J ULTRA MOL STRUCT R, V73, P9, DOI 10.1016/0022-5320(80)90111-2; FROKJAERJENSEN J, 1988, CELL TISSUE RES, V254, P17; GHITESCU L, 1992, J CELL BIOL, V117, P745, DOI 10.1083/jcb.117.4.745; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HUET C, 1980, CELL, V21, P429, DOI 10.1016/0092-8674(80)90479-1; KING GL, 1985, SCIENCE, V227, P1583, DOI 10.1126/science.3883490; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; MAHOLTA V, 1989, CELL, V58, P329; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PREDESCU D, 1994, P NATL ACAD SCI USA, V91, P3014, DOI 10.1073/pnas.91.8.3014; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCHNITZER JE, 1995, AM J PHYSIOL-HEART C, V268, pH48, DOI 10.1152/ajpheart.1995.268.1.H48; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SCHNITZER JE, 1994, BIOCHEM BIOPH RES CO, V199, P11, DOI 10.1006/bbrc.1994.1185; SCHNITZER JE, 1992, AM J PHYSIOL, V263, pH1872, DOI 10.1152/ajpheart.1992.263.6.H1872; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHNITZER JE, 1996, AM J PHYSIOL, V270, P416; SCHNITZER JE, 1993, TRENDS CARDIOVAS MED, V3, P1024; SCHNITZER JE, UNPUB; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SEVERS NJ, 1988, J CELL SCI, V90, P341; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; Van Deurs Bo, 1993, Trends in Cell Biology, V3, P249	48	202	205	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					239	242		10.1126/science.274.5285.239	http://dx.doi.org/10.1126/science.274.5285.239			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824187				2022-12-28	WOS:A1996VM67100041
J	Sullivan, FM; MacNaughton, RJ				Sullivan, FM; MacNaughton, RJ			Evidence in consultations: Interpreted and individualised	LANCET			English	Article							EVIDENCE-BASED MEDICINE; GENERAL-PRACTICE				Sullivan, FM (corresponding author), UNIV GLASGOW,DEPT GEN PRACTICE,WOODSIDE HLTH CTR,GLASGOW G20 7LR,LANARK,SCOTLAND.		Sullivan, Frank/L-8286-2019; Sullivan, Frank m/A-7767-2009	Sullivan, Frank/0000-0002-6623-4964; 				Anderson J.R., 1983, ARCHITECTURE COGNITI; ARBORELIUS E, 1992, FAM PRACT, V9, P61, DOI 10.1093/fampra/9.1.61; Balint M., 1957, DOCTOR; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; BLAKE JM, 1995, LANCET, V345, P899, DOI 10.1016/S0140-6736(95)90014-4; BOREHAM N, 1994, MED EDUC, V28, P9; Brody H., 1987, STORIES SICKNESS; Byrne P.S., 1976, DOCTORS TALKING PATI; CHARLTON BG, 1991, BRIT J GEN PRACT, V41, P355; COVELL DG, 1985, ANN INTERN MED, V103, P569; DAVIDOFF F, 1995, BRIT MED J, V310, P1085, DOI 10.1136/bmj.310.6987.1085; *DEP HLTH, 1995, NEW ADV OR CONTR; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P441, DOI 10.1001/jama.263.3.441; ELLIS J, 1995, LANCET, V346, P407, DOI 10.1016/S0140-6736(95)92781-6; FEINSTEIN AR, 1972, LANCET, V2, P421; Gill P, 1996, BRIT MED J, V312, P819; HOPE T, 1995, J MED ETHICS, V21, P259, DOI 10.1136/jme.21.5.259; JOHNSTONE AH, 1993, INT J SCI EDUC, V15, P663, DOI 10.1080/0950069930150604; LOMAS J, 1988, AM J PREV MED S1, V77, P97; MACNAUGHTON J, 1995, BRIT J GEN PRACT, V45, P571; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; Neighbour R., 1987, INNER CONSULTATION; PENDLETON D, 1995, BRIT J GEN PRACT, V45, P377; PENDLETON D, 1987, CONSULTATION APPROAC; PICKUP AJ, 1983, J ROY COLL GEN PRACT, V33, P486; SACKETT DL, 1993, CLIN EPIDEMIOLOGY BA; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; TANENBAUM SJ, 1993, NEW ENGL J MED, V329, P1268, DOI 10.1056/NEJM199310213291713; TATE P, 1994, DOCTORS COMMUNICATIO; THOMAS KB, 1994, LANCET, V344, P1066, DOI 10.1016/S0140-6736(94)91716-7; VANDERVLEUTEN CPM, 1995, LANCET, V345, P1032, DOI 10.1016/S0140-6736(95)90763-7; WILLIAMSON JW, 1979, INFORMATION DEMONSTR; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W	33	36	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					941	943		10.1016/S0140-6736(96)05219-1	http://dx.doi.org/10.1016/S0140-6736(96)05219-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843817				2022-12-28	WOS:A1996VL09700017
J	Chambers, CD; Johnson, KA; Dick, LM; Felix, RJ; Jones, KL				Chambers, CD; Johnson, KA; Dick, LM; Felix, RJ; Jones, KL			Birth outcomes in pregnant women taking fluoxetine	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXPOSURE; NEWBORN	Background Although fluoxetine is the most frequently prescribed antidepressant drug in the United States, its safety in pregnant women has nor been established. Methods From 1989 through 1995, we prospectively identified 228 pregnant women taking fluoxetine. We compared the outcomes of their pregnancies with those of 254 women identified in a similar manner who were not taking fluoxetine. Results The rate of spontaneous pregnancy loss did not differ significantly between the women treated with fluoxetine and the control women (10.5 percent and 9.1 percent, respectively), nor was the rate of major structural anomalies significantly different (5.5 percent vs. 4.0 percent). Among the 97 infants exposed to fluoxetine who were evaluated for minor anomalies, the incidence of three or more minor anomalies was significantly higher than among 153 similarly examined control infants (15.5 percent vs. 6.5 percent, P=0.03). As compared with the 101 infants exposed to fluoxetine only during the first and second trimesters, the 73 infants exposed during the third trimester had higher rates of premature delivery (relative risk, 4.8; 95 percent confidence interval, 1.1 to 20.8), admission to special-care nurseries (relative risk, 2.6; 95 percent confidence interval, 1.1 to 6.9), and poor neonatal adaptation, including respiratory difficulty, cyanosis on feeding, and jitteriness (relative risk, 8.7; 95 percent confidence interval, 2.9 to 26.6). Birth weight was also lower and birth length shorter in infants exposed to fluoxetine late in gestation. Conclusions Women who take fluoxetine during pregnancy do not have an increased risk of spontaneous pregnancy loss or major fetal anomalies, but women who take fluoxetine in the third trimester are at increased risk for perinatal complications. (C) 1996, Massachusetts Medical Society.	UNIV CALIF SAN DIEGO, MED CTR, DEPT PEDIAT 8446, DIV DYSMORPHOL & TERATOL, SAN DIEGO, CA 92103 USA	University of California System; University of California San Diego				Chambers, Christina D/0000-0003-4675-7722				ABRAMS, 1986, AM J OBSTET GYNECOL, V155, P918; ABRAMS BF, 1986, AM J OBSTET GYNECOL, V154, P503, DOI 10.1016/0002-9378(86)90591-0; BERKOWITZ GS, 1993, EPIDEMIOL REV, V15, P414, DOI 10.1093/oxfordjournals.epirev.a036128; GOLDSTEIN DJ, 1995, J CLIN PSYCHOPHARM, V15, P417, DOI 10.1097/00004714-199512000-00005; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; Hollingshead AB, 1965, 2 FACTOR INDEX SOCIA; LEPPIG KA, 1987, J PEDIATR-US, V110, P531, DOI 10.1016/S0022-3476(87)80543-7; MARDEN PM, 1964, J PEDIATR-US, V64, P357, DOI 10.1016/S0022-3476(64)80188-8; PASTUSZAK A, 1993, JAMA-J AM MED ASSOC, V269, P2246, DOI 10.1001/jama.269.17.2246; ROSA F, 1994, REPROD TOXICOL, V8, P531, DOI 10.1016/0890-6238(94)90036-1; VORHEES CV, 1994, FUND APPL TOXICOL, V23, P194, DOI 10.1006/faat.1994.1098; WALSHSUKYS MC, 1993, CLIN PERINATOL, V20, P127, DOI 10.1016/S0095-5108(18)30415-9; 1995, DRUG FACTS COMP	13	538	544	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1010	1015		10.1056/NEJM199610033351402	http://dx.doi.org/10.1056/NEJM199610033351402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8793924				2022-12-28	WOS:A1996VL45900002
J	Showstack, J; Lurie, N; Leatherman, S; Fisher, E; Inui, T				Showstack, J; Lurie, N; Leatherman, S; Fisher, E; Inui, T			The private-sector challenge	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	The rapid growth of managed care poses challenges and opportunities for the health of the public. The fundamental risk is that both mission and accountability will be defined too narrowly; the opportunity lies in broadening both. What would a socially responsible managed care system look like? Such a system would provide excellent individual care to its enrollees, yet it would also include programs and activities that address broader populations and policies. We propose 8 attributes of such a system that can be used as a guide by managed care systems and to judge whether a managed care system is a responsible, accountable, and responsive contributor to the health of its community. As the role of the public sector shrinks, the private sector must expand its responsibility. It is both prudent and reasonable for managed care systems to seize their unique opportunity to improve the health of the public.	UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA 94143 USA; UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH PUBL HLTH, INST HLTH SERV RES, MINNEAPOLIS, MN 55455 USA; UNITED HEALTHCARE CORP, MINNEAPOLIS, MN USA; DARTMOUTH COLL SCH MED, DEPT MED, HANOVER, NH USA; DARTMOUTH COLL SCH MED, DEPT FAMILY & COMMUNITY MED, HANOVER, NH USA; VET AFFAIRS MED CTR, VET AFFAIRS OUTCOMES GRP, WHITE RIVER JCT, VT USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA; HARVARD PILGRIM HLTH CARE, BOSTON, MA USA	University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; UnitedHealth Group Incorporated; Dartmouth College; Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Showstack, J (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, HLTH PUBL PROGRAM, 735 PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA.		Showstack, Jonathan/L-6556-2013	Showstack, Jonathan/0000-0002-1367-419X				ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; Anders George, 1994, WALL STREET J   0826, pA1; Armstead R C, 1995, Health Care Financ Rev, V16, P25; BRADSHER K, 1995, NY TIMES        0417, pA1; Burner S T, 1995, Health Care Financ Rev, V16, P221; GINSBURG PB, 1988, INQUIRY-J HEALTH CAR, V25, P108; *GROUP HLTH ASS AM, 1995, 1995 NAT DIR HMOS; Harris JR, 1996, JAMA-J AM MED ASSOC, V275, P26, DOI 10.1001/jama.1996.03530250030010; Iezzoni LI, 2012, RISK ADJUSTMENT MEAS, V4th; INGLEHART JK, 1995, NEW ENGL J MED, V332, P1727; JOHNSSON J, 1990, AM MED NEWS     0122, P1; *KAIS PERM, 1993, 1993 QUAL REP CARD; LOHR K, 1995, HLTH DATA INFORMATIO; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MILLER RH, 1994, ANNU REV PUBL HEALTH, V15, P437; MOORE GT, 1994, ACAD MED, V69, P983, DOI 10.1097/00001888-199412000-00017; *NAT COMM QUAL ASS, 1993, HLTH PLAN EMPL DAT I; NEWACHECK PW, 1995, JAMA-J AM MED ASSOC, V274, P1468, DOI 10.1001/jama.274.18.1468; *PEW HLTH PROF COM, 1995, HLTH PROF ED MAN CAR; SCHROEDER SA, 1989, JAMA-J AM MED ASSOC, V262, P803, DOI 10.1001/jama.262.6.803; SHORTELL SM, 1994, HEALTH AFFAIR, V13, P46, DOI 10.1377/hlthaff.13.5.46; 1996, PACIFIC CURRENTS, V2, P1	22	51	51	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1996	276	13					1071	1074		10.1001/jama.276.13.1071	http://dx.doi.org/10.1001/jama.276.13.1071			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK035	8847770				2022-12-28	WOS:A1996VK03500029
J	Bland, JM; Altman, DG				Bland, JM; Altman, DG			Statistics notes: Measurement error proportional to the mean (vol 313, pg 106, 1996)	BRITISH MEDICAL JOURNAL			English	Correction, Addition																		Bland JM, 1996, BRIT MED J, V313, P106, DOI 10.1136/bmj.313.7049.106	1	1060	1087	0	59	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					744	744						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819450				2022-12-28	WOS:A1996VJ44100034
J	Nosten, F; Luxemburger, C; Kyle, DE; Ballou, WR; Wittes, J; Wah, E; Chongsuphajaisiddhi, T; Gordon, DM; White, NJ; Sadoff, JC; Heppner, DG; Bathe, K; Blood, J; Brockman, A; Cobley, UT; Hacking, D; Hogg, D; U, KH; Maelankiri, L; Chuanak, N; Permpanich, B; Price, R; Raimond, D; Schabenberger, O; Singharaj, P; Singhasivanon, P; Slight, T; Tulayon, S; Tway, KL; Ynint, T; VincentiDelmas, M; deVries, A; Webster, HK				Nosten, F; Luxemburger, C; Kyle, DE; Ballou, WR; Wittes, J; Wah, E; Chongsuphajaisiddhi, T; Gordon, DM; White, NJ; Sadoff, JC; Heppner, DG; Bathe, K; Blood, J; Brockman, A; Cobley, UT; Hacking, D; Hogg, D; U, KH; Maelankiri, L; Chuanak, N; Permpanich, B; Price, R; Raimond, D; Schabenberger, O; Singharaj, P; Singhasivanon, P; Slight, T; Tulayon, S; Tway, KL; Ynint, T; VincentiDelmas, M; deVries, A; Webster, HK			Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand	LANCET			English	Article							PLASMODIUM-FALCIPARUM MALARIA; SYNTHETIC VACCINE; FIELD TRIALS; EFFICACY; IMMUNOGENICITY; ARTESUNATE; SAFETY	Background Previous efficacy trials of SPf66 malaria vaccine have produced conflicting results in different populations. We report a randomised double-blind trial of the SPf66 vaccine conducted in Karen children aged 2-15 living in a malarious region of northwestern Thailand. Recombinant hepatitis B vaccine was used as a comparator. Methods The study had a power of 90% to detect an efficacy of 30%, defined as a reduction in the incidence of first cases of symptomatic falciparum malaria after three doses of vaccine. 1221 children received three immunisations acid were eligible for the primary efficacy analysis. Intense active and passive case detection continued over 15 months of follow-up. Findings The SPf66 vaccine was well tolerated, although 26 children had mild or moderately severe local or systemic allergic reactions, compared with none in the comparator group. The vaccine was immunogenic; after three doses, 73% of recipients had seroconverted. There were no deaths due to malaria during the study. During the 15-month period of evaluation there were 379 first cases of symptomatic falciparum malaria (195 in the SPf66 recipients, 184 in the comparator group); an SPf66 efficacy of -9% (95% CI -33 to 14, p=0.41). No significant differences between the two study groups in parasite density or any other measure of malaria-related morbidity were detected. Interpretation These findings are consistent with a recent study showing lack of efficacy of SPf66 among Gambian infants and differ from earlier positive reports from South America and evidence of borderline efficacy from Tanzania. We conclude that SPf66 does not protect against clinical falciparum malaria and that further efficacy trials are not warranted.	SHOKLO MALARIA RES UNIT,MAE SOT,THAILAND; MAHIDOL UNIV,FAC TROP MED,BANGKOK,THAILAND; AFRIMS,DEPT IMMUNOL & MED,BANGKOK,THAILAND; WALTER REED ARMY INST RES,DIV COMMUNICABLE DIS & IMMUNOL,DEPT IMMUNOL,WASHINGTON,DC; STAT COLLABORAT,WASHINGTON,DC; JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND	Mahidol University; Mahidol University; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of Oxford			White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012; Nosten, Francois/AAC-5509-2019	White, Nick/0000-0002-1897-1978; Nosten, Francois/0000-0002-7951-0745; Kyle, Dennis/0000-0002-0238-965X; Price, Richard/0000-0003-2000-2874	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; AMADOR R, 1992, J INFECT DIS, V166, P139, DOI 10.1093/infdis/166.1.139; BALLOU WR, 1995, PARASITOLOGY, V110, pS25, DOI 10.1017/S0031182000001463; *BORL CO, 1992, DBASE 4 LANG REF; DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; Gordon DM, 1996, AM J TROP MED HYG, V55, P63, DOI 10.4269/ajtmh.1996.55.63; HAYASHI J, 1991, J INFECTION, V23, P39, DOI 10.1016/0163-4453(91)94019-G; Luxemburger C, 1996, T ROY SOC TROP MED H, V90, P105, DOI 10.1016/S0035-9203(96)90102-9; LUXEMBURGER C, 1995, AM J TROP MED HYG, V53, P522, DOI 10.4269/ajtmh.1995.53.522; MORENO A, 1995, CURR OPIN IMMUNOL, V7, P607, DOI 10.1016/0952-7915(95)80064-6; NOSTEN F, 1994, J INFECT DIS, V170, P971, DOI 10.1093/infdis/170.4.971; NOSTEN F, IN PRESS AM J TROP M; PATARROYO G, 1992, VACCINE, V10, P175, DOI 10.1016/0264-410X(92)90008-8; PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0; RILEY E, 1995, CURR OPIN IMMUNOL, V7, P612, DOI 10.1016/0952-7915(95)80065-4; ROCHA CL, 1992, PARASITE IMMUNOL, V14, P95, DOI 10.1111/j.1365-3024.1992.tb00009.x; SALCEDO M, 1991, CLIN EXP IMMUNOL, V84, P122, DOI 10.1111/j.1365-2249.1991.tb08134.x; *SAS I, 1995, SAS V 6 08; VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W; 1990, T R SOC TROP MED S2, V84, P1	21	148	152	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					701	707		10.1016/S0140-6736(96)04465-0	http://dx.doi.org/10.1016/S0140-6736(96)04465-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806288				2022-12-28	WOS:A1996VG37400008
J	Topol, EJ; Califf, R; Granger, C; VandeWerf, F; Aylward, P; Simes, J; Col, J; Armstrong, P; Vahanian, A; Neuhaus, K; Rutsch, W; Ardissino, D; Simoons, M; White, H; Betriu, A; Emanuelsson, H; Pfisterer, M; Beatt, K; Bates, E; Cheseboro, J; Ellis, S; Fuster, V; Gibler, W; Gore, J; Guerci, A; Hochman, J; Holmes, D; Kleiman, N; Morris, D; Ohman, M; Phillips, H; Weaver, D; Lee, K; Woodleaf, L; Miller, G; Bahr, R; Worley, S; Schrading, W; Gilchrist, I; Ibarra, J; Krishnaswami, V; Nygaard, T; Dageforde, D; Puma, J; Palmeri, S; Rosing, D; Dale, H; Boyek, T; Morrice, B; Weinberg, S; Noble, W; VanGilder, J; OToole, J; Jesse, R; Loss, D; Wertheimer, J; Ferrari, D; Santer, M; Strahan, N; Schaeffer, J; Aveington, M; Miller, R; Eich, D; Vrobel, T; Kerieakes, D; Sharma, S; Beckwith, W; Micale, P; Polinski, W; Goodfield, P; Paraschos, A; Chandler, A; Talley, J; Morse, H; Sheridan, F; Silverman, M; Baga, V; Ware, J; Seagle, R; Maddox, W; Schrank, J; Gainey, P; Morris, D; Iwaoka, R; Schneider, R; Ingram, R; Hanger, K; Lane, G; Beeson, W; Williams, D; Beasley, C; Spriggs, D; Schlant, R; Sullebarger, J; Smith, J; Mishkel, D; Williams, C; Gibbs, K; Hearon, B; Gonzales, M; Sheikh, K; Dedonis, J; Long, T; Popio, K; Jamal, N; Lambrew, C; Labib, S; Vorchheimer, D; Weiss, R; Mercadante, N; Guerei, A; Rashkow, A; Balleli, L; Gacioch, G; Niles, N; Seidenstein, H; Hollander, G; Wallach, R; Khan, A; Graham, S; Simons, A; Ward, H; Parkes, R; Watkins, M; DeLuccia, W; Urbach, D; Grodman, R; McCord, D; Bleiberg, M; Corbelli, J; Pepe, A; Zwerner, P; Pinsky, L; Petrovich, L; Lindenberg, B; Therrien, M; Sands, M; Rosenfeld, A; Sheikh, S; Riba, A; Hanovich, G; Swenson, L; Holland, K; Schmidt, P; Besley, D; Hession, W; Ferrigni, F; Meyers, D; Duvernoy, W; Abramowitz, B; Stomel, R; Becker, J; Mooss, A; Thompson, J; Calli, L; Penilla, A; McCriskin, J; Millsaps, R; Heinsimer, J; Pfefferkorn, D; Saddin, M; Fintel, D; Harner, R; Kopecky, S; Andres, P; Cook, L; Wefald, F; Vanderlaan, R; Love, J; Zands, M; Santolin, C; Arnold, A; Oatfield, R; Jaeger, K; Dean, E; Swenson, R; Lancaster, L; Raskin, S; Fehrenbacher, G; Lombardo, T; Strunk, B; Perry, J; Lai, P; Rowe, W; Symkoviak, G; Lee, H; Kwee, H; Woolbert, S; Miller, R; Kaplan, J; Titus, B; Wolfe, C; Cislowski, D; Berndt, T; White, R; Brown, D; Hill, D; Hui, G; Spiegel, R; Wesley, G; Mattern, A; Lapin, E; Stern, M; Kraus, M; Olson, H; Scott, R; Mackenzie, B; Hui, W; Roth, S; Goode, E; Burton, J; Senaratne, M; Traboulsi, M; Greenwood, P; Morgan, C; Ervin, F; McDowell, J; Lefkowitz, C; Sauve, M; Turek, M; Finnie, K; Kuruvilla, G; Lange, A; Charles, J; Kells, C; Vizel, S; Baillie, H; Sahay, B; Roth, D; Lubelsky, B; Jablonsky, G; Lesoway, R; Kowk, K; MacMillan, C; Adelmlan, A; Labinaz, M; Guagliumi, G; Branzi, A; Galvani, M; Mafrici, A; Savonitto, S; Fornaro, G; Colombi, E; Zanuttini, D; Ottani, F; Cavallini, C; Camerini, F; Repetto, S; Vassanelli, C; Rovelli, E; Polese, A; Politi, A; Capucci, A; Mambelli, M; Sabate, X; Masia, R; Bescos, LL; Sendon, JL; Jodar, L; RodriquezLlorian, A; MartinLuengo, C; Saenz, L; FernandezAviles, F; Froufe, J; LomaOsorio, A; Bayon, J; Jeffrey, I; Nelson, G; Walsh, W; Leitch, J; Campbell, T; Healey, J; Owensby, D; Ramsey, D; Grigg, L; Ferderman, J; Newman, R; Strickland, J; Lim, P; Counsell, J; Cross, D; Garrahy, P; Coverdale, S; Bett, N; Aroncy, G; Brown, M; Simmons, G; Horowitz, J; Thompson, P; HOckings, B; Hendricks, R; Thomson, A; Rankin, R; Bouma, H; Cozynsen, L; Stolwijk, P; Drost, H; vanKalmthout, P; Engbers, J; Westendorp, P; Voorburg, J; Veerhoek, M; PaoHan, T; Bogerijen, L; Misier, AR; Bosker, H; Smits, W; Tan, T; Castadot, M; Installe, E; DeMeester, A; Boland, J; Legrand, V; Vanwelden, J; Pirenne, B; Emmerechts, C; Beeuwsaert, R; Thiels, H; Beckers, J; Lesseliers, H; Popeye, R; Quiret, J; Maroni, J; Farah, B; Etienne, Y; Funck, F; Thank, XT; Khalife, K; Leclercq, F; Vitoux, B; Cohen, A; Vacheron, A; Barreau, D; Simon, R; Kreft, H; Ditter, H; Zeiher, A; Weizner, M; Wacker, R; Marbach, M; Nast, H; MeyerHofmann, H; SchmitzHubner, U; Bode, M; Maisch, B; Topp, H; Rutsch, W; Lollgen, H; Williams, M; Durham, D; Bruns, B; Hayes, D; Leslie, P; Hart, H; Ikram, H; Mann, S; Kirk, A; Jardine, D; Rankin, R; Audeau, M; Anandaraja, S; Cooper, I; Hogan, J; Hackett, D; Travill, C; Bridgon, G; Burrell, C; Debelder, M; Rozkovec, A; Kooner, J; James, M; Garcia, E; Risenfors, M; Pfisterer, M; Baur, H; Urban, P; Mocetti, T; Angehrn, W; Bertel, O; Amann, F				Topol, EJ; Califf, R; Granger, C; VandeWerf, F; Aylward, P; Simes, J; Col, J; Armstrong, P; Vahanian, A; Neuhaus, K; Rutsch, W; Ardissino, D; Simoons, M; White, H; Betriu, A; Emanuelsson, H; Pfisterer, M; Beatt, K; Bates, E; Cheseboro, J; Ellis, S; Fuster, V; Gibler, W; Gore, J; Guerci, A; Hochman, J; Holmes, D; Kleiman, N; Morris, D; Ohman, M; Phillips, H; Weaver, D; Lee, K; Woodleaf, L; Miller, G; Bahr, R; Worley, S; Schrading, W; Gilchrist, I; Ibarra, J; Krishnaswami, V; Nygaard, T; Dageforde, D; Puma, J; Palmeri, S; Rosing, D; Dale, H; Boyek, T; Morrice, B; Weinberg, S; Noble, W; VanGilder, J; OToole, J; Jesse, R; Loss, D; Wertheimer, J; Ferrari, D; Santer, M; Strahan, N; Schaeffer, J; Aveington, M; Miller, R; Eich, D; Vrobel, T; Kerieakes, D; Sharma, S; Beckwith, W; Micale, P; Polinski, W; Goodfield, P; Paraschos, A; Chandler, A; Talley, J; Morse, H; Sheridan, F; Silverman, M; Baga, V; Ware, J; Seagle, R; Maddox, W; Schrank, J; Gainey, P; Morris, D; Iwaoka, R; Schneider, R; Ingram, R; Hanger, K; Lane, G; Beeson, W; Williams, D; Beasley, C; Spriggs, D; Schlant, R; Sullebarger, J; Smith, J; Mishkel, D; Williams, C; Gibbs, K; Hearon, B; Gonzales, M; Sheikh, K; Dedonis, J; Long, T; Popio, K; Jamal, N; Lambrew, C; Labib, S; Vorchheimer, D; Weiss, R; Mercadante, N; Guerei, A; Rashkow, A; Balleli, L; Gacioch, G; Niles, N; Seidenstein, H; Hollander, G; Wallach, R; Khan, A; Graham, S; Simons, A; Ward, H; Parkes, R; Watkins, M; DeLuccia, W; Urbach, D; Grodman, R; McCord, D; Bleiberg, M; Corbelli, J; Pepe, A; Zwerner, P; Pinsky, L; Petrovich, L; Lindenberg, B; Therrien, M; Sands, M; Rosenfeld, A; Sheikh, S; Riba, A; Hanovich, G; Swenson, L; Holland, K; Schmidt, P; Besley, D; Hession, W; Ferrigni, F; Meyers, D; Duvernoy, W; Abramowitz, B; Stomel, R; Becker, J; Mooss, A; Thompson, J; Calli, L; Penilla, A; McCriskin, J; Millsaps, R; Heinsimer, J; Pfefferkorn, D; Saddin, M; Fintel, D; Harner, R; Kopecky, S; Andres, P; Cook, L; Wefald, F; Vanderlaan, R; Love, J; Zands, M; Santolin, C; Arnold, A; Oatfield, R; Jaeger, K; Dean, E; Swenson, R; Lancaster, L; Raskin, S; Fehrenbacher, G; Lombardo, T; Strunk, B; Perry, J; Lai, P; Rowe, W; Symkoviak, G; Lee, H; Kwee, H; Woolbert, S; Miller, R; Kaplan, J; Titus, B; Wolfe, C; Cislowski, D; Berndt, T; White, R; Brown, D; Hill, D; Hui, G; Spiegel, R; Wesley, G; Mattern, A; Lapin, E; Stern, M; Kraus, M; Olson, H; Scott, R; Mackenzie, B; Hui, W; Roth, S; Goode, E; Burton, J; Senaratne, M; Traboulsi, M; Greenwood, P; Morgan, C; Ervin, F; McDowell, J; Lefkowitz, C; Sauve, M; Turek, M; Finnie, K; Kuruvilla, G; Lange, A; Charles, J; Kells, C; Vizel, S; Baillie, H; Sahay, B; Roth, D; Lubelsky, B; Jablonsky, G; Lesoway, R; Kowk, K; MacMillan, C; Adelmlan, A; Labinaz, M; Guagliumi, G; Branzi, A; Galvani, M; Mafrici, A; Savonitto, S; Fornaro, G; Colombi, E; Zanuttini, D; Ottani, F; Cavallini, C; Camerini, F; Repetto, S; Vassanelli, C; Rovelli, E; Polese, A; Politi, A; Capucci, A; Mambelli, M; Sabate, X; Masia, R; Bescos, LL; Sendon, JL; Jodar, L; RodriquezLlorian, A; MartinLuengo, C; Saenz, L; FernandezAviles, F; Froufe, J; LomaOsorio, A; Bayon, J; Jeffrey, I; Nelson, G; Walsh, W; Leitch, J; Campbell, T; Healey, J; Owensby, D; Ramsey, D; Grigg, L; Ferderman, J; Newman, R; Strickland, J; Lim, P; Counsell, J; Cross, D; Garrahy, P; Coverdale, S; Bett, N; Aroncy, G; Brown, M; Simmons, G; Horowitz, J; Thompson, P; HOckings, B; Hendricks, R; Thomson, A; Rankin, R; Bouma, H; Cozynsen, L; Stolwijk, P; Drost, H; vanKalmthout, P; Engbers, J; Westendorp, P; Voorburg, J; Veerhoek, M; PaoHan, T; Bogerijen, L; Misier, AR; Bosker, H; Smits, W; Tan, T; Castadot, M; Installe, E; DeMeester, A; Boland, J; Legrand, V; Vanwelden, J; Pirenne, B; Emmerechts, C; Beeuwsaert, R; Thiels, H; Beckers, J; Lesseliers, H; Popeye, R; Quiret, J; Maroni, J; Farah, B; Etienne, Y; Funck, F; Thank, XT; Khalife, K; Leclercq, F; Vitoux, B; Cohen, A; Vacheron, A; Barreau, D; Simon, R; Kreft, H; Ditter, H; Zeiher, A; Weizner, M; Wacker, R; Marbach, M; Nast, H; MeyerHofmann, H; SchmitzHubner, U; Bode, M; Maisch, B; Topp, H; Rutsch, W; Lollgen, H; Williams, M; Durham, D; Bruns, B; Hayes, D; Leslie, P; Hart, H; Ikram, H; Mann, S; Kirk, A; Jardine, D; Rankin, R; Audeau, M; Anandaraja, S; Cooper, I; Hogan, J; Hackett, D; Travill, C; Bridgon, G; Burrell, C; Debelder, M; Rozkovec, A; Kooner, J; James, M; Garcia, E; Risenfors, M; Pfisterer, M; Baur, H; Urban, P; Mocetti, T; Angehrn, W; Bertel, O; Amann, F			A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; THROMBOLYSIS; TRIAL; ANGIOPLASTY; INSIGHTS; ASPIRIN	Background Thrombin has a pivotal role in the pathogenesis of acute coronary thrombosis. We compared the clinical efficacy of a potent, direct thrombin inhibitor, recombinant hirudin, with that of heparin (an indirect antithrombin agent) in patients with unstable angina or acute myocardial infarction. Methods At 373 hospitals in 13 countries, 12,142 patients with acute coronary syndromes were randomly assigned to 72 hours of therapy with either intravenous heparin or hirudin. Patients were stratified according to the presence of ST-segment elevation on the base-line electrocardiogram (4131 patients) or its absence (8011 patients), with the latter characteristic considered to indicate unstable angina or non-Q-wave myocardial infarction. Results At 24 hours, the risk of death or myocardial infarction was significantly lower in the group assigned to hirudin therapy than in the group assigned to heparin (1.3 percent vs. 2.1 percent, P = 0.001). The primary end point of death or nonfatal myocardial infarction or reinfarction at 30 days was reached in 9.8 percent of the heparin group as compared with 8.9 percent of the hirudin group (odds ratio for the risk of the end point in the hirudin group, 0.89; 95 percent confidence interval, 0.79 to 1.00; P = 0.06), The predominant effect of hirudin was on myocardial infarction or reinfarction and was not influenced by ST-segment status. There were no significant differences in the incidence of serious or life-threatening bleeding complications, but hirudin therapy was associated with a higher incidence of moderate bleeding (8.8 percent vs. 7.7 percent, P = 0.03), Conclusions For acute coronary syndromes, recombinant hirudin provided a small advantage, as compared with heparin, principally related to a reduction in the risk of nonfatal myocardial infarction. The relative therapeutic effect was more pronounced early (at 24 hours) but dissipated over time, The small benefit was consistent across the spectrum of acute coronary syndromes and was not associated with a greater risk of major bleeding complications. (C) 1996, Massachusetts Medical Society.			Topol, EJ (corresponding author), CLEVELAND CLIN FDN, DEPT CARDIOL F25, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.		Fuster, Valentin/H-4319-2015; Maisch, Bernhard/AAH-9198-2020; Ardissino, Diego/AAC-4041-2022; Guagliumi, Giulio/K-8006-2016; Smith, Jane/B-6254-2009; Schrading, Walter/AAA-4726-2021	Fuster, Valentin/0000-0002-9043-9986; Topol, Eric/0000-0002-1478-4729				[Anonymous], 1994, Circulation, V90, P1631; [Anonymous], 1994, Circulation, V89, P1545; ANTMAN EM, 1995, 68 SCI SESS AM HEART; ASTER RH, 1995, NEW ENGL J MED, V332, P1374, DOI 10.1056/NEJM199505183322011; BITTL JA, 1995, NEW ENGL J MED, V333, P764, DOI 10.1056/NEJM199509213331204; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CANNON CP, 1994, J AM COLL CARDIOL, V23, P993, DOI 10.1016/0735-1097(94)90581-9; Coller BS, 1995, EUR HEART J, V16, P11, DOI 10.1093/eurheartj/16.suppl_L.11; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; DAVIES MJ, 1990, CIRCULATION, V82, P38; DEMETS DL, 1980, BIOMETRIKA, V67, P651; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; FLATHER M, 1995, CIRCULATION, V92, P485; FUSTER V, 1994, CIRCULATION, V90, P2126, DOI 10.1161/01.CIR.90.4.2126; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; FUSTER V, 1995, CIRCULATION, V91, P256; Granger CB, 1996, CIRCULATION, V93, P870, DOI 10.1161/01.CIR.93.5.870; GRANGER CB, 1995, CIRCULATION, V91, P1929, DOI 10.1161/01.CIR.91.7.1929; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; LEE LV, 1995, AM J CARDIOL, V75, P7, DOI 10.1016/S0002-9149(99)80517-7; LEFKOVITS J, 1994, CIRCULATION, V90, P1522, DOI 10.1161/01.CIR.90.3.1522; LINCOFF AM, 1996, AM COLL CARDIOLOGY S, V622; MANTEL N, 1959, J NATL CANCER I, V22, P719; MERLINI PA, 1995, CIRCULATION, V92, P623; NICOLINI FA, 1994, CIRCULATION, V89, P1802, DOI 10.1161/01.CIR.89.4.1802; SERRUYS PW, 1995, NEW ENGL J MED, V333, P757, DOI 10.1056/NEJM199509213331203; SIMOONS ML, 1996, AM COLL CARDIOLOGY S, V602; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1994, CIRCULATION, V89, P1557, DOI 10.1161/01.CIR.89.4.1557; Wallentin L, 1996, LANCET, V347, P561; ZOLDHELYI P, 1995, CIRCULATION, V92, P1405; 1995, CIRCULATION S1, V92, P416	33	656	668	2	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1996	335	11					775	782						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF786	8778585				2022-12-28	WOS:A1996VF78600003
J	Lerer, LB; Matzopoulos, R				Lerer, LB; Matzopoulos, R			Meeting the challenge of railway injury in a South African city	LANCET			English	Article							SUICIDE; EPIDEMIOLOGY; FATALITIES	Background Efficient and safe transport infrastructure is vital for economic growth in developing countries. The city of Cape Town, South Africa, has an extensive rail network with high levels of injury and violence. We investigated the reporting and frequency of railway injuries and examined their reduction through a range of interventions. Methods We analysed railway injury and death reporting by Cape Town's rail utility, state mortuaries, and a regional trauma survey. The data were obtained over 2.5 years, and the use of more than one data source was necessary to increase the size of the data pool and to determine underreporting. Findings There were 379 railway-related deaths and 505 serious injuries during the study period. Most deaths (190) were train-pedestrian collisions, and the fatality rate on the metropolitan lines was about 60 per 100 million passenger journeys. There was substantial under-reporting by the rail utility of both fatal (20% under-reported) and non-fatal injuries (at least 24%). Many injuries occurred during peak commuting times and alcohol played an important part, especially in pedestrian fatalities. Interpretation Our results demonstrate the importance of a comprehensive, sustainable railway injury surveillance system to promote safety engineering and law enforcement in a metropolitan rail system.			Lerer, LB (corresponding author), MRC,COMMUNITY HLTH RES GRP,POB 19070,ZA-7505 TYGERBERG,SOUTH AFRICA.		Matzopoulos, Richard/AAL-9965-2021	Matzopoulos, Richard/0000-0001-9063-6210				BESKOW J, 1994, SOC SCI MED, V38, P447, DOI 10.1016/0277-9536(94)90446-4; *BRIT MED ASS, 1987, BRIT MED ASS GUID, P82; CINA SJ, 1994, J FORENSIC SCI, V39, P668; CLARKE RV, 1994, SOC SCI MED, V38, P443, DOI 10.1016/0277-9536(94)90445-6; DEKOCK C, 1993, FOCUS, V2, P8; HADDON W, 1980, PUBLIC HEALTH REP, V95, P411; LERER LB, 1995, 1994 S AFR MED RES C; MONK M, 1987, EPIDEMIOL REV, V9, P51, DOI 10.1093/oxfordjournals.epirev.a036308; ODONNELL I, 1994, SOC SCI MED, V38, P409, DOI 10.1016/0277-9536(94)90440-5; ODONNELL I, 1994, SOC SCI MED, V38, P437, DOI 10.1016/0277-9536(94)90444-8; PIRIE GH, 1991, APARTHEID CITY URBAN, P172; SCHMIDTKE A, 1994, SOC SCI MED, V38, P419, DOI 10.1016/0277-9536(94)90441-3; SINGER M, 1988, S AFR MED J, V73, P87; SONNECK G, 1994, SOC SCI MED, V38, P453, DOI 10.1016/0277-9536(94)90447-2; SYMONDS RL, 1994, SOC SCI MED, V38, P431, DOI 10.1016/0277-9536(94)90443-X; Tshabangu Mango, 1978, STAFFRIDER, V1, P27; *URB PROBL RES UN, 1990, 43 UPRU; WARD NJ, 1995, ACCIDENT ANAL PREV, V27, P185, DOI 10.1016/0001-4575(94)00057-S; *WORLD BANK, 1933, 1993 WORLD BANK	19	32	33	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					664	666		10.1016/S0140-6736(96)02100-9	http://dx.doi.org/10.1016/S0140-6736(96)02100-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782759				2022-12-28	WOS:A1996VF60900014
J	Lilford, RJ; Braunholtz, D				Lilford, RJ; Braunholtz, D			For debate - The statistical basis of public policy: A paradigm shift is overdue	BRITISH MEDICAL JOURNAL			English	Article							TRIALS	The recent controversy over the increased risk of venous thrombosis with third generation oral contraceptives illustrates the public policy dilemma that can be created by relying on conventional statistical tests and estimates: case-control. studies showed a significant increase in risk and forced a decision either to warn or not to warn. Conventional statistical tests are an improper basis for such decisions because they dichotomise results according to whether they are or are not significant and do not allow decision makers to take explicit account of additional evidence-for example, of biological plausibility or of biases in the studies. A Bayesian approach overcomes both these problems. A Bayesian analysis starts with a ''prior'' probability distribution for the value of interest (for example, a true relative risk)-based on previous knowledge-and adds the new evidence (via a model) to produce a ''posterior'' probability distribution. Because different experts will have different prior beliefs sensitivity analyses are important to assess the effects on the posterior distributions of these differences. Sensitivity analyses should also examine the effects of different assumptions about biases and about the model which links the data with the value of interest. One advantage of this method is that it allows such assumptions to be handled openly and explicitly, Data presented as a series of posterior probability distributions would be a much better guide to policy, reflecting the reality that degrees of belief are often continuous, not dichotomous, and often vary from one person to another in the face of inconclusive evidence.	UNIV LEEDS,NUFFIELD INST HLTH,LEEDS LS2 9PL,W YORKSHIRE,ENGLAND	University of Leeds	Lilford, RJ (corresponding author), UNIV BIRMINGHAM,BIRMINGHAM B16 9PA,W MIDLANDS,ENGLAND.							ARRIGHI HM, 1994, EPIDEMIOLOGY, V5, P189, DOI 10.1097/00001648-199403000-00009; ASHBY D, 1993, STATISTICIAN, V42, P385; BURING JE, 1995, JAMA-J AM MED ASSOC, V274, P654, DOI 10.1001/jama.274.8.654; Eddy D M, 1990, Int J Technol Assess Health Care, V6, P31; Lewis MA, 1996, BRIT MED J, V312, P88; Lilford RJ, 1995, J ROY SOC MED, V88, P552; LILFORD RJ, 1992, J R COLL PHYS, V26, P1; McPherson K, 1996, BRIT MED J, V312, P68; REIJNEN HBM, 1995, BRIT MED J, V311, P1637; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SHELDON TA, 1990, WASTE LOCATION; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527	13	131	132	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					603	607						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806254				2022-12-28	WOS:A1996VG10800023
J	Kawabata, S; Tsutsumi, R; Kohara, A; Yamaguchi, T; Nakanishi, S; Okada, M				Kawabata, S; Tsutsumi, R; Kohara, A; Yamaguchi, T; Nakanishi, S; Okada, M			Control of calcium oscillations by phosphorylation of metabotropic glutamate receptors	NATURE			English	Article							PROTEIN-KINASE-C; INOSITOL TRISPHOSPHATE; SUBSTRATE-SPECIFICITY; SIGNAL TRANSDUCTION; PHORBOL ESTERS; HAMSTER EGGS; CELLS; EXPRESSION; ACTIVATION; ASTROCYTES	STIMULATION of two metabotropic glutamate-receptor subtypes, mGluR1 and mGluR5, triggers the release of Ca2+ from intracellular stores through the inositol-(1,4,5)trisphosphate (InsP(3)) pathway(1-3). Here rye report that glutamate induces single-peaked intracellular Ca2+ mobilization in mGluR1 alpha-transfected cells but elicits Ca2+ oscillations in mGluR5a-transfected cells, The response patterns of the intracellular Ca2+ increase depend upon the identity of a single amino acid, aspartate (at position 854) or threonine (at position 840), located within the G-protein-interacting domains of mGluR1 alpha and mGluR5a, respectively, Pharmacological and peptide mapping analyses indicated that phosphorylation of the threonine residue at position 840 of mGluR5a by protein kinase C (PKC) is responsible for the generation of Ca2+ oscillations in mGluR5a-expressing cells, To our knowledge this is the first evidence that PKC phosphorylation of G-protein-coupled receptors is important in producing oscillations in intracellular Ca2+ signalling.	YAMANOUCHI PHARMACEUT CO LTD,NEUROSCI & GASTROINTESTINAL RES LAB,INST DRUG DISCOVERY RES,TSUKUBA,IBARAKI 305,JAPAN; KYOTO UNIV,FAC MED,DEPT BIOL SCI,KYOTO 606,JAPAN	Astellas Pharmaceuticals; Kyoto University								ABE T, 1992, J BIOL CHEM, V267, P13361; ALALUF S, 1995, FEBS LETT, V367, P301, DOI 10.1016/0014-5793(95)00575-T; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; CARTER WG, 1995, BIOCHEMISTRY-US, V34, P9488, DOI 10.1021/bi00029a025; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CUTHBERTSON KSR, 1985, NATURE, V316, P541, DOI 10.1038/316541a0; GRAY PTA, 1988, J PHYSIOL-LONDON, V406, P35, DOI 10.1113/jphysiol.1988.sp017367; GRYKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HOUSE C, 1987, J BIOL CHEM, V262, P772; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MILLER S, 1995, J NEUROSCI, V15, P6103; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; OGURA A, 1990, J BIOL CHEM, V265, P3577; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; SHIGEMOTO R, 1993, NEUROSCI LETT, V163, P53, DOI 10.1016/0304-3940(93)90227-C; SKOGLUND G, 1988, CANCER RES, V48, P3168; SPANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017, DOI 10.1073/pnas.86.18.7017; SWANN K, 1989, EMBO J, V8, P3711, DOI 10.1002/j.1460-2075.1989.tb08546.x; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315	29	240	243	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					89	92		10.1038/383089a0	http://dx.doi.org/10.1038/383089a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779726				2022-12-28	WOS:A1996VF29500054
J	Cotter, PA; Miller, JF				Cotter, PA; Miller, JF			Triggering bacterial virulence	SCIENCE			English	Editorial Material							YERSINIA-PSEUDOTUBERCULOSIS; TARGET-CELL; EXPRESSION; TRANSDUCTION; SECRETION; PROTEINS; HOMOLOGY; YOPH				Cotter, PA (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90095, USA.							Barinaga M, 1996, SCIENCE, V272, P1261, DOI 10.1126/science.272.5266.1261; BERGMAN T, 1994, J BACTERIOL, V176, P2619, DOI 10.1128/JB.176.9.2619-2626.1994; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; FINLAY BB, 1989, SCIENCE, V243, P940, DOI 10.1126/science.2919285; HUGHES KT, 1993, SCIENCE, V262, P1277, DOI 10.1126/science.8235660; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; PLANO GV, 1995, J BACTERIOL, V177, P3843, DOI 10.1128/jb.177.13.3843-3854.1995; PORTNOY DA, 1984, INFECT IMMUN, V43, P108, DOI 10.1128/IAI.43.1.108-114.1984; RIMPILAINEN M, 1992, J BACTERIOL, V174, P3355, DOI 10.1128/jb.174.10.3355-3363.1992; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; STRALEY SC, 1993, MOL MICROBIOL, V8, P1005, DOI 10.1111/j.1365-2958.1993.tb01644.x; Zhang JP, 1996, SCIENCE, V273, P1234, DOI 10.1126/science.273.5279.1234	15	21	26	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1996	273	5279					1183	1184		10.1126/science.273.5279.1183	http://dx.doi.org/10.1126/science.273.5279.1183			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VE476	8787124				2022-12-28	WOS:A1996VE47600026
J	Hendra, TJ; Gerrish, SP; Forrest, ARW				Hendra, TJ; Gerrish, SP; Forrest, ARW			Lesson of the week - Fatal methadone overdose	BRITISH MEDICAL JOURNAL			English	Article							TOXICITY		ROYAL HALLAMSHIRE HOSP,DEPT CLIN CHEM,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield	Hendra, TJ (corresponding author), ROYAL HALLAMSHIRE HOSP,DEPT GERIATR MED,DIRECTORATE MED,INTENS CARE UNIT,GLOSSOP RD,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							Clark J C, 1995, J Clin Forensic Med, V2, P143, DOI 10.1016/1353-1131(95)90082-9; DRUMMER OH, 1992, AM J FOREN MED PATH, V13, P346, DOI 10.1097/00000433-199212000-00017; GARRIOTT JC, 1973, CLIN TOXICOL, V6, P163, DOI 10.3109/15563657308990514; HARDINGPINK D, 1993, LANCET, V341, P665, DOI 10.1016/0140-6736(93)90427-I; LOIMER N, 1992, DRUG ALCOHOL DEPEN, V30, P241, DOI 10.1016/0376-8716(92)90058-K; MARKS J, 1994, LANCET, V343, P976, DOI 10.1016/S0140-6736(94)90100-7; OLSEN GD, 1977, CLIN PHARMACOL THER, V21, P147; SCHAUBEN JL, 1991, INTENSIVE CARE MED	8	23	24	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					481	482						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776322				2022-12-28	WOS:A1996VE08000029
J	Julia, V; Rassoulzadegan, M; Glaichenhaus, N				Julia, V; Rassoulzadegan, M; Glaichenhaus, N			Resistance to Leishmania major induced by tolerance to a single antigen	SCIENCE			English	Article							CD4(+) T-CELLS; INTERFERON-GAMMA; MURINE LEISHMANIASIS; CUTANEOUS LEISHMANIASIS; TRANSGENIC MICE; TH2 CLONES; EXPRESSION; INTERLEUKIN-4; LYMPHOCYTES; INFECTION	In mice, susceptibility to Leishmania major is associated with the early expansion of T helper 2 cells (T(H)2) cells, but nothing is known of the specificity of these cells. A previously identified antigen, Leishmania homolog of receptors for activated C kinase (LACK), was found to be the focus of this initial response. Mice made tolerant to LACK by the transgenic expression of the antigen in the thymus exhibited both a diminished T(H)2 response and a healing phenotype. Thus, T cells that are activated early and are reactive to a single antigen play a pivotal role in directing the immune response to the entire parasite.	CNRS, INST PHARMACOL MOL & CELLULAIRE, F-06560 VALBONNE, FRANCE; FAC SCI, INSERM, U273, F-06108 NICE 2, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			Rassoulzadegan, Minoo/O-7939-2016					ACHAORBEA H, 1988, CELL, V54, P263, DOI 10.1016/0092-8674(88)90558-2; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; CAMPOSNETO A, 1995, J EXP MED, V182, P1423, DOI 10.1084/jem.182.5.1423; Carrera L, 1996, J EXP MED, V183, P515, DOI 10.1084/jem.183.2.515; CHANG TL, 1990, J IMMUNOL, V145, P2803; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; Guler ML, 1996, SCIENCE, V271, P984, DOI 10.1126/science.271.5251.984; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; KUMAR V, 1995, P NATL ACAD SCI USA, V92, P9510, DOI 10.1073/pnas.92.21.9510; Liblau RS, 1996, P NATL ACAD SCI USA, V93, P3031, DOI 10.1073/pnas.93.7.3031; MORRIS L, 1993, INT IMMUNOL, V5, P761, DOI 10.1093/intimm/5.7.761; MORRIS L, 1992, J IMMUNOL, V149, P2715; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; REINER S, COMMUNICATION; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641; ROBERTS M, 1993, EUR J IMMUNOGENET, V20, P349, DOI 10.1111/j.1744-313X.1993.tb00154.x; SADICK MD, 1987, J IMMUNOL, V139, P1303; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SCOTT P, 1987, J IMMUNOL, V139, P3118; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SHANKAR AH, 1995, J EXP MED, V181, P845, DOI 10.1084/jem.181.3.845; SOARES LRB, 1994, INT IMMUNOL, V6, P785, DOI 10.1093/intimm/6.5.785; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VANEWIJK W, 1988, CELL, V53, P357, DOI 10.1016/0092-8674(88)90156-0; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809	33	193	204	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 18	1996	274	5286					421	423		10.1126/science.274.5286.421	http://dx.doi.org/10.1126/science.274.5286.421			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832890				2022-12-28	WOS:A1996VN17300053
J	Garcia, KC; Degano, M; Stanfield, RL; Brunmark, A; Jackson, MR; Peterson, PA; Teyton, L; Wilson, IA				Garcia, KC; Degano, M; Stanfield, RL; Brunmark, A; Jackson, MR; Peterson, PA; Teyton, L; Wilson, IA			An alpha beta T cell receptor structure at 2.5 angstrom and its orientation in the TCR-MHC complex	SCIENCE			English	Review							DROSOPHILA-MELANOGASTER CELLS; INFLUENZA-VIRUS NEURAMINIDASE; ANTIBODY-ANTIGEN COMPLEXES; TOXIC LYMPHOCYTES-T; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; CRYSTALLOGRAPHIC REFINEMENT; HYPERVARIABLE REGIONS; IMMUNE RECOGNITION; PROTEIN-STRUCTURE	The central event in the cellular immune response to invading microorganisms is the specific recognition of foreign peptides bound to major histocompatibility complex (MHC) molecules by the alpha beta T cell receptor (TCR). The x-ray structure of the complete extracellular fragment of a glycosylated alpha beta TCR was determined at 2.5 angstroms, and its orientation bound to a class I MHC-peptide (pMHC) complex was elucidated from crystals of the TCR-pMHC complex. The TCR resembles an antibody in the variable V alpha and V beta domains but deviates in the constant C alpha domain and in the interdomain pairing of C alpha with C beta. Four of seven possible asparagine-linked glycosylation sites have ordered carbohydrate moieties, one of which lies in the C alpha-C beta interface. The TCR combining site is relatively flat except for a deep hydrophobic cavity between the hypervariable CDR3s (complementarity-determining regions) of the alpha and beta chains. The 2C TCR covers the class I MHC H-2K(b) binding groove so that the V alpha CDRs 1 and 2 are positioned over the amino-terminal region of the bound dEV8 peptide, the V beta chain CDRs 1 and 2 are over the carboxyl-terminal region of the peptide, and the V alpha and V beta CDR3s straddle the peptide between the helices around the central position of the peptide.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; RW JOHNSON PHARMACEUT RES INST LA JOLLA, SAN DIEGO, CA 92121 USA	Scripps Research Institute; Scripps Research Institute			Degano, Massimo/K-4669-2018; Stanfield, Robyn/AAH-3190-2019	Degano, Massimo/0000-0002-0787-1883; 	NCI NIH HHS [R01 CA58896] Funding Source: Medline; PHS HHS [T32-A107244] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABERGEL C, 1991, EUR J IMMUNOL, V21, P3021, DOI 10.1002/eji.1830211218; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; Bentley GA, 1996, ANNU REV IMMUNOL, V14, P563, DOI 10.1146/annurev.immunol.14.1.563; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAT TN, 1986, PROT STRUCT FUNC GEN, V1, P74; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASPARBAUGUIL S, 1994, SCAND J IMMUNOL, V40, P323, DOI 10.1111/j.1365-3083.1994.tb03469.x; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CHIEN Y, 1984, NATURE, V312, P31, DOI 10.1038/312031a0; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOI YW, 1990, NATURE, V346, P471, DOI 10.1038/346471a0; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CHUNG S, 1994, P NATL ACAD SCI USA, V91, P12654, DOI 10.1073/pnas.91.26.12654; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DOHERTY PC, 1976, TRANSPLANT REV, V29, P89; ENGEL I, 1988, CELL, V54, P473, DOI 10.1016/0092-8674(88)90068-2; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; EPP O, 1974, EUR J BIOCHEM, V45, P513, DOI 10.1111/j.1432-1033.1974.tb03576.x; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FRASER MJ, 1989, IN VITRO CELL DEV B, V25, P225; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; FREMONT DH, COMMUNICATION; FUREY WJ, 1990, AM CRYST ASS 40 ANN; FUREY WJ, 1994, ACTA CRYSTALLOGR D, V50, P760; GARCIA KC, UNPUB; GEISLER C, 1992, J IMMUNOL, V148, P3469; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HE XM, 1992, P NATL ACAD SCI USA, V89, P7154, DOI 10.1073/pnas.89.15.7154; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HERON JN, 1991, PROT STRUCT FUNC GEN, V11, P159; HILYARD KL, 1994, P NATL ACAD SCI USA, V91, P9057, DOI 10.1073/pnas.91.19.9057; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOO WFS, 1992, P NATL ACAD SCI USA, V89, P4759, DOI 10.1073/pnas.89.10.4759; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; Kabat EA, 1991, SEQUENCES PROTEINS I; KATAYAMA CD, 1995, EMBO J, V14, P927, DOI 10.1002/j.1460-2075.1995.tb07074.x; KATZ DH, 1973, J EXP MED, V137, P1405, DOI 10.1084/jem.137.6.1405; KEARSE KP, 1994, EMBO J, V13, P4504, DOI 10.1002/j.1460-2075.1994.tb06772.x; KERSH GJ, IN PRESS J EXP MED; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; KURUCZ I, 1995, IMMUNITY, V2, P281, DOI 10.1016/1074-7613(95)90052-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESCAR J, 1994, PROTEIN SCI, V3, P788; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MALBY RL, 1994, STRUCTURE, V2, P733, DOI 10.1016/S0969-2126(00)00074-5; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOVOTNY J, 1991, P NATL ACAD SCI USA, V88, P8646, DOI 10.1073/pnas.88.19.8646; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PATTEN P, 1984, NATURE, V312, P40, DOI 10.1038/312040a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; SAITO H, 1984, NATURE, V312, P36, DOI 10.1038/312036a0; SantAngelo DB, 1996, IMMUNITY, V4, P367, DOI 10.1016/S1074-7613(00)80250-2; SCHIFFER M, 1992, IMMUNOGENETICS, V35, P224, DOI 10.1007/BF00166827; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHEVACH EM, 1973, J EXP MED, V138, P1213, DOI 10.1084/jem.138.5.1213; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; STRONG RK, 1994, J IMMUNOL, V153, P4111; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; Tallquist MD, 1996, J EXP MED, V184, P1017, DOI 10.1084/jem.184.3.1017; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; WARD ES, 1991, SCAND J IMMUNOL, V34, P215, DOI 10.1111/j.1365-3083.1991.tb01539.x; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WILSON IA, 1991, METHOD ENZYMOL, V203, P153; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WILSON IA, 1991, CIBA F SYMP, V5, P139; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; ZEMEL R, 1994, MOL IMMUNOL, V31, P127, DOI 10.1016/0161-5890(94)90085-X	104	1034	1049	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	1996	274	5285					209	219		10.1126/science.274.5285.209	http://dx.doi.org/10.1126/science.274.5285.209			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824178				2022-12-28	WOS:A1996VM67100032
J	Nightingale, SL				Nightingale, SL			Symposium on deadly diseases and people of color: Are clinical trials an option?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1128	1128						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827954				2022-12-28	WOS:A1996VL33200005
J	deLima, J; LloydThomas, AR; Howard, RF; Summer, E; Quinn, TM				deLima, J; LloydThomas, AR; Howard, RF; Summer, E; Quinn, TM			Infant and neonatal pain: Anaesthetists' perceptions and prescribing patterns	BRITISH MEDICAL JOURNAL			English	Article									GREAT ORMOND ST HOSP CHILDREN NHS TRUST,DEPT ANAESTHESIA,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust				Howard, Richard/0000-0001-9271-0074				AYNSLEYGREEN A, 1995, STRESS PAIN INFANCY; AYNSLEYGREEN A, 1995, STRESS PAIN INFANCY, P449; BEYER JE, 1983, PAIN, V17, P71, DOI 10.1016/0304-3959(83)90129-X; LLOYDTHOMAS AR, 1994, PAEDIATRIC ANAESTHES, V4, P3; PURCELLJONES G, 1988, PAIN, V33, P181, DOI 10.1016/0304-3959(88)90089-9	5	58	60	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					787	787						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842071				2022-12-28	WOS:A1996VK56600023
J	Douglas, A; McCann, I				Douglas, A; McCann, I			Doctors' retainer scheme in Scotland: Time for change?	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS; STRESS	Objectives-To describe the present doctors' retainer scheme in Scotland and ascertain the need for change. Design-Semistructured postal questionnaires to current and past members of the doctors' retainer scheme and general practitioner employers. Setting-Scotland, October to December 1994. Subjects-152/160 current and 104/124 former members responded together with 101/118 general practitioner employers. Results-93% of members currently working in general practice were either vocationally trained or had previously worked as principals. 84% of current members held postgraduate qualifications. 73% of former members had left the scheme within 4 years and 72% of current members had been with the scheme for 4 years or less. 66% of current members said that the scheme prevented them from leaving medicine, Both members and employers were dissatisfied with the current limit of two working sessions per week, 77% of employers wanting it increased, 61% of current members would not have joined the scheme if suitable part time work had been available and 46% of those would have preferred to work flexibly, up to 5 sessions per week. 52% of members do not receive BMA rates of pay and, of those, 46% work more than 3.5 hours per session. Conclusion-The scheme appears to be appreciated and would be more so if inconsistencies in pay and conditions were addressed. An increase in the permitted number of weekly sessions would enable these highly qualified doctors to maintain their skills and confidence.			Douglas, A (corresponding author), SCH MED,ABERDEEN POSTGRAD CTR,POSTGRAD MED DEPT,ABERDEEN AB25 2ZD,SCOTLAND.							ALLEN I, 1988, ANY ROOM TOP; Allen I, 1992, PART TIME WORKING GE; Bahrami J, 1994, ED GEN PRACTICE, V5, P26; BAKER M, 1995, BRIT MED J, V310, P1301, DOI 10.1136/bmj.310.6990.1301; HOWIE JGR, 1992, BRIT J GEN PRACT, V42, P181; OSWALD J, 1994, SCOTTISH MED, V13, P6; *PC, 1992, PART TIM TRAIN WORK; *SCOTT HOM HLTH DE, 1972, 5111972 SHM SHHD; *SCOTT OFF HOM HLT, 1991, 1991 SHHDDGM, P19; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545	10	8	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					792	794						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842073				2022-12-28	WOS:A1996VK56600025
J	Cornwell, EE; Berne, TV; Belzberg, H; Asensio, J; Velmahos, G; Murray, J; Demetriades, D				Cornwell, EE; Berne, TV; Belzberg, H; Asensio, J; Velmahos, G; Murray, J; Demetriades, D			Health care crisis from a trauma center perspective - The LA story	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VIOLENCE; INJURIES; IMPACT		UNIV SO CALIF,DEPT SURG,LOS ANGELES,CA	University of Southern California	Cornwell, EE (corresponding author), UNIV SO CALIF,LOS ANGELES CTY MED CTR,1200 N STATE ST,ROOM 9900,LOS ANGELES,CA 90033, USA.							APRAHAMIAN C, 1990, PROBL GEN SURG, V7, P183; BLOOM D, 1995, LOS ANGELES DAI 0619, P4; BLOOM D, 1995, LOS ANGELES DAI 0619, P6; BRADSHER K, 1995, NY TIMES        0417, pA1; BRADSHER K, 1995, NY TIMES        0827, pA20; BROWN ER, 1991, HLTH INSURANCE COVER; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1059, DOI 10.1001/jama.254.8.1059; CHRISTENSEN NM, 1994, ARCH SURG-CHICAGO, V129, P903; *COMM TRAUM AM COL, 1988, RES OPT CAR INJ PAT; CORNWELL EE, 1995, JAMA-J AM MED ASSOC, V273, P1788, DOI 10.1001/jama.273.22.1788; DEMETRIADES D, 1995, ARCH SURG-CHICAGO, V130, P971; DEMETRIADES D, 1995, ARCH SURG-CHICAGO, V130, P216; *EMPL BEN RES I, 1995, EBRI DAT EMPL BEN; FLEMING AW, 1992, ARCH SURG-CHICAGO, V127, P671; GOLDSTEIN A, 1995, WASH POST       0122, pA1; GOLDSTEIN A, 1995, WASHINGTON POST 1019, pA10; GOLDSTEIN A, 1995, WASHINGTON POST 0326, pB1; GOLDSTEIN A, 1995, WASHINGTON POST 0326, pB5; HILTZIK MA, 1995, LOS ANGELES TIM 1030, pA11; Nance ML, 1996, J TRAUMA, V40, P185, DOI 10.1097/00005373-199602000-00001; NAZARIO S, 1995, LOS ANGELES TIM 1030, pA2; OLIPHANT T, 1995, BOSTON GLOBE    0924, P83; Rosenberg Mark L., 1991, VIOLENCE AM PUBLIC H; SACK K, 1995, NY TIMES        0820, pA24; SACK K, 1995, NY TIMES        0125, pA1; SHACKFORD S, 1985, J TRAUMA, V26, P812; SHUIT DP, 1995, LOS ANGELES TIM 0708, pB8; SHUIT DP, 1995, LOS ANGELES TIM 0212, pA16; SHUIT DP, 1995, LOS ANGELES TIM 0708, pB1; SHUIT DP, 1995, LOS ANGELES TIM 0212, pA1; STAIN SC, 1989, ARCH SURG-CHICAGO, V124, P1136; Velmahos GC, 1996, J TRAUMA, V40, P768, DOI 10.1097/00005373-199605000-00015; WEAVER FA, 1990, ARCH SURG-CHICAGO, V125, P1256; 1995, J TRAUMA, V38, P168	34	22	22	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1996	276	12					940	944		10.1001/jama.276.12.940	http://dx.doi.org/10.1001/jama.276.12.940			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH990	8805716				2022-12-28	WOS:A1996VH99000014
J	Boersma, E; Maas, ACP; Deckers, JW; Simoons, ML				Boersma, E; Maas, ACP; Deckers, JW; Simoons, ML			Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour	LANCET			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; LEFT-VENTRICULAR FUNCTION; RANDOMIZED TRIAL; INTRACORONARY STREPTOKINASE; PREHOSPITAL THROMBOLYSIS; INTRAVENOUS STREPTOKINASE; IMPROVED SURVIVAL; HOSPITAL ARRIVAL; UNSTABLE ANGINA; THERAPY	Background There is conclusive evidence from clinical trials that reduction of mortality by fibrinolytic therapy in acute myocardial infarction is related to the time elapsing between onset of symptoms and commencement of treatment. However, the exact pattern of this relation continues to be debated. This paper discusses whether or not appreciable additional gain can be achieved with very early treatment. Methods The relation between treatment delay and shortterm mortality (up to 35 days) was evaluated using tabulated data from all randomised trials of at least 100 patients (n=22; 50 246 patients) that compared fibrinolytic therapy with placebo or control, reported between 1983 and 1993. Findings Benefit of fibrinolytic therapy was 65 (SD 14), 37 (9), 26 (6) and 29 (5) lives saved per 1000 treated patients in the 0-1, 1-2, 2-3, and 3-6 h intervals, respectively. Proportional mortality reduction was significantly higher in patients treated within 2 h compared to those treated later (44% [95% CI 32, 53] vs 20% [15, 25]; p=0.001). The relation between treatment delay and mortality reduction per 1000 treated patients was expressed significantly better by a non-linear (19.4-0.6x+29.3x(-1)) than a linear (34.7-1.6x) regression equation (p=0.03). Interpretation The beneficial effect of fibrinolytic therapy is substantially higher in patients presenting within 2 h after symptom onset compared to those presenting later.	ERASMUS UNIV ROTTERDAM, NL-3015 GD ROTTERDAM, NETHERLANDS; ACAD HOSP ROTTERDAM DIJKZIGT, NL-3015 GD ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC								[Anonymous], 1994, Circulation, V89, P1545; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1993, Lancet, V342, P767; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; ARMSTRONG PW, 1989, J AM COLL CARDIOL, V13, P1469, DOI 10.1016/0735-1097(89)90334-3; BAR FW, 1992, CIRCULATION, V86, P131, DOI 10.1161/01.CIR.86.1.131; BARBASH GI, 1990, AM J CARDIOL, V66, P261, DOI 10.1016/0002-9149(90)90832-L; BOUTEN MJM, 1992, EUR HEART J, V13, P925, DOI 10.1093/oxfordjournals.eurheartj.a060294; BRUNELLI C, 1988, Cardiologia (Rome), V33, P669; BRUNELLI C, 1991, AM J CARDIOL, V68, pB110, DOI 10.1016/0002-9149(91)90393-Y; CASTAIGNE AD, 1989, AM J CARDIOL, V64, pA30, DOI 10.1016/0002-9149(89)90927-2; CHAMBERLAIN DA, 1988, LANCET, V1, P545; DAVIES GJ, 1984, NEW ENGL J MED, V311, P1488, DOI 10.1056/NEJM198412063112306; DORADO DG, 1987, CARDIOVASC RES, V21, P537; FATHORDOUBAD F, 1994, CIRCULATION, V90, P325; FATHORDOUBADI F, 1994, LANCET, V343, P912, DOI 10.1016/S0140-6736(94)90029-9; FLAMENG W, 1990, BASIC RES CARDIOL, V85, P392, DOI 10.1007/BF01907131; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; HAMPTON J, 1993, LANCET, V342, P759; HERMENS WT, 1992, LANCET, V340, P1297, DOI 10.1016/0140-6736(92)93003-6; HOLMBERG S, 1990, AM J CARDIOL, V65, P401; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; HUNT D, 1992, LANCET, V339, P753; IKRAM S, 1986, BRIT MED J, V293, P786, DOI 10.1136/bmj.293.6550.786; Julian DG, 1996, EUR HEART J, V17, P43; KENNEDY JW, 1988, CIRCULATION, V77, P345, DOI 10.1161/01.CIR.77.2.345; KENNEDY JW, 1983, NEW ENGL J MED, V309, P1477, DOI 10.1056/NEJM198312153092402; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; MCALEER B, 1992, CARDIOVASC DRUG THER, V6, P369, DOI 10.1007/BF00054183; MCNEILL AJ, 1991, Q J MED, V79, P487; MCNEILL AJ, 1989, BRIT HEART J, V61, P316; OROURKE M, 1988, CIRCULATION, V77, P1311, DOI 10.1161/01.CIR.77.6.1311; REIMER KA, 1977, CIRCULATION, V56, P786, DOI 10.1161/01.CIR.56.5.786; REIMER KA, 1993, AM J CARDIOL, V72, pG13, DOI 10.1016/0002-9149(93)90102-I; RENTROP KP, 1989, CIRCULATION, V80, P1166, DOI 10.1161/01.CIR.80.5.1166; ROSSI P, 1991, AM J CARDIOL, V68, P585, DOI 10.1016/0002-9149(91)90348-O; SCHAPER W, 1987, J MOL CELL CARDIOL, V19, P19, DOI 10.1016/S0022-2828(87)80542-4; SCHOFER J, 1990, AM J CARDIOL, V66, P1429, DOI 10.1016/0002-9149(90)90528-9; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1993, CIRCULATION, V88, P2556, DOI 10.1161/01.CIR.88.6.2556; SIMOONS ML, 1985, LANCET, V2, P578; THOMPSON PL, 1988, LANCET, V1, P203; TURI ZG, 1986, AM J CARDIOL, V58, P203, DOI 10.1016/0002-9149(86)90047-0; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; VERMEER F, 1986, CIRCULATION, V74, P1379, DOI 10.1161/01.CIR.74.6.1379; VERSTRAETE M, 1985, LANCET, V2, P965; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WEAVER WD, 1995, J AM COLL CARDIOL, V25, pS3; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; WILCOX RG, 1988, LANCET, V2, P525; YARZEBSKI J, 1994, AM HEART J, V128, P255, DOI 10.1016/0002-8703(94)90477-4	52	831	885	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	1996	348	9030					771	775		10.1016/S0140-6736(96)02514-7	http://dx.doi.org/10.1016/S0140-6736(96)02514-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813982	Green Submitted			2022-12-28	WOS:A1996VH98900008
J	Wokke, J				Wokke, J			Riluzole	LANCET			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; AMINO-ACID NEUROTRANSMISSION; CU,ZN SUPEROXIDE-DISMUTASE; MOTOR-NEURON DISEASE; 2-AMINO-6-TRIFLUOROMETHOXY BENZOTHIAZOLE; POSSIBLE ANTAGONIST; GLUTAMATE; MODEL; NEUROTOXICITY; MUTATIONS				Wokke, J (corresponding author), UNIV UTRECHT HOSP, DEPT NEUROL, NL-3508 GA UTRECHT, NETHERLANDS.							BARINAGA M, 1994, SCIENCE, V264, P772, DOI 10.1126/science.8171331; BENAVIDES J, 1985, NEUROPHARMACOLOGY, V24, P1085, DOI 10.1016/0028-3908(85)90196-0; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BENSIMON G, 1994, NEW ENGL J MED, V331, P273; CHERAMY A, 1992, NEUROSCI LETT, V147, P209, DOI 10.1016/0304-3940(92)90597-Z; COURATIER P, 1994, NEUROREPORT, V5, P1012, DOI 10.1097/00001756-199404000-00040; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DOBLE A, 1992, NEUROSCI LETT, V140, P251, DOI 10.1016/0304-3940(92)90114-M; DRACHMAN DB, 1994, ANN NEUROL, V35, P142, DOI 10.1002/ana.410350205; DRACHMAN DB, 1989, ANN NEUROL, V26, P269, DOI 10.1002/ana.410260214; ESTEVEZ AG, 1995, EUR J PHARMACOL, V280, P47, DOI 10.1016/0014-2999(95)00186-O; FISHMAN PS, 1995, NEUROLOGY, V45, P1551, DOI 10.1212/WNL.45.8.1551; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707; HERN JEC, 1992, J NEUROL NEUROSUR PS, V55, P536; JONES CT, 1993, LANCET, V342, P1050, DOI 10.1016/0140-6736(93)92905-9; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LONGO FM, 1994, ANN NEUROL, V36, P125, DOI 10.1002/ana.410360202; MACRAE KD, 1994, NEW ENGL J MED, V331, P272; MALGOURIS C, 1989, J NEUROSCI, V9, P3720; MIZOULE J, 1985, NEUROPHARMACOLOGY, V24, P767, DOI 10.1016/0028-3908(85)90011-5; MURPHY JR, 1994, NEW ENGL J MED, V331, P273; NIGHTINGALE SL, 1995, JAMA-J AM MED ASSOC, V274, P292; Olney J W, 1986, Adv Exp Med Biol, V203, P631; ROOS RR, 1995, NEUROLOGY, V45, P1779, DOI 10.1212/WNL.45.9.1779; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; ROTHSTEIN JD, 1995, J NEUROCHEM, V65, P643; ROWLAND LP, 1994, NEW ENGL J MED, V330, P636, DOI 10.1056/NEJM199403033300911; SHAW PJ, 1995, ANN NEUROL, V38, P691, DOI 10.1002/ana.410380424; SMITH RG, 1992, NEW ENGL J MED, V327, P1721, DOI 10.1056/NEJM199212103272405; STUTZMANN JM, 1988, NEUROSCI LETT, V88, P195, DOI 10.1016/0304-3940(88)90125-5; SWASH M, 1992, NEUROMUSCULAR DISORD, V2, P7, DOI 10.1016/0960-8966(92)90020-7; Tandan Rup, 1994, P3	38	111	112	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	1996	348	9030					795	799		10.1016/S0140-6736(96)03181-9	http://dx.doi.org/10.1016/S0140-6736(96)03181-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813989				2022-12-28	WOS:A1996VH98900015
J	Chen, P; Hochstrasser, M				Chen, P; Hochstrasser, M			Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly	CELL			English	Article							PROTEIN-DEGRADATION; IN-VIVO; UBIQUITIN; ACIDOPHILUM; COMPLEXES; DIMER; CELL	The eukaryotic 20S proteasome is responsible for the degradation of many cellular proteins, but how it is assembled and how its distinct active sites are formed are not understood. Like other proteasome subunits, the yeast Doa3 protein is synthesized in precursor form. We show that the N-terminal propeptide is required for Doa3 incorporation into the proteasome and, remarkably, that the propeptide functions in trans, suggesting it serves a chaperone-like function in proteasome biogenesis. Propeptide processing is not required for proteasome assembly but is needed for maturation of a specific subset of active sites. The likely nucleophile for these sites is provided by the N-terminal threonine of mature Doa3. Additional data indicate that precursor processing is autocatalytic and requires association of the two halves of the proteasome particle, thereby preventing formation of proteolytic sites until the central hydrolytic chamber has been sealed off from the rest of the cell.			Chen, P (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOL BIOL,CHICAGO,IL 60637, USA.			Hochstrasser, Mark/0000-0002-1131-5484	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046904] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07183, GM46904] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1988, MOL REPROD DEV; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; DEMARINI DJ, 1995, MOL CELL BIOL, V15, P6311; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Hochstrasser M, 1995, COLD SPRING HARB SYM, V60, P503, DOI 10.1101/SQB.1995.060.01.054; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; KOPP F, 1995, J MOL BIOL, V248, P264; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	20	307	312	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					961	972		10.1016/S0092-8674(00)80171-3	http://dx.doi.org/10.1016/S0092-8674(00)80171-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808631	Bronze			2022-12-28	WOS:A1996VJ44300014
J	Horsburgh, BC; Kollmus, H; Hauser, H; Coen, DM				Horsburgh, BC; Kollmus, H; Hauser, H; Coen, DM			Translational recoding induced by G-rich mRNA sequences that form unusual structures	CELL			English	Article							ORNITHINE DECARBOXYLASE ANTIZYME; IMMUNODEFICIENCY-VIRUS TYPE-1; PROGRAMMED FRAMESHIFT SITE; RESISTANT HERPES-SIMPLEX; THYMIDINE KINASE; TRANSFER-RNA; DNA-POLYMERASE; TELOMERIC DNA; QUARTET STRUCTURES; EXPRESSION	We investigated a herpesvirus mutant that contains a single base insertion in its thymidine kinase (tk) gene yet expresses low levels of TK via a net + 1 translational recoding event. Within this mutant gene, we defined a G-rich signal that is sufficient to induce recoding. Unlike other translational recoding events, downstream RNA structures or termination codons did not stimulate recoding, and paused ribosomes were not detected. Mutational analysis indicated that specific tRNAs or codon-anticodon slippage were unlikely to account for recoding. Rather, recoding efficiency correlated with the G-richness of the signal and its ability to form unusual structures. These findings identify a mechanism of translational recoding with unique features and potential implications for clinical drug resistance and other biological systems.	GESELL BIOTECHNOL FORSCH MBH,GENET EUKARYOTES,D-38124 BRAUNSCHWEIG,GERMANY	Gesellschaft fur Biotechnologische Forschung mbH	Horsburgh, BC (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026126] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26126, R01 AI026126] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BENHAR I, 1993, CELL, V72, P121, DOI 10.1016/0092-8674(93)90056-V; BRIERLEY I, 1992, J MOL BIOL, V227, P463, DOI 10.1016/0022-2836(92)90901-U; BROWN DG, 1995, NAT STRUCT BIOL, V2, P876, DOI 10.1038/nsb1095-876; COEN DM, 1980, P NATL ACAD SCI-BIOL, V77, P2265, DOI 10.1073/pnas.77.4.2265; COEN DM, 1989, P NATL ACAD SCI USA, V86, P4735; CURRAN JF, 1993, NUCLEIC ACIDS RES, V21, P1837, DOI 10.1093/nar/21.8.1837; DIGARD P, 1993, J VIROL, V67, P398, DOI 10.1128/JVI.67.1.398-406.1993; EFSTATHIOU S, 1989, J GEN VIROL, V70, P869, DOI 10.1099/0022-1317-70-4-869; ENGLUND JA, 1990, ANN INTERN MED, V112, P416, DOI 10.7326/0003-4819-76-3-112-6-416; FARABAUGH PJ, 1993, CELL, V74, P93, DOI 10.1016/0092-8674(93)90297-4; Farabaugh PJ, 1996, MICROBIOL REV, V60, P103, DOI 10.1128/MMBR.60.1.103-134.1996; FYFE JA, 1978, J BIOL CHEM, V253, P8721; GESTELAND RF, 1992, SCIENCE, V257, P1640, DOI 10.1126/science.1529352; GROSJEAN HJ, 1978, P NATL ACAD SCI USA, V75, P610, DOI 10.1073/pnas.75.2.610; GUPTA RC, 1980, BIOCHEMISTRY-US, V19, P1699, DOI 10.1021/bi00549a028; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; HERBST KL, 1994, P NATL ACAD SCI USA, V91, P12525, DOI 10.1073/pnas.91.26.12525; HIRSCH MS, 1989, NEW ENGL J MED, V320, P313, DOI 10.1056/NEJM198902023200510; HWANG CBC, 1994, P NATL ACAD SCI USA, V91, P5461, DOI 10.1073/pnas.91.12.5461; HWANG CBC, 1995, GENE, V152, P191, DOI 10.1016/0378-1119(94)00712-2; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; JACOBSON JG, 1993, J VIROL, V67, P6903, DOI 10.1128/JVI.67.11.6903-6908.1993; KALNIK MW, 1989, J BIOL CHEM, V264, P3702; KIT S, 1987, ANTIMICROB AGENTS CH, V31, P1483, DOI 10.1128/AAC.31.10.1483; KOLLMUS H, 1994, J VIROL, V68, P6087, DOI 10.1128/JVI.68.9.6087-6091.1994; KURLAND CG, 1992, ANNU REV GENET, V26, P29, DOI 10.1146/annurev.ge.26.120192.000333; LARSEN B, 1994, J BACTERIOL, V176, P6842, DOI 10.1128/JB.176.22.6842-6851.1994; LEBOWITZ JH, 1991, GENE, V103, P119, DOI 10.1016/0378-1119(91)90402-W; LINDSLEY D, 1993, P NATL ACAD SCI USA, V90, P5469, DOI 10.1073/pnas.90.12.5469; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; PANDE S, 1995, MOL CELL BIOL, V15, P298, DOI 10.1128/MCB.15.1.298; REIL H, 1993, J VIROL, V67, P5579, DOI 10.1128/JVI.67.9.5579-5584.1993; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; SACKS SL, 1989, ANN INTERN MED, V111, P893, DOI 10.7326/0003-4819-111-11-893; SCHENBORN E, 1993, PROMEGA NOTES, V41, P11; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SOMOGYI P, 1993, MOL CELL BIOL, V13, P6931, DOI 10.1128/MCB.13.11.6931; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; TU CL, 1992, P NATL ACAD SCI USA, V89, P8636, DOI 10.1073/pnas.89.18.8636; VIMALADITHAN A, 1994, MOL CELL BIOL, V14, P8107, DOI 10.1128/MCB.14.12.8107; Weiss R B, 1990, Prog Nucleic Acid Res Mol Biol, V39, P159, DOI 10.1016/S0079-6603(08)60626-1; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415; ZIMMERMAN SB, 1975, J MOL BIOL, V92, P181, DOI 10.1016/0022-2836(75)90222-3	49	57	59	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					949	959		10.1016/S0092-8674(00)80170-1	http://dx.doi.org/10.1016/S0092-8674(00)80170-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808630	Green Published, Bronze			2022-12-28	WOS:A1996VJ44300013
J	Rybin, V; Ullrich, O; Rubino, M; Alexandrov, K; Simon, I; Seabra, MC; Goody, R; Zerial, M				Rybin, V; Ullrich, O; Rubino, M; Alexandrov, K; Simon, I; Seabra, MC; Goody, R; Zerial, M			GTPase activity of Rab5 acts as a timer for endocytic membrane fusion	NATURE			English	Article							GDP-DISSOCIATION INHIBITOR; ELONGATION-FACTOR-TU; NUCLEOTIDE EXCHANGE; BINDING PROTEINS; ENDOSOME FUSION; INVITRO; ASSOCIATION; REGULATOR; EFFECTOR; PATHWAY	THE GTPase cycle is a versatile regulatory mechanism directing many cell functions(1), and Rab family members use it to regulate intracellular transport(2-4). Current models propose that GTP hydrolysis by Rah proteins is either required for membrane fusion or occurs afterwards to allow recycling of the protein(1-4). To measure the GTPase activity of Rab5 in endocytic membrane fusion(5), we engineered a mutant that preferentially binds xanthosine 5'-triphosphate (XTP), Rab5(D136N) and monitored the kinetics of [alpha(32)P]-XTP hydrolysis in situ during endosome fusion in vitro. Surprisingly, nucleotide hydrolysis occurred even in the absence of membrane fusion, indicating that membrane-bound Rab5 undergoes futile cycles of GTP (XTP) binding and hydrolysis. Nucleotide triphosphate hydrolysis by Rab5 is not conditional on membrane Fusion and is reduced by its effector Rabaptin-5 (ref. 6). Our data reveal that the GTP cycle of Rab proteins differs from that of other GTPases (for example, EF-Tu) and indicate that GTP hydrolysis acts as a timer that determines the frequency of membrane docking/fusion events.	EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY; UNIV MAINZ,INST BIOCHEM,D-55128 MAINZ,GERMANY; MAX PLANCK INST MOL PHYSIOL,D-44139 DORTMUND,GERMANY; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235	European Molecular Biology Laboratory (EMBL); Johannes Gutenberg University of Mainz; Max Planck Society; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019; Alexandrov, Kirill/A-5830-2013; Goody, Roger S/J-8845-2014	Seabra, Miguel C/0000-0002-6404-4892; Alexandrov, Kirill/0000-0002-0957-6511; Goody, Roger S/0000-0002-0772-0444				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HUBER LA, 1994, P NATL ACAD SCI USA, V91, P7874, DOI 10.1073/pnas.91.17.7874; JONES S, 1995, J CELL BIOL, V130, P1051, DOI 10.1083/jcb.130.5.1051; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SIMON I, IN PRESS J BIOL CHEM; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P245, DOI 10.1016/0968-0004(94)90149-X; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	30	267	271	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					266	269		10.1038/383266a0	http://dx.doi.org/10.1038/383266a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805704				2022-12-28	WOS:A1996VH31500056
J	Goff, SP				Goff, SP			Operating under a gag order: A block against incoming virus by the Fv1 gene	CELL			English	Review							MURINE LEUKEMIA VIRUSES; LOCUS AFFECTING RESISTANCE; HOST-RANGE RESTRICTIONS; MOUSE EMBRYO; INFECTION		COLUMBIA UNIV, DEPT MICROBIOL & BIOCHEM, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT MOL BIOPHYS, NEW YORK, NY 10032 USA	Columbia University; Columbia University	Goff, SP (corresponding author), COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.		Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547				Best S, 1996, NATURE, V382, P826, DOI 10.1038/382826a0; CORDONNIER A, 1995, J VIROL, V69, P5890, DOI 10.1128/JVI.69.9.5890-5897.1995; DECLEVE A, 1975, VIROLOGY, V65, P320, DOI 10.1016/0042-6822(75)90038-0; DESGROSEILLERS L, 1983, J VIROL, V48, P685, DOI 10.1128/JVI.48.3.685-696.1983; DURANTROISE G, 1977, CELL, V10, P479, DOI 10.1016/0092-8674(77)90035-6; GARDNER M, 1986, CURR TOP MICROBIOL, V127, P338; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; HARTLEY JW, 1970, J VIROL, V5, P221, DOI 10.1128/JVI.5.2.221-225.1970; HARTLEY JW, 1975, VIROLOGY, V65, P128, DOI 10.1016/0042-6822(75)90013-6; Jolicoeur P, 1979, Curr Top Microbiol Immunol, V86, P67; JOLICOEUR P, 1976, P NATL ACAD SCI USA, V73, P2236, DOI 10.1073/pnas.73.7.2236; JOLICOEUR P, 1975, J VIROL, V16, P1593, DOI 10.1128/JVI.16.6.1593-1598.1975; KASHMIRI SVS, 1977, J VIROL, V22, P626, DOI 10.1128/JVI.22.3.626-633.1977; Lilly F., 1973, Advances in Cancer Research, V17, P231, DOI 10.1016/S0065-230X(08)60532-1; ODONNELL PV, 1976, VIROLOGY, V73, P23, DOI 10.1016/0042-6822(76)90057-X; OU CY, 1983, J VIROL, V48, P779, DOI 10.1128/JVI.48.3.779-784.1983; PINCUS T, 1971, J EXP MED, V133, P1219, DOI 10.1084/jem.133.6.1219; REIN A, 1976, CELL, V7, P373, DOI 10.1016/0092-8674(76)90166-5; ROWE WP, 1973, J EXP MED, V137, P850, DOI 10.1084/jem.137.3.850; YOSHIKURA H, 1975, J GEN VIROL, V29, P1, DOI 10.1099/0022-1317-29-1-1	20	57	58	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1996	86	5					691	693		10.1016/S0092-8674(00)80141-5	http://dx.doi.org/10.1016/S0092-8674(00)80141-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797814	hybrid			2022-12-28	WOS:A1996VG37200001
J	Carmeliet, P; Mackman, N; Moons, L; Luther, T; Gressens, P; VanVlaenderen, I; Demunck, H; Kasper, M; Breier, G; Evrard, P; Muller, M; Risau, W; Edgington, T; Collen, D				Carmeliet, P; Mackman, N; Moons, L; Luther, T; Gressens, P; VanVlaenderen, I; Demunck, H; Kasper, M; Breier, G; Evrard, P; Muller, M; Risau, W; Edgington, T; Collen, D			Role of tissue factor in embryonic blood vessel development	NATURE			English	Article							DEFICIENT MICE; MOUSE EMBRYOS; EXPRESSION; CELLS; HEMATOPOIESIS	TISSUE factor, a member of the cytokine-receptor superfamily and high-affinity receptor and cofactor for plasma factor VII/VIIa (ref, 1), is the primary cellular initiator of blood coagulation. It is involved in thrombosis and inflammation associated with sepsis, atherosclerosis and cancer(2), and can participate in other cellular processes including intracellular signalling(3), metastasis(4), tumour-associated angiogenesis(5), and embryogenesis(6). Here we report that inactivation of the tissue factor gene (TF) results in abnormal circulation from yolk sac to embryo beyond embryonic day 8.5, leading to embryo wasting and death, Vitelline vessels from null mice were deficient in smooth-muscle a-actin-expressing mesenchymal cells, which participate in organization of the vessel wall, This implies that tissue factor has a role in blood-vessel development.	CATHOLIC UNIV LEUVEN VIB, CTR TRANSGENE TECHNOL & GENE THERAPY, B-3000 LOUVAIN, BELGIUM; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; TECH UNIV DRESDEN, INST PATHOL, D-01307 DRESDEN, GERMANY; HOP ROBERT DEBRE, LAB NEUROL DEV, F-75019 PARIS, FRANCE; UNIV HOSP LEUVEN, LAB EXPT HEMATOL, B-3000 LOUVAIN, BELGIUM; MAX PLANCK INST PHYSIOL & CLIN RES, WG KERCKHOFF INST, ABT MOL ZELLBIOL, D-6350 BAD NAUHEIM, GERMANY	Flanders Institute for Biotechnology (VIB); KU Leuven; Scripps Research Institute; Scripps Research Institute; Technische Universitat Dresden; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; KU Leuven; University Hospital Leuven; Universite Catholique Louvain; Max Planck Society			gressens, pierre/M-7557-2017; Breier, Georg/E-3580-2016; Carmeliet, Peter/AAQ-5140-2020	gressens, pierre/0000-0002-0909-4221; Breier, Georg/0000-0002-9467-780X; Carmeliet, Peter/0000-0001-7961-1821; Mackman, Nigel/0000-0002-9170-7700; Moons, Lieve (Godelieve)/0000-0003-0186-1411	NHLBI NIH HHS [P01 HL16411] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTIERI DC, 1995, FASEB J, V9, P860; BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHEN BY, 1991, TERATOLOGY, V44, P581, DOI 10.1002/tera.1420440511; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; GRESSENS P, 1992, J NEUROPATH EXP NEUR, V51, P206, DOI 10.1097/00005072-199203000-00010; HUME DA, 1995, BRIT J HAEMATOL, V90, P939, DOI 10.1111/j.1365-2141.1995.tb05220.x; KASPER M, 1995, HISTOCHEM CELL BIOL, V104, P397, DOI 10.1007/BF01458134; Luther T, 1996, AM J PATHOL, V149, P101; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; NEHLS V, 1993, HISTOCHEMISTRY, V99, P1, DOI 10.1007/BF00268014; RICKLES FR, 1992, CANCER METAST REV, V11, P237, DOI 10.1007/BF01307180; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Sato Y, 1996, THROMB HAEMOSTASIS, V75, P389; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	23	564	581	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					73	75		10.1038/383073a0	http://dx.doi.org/10.1038/383073a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779717				2022-12-28	WOS:A1996VF29500049
J	Frank, LA; Paterson, WR; Ackerson, KL; Vasyliunas, VM; Coroniti, FV; Bolton, SJ				Frank, LA; Paterson, WR; Ackerson, KL; Vasyliunas, VM; Coroniti, FV; Bolton, SJ			Plasma observations at Io with the Galileo spacecraft	SCIENCE			English	Article							ATMOSPHERE	Plasma measurements made during the flyby of Io on 7 December 1995 with the Galileo spacecraft plasma analyzers reveal that the spacecraft unexpectedly passed directly through the ionosphere of Io. The ionosphere is identified by a dense plasma that is at rest with respect to Io. This plasma is cool relative to those encountered outside the ionosphere. The composition of the ionospheric plasmas includes O++, O+ and S++, S+, and SO2+ ions. The plasma conditions at Io appear to account for the decrease in the magnetic field, without the need to assume that Io has a magnetized interior.	MAX PLANCK INST AERON,D-3411 KATLENBURG DUHM,GERMANY; UNIV CALIF LOS ANGELES,DEPT PHYS & ASTRON,LOS ANGELES,CA 90095; CALTECH,JET PROP LAB,PASADENA,CA 91109	Max Planck Society; University of California System; University of California Los Angeles; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Frank, LA (corresponding author), UNIV IOWA,DEPT PHYS & ASTRON,IOWA CITY,IA 52242, USA.		Bolton, Scott/M-4392-2019; Paterson, William/F-5684-2012	bolton, scott/0000-0002-9115-0789				BALLESTER GE, 1994, ICARUS, V111, P2, DOI 10.1006/icar.1994.1129; BANKS PM, 1973, AERONOMY A, P217; BIGG EK, 1964, NATURE, V203, P1008, DOI 10.1038/2031008a0; Brown R. A., 1974, EXPLORATION PLANETAR, P527; DESSLER AJ, 1979, ASTROPHYS J, V227, P664, DOI 10.1086/156777; FRANK LA, 1992, SPACE SCI REV, V60, P283, DOI 10.1007/BF00216858; GOLDREICH P, 1969, ASTROPHYS J, V156, P59, DOI 10.1086/149947; GURNETT DA, 1972, ASTROPHYS J, V175, P525, DOI 10.1086/151576; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; KUPO I, 1976, ASTROPHYS J, V205, pL51, DOI 10.1086/182088; MORABITO LA, 1979, SCIENCE, V204, P972, DOI 10.1126/science.204.4396.972; NESS NF, 1979, SCIENCE, V204, P982, DOI 10.1126/science.204.4396.982; NEUBAUER FM, 1980, J GEOPHYS RES-SPACE, V85, P1171, DOI 10.1029/JA085iA03p01171; PIDDINGTON JH, 1968, NATURE, V217, P935, DOI 10.1038/217935a0; SCHNEIDER NM, 1991, ASTROPHYS J, V368, P298, DOI 10.1086/169694; SOUTHWOOD DJ, 1980, J GEOPHYS RES-SPACE, V85, P5959, DOI 10.1029/JA085iA11p05959; STROBEL DF, 1994, ICARUS, V111, P18, DOI 10.1006/icar.1994.1130; WILSON JK, 1994, ICARUS, V111, P31, DOI 10.1006/icar.1994.1131	18	175	177	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					394	395		10.1126/science.274.5286.394	http://dx.doi.org/10.1126/science.274.5286.394			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832882				2022-12-28	WOS:A1996VN17300045
J	Pearce, SHS; Williamson, C; Kifor, O; Bai, M; Coulthard, MG; Davies, M; LewisBarned, N; McCredie, D; Powell, H; KendallTaylor, P; Brown, EM; Thakker, RV				Pearce, SHS; Williamson, C; Kifor, O; Bai, M; Coulthard, MG; Davies, M; LewisBarned, N; McCredie, D; Powell, H; KendallTaylor, P; Brown, EM; Thakker, RV			A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AUTOSOMAL-DOMINANT HYPOPARATHYROIDISM; EXTRACELLULAR CA2+-SENSING RECEPTOR; NEONATAL SEVERE HYPERPARATHYROIDISM; BENIGN HYPOCALCIURIC HYPERCALCEMIA; PARATHYROID-HORMONE GENE; CHILDREN; LINKAGE; CLONING; LOCUS; CELLS	Background The calcium-sensing receptor regulates the secretion of parathyroid hormone in response to changes in extracellular calcium concentrations, and mutations that result in a loss of function of the receptor are associated with familiar hypocalciuric hypercalcemia. Mutations involving a gain of function have been associated with hypocalcemia in two kindreds. We examined the possibility that the latter type of mutation may result in a phenotype of familial hypocalcemia with hypercalciuria. Methods We studied six kindreds given a diagnosis of autosomal dominant hypoparathyroidism on the basis of their hypocalcemia and normal serum parathyroid hormone concentrations, a combination that suggested a defect of the calcium-sensing receptor. The hypocalcemia was associated with hypercalciuria, and treatment with vitamin D resulted in increased hypercalciuria, nephrocalcinosis, and renal impairment. Mutations in the calcium-sensing-receptor gene were identified by DNA-sequence analysis and expressed in human embryonic kidney cells (HEK-293). Results Five heterozygous missense mutations (Asn118Lys, Phe128Leu, Thr151Met, Glu191Lys, and Phe612Ser) were detected in the extracellular domain of the calcium-sensing-receptor gene and shown to cosegregate with the disease. Analysis of the functional expression of three of the mutant receptors in HEK-293 cells demonstrated shifts in the dose-response curves so that the extracellular calcium concentrations needed to produce half-maximal increases in total inositol phosphate in the cells were significantly (P = 0.02 to P < 0.001) lower than those required for the wild-type receptor. Conclusions Gain-of-function mutations in the calcium-sensing receptor are associated with a familial syndrome of hypocalcemia with hypercalciuria that needs to be distinguished from hypoparathyroidism.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,CLIN SCI CTR,MOL ENDOCRINOL GRP,LONDON W12 0NN,ENGLAND; BRIGHAM & WOMENS HOSP,DIV ENDOCRINE HYPERTENS,BOSTON,MA 02115; ROYAL VICTORIA INFIRM,PEDIAT UNIT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; ROYAL VICTORIA INFIRM,ENDOCRINE UNIT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; MANCHESTER ROYAL INFIRM,DEPT MED,MANCHESTER M13 9WL,LANCS,ENGLAND; UNIV OTAGO,DEPT MED,DUNEDIN,NEW ZEALAND; ROYAL CHILDRENS HOSP,MELBOURNE,VIC,AUSTRALIA	Imperial College London; Harvard University; Brigham & Women's Hospital; Newcastle University - UK; Newcastle University - UK; University of Manchester; University of Otago; Royal Children's Hospital Melbourne			Pearce, Simon/AAB-3692-2019	Pearce, Simon/0000-0001-8384-8063; Williamson, Catherine/0000-0002-6226-7611; Thakker, Rajesh/0000-0002-1438-3220	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048330, R01DK044588, R01DK041415] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44588, DK48330, DK41415] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTONEN J, 1994, NAT GENET, V8, P83, DOI 10.1038/ng0994-83; AHN TG, 1986, MEDICINE, V65, P73, DOI 10.1097/00005792-198603000-00001; AIDA K, 1995, J CLIN ENDOCR METAB, V80, P2594, DOI 10.1210/jc.80.9.2594; ARNOLD A, 1990, J CLIN INVEST, V86, P1084, DOI 10.1172/JCI114811; ATTIE MF, 1983, J CLIN INVEST, V72, P667, DOI 10.1172/JCI111016; BILOUS RW, 1992, NEW ENGL J MED, V327, P1069, DOI 10.1056/NEJM199210083271506; BROWN E, 1987, FEBS LETT, V218, P113, DOI 10.1016/0014-5793(87)81029-3; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BROWN EM, 1995, AM J KIDNEY DIS, V25, P506, DOI 10.1016/0272-6386(95)90118-3; CAREY AH, 1992, AM J HUM GENET, V51, P964; CHOU YHW, 1995, AM J HUM GENET, V56, P1075; DAVIES M, 1984, ACTA ENDOCRINOL-COP, V106, P499, DOI 10.1530/acta.0.1060499; FINEGOLD DN, 1994, PEDIATR RES, V36, P414, DOI 10.1203/00006450-199409000-00024; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; GHAZALI S, 1974, ARCH DIS CHILD, V49, P97, DOI 10.1136/adc.49.2.97; Heath H, 1996, J CLIN ENDOCR METAB, V81, P1312, DOI 10.1210/jcem.81.4.8636323; HEATH H, 1993, AM J HUM GENET, V53, P193; HUNTER AGW, 1981, J MED GENET, V18, P431, DOI 10.1136/jmg.18.6.431; JANICIC N, 1995, AM J HUM GENET, V56, P880; KIFOR O, 1992, J BONE MINER RES, V7, P1327; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARKOWITZ ME, 1982, J CLIN ENDOCR METAB, V55, P727, DOI 10.1210/jcem-55-4-727; MARX SJ, 1981, J CLIN ENDOCR METAB, V52, P736, DOI 10.1210/jcem-52-4-736; MOORE ES, 1978, J PEDIATR-US, V92, P906, DOI 10.1016/S0022-3476(78)80358-8; Nussbaum Samuel R., 1994, P157; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; PARKINSON DB, 1992, NAT GENET, V1, P149, DOI 10.1038/ng0592-149; PARKINSON DB, 1993, HUM GENET, V91, P281; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; Perry Y. M., 1994, American Journal of Human Genetics, V55, pA17; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Thakker Rajesh V., 1994, P765; THAKKER RV, 1990, J CLIN INVEST, V86, P40, DOI 10.1172/JCI114712; THAKKER RV, 1989, NEW ENGL J MED, V321, P218, DOI 10.1056/NEJM198907273210403; THAKKER RV, 1986, BONE MINER, V1, P137; TRUMP D, 1995, HUM GENET, V96, P183, DOI 10.1007/BF00207376	41	404	417	1	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1996	335	15					1115	1122		10.1056/NEJM199610103351505	http://dx.doi.org/10.1056/NEJM199610103351505			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN399	8813042	Bronze			2022-12-28	WOS:A1996VN39900005
J	Delbanco, TL; Daley, J; Hartman, EE				Delbanco, TL; Daley, J; Hartman, EE			A 61-year-old man with Parkinson's disease, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Olanow C W, 1996, JAMA, V275, P716, DOI 10.1001/jama.275.9.716	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1171	1171						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827971				2022-12-28	WOS:A1996VL33200028
J	Gray, CM; McCormick, DA				Gray, CM; McCormick, DA			Chattering cells: Superficial pyramidal neurons contributing to the generation of synchronous oscillations in the visual cortex	SCIENCE			English	Article							RECEPTIVE-FIELD PROPERTIES; CAT; ELECTROPHYSIOLOGY; RAT; FACILITATION; HIPPOCAMPUS; MORPHOLOGY; INVITRO; SLICES	In response to visual stimulation, a subset of neurons in the striate and prestriate cortex displays synchronous rhythmic firing in the gamma frequency band (20 to 70 hertz). This finding has raised two fundamental questions: What is the functional significance of synchronous gamma-band activity and how is it generated? This report addresses the second of these two questions. By means of intracellular recording and staining of single cells in the cat striate cortex in vivo, a biophysically distinct class of pyramidal neuron termed ''chattering cells'' is described. These neurons are located in the superficial layers of the cortex, intrinsically generate 20- to 70-hertz repetitive burst firing in response to suprathreshold depolarizing current injection, and exhibit pronounced oscillations in membrane potential during visual stimulation that are largely absent during periods of spontaneous activity. These properties suggest that chattering cells may make a substantial intracortical contribution to the generation of synchronous cortical oscillations and thus participate in the recruitment of large populations of cells into synchronously firing assemblies.	YALE UNIV,SCH MED,NEUROBIOL SECT,NEW HAVEN,CT 06510	Yale University	Gray, CM (corresponding author), UNIV CALIF DAVIS,CTR NEUROSCI,SECT NEUROBIOL PHYSIOL & BEHAV,DAVIS,CA 95616, USA.		McCormick, David A/J-2649-2015; Kobelt, Liza/F-5926-2011	McCormick, David A/0000-0002-9803-8335; 				BRAGIN A, 1995, J NEUROSCI, V15, P47; BRINGUIER V, 1992, NEUROREPORT, V3, P1065, DOI 10.1097/00001756-199212000-00008; CALVIN WH, 1975, BRAIN RES, V83, P498, DOI 10.1016/0006-8993(75)90843-4; CONNORS BW, 1982, J NEUROPHYSIOL, V48, P1302, DOI 10.1152/jn.1982.48.6.1302; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; FRIEDMANHILL SR, 1995, SOC NEUR ABSTR, V21; FRIEN A, 1994, NEUROREPORT, V5, P2273, DOI 10.1097/00001756-199411000-00017; GHOSE GM, 1992, J NEUROPHYSIOL, V68, P1558, DOI 10.1152/jn.1992.68.5.1558; GILBERT CD, 1977, J PHYSIOL-LONDON, V268, P391, DOI 10.1113/jphysiol.1977.sp011863; GILBERT CD, 1983, J NEUROSCI, V3, P1116; Gray C. M., 1987, SOC NEUR ABSTR, V13, P4043; GRAY CM, 1990, EUR J NEUROSCI, V2, P607, DOI 10.1111/j.1460-9568.1990.tb00450.x; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1993, SOC NEUR ABSTR, V19; GRAY CM, 1995, SOC NEUR ABSTR, V21; HAMMOND P, 1985, NEUROSCIENCE, V15, P639, DOI 10.1016/0306-4522(85)90065-X; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P229, DOI 10.1152/jn.1965.28.2.229; JAGADEESH B, 1992, SCIENCE, V257, P552, DOI 10.1126/science.1636094; KANG YN, 1994, J NEUROPHYSIOL, V72, P578, DOI 10.1152/jn.1994.72.2.578; Koenig Peter, 1995, Proceedings of the National Academy of Sciences of the United States of America, V92, P290; LARKMAN A, 1990, J NEUROSCI, V10, P1407; LAUFER M, 1967, VISION RES, V7, P215, DOI 10.1016/0042-6989(67)90086-7; Livingstone MS, 1996, J NEUROPHYSIOL, V75, P2467, DOI 10.1152/jn.1996.75.6.2467; LLINAS RR, 1991, P NATL ACAD SCI USA, V88, P897, DOI 10.1073/pnas.88.3.897; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MASON A, 1990, J NEUROSCI, V10, P1415; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MCCORMICK DA, 1995, SOC NEUR ABSTR, V21; MCCORMICK DA, 1993, SOC NEUR ABSTR, V19; MCCORMICK DA, IN PRESS SOC NEUR AB; MILES R, 1986, J PHYSIOL-LONDON, V373, P397, DOI 10.1113/jphysiol.1986.sp016055; MILNER P, 1985, BER BUNSEN PHYS CHEM, V89, P703; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; Munk MHJ, 1996, SCIENCE, V272, P271, DOI 10.1126/science.272.5259.271; Neuenschwander S, 1996, NATURE, V379, P728, DOI 10.1038/379728a0; NUNEZ A, 1993, J NEUROPHYSIOL, V70, P418, DOI 10.1152/jn.1993.70.1.418; PALMER LA, 1974, BRAIN RES, V67, P27, DOI 10.1016/0006-8993(74)90295-9; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; THOMSON AM, 1993, NEUROSCIENCE, V54, P347, DOI 10.1016/0306-4522(93)90257-G; Traub RD, 1996, J PHYSIOL-LONDON, V493, P471, DOI 10.1113/jphysiol.1996.sp021397; *U CA YAL U I AN C, 1991, NIH PUBL; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; VONDERMALSBURG C, 1981, INTERNAL REPORT MAX; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0	48	620	636	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					109	113		10.1126/science.274.5284.109	http://dx.doi.org/10.1126/science.274.5284.109			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810245				2022-12-28	WOS:A1996VK74800059
J	Sacks, FM; Pfeffer, MA; Moye, LA; Rouleau, JL; Rutherford, JD; Cole, TG; Brown, L; Warnica, JW; Arnold, JMO; Wun, CC; Davis, BR; Braunwald, E				Sacks, FM; Pfeffer, MA; Moye, LA; Rouleau, JL; Rutherford, JD; Cole, TG; Brown, L; Warnica, JW; Arnold, JMO; Wun, CC; Davis, BR; Braunwald, E			The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; SECONDARY PREVENTION TRIAL; ARTERY DISEASE; CARDIOVASCULAR EVENTS; ANGIOGRAPHIC TRIALS; SERUM-CHOLESTEROL; RECURRENT EVENTS; HEART-DISEASE; A-I; ATHEROSCLEROSIS	Background In patients with high cholesterol levels, lowering the cholesterol level reduces the risk of coronary events, but the effect of lowering cholesterol levels in the majority of patients with coronary disease, who have average levels, is less clear. Methods in a double-blind trial lasting five years, we administered either 40 mg of pravastatin per day or placebo to 4159 patients (3583 men and 576 women) with myocardial infarction who had plasma total cholesterol levels below 240 mg per deciliter (mean, 209) and low-density lipoprotein (LDL) cholesterol levels of 115 to 174 mg per deciliter (mean, 139). The primary end point was a fatal coronary event or a nonfatal myocardial infarction. Results The frequency of the primary end point was 10.2 percent in the pravastatin group and 13.2 percent in the placebo group, an absolute difference of 3 percentage points and a 24 percent reduction in risk (95 percent confidence interval, 9 to 36 percent; P=0.003). Coronary bypass surgery was needed in 7.5 percent of the patients in the pravastatin group and 10 percent of those in the placebo group, a 26 percent reduction (P=0.005), and coronary angioplasty was needed in 8.3 percent of the pravastatin group and 10.5 percent of the placebo group, a 23 percent reduction (P=0.01). The frequency of stroke was reduced by 31 percent (P=0.03). There were no significant differences in overall mortality or mortality from noncardiovascular causes. Pravastatin lowered the rate of coronary events more among women than among men. The reduction in coronary events was also greater in patients with higher pretreatment levels of LDL cholesterol. Conclusions These results demonstrate that the benefit of cholesterol-lowering therapy extends to the majority of patients with coronary disease who have average cholesterol levels. (C) 196 Massachusetts Medical Society.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; UNIV TEXAS, SCH PUBL HLTH, HOUSTON, TX USA; UNIV SHERBROOKE, SHERBROOKE, PQ J1K 2R1, CANADA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75235 USA; WASHINGTON UNIV, ST LOUIS, MO USA; FOOTHILLS PROV GEN HOSP, CALGARY, AB T2N 2T9, CANADA; VICTORIA HOSP, LONDON, ON N6A 4G5, CANADA	Harvard University; Harvard Medical School; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Sherbrooke; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL); University of Calgary; University of Victoria; Western University (University of Western Ontario)	Sacks, FM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, 75 FRANCIS ST, BOSTON, MA 02115 USA.		Arnold, Malcolm/G-2869-2011					[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; BURING JE, 1992, CIRCULATION, V85, P22, DOI 10.1161/01.CIR.85.1.22; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; COX DR, 1972, J R STAT SOC B, V34, P187; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; CROUSE JR, 1995, AM J CARDIOL, V75, P862; DAYTON S, 1969, CIRCULATION, V40, pII1; DOBS AS, 1993, METABOLISM, V42, P1146, DOI 10.1016/0026-0495(93)90272-P; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HOLME I, 1995, AM J CARDIOL, V76, pC10, DOI 10.1016/S0002-9149(99)80465-2; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KANNEL WB, 1995, AM J CARDIOL, V76, pC69, DOI 10.1016/S0002-9149(99)80474-3; LAVIE CJ, 1991, AM J CARDIOL, V68, P1087, DOI 10.1016/0002-9149(91)90500-K; MARTIN MJ, 1986, LANCET, V2, P933; Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; PFEFFER MA, 1995, AM J CARDIOL, V76, pC98, DOI 10.1016/S0002-9149(99)80478-0; Ries L, 1994, NIH PUBLICATION, V94-2789; ROSE G, 1977, LANCET, V1, P105; ROSSOUW JE, 1995, AM J CARDIOL, V76, pC86, DOI 10.1016/S0002-9149(99)80476-7; RUBINS HB, 1995, AM J CARDIOL, V75, P1196, DOI 10.1016/S0002-9149(99)80761-9; SACKS FM, 1994, LANCET, V344, P1182, DOI 10.1016/S0140-6736(94)90506-1; SACKS FM, 1995, AM J CARDIOL, V76, pC78, DOI 10.1016/S0002-9149(99)80475-5; SACKS FM, 1991, AM J CARDIOL, V68, P1436, DOI 10.1016/0002-9149(91)90276-Q; SACKS FM, 1992, AM J CARDIOL, V69, P574; SALONEN R, 1995, CIRCULATION, V92, P1758, DOI 10.1161/01.CIR.92.7.1758; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; TONKIN A, 1995, AM J CARDIOL, V76, P474	33	5929	6132	0	298	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1001	1009		10.1056/NEJM199610033351401	http://dx.doi.org/10.1056/NEJM199610033351401			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8801446				2022-12-28	WOS:A1996VL45900001
J	Gourley, MF; Austin, HA; Scott, D; Yarboro, CH; Vaughn, EM; Muir, J; Boumpas, DT; Klippel, JH; Balow, JE; Steinberg, AD				Gourley, MF; Austin, HA; Scott, D; Yarboro, CH; Vaughn, EM; Muir, J; Boumpas, DT; Klippel, JH; Balow, JE; Steinberg, AD			Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						lupus nephritis; methylprednisolone; cyclophosphamide; dose-response relationship, drug; drug therapy, combination	PULSE CYCLOPHOSPHAMIDE; ERYTHEMATOSUS; THERAPY; AZATHIOPRINE; PREDNISONE; DRUGS; MICE	Background: Uncertainty exists about the efficacy and toxicity of bolus therapy with methylprednisolone or of the combination of methylprednisolone and cyclophosphamide in the treatment of lupus nephritis. Objective: To determine 1) whether intensive bolus therapy with methylprednisolone is an adequate substitute for bolus therapy with cyclophosphamide and 2) whether the combination of methylprednisolone and cyclophosphamide is superior to bolus therapy with methylprednisolone or cyclophosphamide alone. Design: Randomized, controlled trial with at least 5 years of follow-up. Setting: Government referral-based research hospital. Patients: 82 patients with lupus nephritis who had 10 or more erythrocytes per high-power field, cellular casts, proteinuria (>1 g of protein per day), and a renal biopsy specimen that showed proliferative nephritis. Interventions: Bolus therapy with methylprednisolone (1 g/m(2) body surface area), given monthly for at least 1 year; bolus therapy with cyclophosphamide (0.5 to 1.0 g/m(2) body surface area), given monthly for 6 months and then quarterly; or bolus therapy with both methylprednisolone and cyclophosphamide. Measurements: 1) Renal remission (defined as <10 dysmorphic erythrocytes per high-power field, the absence of cellular casts, and excretion of <1 g of protein per day without doubling of the serum creatinine level), 2) prevention of doubling of the serum creatinine level, and 3) prevention of renal failure requiring dialysis. Results: Renal remission occurred in 17 of 20 patients in the combination therapy group (85%), 13 of 21 patients in the cyclophosphamide group (62%), and 7 of 24 patients in the methylprednisolone group (29%) (P < 0.001). Twenty-eight patients (43%) did not achieve renal remission. By life-table analysis, the likelihood of remission during the study period was greater in the combination therapy group than in the methylprednisolone group (P = 0.028). Combination therapy and cyclophosphamide therapy were not statistically different. Adverse events were amenorrhea (seen in 41% of the cyclophosphamide group, 43% of the combination therapy group, and 7.4% of the methyl prednisolone group), cervical dysplasia (seen in 11% of the cyclophosphamide group, 7.1% of the combination therapy group, and 0% of the methylprednisolone group), avascular necrosis (seen in 11% of the cyclophosphamide group, 18% of the combination therapy group, and 22% of the methylprednisolone group), herpes tester (seen in 15% of the cyclophosphamide group, 21% of the combination therapy group, and 3.7% of the methylprednisolone group) and at least one infection (seen in 26% of the cyclophosphamide group, 32% of the combination therapy group, and 7.4% of the methylprednisolone group). Conclusions: Monthly bolus therapy with methylprednisolone was less effective than monthly bolus therapy with cyclophosphamide. A trend toward greater efficacy with combination therapy was seen.	NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA								AUSTIN HA, 1984, KIDNEY INT, V25, P689, DOI 10.1038/ki.1984.75; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BELMONT HM, 1995, LUPUS, V4, P104, DOI 10.1177/096120339500400205; BENEDETTI J, 1990, BMDP STATISTICAL SOF, P739; BERTONI M, 1994, SCAND J RHEUMATOL, V23, P82, DOI 10.3109/03009749409103033; BOUMPAS DT, 1991, Q J MED, V81, P975, DOI 10.1093/qjmed/81.3.975; BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N; CADE R, 1973, NEPHRON, V10, P37, DOI 10.1159/000180176; CARETTE S, 1983, ANN INTERN MED, V99, P1, DOI 10.7326/0003-4819-99-1-1; CATHCART ES, 1976, LANCET, V1, P163; DINANT HJ, 1982, ANN INTERN MED, V96, P728, DOI 10.7326/0003-4819-96-6-728; DONADIO JV, 1978, NEW ENGL J MED, V299, P1151, DOI 10.1056/NEJM197811232992102; EISER AR, 1993, CLIN NEPHROL, V40, P155; FREEDMAN MD, 1981, JAMA-J AM MED ASSOC, V245, P607, DOI 10.1001/jama.245.6.607; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; GELFAND MC, 1972, ARTHRITIS RHEUM-US, V15, P239, DOI 10.1002/art.1780150304; HAHN BH, 1975, ANN INTERN MED, V83, P597, DOI 10.7326/0003-4819-83-5-597; ISENBERG DA, 1982, ANN RHEUM DIS, V41, P347, DOI 10.1136/ard.41.4.347; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIMBERLY RP, 1981, AM J MED, V70, P817, DOI 10.1016/0002-9343(81)90538-6; LIEBLING MR, 1982, J RHEUMATOL, V9, P543; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASSARDO L, 1992, LUPUS, V1, P401, DOI 10.1177/096120339200100610; MCCUNE WJ, 1988, NEW ENGL J MED, V318, P1423, DOI 10.1056/NEJM198806023182203; SESSO R, 1994, LUPUS, V3, P107, DOI 10.1177/096120339400300209; STEINBER.AD, 1971, ANN INTERN MED, V75, P165, DOI 10.7326/0003-4819-75-2-165; STEINBERG AD, 1991, ARTHRITIS RHEUM-US, V34, P945, DOI 10.1002/art.1780340803; STEINBERG AD, 1975, ARTHRITIS RHEUM, V18, P9, DOI 10.1002/art.1780180102; STEINBERG AD, 1974, ARTHRITIS RHEUM, V17, P923, DOI 10.1002/art.1780170602; SZTEJNBOK M, 1971, ARTHRITIS RHEUM-US, V14, P639, DOI 10.1002/art.1780140511; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WYSENBEEK AJ, 1990, J RHEUMATOL, V17, P1695; Yarboro CH, 1996, ANN PHARMACOTHER, V30, P752, DOI 10.1177/106002809603000708	33	460	489	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1996	125	7					549	+		10.7326/0003-4819-125-7-199610010-00003	http://dx.doi.org/10.7326/0003-4819-125-7-199610010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ653	8815753				2022-12-28	WOS:A1996VJ65300003
J	Burgmann, H; Georgopoulos, A; Graninger, W; Koppensteiner, R; Maca, T; Minar, E; Schneider, B; Stumpflen, A; Ehringer, H				Burgmann, H; Georgopoulos, A; Graninger, W; Koppensteiner, R; Maca, T; Minar, E; Schneider, B; Stumpflen, A; Ehringer, H			Tissue concentration of clindamycin and gentamicin near ischaemic ulcers with transvenous injection in Bier's arterial arrest	LANCET			English	Article							DIABETIC FOOT; THERAPY; HEPARIN	Background in the treatment of patients with inflamed ischaemic ulcers in peripheral arterial occlusive disease, high tissue concentrations of antibiotics (TCA) are important. With local transvenous pressure injection in Biers' arterial arrest (TVA-Bier) higher TCAs are assumed to be obtained but they have not been measured. Methods Two groups of 16 patients each with ischaemic foot ulcers were studied. In one group, patients received a mean of 284 (SD 116) mg gentamicin and in the other, 1200 mg clindamycin, The antibiotics were given intravenously, intra-arterially, and by TVA-Bier in a randomised order at intervals of 48 hours. Biopsy samples were taken from the edge of the ulcers 20 minutes and 3 hours after TVA-Bier, and 1 hour and 3 hours after intravenous and intra-arterial injection. At the same times blood samples were taken. Findings TCAs of gentamicin and clindamycin with TVA-Bier were significantly higher compared with intravenous or intra-arterial injection. Median TCA-enhancing factor of clindamycin achieved by TVA-Bier at 20 min 1 hour was 18.3 and 14.1 versus intravenous and intra-arterial infusion, respectively, and at 3 hours 7.3 and 5.6, respectively. The median TCA-enhancing factor for gentamicin by TVA-Bier versus intravenous and intra-arterial application was, at 1 hour 20 min, 9.4 and 9.7, respectively, and at 3 hours 1.2 and 1.7, respectively. Interpretation Higher TCAs could be achieved with TVA-Bier than with intravenous or intra-arterial infusion. TCAs were lower when using gentamicin and higher with clindamycin.	UNIV VIENNA,VIENNA GEN HOSP,DIV MED ANGIOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,VIENNA GEN HOSP,DIV INFECT DIS & CHEMOTHERAPY,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,VIENNA GEN HOSP,INST MED STAT,A-1090 VIENNA,AUSTRIA	University of Vienna; University of Vienna; University of Vienna			Graninger, Winfried/AAI-7192-2020; Burgmann, Heinz/N-2409-2013	Burgmann, Heinz/0000-0002-2114-0999				ACEVEDO A, 1990, REV MED CHILE, V118, P881; Acevedo A, 1991, Vasa Suppl, V32, P363; AMENDT K, 1987, VASA-J VASCULAR DIS, V16, P193; BARTLETT JG, 1992, CLINDAMYCIN TREATMEN; BOLLINGER A, 1970, SCHWEIZ MED WSCHR, V100, P774; FRIMODTMOLLER N, 1986, J INFECT DIS, V154, P511, DOI 10.1093/infdis/154.3.511; GEORGOPOULOS A, 1978, ZBL BAKT-INT J MED M, V242, P387; GRUNFELD C, 1992, ADV INTERNAL MED, V37, P103; Hild R, 1967, Dtsch Med J, V18, P329; HILD R, 1977, DIABETISCHE ANGIOPAT, P150; INGERMAN MJ, 1986, J INFECT DIS, V153, P707, DOI 10.1093/infdis/153.4.707; LASSEN NA, 1973, SCAND J CLIN LA S128, V31, P235; MAWER GE, 1974, BR J CLIN PHARM, P45; METZ W, 1987, 18 WELTK SOC INT CHI; NILSSON L, 1981, ANTIMICROB AGENTS CH, V20, P155, DOI 10.1128/AAC.20.2.155; PARTSCH H, 1990, ACTA MED AUST, V17, P35; PARTSCH H, 1993, WMW, V7, P172; SCHOOP W, 1993, WIEN MED WOCHENSCHR, V7, P199; SEIDEL C, 1991, VASA-J VASCULAR DIS, V20, P388; SEIDEL C, 1994, HAUTARZT, V45, P74, DOI 10.1007/PL00013260; SEWELL DL, 1983, AM J KIDNEY DIS, V3, P209, DOI 10.1016/S0272-6386(83)80064-X	21	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					781	783		10.1016/S0140-6736(96)07089-4	http://dx.doi.org/10.1016/S0140-6736(96)07089-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813984				2022-12-28	WOS:A1996VH98900010
J	Loughnan, BA; Gordon, H; Frank, AO				Loughnan, BA; Gordon, H; Frank, AO			Long term backache after childbirth - Study should have been randomised	BRITISH MEDICAL JOURNAL			English	Letter											Loughnan, BA (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND.							MASON V, 1994, PREVALENCE BACK PAIN; Russell R, 1996, BRIT MED J, V312, P1384	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					755	755						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819470				2022-12-28	WOS:A1996VJ44100064
J	Jay, DG				Jay, DG			Role of band 3 in homeostasis and cell shape	CELL			English	Review							HUMAN-ERYTHROCYTE MEMBRANE; ANION-EXCHANGE PROTEIN				Jay, DG (corresponding author), HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.							BRANTON D, 1981, CELL, V24, P24, DOI 10.1016/0092-8674(81)90497-9; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; ELGSAETER A, 1986, SCIENCE, V234, P1217, DOI 10.1126/science.3775380; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; HO MK, 1975, J BIOL CHEM, V250, P675; Inaba M, 1996, J CLIN INVEST, V97, P1804, DOI 10.1172/JCI118610; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; SEKLER I, 1996, SEMIN HEMATOL, V30, P34; TANNER MJA, 1993, SEMIN HEMATOL, V30, P34	11	43	45	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					853	854		10.1016/S0092-8674(00)80160-9	http://dx.doi.org/10.1016/S0092-8674(00)80160-9			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808620	Bronze			2022-12-28	WOS:A1996VJ44300003
J	Sekler, I; Kobayashi, S; Kopito, RR				Sekler, I; Kobayashi, S; Kopito, RR			A cluster of cytoplasmic histidine residues specifies pH dependence of the AE2 plasma membrane anion exchanger	CELL			English	Article							SITE-DIRECTED MUTAGENESIS; INTRACELLULAR PH; NA+/H+ ANTIPORTER; CELL-LINE; CHLORIDE; PROTEIN; BAND-3; TRANSPORT; CLONING; LOCALIZATION	Intracellular pH is maintained by a dynamic equilibrium balancing the opposing forces of proton loading and proton extrusion. By providing an efflux pathway for base, anion exchangers constitute a key component of the plasma membrane proton-loading machinery. The data in this paper identify a histidine-rich sequence within the cytoplasmic domain of the nonerythroid anion exchanger, AE2, that serves as an intracellular pH ''sensor'' that modulates anion exchange activity within the physiological range of cytoplasmic pH. These data reveal an interaction between the two major domains of the anion exchanger and suggest a novel substrate feedback mechanism by which intracellular protons directly control the activity of an acid-loading plasma membrane ion transporter.			Sekler, I (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NIGMS NIH HHS [GM38543] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; BIWERSI J, 1991, BIOCHEMISTRY-US, V30, P7879, DOI 10.1021/bi00246a001; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; DING Y, 1996, IN PRESS J BIOL CHEM; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN J, 1990, J GEN PHYSIOL, V95, P121, DOI 10.1085/jgp.95.1.121; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KOBAYASHI S, 1994, J NEUROSCI, V14, P6266; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1987, J BIOL CHEM, V262, P8035; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KUDRYCKI KE, 1990, J BIOL CHEM, V265, P462; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEE BS, 1991, J BIOL CHEM, V266, P11448; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MASON MJ, 1989, AM J PHYSIOL, V256, pC428, DOI 10.1152/ajpcell.1989.256.2.C428; MUALLEM S, 1988, J BIOL CHEM, V263, P14703; OLSNES S, 1987, BIOCHEMISTRY-US, V26, P2778, DOI 10.1021/bi00384a019; OLSNES S, 1986, J CELL BIOL, V102, P967, DOI 10.1083/jcb.102.3.967; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; RIMON A, 1995, J BIOL CHEM, V270, P26813, DOI 10.1074/jbc.270.45.26813; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SARKADI B, 1985, AM J PHYSIOL, V248, pC480, DOI 10.1152/ajpcell.1985.248.5.C480; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHUSTER VL, 1987, AM J PHYSIOL, V253, pF203, DOI 10.1152/ajprenal.1987.253.2.F203; STUARTTILLEY A, 1994, AM J PHYSIOL, V266, pC559, DOI 10.1152/ajpcell.1994.266.2.C559; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VAUGHANJONES RD, 1982, PHILOS T ROY SOC B, V299, P537, DOI 10.1098/rstb.1982.0150; VAUGHANJONES RD, 1978, J PHYSIOL-LONDON, V282, pP22; VERKMAN AS, 1989, AM J PHYSIOL, V256, pC428; VIGNE P, 1988, J BIOL CHEM, V263, P18023; Wang Z, 1996, J BIOL CHEM, V271, P7835, DOI 10.1074/jbc.271.13.7835; Zhang Y, 1996, J BIOL CHEM, V271, P5741, DOI 10.1074/jbc.271.10.5741	36	22	22	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					929	935		10.1016/S0092-8674(00)80168-3	http://dx.doi.org/10.1016/S0092-8674(00)80168-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808628	Bronze			2022-12-28	WOS:A1996VJ44300011
J	Gardner, CD; Fortmann, SP; Krauss, RM				Gardner, CD; Fortmann, SP; Krauss, RM			Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STANFORD 5-CITY PROJECT; PLASMA TRIGLYCERIDE CONCENTRATION; HEART-DISEASE; RISK-FACTORS; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; SUBCLASS PATTERNS; FAMILIAL HYPERCHOLESTEROLEMIA; APOLIPOPROTEIN-B; HEPATIC LIPASE	Objective.-To investigate the prospective association of low-density lipoprotein (LDL) particle diameter with the incidence of fatal and nonfatal coronary artery disease (CAD). Design.-A nested case-control study. Setting.-Cases and controls were identified from a population-based sample of men and women combining all of the 5 cross-sectional surveys conducted from 1979 to 1990 of the Stanford Five-City Project (FCP). Participants.-Incident CAD cases were identified through FCP surveillance between 1979 and 1992. Controls were matched by sex, 5-year age groups, survey time point, ethnicity, and FCP treatment condition. The sample included 124 matched pairs: 90 pairs of men and 34 pairs of women. Main Outcome Measures.-LDL peak particle diameter (LDL size) was determined by gradient gel electrophoresis on plasma samples collected during the cross-sectional surveys (stored at 70 degrees C for 5-15 years). Established CAD risk-factor data were available from FCP baseline measurements. Results.-LDL size was smaller among CAD cases than controls (mean+/-SD) (26.17+/-1.00 nm vs 26.68+/-0.90 nm; P<.001). The association was graded across control quintiles of LDL size. The significant case-control difference in LDL size was independent of levels of high-density lipoprotein cholesterol (HDL-C), non-HDL cholesterol (non-HDL-C), triglyceride, smoking, systolic blood pressure, and body mass index, but was not significant after adjusting for the ratio of total cholesterol (TC) to HDL-C (TC:HDL-C). Among all the physiological risk factors, LDL size was the best differentiator of CAD status in conditional logistic regression. However, when added to the physiological parameters above, the TC:HDL-C ratio was found to be a stronger independent predictor of CAD status. Conclusion.-LDL size was significantly smaller in CAD cases than in controls in a prospective, population-based study. These findings support other evidence of a role for small, dense LDL particles in the etiology of atherosclerosis.	STANFORD UNIV, SCH MED, STANFORD CTR RES DIS PREVENT, PALO ALTO, CA 94304 USA; STANFORD UNIV, SCH MED, DEPT MED, PALO ALTO, CA 94304 USA; LAWRENCE BERKELEY NATL LAB, DIV LIFE SCI, BERKELEY, CA USA	Stanford University; Stanford University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory			Adiels, Martin/C-9278-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007034, P01HL018574, R01HL021906] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21906, HL 18574, 5 T32 HL07034] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAD Y, 1992, CIRCULATION, V86, P551; AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917; AUSTIN MA, 1990, CIRCULATION, V82, P495, DOI 10.1161/01.CIR.82.2.495; AUWERX JH, 1989, ARTERIOSCLEROSIS, V9, P319, DOI 10.1161/01.ATV.9.3.319; BARAKAT HA, 1990, DIABETES, V39, P1527, DOI 10.2337/diabetes.39.12.1527; CAMEJO G, 1990, CURR OPIN LIPIDOL, V1, P431; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P187, DOI 10.1161/01.ATV.12.2.187; CAMPOS H, 1992, ARTERIOSCLER THROMB, V12, P1410, DOI 10.1161/01.ATV.12.12.1410; CASTELLI WP, 1983, CIRCULATION, V67, P730, DOI 10.1161/01.CIR.67.4.730; CHAIT A, 1993, AM J MED, V94, P350, DOI 10.1016/0002-9343(93)90144-E; CORESH J, 1993, J LIPID RES, V34, P1687; CROUSE JR, 1985, J LIPID RES, V26, P566; DECKELBAUM RJ, 1984, ARTERIOSCLEROSIS, V4, P225, DOI 10.1161/01.ATV.4.3.225; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; DREON DM, 1994, FASEB J, V8, P121, DOI 10.1096/fasebj.8.1.8299884; FARQUHAR JW, 1985, AM J EPIDEMIOL, V122, P323, DOI 10.1093/oxfordjournals.aje.a114104; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; FORTMANN SP, 1986, AM J EPIDEMIOL, V123, P656, DOI 10.1093/oxfordjournals.aje.a114285; FORTMANN SP, 1984, PREV MED, V13, P127, DOI 10.1016/0091-7435(84)90045-8; GRIFFIN BA, 1994, ATHEROSCLEROSIS, V106, P241, DOI 10.1016/0021-9150(94)90129-5; HAINLINE A, 1982, US DHEW PUBLICATION; HAVEL RJ, 1995, NEW ENGL J MED, V332, P1491, DOI 10.1056/NEJM199506013322207; KARPE F, 1994, ATHEROSCLEROSIS, V106, P83, DOI 10.1016/0021-9150(94)90085-X; KINOSHITA M, 1990, J LIPID RES, V31, P701; KINOSIAN B, 1994, ANN INTERN MED, V121, P641, DOI 10.7326/0003-4819-121-9-199411010-00002; KRAUSS RM, 1987, AM HEART J, V113, P578, DOI 10.1016/0002-8703(87)90636-3; KRAUSS RM, 1982, J LIPID RES, V23, P97; KRAUSS RM, 1994, CIRCULATION, V90, P460; Krauss Ronald M., 1994, Current Opinion in Lipidology, V5, P339, DOI 10.1097/00041433-199410000-00005; LAGROST L, 1994, ARTERIOSCLER THROMB, V14, P1327, DOI 10.1161/01.ATV.14.8.1327; LAMONFAVA S, 1989, METABOLISM, V38, P921, DOI 10.1016/0026-0495(89)90243-6; MCKEONE BJ, 1993, J CLIN INVEST, V91, P1926, DOI 10.1172/JCI116411; MCNAMARA JR, 1992, ARTERIOSCLER THROMB, V12, P1284, DOI 10.1161/01.ATV.12.11.1284; MCNAMARA JR, 1987, ARTERIOSCLEROSIS, V7, P483, DOI 10.1161/01.ATV.7.5.483; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; NIGON F, 1991, J LIPID RES, V32, P1741; PARKER DJP, 1984, EPIDEMIOLOGY MED PRA; PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336, DOI 10.1161/01.ATV.12.11.1336; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; REAVEN GM, 1993, J CLIN INVEST, V92, P141, DOI 10.1172/JCI116541; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; SAKAI N, 1991, ARTERIOSCLER THROMB, V11, P71, DOI 10.1161/01.ATV.11.1.71; SELBY JV, 1993, CIRCULATION, V88, P381, DOI 10.1161/01.CIR.88.2.381; SLYPER AH, 1994, JAMA-J AM MED ASSOC, V272, P305, DOI 10.1001/jama.272.4.305; SUPERKO HR, 1992, ATHEROSCLEROSIS, V95, P69, DOI 10.1016/0021-9150(92)90177-I; SWINKELS DW, 1989, ARTERIOSCLEROSIS, V9, P604, DOI 10.1161/01.ATV.9.5.604; SWINKELS DW, 1989, ATHEROSCLEROSIS, V77, P59, DOI 10.1016/0021-9150(89)90010-5; TENG B, 1983, P NATL ACAD SCI-BIOL, V80, P6662, DOI 10.1073/pnas.80.21.6662; TENG B, 1986, J CLIN INVEST, V77, P663, DOI 10.1172/JCI112360; TENG B, 1985, J BIOL CHEM, V260, P5067; THOMPSON GR, 1984, COLOGNE ATHEROSCLERO, V16, P121; TORNVALL P, 1991, ATHEROSCLEROSIS, V90, P67, DOI 10.1016/0021-9150(91)90245-X; TRIBBLE DL, 1992, ATHEROSCLEROSIS, V93, P189, DOI 10.1016/0021-9150(92)90255-F; WILLIAMS PT, 1990, CIRCULATION, V81, P1293, DOI 10.1161/01.CIR.81.4.1293; WINKLEBY MA, 1990, PREV MED, V19, P1, DOI 10.1016/0091-7435(90)90001-Z; ZAMBON A, 1993, ARTERIOSCLER THROMB, V13, P147, DOI 10.1161/01.ATV.13.2.147	56	695	758	2	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 18	1996	276	11					875	881		10.1001/jama.276.11.875	http://dx.doi.org/10.1001/jama.276.11.875			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF787	8782636				2022-12-28	WOS:A1996VF78700030
J	Appleby, PH				Appleby, PH			ABC of work related disorders - Building related illnesses	BRITISH MEDICAL JOURNAL			English	Article											Appleby, PH (corresponding author), THORBUN COLQUHOUN,BLDG HLTH & SAFETY DIV,LONDON,ENGLAND.								0	9	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1996	313	7058					674	677						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8811763				2022-12-28	WOS:A1996VH16500030
J	Wilson, RPH; Hatcher, J; Barton, S; Walley, T				Wilson, RPH; Hatcher, J; Barton, S; Walley, T			Influences of practice characteristics on prescribing in fundholding and non-fundholding general practices: An observational study	BRITISH MEDICAL JOURNAL			English	Article							COSTS; ENGLAND	Objective-To investigate the variation in prescribing among general practices by examining the contribution to this variation of fundholding, training status, partnership status, and the level of deprivation in the practice population and to investigate the extent to which fundholding has been responsible for any changes in prescribing. Design-Analysis of prescribing data (PACT) for the years 1990-1 (before fundholding) and 1993-4 (after fundholding). Use of multiple linear regressions to investigate the variation among practices in total prescribing costs (net ingredient cost per prescribing unit), prescribing volume (items per 1000 prescribing units), and mean cost per item in each of the two years and also the change in these variables between years. Setting-Former Mersey region. Subjects-384 practices. Results-The models developed explained the variation in cost per item (43% of variation explained for 1990-1, 38% for 1993-4) and prescribing volume (34% for 1990-1, 38% for 1993-4) better than the variation in total prescribing costs (3% for 1990-1, 7% for 1993-4). The models developed to explain the change in these variables between years did not explain more than 10% of the variation. Most of the explained variation in the change in total prescribing costs was accounted for by fundholding. Of the pound 3.71 saved by first wave fundholders compared with non-fundholders pound 3.57 was attributable to fundholding alone. Conclusion-In neither year did fundholding make a major contribution to the variation in prescribing behaviour among practices, which was better explained by deprivation, training status, and partnership status, but it did seem largely responsible for differences in the rise of total prescribing costs between fundholders and non-fundholders.	UNIV LIVERPOOL,DEPT PHARMACOL & THERAPEUT,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool								*AUD COMM, 1996, WHAT DOCT ORD STUD G; BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; BRITTEN N, 1995, BRIT MED J, V310, P1067, DOI 10.1136/bmj.310.6986.1067c; Department of Health, 1994, EV HOUS COMM HLTH CO; Eachus J, 1996, BMJ-BRIT MED J, V312, P287; FORSTER DP, 1991, BRIT J GEN PRACT, V41, P67; GLENNERSTER H, 1994, EVALUATING NHS REFOR; *GOV STAT SERV, 1995, STAT B GOV  STAT SER; Griffiths C, 1996, BRIT MED J, V312, P481, DOI 10.1136/bmj.312.7029.481; HEALEY AT, 1994, HEALTH ECON, V3, P47, DOI 10.1002/hec.4730030107; LLOYD DCEF, 1995, BRIT MED J, V310, P165, DOI 10.1136/bmj.310.6973.165; LLOYD DCEF, 1995, BRIT MED J, V310, P1068, DOI 10.1136/bmj.310.6986.1068b; MARINKER M, 1994, CONTROVERSIES HLTH C; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MORTONJONES T, 1993, BRIT MED J, V306, P1731, DOI 10.1136/bmj.306.6894.1731; PRINGLE M, 1994, BR J GEN PRACT, V44, P543; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; STEWARTBROWN S, 1995, BRIT MED J, V311, P1543, DOI 10.1136/bmj.311.7019.1543; Whynes DK, 1996, BRIT MED J, V312, P488, DOI 10.1136/bmj.312.7029.488; Wilson R, 1995, LANCET, V346, P1710, DOI 10.1016/S0140-6736(95)92877-4; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347; Wilson-Davis K, 1992, PHARMACOEPIDEM DR S, V1, P341, DOI [10.1002/pds.2630010606, DOI 10.1002/PDS.2630010606]; 1996, GP MAGAZINE      FEB	24	35	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					595	599						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806250				2022-12-28	WOS:A1996VG10800019
J	Balakin, AG; Smith, L; Fournier, MJ				Balakin, AG; Smith, L; Fournier, MJ			The RNA world of the nucleolus: Two major families of small RNAs defined by different box elements with related functions	CELL			English	Article							SMALL NUCLEAR RNAS; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; SECONDARY STRUCTURE; YEAST; GENE; MRP; INTRON; RIBONUCLEOPROTEINS; IDENTIFICATION	We have discovered that all known yeast and vertebrate small nucleolar RNAs (snoRNAs), except for the MRP/7-2 RNA, fall into two major classes. One class is defined by conserved boxes C and D and the other by a novel element: a consensus ACA triplet positioned 3 nt before the 3' end of the RNA. A role for the ACA box in snoRNA stability has been established by mutational analysis of a yeast ACA snoRNA (snR11). Full function of the box depends on the integrity of an adjacent upstream stem. All members of the yeast ACA family are associated with the GAR1 protein. Binding of this or another common small nucleolar ribonucleoprotein particle protein is predicted to be a critical entry point to snoRNA posttranscriptional life, including precise formation of the snoRNA 3' end.	UNIV MASSACHUSETTS, DEPT BIOCHEM & MOL BIOL, AMHERST, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst					NIGMS NIH HHS [GM19531] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIS JP, 1991, METHOD ENZYMOL, V194, P735; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BALAKIN AG, 1994, J BIOL CHEM, V269, P739; BALAKIN AG, 1993, NUCLEIC ACIDS RES, V21, P5391, DOI 10.1093/nar/21.23.5391; BROWN JW, 1990, CELL, V62, P407, DOI 10.1016/0092-8674(90)90003-W; Caffarelli E, 1996, EMBO J, V15, P1121, DOI 10.1002/j.1460-2075.1996.tb00450.x; CECCONI F, 1994, NUCLEIC ACIDS RES, V22, P732, DOI 10.1093/nar/22.5.732; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; CLARK MW, 1990, J CELL BIOL, V111, P1741, DOI 10.1083/jcb.111.5.1741; DANDEKAR T, 1993, NUCLEIC ACIDS RES, V21, P5386, DOI 10.1093/nar/21.23.5386; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GOLD HA, 1988, P NATL ACAD SCI USA, V85, P5483, DOI 10.1073/pnas.85.15.5483; HARLOW E, 1988, ANTIBODIES; HUANG GM, 1992, MOL CELL BIOL, V12, P4456, DOI 10.1128/MCB.12.10.4456; Kiss T, 1996, MOL CELL BIOL, V16, P1391; KISS T, 1993, EMBO J, V12, P2913, DOI 10.1002/j.1460-2075.1993.tb05953.x; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; LEVERETTE RD, 1992, CELL, V71, P1215, DOI 10.1016/S0092-8674(05)80069-8; LUBBEN B, 1993, NUCLEIC ACIDS RES, V21, P5377, DOI 10.1093/nar/21.23.5377; LUBBEN B, 1995, J BIOL CHEM, V270, P11549, DOI 10.1074/jbc.270.19.11549; LYGEROU Z, 1994, GENE DEV, V8, P1423, DOI 10.1101/gad.8.12.1423; Lygerou Z, 1996, SCIENCE, V272, P268, DOI 10.1126/science.272.5259.268; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; Nicoloso M, 1996, J MOL BIOL, V260, P178, DOI 10.1006/jmbi.1996.0391; OCHMAN H, 1989, PCR TECHNOLOGY PRINC, P105; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PECULIS BA, 1994, GENE DEV, V8, P2241, DOI 10.1101/gad.8.18.2241; QU LH, 1995, NUCLEIC ACIDS RES, V23, P2669, DOI 10.1093/nar/23.14.2669; RIEDEL N, 1986, P NATL ACAD SCI USA, V83, P8097, DOI 10.1073/pnas.83.21.8097; RUFF EA, 1993, P NATL ACAD SCI USA, V90, P635, DOI 10.1073/pnas.90.2.635; SAMARSKY DA, 1995, NUCLEIC ACIDS RES, V23, P2548, DOI 10.1093/nar/23.13.2548; Sambrook J, 1989, MOL CLONING; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; SCHMITT ME, 1993, FASEB J, V7, P208, DOI 10.1096/fasebj.7.1.7678563; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; TERNS MP, 1995, EMBO J, V14, P4860, DOI 10.1002/j.1460-2075.1995.tb00167.x; TYCOWSKI KT, 1993, GENE DEV, V7, P1176, DOI 10.1101/gad.7.7a.1176; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; Watkins NJ, 1996, RNA, V2, P118; WISE JA, 1991, METHOD ENZYMOL, V194, P405; WISE JA, 1983, CELL, V35, P743, DOI 10.1016/0092-8674(83)90107-1; ZUBENKO GS, 1980, GENETICS, V96, P137	47	378	413	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1996	86	5					823	834		10.1016/S0092-8674(00)80156-7	http://dx.doi.org/10.1016/S0092-8674(00)80156-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797828	Bronze			2022-12-28	WOS:A1996VG37200015
J	Hopken, UE; Lu, B; Gerard, NP; Gerard, C				Hopken, UE; Lu, B; Gerard, NP; Gerard, C			The C5a chemoattractant receptor mediates mucosal defence to infection	NATURE			English	Article							PSEUDOMONAS-AERUGINOSA; ANAPHYLATOXIN RECEPTOR; CYSTIC-FIBROSIS; LUNG; MICE; NEUTROPHILS; EXPRESSION; IMMUNE; CELLS	A FAMILY of G-protein-coupled chemoattractant receptors is known to mediate the transport and activation of neutrophils and macrophages. This family includes receptors for chemokines, such as interleukin-8, bacterial formylated peptides, platelet-activating factor, leukotriene B4, and the complement anaphylatoxins(1-3). The apparent redundancy of these receptors suggests that they have an important underlying role in host defence. To isolate the contribution of particular molecules, we disrupted a gene that encodes a single chemoattractant receptor, Here we show that mice deficient in the chemoattractant C5a receptor, in comparison to their wild-type littermates, were unable to clear intrapulmonary-instilled Pseudomonas aeruginosa, despite a marked increase in neutrophil influx, and succumbed to pneumonia, These C5a-receptor-deficient mice challenged with sublethal inocula of Pseudomonas become superinfected with secondary bacterial strains. We conclude that the C5a receptor has a non-redundant function, and is required for mucosal host defence in the lung.	CHILDRENS HOSP,INA SUE PERLMUTTER CYST FIBROSIS LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BETH ISRAEL HOSP,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School								BERGER M, 1989, J CLIN INVEST, V84, P1302, DOI 10.1172/JCI114298; BOZIC CR, 1995, J IMMUNOL, V154, P6048; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CERQUETTI MC, 1986, INFECT IMMUN, V52, P853, DOI 10.1128/IAI.52.3.853-857.1986; CZUPRYNSKI CJ, 1984, J LEUKOCYTE BIOL, V35, P193; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; HORNICK DB, 1990, J CLIN INVEST, V86, P1285, DOI 10.1172/JCI114836; KUDOH I, 1994, AM J PHYSIOL-LUNG C, V267, P551; LARSEN GL, 1982, AM REV RESPIR DIS, V126, P306; Mosser D M, 1994, Immunol Ser, V60, P99; TOEWS GB, 1985, INFECT IMMUN, V50, P207, DOI 10.1128/IAI.50.1.207-212.1985; WILLIAMS JC, 1992, EXP LUNG RES, V18, P155, DOI 10.3109/01902149209020658	17	280	293	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					86	89		10.1038/383086a0	http://dx.doi.org/10.1038/383086a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779720				2022-12-28	WOS:A1996VF29500053
J	Wineapple, B				Wineapple, B			Gertrude Stein reads JAMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		BARKER LF, 1899, NERVOUS SYSTEM ITS C, P721; Engelmann GJ, 1901, J AMER MED ASSOC, V37, P890; LEAR TJJ, 1981, NO PLACE GRACE ANTIM, P30; Solomons Leon, 1896, PSYCHOL REV, V3, P492; STEIN G, AUTOBIOGRAPHY ALICE; STEIN G, EVERYBODYS AUTOBIOGR; STEIN G, 1996, SISTER BROTHER G L S, P411; STEIN G, 1973, FERNHURST QED OTHER, P5; STEIN G, GEOGRAPHY PLAYS; Stein Gertrude, 1898, PSYCHOL REV, V5, P295, DOI [10.1037/h0073997, DOI 10.1037/H0073997]; Walsh, 1977, DOCTORS WANTED NO WO; WINEAPPLE B, 1996, SISTER BROTHER G L S; WINEAPPLE B, IN PRESS AM SCHOLAR	13	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1132	1133						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827956				2022-12-28	WOS:A1996VL33200009
J	Yelin, EH; Criswell, LA; Feigenbaum, PG				Yelin, EH; Criswell, LA; Feigenbaum, PG			Health care utilization and outcomes among persons with rheumatoid arthritis in fee-for-service and prepaid group practice settings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAINTENANCE ORGANIZATION; MEDICAL OUTCOMES; COLORECTAL-CANCER; MANAGED-CARE; DISEASE-ACTIVITY; PLANS; QUALITY; PERFORMANCE; SPECIALTIES; INSURANCE	Objective.-To compare health care utilization and outcomes over an 11-year period among persons with rheumatoid arthritis (RA) in fee-for-service and prepaid group practice settings. Design.-Cohort of persons with RA followed up for as long as ii years. The principal measures were obtained from an annual structured telephone interview conducted by a trained survey worker. Setting.-Persons with RA presenting to a random sample of community rheumatologists in northern California. Patients.-Patients were enrolled in 2 cycles: in 1982 and 1983 and in 1989. Study rheumatologists listed all persons meeting criteria for RA presenting to their offices over a 1-month period. Of the 1062 so listed, we enrolled 1025, or 96.5%. Of the 1025 persons with RA, 227 (22.2%) reported receiving care in prepaid group practice settings. Main Outcome Measures.-As of the end of 1994, 5295 person-years of observation were available for the analysis of the annual level of the utilization and outcome measures; 341 persons had been followed up for all 11 years of the study. The main utilization outcomes measured included office visits, outpatient surgeries, hospital admissions, and painful joints. Results.-The persons with RA in fee-for-service and prepaid group practice settings did not differ in the quantity of health care used in any 1 year for either RA or non-RA reasons. Among those followed up for all 11 years, the persons in fee-for-service and prepaid group practice settings did not differ in the cumulative quantity of health care used over the entire period of study. The 2 groups did not differ on any outcome measure on either an annual or long-term basis. The results of mortality analyses were inconsistent: using Kaplan-Meier estimates, the persons with PA in prepaid group practice settings survived significantly longer (P<.05 by log-rank test); using Cox proportional hazards methods, the proportion dying each year did not differ significantly. Conclusions.-We could find no evidence that persons with RA in fee-for-service and prepaid group practice settings received different quantities of health care or experienced different outcomes on either an annual or long-term basis.	UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA 94143 USA; KAISER PERMANENTE, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, ROISALIND RUSSSELL MED RES CTR ARTHRITIS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Kaiser Permanente; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020684] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-20684] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BYE B, 1982, SURVEY DISABILITY WO; CAREY T, 1990, J CLIN EPIDEMIOL, V43, P1213, DOI 10.1016/0895-4356(90)90022-H; COX DR, 1972, J R STAT SOC B, V34, P187; CRISWELL LA, 1994, ARTHRITIS RHEUM, V37, P476, DOI 10.1002/art.1780370407; DIEHR P, 1984, MED CARE, V22, P1, DOI 10.1097/00005650-198401000-00001; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; FRANCIS AM, 1984, MED CARE, V22, P418, DOI 10.1097/00005650-198405000-00006; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HLATKY MA, 1983, ARCH INTERN MED, V143, P1886, DOI 10.1001/archinte.143.10.1886; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARIM MR, 1988, 674 J HOPK U DEP BIO; Kovar M, 1985, VITAL HLTH STAT, V1; LOGERFO JP, 1979, MED CARE, V17, P1, DOI 10.1097/00005650-197901000-00001; LUBECK DP, 1985, MED CARE, V23, P266, DOI 10.1097/00005650-198503000-00008; LUFT HS, 1978, NEW ENGL J MED, V298, P1336, DOI 10.1056/NEJM197806152982404; LUFT HS, 1981, HLTH MAINTENANCE ORG; Manheim L M, 1995, Arthritis Care Res, V8, P298, DOI 10.1002/art.1790080415; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MASON JH, 1992, ARTHRITIS RHEUM, V35, P156, DOI 10.1002/art.1780350206; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; NEVITT MC, 1986, ANN INTERN MED, V105, P421, DOI 10.7326/0003-4819-105-3-421; NORQUIST GS, 1991, AM J PSYCHIAT, V148, P96; RETCHIN SM, 1990, J GEN INTERN MED, V5, P110, DOI 10.1007/BF02600509; ROGERS WH, 1993, ARCH GEN PSYCHIAT, V50, P517; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; *SAS I INC, 1992, P229 SAS I; SLOSS EM, 1987, ANN INTERN MED, V106, P130, DOI 10.7326/0003-4819-106-1-130; SULLIVAN CB, 1992, HEALTH AFFAIR, V11, P172, DOI 10.1377/hlthaff.11.4.172; TRUPIN L, 1995, MED EXPENDITURES PEO; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; VERNON SW, 1992, CANCER, V69, P2418, DOI 10.1002/1097-0142(19920515)69:10<2418::AID-CNCR2820691006>3.0.CO;2-1; WARE JE, 1986, LANCET, V1, P1017; WEINER JP, 1993, J HEALTH POLIT POLIC, V18, P75, DOI 10.1215/03616878-18-1-75; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P3298, DOI 10.1001/jama.262.23.3298; WILNER S, 1981, NEW ENGL J MED, V304, P784, DOI 10.1056/NEJM198103263041313; YELIN EH, 1985, NEW ENGL J MED, V312, P962, DOI 10.1056/NEJM198504113121506; YELIN EH, 1986, MED CARE, V24, P236, DOI 10.1097/00005650-198603000-00006	40	63	63	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1996	276	13					1048	1053		10.1001/jama.276.13.1048	http://dx.doi.org/10.1001/jama.276.13.1048			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VK035	8847766				2022-12-28	WOS:A1996VK03500025
J	Barodawala, S				Barodawala, S			Care of older people .11. Community care: The independent sector	BRITISH MEDICAL JOURNAL			English	Article								The independent sector, which consists of the voluntary and private sectors, is a vital element in supporting older people in the community. The voluntary sector, coordinated by the Council for Voluntary Service and the National Council for Voluntary Organisations, provides a variety of services, including practical help, reassurance and companionship, and advice, information, campaigning, and advocacy. The private sector owns all of the nursing homes and most of the residential homes and is gradually becoming more involved with the provision of services to help support older people in their own homes. With this increase in size and importance of the independent sector over recent years, there is now a real need for greater communication between the private, voluntary, and statutory agencies in any one region. In some areas, forums made up of representatives of these various sectors meet to discuss relevant issues and construct local policies, thus allowing a more coordinated approach to the delivery of services.			Barodawala, S (corresponding author), ST JAMES UNIV HOSP,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							Travers AF, 1996, BRIT MED J, V313, P482; WANKLYN T, 1996, BRIT MED J, V313, P218	2	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					740	743						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819449				2022-12-28	WOS:A1996VJ44100032
J	Brus, RHP; Bodenheimer, S				Brus, RHP; Bodenheimer, S			High-dose inhaled steroids in asthmatic children	LANCET			English	Letter											Brus, RHP (corresponding author), FOREST LABS INC,909 3RD AVE,NEW YORK,NY 10022, USA.							*GLAX WELLC, 1996, FLOV FLUT PROP PACK; *MED EC CO, 1996, PHYS DISK REF, P1005; Todd G, 1996, LANCET, V348, P27, DOI 10.1016/S0140-6736(96)03339-9	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					820	821		10.1016/S0140-6736(05)65235-X	http://dx.doi.org/10.1016/S0140-6736(05)65235-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813997				2022-12-28	WOS:A1996VH98900041
J	Derkinderen, P; Toutant, M; Burgaya, F; LeBert, M; Siciliano, JC; deFranciscis, V; Gelman, M; Girault, JA				Derkinderen, P; Toutant, M; Burgaya, F; LeBert, M; Siciliano, JC; deFranciscis, V; Gelman, M; Girault, JA			Regulation of a neuronal form of focal adhesion kinase by anandamide	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; ENDOGENOUS CANNABINOID ANANDAMIDE; LONG-TERM POTENTIATION; ACETYLCHOLINE-RECEPTOR; MUTANT MICE; BRAIN; PHOSPHORYLATION; EXPRESSION; CHANNEL; IDENTIFICATION	Anandamide is an endogenous ligand for central cannabinoid receptors and is released after neuronal depolarization. Anandamide increased protein tyrosine phosphorylation in rat hippocampal slices and neurons in culture. The action of anandamide resulted from the inhibition of adenylyl cyclase and cyclic adenosine 3',5'-monophosphate-dependent protein kinase. One of the proteins phosphorylated in response to anandamide was an isoform of pp125-focal adhesion kinase (FAK+) expressed preferentially in neurons. Focal adhesion kinase is a tyrosine kinase involved in the interactions between the integrins and actin-based cytoskeleton. Thus, anandamide may exert neurotrophic effects and play a role in synaptic plasticity.	COLL FRANCE,INSERM,CHAIRE NEUROPHARMACOL,U114,F-75231 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France			Girault, Jean-Antoine/F-7518-2013; Le Bert, Marc/AAR-4577-2021; Derkinderen, Pascal/K-2393-2015	Girault, Jean-Antoine/0000-0002-7900-1705; Le Bert, Marc/0000-0002-5945-3800; 				Boxall AR, 1996, NEURON, V16, P805, DOI 10.1016/S0896-6273(00)80100-2; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; Burgaya F, 1996, MOL BRAIN RES, V37, P63, DOI 10.1016/0169-328X(95)00273-U; CHAMAK B, 1987, J NEUROSCI, V7, P3163; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; DERKINDEREN P, UNPUB; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HOWLETT AC, 1995, ANNU REV PHARMACOL, V35, P607, DOI 10.1146/annurev.pharmtox.35.1.607; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Menegoz M, 1995, NEUROREPORT, V7, P125, DOI 10.1097/00001756-199512290-00030; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SICILIANO JC, 1994, J NEUROCHEM, V62, P950; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WARTMANN M, 1995, FEBS LETT, V359, P133, DOI 10.1016/0014-5793(95)00027-7; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0	32	145	151	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1996	273	5282					1719	1722		10.1126/science.273.5282.1719	http://dx.doi.org/10.1126/science.273.5282.1719			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781236				2022-12-28	WOS:A1996VH40800043
J	Hille, B				Hille, B			A K+ channel worthy of attention	SCIENCE			English	Editorial Material											Hille, B (corresponding author), UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195, USA.							HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; PEDARZANI P, 1993, NEURON, V11, P1023, DOI 10.1016/0896-6273(93)90216-E; SH P, 1996, TRENDS NEUROSCI, V19, P150; STANSFELD CE, IN PRESS P NATL ACAD	6	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1996	273	5282					1677	1677		10.1126/science.273.5282.1677	http://dx.doi.org/10.1126/science.273.5282.1677			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8830412				2022-12-28	WOS:A1996VH40800030
J	Horton, R				Horton, R			The Academy stumbles, then advances, under fire	LANCET			English	Editorial Material																		Carney A, 1996, BRIT MED J, V313, P234, DOI 10.1136/bmj.313.7051.234a; Cash J, 1996, BRIT MED J, V313, P234, DOI 10.1136/bmj.313.7051.234b; Grabham AH, 1996, BRIT MED J, V312, P1604, DOI 10.1136/bmj.312.7046.1604a; Macara AW, 1996, BRIT MED J, V312, P1604, DOI 10.1136/bmj.312.7046.1604; Smith R, 1996, BRIT MED J, V312, P1374, DOI 10.1136/bmj.312.7043.1374; 1996, LANCET, V347, P1419	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					700	700		10.1016/S0140-6736(05)65603-6	http://dx.doi.org/10.1016/S0140-6736(05)65603-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8830206				2022-12-28	WOS:A1996VG37400007
J	Shann, F				Shann, F			How often do children cough?	LANCET			English	Editorial Material											Shann, F (corresponding author), ROYAL CHILDRENS HOSP,INTENS CARE UNIT,MELBOURNE,VIC 3052,AUSTRALIA.		Shann, Frank/C-9510-2011					FALCONER A, 1993, PEDIATR PULM, V15, P209, DOI 10.1002/ppul.1950150405; FULLER RW, 1991, LUNG SCI FDN; Munyard P, 1996, ARCH DIS CHILD, V74, P531, DOI 10.1136/adc.74.6.531; Pio A, 1988, Indian J Pediatr, V55, P197, DOI 10.1007/BF02722181	4	14	16	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					699	700		10.1016/S0140-6736(05)65602-4	http://dx.doi.org/10.1016/S0140-6736(05)65602-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806287				2022-12-28	WOS:A1996VG37400006
J	Crumpacker, CS				Crumpacker, CS			Drug therapy - Ganciclovir	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HERPES-SIMPLEX VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; PREVENT CYTOMEGALOVIRUS DISEASE; OPEN READING FRAME; BONE-MARROW TRANSPLANTATION; DNA-POLYMERASE GENE; HIGH-DOSE ACYCLOVIR; NUCLEOSIDE ANALOG; CONTROLLED TRIAL; INFECTED-CELLS				Crumpacker, CS (corresponding author), BETH ISRAEL HOSP,DIV INFECT DIS,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							AGUT H, 1989, LANCET, V2, P626; ANDERSON RD, 1995, CLIN THER, V17, P425, DOI 10.1016/0149-2918(95)80107-3; ASHTON WT, 1982, BIOCHEM BIOPH RES CO, V108, P1716, DOI 10.1016/S0006-291X(82)80109-5; BALDANTI F, 1995, J VIROL, V69, P796, DOI 10.1128/JVI.69.2.796-800.1995; BIRON KK, 1986, P NATL ACAD SCI USA, V83, P8769, DOI 10.1073/pnas.83.22.8769; BIRON KK, 1985, P NATL ACAD SCI USA, V82, P2473, DOI 10.1073/pnas.82.8.2473; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BROSGART CL, 1995, 35 INT C ANT AG CHEM; BUHLES WC, 1988, REV INFECT DIS, V10, pS495; CHEE MS, 1989, J GEN VIROL, V70, P1151, DOI 10.1099/0022-1317-70-5-1151; CHENG YC, 1983, P NATL ACAD SCI-BIOL, V80, P2767, DOI 10.1073/pnas.80.9.2767; CHENG YC, 1983, J BIOL CHEM, V258, P2460; CHOU SW, 1995, J INFECT DIS, V172, P239, DOI 10.1093/infdis/172.1.239; CHOU SW, 1995, J INFECT DIS, V171, P576, DOI 10.1093/infdis/171.3.576; CRUMPACKER C, 1988, REV INFECT DIS, V10, pS538; CRUMPACKER CS, 1984, P NATL ACAD SCI-BIOL, V81, P1556, DOI 10.1073/pnas.81.5.1556; CRUMPACKER CS, 1992, AM J MED S2A, V92; DEARMOND B, 1991, J ACQ IMMUN DEF SYND, V4, pS53; DIETERICH DT, 1993, J INFECT DIS, V167, P1184, DOI 10.1093/infdis/167.5.1184; DIETERICH DT, 1993, J INFECT DIS, V167, P278, DOI 10.1093/infdis/167.2.278; Drew W L, 1993, Clin Diagn Virol, V1, P179; DREW WL, 1995, NEW ENGL J MED, V333, P615, DOI 10.1056/NEJM199509073331002; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; EIDELBERG D, 1986, NEUROLOGY, V36, P912, DOI 10.1212/WNL.36.7.912; EMANUEL D, 1988, ANN INTERN MED, V109, P777, DOI 10.7326/0003-4819-109-10-777; ENTING R, 1992, LANCET, V340, P559, DOI 10.1016/0140-6736(92)91764-Y; ERICE A, 1989, NEW ENGL J MED, V320, P289, DOI 10.1056/NEJM198902023200505; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; FIELD AK, 1983, P NATL ACAD SCI-BIOL, V80, P4139, DOI 10.1073/pnas.80.13.4139; FLETCHER C, 1986, CLIN PHARMACOL THER, V40, P281, DOI 10.1038/clpt.1986.177; FOX JD, 1995, J INFECT DIS, V172, P1087, DOI 10.1093/infdis/172.4.1087; FREEMAN WR, 1987, AM J OPHTHALMOL, V103, P527, DOI 10.1016/S0002-9394(14)74276-X; FULLER GN, 1990, LANCET, V335, P48, DOI 10.1016/0140-6736(90)90172-2; FULLER GN, 1992, J ACQ IMMUN DEF SYND, V5, pS33; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; GRAVELEAU P, 1989, LANCET, V1, P511; HAMZEH FM, 1991, ANTIMICROB AGENTS CH, V35, P1818, DOI 10.1128/AAC.35.9.1818; HAMZEH FM, 1990, J VIROL, V64, P6184, DOI 10.1128/JVI.64.12.6184-6195.1990; HARDY WD, 1991, J ACQ IMMUN DEF SYND, V4, pS22; HECHT DW, 1988, J INFECT DIS, V157, P187, DOI 10.1093/infdis/157.1.187; HEINEMANN MH, 1989, ARCH OPHTHALMOL-CHIC, V107, P1767, DOI 10.1001/archopht.1989.01070020849025; HIBBERD PL, 1995, ANN INTERN MED, V123, P18, DOI 10.7326/0003-4819-123-1-199507010-00002; HO HT, 1992, MOL PHARMACOL, V41, P197; HOCHSTER H, 1990, ANN INTERN MED, V113, P111, DOI 10.7326/0003-4819-113-2-111; JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031; JACOBSON MA, 1988, ARCH NEUROL-CHICAGO, V45, P1090, DOI 10.1001/archneur.1988.00520340044009; JACOBSON MA, 1991, J INFECT DIS, V163, P1348, DOI 10.1093/infdis/163.6.1348; JACOBSON MA, 1994, AIDS, V8, P451, DOI 10.1097/00002030-199404000-00006; KOTLER DP, 1989, ARCH INTERN MED, V149, P901, DOI 10.1001/archinte.149.4.901; LALEZARI J, 1995, 35 INT C ANT AG CHEM; LIN JC, 1984, J VIROL, V50, P50, DOI 10.1128/JVI.50.1.50-55.1984; LITTLER E, 1992, NATURE, V358, P160, DOI 10.1038/358160a0; LURAIN NS, 1994, J VIROL, V68, P4427, DOI 10.1128/JVI.68.7.4427-4431.1994; LURAIN NS, 1992, J VIROL, V66, P7146, DOI 10.1128/JVI.66.12.7146-7152.1992; MAR EC, 1983, ANTIMICROB AGENTS CH, V24, P518, DOI 10.1128/AAC.24.4.518; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; MARTIN JC, 1983, J MED CHEM, V26, P759, DOI 10.1021/jm00359a023; MERIGAN TC, 1992, NEW ENGL J MED, V326, P1182, DOI 10.1056/NEJM199204303261803; METZGER C, 1994, J VIROL, V68, P8423, DOI 10.1128/JVI.68.12.8423-8427.1994; MILLER RG, 1990, NEUROLOGY, V40, P569, DOI 10.1212/WNL.40.4.569; OGILVIE KK, 1982, CAN J CHEM, V60, P3005, DOI 10.1139/v82-430; OLIVER S, 1985, VIROLOGY, V145, P84, DOI 10.1016/0042-6822(85)90203-X; PAPE JW, 1988, AIDS, V2, pS161, DOI 10.1097/00002030-198800001-00024; PLOTKIN SA, 1985, J INFECT DIS, V152, P833, DOI 10.1093/infdis/152.4.833; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; REED EC, 1990, ANN INTERN MED, V112, P505, DOI 10.7326/0003-4819-112-7-505; SCHAEFFER HJ, 1982, NUCLEOSIDES ANTIVIRA, P1; SCHMIDT GM, 1988, TRANSPLANTATION, V46, P905; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SHEPP DH, 1985, ANN INTERN MED, V103, P368, DOI 10.7326/0003-4819-103-3-368; SINGH N, 1994, ANN INTERN MED, V120, P375, DOI 10.7326/0003-4819-120-5-199403010-00004; SMITH KO, 1982, ANTIMICROB AGENTS CH, V22, P55, DOI 10.1128/AAC.22.1.55; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; STANAT SC, 1991, ANTIMICROB AGENTS CH, V35, P2191, DOI 10.1128/AAC.35.11.2191; SULLIVAN V, 1993, NATURE, V366, P756, DOI 10.1038/366756a0; SULLIVAN V, 1993, ANTIMICROB AGENTS CH, V37, P19, DOI 10.1128/AAC.37.1.19; SULLIVAN V, 1992, NATURE, V359, P85, DOI 10.1038/359085a0; SULLIVAN V, 1991, J INFECT DIS, V164, P781, DOI 10.1093/infdis/164.4.781; SULLIVAN V, 1992, NATURE, V358, P162, DOI 10.1038/358162a0; TATAROWICZ WA, 1992, J INFECT DIS, V166, P904, DOI 10.1093/infdis/166.4.904; TOCCI MJ, 1984, ANTIMICROB AGENTS CH, V25, P247, DOI 10.1128/AAC.25.2.247; VILE RG, 1993, CANCER RES, V53, P3860; WINSTON DJ, 1995, LANCET, V346, P69, DOI 10.1016/S0140-6736(95)92110-9; WOLF DG, 1992, J INFECT DIS, V166, P1412, DOI 10.1093/infdis/166.6.1412; 1996, ARCH OPHTHALMOL-CHIC, V114, P23; 1995, AIDS, V9, P471; 1986, NEW ENGL J MED, V314, P801; 1992, NEW ENGL J MED, V326, P1172	88	335	354	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1996	335	10					721	729		10.1056/NEJM199609053351007	http://dx.doi.org/10.1056/NEJM199609053351007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH266	8786764				2022-12-28	WOS:A1996VH26600007
J	Tariq, SM; Stevens, M; Matthews, S; Ridout, S; Twiselton, R; Hide, DW				Tariq, SM; Stevens, M; Matthews, S; Ridout, S; Twiselton, R; Hide, DW			Cohort study of peanut and tree nut sensitisation by age of 4 years	BRITISH MEDICAL JOURNAL			English	Article							ENVIRONMENTAL-FACTORS; ALLERGIC DISORDERS; FOOD; CHILDREN	Objective-To determine the prevalence of sensitisation to peanuts and tree nuts in all children born during one year in one geographical area. Design-Birth cohort study with structured review at ages 1, 2, and 4 years. Setting-All children born on the Isle of Wight between January 1989 and February 1990. Subjects-Of 1456 children originally included, 1218 were reviewed at age 4 years, Of these, 981 had skin prick tests. Main outcome measures-Positive skin test results, clinical atopic disease, and risk factors for the development of atopy. Results-15 of 1218 (1.2%) children were sensitised to peanuts or tree nuts (13 to peanuts). Six had had allergic reactions to peanuts (0.5% of the population), one to hazelnuts, and one to cashew nuts; three had had anaphylactic reactions, Seven children had positive skin test results or detectable IgE to peanuts without clinical symptoms. Two children who reacted to peanut in infancy had lost their sensitivity by 4 years. Family history of atopy, allergy to egg (odds ratio 9.9, 95% confidence interval 2.1 to 47.9, and eczema (7.3, 2.1 to 26.1) were important predictors for peanut allergy. Conclusions-IgE mediated allergy to peanuts is common in early childhood. In many the allergy persists but a minority may develop tolerance.	ST MARYS HOSP,DEPT BIOCHEM,NEWPORT PO30 5TG,ISLE OF WIGHT,ENGLAND; ST MARYS HOSP,ASTHMA & ALLERGY RES CTR,NEWPORT PO30 5TG,ISLE OF WIGHT,ENGLAND									ARSHAD SH, 1991, CLIN EXP ALLERGY, V21, P373, DOI 10.1111/j.1365-2222.1991.tb01671.x; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; EBERT W, 1990, INVITRO DIAGNOSTICA, V2, P6; FRIES JH, 1982, ANN ALLERGY, V48, P220; GERRARD JW, 1986, ANN ALLERGY, V56, P351; HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; VANASPEREN PP, 1983, ARCH DIS CHILD, V58, P253, DOI 10.1136/adc.58.4.253; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZIMMERMAN B, 1989, J ALLERGY CLIN IMMUN, V83, P764, DOI 10.1016/0091-6749(89)90012-2	11	261	271	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					514	517						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789974	Green Published			2022-12-28	WOS:A1996VF29400014
J	Laugharne, R; Fleminger, S				Laugharne, R; Fleminger, S			Are community mental health teams providing an equitable service? Comparison of source of referrals with inpatient care	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Laugharne, R (corresponding author), ST BARTHOLOMEWS & LONDON MED COLL, JOINT ACAD DEPT PSYCHOL MED, LONDON E1 2AD, ENGLAND.			Laugharne, Richard/0000-0001-9916-343X				PATMORE C, 1992, J MENTAL HLTH, V1, P107; ROBERTSON NC, 1979, PSYCHOL MED, V9, P355, DOI 10.1017/S0033291700030865; SAYCE L, 1991, SOC PSYCH PSYCH EPID, V26, P14, DOI 10.1007/BF00783575; THOMAS RVR, 1992, BRIT J GEN PRACT, V42, P358	4	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 24	1996	313	7055					476	476						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VE080	8776319				2022-12-28	WOS:A1996VE08000026
J	Furchgott, RF				Furchgott, RF			The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT RELAXATION; SMOOTH-MUSCLE; L-ARGININE; CELLS; ACETYLCHOLINE; AORTA	The discovery of endothelium-derived relaxing factor (EDRF) and its importance in the identification of nitric oxide (NO) originated with studies using rabbit aorta to examine drug-receptor interactions in vascular smooth muscle. Smooth muscle relaxation by acetylcholine and a number of other agonists was found to be dependent on the presence of endothelial cells, which, when stimulated by the agonist, released a diffusable, very labile, nonprostanoid substance, termed EDRF, that acted on vascular smooth muscle cells to activate relaxation. The characteristics of EDRF, when released from endothelial cells, were similar to the characteristics of NO, It is now established that EDRF, either as NO or some related nitrosyl substance, has a major role in a variety of important biological processes, including the regulation of vascular tone, local blood flow, and blood pressure, inhibition of platelet aggregation and adhesion, and involvement in postischemic reperfusion, memory function, and central nervous system degenerative diseases.			Furchgott, RF (corresponding author), SUNY HLTH SCI CTR,DEPT PHARMACOL,BOX 29,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.							CHERRY PD, 1982, P NATL ACAD SCI-BIOL, V79, P2106, DOI 10.1073/pnas.79.6.2106; Cobb JP, 1996, JAMA-J AM MED ASSOC, V275, P1192, DOI 10.1001/jama.275.15.1192; FURCHGOTT R F, 1988, P401; FURCHGOTT RF, 1953, J PHARMACOL EXP THER, V108, P129; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; FURCHGOTT RF, 1981, TRENDS PHARMACOL SCI, V2, P173, DOI 10.1016/0165-6147(81)90303-5; FURCHGOTT RF, 1993, CIRCULATION, V87, P3; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; IGNARRO L J, 1988, P427; Khan M.T., 1987, PHARMACOLOGY, P341; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Murad F, 1979, Adv Cyclic Nucleotide Res, V11, P175; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; RAPOPORT RM, 1983, CIRC RES, V52, P352, DOI 10.1161/01.RES.52.3.352; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; STAMLER JS, 1994, CIRCULATION, V89, P2035, DOI 10.1161/01.CIR.89.5.2035	19	148	153	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1186	1188		10.1001/jama.276.14.1186	http://dx.doi.org/10.1001/jama.276.14.1186			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827976				2022-12-28	WOS:A1996VL33200033
J	Webb, E; Ashton, CH; Kelly, P; Kamali, F				Webb, E; Ashton, CH; Kelly, P; Kamali, F			Alcohol and drug use in UK university students	LANCET			English	Article							MEDICAL-STUDENTS; COLLEGE-STUDENTS; PROBLEM DRINKING; YOUNG ADULTHOOD; CONSUMPTION; PERSONALITY; ADOLESCENCE; PATTERNS; SAMPLE	Background Alcohol and illicit drug use are increasing among school children and young adults in the UK. Such increases have also been noted among university students and there is a need for a large survey across different universities and faculties. We report such a survey. Methods information about drinking, use of cannabis and other illicit drugs, other lifestyle variables, and subjective ratings of anxiety and depression was obtained by questionnaire in a cross-faculty sample of 3075 second-year university students (1610 men, 1447 women, 18 sex not stated) from ten UK universities. The questionnaire was personally administered during scheduled lecture hours and almost ail the students participated. The sample reflected the interfaculty and sex distribution and the proportion of non-white students at UK universities. Findings 11% of the students were non-drinkers, Among drinkers, 61% of the men and 48% of the women exceeded ''sensible'' limits of 14 units per week for women and 21 for men. Hazardous drinking (greater than or equal to 36 units per week for women, greater than or equal to 51 for men) was reported by 15% of the drinkers, Binge drinking was declared by 28% of drinkers. 60% of the men and 55% of the women reported having used cannabis once or twice and 20% of the sample reported regular cannabis use (weekly or more often). Experience with other illicit drugs was reported by 33% of the sample, most commonly LSD (lysergic acid diethylamide), amphetamines, Ecstasy (methylenedioxymethamphetamine), and amyl/butyl nitrate which had each been used by 13-18% of students. 34% of these had used several drugs, Drug use had started at school in 46% of the sample; 13% began after entering university. The overwhelming reason given for taking alcohol or drugs was pleasure, Subjective ratings of anxiety on the hospital anxiety depression scale were high, and sleep difficulties were common, but neither related to alcohol or drug use. Interpretation There is a need far better education about alcohol, drugs, and general health in universities. Such education should include all faculties. It remains unclear whether university students' lifestyles are carried over into later life.	UNIV NEWCASTLE UPON TYNE,DEPT PHARMACOL SCI,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT PSYCHIAT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT MED STAT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK								ANDREASSON S, 1993, AM J PUBLIC HEALTH, V83, P845, DOI 10.2105/AJPH.83.6.845; ASHTON CH, 1995, MED EDUC, V29, P187, DOI 10.1111/j.1365-2923.1995.tb02828.x; BALDING J, 1994, YOUNG PEOPLE 1993; BROWN C, 1991, COLL STUDENT J, V25, P451; Calman K, 1995, Health Trends, V27, P71; COGGANS N, 1991, BRIT J ADDICT, V86, P1099; COLLIER DJ, 1989, BRIT MED J, V299, P19, DOI 10.1136/bmj.299.6690.19; *DEP HLTH, 1995, SENS DRINK REP INT; Department of Health, 1992, HLTH NAT STRAT HLTH; DONOVAN JE, 1983, J STUD ALCOHOL, V44, P109, DOI 10.15288/jsa.1983.44.109; Edwards G, 1996, BRIT MED J, V312, P1, DOI 10.1136/bmj.312.7022.1; FILE SE, 1994, J PSYCHOPHARMACOL, V8, P22, DOI 10.1177/026988119400800104; FIRTH J, 1986, BRIT MED J, V292, P1177, DOI 10.1136/bmj.292.6529.1177; Ghodse A H, 1994, Health Trends, V26, P85; Gold M. S, 1991, COMPREHENSIVE HDB AL, P353; GOLDING JF, 1983, PERS INDIV DIFFER, V4, P703, DOI 10.1016/0191-8869(83)90129-0; GOLDING JF, 1987, PSYCHOL HEALTH, V1, P287; Hall W, 1994, NATL DRUG STRATEGY M, V25; HAMMER T, 1990, J ADOLESCENCE, V13, P129, DOI 10.1016/0140-1971(90)90003-P; *HLTH ED AUTH, 1992, THATS LIM GUID SENS; *HM STAT OFF, 1995, ED STAT UK; JACKSON R, 1995, LANCET, V346, P716, DOI 10.1016/S0140-6736(95)91496-X; KLEIN H, 1994, J YOUTH ADOLESCENCE, V23, P251, DOI 10.1007/BF01537448; Marmot M, 1995, LANCET, V346, P1643, DOI 10.1016/S0140-6736(95)92833-2; MENDELSON JH, 1987, PSYCHOPHARMACOLOGY 3, P1565; MOORE L, 1994, HEALTH EDUC RES, V9, P497, DOI 10.1093/her/9.4.497; Nahas GG, 1984, MARIHUANA SCI MED, P109; PAFFENBARGER RS, 1994, MED SCI SPORT EXER, V26, P857; Plant M., 1992, RISK TAKERS ALCOHOL; POLS R, 1991, IS THERE SAFE LEVEL; RITSON EB, 1990, BRIT MED J, V30, P134; WEST R, 1990, BRIT J ADDICT, V85, P479; WRIGHT JD, 1995, BRIT MED J, V310, P20, DOI 10.1136/bmj.310.6971.20; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1995, J R COLL PHYS LOND, V29, P470; 1995, J R COLL PHYS LOND, V29, P266	36	288	300	0	96	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					922	925		10.1016/S0140-6736(96)03410-1	http://dx.doi.org/10.1016/S0140-6736(96)03410-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VL097	8843811				2022-12-28	WOS:A1996VL09700011
J	Czaja, AJ				Czaja, AJ			The variant forms of autoimmune hepatitis	ANNALS OF INTERNAL MEDICINE			English	Review							PRIMARY BILIARY-CIRRHOSIS; CHRONIC ACTIVE HEPATITIS; PRIMARY SCLEROSING CHOLANGITIS; ALPHA-INTERFERON THERAPY; CHRONIC VIRAL-HEPATITIS; C VIRUS-INFECTION; CHRONIC ULCERATIVE-COLITIS; SOLUBLE LIVER ANTIGEN; CLASS-II GENES; ANTIMITOCHONDRIAL ANTIBODIES	Objectives: To review the diagnostic criteria for autoimmune hepatitis, to characterize the variant forms of autoimmune hepatitis, and to indicate appropriate therapies for this condition. Data Sources: A MEDLINE search (1990 to 1995) of the English-language literature, review of a personal library of journals and reprints (1975 to 1995), and review of references selected from the bibliographies of identified articles. Terms used in the MEDLINE search included the names of all autoimmune liver diseases, viral hepatitis and autoimmunity, cryptogenic hepatitis, and overlap syndromes. Study Selection: All articles that discussed atypical clinical features, mixed diagnostic findings, and variations in treatment response were selected. Data Extraction: Data were selected from 548 articles. Data Synthesis: Standardized criteria permit the confident diagnosis of autoimmune hepatitis, but they exclude many patients who have features suggesting autoimmunity. Such patients have findings indicative of both autoimmune hepatitis and another disorder (overlap syndromes) or findings that are inconsistent with the classic definition of autoimmune hepatitis (outlier syndromes). Overlap syndromes include combinations of autoimmune hepatitis and primary biliary cirrhosis, primary sclerosing cholangitis, or chronic viral hepatitis. Treatment of these syndromes requires identification of the predominant disorder and selection of the most appropriate drug regimen. Outlier syndromes include autoimmune cholangitis and cryptogenic chronic hepatitis. Corticosteroids or ursodeoxycholic acid are treatment options for patients with autoimmune cholangitis; corticosteroids can also benefit patients with cryptogenic chronic hepatitis. Grading each clinical feature and developing a composite score can permit comparison of the variants and a determination of the similarity between the variants and autoimmune hepatitis. Conclusions: Variant forms of autoimmune hepatitis are common. Recognition of them is important in assessing common pathogenic mechanisms, developing effective treatment strategies, and refining classification schemes.			Czaja, AJ (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							BACH N, 1992, HEPATOLOGY, V15, P572, DOI 10.1002/hep.1840150403; BEARN AG, 1956, AM J MED, V21, P3, DOI 10.1016/0002-9343(56)90003-1; BELLARY S, 1995, ANN INTERN MED, V123, P32, DOI 10.7326/0003-4819-123-1-199507010-00004; BENARI Z, 1993, HEPATOLOGY, V18, P10, DOI 10.1016/0270-9139(93)90499-D; BERG PA, 1980, LANCET, V2, P1329; BROWN J, 1992, HEPATOLOGY, V15, P175, DOI 10.1002/hep.1840150202; BRUNNER G, 1987, DEUT MED WOCHENSCHR, V112, P1454, DOI 10.1055/s-2008-1068269; BURMAN P, 1986, J CLIN ENDOCR METAB, V63, P1086, DOI 10.1210/jcem-63-5-1086; CASSANI F, 1992, GUT, V33, P1260, DOI 10.1136/gut.33.9.1260; CHOU CK, 1992, HEPATOLOGY, V16, P13, DOI 10.1002/hep.1840160104; CHUNG YH, 1993, AM J GASTROENTEROL, V88, P244; CLIFFORD BD, 1995, HEPATOLOGY, V21, P613, DOI 10.1016/0270-9139(95)90507-3; CZAJA AJ, 1995, DIGEST DIS SCI, V40, P435, DOI 10.1007/BF02065434; CZAJA AJ, 1995, MAYO CLIN PROC, V70, P1154, DOI 10.4065/70.12.1154; Czaja AJ, 1996, DIGEST DIS SCI, V41, P305, DOI 10.1007/BF02093820; CZAJA AJ, 1993, GASTROENTEROLOGY, V104, P1755, DOI 10.1016/0016-5085(93)90656-W; CZAJA AJ, 1995, GASTROENTEROLOGY, V108, P157, DOI 10.1016/0016-5085(95)90020-9; CZAJA AJ, 1984, SEMIN LIVER DIS, V4, P1, DOI 10.1055/s-2008-1040641; CZAJA AJ, 1992, GASTROENTEROLOGY, V103, P1290, DOI 10.1016/0016-5085(92)91518-9; CZAJA AJ, 1993, GASTROENTEROLOGY, V105, P1522, DOI 10.1016/0016-5085(93)90160-E; CZAJA AJ, 1990, J GASTROEN HEPATOL, V5, P343, DOI 10.1111/j.1440-1746.1990.tb01636.x; CZAJA AJ, 1993, GASTROENTEROLOGY, V105, P1824, DOI 10.1016/0016-5085(93)91081-R; CZAJA AJ, 1993, ANN INTERN MED, V119, P510, DOI 10.7326/0003-4819-119-6-199309150-00011; CZAJA AJ, 1995, DIGEST DIS SCI, V40, P33, DOI 10.1007/BF02063938; CZAJA AJ, 1990, MAYO CLIN PROC, V65, P23, DOI 10.1016/S0025-6196(12)62106-5; CZAJA AJ, 1994, GASTROENTEROL CLIN N, V23, P547; CZAJA AJ, 1993, J HEPATOL, V18, P342, DOI 10.1016/S0168-8278(05)80279-X; CZAJA AJ, 1994, CLIN IMMUNOTHER, V1, P413, DOI 10.1007/BF03259034; CZAJA AJ, 1993, HEPATOLOGY, V18, P816, DOI 10.1002/hep.1840180411; DAVIS PA, 1992, HEPATOLOGY, V16, P1128, DOI 10.1016/0270-9139(92)90004-S; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311; DONALDSON PT, 1991, HEPATOLOGY, V13, P701, DOI 10.1016/0270-9139(91)92567-R; FATTOVICH G, 1991, J MED VIROL, V34, P132, DOI 10.1002/jmv.1890340212; FATTOVICH G, 1992, ARCH VIROL, P291; FREGEAU DR, 1989, J IMMUNOL, V142, P3815; FUSSEY SPM, 1988, P NATL ACAD SCI USA, V85, P8654, DOI 10.1073/pnas.85.22.8654; GARCIABUEY L, 1995, GASTROENTEROLOGY, V108, P1770, DOI 10.1016/0016-5085(95)90139-6; GEUBEL AP, 1976, GASTROENTEROLOGY, V71, P444; GOODMAN ZD, 1995, DIGEST DIS SCI, V40, P1232, DOI 10.1007/BF02065530; GORDON SC, 1995, GASTROENTEROLOGY, V108, P1802, DOI 10.1016/0016-5085(95)90143-4; GREEVE M, 1993, HEPATOLOGY, V17, P593, DOI 10.1002/hep.1840170411; HESELTINE L, 1990, GASTROENTEROLOGY, V99, P1786, DOI 10.1016/0016-5085(90)90488-M; JEFFERS LJ, 1992, HEPATOLOGY, V15, P187, DOI 10.1002/hep.1840150204; JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435; KENNY RP, 1986, DIGEST DIS SCI, V31, P705, DOI 10.1007/BF01296447; KLOPPEL G, 1977, VIRCHOWS ARCH A, V373, P143, DOI 10.1007/BF00432159; LACERDA MA, 1995, AM J GASTROENTEROL, V90, P247; LUDWIG J, 1995, AM J GASTROENTEROL, V90, P181; LUDWIG J, 1994, AM J GASTROENTEROL, V89, pS177; LUDWIG J, 1984, LIVER, V4, P105; LUDWIG J, 1979, ARCH PATHOL LAB MED, V103, P467; MAGRIN S, 1994, HEPATOLOGY, V19, P273; MANNS M, 1987, LANCET, V1, P292; MARCELLIN P, 1995, J HEPATOL, V22, P364, DOI 10.1016/0168-8278(95)80291-6; MAYET WJ, 1989, HEPATOLOGY, V10, P24, DOI 10.1002/hep.1840100106; MEEK F, 1980, CLIN EXP IMMUNOL, V41, P43; MEHAL WZ, 1994, GASTROENTEROLOGY, V106, P160, DOI 10.1016/S0016-5085(94)95085-7; MICHIELETTI P, 1994, GUT, V35, P260, DOI 10.1136/gut.35.2.260; MIELIVERGANI G, 1989, HEPATOLOGY, V9, P198, DOI 10.1002/hep.1840090206; MITORO A, 1993, INTERNAL MED, V32, P327, DOI 10.2169/internalmedicine.32.327; MUTIMER DJ, 1989, HEPATOLOGY, V10, P403, DOI 10.1002/hep.1840100402; PAPO T, 1992, ANN INTERN MED, V116, P51, DOI 10.7326/0003-4819-116-1-51; PERDIGOTO R, 1992, J HEPATOL, V14, P325, DOI 10.1016/0168-8278(92)90178-R; RABINOVITZ M, 1992, DIGEST DIS SCI, V37, P1606, DOI 10.1007/BF01296509; Roberts S., 1995, Hepatology, V22, p129A; SALASPURO MP, 1976, ANN CLIN RES, V8, P206; SARACCO G, 1990, J HEPATOL, V11, P339, DOI 10.1016/0168-8278(90)90218-G; SCHEUER PJ, 1992, HEPATOLOGY, V15, P567, DOI 10.1002/hep.1840150402; SCHULTZ M, 1989, LANCET, V1, P1452; SHINDO M, 1992, GASTROENTEROLOGY, V102, P1406; SILVA MO, 1991, GASTROENTEROLOGY, V101, P840, DOI 10.1016/0016-5085(91)90547-X; STECHEMESSER E, 1993, HEPATOLOGY, V18, P1; TAYLOR SL, 1994, AM J SURG PATHOL, V18, P91, DOI 10.1097/00000478-199401000-00009; VANDEWATER J, 1989, NEW ENGL J MED, V320, P1377, DOI 10.1056/NEJM198905253202104; VENTO S, 1989, LANCET, V2, P926; WACHTER B, 1990, J HEPATOL, V11, P232, DOI 10.1016/0168-8278(90)90119-C; WALDENSTROM J, 1950, DTSCH GES VERDAU STO, V15, P113, DOI DOI 10.1016/S0168-8278(02)00408-7; WEBER P, 1994, J HEPATOL, V20, P321, DOI 10.1016/S0168-8278(94)80002-2; WEE A, 1985, ANN INTERN MED, V102, P581, DOI 10.7326/0003-4819-102-5-581; WIESNER RH, 1980, GASTROENTEROLOGY, V79, P200; YOSHIDA T, 1990, GASTROENTEROLOGY, V99, P187, DOI 10.1016/0016-5085(90)91247-4; ZETTERQUIST H, 1992, GUT, V33, P942, DOI 10.1136/gut.33.7.942; Zurgil N, 1989, Autoimmunity, V4, P289, DOI 10.3109/08916938909014705	84	168	179	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1996	125	7					588	598		10.7326/0003-4819-125-7-199610010-00009	http://dx.doi.org/10.7326/0003-4819-125-7-199610010-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ653	8815758				2022-12-28	WOS:A1996VJ65300009
J	Kahrilas, PJ				Kahrilas, PJ			Gastroesophageal reflux disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BARRETTS-ESOPHAGUS; GASTRIC-ACID; H2-RECEPTOR ANTAGONISTS; POSTERIOR LARYNGITIS; TERM TREATMENT; OMEPRAZOLE; THERAPY; ADENOCARCINOMA; LANSOPRAZOLE; MANAGEMENT	Objective.-To review the management of gastroesophageal reflux disease (GERD) in adults with esophageal complications (esophagitis, stricture, adenocarcinoma, or Barrett metaplasia) or extraesophageal complications (otolaryngological manifestations and asthma). Data Sources.-Peer-reviewed publications located via MEDLINE or cross-citation. Study Selection.-Emphasis was placed on new developments in diagnosis and therapeutics. Thus, fewer than 10% of identified citations are discussed. Data Extraction.-Controlled therapeutic trials were emphasized. The validity of pathophysiological observations and uncontrolled trials were critiqued by the author. Data Synthesis.-Esophagitis is typically a chronic, recurring disorder treated with long-term antisecretory therapy, titrated to disease severity, Laparascopic antireflux surgery is an alternative strategy, but neither long-term efficacy data nor an appropriate controlled trial comparing it with proton pump inhibitor therapy exists. The main risk of esophagitis is adenocarcinoma arising from Barrett metaplasia, the incidence of which is increasing. Strong evidence suggests that both reflux-induced asthma and otolaryngological complications (subglottic stenosis, laryngitis, pharyngitis, or cancer) can occur without esophagitis. While the otolaryngological manifestations usually respond to antisecretory medications, reflux-induced asthma responds convincingly only to antireflux surgery. Conclusions.-Although esophagitis and GERD symptoms predictably respond to antisecretory medicines, the risk of adenocarcinoma from Barrett metaplasia dictates that if heartburn is refractory to treatment, chronic (>5 years), or accompanied by dysphagia, odynophagia, or bleeding, it should be evaluated by endoscopy. Thereafter, patients with Barrett metaplasia require surveillance endoscopy to control the cancer risk. Reflux-induced asthma remains a vexing problem in the absence of either medical therapy of proven efficacy or a reliable mechanism of prospectively identifying affected patients.			Kahrilas, PJ (corresponding author), NORTHWESTERN UNIV, SCH MED,DEPT MED,DIV GASTROENTEROL & HEPATOL, PASSAVANT PAVIL, SUITE 746, CHICAGO, IL 60611 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000646] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC00646] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALLISON PR, 1946, J THORAC SURG, V15, P308; BELL NJV, 1992, GUT, V33, P118, DOI 10.1136/gut.33.1.118; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOT WJ, 1993, JAMA-J AM MED ASSOC, V270, P1320, DOI 10.1001/jama.270.11.1320; CAMERON AJ, 1985, NEW ENGL J MED, V313, P857, DOI 10.1056/NEJM198510033131404; CAMERON AJ, 1986, GASTROENTEROLOGY, V91, P338, DOI 10.1016/0016-5085(86)90566-4; CHERRY J, 1968, LARYNGOSCOPE, V78, P1937, DOI 10.1288/00005537-196811000-00007; CLARK GWB, 1994, ARCH SURG-CHICAGO, V129, P609; Cote Donald N., 1995, Comprehensive Therapy, V21, P80; CRAUSAZ FM, 1988, CHEST, V93, P376, DOI 10.1378/chest.93.2.376; DENT J, 1994, GUT, V35, P590, DOI 10.1136/gut.35.5.590; DENT J, 1990, BARRETTS OESOPHAGUS, P17; DORSCH E, 1991, AM J GASTROENTEROL, V86, P1294; FELDMAN M, 1993, AM J GASTROENTEROL, V88, P1212; FENNERTY MB, 1993, ALIMENT PHARM THER, V7, P339; FRESTON JW, 1994, ANN INTERN MED, V121, P232, DOI 10.7326/0003-4819-121-3-199408010-00012; GALMICHE JP, 1988, GUT, V29, P675, DOI 10.1136/gut.29.5.675; GAYNOR EB, 1988, LARYNGOSCOPE, V98, P972; HANSON DG, 1995, ANN OTO RHINOL LARYN, V104, P550, DOI 10.1177/000348949510400709; Harding SM, 1996, AM J MED, V100, P395, DOI 10.1016/S0002-9343(97)89514-9; HATLEBAKK JG, 1993, SCAND J GASTROENTERO, V28, P224, DOI 10.3109/00365529309096076; HETZEL DJ, 1988, GASTROENTEROLOGY, V95, P903, DOI 10.1016/0016-5085(88)90162-X; HINDER RA, 1994, ANN SURG, V220, P472, DOI 10.1097/00000658-199410000-00006; HIRSCHOWITZ BI, 1991, GASTROENTEROLOGY, V101, P1149, DOI 10.1016/0016-5085(91)90062-P; ING AJ, 1994, AM J RESP CRIT CARE, V149, P160, DOI 10.1164/ajrccm.149.1.8111576; JACOB P, 1991, GASTROENTEROLOGY, V100, P305, DOI 10.1016/0016-5085(91)90196-R; KAHRILAS PJ, 1994, GASTROENTEROLOGY, V107, P1865, DOI 10.1016/0016-5085(94)90835-4; Kahrilas PJ, 1996, GASTROENTEROLOGY, V110, P1982, DOI 10.1053/gast.1996.1101982; KAMBIC V, 1984, J LARYNGOL OTOL, V98, P1237, DOI 10.1017/S0022215100148340; KAMEL PL, 1994, AM J MED, V96, P321, DOI 10.1016/0002-9343(94)90061-2; KLINKENBERGKNOL EC, 1994, ANN INTERN MED, V121, P161, DOI 10.7326/0003-4819-121-3-199408010-00001; KOUFMAN JA, 1991, LARYNGOSCOPE, V101, P1; Kuipers EJ, 1996, NEW ENGL J MED, V334, P1018, DOI 10.1056/NEJM199604183341603; LARRAIN A, 1991, CHEST, V99, P1330, DOI 10.1378/chest.99.6.1330; MANSFIELD LE, 1978, ANN ALLERGY, V41, P224; MARKS RD, 1994, GASTROENTEROLOGY, V106, P907, DOI 10.1016/0016-5085(94)90749-8; MERCER CD, 1986, J THORAC CARDIOV SUR, V91, P371; MILLER LG, 1989, ARCH INTERN MED, V149, P2486, DOI 10.1001/archinte.149.11.2486; MORRISON MD, 1988, OTOLARYNG HEAD NECK, V99, P370, DOI 10.1177/019459988809900403; MORSON BC, 1980, J CLIN PATHOL, V33, P711, DOI 10.1136/jcp.33.8.711; NEBEL OT, 1976, AM J DIG DIS, V21, P953, DOI 10.1007/BF01071906; OLSEN NR, 1983, P AM LARYNGOL ASS, V104, P108; ORLANDO RC, 1994, AM J GASTROENTEROL, V89, pS48; PATTERSON DJ, 1983, GASTROENTEROLOGY, V85, P346; Peters JH, 1994, MINIMALLY INVASIVE S; RICHTER JE, 1995, AM J GASTROENTEROL, V90, P423; Robinson M, 1996, ANN INTERN MED, V124, P859, DOI 10.7326/0003-4819-124-10-199605150-00001; SAMPLINER RE, 1994, AM J GASTROENTEROL, V89, P1844; SAMPLINER RE, 1995, DIS ESOPHAGUS, V8, P104; SCHNELL TG, 1992, DIGEST DIS SCI, V37, P137, DOI 10.1007/BF01308357; SCHROEDER PL, 1995, ANN INTERN MED, V122, P809, DOI 10.7326/0003-4819-122-11-199506010-00001; SHAKER R, 1995, GASTROENTEROLOGY, V109, P1575, DOI 10.1016/0016-5085(95)90646-0; SONTAG SJ, 1993, ALIMENT PHARM THERAP, V7, P293; SONTAG SJ, 1990, GASTROENTEROL CLIN N, V19, P683; SONTAG SJ, 1990, GASTROENTEROLOGY, V99, P613, DOI 10.1016/0016-5085(90)90945-W; SPECHLER SJ, 1992, NEW ENGL J MED, V326, P786, DOI 10.1056/NEJM199203193261202; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605; SPECHLER SJ, 1994, LANCET, V344, P1533, DOI 10.1016/S0140-6736(94)90349-2; TIBBLING L, 1984, SCAND J GASTROENTERO, V19, P14; Trus TL, 1996, AM J SURG, V171, P32, DOI 10.1016/S0002-9610(99)80069-5; TUCHMAN DN, 1984, GASTROENTEROLOGY, V87, P872; VIGNERI S, 1995, NEW ENGL J MED, V333, P1106, DOI 10.1056/NEJM199510263331703; WARD PH, 1988, LARYNGOSCOPE, V98, P1195; WESDORP ICE, 1982, GASTROENTEROLOGY, V82, P487; Winklestein A, 1935, J AMER MED ASSOC, V104, P906, DOI 10.1001/jama.1935.02760110034008; WYDNER EL, 1977, CANCER RES, V37, P4608	66	194	215	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1996	276	12					983	988		10.1001/jama.276.12.983	http://dx.doi.org/10.1001/jama.276.12.983			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH990	8805734				2022-12-28	WOS:A1996VH99000040
J	Tranquada, RE				Tranquada, RE			Emergency medical care and the public purse	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									UNIV SO CALIF,SCH PUBL ADM,LOS ANGELES,CA 90089	University of Southern California	Tranquada, RE (corresponding author), UNIV SO CALIF,SCH MED,VKC 368A,LOS ANGELES,CA 90089, USA.							BROWN ER, 1991, HLTH INSURANCE COVER; Cornwell EE, 1996, JAMA-J AM MED ASSOC, V276, P940, DOI 10.1001/jama.276.12.940; COUSINEAU MR, 1994, RISK LOS ANGELES COU, P69; *LEW VHI INC, 1995, REP STAT HLTH CAR CA, P8; ONeill Tip, 1993, ALL POLITICS IS LOCA; *UN WAY LOS ANG, 1994, LOS ANG 1994 STAT CO, P9	6	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1996	276	12					945	946		10.1001/jama.276.12.945	http://dx.doi.org/10.1001/jama.276.12.945			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH990	8805718				2022-12-28	WOS:A1996VH99000016
J	Maquet, P; Peters, JM; Aerts, J; Delfiore, G; Degueldre, C; Luxen, A; Franck, G				Maquet, P; Peters, JM; Aerts, J; Delfiore, G; Degueldre, C; Luxen, A; Franck, G			Functional neuroanatomy of human rapid-eye-movement sleep and dreaming	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; CINGULATE CORTEX; WORKING-MEMORY; AMYGDALA; ORGANIZATION; WAKEFULNESS; PROJECTIONS; STATES; BRAIN; PET	RAPID-EYE-MOVEMENT (REM) sleep is associated with intense neuronal activity, ocular saccades, muscular atonia and dreaming(1,2). The function of REM sleep remains elusive and its neural correlates have not been characterized precisely in man. Here we use positron emission tomography and statistical parametric mapping to study the brain state associated with REM sleep in humans. We report a group study of seven subjects who maintained steady REM sleep during brain scanning and recalled dreams upon awakening. The results show that regional cerebral blood flow is positively correlated with REM sleep in pontine tegmentum, left thalamus, both amygdaloid complexes, anterior cingulate cortex and right parietal operculum. Negative correlations between regional cerebral blood flow and REM sleep are observed bilaterally, in a vast area of dorsolateral prefrontal cortex, in parietal cortex (supramarginal gyrus) as well as in posterior cingulate cortex and precuneus. Given the role of the amygdaloid complexes in the acquisition of emotionally influenced memories, the pattern of activation in the amygdala and the cortical areas provides a biological basis for the processing of some types of memory during REM sleep.	CHU SART TILMAN,DEPT NEUROL,B-4000 LIEGE,BELGIUM	University of Liege	Maquet, P (corresponding author), UNIV LIEGE,CYCLOTRON RES CTR B30,B-4000 LIEGE,BELGIUM.		luxen, andre/C-2116-2009	, Pierre/0000-0003-3106-3357				AGGLETON JP, 1980, BRAIN RES, V190, P347, DOI 10.1016/0006-8993(80)90279-6; AGGLETON JP, 1993, TRENDS NEUROSCI, V16, P328, DOI 10.1016/0166-2236(93)90110-8; AMARAL D G, 1992, P1; AMARAL DG, 1984, J COMP NEUROL, V230, P465, DOI 10.1002/cne.902300402; BECHARA A, 1995, SCIENCE, V269, P1115, DOI 10.1126/science.7652558; BRAUN A R, 1992, Neurology, V42, P182; BUCHSBAUM MS, 1989, LIFE SCI, V45, P1349, DOI 10.1016/0024-3205(89)90021-0; CALVO JM, 1987, BRAIN RES, V403, P22, DOI 10.1016/0006-8993(87)90118-1; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P165; Gallagher M, 1996, CURR OPIN NEUROBIOL, V6, P221, DOI 10.1016/S0959-4388(96)80076-6; Hall C., 1966, CONTENT ANAL DREAMS, DOI DOI 10.1192/BJP.112.490.963; Hobson J. Allan, 1988, DREAMING BRAIN; HONG CCH, 1995, SLEEP, V18, P570; JONES BE, 1991, NEUROSCIENCE, V40, P637, DOI 10.1016/0306-4522(91)90002-6; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; LLINAS RR, 1991, NEUROSCIENCE, V44, P521, DOI 10.1016/0306-4522(91)90075-Y; MADSEN PL, 1991, J CEREBR BLOOD F MET, V11, P502, DOI 10.1038/jcbfm.1991.94; MAQUET P, 1990, BRAIN RES, V513, P136, DOI 10.1016/0006-8993(90)91099-3; OLSON CR, 1992, J COMP NEUROL, V324, P237, DOI 10.1002/cne.903240207; Orem J, 1980, PHYSL SLEEP, P315; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Rechtschaffen A., 1968, BRAIN INFORM SERVICE; SMITH C, 1995, BEHAV BRAIN RES, V69, P137, DOI 10.1016/0166-4328(95)00024-N; SMITH C, 1991, SLEEP, V14, P325, DOI 10.1093/sleep/14.4.325; Steriade M., 1990, THALAMIC OSCILLATION	29	760	775	2	148	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					163	166		10.1038/383163a0	http://dx.doi.org/10.1038/383163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774879				2022-12-28	WOS:A1996VG14800050
J	Marin, I; Franke, A; Bashaw, GJ; Baker, BS				Marin, I; Franke, A; Bashaw, GJ; Baker, BS			The dosage compensation system of Drosophila is co-opted by newly evolved X chromosomes	NATURE			English	Article							EVOLUTION; GENE; EXPRESSION; PHYLOGENY	IN species where males and females differ in number of sex chromosomes, the expression of sex-linked genes is equalized by a process known as dosage compensation. In Drosophila melanogaster, dosage compensation is mediated by the binding of the products of the male-specific lethal (msl) genes to the single male X chromosome. Here we report that the sex- and chromosome-specific binding of three of the msl proteins (MSLs) occurs in other drosophilid species, spanning four genera. Moreover, we show that MSL binding correlates with the evolution of the sex chromosomes: in species that have acquired a second X chromosome arm because of an X-autosome translocation, we observe binding of the MSLs to the 'new' (previously autosomal) arm of the X chromosome, only when its homologue has degenerated. Moreover, in Drosophila miranda, a Y-autosome translocation has produced a new X chromosome (called neo-X), only some regions of which are dosage compensated. In this neo-X chromosome, the pattern of MSL binding correlates with the known pattern of dosage compensation.			Marin, I (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.		Marin, Ignacio/A-9524-2009	Marin, Ignacio/0000-0002-1315-8961				ABRAHAM I, 1974, GENETICS, V78, P119; BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; Bull J.J., 1983, EVOLUTION SEX DETERM; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; DAS M, 1982, CHROMOSOMA, V87, P373, DOI 10.1007/BF00327180; Dobzhansky T, 1935, GENETICS, V20, P0377; GORMAN M, 1995, DEVELOPMENT, V121, P463; GRIMALDI DA, 1990, B AM MUS NAT HIST, V197, P1; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KWIATOWSKI J, 1994, J MOL EVOL, V38, P443, DOI 10.1007/BF00178844; RUSSO CAM, 1995, MOL BIOL EVOL, V12, P391; Steinemann M, 1996, CHROMOSOME RES, V4, P185, DOI 10.1007/BF02254957; STROBEL E, 1978, P NATL ACAD SCI USA, V75, P931, DOI 10.1073/pnas.75.2.931; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	17	86	86	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					160	163		10.1038/383160a0	http://dx.doi.org/10.1038/383160a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774878				2022-12-28	WOS:A1996VG14800049
J	Ebrahim, S				Ebrahim, S			Caring for older people - Ethnic elders	BRITISH MEDICAL JOURNAL			English	Article								The numbers of elderly people from ethnic groups within Britain is rising rapidly as postwar immigrants age. Ethnic elders face problems owing to age-associated increased risks of common chronic diseases, racial discrimination, and poor access to many health services and social services. This disadvantage will be alleviated through increased understanding of health beliefs held by ethnic elders and ensuring better access to services through mechanisms such as employment of more staff from ethnic minority groups in senior positions, better training of staff, and more appropriate and sensitive environments. The myths that family care is sufficient, that no use of services implies no need, and that assimilation into the majority population will occur must be discounted.			Ebrahim, S (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,LONDON NW3 2PF,ENGLAND.							DONALDSON LJ, 1986, BRIT MED J, V293, P1079, DOI 10.1136/bmj.293.6554.1079; GATRAD AR, 1994, BRIT MED J, V309, P521, DOI 10.1136/bmj.309.6953.521; MARMOT MG, 1984, OPCS STUDIES MED POP, V47; MORTON J, 1993, RECENT RES SERVICES; Norman A., 1985, TRIPLE JEOPARDY GROW; *OFF POP CENS SURV, 1991, CENS GREAT BRIT 1991; SQUIRES AJ, 1991, MULTICULTURAL HLTH C	7	28	28	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					610	613						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806256				2022-12-28	WOS:A1996VG10800025
J	McGrath, BP				McGrath, BP			Is white-coat hypertension innocent?	LANCET			English	Editorial Material							AMBULATORY BLOOD-PRESSURE				McGrath, BP (corresponding author), MONASH UNIV,DEPT MED,CLAYTON,VIC 3168,AUSTRALIA.							AYMAN DAVID, 1940, AMER JOUR MED SCI, V200, P465, DOI 10.1097/00000441-194010000-00005; Bidlingmeyer I, 1996, J HYPERTENS, V14, P327, DOI 10.1097/00004872-199603000-00009; CAREK PJ, 1995, AM FAM PHYSICIAN, V52, P163; HOEGHOLM A, 1994, HYPERTENSION, V24, P101, DOI 10.1161/01.HYP.24.1.101; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; KUWAJIMA I, 1993, HYPERTENSION, V22, P826, DOI 10.1161/01.HYP.22.6.826; STAESSEN JA, 1993, J HYPERTENS, V11, P1289; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793	8	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					630	630		10.1016/S0140-6736(05)65069-6	http://dx.doi.org/10.1016/S0140-6736(05)65069-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782749				2022-12-28	WOS:A1996VF60900004
J	Hecht, A; StrahlBolsinger, S; Grunstein, M				Hecht, A; StrahlBolsinger, S; Grunstein, M			Spreading of transcriptional repressor SIR3 from telomeric heterochromatin	NATURE			English	Article							SILENT MATING LOCI; SACCHAROMYCES-CEREVISIAE; HISTONE H3; YEAST; COMPLEX; RAP1; PROTEINS; DOMAINS; TERMINUS	TELOMERIC genes and the HM loci in Saccharomyces cerevisiae are transcriptionally repressed and adopt a heterochromatin-like structure(1,2). The trans-acting factors RAP1, SIR3 and SIR4 are required for telomeric and HM silencing(3-5): and are thought to be chromosomal(6-8), but how they contribute to histone-dependent repression of adjacent chromatin(9-11) is unclear. SIR3 suppresses silencing defects in histones(10), is limiting for silencing adjacent to telomeres(12), and interacts with the H3 and H4 amino termini in vitro(13), Here we show that SIR3 co-immunoprecipitates SIR4, RAP1 and histones from cellular extracts, suggesting the presence of large chromatin-associated protein complexes. Crosslinking experiments show that SIR3 is present at HMRa, HML alpha and telomeres in vivo, and that it spreads from telomeric regions into adjacent chromatin when overexpressed. Thus SIR3 is a structural component of yeast heterochromatin, repressing adjacent genes as it spreads along the chromosome.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles				Hecht, Andreas/0000-0003-2262-2575				APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Harlow E., 1988, ANTIBODIES LAB MANUA; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JOHNSON LM, 1992, EMBO J, V11, P2201, DOI 10.1002/j.1460-2075.1992.tb05279.x; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KURTZ S, 1991, GENE DEV, V5, P618; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LIU C, 1994, GENETICS, V138, P1025; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; MOORE GD, 1983, GENETICS, V105, P327; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; TARTOF KD, 1990, DEVELOPMENT S, V120, P35; TASAKA K, 1984, ACTA HISTOCHEM CYTOC, V17, P283, DOI 10.1267/ahc.17.283; THOMPSON JS, 1993, COLD SPRING HARB SYM, V58, P247, DOI 10.1101/SQB.1993.058.01.029; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	26	439	448	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					92	96		10.1038/383092a0	http://dx.doi.org/10.1038/383092a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779721				2022-12-28	WOS:A1996VF29500055
J	Carlson, R; Smythe, W; Baines, K; Barbinis, E; Becker, K; Burns, R; Calcutt, S; Calvin, W; Clark, R; Danielson, G; Davies, A; Drossart, P; Encrenaz, T; Fanale, F; Granahan, J; Hansen, G; Herrera, P; Hibbitts, C; Hui, J; Irwin, P; Johnson, T; Kamp, L; Kieffer, H; Leader, F; Lellouch, E; LopesGautier, R; Matson, D; McCord, T; Mehlman, R; Ocampo, A; Orton, G; RoosSerote, M; Segura, M; Shirley, J; Soderblom, L; Stevenson, A; Taylor, F; Torson, J; Weir, A; Weissman, P				Carlson, R; Smythe, W; Baines, K; Barbinis, E; Becker, K; Burns, R; Calcutt, S; Calvin, W; Clark, R; Danielson, G; Davies, A; Drossart, P; Encrenaz, T; Fanale, F; Granahan, J; Hansen, G; Herrera, P; Hibbitts, C; Hui, J; Irwin, P; Johnson, T; Kamp, L; Kieffer, H; Leader, F; Lellouch, E; LopesGautier, R; Matson, D; McCord, T; Mehlman, R; Ocampo, A; Orton, G; RoosSerote, M; Segura, M; Shirley, J; Soderblom, L; Stevenson, A; Taylor, F; Torson, J; Weir, A; Weissman, P			Near-infrared spectroscopy and spectral mapping of Jupiter and the Galilean satellites: Results from Galileo's initial orbit	SCIENCE			English	Article							MU-M; 5-MU-M; WATER; BELT	The Near Infrared Mapping Spectrometer performed spectral studies of Jupiter and the Galilean satellites during the June 1996 perijove pass of the Galileo spacecraft. Spectra for a 5-micrometer hot spot on Jupiter are consistent with the absence of a significant water cloud above 8 bars and with a depletion of water compared lo that predicted for solar composition, corroborating results from the Galileo probe. Great Red Spot (GRS) spectral images show that parts of this feature extend upward to 240 millibars, although considerable altitude-dependent structure is found within it. A ring of dense clouds surrounds the GRS and is lower than it by 3 to 7 kilometers. Spectra of Callisto and Ganymede reveal a feature at 4.25 micrometers, attributed to the presence of hydrated minerals or possibly carbon dioxide on their surfaces. Spectra of Europa's high latitudes imply that fine-grained water frost overlies larger grains. Several active volcanic regions were found on lo, with temperatures of 420 to 620 kelvin and projected areas of 5 to 70 square kilometers.	UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90095; UNIV OXFORD,DEPT ATMOSPHER OCEAN & PLANETARY SCI,OXFORD OX1 3PU,ENGLAND; US GEOL SURVEY,FLAGSTAFF,AZ 86001; CALTECH,DIV GEOL & PLANETARY SCI,PASADENA,CA 91125; US GEOL SURVEY,DENVER,CO 80225; OBSERV PARIS,F-92150 MEUDON,FRANCE; UNIV HAWAII,HAWAII INST GEOPHYS & PLANETOL,HONOLULU,HI 96822	University of California System; University of California Los Angeles; University of Oxford; United States Department of the Interior; United States Geological Survey; California Institute of Technology; United States Department of the Interior; United States Geological Survey; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; University of Hawaii System	Carlson, R (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.		Orton, Glenn/AAD-9862-2020; Shirley, James/AAR-1264-2020; Hibbitts, Charles/B-7787-2016; Lopes, Rosaly M.C./D-1608-2016; Drossart, Pierre/H-8670-2013; Davies, Ashley/S-5588-2018	Hibbitts, Charles/0000-0001-9089-4391; Lopes, Rosaly M.C./0000-0002-7928-3167; Irwin, Patrick Gerard Joseph/0000-0002-6772-384X; Taylor, Fred/0000-0002-0675-9769; Calcutt, Simon/0000-0002-0102-3170; Davies, Ashley/0000-0003-1747-8142				ATREYA S, 1996, COMMUNICATION; Atreya S., COMMUNICATION; BAINES KH, 1990, ICARUS, V85, P65, DOI 10.1016/0019-1035(90)90104-H; BAINES KH, 1993, J GEOPHYS RES-PLANET, V98, P5517, DOI 10.1029/92JE02808; BORYSOW J, 1985, ASTROPHYS J, V296, P644, DOI 10.1086/163482; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; CARLSON R, 1990, SPACE SCI REV, V60, P457; CLARK RN, 1990, J GEOPHYS RES-SOLID, V95, P12653, DOI 10.1029/JB095iB08p12653; CLARK RN, 1981, J GEOPHYS RES, V86, P3087, DOI 10.1029/JB086iB04p03087; DROSSART P, 1982, ICARUS, V52, P483, DOI 10.1016/0019-1035(82)90008-2; IRWIN P, IN PRESS ADV SPACE S; KARKOSCHKA E, 1992, ICARUS, V97, P161, DOI 10.1016/0019-1035(92)90125-Q; KLEINER I, 1996, 14 INT C HIGH RES MO; KUNDE V, 1982, ASTROPHYS J, V263, P443, DOI 10.1086/160516; LELLOUCH E, 1989, ICARUS, V77, P457, DOI 10.1016/0019-1035(89)90099-7; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; Orton G, 1996, SCIENCE, V272, P839, DOI 10.1126/science.272.5263.839; Ragent B, 1996, SCIENCE, V272, P854, DOI 10.1126/science.272.5263.854; Seiff A, 1996, SCIENCE, V272, P844, DOI 10.1126/science.272.5263.844; SEIFF A, COMMUNICATION; Spencer JR, 1996, ANNU REV EARTH PL SC, V24, P125, DOI 10.1146/annurev.earth.24.1.125; TOMASKO MG, 1978, ICARUS, V33, P558, DOI 10.1016/0019-1035(78)90191-4; WEIDENSCHILING SJ, 1973, ICARUS, V20, P45; Young RE, 1996, SCIENCE, V272, P837, DOI 10.1126/science.272.5263.837; [No title captured]	25	127	127	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					385	388		10.1126/science.274.5286.385	http://dx.doi.org/10.1126/science.274.5286.385			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832878				2022-12-28	WOS:A1996VN17300041
J	Pilote, L; Miller, DP; Califf, RM; Rao, JS; Weaver, WD; Topol, EJ				Pilote, L; Miller, DP; Califf, RM; Rao, JS; Weaver, WD; Topol, EJ			Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMINOGEN-ACTIVATOR; CARDIAC-CATHETERIZATION; CARDIOGENIC-SHOCK; RANDOMIZED TRIAL; SURGICAL THERAPY; ARTERY SURGERY; HOLDING GUSTO; ANGIOPLASTY; SURVIVAL; MORTALITY	Background Clinical trials and practice guidelines have identified clinical criteria for the use of coronary angiography and revascularization procedures after thrombolysis for acute myocardial infarction. The effect of these criteria on clinical practice has not been extensively evaluated. Methods We used classification-and-regression-tree (CART) and logistic-regression models to study the patients in the first Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial, to identify the variables that best predicted the use of angiography and revascularization procedures after thrombolysis. Results Among the 21,772 U.S. patients in the trial, 71 percent underwent coronary angiography before discharge from the hospital. Of these, 58 percent underwent revascularization (73 percent receiving angioplasty). The CART model for the use of angiography showed that age was the Variable most predictive of angiography; only 53 percent of patients at least 73 years of age underwent angiography, as compared with 76 percent of those under 73. Among the older patients, age was again the most predictive factor; among the younger patients, the availability of angioplasty was a more important predictor (67 percent of patients in hospitals without angioplasty facilities underwent angiography, as compared with 33 percent in hospitals with such facilities). The next most important variable was recurrent ischemia, which was more predictive at hospitals without an gioplasty facilities than at those with them. Both statistical models identified coronary anatomy as the most important predictor of the use and type of revascularization. Conclusions More patients treated with thrombolysis underwent angiography and revascularization before discharge than might be expected. Younger age and the availability of the procedures appeared to be the major determinants of the use of coronary angiography, whereas coronary anatomy largely determined the use and type of revascularization. This process appeared to select low-risk patients for intervention rather than those at higher risk, who would be the most likely to benefit. (C) 1996, Massachusetts Medical Society.	CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; MONTREAL GEN HOSP, MONTREAL, PQ H3G 1A4, CANADA; DUKE UNIV, DURHAM, NC USA; UNIV WASHINGTON, SEATTLE, WA 98195 USA	Cleveland Clinic Foundation; McGill University; Duke University; University of Washington; University of Washington Seattle				Pilote, Louise/0000-0002-6159-0628; Topol, Eric/0000-0002-1478-4729; Miller, Dave/0000-0003-2947-152X				ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; *AM HOSP ASS, 1993, AM HOSP ASS GUID HLT; BARBASH GI, 1990, AM J CARDIOL, V66, P538, DOI 10.1016/0002-9149(90)90478-J; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; Breiman L., 1984, CLASSIFICATION REGRE; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CHAMBERS JM, 1993, STAT MODELS S, P414; DETRE KM, 1984, AM J CARDIOL, V53, P444, DOI 10.1016/0002-9149(84)90010-9; EMOND M, 1994, CIRCULATION, V90, P2645, DOI 10.1161/01.CIR.90.6.2645; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; Ferguson JJ, 1996, CIRCULATION, V93, P843, DOI 10.1161/01.CIR.93.5.843; Granger Christopher B., 1996, Journal of the American College of Cardiology, V27, p181A; Gunnar R M, 1990, Circulation, V82, P664; HENNING H, 1979, CIRCULATION, V59, P1124, DOI 10.1161/01.CIR.59.6.1124; HOLMES DR, 1995, J AM COLL CARDIOL, V26, P668, DOI 10.1016/0735-1097(95)00215-P; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; KNATTERUD G, 1988, JAMA-J AM MED ASSOC, V260, P2849; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LEE KL, 1994, ANN INTERN MED, V120, P876, DOI 10.7326/0003-4819-120-10-199405150-00009; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; MEYER J, 1982, AM HEART J, V103, P132, DOI 10.1016/0002-8703(82)90540-3; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; RIDKER PM, 1994, ANN INTERN MED, V120, P882, DOI 10.7326/0003-4819-120-10-199405150-00010; ROGERS WJ, 1990, CIRCULATION, V81, P1457, DOI 10.1161/01.CIR.81.5.1457; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SIMOONS ML, 1988, LANCET, V1, P199; SPERTUS JA, 1995, ARCH INTERN MED, V155, P2309, DOI 10.1001/archinte.155.21.2309; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1991, ANN INTERN MED, V114, P877, DOI 10.7326/0003-4819-114-10-877; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; VANDEWERF F, 1990, LANCET, V336, P71; YUSUF, 1994, LANCET, V344, P1446; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; 1987, CIRCULATION, V76, pA963	37	151	153	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1198	1205		10.1056/NEJM199610173351606	http://dx.doi.org/10.1056/NEJM199610173351606			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN401	8815943				2022-12-28	WOS:A1996VN40100006
J	Harrison, JF; Fewell, JH; Roberts, SP; Hall, HG				Harrison, JF; Fewell, JH; Roberts, SP; Hall, HG			Achievement of thermal stability by varying metabolic heat production in flying honeybees	SCIENCE			English	Article							BODY-TEMPERATURE REGULATION; APIS-MELLIFERA; FLIGHT; THERMOREGULATION; MECHANISMS; AFRICAN; BEES	Thermoregulation of the thorax allows endothermic insects to achieve power outputs during flight that are among the highest in the animal kingdom. Flying endothermic insects, including the honeybee Apis mellifera, are believed to thermoregulate almost exclusively by varying heat loss. Here it is shown that a rise in air temperature from 20 degrees to 40 degrees C causes large decreases in metabolic heat production and wing-beat frequency in honeybees during hovering, agitated, or loaded flight. Thus, variation in heat production may be the primary mechanism for achieving thermal stability in flying honeybees, and this mechanism may occur commonly in endothermic insects.	UNIV FLORIDA,DEPT ENTOMOL & NEMATOL,GAINESVILLE,FL 32611	State University System of Florida; University of Florida	Harrison, JF (corresponding author), ARIZONA STATE UNIV,DEPT ZOOL,TEMPE,AZ 85287, USA.							Casey T.M., 1989, P257; CASEY TM, 1988, ADV INSECT PHYSL, V20, P120; COELHO JR, 1991, PHYSIOL ZOOL, V64, P823, DOI 10.1086/physzool.64.3.30158209; COOPER PD, 1985, J EXP BIOL, V114, P1; DICKINSON MH, 1995, SCIENCE, V268, P87, DOI 10.1126/science.7701346; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P1, DOI 10.1098/rstb.1984.0049; Harrison JF, 1996, FUNCT ECOL, V10, P81, DOI 10.2307/2390265; HARRISON JF, 1993, NATURE, V363, P258, DOI 10.1038/363258a0; HEINRICH B, 1980, J EXP BIOL, V85, P73; HEINRICH B, 1980, J EXP BIOL, V85, P61; HEINRICH B, 1979, J EXP BIOL, V80, P217; HEINRICH B, 1994, AM SCI, V82, P164; HEINRICH B, 1992, HOT BLOODED INSECTS; MAY ML, 1995, J EXP BIOL, V198, P2385; ROBERTS SP, 1994, AM ZOOL, V34, P142; SCHUCHMANN KL, 1979, IBIS, V121, P85, DOI 10.1111/j.1474-919X.1979.tb05018.x; Spangler Hayward G., 1992, BeeScience, V2, P181; SPANGLER HG, 1991, J KANSAS ENTOMOL SOC, V64, P107	18	56	56	3	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					88	90		10.1126/science.274.5284.88	http://dx.doi.org/10.1126/science.274.5284.88			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810252				2022-12-28	WOS:A1996VK74800052
J	Angus, DC; LindeZwirble, WT; Sirio, CA; Rotondi, AJ; Chelluri, L; Newbold, RC; Lave, JR; Pinsky, MR				Angus, DC; LindeZwirble, WT; Sirio, CA; Rotondi, AJ; Chelluri, L; Newbold, RC; Lave, JR; Pinsky, MR			The effect of managed care on ICU length of stay - Implications for Medicare	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; IMPROVING INTENSIVE-CARE; UNITED-STATES; TRADITIONAL INSURANCE; INCEPTION COHORT; MORTALITY; SEVERITY; OUTCOMES; COSTS; PERFORMANCE	Objective.-To determine whether insurance status (managed care vs traditional commercial and Medicare) influences resource consumption (as measured by length of stay [LOS]) in the intensive care unit (ICU). Design.-Retrospective analysis of the 1992 Massachusetts state hospital discharge database, using prospectively developed and validated risk-stratification models. Setting.-All nonfederal hospitals in Massachusetts. Subjects.-Of all adult hospitalizations where an ICU stay was incurred (n=104 270), we selected those covered by 1 of 4 payer groups (n=88 050): (1) commercial fee-for-service (patients aged <65 years); (2) commercial managed care (patients aged <65 years); (3) traditional Medicare (patients aged greater than or equal to 65 years); and (4) Medicare-sponsored managed care (patients aged greater than or equal to 65 years). Main Outcome Measure.-Mean ICU LOS. Analysis.-The ICU LOS regression models were constructed using split-halves validation to adjust for differences in age, sex, severity of illness, diagnosis, discharge status, and payer. Separate models were constructed for those younger than 65 years and those aged 65 years or older. Robustness of the models was explored using goodness of fit and correlation. The effect of payer on hospital mortality was also explored using logistic regression. Observed minus predicted mean ICU LOS and mortality rates were correlated with managed care penetration at the hospital level. Results.-The ICU LOS models performed well (R(2)=0.84 and R(L)(2), [likelihood ratio statistic]=0.92 for the development set, and R(2)=0.83 and R(L)(2)=0.89 for the validation set). Significant covariables affecting LOS included age, severity of principal illness, comorbidity, reason for admission, and discharge status (P<.001 for each). Among the cohort younger than 65 years (n=27 805), although unadjusted mean ICU LOS was shorter (2.9 vs 3.43 days; P<.05) for those covered by managed care organizations, payer status had no independent effect on ICU LOS (P=.48). Among those older than 65 years, there was neither a difference in unadjusted ICU LOS (3.94 vs 3.88 days; P greater than or equal to.05) nor an independent effect of payer on ICU LOS (P=.35). Unadjusted mortality was lower among managed care patients (3.9% vs 5.1% in patients aged < 65 years [P<.05] and 8.7% vs 12.1% in patients aged greater than or equal to 65 years [P<.05]). Age, severity of principal diagnosis, comorbidity, and reason for admission significantly influenced mortality (P<.001), After controlling for these factors with the mortality model (R(L)(2)=0.92 and 0.89, C statistic [12 df]=8.45 and 17.58, and P=.75 and .13 [where a large P reflects good agreement] for the development and validation sets, respectively), payer continued to have a small but significant effect on mortality (odds ratios ranging from 1.67 at 0.1% probability of death to 1.11 at 30% probability of death). Managed care penetration among the commercially insured varied across hospitals (n=82) from 0% to 68%. There was no correlation between managed care penetration and either ICU LOS (R(2)=0.04; P=.09) or mortality (R(2)=0.0; P=.88). Conclusions.-Though patients covered under managed care consume fewer ICU resources, this appears to be primarily attributable to a difference in patient-related factors. Thus, as managed care case mix changes in the future to include sicker and older patients, the initial advantages of reduced resource consumption may diminish.	UNIV PITTSBURGH, GRAD SCH PUBL HLTH, PITTSBURGH, PA 15213 USA; HLTH PROC MANAGEMENT INC, DOYLESTOWN, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Angus, DC (corresponding author), UNIV PITTSBURGH, MED CTR, DEPT ANESTHESIOL & CRIT CARE MED, DIV CRIT CARE MED, PITTSBURGH, PA 15213 USA.		Angus, Derek C/E-9671-2012					*AG HLTH CAR POL R, 1992, COST FIN ISS HLTH CA, P93; ANGUS DC, 1995, AM J RESP CRIT CARE, V151, pA492; ANGUS DC, 1994, P ASS HLTH SERV RES, P7; ANGUS DC, 1995, CHEST, V108, pS105; ARNOULD RJ, 1984, INQUIRY-J HEALTH CAR, V21, P243; BECK M, 1995, NEWSWEEK        0918, P42; BRADBURY RC, 1991, INQUIRY-J HEALTH CAR, V28, P87; BRAVEMAN P, 1994, NEW ENGL J MED, V331, P444, DOI 10.1056/NEJM199408183310706; CARLISLE DM, 1992, AM J PUBLIC HEALTH, V82, P1626, DOI 10.2105/AJPH.82.12.1626; CLERMONT G, 1995, P INT C HLTH POL RES; CLERMONT G, 1996, CRIT CARE MED S1, V24, pA52; DALEY J, 1994, RISK ADJUSTMENT MEAS, P239; DOWD BE, 1986, MED CARE, V24, P694, DOI 10.1097/00005650-198608000-00005; FETTER RB, 1981, NEW ICD 9 CM DIAGN R; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; HALPERN NA, 1994, CRIT CARE MED, V22, P2001; HANLEY JA, 1988, RADIOLOGY, V168, P568, DOI 10.1148/radiology.168.2.3393683; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HILBE J, 1995, XPLORE INTERACTIVE S, P195; HILBE JM, 1994, AM STAT, V48, P255, DOI 10.2307/2684732; IEZZONI L, 1994, P ASS HLTH SERV RES, P21; Iezzoni L I, 1994, Am J Med Qual, V9, P43, DOI 10.1177/0885713X9400900202; IEZZONI LI, 1995, ANN INTERN MED, V123, P763, DOI 10.7326/0003-4819-123-10-199511150-00004; IEZZONI LI, 1992, MED CARE, V30, P347, DOI 10.1097/00005650-199204000-00005; IEZZONI LI, 1990, JAMA-J AM MED ASSOC, V264, P1426, DOI 10.1001/jama.264.11.1426; IEZZONI LI, 1994, RISK ADJUSTMENT MEAS, P119; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; JOHNSON AN, 1989, INQUIRY-J HEALTH CAR, V26, P388; KNAUS WA, 1982, LANCET, V2, P642; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; LAVE JR, 1994, MED CARE, V32, pJS77; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LINDEZWIRBLE WT, 1995, P 155 ANN JOINT STAT; LUFT HS, 1981, HLTH MAINTENANCE ORG; *MA ASS HMOS, 1996, HMO ENR MASS RES 199, P1; MAKLAN CW, 1994, MED CARE, V32, pJS13; MARTIN DP, 1989, AM J PUBLIC HEALTH, V79, P1628, DOI 10.2105/AJPH.79.12.1628; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; MITCHELL JB, 1994, MED CARE, V32, pJS38; NAESSENS JM, 1992, MAYO CLIN PROC, V67, P1140, DOI 10.1016/S0025-6196(12)61143-4; RAPOPORT J, 1992, ARCH INTERN MED, V152, P2207, DOI 10.1001/archinte.152.11.2207; RAPOPORT J, 1994, CRIT CARE MED, V22, P1385, DOI 10.1097/00003246-199409000-00006; RAPOPORT J, 1990, MED CARE, V28, P338, DOI 10.1097/00005650-199004000-00005; RAPOPORT J, 1995, CRIT CARE MED, V23, P1336, DOI 10.1097/00003246-199508000-00006; SHORTELL SM, 1994, MED CARE, V32, P508, DOI 10.1097/00005650-199405000-00009; SIRIO CA, 1992, CRIT CARE MED, V20, P1207, DOI 10.1097/00003246-199209000-00006; SPRAGGINS EE, 1995, NEWSWEEK        0619, P55; *STAT FL AG HLTH C, 1994, 1994 PAT DAT TAP; *STAT MD, 1993, NONC VERS MAR STAT I; STERN RS, 1989, ARCH INTERN MED, V149, P1185, DOI 10.1001/archinte.149.5.1185; *SYST INC, 1983, DIS STAG CLIN BAS AP; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; *US DEP HHS, 1988, INT CLASS DIS 9 REV; Wagner D P, 1989, Am Rev Respir Dis, V140, pS14; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; YELIN EH, 1986, MED CARE, V24, P236, DOI 10.1097/00005650-198603000-00006; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1432, DOI 10.1097/00003246-199310000-00009; ZIMMERMAN JE, 1994, CRIT CARE MED, V22, P1373, DOI 10.1097/00003246-199409000-00005; ZIMMERMAN JE, 1988, CRIT CARE MED, V16, P318, DOI 10.1097/00003246-198804000-00003; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1443, DOI 10.1097/00003246-199310000-00010; ZINNER MJ, 1995, ARCH SURG-CHICAGO, V130, P937; 1995, P INT C HLTH POL RES; 1986, ICU COST BENEFIT ANA, P101; 1994, FED REGISTER, V59, P1951; 1995, HLTH CARE FINANC R S, P24	67	92	93	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1996	276	13					1075	1082		10.1001/jama.276.13.1075	http://dx.doi.org/10.1001/jama.276.13.1075			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VK035	8847771				2022-12-28	WOS:A1996VK03500030
J	Hellinger, FJ				Hellinger, FJ			The expanding scope of state legislation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL DISCHARGE; POSTPARTUM				Hellinger, FJ (corresponding author), US DEPT HHS,AGCY HLTH CARE POLICY & RES,CTR ORG & DELIVERY STUDIES,SUITE 502,2101 E JEFFERSON ST,ROCKVILLE,MD 20852, USA.							*AM MAN CAR REV AS, 1995, 1995 STAT MAN CAR LE, P172; *ATK CO, 1994, COST IMP AN WILL PRO, P1; *BLUE CROSS BLUE S, 1994, STAT STAT ANY WILL P; BRAVEMAN P, 1995, J PEDIATR, V96, P716; BROOTEN D, 1994, OBSTET GYNECOL, V84, P832; BRUGGEMAN P, 1995, BUSINESS HLTH SC, V13, P28; DERRY TW, 1995, BNAS MANAGED CARE RE, V1, P24; DIMMITT B, 1995, BUSINESS HLTH SC, V13, P29; FEIN EB, 1995, NY TIMES        0929, pB1; Field M. J., 1993, EMPLOYMENT HLTH BENE; FOSTER D, 1995, HOSP LENGTH STAY REA; *GEN ACC OFF, 1993, MAN HLTH CAR EFF EMP, P27; HEGNER R, 1994, STAT HLTH NOTES, V15, P1; Hellinger FJ, 1995, HEALTH AFFAIR, V14, P297, DOI 10.1377/hlthaff.14.4.297; *HLTH CAR INV AN I, 1994, NAT INP PROF 1992 19; HUDSON T, 1994, HOSPITALS HLTH  0420, P40; Jaklevic M C, 1995, Mod Healthc, V25, P107; KENKEL PJ, 1993, MOD HEALTHCARE  0809, P100; KERTESZ L, 1995, MOD HEALTHCARE  0515, P25; LAUDICINA S, 1996, M WASH RES GROUP MAY; MARKUS A, 1995, STATE MANAGED CARE L; Morrissey J, 1995, Mod Healthc, V25, P6; MORRISSEY J, 1996, MOD HEALTHCARE, V26, P20; MORRISSEY J, 1996, MOD HEALTHCARE  0527, P18; *NAT HLTH POL FOR, 1994, CONS HLTH CAR MARK A, P8; NORR KF, 1987, BIRTH-ISS PERINAT C, V14, P135, DOI 10.1111/j.1523-536X.1987.tb01475.x; PAGE L, 1995, AM MED NEWS, V3, P24; PARKER S, 1995, INT MED NEWS    0701, P5; PITTARD WB, 1988, J PEDIATR-US, V112, P257, DOI 10.1016/S0022-3476(88)80066-0; *PROSP PAYM ASS CO, 1995, MED AM HLTH CAR SYST; STAPLETON DC, 1994, NEW EVIDENCE SAVINGS, P11; WELT SI, 1993, AM J PERINAT, V10, P384, DOI 10.1055/s-2007-994768; WINSLOW R, 1995, WALL STREET J   0721, pB1; *WYATT CO, 1991, COST ANAL STAT LEG M; 1995, MANAGED CARE LAW OUT, V7, P3; 1995, AM HLTH LINE, V4, P6; 1995, MANAGED CARE LAW OUT, V7, P10; 1995, BNAS MANAGED CARE RE, V1, P9	38	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1996	276	13					1065	1070		10.1001/jama.276.13.1065	http://dx.doi.org/10.1001/jama.276.13.1065			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK035	8847769				2022-12-28	WOS:A1996VK03500028
J	Lennette, ET; Blackbourn, DJ; Levy, JA				Lennette, ET; Blackbourn, DJ; Levy, JA			Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients	LANCET			English	Article							EPSTEIN-BARR VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; DNA-SEQUENCES; CELL-LINES; AIDS; PREVALENCE; RETROVIRUS; DISEASE	Background Much of the evidence that human herpesvirus type 8 (HHV-8) is associated with Kaposi's sarcoma (KS) has come from molecular studies of HHV-8 DNA. Seroepidemiological studies have been hampered by the lack of a reliable assay. Methods The serological data reported here were obtained by means of a mouse monoclonal antibody-enhanced immunofluorescence assay for antibodies to lytic and latent HHV-8 antigens. 1435 single samples of serum (or plasma) from many different disease groups and parts of the world were assayed. Findings All patients with African endemic KS and 96% of American patients with AIDS-associated KS were seropositive for lytic antigen, as were 90% of American HIV-infected homosexual men; by contrast only 21% of HIV-seropositive drug users and 21% of HIV-seropositive women were positive for HHV-8 antibody. Factor VIII treatment before 1983 did not increase the risk of HHV-8 infection in patients with haemophilia. In the American general population, about 25% of adults (including volunteer blood donors) and 2-8% of children had antibodies to HHV-8. Interpretation Our data are consistent with HHV-8 being primarily associated with sexual transmission, but the HHV-8 seropositivity rate in American children suggests that there is a non-sexual route of HHV-8 infection also. On the evidence available so far, the risk of parenteral transmission is low.	UNIV CALIF SAN FRANCISCO,DEPT MED,DIV HEMATOL ONCOL,SAN FRANCISCO,CA	University of California System; University of California San Francisco	Lennette, ET (corresponding author), VIROLAB INC,1204 10TH ST,BERKELEY,CA 94710, USA.			Blackbourn, David/0000-0002-6703-4497				AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BOSHOFF C, 1995, LANCET, V345, P1043; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COLLANDRE H, 1995, LANCET, V345, P1043, DOI 10.1016/S0140-6736(95)90779-3; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; DELELLIS L, 1995, J INFECT DIS, V172, P1605, DOI 10.1093/infdis/172.6.1605; FRIEDMANKIEN AE, 1982, ANN INTERN MED, V96, P693, DOI 10.7326/0003-4819-96-6-693; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; GRATAMA JW, 1992, J MED VIROL, V37, P39, DOI 10.1002/jmv.1890370107; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; HENLE W, 1974, HUM PATHOL, V5, P551, DOI 10.1016/S0046-8177(74)80006-7; Henle W, 1985, INFECTION IMMUNITY B, P201; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; KAMINSKY LS, 1985, P NATL ACAD SCI USA, V82, P5535, DOI 10.1073/pnas.82.16.5535; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; KOENIG RE, 1987, JAMA-J AM MED ASSOC, V257, P631, DOI 10.1001/jama.257.5.631; LENNETTE ET, 1987, J CLIN MICROBIOL, V25, P199, DOI 10.1128/JCM.25.2.199-202.1987; LENNETTE ET, 1995, EUR J CANCER, V31A, P1875, DOI 10.1016/0959-8049(95)00354-L; LOETHE R, 1963, ACTA PATHOL MICROB S, V161, P1; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Nahmias A J, 1990, Scand J Infect Dis Suppl, V69, P19; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; SAFAI B, 1980, CLIN BULL, V10, P62; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; WOFSY CB, 1986, LANCET, V1, P527; ZIEGLER JL, 1993, LANCET, V342, P1348, DOI 10.1016/0140-6736(93)92252-O	31	453	474	3	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1996	348	9031					858	861		10.1016/S0140-6736(96)03240-0	http://dx.doi.org/10.1016/S0140-6736(96)03240-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826812				2022-12-28	WOS:A1996VK03700012
J	Butler, NL				Butler, NL			Circle of light	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1996	276	12					930	930		10.1001/jama.276.12.930	http://dx.doi.org/10.1001/jama.276.12.930			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH990	8805709				2022-12-28	WOS:A1996VH99000001
J	Smack, DP; Harrington, AC; Dunn, C; Howard, RS; Szkutnik, AJ; Krivda, SJ; Caldwell, JB; James, WD				Smack, DP; Harrington, AC; Dunn, C; Howard, RS; Szkutnik, AJ; Krivda, SJ; Caldwell, JB; James, WD			Infection and allergy incidence in ambulatory surgery patients using white petrolatum vs bacitracin ointment - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STAPHYLOCOCCUS-AUREUS; TOPICAL ANTIBIOTICS; AGENTS; ANAPHYLAXIS; DERMATITIS; WOUNDS	Objective.-To assess the effect of white petrolatum vs bacitracin ointment on wound infection incidence, allergic contact dermatitis incidence, and healing characteristics. Design.-Randomized, double-blind, prospective trial comparing white petrolatum with bacitracin ointment in postprocedure wound care. Setting.-A general outpatient dermatology clinic and a tertiary referral advanced surgical procedure clinic at Waiter Reed Army Medical Center, Washington, DC. Patients.-A total of 922 patients who had dermatologic surgery with a total of 1249 wounds. Main Outcome Measures.-The incidence of infection and allergic contact dermatitis during a follow-up period of 4 weeks. Healing characteristics were secondary outcomes. Results.-Of the 922 patients enrolled, 440 in the white petrolatum group and 444 in the bacitracin group were evaluable for clinical response. The 2 treatment groups had comparable baseline characteristics. Thirteen patients developed postprocedure infection (1.5%), 9 (2.0%) in the white petrolatum group vs 4 (0.9%) in the bacitracin group (95% confidence interval for difference, -0.4% to 2.7%; P=.37). Eight infections (1.8%) in the white petrolatum group were due to Staphylococcus aureus vs none in the bacitracin group (P=.004). No patient in the group using white petrolatum developed allergic contact dermatitis vs 4 patients (0.9%) in the group using bacitracin (P=.12). Additionally, there were no clinically significant differences in healing between the treatment groups on day 1 (P=.98), day 7 (P=.85), or day 28 (P=.28) after the procedure. Conclusions.-White petrolatum is a safe, effective wound care ointment for ambulatory surgery, In comparison with bacitracin, white petrolatum possesses an equally low infection rate and minimal risk for induction of allergy.	WALTER REED ARMY MED CTR, DEPT DERMATOL, WASHINGTON, DC 20307 USA; WALTER REED ARMY MED CTR, DEPT CLIN INVEST, WASHINGTON, DC 20307 USA; WALTER REED ARMY MED CTR, DEPT PHARM, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Army; Walter Reed National Military Medical Center								Anderson V, 1976, Int J Dermatol, V15, P1; BENNETT RG, 1988, FUNDAMENTALS CUTANEO, P141; BJORKNER B, 1973, ACTA DERM-VENEREOL, V53, P487; Comaish J S, 1967, Br J Clin Pract, V21, P97; Eaglstein W H, 1984, Clin Dermatol, V2, P107, DOI 10.1016/0738-081X(84)90032-4; EAGLSTEIN WH, 1980, J INVEST DERMATOL, V74, P90, DOI 10.1111/1523-1747.ep12519981; FALANGA V, 1988, J AM ACAD DERMATOL, V124, P1691; FARLEY M, 1995, AM J CONTACT DERMATI, V6, P28; FISHER AA, 1983, CUTIS, V32, P510; FRAKI JE, 1979, CONTACT DERMATITIS, V5, P97, DOI 10.1111/j.1600-0536.1979.tb04806.x; GERONEMUS RG, 1979, ARCH DERMATOL, V115, P1311, DOI 10.1001/archderm.115.11.1311; GETTE MT, 1992, ARCH DERMATOL, V128, P365, DOI 10.1001/archderm.128.3.365; HAAS AF, 1995, J AM ACAD DERMATOL, V32, P155, DOI 10.1016/0190-9622(95)90119-1; HINMAN CD, 1963, NATURE, V200, P377, DOI 10.1038/200378a0; HIRSCHMANN JV, 1988, ARCH DERMATOL, V124, P1691, DOI 10.1001/archderm.124.11.1691; KELLY DR, 1969, NEW ENGL J MED, V280, P1338, DOI 10.1056/NEJM196906122802408; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; KNOWLES SR, 1995, INT J DERMATOL, V34, P572, DOI 10.1111/j.1365-4362.1995.tb02958.x; LEYDEN JJ, 1987, J FAM PRACTICE, V24, P601; LEYDEN JJ, 1981, AM FAM PHYSICIAN, V23, P121; LINEAWEAVER W, 1985, ARCH SURG-CHICAGO, V120, P267; LIVINGSTON DH, 1990, PLAST RECONSTR SURG, V86, P1059, DOI 10.1097/00006534-199012000-00001; MARKS JG, 1995, J AM CONTACT DERMATI, V6, P160; Mertz P. M., 1986, SWINE BIOMEDICAL RES, V1, P291; MOY JA, 1990, J AM ACAD DERMATOL, V22, P893, DOI 10.1016/0190-9622(90)70120-7; Phillips TJ, 1995, WOUNDS, V3, P83; PIRILA V, 1967, ACTA DERM-VENEREOL, V47, P419; Pollack S V, 1979, J Dermatol Surg Oncol, V5, P477; REED BR, 1985, J AM ACAD DERMATOL, V13, P919, DOI 10.1016/S0190-9622(85)70242-3; ROUPE G, 1969, ARCH DERMATOL, V100, P450, DOI 10.1001/archderm.100.4.450; Rovee D.T., 1972, EPIDERMAL WOUND HEAL, P71; SCHECHTER JF, 1984, ARCH DERMATOL, V120, P909, DOI 10.1001/archderm.120.7.909; SCHERBENSKE JM, 1988, J DERMATOL SURG ONC, V14, P165, DOI 10.1111/j.1524-4725.1988.tb03359.x; SEBBEN JE, 1989, J DERMATOL SURG ONC, V15, P38, DOI 10.1111/j.1524-4725.1989.tb03111.x; Shanson D C, 1981, J Hosp Infect, V2, P11, DOI 10.1016/0195-6701(81)90003-7; TUR E, 1995, J AM ACAD DERMATOL, V33, P217, DOI 10.1016/0190-9622(95)90238-4; VALE MA, 1978, ARCH DERMATOL, V114, P800, DOI 10.1001/archderm.1978.01640170094034; WATCHER MA, 1989, J DERMATOL SURG ONC, V15, P1188, DOI 10.1111/j.1524-4725.1989.tb03232.x; WINTER GD, 1962, NATURE, V193, P293, DOI 10.1038/193293a0; WINTON GB, 1985, J AM ACAD DERMATOL, V13, P1026, DOI 10.1016/S0190-9622(85)70257-5; ZAR JH, 1984, BIOSTAT ANAL, P378; [No title captured]	42	177	177	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1996	276	12					972	977		10.1001/jama.276.12.972	http://dx.doi.org/10.1001/jama.276.12.972			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH990	8805732				2022-12-28	WOS:A1996VH99000038
J	Crouse, JR				Crouse, JR			Heart of the matter in cerebral arterial sclerosis	LANCET			English	Editorial Material							STROKE				Crouse, JR (corresponding author), WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27157, USA.							Blankenhorn DH, 1961, AM J MED SCI, V242, P41; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; Friedlander AH, 1996, BRIT DENT J, V181, P23, DOI 10.1038/sj.bdj.4809143; MOORE WS, 1995, CIRCULATION, V91, P566, DOI 10.1161/01.CIR.91.2.566; Reinmuller R, 1987, DYNAMIC CARDIOVASCUL, V1, P139; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SIRNA S, 1990, STROKE, V21, P14, DOI 10.1161/01.STR.21.1.14; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175	8	12	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					766	766		10.1016/S0140-6736(05)65202-6	http://dx.doi.org/10.1016/S0140-6736(05)65202-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813976				2022-12-28	WOS:A1996VH98900002
J	Gate, JH; Gooding, AR; Podell, E; Zhou, KH; Golden, BL; Szewczak, AA; Kundrot, CE; Cech, TR; Doudna, JA				Gate, JH; Gooding, AR; Podell, E; Zhou, KH; Golden, BL; Szewczak, AA; Kundrot, CE; Cech, TR; Doudna, JA			RNA tertiary structure mediation by adenosine platforms	SCIENCE			English	Article							GROUP-I INTRON; GAAA TETRALOOP; RIBOSOMAL-RNA; ARCHITECTURE; NUCLEOTIDES; SEQUENCE; COMPLEX; DOMAIN	The crystal structure of a group I intron domain reveals an unexpected motif that mediates both intra- and intermolecular interactions. At three separate locations in the 160-nucleotide domain, adjacent adenosines in the sequence lie side-by-side and form a pseudo-base pair within a helix. This adenosine platform opens the minor groove for base stacking or base pairing with nucleotides from a noncontiguous RNA strand. The platform motif has a distinctive chemical modification signature that may enable its detection in other structured RNAs. The ability of this motif to facilitate higher order folding provides one explanation for the abundance of adenosine residues in internal loops of many RNAs.	YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV COLORADO,HOWARD HUGHES MED INST,BOULDER,CO 80309	Yale University; University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder				Golden, Barbara/0000-0002-9741-882X	NIGMS NIH HHS [5T32GM08283-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008283] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; COSTA M, 1995, EMBO J, V14, P1276, DOI 10.1002/j.1460-2075.1995.tb07111.x; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; DAMBERGER SH, 1994, NUCLEIC ACIDS RES, V22, P3508, DOI 10.1093/nar/22.17.3508; DIECKMANN T, IN PRESS RNA; DOUDNA JA, 1995, RNA, V1, P36; HARRIS ME, 1994, EMBO J, V13, P3953, DOI 10.1002/j.1460-2075.1994.tb06711.x; HOLBROOK SR, 1983, BIOPOLYMERS, V22, P1145, DOI 10.1002/bip.360220410; JAEGER L, 1991, J MOL BIOL, V221, P1153, DOI 10.1016/0022-2836(91)90925-V; JIANG F, 1996, NATURE, V382, P171; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; LUZZATI PV, 1955, ACTA CRYSTALLOGR, V5, P802; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P55; SHETTY K, UNPUB; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; Yang YS, 1996, SCIENCE, V272, P1343, DOI 10.1126/science.272.5266.1343	24	84	85	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1996	273	5282					1696	1699						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781229				2022-12-28	WOS:A1996VH40800036
J	Pante, N; Aebi, U				Pante, N; Aebi, U			Sequential binding of import ligands to distinct nucleopore regions during their nuclear import	SCIENCE			English	Article							PORE COMPLEX; PROTEIN IMPORT; IDENTIFICATION; LOCALIZATION; TRANSPORT; ENVELOPE; TRANSLOCATION; ARCHITECTURE; MICROSCOPY; RAN/TC4	Protein import into nuclei is mediated by the nuclear pore complex (NPC) and by cellular factors. To structurally characterize this process, nuclear import of gold-labeled nucleoplasmin was followed by electron microscopy to identify NPC components interacting with the import ligand complex in vivo. Before translocation into the nucleus, nucleoplasmin sequentially bound to two distinct regions. first to the distal part of the cytoplasmic filaments and then at the cytoplasmic entry to the central gated channel, Evidence that the delivery of the import ligand from the first to the second binding region occurred by bending of the cytoplasmic filaments is presented here.			Pante, N (corresponding author), UNIV BASEL, BIOZENTRUM, ME MULLER INST MICROSCOPY, KLINGELBERGSTR 70, CH-4056 BASEL, SWITZERLAND.		Pante, Nelly/GVR-8478-2022					ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AZUMA Y, 1995, P NATL ACAD SCI USA, V92, P5159, DOI 10.1073/pnas.92.11.5159; BASCHONG W, 1990, J ELECTRON MICR TECH, V14, P313, DOI 10.1002/jemt.1060140405; BOULIKAS T, 1993, CRIT REV BIOCH, V62, P219; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GORLICH D, IN PRESS EMBO J; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; Pante N, 1995, INT REV CYTOL, V162B, P225; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; PANTE N, 1994, CURR OPIN STRUC BIOL, V4, P187, DOI 10.1016/S0959-440X(94)90307-7; Pante N, 1995, J CELL SCI, P1; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143	32	118	119	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1996	273	5282					1729	1732		10.1126/science.273.5282.1729	http://dx.doi.org/10.1126/science.273.5282.1729			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781239				2022-12-28	WOS:A1996VH40800046
J	Beynon, J				Beynon, J			Hunger strike in Turkish prisons	LANCET			English	Article											Beynon, J (corresponding author), MED FDN CARE VICTIMS TORTURE,LONDON NW5 3EJ,ENGLAND.							*AMN INT TURK, 1996, POL PRIS SOM 41 TURK; *HUM RIGHTS FDN TU, 1996, DOC CTR REP; 1996, IST TAB OD I HAKL KO	3	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					737	737		10.1016/S0140-6736(05)65605-X	http://dx.doi.org/10.1016/S0140-6736(05)65605-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806296				2022-12-28	WOS:A1996VG37400017
J	Livingstone, WJ; Moore, M; Innes, D; Bell, JE; Simmonds, P; Whitelaw, J; Wyld, R; Robertson, JR; Brettle, RP				Livingstone, WJ; Moore, M; Innes, D; Bell, JE; Simmonds, P; Whitelaw, J; Wyld, R; Robertson, JR; Brettle, RP			Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DENDRITIC CELLS; PROVIRAL DNA; IN-VIVO; TYPE-1; INDIVIDUALS; CD4; MONOCYTES; RECEPTOR; BRAIN	Background Although lymphocytes expressing the CD4 surface receptor for HIV-1 have been identified as the principal target of the virus, the extent to which infection of other cell types of the immune system contributes to immunodeficiency is unknown. We investigated the cell types in peripheral blood infected with HIV and the relation of viral load in different subsets to disease progression. Methods The study group consisted of 16 HIV-infected individuals, eight of whom had clinically defined AIDS with CD4 cell counts less than 200/mu L blood. The main component subsets of peripheral blood mononuclear cells were purified by magnetic bead separation, and included CD4 and CD8 lymphocytes, B lymphocytes, monocytes, and dendritic cells. HIV proviral sequences within these separate populations were quantified by limiting-dilution nested polymerase chain reaction. Findings HIV-1 proviral sequences were detected in T-helper cells, cytotoxic T cells, dendritic cells, and monocytes. CD4 T lymphocytes constituted the main reservoir of HIV in all but one of the symptom-free individuals studied (those with CD4 count >200/mu L). However, in all the individuals with CD4 counts of less than 200/mu L, most infected cells within the peripheral blood mononuclear cell fraction were either dendritic cells or CD8 lymphocytes. Infection of CD8 cells accounted for between 66% and 97% of total proviral load in five of the eight AIDS patients. A strong inverse relation between total CD8 count and the frequency of CD8 T-lymphocyte infection was found. Interpretation This study provides evidence for widespread infection of lymphocytes of the CD8 phenotype, indicating that HIV-1 has a broader tropism for different cell types in vivo than described for cultured virus. Infection of CD8 cells may contribute to the decline of this subset upon disease progression in HIV-infected individuals. Infection of CD8 cells may or may not occur by a non-CD4-dependent mechanism of virus entry.	UNIV EDINBURGH,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,INST CELL ANIM & POPULAT BIOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,WESTERN GEN HOSP,DEPT NEUROPATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh; University of Edinburgh				Simmonds, Peter/0000-0002-7964-4700				BAGASRA O, 1993, AIDS RES HUM RETROV, V9, P69, DOI 10.1089/aid.1993.9.69; CAMERON PU, 1994, AIDS RES HUM RETROV, V10, P61, DOI 10.1089/aid.1994.10.61; CHEHIMI J, 1991, J VIROL, V65, P1812, DOI 10.1128/JVI.65.4.1812-1822.1991; CHEHIMI J, 1993, J GEN VIROL, V74, P1277, DOI 10.1099/0022-1317-74-7-1277; CHENGMAYER C, 1988, ANN NEUROL, V23, pS58, DOI 10.1002/ana.410230716; COLLMAN R, 1990, J VIROL, V64, P4468, DOI 10.1128/JVI.64.9.4468-4476.1990; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEMARIA A, 1991, J IMMUNOL, V146, P220; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DONALDSON YK, 1994, J VIROL, V68, P5991, DOI 10.1128/JVI.68.9.5991-6005.1994; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; FREUDENTHAL PS, 1990, P NATL ACAD SCI USA, V87, P7698, DOI 10.1073/pnas.87.19.7698; HSIA K, 1995, AIDS, V9, P398, DOI 10.1097/00002030-199509040-00015; INNOCENTI P, 1992, AIDS RES HUM RETROV, V8, P261, DOI 10.1089/aid.1992.8.261; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; MACATONIA SE, 1990, IMMUNOLOGY, V71, P38; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MYERS G, 1993, HUMAN RETROVIRUSES A; ODOHERTY U, 1993, J EXP MED, V178, P1067, DOI 10.1084/jem.178.3.1067; PATTERSON S, 1994, RES VIROLOGY, V145, P171, DOI 10.1016/S0923-2516(07)80019-7; PSALLIDOPOULOS MC, 1989, J VIROL, V63, P4626, DOI 10.1128/JVI.63.11.4626-4631.1989; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SCHRIER RD, 1993, J VIROL, V67, P5713, DOI 10.1128/JVI.67.10.5713-5720.1993; SEMENSATO G, 1995, BLOOD, V85, P2308, DOI 10.1182/blood.V85.9.2308.bloodjournal8592308; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SU L, 1995, IMMUNITY, V2, P25, DOI 10.1016/1074-7613(95)90076-4; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; VALENTIN A, 1991, J ACQ IMMUN DEF SYND, V4, P751; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WEISSMAN D, 1995, P NATL ACAD SCI USA, V92, P826, DOI 10.1073/pnas.92.3.826	31	118	121	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					649	654		10.1016/S0140-6736(96)02091-0	http://dx.doi.org/10.1016/S0140-6736(96)02091-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782755				2022-12-28	WOS:A1996VF60900010
J	Doe, CQ				Doe, CQ			Spindle orientation and asymmetric localization in Drosophila: Both inscuteable?	CELL			English	Review							CELL FATE; NUMB; PROSPERO; SEGREGATION; DIVISION; PROTEIN				Doe, CQ (corresponding author), UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,HOWARD HUGHES MED INST,URBANA,IL 61801, USA.							CALLAINI G, 1988, EXP CELL RES, V178, P415, DOI 10.1016/0014-4827(88)90410-7; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Chang F, 1996, CURR BIOL, V6, P651, DOI 10.1016/S0960-9822(09)00440-0; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; GUO M, 1996, IN PRESS NEURON, V17; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; KNUST E, 1994, TRENDS GENET, V10, P275, DOI 10.1016/0168-9525(90)90010-4; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; RHYU MS, 1995, CELL, V82, P523, DOI 10.1016/0092-8674(95)90022-5; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0	16	26	26	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					695	697		10.1016/S0092-8674(00)80142-7	http://dx.doi.org/10.1016/S0092-8674(00)80142-7			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797815	Bronze			2022-12-28	WOS:A1996VG37200002
J	Snaith, ML				Snaith, ML			On the one hand and on the other	LANCET			English	Editorial Material							JOINT HYPERMOBILITY				Snaith, ML (corresponding author), UNIV SHEFFIELD,INST BONE & JOINT MED,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.							ARMSTRONG AL, 1994, J HAND SURG-BRIT EUR, V19B, P340, DOI 10.1016/0266-7681(94)90085-X; BRIDGES AJ, 1992, ANN RHEUM DIS, V51, P793, DOI 10.1136/ard.51.6.793; Jonsson H, 1996, ANN RHEUM DIS, V55, P540, DOI 10.1136/ard.55.8.540; KEITH KT, 1995, J RHEUMATOL, V22, P2132; LARSSON LG, 1993, NEW ENGL J MED, V329, P1079, DOI 10.1056/NEJM199310073291504; PEYRON JG, 1983, J RHEUMATOL S, V9, P17	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					907	908		10.1016/S0140-6736(05)65335-4	http://dx.doi.org/10.1016/S0140-6736(05)65335-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843806				2022-12-28	WOS:A1996VL09700006
J	Fleming, TR; DeMets, DL				Fleming, TR; DeMets, DL			Surrogate end points in clinical trials: Are we being misled?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; ASYMPTOMATIC HIV-INFECTION; CORONARY HEART-DISEASE; LOWERING CHOLESTEROL; RETINITIS-PIGMENTOSA; SERUM-CHOLESTEROL; VITAMIN-A; MORTALITY; AIDS; ENDPOINTS	Phase 3 clinical trials, which evaluate the effect that new interventions have on the clinical outcomes of particular relevance to the patient (such as death, loss of vision, or other major symptomatic event), often require many participants to be followed for a long time. There has recently been great interest in using surrogate end points, such as tumor shrinkage or changes in cholesterol level, blood pressure, CD4 cell count, or other laboratory measures, to reduce the cost and duration of clinical trials. In theory, for a surrogate end point to be an effective substitute for the clinical outcome, effects of the intervention on the surrogate must reliably predict the overall effect on the clinical outcome. In practice, this requirement frequently fails. Among several explanations for this failure is the possibility that the disease process could affect the clinical outcome through several causal pathways that are not mediated through the surrogate, with the intervention's effect on these pathways differing from its effect on the surrogate. Even more likely, the intervention might also affect the clinical outcome by unintended, unanticipated, and unrecognized mechanisms of action that operate independently of the disease process. We use examples from several disease areas to illustrate how surrogate end points have been misleading about the actual effects that treatments have on the health of patients. Surrogate end points can be useful in phase 2 screening trials for identifying whether a new intervention is biologically active and for guiding decisions about whether the intervention is promising enough to justify a large definitive trial with clinically meaningful outcomes. In definitive phase 3 trials, except for rare circumstances in which the validity of the surrogate end point has already been rigorously established, the primary end point should be the true clinical outcome.	UNIV WISCONSIN, SCH MED, CTR CLIN SCI K6 446, DEPT BIOSTAT, MADISON, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Fleming, TR (corresponding author), UNIV WASHINGTON, DEPT BIOSTAT, BOX 357232, SEATTLE, WA 98195 USA.				NATIONAL CANCER INSTITUTE [R01CA018332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029168, R01AI029168] Funding Source: NIH RePORTER; NCI NIH HHS [CA 18332] Funding Source: Medline; NIAID NIH HHS [AI 29168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abernathy GT, 1996, CONTROL CLIN TRIALS, V17, P77; ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1980, Ann Intern Med, V93, P391; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; [Anonymous], 1990, Lancet, V336, P65; [Anonymous], 1979, JAMA, V242, P2562; [Anonymous], 1974, JAMA, V229, P1606; [Anonymous], 1986, Lancet, V1, P397; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022; BOISSEL JP, 1992, EUR J CLIN PHARMACOL, V43, P235, DOI 10.1007/BF02333016; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COMSTOCK GW, 1988, AM REV RESPIR DIS, V138, P479, DOI 10.1164/ajrccm/138.2.479; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; DEGRUTTOLA V, 1993, J ACQ IMMUN DEF SYND, V6, P359; DEGRUTTOLA V, IN PRESS J INFECT DI; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ELLENBERG SS, 1991, BMJ-BRIT MED J, V302, P63, DOI 10.1136/bmj.302.6768.63; ELLENBERG SS, 1989, STAT MED, V8, P405, DOI 10.1002/sim.4780080404; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; FELDMAN AM, 1993, NEW ENGL J MED, V329, P149, DOI 10.1056/NEJM199307153290301; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; Fleming T. R., 1992, STAT SCI, V7, P428; FLEMING TR, 1990, J ACQ IMMUN DEF SYND, V3, pS82; FLEMING TR, 1994, STAT MED, V13, P955, DOI 10.1002/sim.4780130906; FLEMING TR, 1994, STAT MED, V13, P1423, DOI 10.1002/sim.4780131318; FONTANA RS, 1986, J OCCUP ENVIRON MED, V28, P746, DOI 10.1097/00043764-198608000-00038; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; FURBERG CD, 1994, J INTERN MED, V235, P387, DOI 10.1111/j.1365-2796.1994.tb01093.x; GORDON DJ, 1994, CONT ISSUES CHOLESTE; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HERSON J, 1989, STAT MED, V8, P403, DOI 10.1002/sim.4780080403; HILLIS A, 1989, STAT MED, V8, P427, DOI 10.1002/sim.4780080406; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HOLME I, 1993, BRIT HEART J, V69, pS42; HUJOEL PP, 1995, J CLIN PERIODONTOL, V22, P397, DOI 10.1111/j.1600-051X.1995.tb00167.x; HUJOEL PP, 1996, J DENT RES, V75, P370; JACOBSON MA, 1991, BRIT MED J, V302, P73, DOI 10.1136/bmj.302.6768.73; JOHNSON JR, 1985, CANCER TREAT REP, V69, P1155; KOSOROK MR, 1993, BIOMETRIKA, V80, P823, DOI 10.1093/biomet/80.4.823; LAGAKOS SW, 1992, ANN INTERN MED, V116, P599, DOI 10.7326/0003-4819-116-7-599; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LIN DY, 1993, STAT MED, V12, P835, DOI 10.1002/sim.4780120904; LIN DY, 1996, IN PRESS STAT MED; MACHADO SG, 1990, J ACQ IMMUN DEF SYND, V3, P1065; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MASSOF RW, 1993, ARCH OPHTHALMOL-CHIC, V111, P751, DOI 10.1001/archopht.1993.01090060039019; MOERTEL CG, 1984, STAT MED, V3, P455, DOI 10.1002/sim.4780030428; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NOWAK R, 1993, J NIH RES, V5, P37; PACKER M, 1993, CIRCULATION, V88, P301; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PEDERSEN TR, 1994, LANCET, V344, P1383; PEPE MS, 1994, J STAT PLAN INFER, V42, P137, DOI 10.1016/0378-3758(94)90194-5; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; PSATY BZ, 1995, CIRCULATION, V91, P925; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1982, NEW ENGL J MED, V306, P446, DOI 10.1056/NEJM198202253060802; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SANDE MA, 1993, JAMA-J AM MED ASSOC, V270, P2583, DOI 10.1001/jama.270.21.2583; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Tucker GT, 1995, CLIN MEASUREMENT DRU; VANDEWERF F, 1990, LANCET, V336, P71; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WITTES J, 1989, STAT MED, V8, P415, DOI 10.1002/sim.4780080405	76	1179	1221	3	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1996	125	7					605	613		10.7326/0003-4819-125-7-199610010-00011	http://dx.doi.org/10.7326/0003-4819-125-7-199610010-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ653	8815760				2022-12-28	WOS:A1996VJ65300011
J	Davis, AP				Davis, AP			Targeting the vulnerable in emergency situations: Who is vulnerable?	LANCET			English	Article							DISASTERS	Background Emergencies such as wars and natural disasters increase the vulnerability of affected populations and expose these populations to risks such as disease, violence, and hunger. Emergency public health interventions aim to mitigate these effects by providing basic minimum requirements, reducing vulnerability, and reducing exposure to risk. Targeted services are generally aimed at children under 5. Mortality rates among young children are higher than the crude mortality rate (CMR) among the whole population in emergency settings, so attention is focused on this age group. However, even under normal conditions mortality is higher in young children. This analysis compared the relative risk of death for young children with that for older children and adults under normal conditions and in emergency settings. Methods Mortality data from refugee camps set up in response to three different emergencies were examined. Baseline mortality rates in the refugees' countries of origin were calculated from published data. Relative risks between normal and emergency conditions were calculated and compared. Findings Mortality rates were higher among children under 5 than among older children and adults both under normal circumstances acid in the emergency setting in camps in Tanzania, Uganda, and Zaire. However, the relative risk for under-5 versus over-5 mortality was smaller under emergency conditions than under normal circumstances. Thus, children over 5 and adults are disproportionately more affected by exposure to emergency risks than are younger children. Interpretation If the objective of intervention, to reduce mortality, is to be achieved, the population over the age of 5 cannot be ignored. Emergency public health needs to develop specific tools to investigate risk in other age groups (as well as children under 5), to identify causes, and to design programmes to address such needs.	MED SANS FRONTIERES HOLLAND,NAIROBI,KENYA									DICK B, 1991, TROP DOCT, V21, P9, DOI 10.1177/00494755910210S103; *FAO, 1994, 56 FAO; HAKEWILL PA, 1991, TROP DOCT, V21, P24, DOI 10.1177/00494755910210S106; MARLOW M, 1992, INT HLTH EXCHANG DEC; NIEBURG P, 1992, J REFUGEE STUD, V5; NIEBURG P, 1989, REFUGEE PARTICIP JUN; PAQUET C, 1994, DEMOGRAPHY MORTALITY; RIVERS JPW, 1982, DISASTERS, V6, P256, DOI 10.1111/j.1467-7717.1982.tb00548.x; TAILHADES M, 1991, TROP DOCT, V21, P18, DOI 10.1177/00494755910210S105; *WORLD BANK, 1993, 1993 WORLD BANK	10	33	35	1	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1996	348	9031					868	871		10.1016/S0140-6736(96)02134-4	http://dx.doi.org/10.1016/S0140-6736(96)02134-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826815				2022-12-28	WOS:A1996VK03700015
J	Scarlatti, G				Scarlatti, G			Paediatric HIV infection	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; POLYMERASE CHAIN-REACTION; TO-CHILD TRANSMISSION; MATERNAL ANTIBODIES; VIRAL PHENOTYPE; RISK; INFANTS; PREGNANCY; CLEARANCE; DIAGNOSIS	By the year 2000 there will be six million pregnant women and five to ten million children infected with HIV-1. intervention strategies have been planned and in some instances already started. A timely and cost-effective strategy needs to take into account that most HIV-1 infected individuals reside in developing countries. Further studies are needed on immunological and virological factors affecting HIV-1 transmission from mother to child, on differential disease progression in affected children, and on transient infection.			Scarlatti, G (corresponding author), SAN RAFFAELE SCI INST,CTR SAN LUIGI,IMMUNOBIOL LAB,VIA STAMIRA ANCONA 20,I-20127 MILAN,ITALY.		scarlatti, gabriella/H-1482-2018	scarlatti, gabriella/0000-0003-2316-2689				AMADORI A, 1988, LANCET, V1, P852; BATMAN PA, 1994, AIDS, V8, P161, DOI 10.1097/00002030-199402000-00003; BIGGAR RJ, 1996, LANCET, V343, P1647; BORKOWSKY W, 1992, J INFECT DIS, V166, P616, DOI 10.1093/infdis/166.3.616; BORKOWSKY W, 1990, AIDS RES HUM RETROV, V6, P673, DOI 10.1089/aid.1990.6.673; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; CLERICI M, 1993, AIDS, V7, P1427, DOI 10.1097/00002030-199311000-00004; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DEROSSI A, 1993, J PEDIATR-US, V123, P929, DOI 10.1016/S0022-3476(05)80389-0; DEROSSI A, 1993, AIDS RES HUM RETROV, V8, P221; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Fang GW, 1995, P NATL ACAD SCI USA, V92, P12100, DOI 10.1073/pnas.92.26.12100; GALLI L, 1995, AIDS, V9, P445; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; HENIN Y, 1993, J ACQ IMMUN DEF SYND, V6, P72; KLIKS SC, 1994, JAMA-J AM MED ASSOC, V272, P467, DOI 10.1001/jama.272.6.467; LANGSTON C, 1995, J INFECT DIS, V172, P1451, DOI 10.1093/infdis/172.6.1451; LEWIS SH, 1990, LANCET, V335, P565, DOI 10.1016/0140-6736(90)90349-A; MILES SA, 1993, NEW ENGL J MED, V328, P297, DOI 10.1056/NEJM199302043280501; Newell ML, 1996, LANCET, V347, P213, DOI 10.1016/S0140-6736(96)90401-8; OMETTO L, 1995, AIDS, V9, P427, DOI 10.1097/00002030-199509050-00003; PALUMBO PE, 1995, J PEDIATR-US, V126, P592, DOI 10.1016/S0022-3476(95)70357-8; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; ROBERTGUROFF M, 1987, PEDIATR RES, V21, P547, DOI 10.1203/00006450-198706000-00008; ROGERS MF, 1991, PEDIATR INFECT DIS J, V10, P523, DOI 10.1097/00006454-199107000-00009; ROQUES PA, 1995, AIDS, V9, pF19; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; ROUZIOUX C, 1993, AIDS, V7, pS49, DOI 10.1097/00002030-199311002-00011; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; SCARLATTI G, 1993, J INFECT DIS, V168, P207, DOI 10.1093/infdis/168.1.207; SCARLATTI G, 1993, P NATL ACAD SCI USA, V90, P1721, DOI 10.1073/pnas.90.5.1721; SCARLATTI G, 1993, VIROLOGY, V197, P624, DOI 10.1006/viro.1993.1637; SCHUPBACH J, 1989, AIDS, V3, P583, DOI 10.1097/00002030-198909000-00005; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SIMONON A, 1994, J ACQ IMMUN DEF SYND, V7, P952; The European Collaborative Study, 1994, PEDIATRICS, V94, P815; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; TOVO PA, 1991, BRIT J OBSTET GYNAEC, V98, P940, DOI 10.1111/j.1471-0528.1991.tb13520.x; VISCARELLO RR, 1992, AM J OBSTET GYNECOL, V167, P1075, DOI 10.1016/S0002-9378(12)80041-X; 1995, MMWR-MORBID MORTAL W, V44, P1; 1993, PEDIATR INFECT DIS J, V12, P13; 1994, MMWR-MORBID MORTAL W, V43, P1; 1991, LANCET, V337, P253; 1992, J ACQ IMMUN DEF SYND, V5, P1169; 1992, LANCET, V339, P1007; 1992, WKLY EPIDEMIOL REC, V67, P177; 1994, MMWR-MORBID MORTAL W, V43, P285; 1994, LANCET, V343, P1464	50	68	73	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1996	348	9031					863	868		10.1016/S0140-6736(95)11030-5	http://dx.doi.org/10.1016/S0140-6736(95)11030-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826814				2022-12-28	WOS:A1996VK03700014
J	Ferster, D				Ferster, D			Is neural noise just a nuisance?	SCIENCE			English	Editorial Material											Ferster, D (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,2153 SHERIDAN RD,EVANSTON,IL 60208, USA.							ARIELI A, 1995, J NEUROPHYSIOL, V73, P2072, DOI 10.1152/jn.1995.73.5.2072; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; BIALEK W, 1992, TRENDS NEUROSCI, V15, P428, DOI 10.1016/0166-2236(92)90005-S; BIALEK W, 1991, SCIENCE, V252, P1854, DOI 10.1126/science.2063199; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; GEORGOPOULOS AP, 1994, NEURON, V13, P257, DOI 10.1016/0896-6273(94)90345-X; GERSTEIN GL, 1964, BIOPHYS J, V4, P41, DOI 10.1016/S0006-3495(64)86768-0; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SOFTKY WR, 1993, J NEUROSCI, V13, P334; TOLHURST DJ, 1983, VISION RES, V23, P775, DOI 10.1016/0042-6989(83)90200-6	10	49	50	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1812	1812		10.1126/science.273.5283.1812	http://dx.doi.org/10.1126/science.273.5283.1812			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8815544				2022-12-28	WOS:A1996VJ71300032
J	Colot, V; Maloisel, L; Rossignol, JL				Colot, V; Maloisel, L; Rossignol, JL			Interchromosomal transfer of epigenetic states in Ascobolus: Transfer of DNA methylation is mechanistically related to homologous recombination	CELL			English	Article							DOUBLE-STRAND BREAKS; WILMS-TUMOR; MEIOTIC RECOMBINATION; SEQUENCE SPECIFICITY; DENOVO METHYLATION; IMMERSUS; MEIOSIS; YEAST; LOCUS; H19	The transfer of methylation between alleles represents a plausible epigenetic mutational mechanism to explain loss of imprinting in mammals and paramutation in plants. Here, we have exploited advantages unique to the fungus Ascobolus immersus to obtain direct experimental evidence that methylation transfer can occur between homologous chromosomes. A methylated allele and an unmethylated allele of the Ascobolus b2 spore color gene were brought together in individual meiotic cells. Frequent transfer of methylation to the unmethylated allele was observed. This transfer was polarized 5' to 3' along the b2 gene, as is gene conversion, and always accompanied the latter process when tested in the same cross. These and other observations strongly suggest that methylation transfer and recombination are mechanistically related.			Colot, V (corresponding author), UNIV PARIS 11,INST GENET & MICROBIOL,F-91405 ORSAY,FRANCE.		Maloisel, Laurent/G-4556-2012	Maloisel, Laurent/0000-0003-0258-0769				BARRY C, 1993, P NATL ACAD SCI USA, V90, P4557, DOI 10.1073/pnas.90.10.4557; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRINK RA, 1973, ANNU REV GENET, V7, P129, DOI 10.1146/annurev.ge.07.120173.001021; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; COLOT V, 1995, GENETICS, V141, P1299; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; EGGLESTON WB, 1995, GENETICS, V141, P347; Esposito MS, 1981, MOL BIOL YEAST SACCH, P341; FEDOROFF NV, 1995, HOMOLOGOUS RECOMBINA, P349; GOYON C, 1989, MOL CELL BIOL, V9, P2818, DOI 10.1128/MCB.9.7.2818; GOYON C, 1994, J MOL BIOL, V240, P42, DOI 10.1006/jmbi.1994.1416; GOYON C, 1996, MOL CELL BIOL, V19, P3054; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; KERMICLE JL, 1990, DEVELOPMENT, P9; KNUDSON AG, 1993, MED PEDIATR ONCOL, V21, P193, DOI 10.1002/mpo.2950210308; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; LEBLON G, 1978, GENETICS, V90, P475; LEBLON G, 1972, MOL GEN GENET, V115, P36, DOI 10.1007/BF00272216; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lichten M, 1995, ANNU REV GENET, V29, P423, DOI 10.1146/annurev.ge.29.120195.002231; MEYER P, 1993, PLANT J, V4, P89, DOI 10.1046/j.1365-313X.1993.04010089.x; MEYER P, 1995, CURR TOP MICROBIOL, V197, P15; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NICOLAS A, 1989, GENOME, V31, P528, DOI 10.1139/g89-101; NICOLAS A, 1987, GENETICS, V116, P33; PAQUETTE N, 1978, CAN J GENET CYTOL, V20, P9, DOI 10.1139/g78-002; PAQUETTE N, 1978, MOL GEN GENET, V163, P313, DOI 10.1007/BF00271961; PATTERSON GI, 1995, GENE SILENCING HIGHE, P121; RADMAN M, 1993, CHROMOSOMA, V102, P369, DOI 10.1007/BF00360400; RAZIN A, 1994, PROG NUCLEIC ACID RE, V48, P53, DOI 10.1016/S0079-6603(08)60853-3; RHOUNIM L, 1992, EMBO J, V11, P4451, DOI 10.1002/j.1460-2075.1992.tb05546.x; ROSSEN JM, 1966, CR TRAV LAB CARLSB, V35, P233; Rossignol J.-L., 1988, RECOMBINATION GENETI, P23; ROSSIGNOL JL, 1979, P NATL ACAD SCI USA, V89, P2871; SCHWACHA A, 1995, CELL, V83, P783, DOI 10.1016/0092-8674(95)90191-4; Singer-Sam J., 1993, DNA methylation: molecular biology and biological significance., P358; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; ZICKLER D, 1973, CHROMOSOMA, V40, P401, DOI 10.1007/BF00399431	48	104	106	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					855	864		10.1016/S0092-8674(00)80161-0	http://dx.doi.org/10.1016/S0092-8674(00)80161-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808621	Bronze			2022-12-28	WOS:A1996VJ44300004
J	Braverman, LE				Braverman, LE			Is there one successful antithyroid regimen for Graves' disease?	LANCET			English	Editorial Material							DRUGS				Braverman, LE (corresponding author), UNIV MASSACHUSETTS,MED CTR,DIV ENDOCRINOL,WORCESTER,MA 01655, USA.			Braverman, Lewis/0000-0003-1263-1099				ALLANNIC H, 1990, J CLIN ENDOCR METAB, V70, P675, DOI 10.1210/jcem-70-3-675; McIver B, 1996, NEW ENGL J MED, V334, P220, DOI 10.1056/NEJM199601253340403; MYERGEFNER M, 1994, J ENDOCRINOL INVEST, V17, P29; PASCHKE R, 1995, J CLIN ENDOCR METAB, V80, P2470, DOI 10.1210/jc.80.8.2470; ROMALDINI JH, 1983, J CLIN ENDOCR METAB, V57, P563, DOI 10.1210/jcem-57-3-563; Spencer CA, 1996, CLIN CHEM, V42, P140; WENZEL KW, 1984, J CLIN ENDOCR METAB, V58, P62, DOI 10.1210/jcem-58-1-62; Wilson R, 1996, QJM-INT J MED, V89, P381	8	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					697	698		10.1016/S0140-6736(05)65600-0	http://dx.doi.org/10.1016/S0140-6736(05)65600-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806285				2022-12-28	WOS:A1996VG37400004
J	Parr, MJA; Finfer, SR; Morgan, MK				Parr, MJA; Finfer, SR; Morgan, MK			Lesson of the week - Reversible cardiogenic shock complicating subarachnoid haemorrhage	BRITISH MEDICAL JOURNAL			English	Article									ROYAL N SHORE HOSP,ST LEONARDS,NSW 2065,AUSTRALIA	Royal North Shore Hospital				Morgan, Michael/0000-0002-9841-9461; Parr, Michael/0000-0003-3507-474X				KOLIN A, 1984, STROKE, V15, P990, DOI 10.1161/01.STR.15.6.990; NOVITZKY D, 1987, ANN THORAC SURG, V43, P288, DOI 10.1016/S0003-4975(10)60615-7; Novitzky D., 1984, J HEART TRANSPLANT, V4, P63; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004	4	35	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1996	313	7058					681	683						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8811765				2022-12-28	WOS:A1996VH16500032
J	VandeLisdonk, EH; VanWeel, C				VandeLisdonk, EH; VanWeel, C			New referrals, a decreasing phenomenon in 1971-94: Analysis of registry data in the Netherlands	BRITISH MEDICAL JOURNAL			English	Article							MORBIDITY; CHILDHOOD				VandeLisdonk, EH (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT GEN PRACTICE & SOCIAL MED,POB 9101,NL-6500 HB NIJMEGEN,NETHERLANDS.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				DEGRAUW WJC, 1995, DIABETIC MED, V12, P117; KOLNAAR BGM, 1994, BRIT J GEN PRACT, V44, P73; Roland M., 1993, HOSP REFERRALS; VANDENBOSCH WJHM, 1992, FAM PRACT, V9, P290, DOI 10.1093/fampra/9.3.290; VANWEEL C, 1995, J EPIDEMIOL COMMUN H, V49, P29, DOI 10.1136/jech.49.Suppl_1.29	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					602	602						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806253				2022-12-28	WOS:A1996VG10800022
J	Bateman, DN; Campbell, M; Donaldson, LJ; Roberts, SJ; Smith, JM				Bateman, DN; Campbell, M; Donaldson, LJ; Roberts, SJ; Smith, JM			A prescribing incentive scheme for non-fundholding general practices: An observational study	BRITISH MEDICAL JOURNAL			English	Article							COSTS; DRUGS	Objective-To examine the effects of a financial incentive scheme on prescribing in non-fundholding general practices. Design-Observational study. Setting-Non-fundholding general practices in former Northern region in 1993-4. Intervention-Target savings were set for each group of practices; those that achieved them were paid a portion of the savings. Main outcome measures-Financial performance; prescribing patterns in major therapeutic groups and some specific therapeutic areas; rates of generic prescribing; and performance against a measure of prescribing quality. Subjects-459 non-fundholding general practices, grouped into three bands according to the ratio of their indicative prescribing amount to the local average (band A greater than or equal to 10% above average, B between average and 10% above, C below average). Results-102 (23%) of 442 practices achieved their target savings (18%, 19%, and 27% of bands A, B, and C respectively). Band C practices that achieved their target had a lower per capita prescribing frequency for gastrointestinal drugs, inhaled steroids, antidepressants, and hormone replacement therapy. There were no other significant differences in prescribing frequency and no reduction in the quality of prescribing in achieving practices. Total savings of pound 1.54m on indicative prescribing amounts were achieved. Payments from the incentive scheme and discretionary quality awards resulted in pound 463 000 being returned to practices for investment in primary care. Conclusions-The prescribing behaviour of non-fundholding general practitioners responded to financial incentives in a similar way to that of fundholding practitioners. The incentive scheme did not seem to reduce the quality of prescribing.	UNIV NEWCASTLE,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK	Bateman, DN (corresponding author), REG DRUG & THERAPEUT CTR,WOLFSON UNIT,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.			Bateman, David Nicholas/0000-0002-8971-862X				Bateman DN, 1996, BRIT J GEN PRACT, V46, P20; *BR MED ASS ROYAL, 1995, BRIT NAT FORM, V30; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; Eccles MP, 1996, BRIT J GEN PRACT, V46, P287; ILLIFE S, 1993, BRIT MED J, V307, P1156; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; *NHS MAN EX, 1993, 934 HSG NHS MAN EX; ROBERTS SJ, 1994, THORAX, V49, P1090, DOI 10.1136/thx.49.11.1090; ROBERTS SJ, 1995, ALIMENT PHARM THERAP, V9, P137, DOI 10.1111/j.1365-2036.1995.tb00362.x; STEWARTBROWN S, 1995, BRIT MED J, V311, P1543, DOI 10.1136/bmj.311.7019.1543; Wilson R, 1995, LANCET, V346, P1710, DOI 10.1016/S0140-6736(95)92877-4; WILSON RPH, 1995, BRIT MED J, V311, P1347, DOI 10.1136/bmj.311.7016.1347	12	36	37	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					535	538						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789984				2022-12-28	WOS:A1996VF29400025
J	Skinner, R; Pearson, ADJ; English, MW; Price, L; Wyllie, RA; Coulthard, MG; Craft, AW				Skinner, R; Pearson, ADJ; English, MW; Price, L; Wyllie, RA; Coulthard, MG; Craft, AW			Risk factors for ifosfamide nephrotoxicity in children	LANCET			English	Article							HYPOPHOSPHATEMIC RICKETS; TUBULAR TOXICITY; FANCONI SYNDROME; RENAL-FUNCTION; CANCER	Background Risk factors for long-term nephrotoxicity after ifosfamide for childhood cancers are not fully known. We have studied patient-related and treatment-related risk factors for chronic ifosfamide nephrotoxicity. Methods A group of 23 children who had received ifosfamide at age 2.1-16.2 years (median 6.9) for various cancers were assessed for nephrotoxicity, at 1-28 (2) months after the end of treatment, by renal function testing, laboratory values, and a grading score (none, mild, moderate, severe). No patient had received cisplatin or undergone nephrectomy. 13 children were reassessed at 10-26 (23) months; eight had died and two were not evaluable. The median total ifosfamide dose was 100.8 (9.0-160.4) g/m(2) over a median of 15 courses every 3 weeks as a 48-72 h continuous intravenous infusion (in 22 cases), with mesna and hydration. Findings Glomerular filtration rate was below normal in ten (45%) of 22 evaluable children; their rate was 61-85 mL/min per 1.73 m(2). Proximal tubular toxicity led to hypophosphataemic rickets and/or renal tubular acidosis in six children, and distal tubular toxicity caused nephrogenic diabetes insipidus in one. Of the risk factors analysed by multiple regression, only total ifosfamide dose was associated with proximal tubular toxicity. Only two of ten evaluable patients who received under 100 g/m(2) developed moderate nephrotoxicity, whereas six of ten who received over this dose had moderate or severe nephrotoxicity, Interpretation High total ifosfamide dose was the only risk factor we identified. Although inter-patient variability was high, cumulative doses of 100 g/m(2) or higher should be avoided in children with cancer.			Skinner, R (corresponding author), UNIV NEWCASTLE UPON TYNE, ROYAL VICTORIA INFIRM, SIR JAMES SPENCE INST CHILD HLTH, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND.							ARNDT C, 1994, CANCER CHEMOTH PHARM, V34, P431, DOI 10.1007/s002800050166; ASHRAF MS, 1994, EUR J PEDIATR, V153, P90, DOI 10.1007/BF01959214; BURK CD, 1990, J PEDIATR-US, V117, P331, DOI 10.1016/S0022-3476(05)80557-8; CARON HN, 1992, MED PEDIATR ONCOL, V20, P42, DOI 10.1002/mpo.2950200109; DESCHEPPER J, 1993, ACTA PAEDIATR, V82, P373; HENEY D, 1989, LANCET, V2, P103; MONCRIEFF M, 1989, CANCER CHEMOTH PHARM, V23, P121; NEWBURYECOB RA, 1989, LANCET, V1, P1328; PRATT CB, 1991, J CLIN ONCOL, V9, P1495, DOI 10.1200/JCO.1991.9.8.1495; ROSSI R, 1994, J CLIN ONCOL, V12, P159, DOI 10.1200/JCO.1994.12.1.159; SHAW PJ, 1990, LANCET, V335, P1022, DOI 10.1016/0140-6736(90)91076-M; SKINNER R, 1989, BRIT MED J, V298, P1560, DOI 10.1136/bmj.298.6687.1560; SKINNER R, 1994, MED PEDIATR ONCOL, V22, P153, DOI 10.1002/mpo.2950220219; SKINNER R, 1991, CANCER CHEMOTH PHARM, V28, P81, DOI 10.1007/BF00689694; SKINNER R, 1993, J CLIN ONCOL, V11, P173, DOI 10.1200/JCO.1993.11.1.173; SKINNER R, 1990, ARCH DIS CHILD, V65, P732, DOI 10.1136/adc.65.7.732; SKINNER R, 1992, BRIT J CANCER, V66, pS30; SMEITINK J, 1988, EUR J PEDIATR, V148, P164, DOI 10.1007/BF00445929; VANGOOL S, 1992, MED PEDIATR ONCOL, V20, P254, DOI 10.1002/mpo.2950200316; ZALUPSKI M, 1988, J NATL CANCER I, V80, P556, DOI 10.1093/jnci/80.8.556	20	64	68	2	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	1996	348	9027					578	580		10.1016/S0140-6736(96)03480-0	http://dx.doi.org/10.1016/S0140-6736(96)03480-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774570				2022-12-28	WOS:A1996VF18600011
J	Derbyshire, SWG; Furedi, A				Derbyshire, SWG; Furedi, A			For debate - Do fetuses feel pain? ''Fetal pain'' is a misnomer	BRITISH MEDICAL JOURNAL			English	Article									UNIV MANCHESTER,HOPE HOSP,CTR RHEUMAT DIS,SALFORD M6 8HD,LANCS,ENGLAND; BIRTH CONTROL TRUST,LONDON W1N 7RD,ENGLAND	University of Manchester				Derbyshire, Stuart/0000-0002-2766-3424				FITZGERALD M, 1994, TXB PAIN, P153; Fitzgerald M., 1995, FOETAL PAIN UPDATE C; GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; LEVENTHAL H, 1984, ADV EXP SOC PSYCHOL, V17, P117, DOI 10.1016/S0065-2601(08)60119-7; MRZLJAK L, 1988, J COMP NEUROL, V271, P355, DOI 10.1002/cne.902710306; *OFF NAT STAT HMSO, 1995, ABORT STAT, P19	6	34	35	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					795	795						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842074				2022-12-28	WOS:A1996VK56600027
J	Szawarski, Z				Szawarski, Z			For debate - Do fetuses feel pain? Probably no pain in the absence of ''self''	BRITISH MEDICAL JOURNAL			English	Article											Szawarski, Z (corresponding author), UNIV WALES SWANSEA,CTR PHILOSOPHY & HLTH CARE,SWANSEA SA2 8PP,W GLAM,WALES.							Butler Nance Cunningham, 1989, Bioethics, V3, P181, DOI 10.1111/j.1467-8519.1989.tb00339.x; Campbell Neil, 1989, Bioethics, V3, P200, DOI 10.1111/j.1467-8519.1989.tb00340.x; DENNETT DC, 1993, CONSCIOUSNESS EXPLAI, P431; Nagel Thomas, 1979, MORTAL QUESTIONS, P165; Searle J., 1992, REDISCOVERY MIND BRA, P151	5	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					796	797						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842076				2022-12-28	WOS:A1996VK56600028
J	Beach, RC				Beach, RC			Management of childhood constipation	LANCET			English	Editorial Material											Beach, RC (corresponding author), NORFOLK & NORWICH HLTH CARE NHS TRUST, JENNY LIND CHILDRENS DEPT, NORFOLK NR1 3SR, ENGLAND.							CLADEN G, 1991, CONSTIPATION CHILDHO; GLEGHORN EE, 1991, CLIN PEDIATR, V30, P669, DOI 10.1177/000992289103001203; PARTIN JC, 1992, PEDIATRICS, V89, P1007; Sprague-McRae J M, 1993, Nurse Pract, V18, P52; Sprague-McRae JM, 1993, NURSE PRACT, V18, P56	5	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	1996	348	9030					766	767		10.1016/S0140-6736(05)65203-8	http://dx.doi.org/10.1016/S0140-6736(05)65203-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813977				2022-12-28	WOS:A1996VH98900003
J	Medvinsky, A; Dzierzak, E				Medvinsky, A; Dzierzak, E			Definitive hematopoiesis is autonomously initiated by the AGM region	CELL			English	Article							FETAL LIVER HEMATOPOIESIS; PRIMORDIAL GERM-CELLS; EMBRYONIC YOLK-SAC; STEM-CELLS; MOUSE EMBRYO; IN-VITRO; PARAAORTIC SPLANCHNOPLEURA; ONTOGENY; PRECURSORS; MIGRATION	The adult hematopoietic system of mammals is a dynamic hierarchy of cells with the hematopoietic stem cell at its foundation. During embryonic development, the source and expansion potential of this cell remain unclear. Two sites of hematopoietic activity, the yolk sac and aorta-gonad-mesonephros (AGM) region, function in mouse ontogeny at the pre-liver stage of hematopoiesis. However, cellular interchange between these tissues obscures the embryonic site of hematopoietic stem cell generation. Here we present the results of a novel in vitro organ culture system demonstrating that, at day 10 in gestation, hematopoietic stem cells initiate autonomously and exclusively within the AGM region. Furthermore, we provide evidence for the in vitro expansion of hematopoietic stem cells within the AGM region. These results strongly suggest that the AGM region is the source of the definitive adult hematopoietic system, which subsequently colonizes the liver.			Medvinsky, A (corresponding author), NATL INST MED RES,THE RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CUMANO A, 1993, P NATL ACAD SCI USA, V90, P6429, DOI 10.1073/pnas.90.14.6429; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; Dieterlen-Lievre F, 1993, SEMIN DEV BIOL, V4, P325; DIETERLENLIEVRE F, 1975, J EMBRYOL EXP MORPH, V33, P607; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; FLEISCHMAN RA, 1982, CELL, V30, P351, DOI 10.1016/0092-8674(82)90233-1; GODIN I, 1995, P NATL ACAD SCI USA, V92, P773, DOI 10.1073/pnas.92.3.773; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; HARRISON DE, 1987, BLOOD, V69, P1021; HARRISON DE, 1979, BLOOD, V54, P1152; HUANG H, 1993, P NATL ACAD SCI USA, V90, P10110, DOI 10.1073/pnas.90.21.10110; JENKINSON EJ, 1982, EUR J IMMUNOL, V12, P583, DOI 10.1002/eji.1830120710; JOHNSON GR, 1985, EXP HEMATOL, V13, P200; JOHNSON GR, 1975, NATURE, V258, P726, DOI 10.1038/258726a0; JORDAN CT, 1990, GENE DEV, V4, P220, DOI 10.1101/gad.4.2.220; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KAU CL, 1983, J IMMUNOL, V131, P2262; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P465; KINOSHITA K, 1995, DEVELOPMENT, V121, P1581; Kratochwil K., 1983, P99; LASSILA O, 1978, NATURE, V272, P353, DOI 10.1038/272353a0; LIU CP, 1991, DEVELOPMENT, V113, P1315; MAENO M, 1985, DEV BIOL, V110, P503, DOI 10.1016/0012-1606(85)90108-3; MARTIN C, 1978, CELL DIFFER DEV, V7, P115, DOI 10.1016/0045-6039(78)90012-X; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; MEDVINSKY A, 1993, SEMIN DEV BIOL, V4, P333; Medvinsky AL, 1996, BLOOD, V87, P557, DOI 10.1182/blood.V87.2.557.bloodjournal872557; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MORRISON SJ, 1995, P NATL ACAD SCI USA, V92, P10302, DOI 10.1073/pnas.92.22.10302; MULLER AM, 1993, DEVELOPMENT, V118, P1343; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PALACIOS R, 1993, P NATL ACAD SCI USA, V90, P6581, DOI 10.1073/pnas.90.14.6581; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PERAH G, 1977, J CELL PHYSIOL, V91, P193, DOI 10.1002/jcp.1040910205; RICH IN, 1995, BLOOD, V86, P463, DOI 10.1182/blood.V86.2.463.bloodjournal862463; RUSSELL ELIZABETH S., 1966, P351; SAMOYLINA NL, 1990, SOV J DEVEL BIOL, V21, P127; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SERRA R, 1995, DEVELOPMENT, V121, P3057; SONODA T, 1983, DEV BIOL, V97, P89, DOI 10.1016/0012-1606(83)90066-0; SYMANN M, 1978, EXP HEMATOL, V6, P749; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TURPEN JB, 1982, DEV BIOL, V89, P138, DOI 10.1016/0012-1606(82)90302-5; TURPEN JB, 1981, DEV BIOL, V85, P99, DOI 10.1016/0012-1606(81)90239-6; Weissman I, 1978, DIFFERENTIATION NORM, V5, P33; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	50	1089	1114	2	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					897	906		10.1016/S0092-8674(00)80165-8	http://dx.doi.org/10.1016/S0092-8674(00)80165-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808625	Green Published, Bronze			2022-12-28	WOS:A1996VJ44300008
J	Vlieghe, D; VanMeervelt, L; Dautant, A; Gallois, B; Precigoux, G; Kennard, O				Vlieghe, D; VanMeervelt, L; Dautant, A; Gallois, B; Precigoux, G; Kennard, O			Parallel and antiparallel (G center dot GC)(2) triple helix fragments in a crystal structure	SCIENCE			English	Article							BASE TRIPLETS; NUCLEIC-ACIDS; DNA TRIPLER; TRANSCRIPTION; RECOMBINATION; RECOGNITION; STABILITY; DATABASE; PACKAGE	Nucleic acid triplexes are formed by sequence-specific interactions between single-stranded polynucleotides and the double helix. These triplexes are implicated in genetic recombination in vivo and have application to areas that include genome analysis and antigene therapy. Despite the importance of the triple helix, only limited high-resolution structural information is available. The x-ray crystal structure of the oligonucleotide d(GGCGAATTGG) is described; it was designed to contain the d(G . GC)(2) fragment and thus provide the basic repeat unit oi a DNA triple helix. Parameters derived from this crystal structure have made it possible to construct models of both parallel and antiparallel triple helices.	CAMBRIDGE CRYSTALLOG DATA CTR, CAMBRIDGE CB2 1EZ, ENGLAND; KATHOLIEKE UNIV LEUVEN, DEPT CHEM, B-3001 HEVERLEE, BELGIUM; UNIV BORDEAUX 2, UNITE BIOPHYS STRUCT, EP CNRS, F-33405 TALENCE, FRANCE	University of Cambridge; KU Leuven; UDICE-French Research Universities; Universite de Bordeaux			Van Meervelt, Luc/AAD-2878-2022	Van Meervelt, Luc/0000-0003-2186-5209				ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEAL PA, 1991, SCIENCE, V251, P1360, DOI 10.1126/science.2003222; BERMAN HM, 1992, BIOPHYS J, V63, P751, DOI 10.1016/S0006-3495(92)81649-1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETTS L, 1995, SCIENCE, V270, P1838, DOI 10.1126/science.270.5243.1838; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DERVAN PB, 1992, NATURE, V359, P87, DOI 10.1038/359087a0; DIEKMANN S, 1989, EMBO J, V8, P1; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; JIANG SP, 1994, J BIOMOL STRUCT DYN, V12, P383, DOI 10.1080/07391102.1994.10508747; KOHWI Y, 1992, J MOL BIOL, V223, P817, DOI 10.1016/0022-2836(92)90242-C; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEBRET M, 1991, J CHIM PHYS PCB, V88, P2489, DOI 10.1051/jcp/1991882489; LEONARD GA, 1995, ACTA CRYSTALLOGR D, V51, P136, DOI 10.1107/S0907444994004713; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, P50; LIU KL, 1994, NAT STRUCT BIOL, V1, P11, DOI 10.1038/nsb0194-11; MAHLER LJ, 1989, SCIENCE, V245, P725; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PIRIOU JM, 1994, BIOPHYS CHEM, V50, P323, DOI 10.1016/0301-4622(93)E0103-C; RADHAKRISHNAN I, 1993, STRUCTURE, V1, P135, DOI 10.1016/0969-2126(93)90028-F; RADHAKRISHNAN I, 1994, BIOCHEMISTRY-US, V33, P11405, DOI 10.1021/bi00204a001; RAGHUNATHAN G, 1993, BIOCHEMISTRY-US, V32, P455, DOI 10.1021/bi00053a009; RAO BJ, 1994, P NATL ACAD SCI USA, V91, P6161, DOI 10.1073/pnas.91.13.6161; SHCHYOLKINA AK, 1995, FEBS LETT, V367, P81, DOI 10.1016/0014-5793(95)00519-F; Sheldrick G., 2015, ACTA CRYSTALLOGR C, V71, DOI DOI 10.1107/S2053229614024218; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; SUN JS, 1993, CURR OPIN STRUC BIOL, V3, P345, DOI 10.1016/S0959-440X(05)80105-8; VANMEERVELT L, 1995, NATURE, V374, P742, DOI 10.1038/374742a0; ZHURKIN VB, 1994, J MOL BIOL, V239, P181, DOI 10.1006/jmbi.1994.1362	34	74	74	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1996	273	5282					1702	1705		10.1126/science.273.5282.1702	http://dx.doi.org/10.1126/science.273.5282.1702			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781231				2022-12-28	WOS:A1996VH40800038
J	Jones, AH				Jones, AH			Images of physicians in literature: Medical Bildungsromans	LANCET			English	Article											Jones, AH (corresponding author), UNIV TEXAS,MED BRANCH,INST MED HUMANITIES,ASHBEL SMITH BLDG SUITE 2210,301 UNIV BLVD,GALVESTON,TX 77555, USA.							BORGENICHT L, 1981, NEW ENGL J MED, V304, P1112, DOI 10.1056/NEJM198104303041824; BRIEGER GH, 1982, MOEBIUS, V2, P32; CRAWSHAW R, 1984, PHAROS, V47, P49; DEKRUIF P, 1962, SWEEPING WIND MEMOIR, P54; Eliot George, 1977, MIDDLEMARCH; FISHBEIN M, 1969, AUTOBIOGRAPHY, P99; Frame Donald, 1968, MISANTHROPE OTHER PL; HUNTER KM, 1983, HOUSE GOD LIT MED, V2, P135; JONES AH, 1994, 23 ANN M AM OSL SOC; JONES AH, 1986, CONNECTICUT SCHOLAR, V8, P38; Lewis S., 1925, ARROWSMITH; McLellan MF, 1996, LANCET, V348, P458, DOI 10.1016/S0140-6736(96)02421-X; Rosenberg Charles E., 1963, AM QUART, V15, P447; SCHORER M, 1961, S LEWIS AM LIFE, P337; SCHORER M, 1925, AFTERWORD, P431; SHEM S, 1988, HOUSE GOD, P5; SHEM S, 1990, JAMA-J AM MED ASSOC, V264, P1746; SHEM S, 1990, JAMA-J AM MED ASSOC, V264, P1743; Shem Samuel, 1978, HOUSE GOD; 1981, NEW ENGL J MED, V305, P1288; 1981, NEW ENGL J MED, V305, P411	21	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					734	736		10.1016/S0140-6736(96)07315-1	http://dx.doi.org/10.1016/S0140-6736(96)07315-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8830207				2022-12-28	WOS:A1996VG37400016
J	Moqtaderi, Z; Bai, Y; Poon, D; Weil, PA; Struhl, K				Moqtaderi, Z; Bai, Y; Poon, D; Weil, PA; Struhl, K			TBP-associated factors are not generally required for transcriptional activation in yeast	NATURE			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; IN-VIVO; SACCHAROMYCES-CEREVISIAE; GENE; HOLOENZYME; PROMOTER; COMPLEX; RECRUITMENT; REPRESSION	THE transcription factor TFIID, a central component of the eukaryotic RNA polymerase II (Pol II) transcription apparatus, comprises the TATA-binding protein (TBP) and approximately ten TBP-associated factors (TAFs)(1). Although the essential role of TBP in all eukaryotic transcription has been extensively analysed in vivo and in vitro(2,3), the function of the TAFs is less clear. In vitro, TAFs are dispensable for basal transcription but are required for the response to activators(1). In addition, specific TAFs may act as molecular bridges between particular activators and the general transcription machinery(4,5). In vivo, TAFs are required for yeast(6,7) and mammalian(8) cell growth, but little is known about their specific transcriptional functions. Using conditional alleles created by a new double-shutoff method, we show here that TAF depletion in yeast cells fan reduce transcription from some promoters lacking conventional TATA elements. However, TAF depletion has surprisingly little effect on transcriptional enhancement by several activators, indicating that TAFs are not generally required for transcriptional activation in yeast.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; VANDERBILT UNIV,MED CTR,DEPT MOL PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Harvard University; Harvard Medical School; Vanderbilt University								ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHEN W, 1985, EMBO J, V4, P3272; CORMACK BP, 1994, GENE DEV, V8, P1335, DOI 10.1101/gad.8.11.1335; GRIGGS DW, 1991, P NATL ACAD SCI USA, V88, P8597, DOI 10.1073/pnas.88.19.8597; HERNANDEZ N, 1993, GENE DEV, V7, P4291; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; IYER V, 1995, MOL CELL BIOL, V15, P7059; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LEE M, 1995, MOL CELL BIOL, V15, P5461; MARTENS JA, 1994, J BIOL CHEM, V269, P15661; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; RAY BL, 1991, CURR GENET, V20, P25, DOI 10.1007/BF00312761; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; Struhl K, 1995, ANNU REV GENET, V29, P651, DOI 10.1146/annurev.ge.29.120195.003251; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S	30	247	253	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					188	191		10.1038/383188a0	http://dx.doi.org/10.1038/383188a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774887				2022-12-28	WOS:A1996VG14800058
J	Jorgensen, HL; Scholler, J; Sand, JC; Bjuring, M; Hassager, C; Christiansen, C				Jorgensen, HL; Scholler, J; Sand, JC; Bjuring, M; Hassager, C; Christiansen, C			Relation of common allelic variation at vitamin D receptor locus to bone mineral density and postmenopausal bone loss: Cross sectional and longitudinal population study	BRITISH MEDICAL JOURNAL			English	Article							X-RAY ABSORPTIOMETRY; PHOTON ABSORPTIOMETRY; GENE POLYMORPHISMS; OSTEOPOROTIC WOMEN; SINGLE-PHOTON; LUMBAR-SPINE; FRACTURES; MASS; GENOTYPE; TWIN	Objective-To determine whether common allelic variation at the vitamin D receptor locus is related to bose mineral density and postmenopausal bone loss. Design-Cross sectional and longitudinal population study. Setting-Outpatient clinic in research centre. Subjects-599 healthy women aged 27 to 72 and 125 women with low bone mass aged 55-77 had bone mineral density measured once in the cross sectional study. 136 women aged 45-54 were followed up for 18 years in the longitudinal study. Main outcome measures-Bone mineral density measured at the lumbar spine, hip, and forearm and rate of bone loss at different times over 18 years in relation to vitamin D receptor genotype as defined by the endonucleases ApaI, BsmI, and TaqI. Results-Vitamin D receptor genotype was not related to bone mineral density at any site. The maximum difference between homozygotes was 1.3% (P = 0.33, n = 723). Women with low bone mineral density had almost the same genotype frequencies as the women with normal bone mineral densities. Vitamin D receptor genotype was not related to early postmenopausal bone loss from age 51 to 53 (mean (SD) total loss at the lower forearm -3.6% (3.6%)), late postmenopausal bone loss from age 63 to 69 (at the hip -6.2% (8.7%)), or to long term postmenopausal loss from age 51 to 69 (at the lower forearm -24.5% (11.4%)). Conclusion-Common allelic variation at the vitamin D receptor locus as defined by the endonucleases ApaI, BsmI, and TaqI is related neither to bone mineral density nor to the rate of bone loss in healthy postmenopausal Danish women.			Jorgensen, HL (corresponding author), CTR CLIN & BASIC RES,BALLERUP BYVEJ 222,DK-2750 BALLERUP,DENMARK.		Jorgensen, Henrik/ABI-8236-2020	Jorgensen, Henrik Lovendahl/0000-0001-6374-761X				BORG J, 1995, OSTEOPOROSIS INT, V5, P377, DOI 10.1007/BF01622260; CHRISTIANSEN C, 1980, EUR J CLIN INVEST, V10, P273, DOI 10.1111/j.1365-2362.1980.tb00033.x; CHRISTIANSEN C, 1987, Lancet, V1, P1105; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; FERRARI S, 1995, LANCET, V345, P423, DOI 10.1016/S0140-6736(95)90404-2; FLEET JC, 1995, J BONE MINER RES, V10, P985; HANSEN MA, 1990, J NUCL MED, V31, P1156; HUSMEYER FG, 1994, J CLIN INVEST, V94, P2130; KEEN RW, 1995, LANCET, V345, P990, DOI 10.1016/S0140-6736(95)90740-8; KELLY TL, 1994, CALCIFIED TISSUE INT, V54, P212, DOI 10.1007/BF00301681; KRALL EA, 1995, J BONE MINER RES, V10, P978; LOONEY JE, 1995, J CLIN ENDOCR METAB, V80, P2158, DOI 10.1210/jc.80.7.2158; MELTON LJ, 1993, BONE, V14, pS1; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; NILAS L, 1985, J NUCL MED, V26, P1257; OVERGAARD K, 1992, CALCIFIED TISSUE INT, V50, P30, DOI 10.1007/BF00297294; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; RIGGS BL, 1995, J BONE MINER RES, V10, P991; *SAS I, 1987, SAS STAT GUID PERS C; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SPECTOR TD, 1995, BRIT MED J, V310, P1357, DOI 10.1136/bmj.310.6991.1357; Uitterlinden A. G., 1995, Calcified Tissue International, V56, P474; 1993, JAMA-J AM MED ASSOC, V94, P646	24	59	61	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					586	590						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806247	Green Published			2022-12-28	WOS:A1996VG10800016
J	Nugent, CI; Hughes, TR; Lue, NF; Lundblad, V				Nugent, CI; Hughes, TR; Lue, NF; Lundblad, V			Cdc13p: A single-strand telomeric DNA binding protein with a dual role in yeast telomere maintenance	SCIENCE			English	Article							OXYTRICHA MACRONUCLEAR DNA; SACCHAROMYCES-CEREVISIAE; RNA COMPONENT; SENESCENCE; CELLS; VARIABILITY; THERMOPHILA; CHECKPOINT; MUTANTS; REPEAT	The CDC13 gene has previously been implicated in the maintenance of telomere integrity in Saccharomyces cerevisiae, With the use of two classes of mutations, here it is shown that CDC13 has two discrete roles at the telomere. The cdc13-2(est) mutation perturbs a function required in vivo for telomerase regulation but not in vitro for enzyme activity, whereas cdc13-1(ts) defines a separate essential role at the telomere. In vitro, purified Cdc13p binds to single-strand yeast telomeric DNA. Therefore, Cdc13p is a telomere-binding protein required to protect the telomere and mediate access of telomerase to the chromosomal terminus.	BAYLOR COLL MED,DEPT MOL & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,CELL & MOL BIOL PROGRAM,HOUSTON,TX 77030; CORNELL UNIV,COLL MED,DEPT MICROBIOL,NEW YORK,NY 10021	Baylor College of Medicine; Baylor College of Medicine; Cornell University			Lue, Neal/AAO-6759-2020	Lue, Neal/0000-0001-9700-6895				ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARTWELL LH, 1985, GENETICS, V110, P381; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HIYAMA K, 1995, J IMMUNOL, V155, P3711; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LENDVAY T, IN PRESS GENETICS; LOUIS EJ, 1990, GENETICS, V124, P533; LUE NF, 1995, J BIOL CHEM, V270, P21453, DOI 10.1074/jbc.270.37.21453; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; ROSS LL, UNPUB; SHENG H, 1995, MOL CELL BIOL, V15, P1144; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; VIRTAPEARLMAN V, UNPUB; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZENTGRAF H, 1995, NUCLEIC ACIDS RES, V23, P3347, DOI 10.1093/nar/23.16.3347	32	512	525	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					249	252		10.1126/science.274.5285.249	http://dx.doi.org/10.1126/science.274.5285.249			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824190				2022-12-28	WOS:A1996VM67100044
J	Tereskerz, PM; Pearson, RD; Jagger, J				Tereskerz, PM; Pearson, RD; Jagger, J			Occupational exposure to blood among medical students	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NEEDLESTICK INJURIES; RATES; RISK				Tereskerz, PM (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROSURG,BOX 407,CHARLOTTESVILLE,VA 22908, USA.							*ACCR LIAIS COMM M, 1995, FUNCT STRUCT MED SCH, P17; BAIG EF, 1994, J FLA BAR, V68, P75; CHINA HP, 1993, ANN ACAD MED SINGAP, V22, P338; CHOUDHURY RP, 1992, J HOSP INFECT, V22, P143, DOI 10.1016/0195-6701(92)90098-7; DEVRIES B, 1994, MED J AUSTRALIA, V160, P398; DORGAN CA, 1995, STAT RECORD HLTH MED, P596; GLANTZ LH, 1992, MILBANK Q, V70, P43, DOI 10.2307/3350085; GOMPERTZ S, 1990, J SOC OCCUP MED, V40, P19; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; JAGGER J, 1991, INFECT CONT HOSP EP, V12, P211, DOI 10.2307/30146993; KIRKPATRICK BL, 1993, J HOSP INFECT, V23, P315, DOI 10.1016/0195-6701(93)90149-T; KOENIG S, 1995, AM J INFECT CONTROL, V23, P40, DOI 10.1016/0196-6553(95)90007-1; ONEILL TM, 1992, ARCH INTERN MED, V152, P1451, DOI 10.1001/archinte.152.7.1451; RESNIC FS, 1995, ARCH INTERN MED, V155, P75, DOI 10.1001/archinte.155.1.75; STOTKA JL, 1991, INFECT CONT HOSP EP, V12, P583; TERESKERZ P, 1995, ADV EXPOSURE PREV, V1, P10; TERESKERZ PM, 1995, ADV EXPOSURE PREV, V2, P7; TESCH B, 1993, ACAD MED, V68, P87, DOI 10.1097/00001888-199301000-00014; VERGILIO JA, 1993, ARCH SURG-CHICAGO, V128, P36; WATERMAN J, 1994, J HOSP INFECT, V26, P149, DOI 10.1016/0195-6701(94)90058-2; 1989, MMWR-MORBID MORTAL W, V38, P746; 1995, MMWR-MORBID MORTAL W, V44, P929; 1996, MMWR-MORBID MORTAL W, V45, P468; 1996, INFECT CONT HOSP EP, V17, P476; 1989, MMWR-MORBID MORTAL W, V38, P1; 1991, MMWR-MORBID MORTAL W, V40, P1	26	37	42	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1996	335	15					1150	1153		10.1056/NEJM199610103351512	http://dx.doi.org/10.1056/NEJM199610103351512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN399	8813049				2022-12-28	WOS:A1996VN39900012
J	Felsenfeld, DP; Choquet, D; Sheetz, MP				Felsenfeld, DP; Choquet, D; Sheetz, MP			Ligand binding regulates the directed movement of beta 1 integrins on fibroblasts	NATURE			English	Article							LOCOMOTING CELLS; FIBRONECTIN; ASSOCIATIONS; EXPRESSION; CONTACTS; SUBUNIT	To enable cells to crawl, adhesion receptors such as integrins most bind to extracellular molecules and simultaneously interact with force-generating components of the cytoskeleton(1,2). We show here that the binding of extracellular ligand in living cells induces the attachment of beta 1 integrins to the retrograde-snoring cytoskeleton, Unliganded integrins are not associated with the rearward-moving cytoskeleton: gold particles attached to beta 1 integrin by a monoclonal antibody diffuse inn the membrane, However, addition of soluble RGD peptide (single-letter amino-acid code) or the use of fibronectin-coated gold particles causes the attachment of integrins to the rearward-moving cytoskeleton. Deletion of the beta 1 cytoplasmic tail blocks cytoskeletal attachment. The directed movement of integrins in response to ligand indicates that ligand binding is the critical step in regulating organized receptor movement on the cell surface and the migration of adherent cells.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University			Choquet, Daniel/K-7893-2018; Choquet, Daniel/GOJ-8825-2022; Choquet, Daniel/E-4203-2013	Choquet, Daniel/0000-0003-4726-9763; Choquet, Daniel/0000-0003-4726-9763; 				BUCK CA, 1987, J CELL SCI, P231; DUBAND JL, 1988, J CELL BIOL, V107, P1385, DOI 10.1083/jcb.107.4.1385; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MUELLER SC, 1989, J CELL BIOL, V109, P3455, DOI 10.1083/jcb.109.6.3455; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SCHNAPP BJ, 1988, CELL MOTIL CYTOSKEL, V10, P47, DOI 10.1002/cm.970100109; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853	22	196	197	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	1996	383	6599					438	440		10.1038/383438a0	http://dx.doi.org/10.1038/383438a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837776				2022-12-28	WOS:A1996VL46300062
J	Wallace, C; Siminoski, K				Wallace, C; Siminoski, K			The Pemberton sign	ANNALS OF INTERNAL MEDICINE			English	Article							GOITER		UNIV ALBERTA, EDMONTON, AB, CANADA	University of Alberta								BAILEY H, 1949, IOP, P115; BLUM M, 1974, JAMA-J AM MED ASSOC, V227, P189, DOI 10.1001/jama.227.2.189; KATLIC MR, 1985, AM J SURG, V149, P283, DOI 10.1016/S0002-9610(85)80086-6; KATLIC MR, 1985, ANN THORAC SURG, V39, P391, DOI 10.1016/S0003-4975(10)62645-8; KLAASENUDDING LM, 1983, NETH J MED, V26, P228; PEMBERTON HS, 1946, LANCET, V251, P509; REEVE TS, 1962, SURG GYNECOL OBSTET, V115, P223; SANDERS LE, 1992, ARCH SURG-CHICAGO, V127, P609; SY WM, 1982, BRIT J RADIOL, V55, P301, DOI 10.1259/0007-1285-55-652-301	9	12	12	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1996	125	7					568	569		10.7326/0003-4819-125-7-199610010-00006	http://dx.doi.org/10.7326/0003-4819-125-7-199610010-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ653	8815756				2022-12-28	WOS:A1996VJ65300006
J	Gold, DR; Wang, XB; Wypij, D; Speizer, FE; Ware, JH; Dockery, DW				Gold, DR; Wang, XB; Wypij, D; Speizer, FE; Ware, JH; Dockery, DW			Effects of cigarette smoking on lung function in adolescent boys and girls	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY-FUNCTION GROWTH; CHILDREN; SMOKERS; SPLINES; HEALTH; AGE; ADULTS	Background Little is known about the sex-specific effects of cigarette smoking on the level and growth of lung function in adolescence, when 71 percent of people in the United States who smoke tried their first cigarette. Methods We studied the effects of cigarette smoking on the level and rate of growth of pulmonary function in a cohort of 5158 boys and 4902 girls 10 to 18 years of age, examined annually between 1974 and 1989 in six cities in the United States. Results We found a dose-response relation between smoking and lower levels of both the ratio of forced expiratory volume in one second to forced vital capacity (FEV(1)/FVC) and the forced expiratory flow between 25 and 75 percent of FVC (FEF(25-75)). Each pack per day of smoking was associated with a 3.2 percent reduction in FEF(25-75) for girls (P=0.01) and a 3.5 percent reduction in FEF(25-75) for boys (P=0.007). Whereas the FVC level was elevated in smokers, the rate of growth of FVC and FEV(1) was reduced. Among adolescents of the same sex, smoking five or more cigarettes a day, as compared with never smoking, was associated with 1.09 percent slower growth of FEV(1) per year in girls (95 percent confidence interval, 0.70 to 1.47 percent) and 0.20 percent slower growth in boys (95 percent confidence interval, -0.16 to 0.56 percent), and with 1.25 percent slower growth of FEF(25-75) per year in girls (95 percent confidence interval, 0.38 to 2.13 percent) and 0.93 percent slower growth in boys (95 percent confidence interval, 0.21 to 1.65 percent). Whereas girls who did not smoke reached a plateau in lung function at 17 to 18 years of age, girls of the same age who smoked had a decline of FEV(1) and FEF(25-75). Conclusions Cigarette smoking is associated with evidence of mild airway obstruction and slowed growth of lung function in adolescents. Adolescent girls may be more vulnerable than boys to the effects of smoking on the growth of lung function.	HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Gold, DR (corresponding author), BRIGHAM & WOMENS HOSP,CHANNING LAB,DEPT MED,180 LONGWOOD AVE,BOSTON,MA 02115, USA.		, dwdockery/AAO-7272-2021	Wypij, David/0000-0001-8367-8711; Dockery, Douglas/0000-0002-6052-4880	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES001108] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES01108] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON DO, 1965, CAN MED ASSOC J, V92, P1066; CHALON J, 1971, J AMER MED ASSOC, V218, P1928, DOI 10.1001/jama.218.13.1928; CHEN Y, 1991, AM REV RESPIR DIS, V143, P1224, DOI 10.1164/ajrccm/143.6.1224; *DEP HLTH HUM SERV, 1989, DHHS PUBL; *DEP HLTH HUM SERV, 1994, PREV TOB US YOUNG PE; *DEP HLTH HUM SERV, 1980, HLTH CONS SMOK WOM R; DOCKERY DW, 1988, AM REV RESPIR DIS, V137, P286, DOI 10.1164/ajrccm/137.2.286; FERRIS BG, 1979, AM REV RESPIR DIS, V120, P767; FERRIS BG, 1968, ARCH ENVIRON HEALTH, V16, P541, DOI 10.1080/00039896.1968.10665102; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10, DOI 10.1164/ajrccm/148.1.10; HAYASHI M, 1977, AM REV RESPIR DIS, V115, P595; HAYASHI M, 1978, CHEST, V73, P515, DOI 10.1378/chest.73.4.515; KANNER RE, 1994, AM J RESP CRIT CARE, V150, P956, DOI 10.1164/ajrccm.150.4.7921469; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MACKLEM PT, 1974, AM REV RESPIR DIS, V109, P567; PETERS JM, 1967, AM REV RESPIR DIS, V95, P774; SMITH PL, 1979, AM STAT, V33, P57, DOI 10.2307/2683222; TAGER IB, 1985, AM REV RESPIR DIS, V131, P752; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; WALTER S, 1979, AM REV RESPIR DIS, V119, P717; WANG XB, 1993, PEDIATR PULM, V15, P75, DOI 10.1002/ppul.1950150204; WANG XB, 1993, AM REV RESPIR DIS, V148, P1502, DOI 10.1164/ajrccm/148.6_Pt_1.1502; WANG XB, 1994, AM J RESP CRIT CARE, V149, P1420, DOI 10.1164/ajrccm.149.6.8004293; WARE JH, 1984, AM REV RESPIR DIS, V129, P366; WEGMAN EJ, 1983, J AM STAT ASSOC, V78, P351, DOI 10.2307/2288640; WRIGHT JL, 1992, AM REV RESPIR DIS, V146, P240, DOI 10.1164/ajrccm/146.1.240; WYPIJ D, 1993, STAT SINICA, V3, P329; XU XP, 1992, AM REV RESPIR DIS, V146, P1345, DOI 10.1164/ajrccm/146.5_Pt_1.1345; ZAMEL N, 1983, J ASTHMA, V20, P307, DOI 10.3109/02770908309077089	29	321	332	0	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1996	335	13					931	937		10.1056/NEJM199609263351304	http://dx.doi.org/10.1056/NEJM199609263351304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK148	8782500	Bronze			2022-12-28	WOS:A1996VK14800004
J	Dey, P; Collins, S; Desai, M; Woodman, C				Dey, P; Collins, S; Desai, M; Woodman, C			Adequacy of cervical cytology sampling with the Cervex brush and the Aylesbury spatula: A population based randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare the adequacy of cervical cytology sampling with two sampling instruments commonly used in primary care-namely, the Aylesbury spatula and the Cervex brush. Design-Pair matched, population based randomised controlled trial. Setting-86 general practices and family planning clinics in Greater Manchester. Subjects-15 882 cervical smears taken from women aged 20-64 years as part of the national instruments, cervical screening programme. Interventions-Participating centres were allocated to sample with either the Cervex brush or the Aylesbury spatula. Main outcome measure-Inadequate smear rate. Results-5.4% and 5.5% (433/8086 and 426/7796) of smears taken with the Cervex brush and the Aylesbury spatula respectively were reported as inadequate (odds ratio 0.95; 95% confidence interval 0.74 to 1.22). Conclusion-The Cervex brush offers no advantage over the Aylesbury spatula in reducing inadequate smear rates in the primary care setting.	CHRISTIE HOSP NATL HLTH SERV TRUST,DEPT CYTOPATHOL,MANCHESTER M20 4QL,LANCS,ENGLAND; UNIV MANCHESTER,CTR CANC EPIDEMIOL,MANCHESTER M20 4QL,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; University of Manchester								BOON ME, 1989, ACTA CYTOL, V33, P843; DONNER A, 1993, J CLIN EPIDEMIOL, V46, P123, DOI 10.1016/0895-4356(93)90050-B; DONNER A, 1987, AM J EPIDEMIOL, V126, P972, DOI 10.1093/oxfordjournals.aje.a114735; HAVELOCK C, 1994, COST CERVICAL SCREEN; KIVALAHAN C, 1985, ACTA CYTOL, V30, P258; SZAREWSKI A, 1990, GENITOURIN MED, V66, P439; SZAREWSKI A, 1993, ACTA CYTOL, V37, P457; WOODMAN CBJ, 1989, LANCET, V2, P88; WOODMAN CBJ, 1993, J PUBLIC HEALTH MED, V15, P327, DOI 10.1093/oxfordjournals.pubmed.a042884; 1991, BR J GEN PRACT, V41, P192; 1990, CYTOPATHOLOGY, V1, P129	11	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					721	723						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819441				2022-12-28	WOS:A1996VJ44100022
J	Dale, N; Gilday, D				Dale, N; Gilday, D			Regulation of rhythmic movements by purinergic neurotransmitters in frog embryos	NATURE			English	Article							SWIMMING MOTOR PATTERN; XENOPUS-EMBRYOS; SPINAL-CORD; RESPONSES; STIMULATION; GENERATION; INVITRO	MANY rhythmic motor behaviours, including swimming(1), walking(2) scratching(3), swallowing(4), micturition(5) and sexual climax(6), are episodic: even in the absence of sensory inputs they exhibit a gradual run-down in frequency before spontaneously terminating. We have investigated whether the purinergic transmitters, ATP and adenosine, control run-down of swimming in the Xenopus embryo(7). By using specific agonists and antagonists for the purinergic receptors, we have shown that ATP (or a related substance) is released during swimming and activates P2y receptors to reduce voltage-gated K+ currents and cause an increase in the excitability of the spinal motor circuits. Adenosine is also produced during motor activity, possibly through the actions of ectonucleotidases. The activation by adenosine of P1 receptors reduces the voltage-gated Ca2+ currents, lowers excitability of the motor circuits, and so opposes the actions of ATP. A gradually changing balance between ATP and adenosine therefore seems to underlie the run-down of the motor pattern for swimming in Xenopus. We believe this to be the first time that ATP and adenosine have been found to be involved in motor pattern these two may offer a general feedback mechanism that underlies run down of all episodic motor patterns in vertebrates.	UNIV BRISTOL, SCH BIOL SCI, BRISTOL BS8 1UG, AVON, ENGLAND	University of Bristol	Dale, N (corresponding author), UNIV ST ANDREWS, SCH BIOL & MED SCI, BUTE MED BLDG, ST ANDREWS KY16 9RU, FIFE, SCOTLAND.		Dale, Nicholas/C-7772-2011	Dale, Nicholas/0000-0003-2196-2949				Dale N, 1995, J PHYSIOL-LONDON, V489, P489, DOI 10.1113/jphysiol.1995.sp021067; DALE N, 1991, EUR J NEUROSCI, V3, P1025, DOI 10.1111/j.1460-9568.1991.tb00039.x; Dale N, 1995, J PHYSIOL-LONDON, V489, P473, DOI 10.1113/jphysiol.1995.sp021066; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GORDON EL, 1986, J BIOL CHEM, V261, P5496; HOYLE CHV, 1990, BRIT J PHARMACOL, V99, P617, DOI 10.1111/j.1476-5381.1990.tb12979.x; IWAHARA T, 1991, SOMATOSENS MOT RES, V8, P281, DOI 10.3109/08990229109144751; JEAN A, 1984, J AUTONOM NERV SYST, V10, P225, DOI 10.1016/0165-1838(84)90017-1; KAHN JA, 1982, J EXP BIOL, V99, P185; LAMBRECHT G, 1992, EUR J PHARMACOL, V217, P217, DOI 10.1016/0014-2999(92)90877-7; MCCLELLAN AD, 1983, BRAIN RES, V269, P237, DOI 10.1016/0006-8993(83)90133-6; MCKENNA KE, 1991, AM J PHYSIOL, V261, pR1276, DOI 10.1152/ajpregu.1991.261.5.R1276; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; ROBERTSON GA, 1985, J NEUROPHYSIOL, V53, P1517, DOI 10.1152/jn.1985.53.6.1517; SHEFCHYK SJ, 1989, NEUROSCI LETT, V99, P175, DOI 10.1016/0304-3940(89)90285-1; WALL MJ, 1994, J NEUROPHYSIOL, V72, P337, DOI 10.1152/jn.1994.72.1.337; WALL MJ, 1995, J PHYSIOL-LONDON, V487, P557, DOI 10.1113/jphysiol.1995.sp020900	17	107	108	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 19	1996	383	6597					259	263		10.1038/383259a0	http://dx.doi.org/10.1038/383259a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805702				2022-12-28	WOS:A1996VH31500054
J	Leach, CL; Greenspan, JS; Rubenstein, SD; Shaffer, TH; Wolfson, MR; Jackson, JC; DeLemos, R; Fuhrman, BP				Leach, CL; Greenspan, JS; Rubenstein, SD; Shaffer, TH; Wolfson, MR; Jackson, JC; DeLemos, R; Fuhrman, BP			Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGENITAL DIAPHRAGMATIC-HERNIA; GAS-EXCHANGE; EXOGENOUS SURFACTANT; LAMBS; LUNG; OXYGENATION; THERAPY; BIRTH	Background The intratracheal administration of a perfluorocarbon liquid during continuous positive-pressure ventilation (partial liquid ventilation) improves lung function in animals with surfactant deficiency. Whether partial liquid ventilation is effective in the treatment of infants with severe respiratory distress syndrome is not known. Methods We studied the efficacy of partial liquid ventilation with perflubron in 13 premature infants with severe respiratory distress syndrome in whom conventional treatment, including surfactant therapy, had failed. Partial liquid ventilation was initiated by instilling perflubron during conventional mechanical ventilation to a volume approximating the functional residual capacity. Infants were considered to have completed the study if they received partial liquid ventilation for at least 24 hours. Results Ten infants received partial liquid ventilation for 24 to 76 hours. In the other th ree infants, partial liquid ventilation was discontinued within four hours in favor of high-frequency ventilation, which was not permitted by the protocol, and the data from these infants were excluded from the analysis. Within one hour after the instillation of perflubron, the arterial oxygen tension increased by 138 percent and the dynamic compliance increased by 61 percent; the mean (+/-SD) oxygenation index was reduced from 49+/-60 to 17+/-16. Chest radiographs showed symmetric filling, with patchy clearing during the return from partial liquid to gas ventilation. There were no adverse events clearly attributable to partial liquid ventilation, Infants were weaned from partial liquid to gas ventilation without complications. Eight infants survived to 36 weeks' corrected gestational age. Conclusions Partial liquid ventilation leads to clinical improvement and survival in some infants with severe respiratory distress syndrome who are not predicted to survive. (C) 1996, Massachusetts Medical Society.	SUNY BUFFALO,DEPT PEDIAT,BUFFALO,NY; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PEDIAT,PHILADELPHIA,PA 19107; TEMPLE UNIV,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19122; TEMPLE UNIV,SCH MED,DEPT PHYSIOL,PHILADELPHIA,PA 19122; ST CHRISTOPHERS HOSP CHILDREN,PHILADELPHIA,PA 19133; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; CHILDRENS HOSP & MED CTR,SEATTLE,WA 98105; UNIV SO CALIF,MED CTR,DEPT PEDIAT,LOS ANGELES,CA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California	Leach, CL (corresponding author), CHILDRENS HOSP BUFFALO,DIV NEONATOL,219 BRYANT ST,BUFFALO,NY 14222, USA.							AVERY ME, 1991, NEW ENGL J MED, V324, P910, DOI 10.1056/NEJM199103283241308; CHARON A, 1989, PEDIATRICS, V83, P348; CLARK LC, 1966, SCIENCE, V152, P1755, DOI 10.1126/science.152.3730.1755; CURTIS SE, 1993, J APPL PHYSIOL, V75, P2696, DOI 10.1152/jappl.1993.75.6.2696; DELEMOS R, 1994, PEDIATR RES, V35, pA330; FUHRMAN BP, 1991, CRIT CARE MED, V19, P712, DOI 10.1097/00003246-199105000-00019; GREENSPAN JS, 1990, J PEDIATR-US, V117, P106, DOI 10.1016/S0022-3476(05)82457-6; Haycock KH, 1992, STATVIEW; IKEGAMI M, 1984, J APPL PHYSIOL, V57, P1134, DOI 10.1152/jappl.1984.57.4.1134; IKEGAMI M, 1987, AM REV RESPIR DIS, V136, P892, DOI 10.1164/ajrccm/136.4.892; JOBE A, 1984, J CLIN INVEST, V73, P848, DOI 10.1172/JCI111280; KENDIG JW, 1991, NEW ENGL J MED, V324, P865, DOI 10.1056/NEJM199103283241301; KOBAYASHI T, 1991, PEDIATR RES, V29, P353, DOI 10.1203/00006450-199104000-00005; KYLSTRA JA, 1972, J APPL PHYSIOL, V33, P32, DOI 10.1152/jappl.1972.33.1.32; LEACH CL, 1995, J PEDIATR-US, V126, P412, DOI 10.1016/S0022-3476(95)70461-2; LEACH CL, 1993, CRIT CARE MED, V21, P1270, DOI 10.1097/00003246-199309000-00008; LEACH CL, 1995, PEDIATR RES, V37, pA220; LEACH CL, 1994, PEDIATR RES, V35, pA394; LOWE CA, 1986, J APPL PHYSIOL, V60, P154, DOI 10.1152/jappl.1986.60.1.154; MAJOR D, 1995, J PEDIATR SURG, V30, P1178, DOI 10.1016/0022-3468(95)90016-0; Papo MC, 1996, CRIT CARE MED, V24, P466, DOI 10.1097/00003246-199603000-00017; SALMAN NH, 1995, CRIT CARE MED, V23, P919, DOI 10.1097/00003246-199505000-00021; SEGERER H, 1991, PEDIATR RES, V30, P591, DOI 10.1203/00006450-199112000-00022; SHAFFER TH, 1976, PEDIATR RES, V10, P227, DOI 10.1203/00006450-197604000-00005; SHAFFER TH, 1995, FASEB J, V9, pA17; Steinhorn DM, 1996, CRIT CARE MED, V24, P1252, DOI 10.1097/00003246-199607000-00031; Volpe JJ, 1995, NEUROLOGY NEWBORN, P403; WILCOX DT, 1995, CRIT CARE MED, V23, P1858, DOI 10.1097/00003246-199511000-00012; WOLFSON MR, 1995, PEDIATR RES, V37, pA246	29	327	334	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	1996	335	11					761	767		10.1056/NEJM199609123351101	http://dx.doi.org/10.1056/NEJM199609123351101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF786	8778584				2022-12-28	WOS:A1996VF78600001
J	Knight, SC; Patterson, S				Knight, SC; Patterson, S			AIDS - Beyond helper T cells	LANCET			English	Editorial Material							RESPONSES				Knight, SC (corresponding author), NORTHWICK PK INST MED RES,UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,HARROW HA1 3UJ,MIDDX,ENGLAND.							HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Knight SC, 1996, AIDS, V10, P807, DOI 10.1097/00002030-199607000-00003; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; ROWLANDJONES SL, 1995, CURR OPIN IMMUNOL, V7, P448, DOI 10.1016/0952-7915(95)80087-5; SotoRamirez LE, 1996, SCIENCE, V271, P1291, DOI 10.1126/science.271.5253.1291; ZINKERNAGEL RM, 1995, CURR OPIN IMMUNOL, V7, P462, DOI 10.1016/0952-7915(95)80089-1	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					631	631		10.1016/S0140-6736(05)65070-2	http://dx.doi.org/10.1016/S0140-6736(05)65070-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782750				2022-12-28	WOS:A1996VF60900005
J	Conley, KE; Lindstedt, SL				Conley, KE; Lindstedt, SL			Minimal cost per twitch in rattlesnake tail muscle	NATURE			English	Article							INSECT MUSCLE; P-31 NMR; FLIGHT; ENERGETICS; MORPHOLOGY; EFFICIENCY; FREQUENCY; CAPACITY; OXYGEN; POWER	SOUND production is one of the most energetically costly activities in animals(1), Minimizing contraction costs is one means of achieving the high activation rates necessary for sound production (20-550 Hz) (refs 1-3) without exceeding energy supplies. Rattlesnakes produce a sustained, high-frequency warning sound by extremely rapid contraction of their tailshaker muscles (20-90 Hz) (refs 4, 5), The ATP cost per twitch is only 0.015 pmol ATP per g muscle per twitch during rattling, as measured by in vivo magnetic resonance. The reduced volume density of myofibre (32%) in tailshaker muscle is consistent with contraction cost being minimized (crossbridge cycling), in contrast to the con tractile costs of vertebrate locomotory and asynchronous insect flight muscle, Thus tailshaker muscle is an example of sound-producing muscle designed for 'high frequency, minimal cost'. The high rates of rattling are achieved by minimizing contractile use of ATP, which reduces the cost per twitch to among the lowest found for striated muscle.	UNIV WASHINGTON,MED CTR,CTR BIOENGN,SEATTLE,WA 98195; NO ARIZONA UNIV,DEPT BIOL SCI,PHYSIOL & FUNCT MORPHOL GRP,FLAGSTAFF,AZ 86011	University of Washington; University of Washington Seattle; Northern Arizona University	Conley, KE (corresponding author), UNIV WASHINGTON,MED CTR,DEPT RADIOL,BOX 357115,SEATTLE,WA 98195, USA.							ADAMS GR, 1990, J APPL PHYSIOL, V69, P968, DOI 10.1152/jappl.1990.69.3.968; BARTHOLOMEW GA, 1978, J EXP BIOL, V76, P11; BLEI ML, 1993, J PHYSIOL-LONDON, V465, P203, DOI 10.1113/jphysiol.1993.sp019673; Casey T. M., 1989, ENERGY TRANSFORMATIO, P200; CASEY TM, 1985, J EXP BIOL, V116, P271; CHADWICK LE, 1954, SCIENCE, V119, P442, DOI 10.1126/science.119.3092.442; DICKINSON MH, 1995, SCIENCE, V268, P87, DOI 10.1126/science.7701346; ELLINGTON CP, 1991, J EXP BIOL, V160, P71; FOLEY JM, 1993, NMR BIOMED, V6, P32, DOI 10.1002/nbm.1940060106; GILMOUR KM, 1993, J EXP BIOL, V183, P101; HEINEMAN FW, 1990, J CLIN INVEST, V85, P843, DOI 10.1172/JCI114511; HOPPELER H, 1987, RESP PHYSIOL, V69, P27, DOI 10.1016/0034-5687(87)90099-5; JOSEPHSON RK, 1985, J EXP BIOL, V117, P357; JOSEPHSON RK, 1981, J EXP BIOL, V91, P219; JOSEPHSON RK, 1985, J EXP BIOL, V118, P185; JOSEPHSON RK, 1991, J PHYSIOL-LONDON, V442, P413, DOI 10.1113/jphysiol.1991.sp018800; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; KUSMERICK MJ, 1976, J PHYSIOL-LONDON, V254, P711; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; PRESTWICH KN, 1994, AM ZOOL, V34, P625, DOI 10.1093/icb/34.6.625; Rall J A, 1985, Exerc Sport Sci Rev, V13, P33; Schaeffer PJ, 1996, J EXP BIOL, V199, P351; SCHULTZ E, 1980, TISSUE CELL, V12, P323, DOI 10.1016/0040-8166(80)90008-7; SCHWERZMANN K, 1989, P NATL ACAD SCI USA, V86, P1583, DOI 10.1073/pnas.86.5.1583; STEVENS ED, 1977, PHYSIOL ZOOL, V50, P31, DOI 10.1086/physzool.50.1.30155713; STOKES DR, 1975, J EXP ZOOL, V194, P379, DOI 10.1002/jez.1401940205; TEAGUE WE, 1992, J BIOL CHEM, V267, P14084; TREGEAR R, 1993, HDB PHYSL SKELETAL M, P487	28	29	29	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					71	72		10.1038/383071a0	http://dx.doi.org/10.1038/383071a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779716				2022-12-28	WOS:A1996VF29500048
J	Hourihane, JO; Dean, TP; Warner, JO				Hourihane, JO; Dean, TP; Warner, JO			Peanut allergy in relation to heredity, maternal diet, and other atopic diseases: Results of a questionnaire survey, skin prick testing, and food challenges	BRITISH MEDICAL JOURNAL			English	Article							PREDICTION; AVOIDANCE; INCREASE; CHILDREN; ASTHMA	Objectives-To determine rates of other atopic manifestations in people with peanut allergy and the prevalence of such allergy in their families. Design-A survey of people with self reported peanut allergy and people referred by their general practitioner for suspected peanut allergy; survey and skin testing of 50 children with reported peanut allergy and their available first degree relatives. Subjects-622 adults and children with reported,suspected, or known peanut allergy. Main outcome measures-Prevalence of peanut allergy and other allergies in the families of people with peanut allergy. Results-622 valid completed questionnaires were returned out of the 833 questionnaires dispatched (74.7%). All forms of atopy were both more common in successive generations (P<0.0001) and more common in maternal than paternal relatives (P<0.0001). Peanut allergy was reported by 0.1% (3/2409) of grandparents, 0.6% (7/1213) of aunts and uncles, 1.6% (19/1218) of parents, and 6.9% (42/610) of siblings. Consumption of peanuts while pregnant or breast feeding was more common among mothers of probands aged less than or equal to 5 years than mothers of probands aged >5 years (P<0.001). Age of onset correlated inversely with year of birth (r = -0.6, P<0.001). Skin prick testing of 50 children with reported peanut allergy and their families: 7 probands (14%) had a negative result for peanut. Peanut allergy was refuted by food challenge in all those tested (5/7). No parent and 13% (5/39) of siblings had a positive result on skin prick testing for peanut. Two of these siblings had negative challenge with peanuts. The prevalence of peanut allergy in siblings is therefore 3/39 (7%). Conclusions-Peanut allergy is more common in siblings of people with peanut allergy than in the parents or the general population. Its apparently increasing prevalence may reflect a general increase of atopy, which is inherited more commonly from the mother. Peanut allergy is presenting earlier in life, possibly reflecting increased consumption of peanut by pregnant and nursing mothers.			Hourihane, JO (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.		Warner, John/AAF-9587-2020	Dean, Taraneh/0000-0002-0123-7646				ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P433, DOI 10.1016/0091-6749(87)90359-9; BERGMANN KE, 1990, CLIN EXP ALLERGY, V20, P21, DOI 10.1111/j.1365-2222.1990.tb02466.x; Bicknell C. M., 1996, Journal of Allergy and Clinical Immunology, V97, P239, DOI 10.1016/S0091-6749(96)80444-1; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; HOWELL WM, 1995, THORAX, V50, P815, DOI 10.1136/thx.50.8.815; KEATING MU, 1990, J ALLERGY CLIN IMMUN, V86, P41, DOI 10.1016/S0091-6749(05)80121-6; MARSH DG, 1995, INT ARCH ALLERGY IMM, V107, P25, DOI 10.1159/000236920; Moneret-Vautrin D A, 1994, Pediatr Allergy Immunol, V5, P184, DOI 10.1111/j.1399-3038.1994.tb00236.x; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P23; YOUNG E, 1994, LANCET, V343, P1127, DOI 10.1016/S0140-6736(94)90234-8; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	19	248	253	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					518	521						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789975	Green Published			2022-12-28	WOS:A1996VF29400015
J	MartinDuPan, RC; Weintraub, J; Meyer, P; Colby, T				MartinDuPan, RC; Weintraub, J; Meyer, P; Colby, T			A distressed woman with epigastric pain	LANCET			English	Article									UNIV GENEVA,CONTONAL HOSP,CH-1206 GENEVA,SWITZERLAND; LAB WEINTRAUB,CH-1206 GENEVA,SWITZERLAND; MAYO CLIN SCOTTSDALE,DEPT PATHOL,SCOTTSDALE,AZ	University of Geneva; Mayo Clinic; Mayo Clinic Phoenix								ANDREOLA S, 1990, CANCER, V65, P1211, DOI 10.1002/1097-0142(19900301)65:5<1211::AID-CNCR2820650530>3.0.CO;2-M; ARTOPOULOS JG, 1994, HEPATO-GASTROENTEROL, V41, P442; HOLTMANN G, 1992, SCAND J GASTROENTERO, V27, P917, DOI 10.3109/00365529209000163; YASOSHIMA H, 1993, ACTA PATHOL JAPON, V43, P783	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					586	586		10.1016/S0140-6736(96)05012-X	http://dx.doi.org/10.1016/S0140-6736(96)05012-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774573				2022-12-28	WOS:A1996VF18600014
J	Cassel, CK; Vladeck, BC				Cassel, CK; Vladeck, BC			ICD-9 code for palliative or terminal care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									US HLTH CARE FINANCING ADM,WASHINGTON,DC 20201		Cassel, CK (corresponding author), MT SINAI MED CTR,NEW YORK,NY 10029, USA.							Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; *NAT CTR HLTH STAT, 1991, VIT STAT US, V2; 1996, FED REGISTER, V61, P27451; 1996, FED REGISTER, V61, P27542; 1995, JAMA-J AM MED ASSOC, V274, P1591	5	58	58	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1232	1234		10.1056/NEJM199610173351612	http://dx.doi.org/10.1056/NEJM199610173351612			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN401	8815949				2022-12-28	WOS:A1996VN40100012
J	Levy, MH				Levy, MH			Drug therapy: Pharmacologic treatment of cancer pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONTROLLED-RELEASE; IMMEDIATE-RELEASE; TERMINAL CANCER; INTRAVENOUS PAMIDRONATE; NARCOTIC ANALGESICS; ADJUVANT ANALGESICS; DIABETIC NEUROPATHY; CLINICAL EFFICACY; PALLIATIVE CARE				Levy, MH (corresponding author), FOX CHASE CANC CTR, 7701 BURHOLME AVE, PHILADELPHIA, PA 19111 USA.							*AC PAIN MAN GUID, 1992, AHCPR PUBLICATION; *AM CANC SOC, 1995, CANC FACTS FIG 1995; *AM PAIN SOC, 1992, PRINC AN US TREATM A; ARBIT E, 1993, MANAGEMENT CANC RELA; AU E, 1994, J CLIN ONCOL, V12, P2751, DOI 10.1200/JCO.1994.12.12.2751; BEDDER MD, 1991, J PAIN SYMPTOM MANAG, V6, P368, DOI 10.1016/0885-3924(91)90028-3; Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802; Bottomley D M, 1990, J Pain Symptom Manage, V5, P259, DOI 10.1016/0885-3924(90)90020-K; BRESCIA FJ, 1992, J CLIN ONCOL, V10, P149, DOI 10.1200/JCO.1992.10.1.149; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; BROOKS PM, 1991, NEW ENGL J MED, V325, P747; BRUERA E, 1989, PAIN, V39, P13, DOI 10.1016/0304-3959(89)90169-3; BRUERA E, 1994, J PAIN SYMPTOM MANAG, V9, P515, DOI 10.1016/0885-3924(94)90113-9; Bruera E, 1989, J Pain Symptom Manage, V4, P3, DOI 10.1016/0885-3924(89)90057-2; CHERNY NI, 1994, CA-CANCER J CLIN, V44, P262, DOI 10.3322/canjclin.44.5.263; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; CLEELAND CS, 1984, CANCER, V53, P2264; Coyle N, 1990, J Pain Symptom Manage, V5, P83; CRAMOND T, 1993, J PAIN SYMPTOM MANAG, V8, P465, DOI 10.1016/0885-3924(93)90189-3; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DECONNO F, 1995, J CLIN ONCOL, V13, P1004, DOI 10.1200/JCO.1995.13.4.1004; DEJGARD A, 1988, LANCET, V1, P9; DESMEULES J, 1991, EUR J CLIN PHARMACOL, V41, P23, DOI 10.1007/BF00280101; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; DOYLE D, 1993, OXFORD TXB PALIATIVE; DUPEN SL, 1992, J PAIN SYMPTOM MANAG, V7, P125, DOI 10.1016/0885-3924(92)90124-Z; EISELE JH, 1992, PAIN, V49, P231, DOI 10.1016/0304-3959(92)90146-3; EISENACH JC, 1995, PAIN, V61, P391, DOI 10.1016/0304-3959(94)00209-W; EISENBERG E, 1994, J CLIN ONCOL, V12, P2756, DOI 10.1200/JCO.1994.12.12.2756; FERRELL BR, 1995, J CLIN ONCOL, V13, P2158, DOI 10.1200/JCO.1995.13.9.2158; FERRELL BR, 1994, J PAIN SYMPTOM MANAG, V9, P221, DOI 10.1016/0885-3924(94)90099-X; FERRERBRECHNER T, 1985, SEMIN ANESTHES, V4, P313; FINE PG, 1991, PAIN, V45, P149, DOI 10.1016/0304-3959(91)90181-V; FINN JW, 1993, J CLIN ONCOL, V11, P967, DOI 10.1200/JCO.1993.11.5.967; FISHMAN B, 1987, CANCER-AM CANCER SOC, V60, P1151, DOI 10.1002/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G; FOLEY KM, 1993, SYMP PAIN R, P331; FROMM GH, 1994, J PAIN SYMPTOM MANAG, V9, P500, DOI 10.1016/0885-3924(94)90111-2; GALER BS, 1992, PAIN, V49, P87, DOI 10.1016/0304-3959(92)90192-E; GLARE PA, 1993, J CLIN ONCOL, V11, P973, DOI 10.1200/JCO.1993.11.5.973; GLOVER D, 1994, CANCER, V74, P2949, DOI 10.1002/1097-0142(19941201)74:11<2949::AID-CNCR2820741110>3.0.CO;2-Q; GREENE WR, 1991, SOUTHERN MED J, V84, P332, DOI 10.1097/00007611-199103000-00009; GROND S, 1994, J PAIN SYMPTOM MANAG, V9, P372, DOI 10.1016/0885-3924(94)90174-0; HANKS GW, 1989, CANCER, V63, P2378, DOI 10.1002/1097-0142(19890601)63:11<2378::AID-CNCR2820631150>3.0.CO;2-8; HANKS GW, 1995, J PAIN SYMPTOM MANAG, V10, P87, DOI 10.1016/S0885-3924(08)80004-8; HAYS H, 1994, CANCER-AM CANCER SOC, V74, P1808, DOI 10.1002/1097-0142(19940915)74:6<1808::AID-CNCR2820740625>3.0.CO;2-Y; HOLLANDER D, 1994, AM J MED, V96, P274, DOI 10.1016/0002-9343(94)90153-8; Jacox A, 1994, AHCPR PUBLICATION; JAEGER H, 1992, PAIN, V48, P21, DOI 10.1016/0304-3959(92)90127-W; Jaffe JH, 1989, ADV PAIN RES THER, V11, P163; Johnson J. R., 1994, Palliative Medicine, V8, P129, DOI 10.1177/026921639400800206; Kaiko R., 1996, Clinical Pharmacology and Therapeutics, V59, P130, DOI 10.1038/sj.clpt.1996.19; KAIKO RF, 1989, CANCER, V63, P2348, DOI 10.1002/1097-0142(19890601)63:11<2348::AID-CNCR2820631146>3.0.CO;2-V; KALSO E, 1990, CLIN PHARMACOL THER, V47, P639, DOI 10.1038/clpt.1990.85; KERR IG, 1988, ANN INTERN MED, V108, P554, DOI 10.7326/0003-4819-108-4-554; LEVY M H, 1991, Cancer Bulletin (Houston), V43, P412; LEVY MH, 1989, CANCER, V63, P2328, DOI 10.1002/1097-0142(19890601)63:11<2328::AID-CNCR2820631143>3.0.CO;2-5; LEVY MH, 1994, SEMIN ONCOL, V21, P718; MACDONALD N, 1993, PAIN, V53, P353, DOI 10.1016/0304-3959(93)90232-E; MAX MB, 1995, JAMA-J AM MED ASSOC, V274, P1874, DOI 10.1001/jama.1995.03530230060032; MAX MB, 1992, NEW ENGL J MED, V326, P1250, DOI 10.1056/NEJM199205073261904; MCQUAY HJ, 1988, CANCER SURV, V7, P141; MELLICK GA, 1995, J PAIN SYMPTOM MANAG, V10, P265, DOI 10.1016/0885-3924(95)00001-F; MERCADANTE S, 1994, J PAIN SYMPTOM MANAG, V9, P406, DOI 10.1016/0885-3924(94)90178-3; Moyle J, 1995, J PAIN SYMPTOM MANAG, V10, P643, DOI 10.1016/0885-3924(95)00125-5; PATT RB, 1993, CANC PAIN; PAYNE R, 1987, MED CLIN N AM, V71, P313, DOI 10.1016/S0025-7125(16)30873-2; PAYNE R, 1992, J PAIN SYMPTOM MANAG, V7, pS40, DOI 10.1016/0885-3924(92)90052-J; PETER C, 1994, J PAIN SYMPTOM MANAG, V9, P392, DOI 10.1016/0885-3924(94)90177-5; Portenoy R K, 1990, J Pain Symptom Manage, V5, pS46; PORTENOY RK, 1992, CANCER-AM CANCER SOC, V70, P1616, DOI 10.1002/1097-0142(19920915)70:6<1616::AID-CNCR2820700630>3.0.CO;2-7; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; POTTER WZ, 1991, NEW ENGL J MED, V325, P633; PUROHIT OP, 1994, BRIT J CANCER, V70, P554, DOI 10.1038/bjc.1994.344; QUILTY PM, 1994, RADIOTHER ONCOL, V31, P33, DOI 10.1016/0167-8140(94)90411-1; REDDY S, 1994, J PAIN SYMPTOM MANAG, V9, P510, DOI 10.1016/0885-3924(94)90112-0; Report of a WHO Expert Committee, 1990, WHO TECH REP SER, V804, P1; ROBINSON RG, 1995, JAMA-J AM MED ASSOC, V274, P420, DOI 10.1001/jama.274.5.420; ROSEN SM, 1994, SEMIN ONCOL, V21, P740; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; SAWYNOK J, 1993, PHARMACOL REV, V45, P43; Schug S A, 1990, J Pain Symptom Manage, V5, P27, DOI 10.1016/S0885-3924(05)80006-5; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; SINDRUP SH, 1992, EUR J CLIN PHARMACOL, V42, P587; STROM BL, 1994, JAMA-J AM MED ASSOC, V272, P1866, DOI 10.1001/jama.272.23.1866; STUART JJ, 1981, PHARMATHERAPEUTICA, V2, P547; STUART MJ, 1972, NEW ENGL J MED, V287, P1105, DOI 10.1056/NEJM197211302872201; STUBHAUG A, 1995, PAIN, V62, P111, DOI 10.1016/0304-3959(95)00056-X; SUNSHINE A, 1994, DRUGS, V47, P8, DOI 10.2165/00003495-199400471-00004; SUNSHINE A, 1995, CLIN PHARMACOL THER, V57, P137; SZANTO J, 1992, ONCOLOGY, V49, P180; TANELIAN DL, 1995, PAIN FORUM, V4, P75; THIRLWELL MP, 1989, CANCER, V63, P2275, DOI 10.1002/1097-0142(19890601)63:11<2275::AID-CNCR2820631136>3.0.CO;2-4; Twycross RG, 1994, PAIN RELIEF ADV CANC; VAINIO A, 1995, LANCET, V346, P667, DOI 10.1016/S0140-6736(95)92281-4; VALENTINI M, 1995, J CLIN ONCOL, V13, P2637, DOI 10.1200/JCO.1995.13.10.2637; VENTAFRIDDA V, 1990, ADV PAIN RES THER, V16, P451; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WARD SE, 1993, PAIN, V52, P319, DOI 10.1016/0304-3959(93)90165-L; WATANABE S, 1994, J PAIN SYMPTOM MANAG, V9, P442, DOI 10.1016/0885-3924(94)90200-3; WHITCOMB DC, 1994, JAMA-J AM MED ASSOC, V272, P1845, DOI 10.1001/jama.272.23.1845; WILDERSMITH CH, 1994, ANN ONCOL, V5, P141, DOI 10.1093/oxfordjournals.annonc.a058765; ZHUKOVSKY DS, 1995, J PAIN SYMPTOM MANAG, V10, P113, DOI 10.1016/0885-3924(94)00072-S	102	336	348	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1996	335	15					1124	1132		10.1056/NEJM199610103351507	http://dx.doi.org/10.1056/NEJM199610103351507			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN399	8813044				2022-12-28	WOS:A1996VN39900007
J	Robertson, SE; Hull, BP; Tomori, O; Bele, O; LeDuc, JW; Esteves, K				Robertson, SE; Hull, BP; Tomori, O; Bele, O; LeDuc, JW; Esteves, K			Yellow fever - A decade of reemergence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COST-EFFECTIVENESS; VACCINATION; IMMUNIZATION; PREGNANCY; NIGERIA; GAMBIA	Since the 1980s, yellow fever has reemerged across Africa and in South America. The total of 18 735 yellow fever cases and 4522 deaths reported from 1987 to 1991 represents the greatest amount of yellow fever activity reported to the World Health Organization (WHO) for any 5-year period since 1948. There is an excellent vaccine against yellow fever, At present, a high proportion of travelers to at-risk areas are reported to be immunized, reflecting widespread knowledge about the International Health Regulations. In South America, yellow fever remains an occupational hazard for forest workers, who should be immunized. However, Aedes aegypti mosquitoes are now present in urban areas in the Americas (including southern parts of the United States), and there is concern that yellow fever could erupt in explosive outbreaks, In Africa, a large proportion of cases have occurred in children, The WHO, the United Nations Children's Fund (UNICEF), and the World Bank have recommended that 33 African countries at risk for yellow fever add the vaccine to the routine Expanded Programme on Immunization; studies show that this would be highly cost-effective, To date, financing yellow fever vaccine has been a major problem for these countries, which are among the poorest in the world. For this reason, WHO has launched an appeal to raise $70 million for yellow fever control in Africa.	WHO REG OFF AFRICA, EXPANDED PROGRAMME IMMUNIZAT, BRAZZAVILLE, REP CONGO; WHO, DIV EMERGING & OTHER COMMUNICABLE DIS SURVEILLANC, CH-1211 GENEVA 27, SWITZERLAND	World Health Organization; World Health Organization	Robertson, SE (corresponding author), WHO, GLOBAL PROGRAMME VACCINES & IMMUNIZAT, CH-1211 GENEVA 27, SWITZERLAND.		TOMORI, OYEWALE/X-3021-2019; TOMORI, OYEWALE/GWQ-4419-2022	TOMORI, OYEWALE/0000-0002-6959-5749				ADDY PAK, 1986, E AFR MED J      JUN, P422; AMBROSCH F, 1994, VACCINE, V12, P625, DOI 10.1016/0264-410X(94)90267-4; [Anonymous], 1995, Bull Pan Am Health Organ, V29, P184; [Anonymous], 1996, WKLY EPIDEMIOL REC, V71, P181; BRES PLJ, 1986, B WORLD HEALTH ORGAN, V64, P775; CHAMBON L, 1967, B WORLD HEALTH ORGAN, V36, P113; *CTR DIS CONTR PRE, 1995, HLTH HUM SERV PUBL; *DEP EC SOC INF PO, 1994, WORLD POP PROSP 1994; *DEP HLTH WELSH OF, 1995, HLTH INF OV TRAV; *DIV EP SURV HLTH, 1992, WHOHST921 DIV EP SUR; *EXP PROGR IMM, 1996, WHOEPICEIS9607; *EXP PROGR IMM AFR, 1994, FIELD GUID DISTR LEV; *EXP PROGR IMM PRO, 1993, PROD INF SHEETS 1993; FISCH A, 1994, P 4 INT SEM IMM AFR, P205; GATEFF C, 1973, ANN INST PASTEUR MIC, VB124, P387; GOUJON C, 1995, J TRAVEL MED, V2, P145; GROOT H, 1962, B WORLD HEALTH ORGAN, V27, P699; Lederberg J., 1992, I MED US COMMITTEE; LeDuc JW, 1996, JAMA-J AM MED ASSOC, V275, P318, DOI 10.1001/jama.275.4.318; MEEGAN J, 1991, WHOEPIGEN916; MONATH TP, 1993, AM J TROP MED HYG, V48, P274, DOI 10.4269/ajtmh.1993.48.274; MONATH TP, 1991, AM J TROP MED HYG, V45, P1; MONATH TP, 1980, AM J TROP MED HYG, V29, P912, DOI 10.4269/ajtmh.1980.29.912; MONATH TP, 1987, REV INFECT DIS, V9, P165; NASIDI A, 1993, T ROY SOC TROP MED H, V87, P337, DOI 10.1016/0035-9203(93)90156-K; NASIDI A, 1989, T ROY SOC TROP MED H, V83, P401, DOI 10.1016/0035-9203(89)90518-X; OKELLO GBA, 1993, LANCET, V341, P489, DOI 10.1016/0140-6736(93)90237-B; POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895; RAWLINS SC, 1990, T ROY SOC TROP MED H, V84, P142, DOI 10.1016/0035-9203(90)90411-7; RECEVEUR MC, 1993, B SOC PATHOL EXOT, V86, P406; ROBERTSON RL, 1992, HEALTH POLICY PLANN, V7, P111, DOI 10.1093/heapol/7.2.111; ROBERTSON SE, 1993, WHOEPIGEN9318; RUBEN FL, 1973, B WORLD HEALTH ORGAN, V48, P175; SMITH HH, 1951, YELLOW FEVER, P543; TAGLIANTESARACI.J, 1994, P 4 INT SEM IMM AFR, P224; TIKASINGH ES, 1991, STUDIES NATURAL HIST; TOMORI O, 1994, P 4 INT SEM IMM AFR, P107; TSAI TF, 1993, J INFECT DIS, V168, P1520, DOI 10.1093/infdis/168.6.1520; VINCENS R, 1990, B WORLD HEALTH ORGAN, V71, P173; *WHO, 1996, INT TRAV HLTH VACC R; *WHO, 1991, YELL FEV VACC CTR IN; *WHO, 1996, YELL FEV VACC NEAR 1; *WORLD BANK, 1993, 1993 WORLD BANK; World Health Organization, 1986, PREV CONTR YELL FEV; YVONNET B, 1986, J MED VIROL, V19, P307, DOI 10.1002/jmv.1890190403; 1995, WKLY EPIDEMIOL REC, V70, P163; 1994, WKLY EPIDEMIOL REC, V69, P243; 1995, WKLY EPIDEMIOL REC, V70, P107; 1994, WKLY EPIDEMIOL REC, V69, P44; 1996, WKLY EPIDEMIOL REC, V71, P103; 1993, WKLY EPIDEMIOL REC, V68, P159; 1996, WKLY EPIDEMIOL REC, V71, P69; 1983, WKLY EPIDEMIOL REC, V58, P313; 1995, WKLY EPIDEMIOL REC, V70, P235; 1994, WKLY EPIDEMIOL REC, V69, P260; 1980, WKLY EPIDEMIOL REC, V55, P345; 1995, WKLY EPIDEMIOL REC, V70, P360; 1995, WKLY EPIDEMIOL REC, V70, P65; 1994, WKLY EPIDEMIOL REC, V69, P76; 1994, WKLY EPIDEMIOL REC, V69, P93; 1989, WKLY EPIDEMIOL REC, V64, P37; 1995, WKLY EPIDEMIOL REC, V70, P367; 1995, WKLY EPIDEMIOL REC, V70, P333; 1995, WKLY EPIDEMIOL REC, V70, P175	64	155	161	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1157	1162		10.1001/jama.276.14.1157	http://dx.doi.org/10.1001/jama.276.14.1157			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827969				2022-12-28	WOS:A1996VL33200026
J	Brand, PLP; Gerritsen, J; vanAalderen, WMC				Brand, PLP; Gerritsen, J; vanAalderen, WMC			A baby with eczema and an abnormal sweat test	LANCET			English	Article											Brand, PLP (corresponding author), BEATRIX CHILDRENS HOSP,DEPT PAEDIAT PULMONOL,POB 30001,NL-9700 RB GRONINGEN,NETHERLANDS.		Brand, Paul/ABB-3693-2021					GIBSON LE, 1959, PEDIATRICS, V23, P545; KIBEL MA, 1978, LANCET, V2, P1050; LITTLEWOOD JM, 1986, ARCH DIS CHILD, V61, P1041, DOI 10.1136/adc.61.11.1041; Orenstein DM, 1996, RUDOLPHS PEDIAT, P1640; VEEZE HJ, 1994, J CLIN INVEST, V93, P461, DOI 10.1172/JCI116993	5	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					932	932		10.1016/S0140-6736(96)06337-4	http://dx.doi.org/10.1016/S0140-6736(96)06337-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843814				2022-12-28	WOS:A1996VL09700014
J	Robinson, JC				Robinson, JC			Decline in hospital utilization and cost inflation under managed care in California	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPETITION; CONTAINMENT; CAPITATION; SERVICES; MARKET	Objective.-To measure the impact of health maintenance organizations (HMOs) on hospital capacity, utilization, and expenditures between 1983 and 1993. Design.-Multivariate regression analysis. Setting.-Private nonprofit and for-profit hospitals in California with 25 or more beds. Patients.-Patient discharge abstract data were used to measure growth of HMO penetration of local hospital markets. Interventions.-None. Main Outcome Measures.-Hospital closures, changes in bed capacity, changes in acute care admissions and length of stay, psychiatric inpatient days, subacute inpatient days, inpatient and outpatient surgical procedures, ambulatory patient visits, and hospital expenditures. Results.-Between 1983 and 1993 hospital expenditures grew 44% less rapidly in markets with high HMO penetration than in markets with low HMO penetration. Of this, 28% was due to reductions in the volume and mix of services, 6% was due to reductions in bed capacity, and 10% was due to changes in the intensity of services provided. Health maintenance organizations accelerated the substitution of outpatient for inpatient surgery, the shift from acute to subacute inpatient days, and the reduction of psychiatric hospitalization. Conclusion.-Managed care is shifting the acute care hospital from the center toward the periphery of the health care system.			Robinson, JC (corresponding author), UNIV CALIF BERKELEY, SCH PUBL HLTH, BERKELEY, CA 94720 USA.							*AM HOSP ASS, 1994, HOSP STAT AHA PROF A; BERGTHOLD L, 1984, J HEALTH POLIT POLIC, V9, P203, DOI 10.1215/03616878-9-2-203; Coulam R F, 1991, Health Care Financ Rev Annu Suppl, P45; DOW MM, 1994, MANAGED CARE DIGEST; *GOV COMM, 1993, GRAND ALL VERT INT S; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; Helbing C, 1992, Health Care Financ Rev Annu Suppl, P55; JOSKOW PL, 1980, BELL J ECON, V11, P421, DOI 10.2307/3003372; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; LUFT HS, 1986, INQUIRY-J HEALTH CAR, V23, P83; LUFT HS, 1978, NEW ENGL J MED, V298, P1336, DOI 10.1056/NEJM197806152982404; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MELNICK GA, 1988, JAMA-J AM MED ASSOC, V260, P2669, DOI 10.1001/jama.260.18.2669; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; Robinson JC, 1996, J LAW ECON, V39, P357, DOI 10.1086/467352; ROBINSON JC, 1987, NEW ENGL J MED, V317, P85, DOI 10.1056/NEJM198707093170205; ROBINSON JC, 1994, MILBANK Q, V72, P259, DOI 10.2307/3350296; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; ROBINSON JC, 1987, JAMA-J AM MED ASSOC, V257, P3241, DOI 10.1001/jama.257.23.3241; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; ROBINSON JC, 1991, JAMA-J AM MED ASSOC, V266, P2719, DOI 10.1001/jama.266.19.2719; ROBINSON JC, 1988, JAMA-J AM MED ASSOC, V260, P2676, DOI 10.1001/jama.260.18.2676; Rosenberg Charles E., 1987, CARE STRANGERS RISE; SCHWARTZ WB, 1991, NEW ENGL J MED, V324, P1037, DOI 10.1056/NEJM199104113241506; Starr P, 1982, SOCIAL TRANSFORMATIO; Stevens Rosemary, 1989, SICKNESS WEALTH AM H	26	104	104	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	1996	276	13					1060	1064		10.1001/jama.276.13.1060	http://dx.doi.org/10.1001/jama.276.13.1060			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VK035	8847768	Green Submitted			2022-12-28	WOS:A1996VK03500027
J	Cole, AP; Root, DE; Mukherjee, P; Solomon, EI; Stack, TDP				Cole, AP; Root, DE; Mukherjee, P; Solomon, EI; Stack, TDP			Trinuclear intermediate in the copper-mediated reduction of O-2: Four electrons from three coppers	SCIENCE			English	Article							MAGNETIC CIRCULAR-DICHROISM; ACTIVE-SITE; NATIVE LACCASE; ASCORBATE OXIDASE; DIOXYGEN; REACTIVITY; COMPLEXES; HEMOCYANIN; PROTEINS; PEROXIDE	The reaction of metal complexes with dioxygen (O-2) generally proceeds in 1:1, 2:1, or 4:1 (metal:O-2) stoichiometry. A discrete, structurally characterized 3:1 product is presented. This mixed-valence trinuclear copper cluster, which contains copper in the highly oxidized trivalent oxidation state, exhibits O-2 bond scission and intriguing structural, spectroscopic, and redox properties. The relevance of this synthetic complex to the reduction of O-2 at the trinuclear active sites of multicopper oxidases is discussed.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305	Stanford University				Solomon, Edward/0000-0003-0291-3199	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031450, R01DK031450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050730, R01GM050730] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK31450] Funding Source: Medline; NIGMS NIH HHS [GM50730] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLENDORF MD, 1985, P NATL ACAD SCI USA, V82, P3063, DOI 10.1073/pnas.82.10.3063; BALDWIN MJ, 1992, J AM CHEM SOC, V114, P10421, DOI 10.1021/ja00052a043; CHANG D, 1984, INORG CHEM, V23, P817, DOI 10.1021/ic00175a006; CHAUDHURI P, 1985, ANGEW CHEM INT EDIT, V24, P57, DOI 10.1002/anie.198500571; CLARK PA, 1992, J AM CHEM SOC, V114, P1108, DOI 10.1021/ja00029a061; COLE JL, 1990, J AM CHEM SOC, V112, P9534, DOI 10.1021/ja00182a013; COLE JL, 1990, J AM CHEM SOC, V112, P2243, DOI 10.1021/ja00162a025; Comarmond J., 1985, CHEM COMMUN, V74; EVANS DF, 1959, J CHEM SOC, P2003, DOI 10.1039/jr9590002003; FUJISAWA K, 1994, J AM CHEM SOC, V116, P12079, DOI 10.1021/ja00105a069; HARATA M, 1994, J AM CHEM SOC, V116, P10817, DOI 10.1021/ja00102a070; HESTERMANN K, 1969, Z ANORG ALLG CHEM, V367, P249, DOI 10.1002/zaac.19693670506; Karlin K.D., 1993, BIOINORGANIC CHEM CO; KARLIN KD, 1995, ACTIVE OXYGEN BIOCH, V3, P188; LEVANDA C, 1977, J AM CHEM SOC, V99, P2964, DOI 10.1021/ja00451a019; LYNCH WE, 1994, J AM CHEM SOC, V116, P11030, DOI 10.1021/ja00103a019; MAGNUS KA, 1994, CHEM REV, V94, P727, DOI 10.1021/cr00027a009; MAHAPATRA S, 1994, J AM CHEM SOC, V116, P9785, DOI 10.1021/ja00100a068; MESSERSCHMIDT A, 1993, J MOL BIOL, V230, P997, DOI 10.1006/jmbi.1993.1215; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; RYDEN L, 1976, BIOCHEMISTRY-US, V15, P3411, DOI 10.1021/bi00661a003; SCHATZ PN, 1978, MOL PHYS, V35, P1537, DOI 10.1080/00268977800101151; Shin W, 1996, J AM CHEM SOC, V118, P3202, DOI 10.1021/ja953621e; SOLOMON EI, 1992, CHEM REV, V92, P521, DOI 10.1021/cr00012a003; SOLOMON EI, 1993, SCIENCE, V259, P1575, DOI 10.1126/science.8384374; SORRELL TN, 1995, INORG CHEM, V34, P952, DOI 10.1021/ic00108a030; SPIRASOLOMON DJ, 1986, J AM CHEM SOC, V108, P5318, DOI 10.1021/ja00277a043; YOUNGBLOOD MP, 1980, INORG CHEM, V19, P3068, DOI 10.1021/ic50212a048; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	30	247	248	2	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1848	1850		10.1126/science.273.5283.1848	http://dx.doi.org/10.1126/science.273.5283.1848			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791587				2022-12-28	WOS:A1996VJ71300041
J	Ivanov, PC; Rosenblum, MG; Peng, CK; Mietus, J; Havlin, S; Stanley, HE; Goldberger, AL				Ivanov, PC; Rosenblum, MG; Peng, CK; Mietus, J; Havlin, S; Stanley, HE; Goldberger, AL			Scaling behaviour of heartbeat intervals obtained by wavelet-based time-series analysis	NATURE			English	Article								BIOLOGICAL time-series analysis is used to identify hidden dynamical patterns which could yield important insights into underlying physiological mechanisms, Such analysis is complicated by the fact that biological signals are typically both highly irregular and non-stationary, that is, their statistical character changes slowly or intermittently as a result of variations in background influences(1-3). Previous statistical analyses of heart beat dynamics(4-6) have identified long-range correlations and power-law scaling in the normal heartbeat, but not the phase interactions between the different frequency components of the signal, Here we introduce a new approach, based on the wavelet transform and an analytic signal approach, which can characterize non-stationary behaviour and elucidate such phase interactions, We find that, when suitably rescaled, the distributions of the variations in the beat-to-beat intervals for all healthy subjects are described by a single function stable over a Hide range of timescales. However, a similar scaling function does not exist for a group with cardiopulmonary instability caused by sleep apnoea. We attribute the functional form of the scaling observed in the healthy subjects to underlying nonlinear dynamics, which seem to be essential to normal heart function, The approach introduced here should be useful in the analysis of other nonstationary biological signals.	BOSTON UNIV,DEPT PHYS,BOSTON,MA 02215; HARVARD UNIV,BETH ISRAEL HOSP,DIV CARDIOVASC,SCH MED,BOSTON,MA 02215; BAR ILAN UNIV,DEPT PHYS,IL-52900 RAMAT GAN,ISRAEL; BAR ILAN UNIV,GONDA GOLDSCHMIED CTR,IL-52900 RAMAT GAN,ISRAEL	Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Bar Ilan University; Bar Ilan University	Ivanov, PC (corresponding author), BOSTON UNIV,CTR POLYMER STUDIES,BOSTON,MA 02215, USA.		Peng, Chung-Kang/E-1489-2011; Peng, Chung-Kang/N-1308-2019; Ivanov, Plamen Ch./E-8004-2012; Havlin, Shlomo/ABF-1527-2020	Peng, Chung-Kang/0000-0003-3666-9833; Peng, Chung-Kang/0000-0003-3666-9833; Ivanov, Plamen Ch./0000-0001-7629-762X; 				AGHILI AA, 1995, PHYS REV LETT, V74, P1254, DOI 10.1103/PhysRevLett.74.1254; AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; ARNEODO A, 1995, PHYS REV LETT, V74, P3293, DOI 10.1103/PhysRevLett.74.3293; Barabasi A.-L., 1995, FRACTAL CONCEPTS SUR; BASSINGTHWAIGHT.JB, 1994, FRACTAL PHYSL; BOX GEP, 1994, TIME SERIES ANAL; DAUBECHIES I, 1988, COMMUN PUR APPL MATH, V41, P909, DOI 10.1002/cpa.3160410705; Gabor D., 1946, J I ELECT ENG LOND, V93, P429, DOI DOI 10.1049/JI-3-2.1946.0074; GERSTEIN GL, 1964, BIOPHYS J, V4, P41, DOI 10.1016/S0006-3495(64)86768-0; GROSSMANN A, 1985, MATH PHYSICS LECT RE; GUILLEMINAULT C, 1984, LANCET, V1, P126; KERTESZ J, 1994, FRACTALS SCI; KITNEY R, 1982, Automedica (London), V4, P141; LIEBOVITCH LS, 1989, BIOPHYS J, V55, P373, DOI 10.1016/S0006-3495(89)82815-2; LIPSITZ LA, 1995, BRIT HEART J, V74, P340; *MIT BIH DAT DISTR, 1992, MIT BIH POL DAT CD R; MUZY JF, 1994, INT J BIFURCAT CHAOS, V4, P245, DOI 10.1142/S0218127494000204; PANTER D, 1965, MODULATION NOISE SPE; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; SHLESINGER MF, 1987, ANN NY ACAD SCI, V504, P214, DOI 10.1111/j.1749-6632.1987.tb48734.x; Stauffer D., 1996, NEWTON MANDELBROT PR; Stratonovich R. L., 1981, TOPICS THEORY RANDOM, VI; Vainshtein L. A., 1983, SEPARATION FREQUENCI	23	434	448	4	62	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 26	1996	383	6598					323	327		10.1038/383323a0	http://dx.doi.org/10.1038/383323a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ439	8848043				2022-12-28	WOS:A1996VJ43900040
J	White, L; Petrovitch, H; Ross, W; Masaki, KH; Abbott, RD; Teng, EL; Rodriguez, BL; Blanchette, PL; Havlik, RJ; Wergowske, G; Chiu, D; Foley, DJ; Murdaugh, C; Curb, JD				White, L; Petrovitch, H; Ross, W; Masaki, KH; Abbott, RD; Teng, EL; Rodriguez, BL; Blanchette, PL; Havlik, RJ; Wergowske, G; Chiu, D; Foley, DJ; Murdaugh, C; Curb, JD			Prevalence of dementia in older Japanese-American men in Hawaii - The Honolulu-Asia Aging Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE; INFORMANT QUESTIONNAIRE; COGNITIVE DECLINE; SENILE DEMENTIA; ELDERLY IQCODE; POPULATION; EPIDEMIOLOGY; COMMUNITY; EDUCATION; STATE	Objective.-To determine prevalence of dementia and its subtypes in Japanese-American men and compare these findings with rates reported for populations in Japan and elsewhere. Design and Setting.-The Honolulu Heart Program is a prospective population-based study of cardiovascular disease established in 1965. Prevalence estimates were computed from cases identified at the 1991 to 1993 examination. Cognitive performance was assessed using Standardized methods, instruments, and diagnostic criteria. Participants.-Subjects were 3734 Japanese-American men (80% of surviving cohort) aged 71 through 93 years, living in the community or in institutions. Main Outcome Measures.-Age-specific, age-standardized, and cohort prevalence estimates were computed for dementia (all cause) defined by 2 sets of diagnostic criteria and 4 levels of severity. Prevalence levels for Alzheimer disease and vascular dementia were also estimated. Results.-Dementia prevalence by Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised ranged from 2.1% in men aged 71 through 74 years to 33.4% in men aged 85 through 93 years. Age-standardized prevalence was 7.6%, Prevalence estimates for the cohort were 9.3% for dementia (all cause), 5.4% for Alzheimer disease (primary or contributing), and 4.2% for vascular dementia (primary or contributing). More than 1 possible cause was found in 26% of cases. The Alzheimer disease/vascular dementia ratio was 1.5 for cases attributed primarily to Alzheimer disease or vascular dementia. Conclusions.-Prevalence of Alzheimer disease in older Japanese-American men in Hawaii appears to be higher than in Japan but similar to European-ancestry populations. Prevalence of vascular dementia appears to be only slightly lower than in Japan, but higher than in European-ancestry populations. Further cross-national research with emphasis on standardized diagnostic methods is needed.	NIA,NIH,BETHESDA,MD 20892; NINR,NIH,BETHESDA,MD 20892; DEPT VET AFFAIRS,HONOLULU,HI; UNIV HAWAII,JOHN A BURNS SCH MED,DEPT MED,HONOLULU,HI 96822; UNIV VIRGINIA,DIV BIOSTAT,CHARLOTTESVILLE,VA; UNIV SO CALIF,LOS ANGELES,CA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Nursing Research (NINR); University of Hawaii System; University of Virginia; University of Southern California	White, L (corresponding author), KUAKINI MED CTR,HONOLULU ASIA AGING STUDY,HONOLULU HEART PROGRAM,347 N KUAKININ ST,HONOLULU,HI 96817, USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC005102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [N01AG042149] Funding Source: NIH RePORTER; NHLBI NIH HHS [N0-HC-05102] Funding Source: Medline; NIA NIH HHS [N01-AG-4-2149] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BACHMAN DL, 1992, NEUROLOGY, V42, P115, DOI 10.1212/WNL.42.1.115; BECKETT LA, 1992, J CLIN EPIDEMIOL, V45, P393, DOI 10.1016/0895-4356(92)90040-T; BERG L, 1988, MT SINAI J MED, V55, P87; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; BROCK DB, 1990, NIH PUBLICATION; BROCK DB, 1986, NIH PUBLICATION; CHIU HC, 1992, NEUROLOGY, V42, P473; Cochran W.G., 2007, SAMPLING TECHNIQUES; CUMMINGS JL, 1992, DEMENTIA CLIN APPROA, P1; EBLY EM, 1994, NEUROLOGY, V44, P1593, DOI 10.1212/WNL.44.9.1593; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; Graves A B, 1994, Int Psychogeriatr, V6, P209, DOI 10.1017/S1041610294001778; HASEGAWA K, 1986, International Journal of Geriatric Psychiatry, V1, P45, DOI 10.1002/gps.930010108; Hasegawa K., 1983, AGING EIGHTIES, P207; HOMMA A, 1984, GERIATR PSYCHIAT, V1, P164; HOSMER DW, 1989, APPL LOGISTIC REGRES; JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742; JORM AF, 1991, PSYCHOL MED, V21, P785, DOI 10.1017/S0033291700022418; JORM AF, 1991, EUR ARCH PSY CLIN N, V240, P218, DOI 10.1007/BF02189530; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; Karasawa A, 1990, PSYCHOGERIATRICS BIO, P24; KITTNER SJ, 1986, J CHRON DIS, V39, P163, DOI 10.1016/0021-9681(86)90019-6; KOKMEN E, 1989, NEUROLOGY, V39, P773, DOI 10.1212/WNL.39.6.773; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P176; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; UEDA K, 1992, STROKE, V23, P798, DOI 10.1161/01.STR.23.6.798; WELSH K, 1991, ARCH NEUROL-CHICAGO, V48, P278, DOI 10.1001/archneur.1991.00530150046016; WHITE LR, 1992, CURR SCI INDIA, V63, P456; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161	37	368	369	1	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1996	276	12					955	960		10.1001/jama.276.12.955	http://dx.doi.org/10.1001/jama.276.12.955			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VH990	8805729				2022-12-28	WOS:A1996VH99000035
J	Brahams, D				Brahams, D			Caesarean sections by court order	LANCET			English	Editorial Material																		[Anonymous], 1988, LANCET, V1, P369; BRAHAMS D, 1988, LANCET, V1, P1006; BRAHAMS D, 1993, LANCET, V341, P428; 1996, HEMPSONS LAWYER, P503	4	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	1996	348	9030					770	770		10.1016/S0140-6736(05)65207-5	http://dx.doi.org/10.1016/S0140-6736(05)65207-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813981				2022-12-28	WOS:A1996VH98900007
J	Vassallo, DJ				Vassallo, DJ			The saga of brucellosis: Controversy over credit for linking Malta fever with goats' milk	LANCET			English	Article											Vassallo, DJ (corresponding author), MUSGRAVE PK HOSP,DUKE CONNAUGHT UNIT,TAUNTON BFP0 801,SOMERSET,ENGLAND.		Vassallo, David J/B-4888-2013					BOYCE RW, 1909, MOSQUITO MAN, P215; BRUCE D, 1907, J R ARMY MED CORPS, V8, P225; BRUCE D, 1996, MICROSOFT ENCARTA 96, P96; BRUCE D, 1905, INTRO REPORTS MEDI 3, P3; BRUCE D, 1907, TIMES           1001, P9; BRUCE D, 1906, J R ARMY MED CORPS, V6, P330; BRUCE D, 1908, SYSTEM MED, V3, P17; BRUCE D, 1931, TIMES           1128, P12; CASSAR P, 1980, T ZAMMITS LAB; Cassar P., 1981, T ZAMMIT CONTROVERSY; CASSAR P, 1983, SUNDAY TIMES MA 0828, P24; DALRYMPLECHAMPN.W, 1960, BRUCELLA INFECT UNDU; Domeier William, 1810, OBSERVATIONS CLIMATE; GAUCI AJA, 1995, MALTESE MED J, V7, P7; HADWEN WR, 1926, DIFFICULTIES DEGUERR, P197; HILL L, 1941, BRIT MED J, V1, P258; Horrocks WH, 1905, P R SOC LOND B-CONTA, V76, P378, DOI 10.1098/rspb.1905.0031; HORROCKS WH, 1906, REPORTS MEDITERRAN 4, P37; Hughes M.L., 1897, MEDITERRANEAN MALTA; KENNEDY JC, 1905, REPORTS MEDITERRAN 3, P91; KIRKPATRICK HC, 1907, TIMES           0912, P2; MCNAUGHT JG, 1935, BRIT MED J, V2, P1077; MEE A, 1941, CHILDRENS ENCY, P2623; SCICLUNA GC, 1906, MILCH GOAT FACTOR PR; SHAW EA, 1906, REPORTS MEDITERRAN 4, P16; Vassallo D J, 1992, J R Army Med Corps, V138, P140; Vassallo D J, 1993, J R Nav Med Serv, V79, P91; VASSALLO DJ, 1994, BRIT MED J, V309, P1578; Williams E, 1989, BRUCELLOSIS CLIN LAB, P11; WILLIAMS H, 1952, CONQUEST FEAR, P101; Zammit T, 1905, P R SOC LOND B-CONTA, V76, P377, DOI 10.1098/rspb.1905.0030; ZAMMIT T, 1902, J STATE MED, V10, P399; ZAMMIT T, 1906, REPORTS MEDITERRAN 4, P96; Zammit T., 1905, REPORTS ROYAL SOC 4, V3, P83; 1907, TIMES           0830, P5; 1996, TIMES MALTA     0413, P24; 1911, ENCYCL BRITANNICA, V17, P514	37	12	13	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					804	808		10.1016/S0140-6736(96)05470-0	http://dx.doi.org/10.1016/S0140-6736(96)05470-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813991				2022-12-28	WOS:A1996VH98900017
J	Gerberding, JL				Gerberding, JL			Prophylaxis for occupational exposure to HIV	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE WORKERS; ZIDOVUDINE; INFECTION; BLOOD; 3'-AZIDO-3'-DEOXYTHYMIDINE; DISEASE; THERAPY; SUPPRESSION; EFFICACY	Effective prophylaxis for infection with the human immunodeficiency virus (HIV) is important for health care providers at risk for exposure to infected blood. The average risk from percutaneous exposure is approximately 0.3%, but exposures involving a high titer of HIV or a large volume of infectious material are apt to be much riskier. A convergence of indirect evidence strongly suggests that chemoprophylaxis with zidovudine after exposure to HIV may be efficacious. Treatment with zidovudine after percutaneous exposure appears to reduce the odds of infection by almost 80%. Zidovudine prophylaxis effectively prevents perinatal HIV transmission, and treatment during acute retroviral infection may attenuate HIV disease. Reports of ''aborted'' HIV infection among health care providers who have been stuck with contaminated needles suggest that antiretroviral treatment in the window of opportunity after exposure to HIV could prevent virus propagation and allow local cutaneous host defenses to clear the infection. Although efficacy has not been shown in controlled clinical trials, these data support a potential benefit from treatment after exposure. It is difficult to define the optimal regimen that should be used for prophylaxis, given the emergence of antiretroviral resistance among source patients. Current recommendations favor the use of zidovudine plus lamivudine for 4 weeks. Use of indinavir or other protease inhibitors is advised when the source patient is likely to harbor resistant virus or when exposure is especially hazardous.			Gerberding, JL (corresponding author), SAN FRANCISCO GEN HOSP, MED SERV 5H22, EPIDEMIOL & PREVENT INTERVENT CTR, 1001 POTRERO AVE, SAN FRANCISCO, CA 94110 USA.							[Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1996, Med Lett Drugs Ther, V38, P35; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CLERICI M, 1994, JAMA-J AM MED ASSOC, V271, P42, DOI 10.1001/jama.271.1.42; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Dilley JW, 1990, FOCUS, V5, P3; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; FAHRNER R, 1994, INT C ANT AG CHEM WA, P133; GERBERDING JL, 1992, CLIN INFECT DIS, V14, P1179, DOI 10.1093/clinids/14.6.1179; GERBERDING JL, 1995, NEW ENGL J MED, V332, P444, DOI 10.1056/NEJM199502163320707; GERBERDING JL, 1995, MED MANAGEMENT AIDS, P89; HENDERSON DK, 1989, J INFECT DIS, V160, P321, DOI 10.1093/infdis/160.2.321; HEPTONSTALL J, 1995, OCCUPATIONAL HIV SUM; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; IPPOLITO G, 1993, ARCH INTERN MED, V153, P1451, DOI 10.1001/archinte.153.12.1451; LAFON SW, 1988, J INFECT DIS, V158, P503, DOI 10.1093/infdis/158.2.503; LAFON SW, 1990, INT C ANT AG CHEM WA, P489; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; MAST ST, 1993, J INFECT DIS, V168, P1589, DOI 10.1093/infdis/168.6.1589; MATHES LE, 1992, ANTIMICROB AGENTS CH, V36, P2715, DOI 10.1128/AAC.36.12.2715; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; Merrill DP, 1996, J INFECT DIS, V173, P355, DOI 10.1093/infdis/173.2.355; PURO V, 1992, AIDS, V6, P963, DOI 10.1097/00002030-199209000-00009; RUPRECHT RM, 1986, NATURE, V323, P467, DOI 10.1038/323467a0; SAAG MS, 1991, J INFECT DIS, V164, P72, DOI 10.1093/infdis/164.1.72; TAVARES L, 1987, CANCER RES, V47, P3190; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; VANROMPAY KKA, 1992, ANTIMICROB AGENTS CH, V36, P2381, DOI 10.1128/AAC.36.11.2381; 1995, MMWR-MORBID MORTAL W, V44, P929; 1996, MMWR-MORBID MORTAL W, V45, P468	30	91	91	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					497	501		10.7326/0003-4819-125-6-199609150-00011	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779463				2022-12-28	WOS:A1996VF88200012
J	Mauriege, P; Bouchard, C				Mauriege, P; Bouchard, C			Trp65Arg mutation in beta 3-adrenoceptor gene of doubtful significance for obesity and insulin resistance	LANCET			English	Editorial Material							BETA(3)-ADRENERGIC-RECEPTOR GENE; RECEPTOR; WEIGHT; GAIN				Mauriege, P (corresponding author), UNIV LAVAL,PHYS ACT SCI LAB,QUEBEC CITY,PQ G1K 7P4,CANADA.		Bouchard, Claude/AAE-2035-2019; Bouchard, Claude/A-7637-2009	Bouchard, Claude/0000-0002-0048-491X				ARCH JRS, 1993, MED RES REV, V13, P663, DOI 10.1002/med.2610130604; Bouchard C, 1996, OBES RES, V4, P81, DOI 10.1002/j.1550-8528.1996.tb00516.x; CLEMENT K, 1995, NEW ENGL J MED, V333, P352, DOI 10.1056/NEJM199508103330605; EMORINE L, 1994, TRENDS PHARMACOL SCI, V15, P3, DOI 10.1016/0165-6147(94)90118-X; Fujisawa T, 1996, DIABETOLOGIA, V39, P349, DOI 10.1007/s001250050452; GAGNON J, IN PRESS J CLIN INVE; KADOWAKI H, 1995, BIOCHEM BIOPH RES CO, V215, P555, DOI 10.1006/bbrc.1995.2500; LAFONTAN M, 1994, CELL SIGNAL, V6, P363, DOI 10.1016/0898-6568(94)90085-X; Li LS, 1996, DIABETOLOGIA, V39, P857, DOI 10.1007/s001250050521; LONNQVIST F, 1995, J CLIN INVEST, V95, P1109, DOI 10.1172/JCI117758; MAURIEGE P, 1995, J LIPID RES, V36, P672; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; WALSTON J, 1995, NEW ENGL J MED, V333, P343, DOI 10.1056/NEJM199508103330603; WIDEN E, 1995, NEW ENGL J MED, V333, P348, DOI 10.1056/NEJM199508103330604; ZURLO F, 1990, AM J PHYSIOL, V259, P650	15	35	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					698	699		10.1016/S0140-6736(05)65601-2	http://dx.doi.org/10.1016/S0140-6736(05)65601-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806286				2022-12-28	WOS:A1996VG37400005
J	Ploeckinger, B; Dantendorfer, K; Ulm, M; Baischer, W; Derfler, K; Musalek, M; Dadak, C				Ploeckinger, B; Dantendorfer, K; Ulm, M; Baischer, W; Derfler, K; Musalek, M; Dadak, C			Rapid decrease of serum cholesterol concentration and postpartum depression	BRITISH MEDICAL JOURNAL			English	Article									UNIV VIENNA,DEPT PSYCHIAT,A-1010 VIENNA,AUSTRIA; UNIV VIENNA,DEPT INTERNAL MED,VIENNA,AUSTRIA	University of Vienna; University of Vienna	Ploeckinger, B (corresponding author), UNIV VIENNA,DEPT OBSTET & GYNECOL,KLIN FRAUENHEILKUNDE,WAHRINGER GURTEL 18-20,A-1090 VIENNA,AUSTRIA.			Derfler, Kurt/0000-0003-2062-7620				ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; FOWKES FGR, 1992, LANCET, V340, P995, DOI 10.1016/0140-6736(92)93009-C; HARRIS B, 1994, BRIT MED J, V308, P949, DOI 10.1136/bmj.308.6934.949; KAPLAN JR, 1991, PSYCHOSOM MED, V53, P634, DOI 10.1097/00006842-199111000-00005; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70	5	38	38	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 14	1996	313	7058					664	664						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8845727				2022-12-28	WOS:A1996VH16500022
J	Reiner, L				Reiner, L			Israel: Justice in heaven	LANCET			English	Article											Reiner, L (corresponding author), PHYSICIANS HUMAN RIGHTS,100 BOYLSTON ST,SUITE 702,BOSTON,MA 02116, USA.								0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					737	738		10.1016/S0140-6736(05)65606-1	http://dx.doi.org/10.1016/S0140-6736(05)65606-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806297				2022-12-28	WOS:A1996VG37400018
J	Samuelsson, O; Pennert, K; Andersson, O; Berglund, G; Hedner, T; Persson, B; Wedel, H; Wilhelmsen, L				Samuelsson, O; Pennert, K; Andersson, O; Berglund, G; Hedner, T; Persson, B; Wedel, H; Wilhelmsen, L			Diabetes mellitus and raised serum triglyceride concentration in treated hypertension - Are they of prognostic importance? Observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; CARDIOVASCULAR RISK-FACTORS; IMPAIRED GLUCOSE-TOLERANCE; ANTIHYPERTENSIVE DRUGS; INSULIN RESISTANCE; BLOOD-PRESSURE; MEN; PATHOGENESIS; MANAGEMENT; MORTALITY	Objective-To analyse whether metabolic changes during longterm treatment with antihypertensive drugs are associated with an increased risk of coronary heart disease. Design-Observational study. Setting-Gothenburg, Sweden. Subjects-686 middle aged hypertensive men, recruited after screening of a random population sample, and followed for 15 years during treatment with predominantly beta adrenoceptor blockers or thiazide diuretics, or both. Coronary heart disease and diabetes mellitus were registered at yearly patient examinations. Entry characteristics, as well as within study serum concentrations of cholesterol and triglycerides and the development of diabetes mellitus, were related to the incidence of coronary heart disease in a time dependent Cox's regression analysis. Main outcome variable-Coronary heart disease morbidity. Results-Diabetes mellitus, raised serum cholesterol and triglyceride concentrations present at the beginning of the study were all significantly predictive of coronary heart disease in univariate analysis. The relative risk of diabetes mellitus and of a 1 mmol/l increase in the cholesterol and triglyceride concentrations was 2.12 (95% confidence interval 1.11 to 4.07), 1.21 (1.05 to 1.39), and 1.21 (1.03 to 1.43) respectively. However, when the within study metabolic variables were analysed, only the serum cholesterol concentration was significantly and independently associated with coronary heart disease (relative risk 1.07 (1.02 to 1.13)). Although the triglyceride concentrations increased slightly during the follow up, the within study serum triglyceride concentrations were not associated with the incidence of coronary heart disease (1.04 (0.96 to 1.10)). New diabetes mellitus-that is, onset during follow up-was not significantly associated with an increased risk for coronary heart disease (1.48 (0.37 to 6.00)). Conclusions-Metabolic disturbances such as diabetes mellitus and hyperlipidaemia presenting before the start of antihypertensive treatment have a prognostic impact in middle aged, treated hypertensive men. Moreover, while within study cholesterol concentration was an independent predictor of coronary heart disease, drug related diabetes mellitus and raised serum triglyceride concentrations that are associated with treatment do not seem to have any major impact on the coronary heart disease prognosis in this category of patients.	SAHLGRENS UNIV HOSP, DEPT MED, ANGIOL SECT, GOTHENBURG, SWEDEN; SAHLGRENS UNIV HOSP, DEPT CLIN PHARMACOL, GOTHENBURG, SWEDEN; CLIN DATA CARE AB, LUND, SWEDEN; LUND UNIV, MALMO GEN HOSP, DEPT MED, S-21401 MALMO, SWEDEN; NORDIC SCH PUBL HLTH, DEPT EPIDEMIOL & BIOSTAT, GOTHENBURG, SWEDEN; OSTRA HOSP, DEPT MED, S-41685 GOTHENBURG, SWEDEN	Sahlgrenska University Hospital; Sahlgrenska University Hospital; Lund University; Sahlgrenska University Hospital	Samuelsson, O (corresponding author), SAHLGRENS UNIV HOSP, DEPT MED, NEPHROL SECT, S-41345 GOTHENBURG, SWEDEN.							ALTMAN DG, 1994, STAT MED, V13, P301, DOI 10.1002/sim.4780130402; [Anonymous], 1985, J Hypertens, V3, P379; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1980, LANCET, V1, P1261; [Anonymous], 1993, Blood Press, V2, P312; AUSTIN MA, 1991, ARTERIOSCLER THROMB, V11, P2, DOI 10.1161/01.ATV.11.1.2; BENGTSSON C, 1984, BMJ-BRIT MED J, V289, P1495, DOI 10.1136/bmj.289.6457.1495; BRENNAN PJ, 1988, BRIT HEART J, V59, P364; COLLINS P, 1992, EUR HEART J, V13, P560, DOI 10.1093/oxfordjournals.eurheartj.a060214; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COX DR, 1972, J R STAT SOC B, V34, P187; DAHLOF B, 1993, BLOOD PRESSURE, V2, P137; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; ELLIOTT WJ, 1995, AM J MED, V99, P261, DOI 10.1016/S0002-9343(99)80158-2; FORD CE, 1988, JAMA-J AM MED ASSOC, V259, P2113; FRAYN KN, 1992, CLIN SCI, V82, P1, DOI 10.1042/cs0820001; FREIS ED, 1995, ANN INTERN MED, V122, P223, DOI 10.7326/0003-4819-122-3-199502010-00011; FULLER JH, 1980, LANCET, V1, P1373; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAFFNER SM, 1993, J CLIN ENDOCR METAB, V76, P541, DOI 10.1210/jc.76.3.541; HANSSON L, 1990, J HYPERTENS, V8, P985; HARPER R, 1994, BRIT MED J, V309, P226, DOI 10.1136/bmj.309.6949.226; JACOBY RM, 1992, J AM COLL CARDIOL, V20, P736, DOI 10.1016/0735-1097(92)90033-J; JARRETT RJ, 1992, LANCET, V340, P469, DOI 10.1016/0140-6736(92)91781-3; Julius S, 1992, Blood Press, V1, P9, DOI 10.3109/08037059209065119; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KANNEL WB, 1989, J CARDIOVASC PHARM, V13, pS4, DOI 10.1097/00005344-198900131-00003; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KJELSBERG MO, 1986, PREV MED, V15, P254; LITHELL HOL, 1991, DIABETES CARE, V14, P203, DOI 10.2337/diacare.14.3.203; MORALES PA, 1993, DIABETES, V42, P154, DOI 10.2337/diabetes.42.1.154; MOSER M, 1993, CLEV CLIN J MED, V60, P27; NILSSON P, 1993, J INTERN MED, V233, P239, DOI 10.1111/j.1365-2796.1993.tb00982.x; NORTHCOTE RJ, 1991, J HYPERTENS, V9, pS21, DOI 10.1097/00004872-199112007-00006; POLLARE T, 1989, THESIS UPPSALA U UPP; REAVEN GM, 1993, J CLIN ENDOCR METAB, V76, P537, DOI 10.1210/jc.76.3.537; REAVEN GM, 1991, DIABETES CARE, V14, P33, DOI 10.2337/diacare.14.4.33; RESNICK LM, 1993, AM J HYPERTENS, V6, pS123, DOI 10.1093/ajh/6.4S.123S; ROSE G, 1982, BRIT MED J, V284, P1600, DOI 10.1136/bmj.284.6329.1600; ROSENGREN A, 1989, BRIT MED J, V299, P1127, DOI 10.1136/bmj.299.6708.1127; ROSMAN J, 1990, Journal of Drug Development, V3, P129; SAMUELSSON O, 1985, ACTA MED SCAND, P1; SAS Institute, 1991, SAS STAT SOFTW PHREG; SCHWARTZ CJ, 1992, DIABETES CARE, V15, P1156, DOI 10.2337/diacare.15.9.1156; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SKARFORS ET, 1989, BRIT MED J, V298, P1147, DOI 10.1136/bmj.298.6681.1147; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; SOWERS JR, 1991, AM HEART J, V122, P932, DOI 10.1016/0002-8703(91)90814-X; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STANDLEY PR, 1993, AM J KIDNEY DIS, V21, P39; WEBER MA, 1993, ARCH INTERN MED, V153, P149, DOI 10.1001/archinte.153.2.149; WEINBERGER MH, 1986, AM J MED, V80, P64, DOI 10.1016/0002-9343(86)90162-2; WHO Expert Committee on Diabetes Mellitus, 1980, WHO TECHN REP SER, V646; WILHELMSEN L, 1972, Preventive Medicine, V1, P153, DOI 10.1016/0091-7435(72)90082-5; WINGARD DL, 1995, DIABETES CARE, V18, P1299, DOI 10.2337/diacare.18.9.1299; Wolfe RA, 1996, AM J KIDNEY DIS, V27, P124, DOI 10.1016/S0272-6386(96)90039-6; YUDKIN JS, 1991, BMJ-BRIT MED J, V303, P730, DOI 10.1136/bmj.303.6805.730; 1993, BLOOD PRESSURE, V2, P86; 1986, LANCET, V2, P1075; 1995, J INTERN MED S737, V238, P1	60	32	32	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	1996	313	7058					660	663						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8811759				2022-12-28	WOS:A1996VH16500021
J	Gershon, D				Gershon, D			NIH lends a hand with loan repayment	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					197	198		10.1038/383197a0	http://dx.doi.org/10.1038/383197a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774889	Bronze			2022-12-28	WOS:A1996VG14800061
J	Cheng, K; Smyth, RL; Govan, JRW; Doherty, C; Winstanley, C; Denning, N; Heaf, DP; vanSaene, H; Hart, CA				Cheng, K; Smyth, RL; Govan, JRW; Doherty, C; Winstanley, C; Denning, N; Heaf, DP; vanSaene, H; Hart, CA			Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic	LANCET			English	Article							BURKHOLDERIA CEPACIA; CF-CENTER; COMMUNICABILITY; MICROBIOLOGY; COLONIZATION; INFECTIONS	Background Pseudomonas aeruginosa colonisation of the airways of patients with cystic fibrosis (CF) is associated with considerable respiratory morbidity. Although segregation of colonised patients from non-colonised patients to prevent cross-infection has been recommended, there is little evidence that such cross-infection is widespread. We observed that a high proportion of children attending our CF clinic were colonised with P aeruginosa that was resistant to ceftazidime and other beta-lactam antibiotics. We used two genomic fingerprinting techniques to see whether this may have arisen from epidemic spread of a single strain. Methods The prevalence of P aeruginosa colonisation and the antibiotic susceptibility of the organisms was determined from review of laboratory reports in the case-notes of 120 children with CF. Isolates were cultured from the sputum of 65 children colonised with ceftazidime-resistant P aeruginosa. Polymorphisms in total bacterial DNA from 92 isolates were analysed with two molecular fingerprinting techniques-pulsed-field gel electrophoresis after restriction enzyme digestion and assessment of flagellin gene polymorphisms by amplification of the whole gene and restriction enzyme digestion. Results 92 (76.7%) of 120 children were colonised with P aeruginosa, and 65 of the 92 harboured isolates that were resistant to ceftazidime. Only three of the 92 children had never been treated with ceftazidime. The results of the two molecular-fingerprinting techniques were concordant and showed that 55 of 65 children harboured the same epidemic strain. This strain was resistant to ceftazidime, azlocillin, and imipenem, and sensitive to tobramycin and ciprofloxacin. Interpretation This study provides the first molecular evidence of a long-term outbreak of P aeruginosa in a CF centre. We suggest that careful surveillance of the prevalence of antibiotic resistance in CF centres should be instituted with measures to prevent cross-infection. We believe that antipseudomonal monotherapy should be considered with caution.	UNIV LIVERPOOL,DEPT MED MICROBIOL & GENITOURINARY MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT CHILD HLTH,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV EDINBURGH,DEPT MED MICROBIOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; COVENTRY UNIV,SCH NAT & ENVIRONM SCI,COVENTRY,W MIDLANDS,ENGLAND	University of Liverpool; University of Liverpool; University of Edinburgh; Coventry University				Winstanley, Craig/0000-0002-2662-8053				BINGEN E, 1993, EPIDEMIOLOGY PULMONA; BUTLER SL, 1995, J CLIN MICROBIOL, V33, P1001, DOI 10.1128/JCM.33.4.1001-1004.1995; CHEN HY, 1995, J MED MICROBIOL, V43, P300, DOI 10.1099/00222615-43-4-300; CIOFU O, 1994, APMIS, V102, P674, DOI 10.1111/j.1699-0463.1994.tb05219.x; DALZELL AM, 1991, THORAX, V46, P239, DOI 10.1136/thx.46.4.239; GILLIGAN PH, 1991, CLIN MICROBIOL REV, V4, P35, DOI 10.1128/CMR.4.1.35-51.1991; GOVAN JRW, 1993, LANCET, V342, P15, DOI 10.1016/0140-6736(93)91881-L; GOVAN JRW, 1992, BRIT MED BULL, V48, P912, DOI 10.1093/oxfordjournals.bmb.a072585; GOVAN JRW, 1996, PRACTICAL MED MICROB, P413; GROTHUES D, 1988, J CLIN MICROBIOL, V26, P1973, DOI 10.1128/JCM.26.10.1973-1977.1988; HOOGKAMPKORSTANJE JAA, 1980, A VAN LEEUW J MICROB, V46, P100, DOI 10.1007/BF00422237; National Committee for Clinical Laboratory Standards, 1990, M7A2 NCCLS; PADOAN R, 1987, PEDIATR INFECT DIS J, V6, P648, DOI 10.1097/00006454-198707000-00006; PEDERSEN SS, 1986, J ANTIMICROB CHEMOTH, V17, P505, DOI 10.1093/jac/17.4.505; SPEERT DP, 1987, J HOSP INFECT, V9, P11, DOI 10.1016/0195-6701(87)90089-2; SPEERT DP, 1982, J PEDIATR-US, V101, P227, DOI 10.1016/S0022-3476(82)80127-3; SPEERT DP, 1989, J PEDIATR-US, V114, P1068, DOI 10.1016/S0022-3476(89)80476-7; SUN L, 1995, NAT MED, V1, P661, DOI 10.1038/nm0795-661; Thomassen M J, 1985, Pediatr Pulmonol, V1, P40, DOI 10.1002/ppul.1950010110; TUMMLER B, 1991, J CLIN MICROBIOL, V29, P1265; Winstanley C, 1996, MICROBIOL-UK, V142, P2145, DOI 10.1099/13500872-142-8-2145; WOLZ C, 1989, EPIDEMIOL INFECT, V102, P205, DOI 10.1017/S0950268800029873; 1994, J INFECT DIS, V169, P134	23	329	330	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					639	642		10.1016/S0140-6736(96)05169-0	http://dx.doi.org/10.1016/S0140-6736(96)05169-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782753				2022-12-28	WOS:A1996VF60900008
J	Reilly, KM; Melton, DA				Reilly, KM; Melton, DA			Short-range signaling by candidate morphogens of the TGF beta family and evidence for a relay mechanism of induction	CELL			English	Article							GROWTH-FACTOR-BETA; XENOPUS-LAEVIS; MESODERM INDUCTION; VG1 PROTEIN; DROSOPHILA EMBRYO; MESSENGER-RNAS; EARLY RESPONSE; REQUIRES FGF; II RECEPTOR; C-ELEGANS	The specification and patterning of cell fates by a morphogen gradient is a unifying theme of developmental biology, yet little evidence exists for the presence of gradients in vivo or to show how such putative gradients form. Vg1 and activin are candidate morphogens involved in Xenopus mesoderm induction. This study suggests that these TGF beta family members act on adjacent cells but do not travel through the intact extracellular space to induce distant cells directly. Moreover, we present evidence for the presence of secondary inducing signals that could be involved in relaying signals to distant cells. These results suggest that if a localized cellular source of an inducer acts to pattern mesodermal cells at a distance in Xenopus embryos, it does so by a relay mechanism.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute	Reilly, KM (corresponding author), HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.		Reilly, Karlyne/V-4475-2019; Young, Richard A/F-6495-2012	Reilly, Karlyne/0000-0001-9109-4409; Young, Richard A/0000-0001-8855-8647				ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; BAUER DV, 1994, DEVELOPMENT, V120, P1179; BHUSHAN A, 1994, MOL CELL BIOL, V14, P4280, DOI 10.1128/MCB.14.6.4280; COOKE J, 1987, DEVELOPMENT, V101, P893; CORNELL RA, 1994, DEVELOPMENT, V120, P453; CORNELL RA, 1995, DEVELOPMENT, V121, P2429; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1987, DEVELOPMENT, V99, P527; DOHRMANN CE, 1993, DEV BIOL, V157, P474, DOI 10.1006/dbio.1993.1150; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GARNER LW, 1995, DEV BIOL, V171, P240; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GRUNZ H, 1986, ROUX ARCH DEV BIOL, V195, P467, DOI 10.1007/BF00375751; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Henry GL, 1996, DEVELOPMENT, V122, P1007; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; ITOH K, 1994, DEVELOPMENT, V120, P2703; KALT MR, 1971, J EMBRYOL EXP MORPH, V26, P37; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KENGAKU M, 1995, DEVELOPMENT, V121, P3121; KENYON C, 1995, CELL, V82, P171, DOI 10.1016/0092-8674(95)90302-X; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KOGA M, 1995, DEVELOPMENT, V121, P2655; KONDAIAH P, 1988, J BIOL CHEM, V263, P18313; Korc Murray, 1993, P751; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LABONNE C, 1994, DEVELOPMENT, V120, P463; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEMAIRE P, 1994, DEVELOPMENT, V120, P1191; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Mangold O, 1927, ROUX ARCH DEV BIOL, V111, P341; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; PENG HB, 1991, XENOPUS LAEVIS PRACT, P657; REBAGLIATI MR, 1993, DEV BIOL, V159, P574, DOI 10.1006/dbio.1993.1265; REPRESA J, 1989, International Journal of Developmental Biology, V33, P397; SIMKE JS, 1995, NATURE, V375, P142; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SLACK JMW, 1987, TRENDS BIOCHEM SCI, V12, P200, DOI 10.1016/0968-0004(87)90094-6; SLACK JMW, 1991, DEVELOPMENT, V113, P661; Smith J, 1996, NATURE, V381, P367, DOI 10.1038/381367a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; SUDARWAT.S, 1971, ROUX ARCH DEV BIOL, V166, P189, DOI 10.1007/BF00650029; SYMES K, 1994, DEVELOPMENT, V120, P2339; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VODICKA MA, 1995, DEVELOPMENT, V121, P3505; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	63	88	90	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1996	86	5					743	754		10.1016/S0092-8674(00)80149-X	http://dx.doi.org/10.1016/S0092-8674(00)80149-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797821	Bronze			2022-12-28	WOS:A1996VG37200008
J	Chakravarti, D; LaMorte, VJ; Nelson, MC; Nakajima, T; Schulman, IG; Juguilon, H; Montminy, M; Evans, RM				Chakravarti, D; LaMorte, VJ; Nelson, MC; Nakajima, T; Schulman, IG; Juguilon, H; Montminy, M; Evans, RM			Role of CBP/P300 in nuclear receptor signalling	NATURE			English	Article							THYROID-HORMONE RECEPTOR; TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; RETINOIC ACID; CO-REPRESSOR; PROTEIN; SUPERFAMILY; MEDIATOR; PATHWAYS; BINDING	THE nuclear receptor superfamily includes receptors for steroids, retinoids, thyroid hormone and vitamin D, as well as many related proteins(1-3). An important feature of the action of the lipophilic hormones and vitamins is that the maintenance of homeostatic function requires both intrinsic positive and negative regulation(4,5). Here we provide in vitro and in vivo evidence that identifies the CREB-binding protein (CBP) and its homologue P300 (refs 6, 7) as cofactors mediating nuclear-receptor-activated gene transcription. The role of CBP/P300 in the transcriptional response to cyclic AMP, phorbol esters, serum, the lipophilic hormones and as the target of the E1A oncoprotein suggests they may serve as integrators of extracellular and intracellular signalling pathways.	SALK INST BIOL STUDIES,GENE EXPRESS LAB,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Salk Institute; Salk Institute; Howard Hughes Medical Institute; Salk Institute			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAUR EV, 1995, EMBO J, V15, P110; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; ORIATE SA, 1995, SCIENCE, V270, P1354; Parker D, 1996, MOL CELL BIOL, V16, P694; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y	26	823	860	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					99	103		10.1038/383099a0	http://dx.doi.org/10.1038/383099a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779723				2022-12-28	WOS:A1996VF29500057
J	Hadgu, A				Hadgu, A			The discrepancy in discrepant analysis	LANCET			English	Review							LIGASE CHAIN-REACTION; CHLAMYDIA-TRACHOMATIS INFECTION; ENDOCERVICAL SPECIMENS; REACTION ASSAY; DIAGNOSIS; WOMEN; URINE	Discrepant analysis is a widely used technique that attempts to provide estimates of sensitivity and specificity in the presence of an imperfect gold-standard. This technique has been applied by many researchers to estimate the sensitivity and specificity of DNA-amplification tests for Chlamydia trachomatis such as the plasmid-based ligase chain-reaction and polymerase chain-reaction tests. However, the sensitivity and specificity estimates obtained by discrepant analysis are upwardly biased, and this bias remains even when a perfect test is used to resolve the discrepant results. This technique should not be adopted for evaluating the performance of a diagnostic test.			Hadgu, A (corresponding author), CTR DIS CONTROL & PREVENT,CTR HIV STD & TB PREVENT,DIV STD PREVENT,1600 CLIFTON RD,MAILSTOP E63,ATLANTA,GA 30333, USA.		Toon, Christopher W/G-3610-2012					BASS CA, 1993, J CLIN MICROBIOL, V31, P2648, DOI 10.1128/JCM.31.10.2648-2653.1993; BASSIRI M, 1995, J CLIN MICROBIOL, V33, P898, DOI 10.1128/JCM.33.4.898-900.1995; DEBARBEYRAC B, 1994, GENITOURIN MED, V70, P162; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; LOEFFELHOLZ MJ, 1992, J CLIN MICROBIOL, V30, P2847, DOI 10.1128/JCM.30.11.2847-2851.1992; SCHACHTER J, 1995, J INFECT DIS, V172, P1411, DOI 10.1093/infdis/172.5.1411; SCHACHTER J, 1994, J CLIN MICROBIOL, V32, P2540, DOI 10.1128/JCM.32.10.2540-2543.1994	7	106	112	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 31	1996	348	9027					592	593		10.1016/S0140-6736(96)05122-7	http://dx.doi.org/10.1016/S0140-6736(96)05122-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774575				2022-12-28	WOS:A1996VF18600016
J	Brennan, P; Harrison, B; Barrett, E; Chakravarty, K; Scott, D; Silman, A; Symmons, D				Brennan, P; Harrison, B; Barrett, E; Chakravarty, K; Scott, D; Silman, A; Symmons, D			A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: Prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							JOINT DESTRUCTION; PROGRESSION; DISEASE; DAMAGE; GOLD	Objective-To produce a practical algorithm to predict which patients with early rheumatoid arthritis will develop radiological erosions. Design-Primary care based prospective cohort study. Setting-All general practices in the Norwich Health Authority, Norfolk Subjects-175 patients notified to the Norfolk Arthritis Register were visited by a metrologist soon after they had presented to their general practitioners with inflammatory polyarthritis, and again after a further 12 months. All the patients satisfied the American Rheumatism Association's 1987 criteria for rheumatoid arthritis and were seen by a metrologist within six months of the onset of symptoms. The study population was randomly split into a prediction sample (n = 105) for generating the algorithm and a validation sample (n = 70) for testing it. Main outcome measures-Predictor variables measured at baseline included rheumatoid factor status, swelling of specific joint areas, duration of morning stiffness, nodules, disability score, age, sex, and disease duration when the patient first presented. The outcome variable was the presence of radiological erosions in the hands or feet, or both, after 12 months. Results-A simple algorithm based on a combination of three variables-a positive rheumatoid factor test, swelling of at least two large joints, and a disease duration of more than three months-was best able to predict erosions. When the accuracy of this algorithm was tested with the validation sample, the erosion status of 79% of patients was predicted correctly. Conclusions-A simple algorithm based on three easily measured items of information can predict which patients are at high risk and which are at low risk of developing radiological erosions.	ST MICHAELS HOSP,NORFOLK ARTHRIT REGISTER,AYLSHAM,NORFOLK,ENGLAND		Brennan, P (corresponding author), UNIV MANCHESTER,SCH MED,ARTHRIT & RHEUMATISM EPIDEMIOL RES UNIT,MANCHESTER M13 9PT,LANCS,ENGLAND.			Symmons, Deborah/0000-0002-8625-1200				ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BROOK A, 1977, ANN RHEUM DIS, V36, P71, DOI 10.1136/ard.36.1.71; CARUSO I, 1990, J RHEUMATOL, V17, P1263; DAWES PT, 1986, ANN RHEUM DIS, V45, P945, DOI 10.1136/ard.45.11.945; DECARVALHO A, 1980, ACTA RADIOL DIAGN, V21, P551, DOI 10.1177/028418518002100419; EBERHARDT KB, 1990, RHEUMATOL INT, V10, P135, DOI 10.1007/BF02274837; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; Kaarela K, 1985, Scand J Rheumatol Suppl, V57, P1; KAY EA, 1992, BRIT J RHEUMATOL, V31, P477; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; LARSEN A, 1977, ACTA RADIOL DIAGN, V18, P481, DOI 10.1177/028418517701800415; LUUKKAINEN R, 1983, CLIN EXP RHEUMATOL, V1, P295; LUUKKAINEN R, 1977, SCAND J RHEUMATOL, V6, P189, DOI 10.3109/03009747709095448; MOTTONEN TT, 1988, ANN RHEUM DIS, V47, P648, DOI 10.1136/ard.47.8.648; SHARP JT, 1989, ARTHRITIS RHEUM-US, V32, P221, DOI 10.1002/anr.1780320218; SJOBLOM KG, 1984, SCAND J RHEUMATOL, V13, P21; *STAT CORP, 1995, STAT STAT SOFTW REL; SUAREZALMAZOR ME, 1994, J RHEUMATOL, V21, P1438; SYMMONS DPM, 1994, BRIT J RHEUMATOL, V33, P735; TEITSSON I, 1984, ANN RHEUM DIS, V43, P673, DOI 10.1136/ard.43.5.673; VANDERHEIDE A, 1995, ARTHRITIS RHEUM, V38, P1466; VANDERHEIJDE DMF, 1988, SEMIN ARTHRITIS RHEU, V17, P284; VANZEBEN D, 1993, J RHEUMATOL, V20, P1288; WESTEDT ML, 1986, ANN RHEUM DIS, V45, P809, DOI 10.1136/ard.45.10.809; YOUNG A, 1988, BRIT J RHEUMATOL, V27, P94	25	86	88	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					471	476						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VE080	8776318				2022-12-28	WOS:A1996VE08000025
J	Holmes, J; Gilbody, S				Holmes, J; Gilbody, S			Differences in use of abbreviated mental test score by geriatricians and psychiatrists	BRITISH MEDICAL JOURNAL			English	Article											Holmes, J (corresponding author), UNIV LEEDS,GEN INFIRM,DEPT LIAISONS PSYCHIAT,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.		Gilbody, Simon/AAY-3720-2021; Gilbody, Simon/E-6543-2010	Gilbody, Simon/0000-0002-8236-6983; 				ARDERN M, 1993, INT J GERIATR PSYCH, V8, P929, DOI 10.1002/gps.930081107; GUSTAFSON Y, 1991, J AM GERIATR SOC, V39, P760, DOI 10.1111/j.1532-5415.1991.tb02697.x; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; RABINS PV, 1982, BRIT J PSYCHIAT, V140, P149, DOI 10.1192/bjp.140.2.149; 1981, J R COLL PHYSICIANS, V15, P141	5	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 24	1996	313	7055					465	465						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VE080	8776314				2022-12-28	WOS:A1996VE08000021
J	Mashimo, H; Wu, DC; Podolsky, DK; Fishman, MC				Mashimo, H; Wu, DC; Podolsky, DK; Fishman, MC			Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor	SCIENCE			English	Article							PANCREATIC SPASMOLYTIC POLYPEPTIDE; EXPRESSION; PEPTIDES; CELLS; RAT; IDENTIFICATION; DISRUPTION; SECRETION; LETHALITY; TISSUES	The mechanisms that maintain the epithelial integrity of the gastrointestinal tract remain largely undefined. The gene encoding intestinal trefoil factor (ITF), a protein secreted throughout the small intestine and colon, was rendered nonfunctional in mice by targeted disruption. Mice lacking ITF had impaired mucosal healing and died from extensive colitis after oral administration of dextran sulfate sodium, an agent that causes mild epithelial injury in wild-type mice. ITF-deficient mice manifested poor epithelial regeneration after injury. These findings reveal a central role for ITF in the maintenance and repair of the intestinal mucosa.	MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,CTR STUDY INFLAMMATORY BOWEL DIS,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP EAST,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital					NIDDK NIH HHS [R01DK46906, P30DK43351, T32DK07191] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007191, R01DK046906, P30DK043351] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; CARR MD, 1992, BIOCHEMISTRY-US, V31, P1998, DOI 10.1021/bi00122a015; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; Fox JG, 1996, GASTROENTEROLOGY, V110, P155, DOI 10.1053/gast.1996.v110.pm8536852; HANBY AM, 1993, J PATHOL, V169, P355, DOI 10.1002/path.1711690313; JEFFREY GP, 1994, GASTROENTEROLOGY, V106, P336, DOI 10.1016/0016-5085(94)90590-8; JORGENSEN KD, 1982, REGUL PEPTIDES, V3, P231, DOI 10.1016/0167-0115(82)90128-8; KIM HS, 1992, SCAND J GASTROENTERO, V27, P529, DOI 10.3109/00365529209000116; KINDON H, 1995, GASTROENTEROLOGY, V109, P516, DOI 10.1016/0016-5085(95)90340-2; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MASHIMO H, 1995, BIOCHEM BIOPH RES CO, V210, P31, DOI 10.1006/bbrc.1995.1623; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; PODOLSKY DK, 1986, J CLIN INVEST, V77, P1263, DOI 10.1172/JCI112429; PODOLSKY DK, 1993, J BIOL CHEM, V268, P6694; PODOLSKY DK, 1988, CANCER RES, V48, P418; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; STROBER W, 1993, CELL, V75, P203, DOI 10.1016/0092-8674(93)80062-J; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; THIM L, 1982, REGUL PEPTIDES, V3, P221, DOI 10.1016/0167-0115(82)90127-6; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WELLS CL, 1990, J ACQ IMMUN DEF SYND, V3, P361; WRIGHT NA, 1990, J PATHOL, V162, P279, DOI 10.1002/path.1711620402	27	597	624	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					262	265		10.1126/science.274.5285.262	http://dx.doi.org/10.1126/science.274.5285.262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824194				2022-12-28	WOS:A1996VM67100048
J	Porter, JA; Young, KE; Beachy, PA				Porter, JA; Young, KE; Beachy, PA			Cholesterol modification of hedgehog signaling proteins in animal development	SCIENCE			English	Article							LEMLI-OPITZ SYNDROME; CELL-CELL COMMUNICATION; SONIC-HEDGEHOG; POLARITY GENE; AUTOPROTEOLYTIC CLEAVAGE; XENOPUS-LAEVIS; DROSOPHILA; EXPRESSION; INDUCTION; HOMOLOG	Hedgehog (Hh) proteins comprise a family of secreted signaling molecules essential for patterning a variety of structures in animal embryogenesis. During biosynthesis, Hh undergoes an autocleavage reaction, mediated by its carboxyl-terminal domain, that produces a lipid-modified amino-terminal fragment responsible for all known Hh signaling activity. Here it is reported that cholesterol is the lipophilic moiety covalently attached to the amino-terminal signaling domain during autoprocessing and that the carboxyl-terminal domain acts as an intramolecular cholesterol transferase. This use of cholesterol to modify embryonic signaling proteins may account for some of the effects of perturbed cholesterol biosynthesis on animal development.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University								Alberts B., 1994, MOL BIOL CELL; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BROWN MS, 1992, CELL, V71, P187, DOI 10.1016/0092-8674(92)90346-E; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHANG DT, 1994, DEVELOPMENT, V120, P3339; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Christie W.W., 2003, LIPID ANAL; COHEN BI, 1975, STEROIDS, V25, P365, DOI 10.1016/0039-128X(75)90093-8; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; Dupont J., 1982, CHOLESTEROL SYSTEMS; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EKKER SC, 1995, DEVELOPMENT, V121, P2337; EKKER SC, 1995, CURR BIOL, V5, P944, DOI 10.1016/S0960-9822(95)00185-0; ERICSON J, 1995, CELL, V81, P747, DOI 10.1016/0092-8674(95)90536-7; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; Field M. C., 1992, LIPID MODIFICATION P, P155; Forbes AJ, 1996, DEVELOPMENT, V122, P1125; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GIBBONS GF, 1982, BIOCH CHOLESTEROL; HABERLAND ME, 1973, P NATL ACAD SCI USA, V70, P2313, DOI 10.1073/pnas.70.8.2313; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAI CJ, 1995, DEVELOPMENT, V121, P2349; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LOWRY RR, 1968, J LIPID RES, V9, P397; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MACDONALD R, 1995, DEVELOPMENT, V121, P3267; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; Moore DD, 1995, GLOB MOB SURV; Morrison R.T., 1973, ORGANIC CHEM, V3rd; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OPITZ JM, 1994, AM J MED GENET, V50, P344, DOI 10.1002/ajmg.1320500408; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; PORTER JW, UNPUB; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RODRIGUEZ RJ, 1985, METHOD ENZYMOL, V111, P37; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; ROUX C, 1979, TERATOLOGY, V19, P39, DOI 10.1002/tera.1420190107; ROUX C, 1966, CR SOC BIOL, V160, P1353; ROUX C, 1979, TERATOLOGY, V19, P35, DOI 10.1002/tera.1420190106; ROUX C, 1995, 23 ANN C EUR TER SOC; ROUX CHARLES, 1964, ARCH FRANC PEDIAT, V21, P451; Salen G, 1996, J LIPID RES, V37, P1169; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SILBERKANG M, 1983, J BIOL CHEM, V258, P8503; SVOBODA JA, 1995, LIPIDS, V30, P263, DOI 10.1007/BF02537831; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WALSH JP, 1992, METHOD ENZYMOL, V209, P153; XU GR, 1995, GASTROENTEROLOGY, V109, P1301, DOI 10.1016/0016-5085(95)90592-8; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5	63	1062	1106	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					255	259		10.1126/science.274.5285.255	http://dx.doi.org/10.1126/science.274.5285.255			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824192				2022-12-28	WOS:A1996VM67100046
J	Nightingale, SL				Nightingale, SL			Final regulations to reduce children's use of tobacco issued	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, JAMA-J AM MED ASSOC, V274, P1109	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1128	1128						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827954				2022-12-28	WOS:A1996VL33200007
J	Altman, JD; Moss, PAH; Goulder, PJR; Barouch, DH; McHeyzerWilliams, MG; Bell, JI; McMichael, AJ; Davis, MM				Altman, JD; Moss, PAH; Goulder, PJR; Barouch, DH; McHeyzerWilliams, MG; Bell, JI; McMichael, AJ; Davis, MM			Phenotypic analysis of antigen-specific T lymphocytes	SCIENCE			English	Article							MEMORY B-CELLS; PERIPHERAL-BLOOD; ESCHERICHIA-COLI; IMMUNE-RESPONSE; HIGH-FREQUENCY; IN-VIVO; VIRUS; KINETICS; HIV-1; COMPLEXES	Identification and characterization of antigen-specific T lymphocytes during the course of an immune response is tedious and indirect. To address this problem, the peptide-major histocompatability complex (MHC) ligand for a given population of T cells was multimerized to make soluble peptide-MHC tetramers. Tetramers of human lymphocyte antigen A2 that were complexed with two different human immunodeficiency virus (HIV)-derived peptides or with a peptide derived from influenza A matrix protein bound to peptide-specific cytotoxic T cells in vitro and to T cells from the blood of HIV-infected individuals. In general, tetramer binding correlated well with cytotoxicity assays, This approach should be useful in the analysis of T cells specific for infectious agents, tumors, and autoantigens.	STANFORD UNIV,BECKMAN CTR,DEPT MICROBIOL & IMMUNOL,HOWARD HUGHES MED INST,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,STANFORD,CA 94305; JOHN RADCLIFFE HOSP,INST MOL MED,OXFORD OX3 9DU,ENGLAND	Howard Hughes Medical Institute; Stanford University; Stanford University; University of Oxford			Barouch, Dan/Y-3918-2019	Davis, Mark/0000-0001-6868-657X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRUNO L, 1995, IMMUNITY, V2, P37, DOI 10.1016/1074-7613(95)90077-2; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; Doherty PC, 1996, IMMUNOL REV, V150, P23, DOI 10.1111/j.1600-065X.1996.tb00694.x; EWING C, 1995, VIROLOGY, V210, P179, DOI 10.1006/viro.1995.1329; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; HAYAKAWA K, 1987, P NATL ACAD SCI USA, V84, P1379, DOI 10.1073/pnas.84.5.1379; HOFFENBACH A, 1989, J IMMUNOL, V142, P452; HOLTER W, 1985, CELL IMMUNOL, V90, P322, DOI 10.1016/0008-8749(85)90197-2; HOU S, 1993, J IMMUNOL, V150, P5494; JOHNSON RP, 1991, J IMMUNOL, V147, P1512; JULIUS MH, 1972, P NATL ACAD SCI USA, V69, P1934, DOI 10.1073/pnas.69.7.1934; KO HS, 1979, J EXP MED, V150, P246, DOI 10.1084/jem.150.2.246; KOUP RA, 1991, J EXP MED, V174, P1593, DOI 10.1084/jem.174.6.1593; LEHNER PJ, 1995, J EXP MED, V181, P79, DOI 10.1084/jem.181.1.79; MACDONALD HR, 1993, J EXP MED, V177, P1487, DOI 10.1084/jem.177.5.1487; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MCHEYZERWILLIAMS MG, 1991, NATURE, V350, P502, DOI 10.1038/350502a0; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PARISH CR, 1993, J IMMUNOL, V150, P4833; REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641; ROEDERER M, IN PRESS HDB EXPT IM, V4; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Selin LK, 1996, J EXP MED, V183, P2489, DOI 10.1084/jem.183.6.2489; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TRIPP RA, 1995, J IMMUNOL, V154, P5870; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; WALKER PR, 1995, J IMMUNOL, V155, P3443; Zimmermann C, 1996, J EXP MED, V183, P1367, DOI 10.1084/jem.183.4.1367	34	2964	3353	4	195	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 4	1996	274	5284					94	96		10.1126/science.274.5284.94	http://dx.doi.org/10.1126/science.274.5284.94			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VK748	8810254				2022-12-28	WOS:A1996VK74800054
J	Wang, XT; Culotta, VC; Klee, CB				Wang, XT; Culotta, VC; Klee, CB			Superoxide dismutase protects calcineurin from inactivation	NATURE			English	Article							PHOSPHOPROTEIN PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; ACTIVE-SITE; KINASE; IDENTIFICATION; ADAPTATION; COMPLEXES; GENE	CALCINEURIN is the only protein phosphatase known to be under the control of Ca2+ and calmodulin(1,2). It is targeted by immuno-suppressive drugs and has a critical role in T-cell activation(3,4). It is specifically inhibited by immunosuppressant immunophilin complexes, which enabled its function in regulating a wide range of cellular responses to Ca2+-mobilizing signals(5,6) to be identified. Calcineurin in situ is 10-20 times more active than in the purified form and is subject to a time- and Ca2+/calmodulin-dependent reversible inactivation that is facilitated by small, heat-stable molecules(7). Here we identify a factor that prevents the inactivation of calcineurin be vitro and in vivo as the enzyme superoxide dismutase, which indicates that inactivation may be the result of oxidative damage to the Fe-Zn active centre of calcineurin. The redox state of iron provides a mechanism to regulate calcineurin activity by desensitizing the enzyme and coupling Ca2+-dependent protein dephosphorylation to the redox state of the cell. The protection of calcineurin against inactivation by superoxide dismutase constitutes a new physiological role for this enzyme which enables the Ca2+-dependent regulation of cellular processes to be modulated by the redox potential.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DIV TOXICOL SCI,BALTIMORE,MD 21205	Johns Hopkins University	Wang, XT (corresponding author), NCI,BIOCHEM LAB,NIH,BETHESDA,MD 20892, USA.							BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; CARRICO RJ, 1969, J BIOL CHEM, V244, P6087; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DELABAR JM, 1987, EUR J BIOCHEM, V166, P181, DOI 10.1111/j.1432-1033.1987.tb13500.x; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HIRATA D, 1995, MOL GEN GENET, V249, P257, DOI 10.1007/BF00290525; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; KINCAID RL, 1991, ADV PROT PHOSPHATASE, V6, P73; KING MM, 1984, J BIOL CHEM, V259, P8847; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LIU XF, 1992, J BIOL CHEM, V267, P18298; MARTIN BL, 1986, J BIOL CHEM, V261, P4545; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; PATERSON D, 1994, MOL GENET MED, V4, P79; Qin K. -F., 1995, FASEB J, V9, pA1347; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; SEMMER PM, 1995, FEBS LETT, V374, P237; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; WANG H, 1991, BIOCHEMISTRY-US, V30, P3019, DOI 10.1021/bi00226a006; YU L, 1995, J AM CHEM SOC, V117, P10147, DOI 10.1021/ja00145a040	30	233	243	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1996	383	6599					434	437		10.1038/383434a0	http://dx.doi.org/10.1038/383434a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VL463	8837775				2022-12-28	WOS:A1996VL46300061
J	Roberts, I; Power, C				Roberts, I; Power, C			Does the decline in child injury mortality vary by social class? A comparison of class specific mortality in 1981 and 1991	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine whether the decline in child injury death rates between 1981 and 1991 varied by social class. Design-Comparison of class specific child injury death rates for 1979, 1980, 1982, and 1983, with those for the four years 1989-92. Setting-England and Wales. Subjects-Children aged 0-15 years. Main outcome measures-Death rates from injury and poisoning. Results-Death rates from injury and poisoning have fallen for children in all social classes, The decline for children in social classes IV and V (21% and 2% respectively), however, is smaller than that for children in social classes I and II (32% and 37%). As a result of the differential decline in injury death rates, socioeconomic mortality differentials have increased. In the four years 1979-80 and 1982-83 the injury death rate for children in social class V was 3.5 times that of children in social class I. For the four years 1989-92 the injury death rate for children in social class V was 5.0 times that of children in social class I. Poisson regression modelling showed that the trend in the decline in death rates across the social classes was unlikely to have arisen by chance alone. Conclusions-Socioeconomic inequalities in child injury death rates have increased. If these gradients persist, the Health of the Nation's target is likely to be met for children in the non-manual social classes but not for those in the manual social classes.			Roberts, I (corresponding author), UNIV LONDON,INST CHILD HLTH,CHILD HLTH MONITORING UNIT,LONDON WC1N 1EH,ENGLAND.							Benzeval M, 1995, TACKLING INEQUALITIE; Bradshaw J., 1991, 6 DEP SOC SEC; *DEP HLTH, 1995, VAR HLTH WHAT CAN DE; *DEP HLTH, 1995, 2 DEP HLTH; Department of Health, 1992, HLTH NAT STRAT HLTH; EVANS L, 1992, AM J PUBLIC HEALTH, V82, P1105, DOI 10.2105/AJPH.82.8.1105; HASKEY J, 1993, POPULATION TRENDS, V72, P34; HASKEY J, 1994, POPULATION TRENDS, V78, P5; *HOM OFF, 1994, HOUS FIR ENGL WAL IN; JUDGE K, 1993, BRIT MED J, V306, P677, DOI 10.1136/bmj.306.6879.677; MARE RD, 1982, AM J PUBLIC HEALTH, V72, P539, DOI 10.2105/AJPH.72.6.539; MCLOONE P, 1994, BRIT MED J, V309, P1465, DOI 10.1136/bmj.309.6967.1465; PAUL CL, 1992, J PAEDIATR CHILD H, V28, P22, DOI 10.1111/j.1440-1754.1992.tb02612.x; PHILLIMORE P, 1994, BRIT MED J, V309, P57; *US BUR CENS, 1988, 1979 1980 CENS POP; *US CENS POP, 1991, CENS POP, V3; WILKINSON RG, 1994, UNFAIR SHARES EFFECT; WOODROFFE C, 1993, CHILDREN TEENAGERS H	18	172	176	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					784	786						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842070				2022-12-28	WOS:A1996VK56600022
J	Stumpflen, I; Stumpflen, A; Wimmer, M; Bernaschek, G				Stumpflen, I; Stumpflen, A; Wimmer, M; Bernaschek, G			Effect of detailed fetal echocardiography as part of routine prenatal ultrasonographic screening on detection of congenital heart disease	LANCET			English	Article							LOW-RISK; DOPPLER ECHOCARDIOGRAPHY; SONOGRAPHIC DIAGNOSIS; 4-CHAMBER VIEW; HUMAN-FETUS; POPULATION; MALFORMATIONS; ACCURACY; DEFECTS; BIRTHS	Background Cardiac abnormalities are frequently not detected by routine ultrasound screening examinations. Although detailed fetal echocardiography is more sensitive in detection of congenital heart disease, it is used only for high-risk cases. The main aim of this study was to assess the prenatal detection of congenital heart disease by detailed fetal echocardiography in an unselected, consecutive group of pregnant women. Methods Between Jan 1, 1993, and Sept 30, 1994, all women who attended our antenatal-care unit were routinely offered a detailed fetal echocardiography examination at 18-28 weeks' gestation. 3085 consecutive women were screened: 2181 were screening cases with no known risk factor for congenital heart disease; 540 had maternal risk factors for congenital heart disease, such as a family history or coexisting maternal disease; 364 had sonographically detected abnormalities. The examination included the four-chamber view, outflow-tract scan, and colour-flow mapping; doppler and M-mode investigations were also done when appropriate. Findings 46 cases of congenital heart disease were detected prenatally by echocardiography-15 in the group with no risk factors, three in the group with maternal risk factors, and 28 in the group with sonographic abnormalities. Postnatal assessments found six further cases of congenital heart disease that had not been detected prenatally, but these were all minor cases. There were no false-positive diagnoses (sensitivity 85.5%, specificity 100%). The incidence of congenital heart disease in screening cases with no risk factors and in those with maternal risk factors was low (6.9% per 1000, 5.6 per 1000) and similar to the expected overall incidence of 8.0 per 1000 livebirths in the general population. In the group with sonographic abnormalities congenital heart disease was found significantly more often (79.9 per 1000). Interpretation inclusion of detailed fetal echocardiography as a screening examination has a substantial effect on detection of congenital heart disease since a major proportion of prenatally detectable cases occur in a low-risk population.	UNIV VIENNA,SCH MED,DEPT PRENATAL DIAG & THERAPY,A-1097 VIENNA,AUSTRIA; UNIV VIENNA,SCH MED,DEPT INTERNAL MED 2,A-1097 VIENNA,AUSTRIA; UNIV VIENNA,SCH MED,DEPT PAEDIAT CARDIOL,A-1097 VIENNA,AUSTRIA	University of Vienna; University of Vienna; University of Vienna								ACHIRON R, 1992, BRIT MED J, V304, P671, DOI 10.1136/bmj.304.6828.671; ACHIRON R, 1994, J ULTRAS MED, V13, P783; ALLAN L, 1994, ULTRASOUND OBST GYN, V4, P441, DOI 10.1046/j.1469-0705.1994.04060441.x; Allan L D, 1986, MANUAL FETAL ECHOCAR; ALLAN LD, 1980, BRIT HEART J, V44, P444; ALLAN LD, 1986, BRIT MED J, V292, P1717, DOI 10.1136/bmj.292.6537.1717; ALLAN LD, 1986, AM J CARDIOL, V58, P334, DOI 10.1016/0002-9149(86)90072-X; ALLAN LD, 1985, BRIT HEART J, V54, P523; BROMLEY B, 1992, AM J OBSTET GYNECOL, V166, P1473, DOI 10.1016/0002-9378(92)91622-H; COPEL JA, 1987, AM J OBSTET GYNECOL, V157, P648, DOI 10.1016/S0002-9378(87)80022-4; COPEL JA, 1991, OBSTET GYNECOL, V78, P1; DALTON ME, 1993, NEW ENGL J MED, V328, P114; DEVORE GR, 1987, AM J OBSTET GYNECOL, V156, P1054, DOI 10.1016/0002-9378(87)90110-4; DEVORE GR, 1994, ULTRASOUND OBST GYN, V6, P463; FERENCZ C, 1987, TERATOLOGY, V35, P367, DOI 10.1002/tera.1420350311; GEMBRUCH U, 1991, J PERINAT MED, V19, P27, DOI 10.1515/jpme.1991.19.1-2.27; GEMBRUCH U, 1989, PRENATAL DIAG, V9, P535, DOI 10.1002/pd.1970090802; GEMBRUCH U, 1990, OBSTET GYNECOL, V75, P496; GREENWOOD RD, 1975, PEDIATRICS, V55, P485; HOFFMAN JIE, 1978, AM J CARDIOL, V42, P641, DOI 10.1016/0002-9149(78)90635-5; KLEINMAN CS, 1980, PEDIATRICS, V65, P1059; MITCHELL SC, 1971, CIRCULATION, V43, P323, DOI 10.1161/01.CIR.43.3.323; OTT WJ, 1995, AM J OBSTET GYNECOL, V172, P1741, DOI 10.1016/0002-9378(95)91406-4; REED KL, 1986, CIRCULATION, V73, P41, DOI 10.1161/01.CIR.73.1.41; REED KL, 1988, FETAL ECHOCARDIOGRAP; ROTTEM S, 1989, LANCET, V1, P444; SAARIKEMPPAINEN A, 1990, LANCET, V336, P387, DOI 10.1016/0140-6736(90)91941-3; SAHN DJ, 1980, CIRCULATION, V62, P588, DOI 10.1161/01.CIR.62.3.588; SANDOR GGS, 1986, OBSTET GYNECOL, V67, P358; TEGNANDER E, 1995, ULTRASOUND OBST GYN, V5, P372, DOI 10.1046/j.1469-0705.1995.05060372.x; TODROS T, 1992, J MATERN-FETAL INVES, V2, P157; WIGTON TR, 1993, OBSTET GYNECOL, V82, P219	32	210	226	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1996	348	9031					854	857		10.1016/S0140-6736(96)04069-X	http://dx.doi.org/10.1016/S0140-6736(96)04069-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826811				2022-12-28	WOS:A1996VK03700011
J	Donnan, GA; Davis, SM; Chambers, BR; Gates, PC; Hankey, GJ; McNeil, JJ; Rosen, D; StewartWynne, EG; Tuck, RR				Donnan, GA; Davis, SM; Chambers, BR; Gates, PC; Hankey, GJ; McNeil, JJ; Rosen, D; StewartWynne, EG; Tuck, RR			Streptokinase for acute ischemic stroke with relationship to time of administration	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; THROMBOLYTIC THERAPY; INTRACAROTID UROKINASE; FIBRINOLYTIC THERAPY; CEREBRAL INFARCTION; TERRITORY STROKE; EMBOLIC STROKE; URGENT THERAPY; OCCLUSION; ARTERY	Objectives.-To determine whether the administration of 1.5 million units of streptokinase intravenously within 4 hours of the onset of acute ischemic stroke would reduce morbidity and mortality at 3 months and whether outcomes may be better for those receiving therapy with in 3 hours of stroke onset compared with those receiving it after 3 hours. Design.-Randomized, double-blind, placebo-controlled trial with 3-month follow-up. Participants.-A total of 340 patients, aged 18 to 85 years, with moderate to severe strokes were randomized from 40 centers throughout Australia from June 1992 to November 1994. Intervention.-Administration of 1.5 million units of streptokinase or placebo intravenously in 100 mt of normal saline over 1 hour. Main Outcome Measure.-Combined death and disability score (Barthel index <60) 3 months after the stroke. Results.-Using an intention-to-treat analysis with a combined death and disability score at 3 months after stroke as the primary end point, we found a nonsignificant overall trend toward unfavorable outcomes for streptokinase vs placebo (relative risk [RR] of unfavorable outcome, 1.08; 95% confidence interval [CI], 0.74-1.58) and an excess of hematomas (13.2% [12.6% symptomatic] in the treated group, 3% [2.4% symptomatic] for placebo [P<.01]). However, poor outcomes were confined to patients receiving therapy more than 3 hours after stroke onset (RR of unfavorable outcome, 1.22; 95% CI, 0.80-1.86). In contrast, among the 70 patients who were entered into the trial within 3 hours of stroke onset, there was a trend toward improved outcomes for those who received streptokinase (FIR of unfavorable outcome, 0.66; 95% CI, 0.28-1.58), and this outcome pattern was significantly better than for those receiving therapy after 3 hours (P=.04). Streptokinase administration resulted in excess deaths in the group treated after 3 hours (RR, 1.98; 95% CI, 1.18-3.35), but not among those treated within 3 hours (RR, 1.11; 95% CI, 0.38-3.21). Conclusion.-The administration of streptokinase within 4 hours of acute ischemic stroke increased morbidity and mortality at 3 months. While treatment within 3 hours of stroke was safer and associated with significantly better outcomes than later treatment, it showed no significant benefit over placebo, The timing of thrombolytic therapy for acute stroke is critical.	ROYAL MELBOURNE HOSP, MELBOURNE, VIC, AUSTRALIA; GEELONG HOSP, GEELONG, VIC, AUSTRALIA; ROYAL PERTH HOSP, PERTH, WA, AUSTRALIA; ALFRED HOSP, VICTORIA, BC, CANADA; ROYAL PRINCE ALFRED HOSP, SYDNEY, NSW, AUSTRALIA; WODEN VALLEY HOSP, CANBERRA, ACT, AUSTRALIA	Royal Melbourne Hospital; Geelong Hospital; Royal Perth Hospital; University of Western Australia; University of Sydney; Australian National University; Canberra Hospital	Donnan, GA (corresponding author), AUSTIN & REPATRIAT MED CTR, HEIDELBERG, VIC, AUSTRALIA.		DONNAN, GEOFFREY A/A-9947-2008; Simes, Robert John/P-1497-2014; Davis, Stephen M/L-5260-2013; Hankey, Graeme J/H-4968-2014; McNeil, John/L-6440-2019	Davis, Stephen M/0000-0003-0962-2300; Hankey, Graeme J/0000-0002-6044-7328; McNeil, John/0000-0002-1049-5129; Donnan, Geoffrey/0000-0001-6324-3403				[Anonymous], 1988, LANCET, V2, P349; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BELL BA, 1985, J NEUROSURG, V62, P31, DOI 10.3171/jns.1985.62.1.0031; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; CANDELISE L, 1995, LANCET, V346, P1509; COTE R, 1986, STROKE, V17, P731, DOI 10.1161/01.STR.17.4.731; Crowell RM, 1970, STROKE, V1, P439, DOI 10.1161/01.STR.1.6.439; del Zoppo GJ, 1993, THROMBOLYTIC THERAPY, P80; DELZOPPO G, 1993, THROMBOLYTIC THERAPY, V2; DELZOPPO GJ, 1988, STROKE, V19, P307, DOI 10.1161/01.STR.19.3.307; DELZOPPO GJ, 1986, STROKE, V17, P638, DOI 10.1161/01.STR.17.4.638; DONNAN GA, 1995, LANCET, V345, P578; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HAIN RF, 1952, J NEUROPATH EXP NEUR, V11, P34, DOI 10.1097/00005072-195201000-00004; HALEY EC, 1992, STROKE, V23, P641, DOI 10.1161/01.STR.23.5.641; HALLENBECK JM, 1990, ARCH NEUROL-CHICAGO, V47, P1245, DOI 10.1001/archneur.1990.00530110107027; HENZE T, 1987, LANCET, V2, P1391; Hommel M, 1996, NEW ENGL J MED, V335, P145; HORNIG CR, 1986, STROKE, V17, P179, DOI 10.1161/01.STR.17.2.179; JORGENSEN L, 1969, J NEUROL SCI, V9, P285, DOI 10.1016/0022-510X(69)90078-1; KAMIJYO Y, 1977, J NEUROPATH EXP NEUR, V36, P338, DOI 10.1097/00005072-197703000-00008; LEFTOVITZ J, 1992, AUST NZ J MED, V22, P30; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; MORI E, 1988, STROKE, V19, P802, DOI 10.1161/01.STR.19.7.802; OKADA Y, 1989, STROKE, V20, P598, DOI 10.1161/01.STR.20.5.598; PETITO CK, 1979, J NEUROPATH EXP NEUR, V38, P222, DOI 10.1097/00005072-197905000-00003; SLIVKA A, 1987, STROKE, V18, P1148, DOI 10.1161/01.STR.18.6.1148; VERSTRAETE M, 1986, BLOOD, V67, P1529; YAMAGUCHI T, 1993, CEREBROVASC DIS, V3, P269, DOI 10.1159/000108714; ZEUMER H, 1984, NEURORADIOLOGY, V26, P315; ZIVIN JA, 1985, SCIENCE, V230, P1289, DOI 10.1126/science.3934754; ZIVIN JA, 1988, ARCH NEUROL-CHICAGO, V45, P387, DOI 10.1001/archneur.1988.00520280033012	34	315	321	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1996	276	12					961	966		10.1001/jama.276.12.961	http://dx.doi.org/10.1001/jama.276.12.961			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH990	8805730				2022-12-28	WOS:A1996VH99000036
J	Booth, H; Pollitt, C; Jessen, EC; Hendrick, DJ; Cant, AJ				Booth, H; Pollitt, C; Jessen, EC; Hendrick, DJ; Cant, AJ			When is referral of Heaf test positive schoolchildren worth while? Prospective study	BRITISH MEDICAL JOURNAL			English	Article							BCG		NEWCASTLE GEN HOSP,DEPT PAEDIAT INFECTR DIS,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND; NEWCASTLE GEN HOSP,DEPT RESP MED,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital; Newcastle General Hospital								[Anonymous], 1978, Tubercle, V59, P245; CAPEWELL S, 1986, BRIT J DIS CHEST, V80, P254, DOI 10.1016/0007-0971(86)90061-6; Hollyoak V, 1992, Commun Dis Rep CDR Rev, V2, pR67; JOSEPH CA, 1992, BRIT MED J, V305, P495, DOI 10.1136/bmj.305.6852.495; 1994, THORAX, V49, P1193	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					726	727						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819443				2022-12-28	WOS:A1996VJ44100024
J	Bozic, CR; Lu, B; Hopken, UE; Gerard, C; Gerard, NP				Bozic, CR; Lu, B; Hopken, UE; Gerard, C; Gerard, NP			Neurogenic amplification of immune complex inflammation	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; PASSIVE ARTHUS REACTION; MAST-CELLS; SUBSTANCE-P; FC-RECEPTORS; MICE; NEUROPEPTIDES; MOUSE; INVOLVEMENT; PERITONITIS	The formation of intrapulmonary immune complexes in mice generates a vigorous inflammatory response characterized by microvascular permeability and polymorphonuclear neutrophil influx. Gene-targeted disruption of the substance P receptor (NK-1R) protected the lung from immune complex injury, as did disruption of the C5a anaphylatoxin receptor. Immunoreactive substance P was measurable in fluids lining the lung at time points before neutrophil influx and may thus be involved in an early step in the inflammatory response to immune complexes in the lung.	CHILDRENS HOSP,INA SUE PERLMUTTER LAB,BOSTON,MA 02115	Harvard University; Boston Children's Hospital					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036162, R01HL051366, R37HL036162] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51366, HL36162] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANSEL JC, 1993, J IMMUNOL, V150, P4478; Arthus M, 1903, CR SOC BIOL, V55, P817; BALUK P, 1996, AM J RESP CRIT CARE, V153, pA161; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; BOOMSMA JD, 1992, CHEST, V101, pS389, DOI 10.1378/chest.101.6_Supplement.389S; BOST K L, 1992, Regional Immunology, V4, P105; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BUCKLEY TL, 1994, J IMMUNOL, V153, P4169; BUNNETT N, COMMUNICATION; COCHRANE CG, 1974, INFLAMMATORY PROCESS, V3, pCH3; DAVIES KA, 1994, SPRINGER SEMIN IMMUN, V15, P397, DOI 10.1007/BF01837367; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; HOPKEN UE, IN PRESS NATURE; INOUE H, 1993, BRIT J PHARMACOL, V110, P1614, DOI 10.1111/j.1476-5381.1993.tb14009.x; LARSEN GL, 1981, AM REV RESPIR DIS, V123, P434; LUBERNAROD J, 1994, J IMMUNOL, V152, P819; MANTIONE CR, 1990, BRIT J PHARMACOL, V99, P516, DOI 10.1111/j.1476-5381.1990.tb12960.x; MAZUMDAR S, 1992, AM J GASTROENTEROL, V87, P176; PASCUAL DW, 1990, IMMUNOLOGY, V71, P52; RAMOS BF, 1994, J IMMUNOL, V152, P1380; RAMOS BF, 1992, EUR J IMMUNOL, V22, P2381, DOI 10.1002/eji.1830220930; RAMOS BF, 1990, J IMMUNOL, V145, P1868; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; WARREN JS, 1989, J CLIN INVEST, V84, P1873, DOI 10.1172/JCI114374; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922; ZHANG Y, 1991, J CLIN INVEST, V88, P841, DOI 10.1172/JCI115385	27	282	287	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1996	273	5282					1722	1725		10.1126/science.273.5282.1722	http://dx.doi.org/10.1126/science.273.5282.1722			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781237				2022-12-28	WOS:A1996VH40800044
J	Valcarcel, J; Gaur, RK; Singh, R; Green, MR				Valcarcel, J; Gaur, RK; Singh, R; Green, MR			Interaction of U2AF(65) RS region with pre-mRNA of branch point and promotion base pairing with U2 snRNA	SCIENCE			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; PROTEIN-PROTEIN INTERACTIONS; RNA-BINDING PROTEINS; SPLICING FACTOR U2AF; MESSENGER-RNA; PREMESSENGER RNA; CONSERVED FAMILY; AUXILIARY FACTOR; SITE SELECTION; RECOGNITION	The mammalian splicing factor U2AF(65) binds to the polypyrimidine tract adjacent to the 3' splice site and promotes assembly of U2 small nuclear ribonucleoprotein on the upstream branch point, an interaction that involves base pairing with U2 small nuclear RNA(snRNA). U2AF(65) contains an RNA binding domain, required for interaction with the polypyrimidine tract, and an arginine-serine-rich (RS) region, required for U2 snRNP recruitment and splicing, Here it is reported that binding of U2AF(65) to the polypyrimidine tract directed the RS domain to contact the branch point and promoted U2 snRNA-branch point base pairing even in the absence of other splicing factors. Analysis of RS domain mutants indicated that the ability ol U2AF(65) to contact the branch point, to promote the U2 snRNA-branch point interaction, and to support splicing are related activities, requiring only a few basic amino acids. Thus, the U2AF(65) RS domain plays a direct role in modulating spliceosomal RNA-RNA interactions.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOL MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester			Valcarcel, Juan/O-9814-2014	Valcarcel, Juan/0000-0001-5398-3571				AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; ERICSON G, 1988, ANAL BIOCHEM, V174, P215, DOI 10.1016/0003-2697(88)90538-6; FEUGHELMAN M, 1955, NATURE, V175, P834, DOI 10.1038/175834a0; FLECKNER J, UNPUB; GAUR RK, 1995, RNA, V1, P407; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; HODGES PE, 1994, CURR BIOL, V4, P264, DOI 10.1016/S0960-9822(00)00061-0; KLEINSCHMIDT AM, 1989, NUCLEIC ACIDS RES, V17, P4817, DOI 10.1093/nar/17.12.4817; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LEE CG, 1993, J BIOL CHEM, V268, P13472; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MIRFAKHRAI M, 1993, NUCLEIC ACIDS RES, V21, P3591, DOI 10.1093/nar/21.15.3591; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; ONO W, 1994, MOL CELL BIOL, V14, P7611, DOI 10.1128/MCB.14.11.7611; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; PATTON JR, 1987, MOL CELL BIOL, V7, P4030, DOI 10.1128/MCB.7.11.4030; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SMITH CWJ, 1989, CELL, V56, P749, DOI 10.1016/0092-8674(89)90678-8; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TEARE J, 1990, NUCLEIC ACIDS RES, V18, P855, DOI 10.1093/nar/18.4.855; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; VALCARCEL J, UNPUB; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	46	232	233	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1996	273	5282					1706	1709		10.1126/science.273.5282.1706	http://dx.doi.org/10.1126/science.273.5282.1706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781232				2022-12-28	WOS:A1996VH40800039
J	Kennedy, AL				Kennedy, AL			The gift	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					513	513		10.7326/0003-4819-125-6-199609150-00016	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00016			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779468				2022-12-28	WOS:A1996VF88200017
J	Zureik, M; Courbon, D; Ducimetiere, P				Zureik, M; Courbon, D; Ducimetiere, P			Serum cholesterol concentration and death from suicide in men: Paris prospective study I	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARASUICIDE; PREVENTION	Objective-To investigate whether low serum cholesterol concentration or changing serum cholesterol concentration is associated with risk of suicide in men. Design-Cohort study with annual repeat measurements of serum cholesterol concentration (for up to four years). Setting-Paris, France. Subjects-6393 working men, aged 43-52 in 1967-72, who had at least three measurements of serum cholesterol concentration. Main outcome measures-Individual change over time in serum cholesterol concentration (estimated using within person linear regression method); death hom suicide during average of 17 years) follow up after last examination. Results-32 men committed suicide during follow up. After adjustment for age and other factors, relative risk of suicide for men with low average serum cholesterol concentration (<4.78 mmol/l) compared with those with average serum cholesterol concentration of 4.78-6.21 mmol/l was 3.16 (95% confidence interval 1.38 to 7.22, P = 0.007). Men whose serum cholesterol concentration decreased by more than 0.13 mmol/l a year had multivariate adjusted relative risk of 2.17 (0.97 to 4.84, P = 0.056) compared with those whose cholesterol remained stable (change of less than or equal to 0.13 mmol/l a year). Conclusion-Both low serum cholesterol concentration and declining cholesterol concentration were associated with increased risk of death from suicide in men. Although there is some evidence in favour of a concomitant rather than a causal effect for interpreting these associations, long term surveillance of subjects included in trials of lipid lowering treatments seems warranted.			Zureik, M (corresponding author), HOP BROUSSAIS, NATL INST HLTH & MED RES, INSERM, U258, 96 RUE DIDOT, F-75014 PARIS, FRANCE.		Zureik, Mahmoud/F-7855-2018	Zureik, Mahmoud/0000-0002-8393-4217				ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; GALLERANI M, 1995, BMJ-BRIT MED J, V310, P1632, DOI 10.1136/bmj.310.6995.1632; LAW MR, 1995, BMJ-BRIT MED J, V311, P807, DOI 10.1136/bmj.311.7008.807a; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; Lecomte D, 1995, Encephale, V21, P41; MAGNI G, 1988, NEUROPSYCHOBIOLOGY, V20, P126, DOI 10.1159/000118485; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; PEDERSEN TR, 1994, LANCET, V344, P1383; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Steegmans PHA, 1996, BRIT MED J, V312, P221, DOI 10.1136/bmj.312.7025.221; STEEGMANS PHA, 1995, CARDIOVASC RISK FACT, V5, P267	11	128	130	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	1996	313	7058					649	651						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8811757	Green Published			2022-12-28	WOS:A1996VH16500018
J	Abdulla, KA; Davidson, NM				Abdulla, KA; Davidson, NM			A woman who collapsed after painting her soles	LANCET			English	Article							PARA-PHENYLENEDIAMINE				Abdulla, KA (corresponding author), NW ARMED FORCES HOSP,DEPT INTERNAL MED,POB 100,TABUK,SAUDI ARABIA.							BAUD F, 1983, LANCET, V2, P514; CHUGH KS, 1982, J MED, V13, P131; DARCY PF, 1982, PHRM INT, P217; ELANSARY EH, 1983, LANCET, V1, P1341, DOI 10.1016/S0140-6736(83)92456-X; GOSSELIN RE, 1984, CLIN TOXICOLOGY COMM, P210	5	30	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					658	658		10.1016/S0140-6736(96)04506-0	http://dx.doi.org/10.1016/S0140-6736(96)04506-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782757				2022-12-28	WOS:A1996VF60900012
J	Apseloff, G; Foulds, G; LaBoyGoral, L; Kraut, E; Vincent, J				Apseloff, G; Foulds, G; LaBoyGoral, L; Kraut, E; Vincent, J			Severe neutropenia caused by recommended prophylactic doses of rifabutin	LANCET			English	Letter							COMPLEX; AZT		PFIZER INC,PFIZER CENT RES,GROTON,CT 06340; OHIO STATE UNIV,COLL MED,DEPT INTERNAL MED,COLUMBUS,OH 43210	Pfizer; Ohio State University	Apseloff, G (corresponding author), OHIO STATE UNIV,COLL MED,DEPT PHARMACOL,DIV CLIN PHARMACOL,COLUMBUS,OH 43210, USA.							BRUGHERA M, 1995, EXP TOXICOL PATHOL, V47, P1; GONZALEZMONTANER LJ, 1994, TUBERCLE LUNG DIS, V75, P341, DOI 10.1016/0962-8479(94)90079-5; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; YARCHOAN R, 1988, LANCET, V1, P76	5	29	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 7	1996	348	9028					685	685		10.1016/S0140-6736(05)65109-4	http://dx.doi.org/10.1016/S0140-6736(05)65109-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782773				2022-12-28	WOS:A1996VF60900049
J	Imbert, V; Rupec, RA; Livolsi, A; Pahl, HL; Traenckner, EBM; MuellerDieckmann, C; Farahifar, D; Rossi, B; Auberger, P; Baeuerle, PA; Peyron, JF				Imbert, V; Rupec, RA; Livolsi, A; Pahl, HL; Traenckner, EBM; MuellerDieckmann, C; Farahifar, D; Rossi, B; Auberger, P; Baeuerle, PA; Peyron, JF			Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha	CELL			English	Article							SIGNAL-INDUCED PHOSPHORYLATION; REL-ASSOCIATED PP40; T-CELL ACTIVATION; TRANSCRIPTION FACTORS; KINASE; PROTEIN; INHIBITOR; TRANSDUCTION; RECEPTOR; DISSOCIATION	The transcription factor NF-kappa B regulates genes participating in immune and inflammatory responses. In T lymphocytes, NF-kappa B is sequestered in the cytosol by the inhibitor I kappa B-alpha and released after serine phosphorylation of I kappa B-alpha that regulates its ubiquitin-dependent degradation. We report an alternative mechanism of NF-kappa B activation. Stimulation of Jurkat T cells with the protein tyrosine phosphatase inhibitor and T cell activator pervanadate led to NF-kappa B activation through tyrosine phosphorylation but not degradation of I kappa B-alpha. Pervanadate-induced I kappa B-alpha phosphorylation and NF-kappa B activation required expression of the T cell tyrosine kinase p56(lck). Reoxygenation of hypoxic cells appeared as a physiological effector of I kappa B-alpha tyrosine phosphorylation. Tyrosine phosphorylation of I kappa B-alpha represents a proteolysis-independent mechanism of NF-kappa B activation that directly couples NF-kappa B to cellular tyrosine kinase.	UNIV FREIBURG, INST BIOCHEM, D-79104 FREIBURG, GERMANY	University of Freiburg	Imbert, V (corresponding author), FAC MED PASTEUR, INSERM U364, F-06107 NICE 02, FRANCE.		Peyron, Jean-Francois/M-5682-2016; Jean-Francois, Peyron/AAA-9496-2022; Pahl, Heike/AGM-5260-2022; AUBERGER, Patrick/G-1491-2013; Imbert, Véronique/I-6093-2016	Peyron, Jean-Francois/0000-0001-6113-916X; Jean-Francois, Peyron/0000-0001-6113-916X; AUBERGER, Patrick/0000-0002-2481-8275; Imbert, Véronique/0000-0003-2103-6718				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DRUKER BJ, 1994, J BIOL CHEM, V269, P5387; EICHER DM, 1994, J IMMUNOL, V152, P2710; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Imbert V, 1996, J INFLAMM, V46, P65; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; KOONG AC, 1994, CANCER RES, V54, P1425; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SECRIST JP, 1990, J BIOL CHEM, V265, P20394; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	618	638	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 6	1996	86	5					787	798		10.1016/S0092-8674(00)80153-1	http://dx.doi.org/10.1016/S0092-8674(00)80153-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VG372	8797825	Bronze			2022-12-28	WOS:A1996VG37200012
J	Snashall, D				Snashall, D			ABC of work related disorders: Occupational infections	BRITISH MEDICAL JOURNAL			English	Article											Snashall, D (corresponding author), GUYS & ST THOMASS HOSP NHS TRUST,OCCUPAT HLTH SERV,LONDON,ENGLAND.								0	8	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					551	554						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789989	Green Published			2022-12-28	WOS:A1996VF29400032
J	Garrard, TL; Stone, EC; Murphy, N				Garrard, TL; Stone, EC; Murphy, N			Effects of absorption by Io on composition of energetic heavy ions	SCIENCE			English	Article								The Galileo heavy ion counter is sensitive to ions with atomic numbers Z greater than or equal to 6 and energies greater than similar to 6 MeV per nucleon, During Galileo's passage through Jupiter's inner magnetosphere, the observed composition of these heavy ions was consistent with the presence of singly ionized iogenic. O, Na, and S and highly ionized solar C, O, and Ne. The solar component is absorbed more strongly by Io because its gyroradius is smaller than Io's diameter.	CALTECH,JET PROP LAB,PASADENA,CA 91109	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Garrard, TL (corresponding author), CALTECH,SPACE RADIAT LAB,PASADENA,CA 91125, USA.							GARRARD TL, 1992, SPACE SCI REV, V60, P305, DOI 10.1007/BF00216859; GEHRELS N, 1981, J GEOPHYS RES-SPACE, V86, P8906, DOI 10.1029/JA086iA11p08906; GEHRELS N, 1983, J GEOPHYS RES-SPACE, V88, P5537, DOI 10.1029/JA088iA07p05537; KRIMIGIS SM, 1979, SCIENCE, V204, P998, DOI 10.1126/science.204.4396.998; KRIMIGIS SM, 1979, SCIENCE, V206, P977, DOI 10.1126/science.206.4421.977; Luhn A., 1984, ADV SPACE RES, V4, P161, DOI DOI 10.1016/0273-1177(84)90307-7; PARANICAS C, 1994, J GEOPHYS RES-SPACE, V99, P19433, DOI 10.1029/94JA01573; VOGT RE, 1979, SCIENCE, V204, P1003, DOI 10.1126/science.204.4396.1003; VOGT RE, 1979, SCIENCE, V206, P984, DOI 10.1126/science.206.4421.984; [No title captured]	10	14	14	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					393	394		10.1126/science.274.5286.393	http://dx.doi.org/10.1126/science.274.5286.393			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832881				2022-12-28	WOS:A1996VN17300044
J	Narula, J; Haider, N; Virmani, R; DiSalvo, TG; Kolodgie, FD; Hajjar, RJ; Schmidt, U; Semigran, MJ; Dec, GW; Khaw, BA				Narula, J; Haider, N; Virmani, R; DiSalvo, TG; Kolodgie, FD; Hajjar, RJ; Schmidt, U; Semigran, MJ; Dec, GW; Khaw, BA			Apoptosis in myocytes in end-stage heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGRAMMED CELL-DEATH; PRESSURE-OVERLOAD; DNA FRAGMENTATION; IMMATURE THYMOCYTES; HYPERTROPHY; EXPRESSION; PROTEIN; IDENTIFICATION; CARDIOMYOCYTES; PROTOONCOGENE	Background Heart failure can result from a variety of causes, including ischemic, hypertensive, toxic, and inflammatory heart disease. However, the cellular mechanisms responsible for the progressive deterioration of myocardial function observed in heart failure remain unclear and may result from apoptosis (programmed cell death). Methods We examined seven explanted hearts obtained during cardiac transplantation for evidence of apoptosis, All seven patients had severe chronic heart failure: four had idiopathic dilated cardiomyopathy, and three had ischemic cardiomyopathy, DNA fragmentation (an indicator of apoptosis) was identified histochemically by in situ end-labeling as well as by agarose-gel electrophoresis of end-labeled DNA. Myocardial tissues obtained from four patients who had had a myocardial infarction one to two days previously were used as positive controls, and heart tissues obtained from Sour persons who died in motor vehicle accidents were used as negative controls for the end-labeling studies. Results Hearts from all four patients with idiopathic dilated cardiomyopathy and from one of the three patients with ischemic cardiomyopathy had histochemical evidence of DNA fragmentation, All four myocardial samples from patients with dilated cardiomyopathy also demonstrated DNA laddering, a characteristic of apoptosis, whereas this was not seen in any of the samples from patients with ischemic cardiomyopathy. Histologic evidence of apoptosis was also observed in the central necrotic zone of acute myocardial infarcts, but not in myocardium remote from the infarcted zone. Rare isolated apoptotic myocytes were seen in the myocardium from the four persons who died in motor vehicle accidents. Conclusions Loss of myocytes due to apoptosis occurs in patients with end-stage cardiomyopathy and may contribute to progressive myocardial dysfunction. (C) 1996, Massachusetts Medical Society.	NORTHEASTERN UNIV, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; ARMED FORCES INST PATHOL, WASHINGTON, DC 20306 USA	Northeastern University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; United States Department of Defense								ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BING OHL, 1994, J MOL CELL CARDIOL, V26, P943, DOI 10.1006/jmcc.1994.1115; BRAUNWALD E, 1992, HEART DISEASE TXB CA, P393; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CONNOR J, 1988, PROSTATE, V13, P119, DOI 10.1002/pros.2990130204; DEC GW, 1992, J NUCL MED, V33, P477; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GWATHMEY JK, 1985, CIRC RES, V57, P836, DOI 10.1161/01.RES.57.6.836; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ITOH G, 1995, AM J PATHOL, V146, P1325; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; KATZ AM, 1994, ANN INTERN MED, V121, P363, DOI 10.7326/0003-4819-121-5-199409010-00009; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; MARCUS ML, 1981, AM J PHYSIOL, V241, pH358, DOI 10.1152/ajpheart.1981.241.3.H358; MARTIKAINEN P, 1991, CANCER RES, V51, P4693; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1990, J BIOL CHEM, V265, P3009; MURGIA M, 1992, J BIOL CHEM, V267, P10939; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SANDFORD NL, 1984, PATHOLOGY, V16, P406, DOI 10.3109/00313028409084731; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SEARLE J, 1982, PATHOL ANNU, V17, P229; TAKAHASHI T, 1992, J CLIN INVEST, V89, P939, DOI 10.1172/JCI115675; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; UCKER DS, 1991, NEW BIOL, V3, P103; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; [No title captured]	40	1132	1183	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 17	1996	335	16					1182	1189		10.1056/NEJM199610173351603	http://dx.doi.org/10.1056/NEJM199610173351603			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN401	8815940				2022-12-28	WOS:A1996VN40100003
J	Li, Y; Benezra, R				Li, Y; Benezra, R			Identification of a human mitotic checkpoint gene: hsMAD2	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; MITOSIS; ANAPHASE; PROTEIN; CELLS; KINETOCHORES; NOCODAZOLE; ONSET	In Saccharomyces cerevisiae, MAD2 is required for mitotic arrest if the spindle assembly is perturbed. The human homolog of MAD2 was isolated and shown to be a necessary component of the mitotic checkpoint in HeLa cells by antibody electroporation experiments. Human, or Homo sapiens, MAD2 (hsMAD2) was localized at the kinetochore after chromosome condensation but was no longer observed at the kinetochore in metaphase, suggesting that MAD2 might monitor the completeness of the spindle-kinetochore attachment. Finally, T47D, a human breast tumor cell line that is sensitive to taxol and nocodazole, had reduced MAD2 expression and failed to arrest in mitosis after nocodazole treatment. Thus, defects in the mitotic checkpoint may contribute to the sensitivity of certain tumors to mitotic spindle inhibitors.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-08748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; DELLARCO VL, 1985, ANEUPLOIDY ETIOLOGY; EARNSHAW WC, 1994, BIOESSAYS, V16, P639, DOI 10.1002/bies.950160908; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; GORBSKY GJ, 1995, TRENDS CELL BIOL, V5, P143, DOI 10.1016/S0962-8924(00)88968-0; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JORDAN MA, 1992, J CELL SCI, V102, P401; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LI Y, UNPUB; MELLOR J, 1990, EMBO J, V9, P4017, DOI 10.1002/j.1460-2075.1990.tb07623.x; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; WANG YC, 1995, MOL CELL BIOL, V15, P6838	25	522	549	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 11	1996	274	5285					246	248		10.1126/science.274.5285.246	http://dx.doi.org/10.1126/science.274.5285.246			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824189				2022-12-28	WOS:A1996VM67100043
J	Blumenthal, D				Blumenthal, D			Quality of health care .4. The origins of the quality-of-care debate	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHYSICIANS; OUTCOMES				Blumenthal, D (corresponding author), MASSACHUSETTS GEN HOSP, HLTH POLICY RES & DEV UNIT, 50 STANIFORD ST, BOSTON, MA 02114 USA.							BARRY MJ, 1995, MED CARE, V33, pAS145; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BLUMENTHAL D, 1994, NEW ENGL J MED, V331, P1017, DOI 10.1056/NEJM199410133311511; BLUMENTHAL D, 1993, JAMA-J AM MED ASSOC, V269, P2775, DOI 10.1001/jama.269.21.2775; BLUMENTHAL D, 1992, NEW ENGL J MED, V326, P1330, DOI 10.1056/NEJM199205143262005; CARLSON KJ, 1994, OBSTET GYNECOL, V83, P556, DOI 10.1097/00006250-199404000-00012; Chassin MR, 1996, NEW ENGL J MED, V335, P1060, DOI 10.1056/NEJM199610033351413; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; CLASSEN DC, 1992, JAMA-J AM MED ASSOC, V267, P1922; DETSKY AS, 1995, NEW ENGL J MED, V333, P589, DOI 10.1056/NEJM199508313330911; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GESENSWAY D, 1996, ACP OBSERVER, V16, P1; GIBSON PG, 1995, ANN INTERN MED, V123, P488, DOI 10.7326/0003-4819-123-7-199510010-00002; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; Gray Bradford H., 1991, PROFIT MOTIVE PATIEN, P71; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; Meyer GS, 1996, JAMA-J AM MED ASSOC, V276, P672, DOI 10.1001/jama.276.9.672; Millman M., 1993, ACCESS HLTH CARE AM; MULLEY AG, 1995, IMPROVING CLIN PRACT, P73; NEUHAUSER D, 1995, IMPROVING CLIN PRACT, P111; PALMER RH, 1993, QUALITY IMPROVEMENT; Robinson JC, 1996, HEALTH AFFAIR, V15, P7, DOI 10.1377/hlthaff.15.1.7; Schroeder SA, 1996, NEW ENGL J MED, V334, P1130, DOI 10.1056/NEJM199604253341713; Shore MF, 1996, NEW ENGL J MED, V334, P116, DOI 10.1056/NEJM199601113340211; Starr P, 1982, SOCIAL TRANSFORMATIO; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; VAYDA E, 1973, NEW ENGL J MED, V289, P1224, DOI 10.1056/NEJM197312062892305; WARE JE, 1986, LANCET, V1, P1017; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weissman JS., 1994, FALLING SAFETY NET I; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; [No title captured]	39	123	123	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1996	335	15					1146	1149		10.1056/NEJM199610103351511	http://dx.doi.org/10.1056/NEJM199610103351511			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN399	8813048				2022-12-28	WOS:A1996VN39900011
J	Hammer, SM; Katzenstein, DA; Hughes, MD; Gundacker, H; Schooley, RT; Haubrich, RH; Henry, WK; Lederman, MM; Phair, JP; Niu, M; Hirsch, MS; Merigan, TC; Blaschke, TF; Simpson, D; McLaren, C; Rooney, J; Salgo, M				Hammer, SM; Katzenstein, DA; Hughes, MD; Gundacker, H; Schooley, RT; Haubrich, RH; Henry, WK; Lederman, MM; Phair, JP; Niu, M; Hirsch, MS; Merigan, TC; Blaschke, TF; Simpson, D; McLaren, C; Rooney, J; Salgo, M			A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PLACEBO-CONTROLLED TRIAL; CLINICAL-TRIALS; DOUBLE-BLIND; ZIDOVUDINE; EFFICACY; DIDANOSINE; PROTEASE; SAFETY; TYPE-1	Background This double-blind study evaluated treatment with either a single nucleoside or two nucleosides in adults infected with human immunodeficiency virus type 1 (HIV-1) whose CD4 cell counts were from 200 to 500 per cubic millimeter. Methods We randomly assigned 2467 HIV-1-infected patients (43 percent without prior antiretroviral treatment) to one of four daily regimens: 600 mg of zidovudine; 600 mg of zidovudine plus 400 mg of didanosine; 600 mg of zidovudine plus 2.25 mg of zalcitabine; or 400 mg of didanosine. The primary end point was a greater than or equal to 50 percent decline in the CD4 cell count, development of the acquired immunodeficiency syndrome (AIDS), or death. Results Progression to the primary end point was more frequent with zidovudine alone (32 percent) than with zidovudine plus didanosine (18 percent; relative hazard ratio, 0.50; P<0.001), zidovudine plus zalcitabine (20 percent; relative hazard ratio, 0.54; P<0.001), or didanosine alone (22 percent; relative hazard ratio, 0.61; P<0.001). The relative hazard ratios for progression to an AIDS-defining event or death were 0.64 (P=0.005) for zidovudine plus didanosine, as compared with zidovudine alone, 0.77 (P=0.085) for zidovudine plus zalcitabine, and 0.69 (P=0.019) for didanosine alone. The relative hazard ratios for death were 0.55 (P=0.008), 0.71 (P=0.10), and 0.51 (P=0.003), respectively. For zidovudine plus zalcitabine, the benefits were limited to those without previous treatment. Conclusions Treatment with zidovudine plus didanosine, zidovudine plus zalcitabine, or didanosine alone slows the progression of HIV disease and is superior to treatment with zidovudine alone. Antiretroviral therapy can improve survival in patients with 200 to 500 CD4 cells per cubic millimeter.	HARVARD UNIV,SCH MED,BOSTON,MA; STANFORD UNIV,STANFORD,CA 94305; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; UNIV COLORADO,DENVER,CO 80202; UNIV CALIF SAN DIEGO,SAN DIEGO,CA 92103; UNIV MINNESOTA,MINNEAPOLIS,MN 55455; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; NORTHWESTERN UNIV,CHICAGO,IL 60611; NIAID,DIV AIDS,BETHESDA,MD 20892; MT SINAI MED CTR,NEW YORK,NY 10029; BRISTOL MYERS SQUIBB CO,NEW YORK,NY 10154; HOFFMANN LA ROCHE INC,NUTLEY,NJ 07110	Harvard University; Harvard Medical School; Stanford University; Harvard University; Harvard T.H. Chan School of Public Health; University of Colorado System; University of Colorado Denver; University of California System; University of California San Diego; University of Minnesota System; University of Minnesota Twin Cities; Case Western Reserve University; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Icahn School of Medicine at Mount Sinai; Bristol-Myers Squibb; Roche Holding			Merigan, Thomas/AGQ-7464-2022	katzenstein, david/0000-0002-8593-4560				Armitage P., 1971, STAT METHODS MED RES, V1; BAKER CJ, 1996, 11 INT C AIDS PROG S, P12; Bartlett JA, 1996, ANN INTERN MED, V125, P161, DOI 10.7326/0003-4819-125-3-199608010-00001; CALIENDO AM, 1994, CLIN INFECT DIS, V18, P516, DOI 10.1093/clinids/18.4.516; CALIENDO AM, 1994, CLIN INFECT DIS, V19, P379; Cameron D. W., 1996, P24; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; COLLIER AC, 1993, ANN INTERN MED, V119, P786, DOI 10.7326/0003-4819-119-8-199310150-00003; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; *DIV AIDS, 1996, TABL GRAD SEV AD ADV; DOLIN R, 1995, ARCH INTERN MED, V155, P961, DOI 10.1001/archinte.155.9.961; DOLIN R, 1995, ARCH INTERN MED, V155, P2255; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; FISCHL MA, 1995, ANN INTERN MED, V122, P24, DOI 10.7326/0003-4819-122-1-199501010-00004; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GULICK R, 1996, 11 INT C AIDS VANC S, P19; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HUGHES MD, 1993, STAT MED, V12, P901, DOI 10.1002/sim.4780121002; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; Katlama C, 1996, JAMA-J AM MED ASSOC, V276, P118, DOI 10.1001/jama.276.2.118; KITCHEN VS, 1995, LANCET, V345, P952, DOI 10.1016/S0140-6736(95)90699-1; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MASSARI F, 1995, 35 INT C ANT AG CHEM, P9; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; Myers Maureen W., 1996, P22; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PAVIA AT, 1995, 35 INT C ANT AG CHEM, P235; Pocock SJ., 2013, CLIN TRIALS PRACTICA; REY D, 1996, 5 INT WORKSH HIV DRU, P38; Saravolatz LD, 1996, NEW ENGL J MED, V335, P1099, DOI 10.1056/NEJM199610103351503; Schapiro JM, 1996, ANN INTERN MED, V124, P1039, DOI 10.7326/0003-4819-124-12-199606150-00003; Staszewski S, 1996, JAMA-J AM MED ASSOC, V276, P111, DOI 10.1001/jama.276.2.111; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1995, NEW ENGL J MED, V333, P401, DOI 10.1056/NEJM199508173330701; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; YARCHOAN R, 1994, J INFECT DIS, V169, P9, DOI 10.1093/infdis/169.1.9; 1987, MMWR MORB MORTAL S1S, V36, pS3; 1994, LANCET, V343, P871; 1996, LANCET, V348, P283	47	771	789	1	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	1996	335	15					1081	1090		10.1056/NEJM199610103351501	http://dx.doi.org/10.1056/NEJM199610103351501			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VN399	8813038				2022-12-28	WOS:A1996VN39900001
J	Doyle, KM; CluetteBrown, JE; Dube, DM; Bernhardt, TG; Morse, CR; Laposata, M				Doyle, KM; CluetteBrown, JE; Dube, DM; Bernhardt, TG; Morse, CR; Laposata, M			Fatty acid ethyl esters in the blood as markers for ethanol intake	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALCOHOL-CONSUMPTION; METABOLISM; SERUM; ABUSE	Objective.-To determine the clinical utility of farcy acid ethyl esters (FAEEs) in the blood as a short-term confirmatory marker for ethanol intake and a longer-term marker for ethanol intake after ethanol is no longer detectable. Design.-Single-center controlled clinical trial and a blinded comparison involving 48 blood samples that were positive, negative, or equivocal for blood ethanol. Participants.-Seven healthy subjects (4 men and 3 women, aged 21 to 23 years) participated in the clinical trial. Blood samples from participants for the blinded comparison portion of the study were numbered from 1 to 48 and not identified by name. Intervention.-The 7 healthy subjects ingested a known amount of ethanol at a fixed rate. The concentration of FAEEs in the blood alter ethanol intake was determined for a period of up to 24 hours. There was no intervention in the blinded comparison study. Main Outcome Measures.-In the clinical trial, a pharmacokinetic analysis of FAEE concentration in the blood after ethanol intake was completed for 7 individuals whose blood ethanol level was elevated from 25 to 35 mmol/L. In the blinded comparison, the 48 blood samples that were positive, negative, or equivocal for blood ethanol were analyzed for FAEE concentration. Results.-In the clinical trial, the disappearance of FAEEs from the blood followed a decay curve that initially resembled the decay curve for blood ethanol. However, because of a very slow secondary elimination phase, the FAEEs were found to persist in the blood for at least 24 hours after ethanol intake was completed, In the blinded comparison, all 20 samples that were positive for ethanol were positive for FAEEs, 7 of 7 samples equivocal for ethanol were positive for FAEEs, and 21 of 21 negative samples for ethanol were negative for FAEEs. Conclusions.-Serum concentration of FAEEs can serve as an excellent shortterm confirmatory test for ethanol intake as well as a longer-term marker of ethanol ingestion. Measurement of FAEEs in the blood may be a more sensitive indicator of ethanol ingestion than the measurement of blood ethanol.	MASSACHUSETTS GEN HOSP, DIV CLIN LABS, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								Aleryani S, 1996, CLIN CHEM, V42, P24; BERNHARDT TG, 1995, J CHROMATOGR B, V675, P189; CHICK J, 1981, LANCET, V1, P1249; DOYLE KM, 1994, J LIPID RES, V35, P428; HABER PS, 1993, J LAB CLIN MED, V121, P259; HAMAMOTO T, 1990, BIOCHEM PHARMACOL, V39, P241, DOI 10.1016/0006-2952(90)90022-D; HARRIS JA, 1919, CARNEGIE I WASHINGTO, V279; KHAVARI KA, 1978, J STUD ALCOHOL, V39, P1525, DOI 10.15288/jsa.1978.39.1525; LANGE LG, 1983, J CLIN INVEST, V72, P724, DOI 10.1172/JCI111022; LANGE LG, 1981, J BIOL CHEM, V256, P2968; LAPOSATA EA, 1986, SCIENCE, V231, P497, DOI 10.1126/science.3941913; LAPOSATA M, 1995, PROSTAG LEUKOTR ESS, V52, P87, DOI 10.1016/0952-3278(95)90003-9; LIEBER CS, 1968, SCIENCE, V162, P917, DOI 10.1126/science.162.3856.917; LOCHNER A, 1969, AM HEART J, V78, P770, DOI 10.1016/0002-8703(69)90443-8; MIHAS AA, 1992, AM J MED SCI, V303, P415, DOI 10.1097/00000441-199206000-00014; NEWSOME WH, 1965, CAN J BIOCHEM CELL B, V43, P1223, DOI 10.1139/o65-134; PATTON S, 1966, NATURE, V209, P616, DOI 10.1038/209616b0; PENN R, 1983, BRIT MED J, V286, P531, DOI 10.1136/bmj.286.6364.531; Pesce AJ, 1984, CLIN CHEM THEORY ANA, P1332; RASKIN NH, 1972, J NEUROCHEM, V19, P273, DOI 10.1111/j.1471-4159.1972.tb01337.x; ROSMAN AS, 1992, MEASURING ALCOHOL CONSUMPTION, P99; STIBLER H, 1991, CLIN CHEM, V37, P2029; SZCZEPIORKOWSKI ZM, 1995, GASTROENTEROLOGY, V108, P515, DOI 10.1016/0016-5085(95)90081-0	23	93	95	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	1996	276	14					1152	1156		10.1001/jama.276.14.1152	http://dx.doi.org/10.1001/jama.276.14.1152			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL332	8827968				2022-12-28	WOS:A1996VL33200025
J	Bradford, WZ; Martin, JN; Reingold, AL; Schecter, GF; Hopewell, PC; Small, PM				Bradford, WZ; Martin, JN; Reingold, AL; Schecter, GF; Hopewell, PC; Small, PM			The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; MALABSORPTION; RIFAMPIN	Background The increasing incidence of tuberculosis caused by drug-resistant Mycobacterium tuberculosis is thought in part to reflect inadequate implementation of standard tuberculosis control measures. However, in San Francisco, USA, which has an effective tuberculosis control programme, we have recently observed an increase in cases of acquired drug-resistance. Methods To explore further this observation, we analysed the secular trend of acquired drug-resistance and conducted a population-based case-control study oi all reported tuberculosis cases In the city of San Francisco between 1985 and 1994. Findings We identified 14 patients with tuberculosis caused by fully susceptible M tuberculosis who subsequently developed drug-resistance. Of these acquired drug-resistance cases, two occurred between 1985 and 1989, whereas 12 occurred between 1990 and 1994 (p=0.028); In the case-contra[ study, AIDS 20.2, 95% CI 1.12-363.6), nan;compliance with therapy (19.7, 1.66-234.4), and gastrointestinal symptoms (11.5, 1.23-107.0) were independently associated with acquired drug-resistance; Between 1990 and 1994, one in 16 tuberculosis patients with AIDS and either gastrointestinal symptoms or non-compliance developed acquired drug-resistance. Interpretation The substantial increase in acquired drug-resistance in San Francisco seems to bera product of the increasing prevalence: of HIV/M tuberculosis coinfection. Our data suggest that the interface of the HIV and tuberculosis epidemics fosters acquired drug-resistance, and that traditional tuberculosis control measures may not be sufficient in communities with high rates of HIV infection.	SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; FRANCES J CURRY NATL TB CTR,SAN FRANCISCO,CA; UNIV CALIF BERKELEY,SCH PUBL HLTH,DIV PUBL HLTH BIOL & EPIDEMIOL,BERKELEY,CA 94720; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; DEPT PUBL HLTH,SAN FRANCISCO,CA; STANFORD UNIV,SCH MED,DEPT MED,PALO ALTO,CA 94304	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California System; University of California San Francisco; Stanford University					NIAID NIH HHS [AI34238, AI01137] Funding Source: Medline; NIMH NIH HHS [T32 MH-19105] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; DAVID HL, 1970, APPL MICROBIOL, V20, P810, DOI 10.1128/AEM.20.5.810-814.1970; DYLEWSKI J, 1990, J INFECT DIS, V162, P778, DOI 10.1093/infdis/162.3.778; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GOLLAPUDI S, 1994, BIOCHEM BIOPH RES CO, V199, P1181, DOI 10.1006/bbrc.1994.1355; GREENLAND S, 1982, AM J EPIDEMIOL, V116, P547, DOI 10.1093/oxfordjournals.aje.a113439; HACEK D, 1992, CLIN MICROBIOLOGY PR; LUFTEY M, 1996, AM J RESP CRIT CARE, V153, P837; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MITCHISON DA, 1984, BRIT MED BULL, V40, P84, DOI 10.1093/oxfordjournals.bmb.a071952; NOLAN CM, 1995, AM J RESP CRIT CARE, V152, P1067, DOI 10.1164/ajrccm.152.3.7663785; PATEL KB, 1995, NEW ENGL J MED, V332, P336, DOI 10.1056/NEJM199502023320518; PELOQUIN CA, 1993, NEW ENGL J MED, V329, P1122, DOI 10.1056/NEJM199310073291513; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; *RETR PHYS DESK RE, 1992, MED EC DAT, P802; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; 1994, AM J RESP CRIT CARE, V149, P1359	19	83	84	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					928	931		10.1016/S0140-6736(96)03027-9	http://dx.doi.org/10.1016/S0140-6736(96)03027-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843813				2022-12-28	WOS:A1996VL09700013
J	Carnes, M				Carnes, M			Balancing family and career: Advice from the trenches	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									UNIV WISCONSIN, MADISON, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Carnes, M (corresponding author), MIDDLETON VET HOSP, CTR GERIATR RES EDUC & CLIN, 2500 OVERLOOK TERRACE, MADISON, WI 53705 USA.								0	11	11	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1996	125	7					618	620		10.7326/0003-4819-125-7-199610010-00014	http://dx.doi.org/10.7326/0003-4819-125-7-199610010-00014			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ653	8815763				2022-12-28	WOS:A1996VJ65300014
J	Colledge, NR; BarrHamilton, RM; Lewis, SJ; Sellar, RJ; Wilson, JA				Colledge, NR; BarrHamilton, RM; Lewis, SJ; Sellar, RJ; Wilson, JA			Evaluation of investigations to diagnose the cause of dizziness in elderly people: A community based controlled study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERSISTENT DIZZINESS; POPULATION; PREVALENCE; ANXIETY; BALANCE; BRAIN; SWAY	Objective-To compare the findings in dizzy elderly people with those in controls of a similar age to identify which investigations differentiate dizzy from non-dizzy patients and to design an investigational algorithm. Design-Community based study of clinical and laboratory findings in dizzy and control elderly people. Setting-Research outpatient clinic at a teaching hospital. Subjects-149 dizzy and 97 control subjects aged over 65 years recruited from a community survey and articles in the local press. Main outcome measures-Findings on physical examination, blood testing, electrocardiography (at rest and over 24 hours), electronystagmography, posturography, and magnetic resonance imaging of head and neck (125 (84%) dizzy subjects and 86 (89%) controls); hospital anxiety and depression score; responses to hyperventilation, carotid sinus massage, and the Hallpike manoeuvre. Results-Blood profile, electrocardiography, electronystagmography, and magnetic resonance imaging failed to distinguish dizzy from control subjects because of the frequency of asymptomatic abnormalities in controls. Posturography and clinical assessment (physical examination, dizziness provocation, and psychological assessment) showed significant differences between the groups. A cause of the dizziness was identified from clinical diagnostic criteria based on accepted definitions in 143 subjects, with 126 having more than one cause. The most common diagnoses were central vascular disease (105) and cervical spondylosis (98), often accompanied by poor vision and anxiety. Conclusion-Expensive investigations are rarely helpful in dizzy elderly people. The cause of the dizziness can be diagnosed in most cases on the basis of a thorough clinical examination without recourse to hospital referral.	UNIV EDINBURGH, DEPT MED, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; ROYAL INFIRM EDINBURGH NHS TRUST, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; UNIV NEWCASTLE UPON TYNE, DEPT OTORHINOLARYNGOL HEAD & NECK SURG, NEWCASTLE UPON TYNE NE7 7DN, TYNE & WEAR, ENGLAND	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; Newcastle University - UK				wilson, janet/0000-0002-6416-5870				AYLARD PR, 1987, J PSYCHOSOM RES, V31, P261, DOI 10.1016/0022-3999(87)90083-3; BELAL A, 1986, J LARYNGOL OTOL, V100, P1037, DOI 10.1017/S0022215100100520; BROCKLEHURST JC, 1982, AGE AGEING, V11, P1, DOI 10.1093/ageing/11.1.1; COLLEDGE NR, 1994, GERONTOLOGY, V40, P273, DOI 10.1159/000213596; COLLEDGE NR, 1994, AGE AGEING, V23, P117, DOI 10.1093/ageing/23.2.117; DAVIS LE, 1994, J AM GERIATR SOC, V42, P1184, DOI 10.1111/j.1532-5415.1994.tb06986.x; DAY JJ, 1990, AGE AGEING, V19, P144, DOI 10.1093/ageing/19.2.144; DIX MR, 1952, ANN OTO RHINOL LARYN, V61, P987, DOI 10.1177/000348945206100403; DRACHMAN DA, 1972, NEUROLOGY, V22, P323, DOI 10.1212/WNL.22.4.323; DRAYER BP, 1988, RADIOLOGY, V166, P797, DOI 10.1148/radiology.166.3.3277248; DROLLER H, 1953, J Laryngol Otol, V67, P689, DOI 10.1017/S0022215100049185; ENSRUD KE, 1992, ARCH INTERN MED, V152, P1058, DOI 10.1001/archinte.152.5.1058; EVANS JG, 1990, AGE AGEING, V19, P43, DOI 10.1093/ageing/19.1.43; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; Hopkins A., 1993, CLIN NEUROLOGY MODER; HU MH, 1994, J GERONTOL, V49, pM52, DOI 10.1093/geronj/49.2.M52; KATSARKAS A, 1994, OTOLARYNG HEAD NECK, V110, P296, DOI 10.1016/S0194-5998(94)70772-3; KROENKE K, 1992, ANN INTERN MED, V117, P898, DOI 10.7326/0003-4819-117-11-898; Ledin T, 1990, J Vestib Res, V1, P129; MCINTOSH S, 1993, AGE AGEING, V22, P53, DOI 10.1093/ageing/22.1.53; NEDZELSKI JM, 1986, J OTOLARYNGOL, V15, P101; ORMA EJ, 1957, GERIATRICS, V12, P49; QUINN N, 1995, BRIT MED J, V310, P447, DOI 10.1136/bmj.310.6977.447; SIXT E, 1987, AGE AGEING, V16, P393, DOI 10.1093/ageing/16.6.393; SLOANE P, 1989, J AM GERIATR SOC, V37, P101, DOI 10.1111/j.1532-5415.1989.tb05867.x; SLOANE PD, 1989, J AM GERIATR SOC, V37, P1031, DOI 10.1111/j.1532-5415.1989.tb06916.x; STARK RJ, 1983, J NEUROL NEUROSUR PS, V46, P883, DOI 10.1136/jnnp.46.10.883; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	28	132	141	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	1996	313	7060					788	792						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842072				2022-12-28	WOS:A1996VK56600024
J	Doxiadis, IIN; Smits, JMA; Schreuder, GMT; Persijn, GG; vanHouwelingen, HC; vanRood, JJ; Claas, FHJ				Doxiadis, IIN; Smits, JMA; Schreuder, GMT; Persijn, GG; vanHouwelingen, HC; vanRood, JJ; Claas, FHJ			Association between specific HLA combinations and probability of kidney allograft loss: The taboo concept	LANCET			English	Article							RENAL-TRANSPLANTATION; GRAFT-SURVIVAL; DR MISMATCHES; RECIPIENTS; ANTIGENS; HLA-DRW6; MARKER	Background HLA matching improves the outcome of cadaveric renal transplantation. However, many allografts function well even in the presence of one or more HLA mismatches, which raises the question of whether some mismatches are better recognised by the recipient's immune system than others. We aimed to identify mismatched HLA donor-recipient combinations that were associated with increased graft loss. Methods We selected 2877 first, unrelated renal transplants with a single HLA A, B, or DR mismatch, undertaken between 1982 and 1992, from the Eurotransplant database. To enhance statistical power the analysis was restricted to mismatches of an HLA antigen that occurred in 100 or more donors. 1342 transplants met this criterion and were grouped into a definition set (n=873) and a validation set (n=469). In the definition set, we studied further only those recipient HLA antigens that occurred in at least 30 cases within each donor antigen mismatch subset. By a Cox proportional hazards model, donor-recipient combinations that led to significantly higher graft loss than in the whole group were defined. Such combinations were classified as taboo; the remaining combinations were classified as indifferent. Findings 106 individual recipient antigens were found al least 30 times with a corresponding donor mismatch in the definition set; 11 of the 106 had a significant effect on graft survival. Seven combinations were classified as taboo. Taboo combinations, confirmed as such in the validation set, were associated with graft survival of 81% at one year and 50% at 5 years, significantly lower than the rates in the group with indifferent combinations (89% and 69%; p=0.04) or among 1190 recipients with no mismatches (89% and 72%; p=0.03). The findings were substantiated by a multivariate analysis that included the effect of patient immunisation, cold ischaemia time, age, and sex. Interpretation Mismatched donor antigens are differentially recognised depending on the HLA phenotype of the recipient. The findings may have important clinical consequences for graft survival after transplantation.	UNIV LEIDEN HOSP,BLOOD BANK,NL-2333 AA LEIDEN,NETHERLANDS; EUROTRANSPLANT FDN,LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT MED STAT,NL-2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC	Doxiadis, IIN (corresponding author), UNIV LEIDEN HOSP,DEPT IMMUNOHAEMATOL,NL-2333 AA LEIDEN,NETHERLANDS.		van houwelingen, hans c/C-1872-2008; Doxiadis, ilias/AAH-9875-2020	van houwelingen, hans c/0000-0002-0494-4637; 				ALAMARTINE E, 1992, TRANSPL P, V24, P2461; BUSSON M, 1979, TRANSPLANTATION, V28, P313, DOI 10.1097/00007890-197910000-00009; COHEN B, 1994, EUROTRANSPLKANT ANN; COOK DJ, 1987, TRANSPLANT P, V19, P675; DOBBE CME, 1990, TRANSPLANTATION, V50, P446, DOI 10.1097/00007890-199009000-00017; DYER PA, 1985, TRANSPLANT P, V17, P2248; FORSBERG B, 1992, TRANSPLANT P, V24, P2463; GJERTSON DW, 1991, NEW ENGL J MED, V324, P1032, DOI 10.1056/NEJM199104113241505; GOULMY E, 1992, TRANSPLANTATION, V53, P1381, DOI 10.1097/00007890-199206000-00046; HENDRIKS GFJ, 1983, LANCET, V2, P187; KREISLER JM, 1988, TRANSPLANTATION, V45, P1071, DOI 10.1097/00007890-198806000-00014; MARUYA E, 1994, CLIN TRANSPLANTS 199, P511; OPELZ G, 1977, TRANSPLANTATION, V24, P106, DOI 10.1097/00007890-197708000-00003; OPELZ G, 1988, LANCET, V2, P61; OPELZ G, 1985, HISTOCOMPATIBILITY T, P342; POHANKA E, 1983, LANCET, V2, P402; SOULILLOU JP, 1983, NEW ENGL J MED, V308, P969; TAKEMOTO S, 1994, HUM IMMUNOL S1, V40, P17; VANROOD JJ, 1967, HISTOCOMPATIBILITY T, P451; VANROOD JJ, 1994, CLIN TRANSPLANTS 199, P285; VEREERSTRAETEN P, 1989, CLIN TRANSPLANT, V3, P54; VEREERSTRAETEN P, 1995, TRANSPLANTATION, V60, P253, DOI 10.1097/00007890-199508000-00008; VEREERSTRAETEN P, 1987, TRANSPLANT P, V19, P364	23	94	95	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 28	1996	348	9031					850	853		10.1016/S0140-6736(96)02296-9	http://dx.doi.org/10.1016/S0140-6736(96)02296-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK037	8826810				2022-12-28	WOS:A1996VK03700010
J	Key, TJA; Thorogood, M; Appleby, PN; Burr, ML				Key, TJA; Thorogood, M; Appleby, PN; Burr, ML			Dietary habits and mortality in 11000 vegetarians and health conscious people: Results of a 17 year follow up	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; 7TH-DAY ADVENTISTS; BREAST-CANCER; RISK; ASSOCIATION; CONSUMPTION; POPULATION; VEGETABLES; STROKE; CHOLESTEROL	Objective-To investigate the association of dietary habits with mortality in a cohort of vegetarians and other health conscious people. Design-Observational study. Setting-United Kingdom. Subjects-4336 men and 6435 women recruited through health food shops, vegetarian societies, and magazines. Main outcome measures-Mortality ratios for vegetarianism and for daily versus less than daily consumption of wholemeal bread, bran cereals, nuts or dried fruit, fresh fruit, and raw salad in relation to all cause mortality and mortality fi om ischaemic heart disease, cerebrovascular disease, all malignant neoplasms, lung cancer, colorectal cancer, and breast cancer. Results-2064 (19%) subjects smoked, 4627 (43%) were vegetarian, 6699 (62%) ate wholemeal bread daily, 2948 (27%) ate bran cereals daily, 4091 (38%) ate nuts or dried fruit daily, 8304 (77%) ate fresh fruit daily, and 4105 (38%) ate raw salad daily. After a mean of 16.8 years follow up there were 1343 deaths before age 80. Overall the cohort had a mortality about half that of the general population. Within the cohort, daily consumption of fresh fruit was associated with significantly reduced mortality from ischaemic heart disease (rate ratio adjusted for smoking 0.76 (95% confidence interval 0.60 to 0.97)), cerebrovascular disease (0.68 (0.47 to 0.98)), and for all causes combined (0.79 (0.70 to 0.90)). Conclusions-In this cohort of health conscious individuals, daily consumption of fresh fruit is associated with a reduced mortality from ischaemic heart disease, cerebrovascular disease, and all causes combined.	LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, LONDON WC1E 6HT, ENGLAND; UNIV WALES COLL CARDIFF, COLL MED, CTR APPL PUBL HLTH MED, CARDIFF CF1 3NW, S GLAM, WALES	University of London; London School of Hygiene & Tropical Medicine; Cardiff University	Key, TJA (corresponding author), RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, CANC EPIDEMIOL UNIT, OXFORD OX2 6HE, ENGLAND.							ACHESON RM, 1983, LANCET, V1, P1191; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BURKITT DP, 1973, BMJ-BRIT MED J, V1, P274, DOI 10.1136/bmj.1.5848.274; BURR ML, 1988, AM J CLIN NUTR, V48, P830, DOI 10.1093/ajcn/48.3.830; BURR ML, 1981, J HUM NUTR, V35, P437; BURR ML, 1982, AM J CLIN NUTR, V36, P873, DOI 10.1093/ajcn/36.5.873; CHANGCLAUDE J, 1992, EPIDEMIOLOGY, V3, P395, DOI 10.1097/00001648-199209000-00003; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; Gaziano J. Michael, 1995, Annals of Epidemiology, V5, P255, DOI 10.1016/1047-2797(94)00090-G; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; GRAMENZI A, 1990, BMJ-BRIT MED J, V300, P771, DOI 10.1136/bmj.300.6727.771; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; KAHN HA, 1984, AM J EPIDEMIOL, V119, P775, DOI 10.1093/oxfordjournals.aje.a113798; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; MILLS PK, 1988, AM J EPIDEMIOL, V127, P440, DOI 10.1093/oxfordjournals.aje.a114821; Pandey DK, 1995, AM J EPIDEMIOL, V142, P1269, DOI 10.1093/oxfordjournals.aje.a117594; PHILLIPS RL, 1980, JNCI-J NATL CANCER I, V65, P1097; POTTER JD, 1995, EUR J CANCER, V31A, P1033, DOI 10.1016/0959-8049(95)00125-3; RAO DN, 1994, BRIT J CANCER, V70, P129, DOI 10.1038/bjc.1994.261; SNOWDON DA, 1984, PREV MED, V13, P490, DOI 10.1016/0091-7435(84)90017-3; THOROGOOD M, 1994, BMJ-BRIT MED J, V308, P1667, DOI 10.1136/bmj.308.6945.1667; White A, 1993, HLTH SURVEY ENGLAND; World Health Organization, 1967, INT CLASS DIS; World Health Organization, 1977, INT CLASS DIS	28	220	223	1	71	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	1996	313	7060					775	779						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842068	Green Published			2022-12-28	WOS:A1996VK56600020
J	Chapman, S				Chapman, S			Letter from Washington DC - Guns don't die. People do	BRITISH MEDICAL JOURNAL			English	Editorial Material											Chapman, S (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,DEPT PUBL HLTH & COMMUNITY MED,WESTMEAD,NSW 2145,AUSTRALIA.							ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; FINGERHUT L, 1994, 242 ADV DAT VIT HLTH; Kleck G., 1991, POINT BLANK GUNS VIO; PIERRE RE, 1996, WASHINGTON POST 0820, pB3; SUGARMANN J, 1996, NUMBER GUN DEALERS P; *VIOL POL CTR, 1992, MOR GUN DEAL GAS STA; 1994, MMWR-MORBID MORTAL W, V43, P37	7	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					739	740						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819448				2022-12-28	WOS:A1996VJ44100031
J	Chopra, KB; Peters, RA; OToole, PA; Williams, SGJ; Gimson, AES; Lombard, MG; Westaby, D				Chopra, KB; Peters, RA; OToole, PA; Williams, SGJ; Gimson, AES; Lombard, MG; Westaby, D			Randomised study of endoscopic biliary endoprosthesis versus duct clearance for bileduct stones in high-risk patients	LANCET			English	Article							LONG-TERM TREATMENT; FOLLOW-UP; SPHINCTEROTOMY; EXPLORATION; MANAGEMENT	Background The value of an endoprosthesis for long-term management of bileduct stones has not been formally established. The main theoretical advantage of endoprosthesis insertion (BE) over conventional endoscopic duct clearance (DC) is the prevention of stone impaction, with obstruction and consequent cholangitis or pancreatitis. In a randomised study we compared the results of these two methods in patients with symptomatic bileduct stones who were at high risk because of old age (>70 yr) or serious debilitating disease. Methods 43 high-risk patients were randomised to BE with a 7F double-pigtail endoprosthesis and (0.75 cm sphincterotomy, and 43 to DC with standard 1.25-1.50 cm sphincterotomy and stone extraction by balloon or basket, with or without mechanical lithotripsy. The principal endpoint was the rate of biliary related complications. Findings In the BE group biliary drainage was achieved in the first session in all but one patient (who required 2 sessions). In the DC group, 24 patients had duct clearance at the first attempt and 35 (81%) after a median of 2 sessions (range 2-4); eight of this group had an endoprosthesis inserted to maintain long-term drainage. At 72 h the complication rates were 7% in the BE group and 16% in the DC group (p=018). However, the long-term complication rate for BE was higher: by Kaplan-Meier analysis, at a median of 20 months the proportions free of biliary complications were 64% BE and 86% DC (p=0.03, log-rank test). Interpretation For immediate endoprosthesis insertion proved alternative to duct clearance. Because of the risk of subsequent cholangitis, its use as a definitive treatment should be confined to highly selected cases.	CHELSEA & WESTMINSTER HOSP,GASTROINTESTINAL UNIT,LONDON SW10 9NH,ENGLAND; UNIV LIVERPOOL,DEPT MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,AINTREE HOSP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,INST LIVER STUDIES,LONDON,ENGLAND	Imperial College London; University of Liverpool; Aintree University Hospitals NHS Foundation Trust; University of Liverpool; University of London; King's College London								CLASSEN M, 1988, ENDOSCOPY, V20, P21, DOI 10.1055/s-2007-1018119; COTTON PB, 1984, GUT, V25, P587, DOI 10.1136/gut.25.6.587; COTTON PB, 1987, GASTROINTEST ENDOSC, V33, P411, DOI 10.1016/S0016-5107(87)71675-7; FOUTCH PG, 1989, AM J GASTROENTEROL, V84, P527; Glenn F, 1975, Curr Probl Surg, P1; KIIL J, 1989, SURGERY, V105, P51; MAXTON DG, 1995, GUT, V36, P446, DOI 10.1136/gut.36.3.446; MOTSON RW, 1985, RETAINED COMMON BILE; NEOPTOLEMOS JP, 1987, BRIT J SURG, V74, P916, DOI 10.1002/bjs.1800741014; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; PETERS R, 1992, GUT, V33, P1412, DOI 10.1136/gut.33.10.1412; SHERMAN S, 1990, SEMIN LIVER DIS, V10, P205, DOI 10.1055/s-2008-1040476; SULLIVAN DM, 1982, AM J SURG, V143, P218, DOI 10.1016/0002-9610(82)90072-1; VAIRA D, 1989, LANCET, V2, P431; VANSTEENBERGEN W, 1992, J AM GERIATR SOC, V40, P57, DOI 10.1111/j.1532-5415.1992.tb01830.x; VELLACOTT KD, 1979, BRIT J SURG, V66, P389, DOI 10.1002/bjs.1800660605	16	70	76	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					791	793		10.1016/S0140-6736(96)06316-7	http://dx.doi.org/10.1016/S0140-6736(96)06316-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813987				2022-12-28	WOS:A1996VH98900013
J	Lipsky, JJ				Lipsky, JJ			Antiretroviral drugs for AIDS	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; CUBIC MILLIMETER; HIV-1 INFECTION; THERAPY; ZIDOVUDINE; PLASMA; RESISTANCE; INHIBITORS; EFFICACY	Treatment of HIV disease with antiretroviral agents has changed considerably. We now know that monotherapy is not the best strategy in most cases to combat rapid turnover of virus and development of resistance (the exception being mother-to-child transmission) and various combination drug regimens are being explored. Apart from the main drug groups, consisting of nucleoside analogues, proteinase inhibitors, and reverse-transcriptase inhibitors, many new compounds are under development. The timing of therapy may likewise be important, and the indications of benefit from early initiation of treatment need to be confirmed in randomised trials. Overall, there is far more optimism about the use of drugs in HIV infection than there was several years ago.	MAYO CLIN & MAYO FDN,DEPT PHARM,CLIN PHARMACOL UNIT,ROCHESTER,MN 55905	Mayo Clinic	Lipsky, JJ (corresponding author), MAYO CLIN & MAYO FDN,DEPT MED,200 1ST ST SW,ROCHESTER,MN 55905, USA.							[Anonymous], 1996, Med Lett Drugs Ther, V38, P35; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; Balter M, 1996, SCIENCE, V272, P1740, DOI 10.1126/science.272.5269.1740; Bartlett JG, 1996, ANN INTERN MED, V124, P1086, DOI 10.7326/0003-4819-124-12-199606150-00011; CHOW YK, 1993, NATURE, V361, P650, DOI 10.1038/361650a0; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; Domingo E, 1996, FASEB J, V10, P859, DOI 10.1096/fasebj.10.8.8666162; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FLEXNER C, 1994, J INFECT DIS, V170, P1394, DOI 10.1093/infdis/170.6.1394; Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006; HIRSCH MS, 1993, NEW ENGL J MED, V328, P1686, DOI 10.1056/NEJM199306103282307; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; KILBY JM, 1994, INFECT AGENT DIS, V3, P313; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; KITCHEN VS, 1995, LANCET, V345, P952, DOI 10.1016/S0140-6736(95)90699-1; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MIZRACHI Y, 1995, AIDS, V9, P153, DOI 10.1097/00002030-199509020-00006; MORROW CD, 1994, AM J PHYSIOL, V266, pC1135, DOI 10.1152/ajpcell.1994.266.5.C1135; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; REICHMAN RC, 1995, J INFECT DIS, V171, P297, DOI 10.1093/infdis/171.2.297; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; SANDE MA, 1993, JAMA-J AM MED ASSOC, V270, P2583, DOI 10.1001/jama.270.21.2583; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; VOLBERDING PA, 1995, NEW ENGL J MED, V333, P401, DOI 10.1056/NEJM199508173330701; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wiznia AA, 1996, JAMA-J AM MED ASSOC, V275, P1504, DOI 10.1001/jama.275.19.1504; 1994, LANCET, V343, P871; 1996, PRESCRIBERS LETT, V3, P35; 1996, LANCET, V348, P283	45	72	73	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					800	803		10.1016/S0140-6736(95)12333-4	http://dx.doi.org/10.1016/S0140-6736(95)12333-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813990				2022-12-28	WOS:A1996VH98900016
J	Lipworth, BJ; Clark, D				Lipworth, BJ; Clark, D			High-dose inhaled steroids in asthmatic children	LANCET			English	Letter											Lipworth, BJ (corresponding author), UNIV DUNDEE,SCH MED,NINEWELLS HOSP,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND.							Clark DJ, 1996, THORAX, V51, P262, DOI 10.1136/thx.51.3.262; HOGGER P, 1994, STEROIDS, V59, P597, DOI 10.1016/0039-128X(94)90054-X; LIPWORTH BJ, 1995, THORAX, V50, P105, DOI 10.1136/thx.50.2.105; THORSSON L, IN PRESS BR J CLIN P; Todd G, 1996, LANCET, V348, P27, DOI 10.1016/S0140-6736(96)03339-9	5	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					820	820		10.1016/S0140-6736(05)65234-8	http://dx.doi.org/10.1016/S0140-6736(05)65234-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813996				2022-12-28	WOS:A1996VH98900040
J	Meredith, C; Symonds, P; Webster, L; Lamont, D; Pyper, E; Gillis, CR; Fallowfield, L				Meredith, C; Symonds, P; Webster, L; Lamont, D; Pyper, E; Gillis, CR; Fallowfield, L			Information needs of cancer patients in west Scotland: Cross sectional survey of patients' views	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EARLY BREAST-CANCER; PREFERENCES; DIAGNOSIS; TALKING	Objective-To assess the needs of patients with cancer for information about their condition. Design-Cross sectional survey of patients' views by means of semistructured interview with questionnaire. Setting-A regional cancer centre and two university hospitals in west Scotland. Subjects-250 (93%) of 269 cancer patients invited to participate in study who were selected by age, sex, socioeconomic status, and tumour site to be representative of cancer patients in west Scotland. Main outcome measures-Patients' need to know whether they had cancer, the medical name of their illness, progress through treatment, how treatment works, side effects, chances of cure, and treatment options. Results-79% (95% confidence interval 73% to 84%) of patients wanted as much information as possible, and 96% (93% to 98%) had a need or an absolute need to know if they had cancer. Most patients also wanted to know the chance of cure (91% (87% to 94%)) and about side effects of treatment (94% (90% to 97%)). When the replies were cross tabulated with patients' age, sex, deprivation score, and type of treatment there was a linear trend for patients from more affluent areas to want more information and those from deprived areas to want less. There was a strong preference for diagnosis of cancer to be given by a hospital doctor (60% (53% to 66%). Conclusion-Almost all patients wanted to know their diagnosis, and most wanted to know about prognosis, treatment options, and side effects.	WESTERN INFIRM & ASSOCIATED HOSP, BEATSON ONCOL CTR, GLASGOW G11 6NT, LANARK, SCOTLAND; GLASGOW CALEDONIAN UNIV, FAC HLTH, GLASGOW G13 1PP, LANARK, SCOTLAND; RUCHILL HOSP, W SCOTLAND CANC SURVEILLANCE UNIT, GLASGOW G20 9NB, LANARK, SCOTLAND; UCL, SCH MED, DEPT ONCOL, CRC COMMUN & COUNSELLING RES CTR, LONDON W1P 7PL, ENGLAND	Beatson Oncology Centre; Glasgow Caledonian University; University of Glasgow; University of London; University College London; UCL Medical School				Fallowfield, Lesley/0000-0003-0577-4518				*AUD COMM, 1993, 12 NHS AUD COMM; Carstairs V., 1991, DEPRIVATION HLTH SCO; CASSILETH BR, 1980, ANN INTERN MED, V92, P832, DOI 10.7326/0003-4819-92-6-832; FALLOWFIELD L, 1994, LANCET, V344, P1576, DOI 10.1016/S0140-6736(94)90386-7; FALLOWFIELD LJ, 1986, BMJ-BRIT MED J, V293, P1331, DOI 10.1136/bmj.293.6558.1331; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; FLETCHER C, 1980, BRIT MED J, V281, P994, DOI 10.1136/bmj.281.6246.994; HOLLAND JC, 1987, CANCER INVEST, V5, P151, DOI 10.3109/07357908709018468; JONES SJ, 1981, BRIT MED J, V2, P291; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; SLEVIN ML, 1987, BRIT J HOSP MED, V38, P56; THOMSEN OO, 1993, LANCET, V341, P473, DOI 10.1016/0140-6736(93)90218-6; WILKES E, 1984, PALLIATIVE CARE MANA, P9	13	390	397	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	1996	313	7059					724	726						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819442				2022-12-28	WOS:A1996VJ44100023
J	Glen, SK; Elliott, HL; Curzio, JL; Lees, KR; Reid, JL				Glen, SK; Elliott, HL; Curzio, JL; Lees, KR; Reid, JL			White-coat hypertension as a cause of cardiovascular dysfunction	LANCET			English	Article							SYSTEMIC HYPERTENSION; DIASTOLIC FUNCTION; BLOOD-PRESSURE; HEART; ECHOCARDIOGRAPHY; PROGRESSION; STIFFNESS; COMMON; ARTERY; TRIAL	Background The increasing use of 24 h ambulatory blood pressure monitoring has allowed diagnosis of white-coat hypertension, in which blood pressures are higher on clinic measurements than on ambulatory monitoring. Treatment is not generally thought to be necessary for this disorder. However, there is evidence that patients with white-coat hypertension develop renal impairment and left ventricular hypertrophy. We undertook this study to assess whether white-coat hypertension, in the absence of cardiovascular structural abnormalities, is associated with cardiovascular functional abnormalities. Methods Cardiovascular function was assessed by ultrasonography in three groups of patients classified as normotensive, persistently hypertensive, or white-coat hypertensive (23, 20, and 22 patients, respectively) on the basis of ambulatory blood pressure monitoring, carried out for 28 h with recordings taken every 15 min during the day and every 20 min during the night, acid clinic measurements, made with a semi-automatic oscillometric device. Results Similar abnormalities of diastolic left ventricular function were identified in the patients with persistent hypertension and those with white-coat hypertension; both groups differed in these indices from the normotensive group (E/A ratios 0.94 [SD 0.23], 1.06 [0.21], and 1.24 [0.31] respectively; ANOVA p<0.005). In addition, the white-coat and persistently hypertensive groups, when compared with the normotensive group, showed similar abnormalities of elasticity, compliance, and stiffness (stiffness index 4.32 [1.90], 4.53 [1.38], and 3.27 [0.95] respectively; ANOVA p<0.05) of the large arteries. Interpretation Functional cardiovascular abnormalities were identified in white-coat hypertensive patients who had no identifiable structural abnormalities. Such functional abnormalities can be reversed by antihypertensive treatment. We propose that patients with white-coat hypertension might benefit from antihypertensive treatment as well as those with persistent hypertension. This hypothesis should be addressed in prospective clinical trials.	UNIV GLASGOW, WESTERN INFIRM, DEPT MED & THERAPEUT, GLASGOW G11 6NT, LANARK, SCOTLAND	University of Glasgow								ARCARO G, 1991, J HYPERTENS, V9, P947; BETOCCHI S, 1987, AM J CARDIOL, V59, P624, DOI 10.1016/0002-9149(87)91181-7; BYRD LH, 1988, AM J HYPERTENS, V1, P80; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; HOEGHOLM A, 1994, HYPERTENSION, V24, P101, DOI 10.1161/01.HYP.24.1.101; IRIARTE M, 1993, AM J CARDIOL, V71, P308, DOI 10.1016/0002-9149(93)90796-F; KAWASAKI T, 1987, CARDIOVASC RES, V21, P678, DOI 10.1093/cvr/21.9.678; KRAKOFF LR, 1988, AM HEART J, V116, P1152, DOI 10.1016/0002-8703(88)90180-9; KUWAJIMA I, 1993, HYPERTENSION, V22, P826, DOI 10.1161/01.HYP.22.6.826; LERMAN CE, 1989, J GEN INTERN MED, V4, P226, DOI 10.1007/BF02599528; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; MANCIA G, 1983, LANCET, V2, P695; NISHIMURA RA, 1989, MAYO CLIN PROC, V64, P181, DOI 10.1016/S0025-6196(12)65673-0; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PICKERING TG, 1994, J HYPERTENS, V12, pS29; ROMAN MJ, 1992, CIRCULATION, V86, P1909, DOI 10.1161/01.CIR.86.6.1909; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SFAR ME, 1985, J CARDIOVASC PHAR S2, V7, pS51; SWALES JD, 1994, LANCET, V344, P380; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793; WATERS D, 1990, CIRCULATION, V82, P1940, DOI 10.1161/01.CIR.82.6.1940; ZANCHETTI A, 1993, J HYPERTENS, V11, P905	22	141	144	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 7	1996	348	9028					654	657		10.1016/S0140-6736(96)02303-3	http://dx.doi.org/10.1016/S0140-6736(96)02303-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF609	8782756				2022-12-28	WOS:A1996VF60900011
J	Gardina, PJ; Manson, MD				Gardina, PJ; Manson, MD			Attractant signaling by an aspartate chemoreceptor dimer with a single cytoplasmic domain	SCIENCE			English	Article							DIRECTED CROSS-LINKING; LIGAND-BINDING DOMAIN; ESCHERICHIA-COLI; RECEPTOR; CHEMOTAXIS; DIMERIZATION; TRANSDUCTION; CELL	Signal transduction across cell membranes often involves interactions among identical receptor subunits, but the contribution of individual subunits is not well understood. The chemoreceptors of enteric bacteria med late attractant responses by interrupting a phosphotransfer circuit initiated at receptor complexes with the protein kinase CheA. The aspartate receptor (Tar) is a homodimer, and oligomerized cytoplasmic domains stimulate CheA activity much more than monomers do in vitro. Intragenic complementation was used to show in Escherichia coli that heterodimers containing one full-length acid one truncated Tar subunit mediated responses to aspartate in the presence of full-length Tar homodimers that could not bind aspartate. Thus, a Tar dimer containing only one cytoplasmic domain can initiate an attractant (inhibitory) signal, although it may not be able to stimulate kinase activity of CheA.	TEXAS A&M UNIV,DEPT BIOL,COLLEGE STN,TX 77840	Texas A&M University System; Texas A&M University College Station					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039736] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39736] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BOURRET R, UNPUB; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DANIELSON MA, 1994, BIOCHEMISTRY-US, V33, P6100, DOI 10.1021/bi00186a009; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GARDINA P, 1992, J BACTERIOL, V174, P528; GARDINA P, UNPUB; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KRIKOS A, 1983, CELL, V33, P615, DOI 10.1016/0092-8674(83)90442-7; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; MADDOCK JR, 1993, SCIENCE, V259, P1717; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; OOSAWA K, 1988, J BACTERIOL, V170, P1326; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; STOCK JB, 1996, CELLULAR MOL BIOL, P1103; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; WOLFE AJ, 1994, J BACTERIOL, V176, P483; YANG Y, 1993, J MOL BIOL, V232, P493, DOI 10.1006/jmbi.1993.1405; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	25	81	81	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					425	426		10.1126/science.274.5286.425	http://dx.doi.org/10.1126/science.274.5286.425			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832892				2022-12-28	WOS:A1996VN17300055
J	Jory, WC				Jory, WC			Refractive surgery	LANCET			English	Editorial Material											Jory, WC (corresponding author), LONDON CTR REFRACT SURG,LONDON W1N 1PD,ENGLAND.							CHOYCE DP, 1996, AM SOC CAT REFR SURG; GARTRY DS, 1995, BRIT MED J, V310, P979, DOI 10.1136/bmj.310.6985.979; JORY W, 1995, EUR J IMPLANT REFRAC, V7, P17; KRIEGEROWSKI M, 1996, AM SOC CAT REF SURG; ROBIN JB, 1991, REFRACT CORNEAL SURG, V1, P112; ROSEN ES, 1994, EUR J IMPLANT REF SU, V6, P309; *ROYAL COL OPHTH, 1995, EXC LAS PHOT KER BES; WILLIAMS DK, 1966, UK IR SOC CAT REF SU	8	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					904	905		10.1016/S0140-6736(05)65332-9	http://dx.doi.org/10.1016/S0140-6736(05)65332-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843803				2022-12-28	WOS:A1996VL09700003
J	Brown, J; Worthington, MG; Lathi, ES				Brown, J; Worthington, MG; Lathi, ES			Learning from our errors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TUBERCULOMA		ST ELIZABETHS MED CTR BOSTON,DEPT INFECT DIS,BOSTON,MA; ST ELIZABETHS MED CTR BOSTON,DEPT NEUROL,BOSTON,MA	St. Elizabeth's Medical Center; St. Elizabeth's Medical Center	Brown, J (corresponding author), BOSTON MED CTR,DEPT EMERGENCY MED,818 HARRISON AVE,BOSTON,MA 02118, USA.							APUZZO MLJ, 1987, NEUROSURGERY, V20, P930, DOI 10.1227/00006123-198706000-00019; BOUCHAMA A, 1991, NEUROSURGERY, V28, P405, DOI 10.1227/00006123-199103000-00011; Folkerth R D, 1994, Neurosurg Clin N Am, V5, P1; GROVES R, 1966, ACTA NEUROL SCAND, V42, P268; GRUNERT P, 1994, NEUROSURG REV, V17, P59, DOI 10.1007/BF00309989; KASSIRER JP, 1989, AM J MED, V86, P433, DOI 10.1016/0002-9343(89)90342-2; Kassirer JP., 2009, LEARNING CLIN REASON; Kepes J J, 1994, Neurosurg Clin N Am, V5, P19; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; PAUKER SG, 1975, NEW ENGL J MED, V293, P229, DOI 10.1056/NEJM197507312930505; RAJSHEKHAR V, 1993, BRIT J NEUROSURG, V7, P665, DOI 10.3109/02688699308995096; RAJSHEKHAR V, 1990, British Journal of Neurosurgery, V4, P391, DOI 10.3109/02688699008992761; REYES MG, 1991, NEUROSURGERY, V29, P575, DOI 10.1227/00006123-199110000-00015; VENGSARKAR US, 1986, J NEUROSURG, V64, P568, DOI 10.3171/jns.1986.64.4.0568	14	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	1996	335	14					1049	1053		10.1056/NEJM199610033351409	http://dx.doi.org/10.1056/NEJM199610033351409			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL459	8793931				2022-12-28	WOS:A1996VL45900009
J	Olson, BR; Forman, MR; Lanza, E; McAdam, PA; Beecher, G; Kimzey, LM; Campbell, WS; Raymond, EG; Brentzel, SL; GuttschesEbeling, B				Olson, BR; Forman, MR; Lanza, E; McAdam, PA; Beecher, G; Kimzey, LM; Campbell, WS; Raymond, EG; Brentzel, SL; GuttschesEbeling, B			Relation between sodium balance and menstrual cycle symptoms in normal women	ANNALS OF INTERNAL MEDICINE			English	Article							PREMENSTRUAL-SYNDROME; ALDOSTERONE; PROGESTERONE; VASOPRESSIN; PREGNANCY	Objective: To determine whether sodium balance affects expression of menstrual symptoms. Design: Prospective study of menstrual symptoms during three cycles: a baseline month (usual intake of sodium, 115 mmol/d) followed by 2 months of sodium restriction (intake of sodium, 73.0 mmol/d). Added salt was allowed during the last month, Investigators were aware of the diet sequence. Setting: Outpatient. Meals were prepared by a metabolic kitchen during the 2 months that the participants received salt-restricted diets. Participants: 13 healthy menstruant women. Measurements: Plasma sodium levels, urinary sodium excretion, and plasma renin activity were measured for five time periods during the baseline cycle and the two cycles of salt-restricted diet. Eleven women completed a questionnaire assessing somatic symptoms and sensory cravings at the same time every day during the 3-month study period. Results: Sodium restriction was associated with a mean decrease (+/- one half of the 95% CI) in plasma sodium levels of 0.9 +/- 0.9 mmol/L from a mean of 139.3 mmol/L during the baseline cycle (P = 0.018), a decrease in urinary sodium excretion of 40.3 +/- 18 mmol/d from a mean of 117 mmol/d during the baseline cycle (P = 0.001), and an increase in plasma renin activity of 0.14 +/- 0.08 ng/(L - s) from a mean of 0.28 ng/(L s) during the baseline cycle (P = 0.008). During the luteal phase of the sodium restriction cycle, significant decreases in plasma sodium levels of 1.23 +/- 0.5 mmol/L (from values of 138.8 mmol/L during the follicular phase) and increases in urinary sodium excretion of 27.2 +/- 10 mmol/d (from values of 65.5 mmol/d during the follicular phase) preceded periods when menstrual symptoms were most severe. Ratings of breast tenderness increased sixfold to eightfold in the late luteal phase (P < 0.001) and those of swelling or bloating increased twofold to threefold during early menses (P < 0.001) compared with nadir symptom ratings during each cycle. Sodium cravings increased in the luteal phase of all cycles but were not accompanied by increased sodium intake when access to added salt was allowed. Conclusions: Breast tenderness and bloating did not result from sodium retention in the luteal phase of the menstrual cycle. During normal and sodium-restricted diet cycles, women actually had urinary sodium loss, not retention, during the luteal phase; severity of menstrual symptoms was unchanged.	USDA, BELTSVILLE, MD 20705 USA; NCI, NIH, BETHESDA, MD 20892 USA	United States Department of Agriculture (USDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								DAVISON JM, 1988, J CLIN INVEST, V81, P798, DOI 10.1172/JCI113386; FROLICH M, 1976, ACTA ENDOCRINOL-COP, V81, P548, DOI 10.1530/acta.0.0810548; FRYE CA, 1994, PHYSIOL BEHAV, V55, P193, DOI 10.1016/0031-9384(94)90031-0; HALBREICH U, 1985, CAN J PSYCHIAT, V30, P489, DOI 10.1177/070674378503000706; KATZ FH, 1972, J CLIN ENDOCR METAB, V34, P819, DOI 10.1210/jcem-34-5-819; LANDAU RL, 1958, J CLIN ENDOCR METAB, V18, P1237, DOI 10.1210/jcem-18-11-1237; MICHELAKIS AM, 1975, AM J OBSTET GYNECOL, V123, P724, DOI 10.1016/0002-9378(75)90495-0; MUNDAY MR, 1981, CLIN ENDOCRINOL, V14, P1, DOI 10.1111/j.1365-2265.1981.tb00359.x; OBRIEN PMS, 1979, BRIT J OBSTET GYNAEC, V86, P142; RUBINOW DR, 1984, AM J PSYCHIAT, V141, P684; SAGNELLA GA, 1989, AM J PHYSIOL, V256, pR1171, DOI 10.1152/ajpregu.1989.256.6.R1171; SCHMIDT PJ, 1991, NEW ENGL J MED, V324, P1174, DOI 10.1056/NEJM199104253241705; Schnurr PP, 1989, PSYCHOL ASSESSMENT, V1, P277; SMEATON TC, 1977, J CLIN ENDOCR METAB, V44, P1; SPRUCE BA, 1985, CLIN ENDOCRINOL, V22, P37, DOI 10.1111/j.1365-2265.1985.tb01062.x; STEINER M, 1980, ACTA PSYCHIAT SCAND, V62, P177, DOI 10.1111/j.1600-0447.1980.tb00605.x; SUNDSFJORD JA, 1970, ACTA ENDOCRINOL-COP, V64, P452, DOI 10.1530/acta.0.0640452; THOMPSON CJ, 1988, CLIN ENDOCRINOL, V28, P629, DOI 10.1111/j.1365-2265.1988.tb00237.x; VOKES TJ, 1988, AM J PHYSIOL, V254, pR641, DOI 10.1152/ajpregu.1988.254.4.R641; WHIPP GT, 1978, AUST J EXP BIOL MED, V56, P545, DOI 10.1038/icb.1978.60	20	25	27	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1996	125	7					564	567		10.7326/0003-4819-125-7-199610010-00005	http://dx.doi.org/10.7326/0003-4819-125-7-199610010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	VJ653	8815755				2022-12-28	WOS:A1996VJ65300005
J	Hsich, G; Kinney, K; Gibbs, CJ; Lee, KH; Harrington, MG				Hsich, G; Kinney, K; Gibbs, CJ; Lee, KH; Harrington, MG			The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CREUTZFELDT-JAKOB-DISEASE; GROWTH-HORMONE THERAPY; 2-DIMENSIONAL ELECTROPHORESIS; 14-3-3-PROTEINS; DIAGNOSIS; KINASE; ACTIVATION; TISSUE; GELS; RAF	Background There is no practical and reliable premortem test for Creutzfeldt-Jakob disease and the related transmissible spongiform encephalopathies. Two proteins, designated 130 and 131, which have been detected in low concentrations in cerebrospinal fluid from patients with Creutzfeldt-Jakob disease, appear to be sensitive and specific markers for the disease. Attempts to identify these proteins, however, have been unsuccessful. We hypothesized that they may be present in the normal brain. Methods We detected proteins 130 and 131 in normal human brain, partially sequenced their amino acids, and found that they matched the brain protein known as 14-3-3. We then developed a simple, rapid immunoassay for this protein and tested it in cerebrospinal fluid samples from 71 humans and 30 animals with spongiform encephalopathies and in control samples from 186 humans and 94 animals. Results The immunoassay detected the 14-3-3 protein in cerebrospinal fluid from 68 of the 71 patients with Creutzfeldt-Jakob disease (96 percent; 95 percent confidence interval, 92 to 99 percent). Among 94 patients with other dementias, the specificity was 96 percent. If one excludes the three patients with dementia who had had strokes within one month before testing, the specificity was 99 percent. The test was positive in 12 of 24 patients with viral encephalitis. In animals the sensitivity of the assay was 87 percent and the specificity was 99 percent. Conclusions In patients with dementia, a positive immunoassay for the 14-3-3 brain protein in cerebrospinal fluid strongly supports a diagnosis of Creutzfeldt-Jakob disease. This finding, however, does not support the use of the test in patients without clinically evident dementia.	NIH,CENT NERVOUS SYST STUDIES LAB,BASIC NEUROSCI PROGRAM,DIV INTRAMURAL RES,BETHESDA,MD 20892; CALTECH,DIV BIOL,PASADENA,CA 91125	National Institutes of Health (NIH) - USA; California Institute of Technology			Lee, Kelvin H/A-4673-2010; Crozier, Laura/C-2170-2011	Lee, Kelvin H/0000-0003-0908-2981; Harrington, Michael/0000-0002-7923-8032	NIA NIH HHS [AG05131, P30AG1230] Funding Source: Medline; NINDS NIH HHS [NS30531] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030531] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEBERSOLD RH, 1988, ELECTROPHORESIS, V9, P520, DOI 10.1002/elps.1150090912; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; Asher D. M., 1986, LABORATORY SAFETY PR, P59; AWERBUCH G, 1988, INT J NEUROSCI, V42, P1, DOI 10.3109/00207458808985754; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1375, DOI 10.1002/elps.11501401212; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1357, DOI 10.1002/elps.11501401209; BLISARD KS, 1990, J NEUROL SCI, V99, P75, DOI 10.1016/0022-510X(90)90201-W; BOSTON PF, 1982, J NEUROCHEM, V38, P1466, DOI 10.1111/j.1471-4159.1982.tb07927.x; BOSTON PF, 1982, J NEUROCHEM, V38, P1475, DOI 10.1111/j.1471-4159.1982.tb07928.x; BROWN P, 1986, NEW ENGL J MED, V314, P547, DOI 10.1056/NEJM198602273140904; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; BROWN P, 1986, ANN NEUROL, V20, P597, DOI 10.1002/ana.410200507; BROWN P, 1994, NEURODEGENER DIS, P839; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CROXSON M, 1988, NEUROLOGY, V38, P1128, DOI 10.1212/WNL.38.7.1128; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GAJDUSEK DC, 1996, FIELDS VIROLOGY, V2, P2851; HARRINGTON M G, 1991, Methods (Orlando), V3, P98, DOI 10.1016/S1046-2023(05)80201-4; HARRINGTON MG, 1986, NEW ENGL J MED, V315, P279, DOI 10.1056/NEJM198607313150502; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JIMI T, 1992, CLIN CHIM ACTA, V211, P37, DOI 10.1016/0009-8981(92)90103-W; MACARIO ME, 1991, BRIT MED J, V302, P1149, DOI 10.1136/bmj.302.6785.1149; MANAKA H, 1992, NEUROSCI LETT, V139, P47, DOI 10.1016/0304-3940(92)90854-Z; MARZEWSKI DJ, 1988, NEUROLOGY, V38, P1131, DOI 10.1212/WNL.38.7.1131; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; PRUSINER SB, 1996, FIELDS VIROLOGY, V2, P2901; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; Rosner B., 1986, FUNDAMENTALS BIOSTAT, V2nd, P442; SOLOMON JE, 1993, COMPUT APPL BIOSCI, V9, P133; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; ZERR I, 1995, LANCET, V345, P1609, DOI 10.1016/S0140-6736(95)90118-3	37	523	543	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1996	335	13					924	930		10.1056/NEJM199609263351303	http://dx.doi.org/10.1056/NEJM199609263351303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK148	8782499				2022-12-28	WOS:A1996VK14800003
J	Miller, MA; Sutter, RW; Strebel, PM; Hadler, SC				Miller, MA; Sutter, RW; Strebel, PM; Hadler, SC			Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; POLIOMYELITIS; DISEASE	Objective.-To evaluate the economic consequences of introducing inactivated poliovirus vaccine (IPV) into the routine vaccination schedule in the United States to reduce vaccine-associated paralytic poliomyelitis (VAPP). Design.-Cost-benefit and cost-effectiveness models were formulated to compare the current national 4-dose live attenuated oral poliovirus vaccine (OPV) schedule with a 4-dose IPV schedule or a sequential schedule of 2 doses of IPV followed by 2 doses of OPV. Model assumptions were derived from the National Health Interview Survey (1994), current prices for OPV and IPV, a Delphi panel, compensatory awards by the National Vaccine Injury Compensation Program, and published and unpublished reports. Main Outcome Measures.-Annual societal incremental cost relative to the current schedule for the cost-benefit model; cost per VAPP case prevented for the cost-effectiveness model. Results.-Changing to an IPV-only or a sequential schedule would cost $28.1 million and $14.7 million, respectively. The costs per case of VAPP prevented were estimated as $3.0 million and $3.1 million for each option, respectively. Outcomes were most sensitive to the number of additional visits that may occur to avoid multiple injections. Conclusions. The introduction of IPV into the routine vaccination schedule would not be cost-beneficial at current vaccine prices and with the current compensation awards paid to VAPP cases. The analysis provides a range of costs that policymakers need to consider if they wish to prevent VAPP. Although these costs are higher than those of other public health prevention programs, they may be justified because VAPP continues to occur as a result of government-mandated vaccination policies in the absence of known wild poliovirus transmission in the United States.	CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,DIV EPIDEMIOL & SURVEILLANCE,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								*CDC, 1991, 93 US DEP HLTH HUM S; DEQUADROS CA, 1993, BIOLOGICALS, V21, P335, DOI 10.1006/biol.1993.1093; HADDIX AC, 1996, PREVENTION EFFECTIVE, P187; Hatziandreu EJ, 1994, COST BENEFIT ANAL OP; *I MED, 1988, IOM PUBL, V8804, P1; LANDAUER KS, 1957, 35 ANN SESS AM C PHY; LANE JM, 1971, ANNU REV MED, V22, P251, DOI 10.1146/annurev.me.22.020171.001343; *NAT CTR HLTH STAT, 1995, 1994 US DEP HLTH HUM; NIGHTINGALE EO, 1977, NEW ENGL J MED, V297, P249, DOI 10.1056/NEJM197708042970505; PREVOTS DR, 1994, ARCH PEDIAT ADOL MED, V148, P479, DOI 10.1001/archpedi.1994.02170050037007; Rice D P, 1985, Health Care Financ Rev, V7, P61; SCHONBERGER LB, 1984, REV INFECT DIS S, V6, P424; SENCER DJ, 1973, S SERIES IMMUNOBIOLO, V22, P37; STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568; Sutter RW, 1994, INFECT MED, V11, P426; Weibel RE, 1996, AM J PUBLIC HEALTH, V86, P734, DOI 10.2105/AJPH.86.5.734; WOODIN KA, 1995, ARCH PEDIAT ADOL MED, V149, P845, DOI 10.1001/archpedi.1995.02170210019003; 1994, EPIDEMIOL B, V15, P1; 1995, MMWR-MORBID MORTAL W, V43, P957; 1996, MMWR-MORBID MORTAL W, V45, P676; 1996, MMWR-MORBID MORTAL W, V45, P145; 1994, MMWR-MORBID MORTAL W, V43, P720; 1987, MMWR-MORBID MORTAL W, V36, P795; 1971, MMWR-MORBID MORTAL W, V20, P339	24	71	73	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	1996	276	12					967	971		10.1001/jama.276.12.967	http://dx.doi.org/10.1001/jama.276.12.967			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH990	8805731				2022-12-28	WOS:A1996VH99000037
J	Sharp, SJ; Thompson, SG; Altman, DG				Sharp, SJ; Thompson, SG; Altman, DG			The relation between treatment benefit and underlying risk in meta-analysis	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; RANDOMIZED TRIALS; ODDS RATIO; METAANALYSIS; REGRESSION; HYPERTENSION; INFARCTION; SURVIVAL; SURGERY; TRENDS	In meta-analyses of clinical trials comparing a treated group with a control group it has been common to ask whether the treatment benefit varies according to the underlying risk of the patients in the different trials, with the hope of defining which patients would benefit most and which least from medical interventions. The usual analysis used to investigate this issue, however, which uses the observed proportions of events in the control groups of the trials as a measure of the underlying risk, is flawed and produces seriously misleading results. This arises through a bias due to regression to the mean and will be particularly acute in meta-analyses which include some small trials or in which the variability in the true underlying risks across trials is small. Approaches which previously have been thought to be more appropriate are to substitute the average proportion of events in the control and treated groups as the measure of underlying risk or to plot the proportion of events in the treated group against that in the control group (L'Abbe plot). However, these are still subject to bias in most circumstances. Because of the potentially seriously flawed conclusions that can result from such analyses, they should be replaced either by statistically appropriate (but more complex) approaches or, preferably, by analyses which investigate the dependence of the treatment effect on measured baseline characteristics of the patients in each trial.	ROYAL POSTGRAD MED SCH,DEPT MED STAT & EVALUAT,LONDON W12 0NN,ENGLAND; INST HLTH SCI,MED STAT GRP,IMPERIAL CANC RES FUND,CTR STAT MED,OXFORD OX3 7LF,ENGLAND	Imperial College London; University of Oxford	Sharp, SJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,MED STAT UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.							ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; APPEL LJ, 1993, ARCH INTERN MED, V153, P1429, DOI 10.1001/archinte.153.12.1429; ARMITAGE P, 1994, STAT METHODS MED RES, P288; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; BLAND JM, 1994, BRIT MED J, V309, P780, DOI 10.1136/bmj.309.6957.780; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; BLOMQVIST N, 1977, J AM STAT ASSOC, V72, P746, DOI 10.2307/2286454; BOISSEL JP, 1993, J CARDIOVASC PHARM, V22, P356, DOI 10.1097/00005344-199309000-00003; BRAND R, 1992, STAT MED, V11, P2077, DOI 10.1002/sim.4780111605; CATTANEO M, 1993, LANCET, V342, P812, DOI 10.1016/0140-6736(93)91581-6; CHALMERS TC, 1991, STAT MED, V10, P971, DOI 10.1002/sim.4780100618; Cox DR., 1989, ANAL BINARY DATA; EGGER M, 1995, J HYPERTENS, V13, P813, DOI 10.1097/00004872-199507000-00014; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; HAYES RJ, 1988, STAT MED, V7, P915, DOI 10.1002/sim.4780070903; HOES AW, 1995, J HYPERTENS, V13, P805; HOROWITZ R, 1995, J CLIN EPIDEMIOL, V48, P41; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; MCINTOSH M, 1995, HARVARD MED SCH TECH, V4, P1; PAGLIARO L, 1992, ANN INTERN MED, V117, P59, DOI 10.7326/0003-4819-117-1-59; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; SENN S, 1994, STAT MED, V13, P293, DOI 10.1002/sim.4780130310; SMITH GD, 1994, BMJ-BRIT MED J, V308, P72, DOI 10.1136/bmj.308.6921.72; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; VANHOUWELINGEN HC, 1993, STAT MED, V12, P2273, DOI 10.1002/sim.4780122405; VICTOR N, 1995, J CLIN EPIDEMIOL, V48, P5, DOI 10.1016/0895-4356(94)00107-2; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	29	128	129	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					735	738						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819447				2022-12-28	WOS:A1996VJ44100030
J	Espinoza, FH; Farrell, A; ErdjumentBromage, H; Tempst, P; Morgan, DO				Espinoza, FH; Farrell, A; ErdjumentBromage, H; Tempst, P; Morgan, DO			A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK	SCIENCE			English	Article							TRANSCRIPTION FACTOR TFIIH; RING FINGER PROTEIN; CATALYTIC SUBUNIT; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; P40(MO15); MO15; PHOSPHORYLATION; ASSOCIATION; P34(CDC2)	Progress through the cell cycle is governed by the cyclin-dependent kinases (CDKs), the activation oi which requires phosphorylation by the CDK-activating kinase (CAK). In vertebrates, CAK is a trimeric enzyme containing CDK7, cyclin H, and MAT1. CAK from the budding yeast Saccharomyces cerevisiae was identified as an unusual 44-kilodalton protein kinase, Cak1, that is only distantly related to CDKs. Cak1 accounted for most CAK activity in yeast cell lysates, and its activity was constant throughout the cell cycle. The CAK1 gene was essential for cell viability. Thus, the major CAK in S. cerevisiae is distinct from the vertebrate enzyme, suggesting that budding yeast and vertebrates may have evolved different mechanisms of CDK activation.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOL BIOL, NEW YORK, NY 10021 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center				Espinoza, Francisco/0000-0002-1855-1914; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Morgan, David/0000-0001-8753-4416				BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; Buck V, 1995, EMBO J, V14, P6173, DOI 10.1002/j.1460-2075.1995.tb00308.x; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Damagnez V, 1995, EMBO J, V14, P6164, DOI 10.1002/j.1460-2075.1995.tb00307.x; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; ESPINOZA FH, UNPUB; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RA, UNPUB; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURAKAMI Y, 1995, NAT GENET, V10, P261, DOI 10.1038/ng0795-261; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316	34	139	142	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	1996	273	5282					1714	1717		10.1126/science.273.5282.1714	http://dx.doi.org/10.1126/science.273.5282.1714			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH408	8781234				2022-12-28	WOS:A1996VH40800041
J	Tyden, G; Reinholt, FP; Sundkvist, G; Bolinder, J				Tyden, G; Reinholt, FP; Sundkvist, G; Bolinder, J			Recurrence of autoimmune diabetes mellitus in recipients of cadaveric pancreatic grafts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISLET-CELL ANTIBODIES; IDDM PATIENTS; TRANSPLANTATION; DISEASE		KAROLINSKA INST,HUDDINGE HOSP,DIV PATHOL,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,HUDDINGE HOSP,DIV MED,S-14186 HUDDINGE,SWEDEN; MALMO UNIV HOSP,DEPT ENDOCRINOL,MALMO,SWEDEN	Karolinska Institutet; Karolinska Institutet; Lund University; Skane University Hospital	Tyden, G (corresponding author), KAROLINSKA INST,HUDDINGE HOSP,DIV TRANSPLANTAT SURG,S-14186 HUDDINGE,SWEDEN.			Bolinder, Jan/0000-0003-0035-0142				BOSI E, 1989, DIABETES, V38, P82, DOI 10.2337/diab.38.1.S82; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; FOULIS AK, 1986, DIABETOLOGIA, V29, P267, DOI 10.1007/BF00452061; GOTTSATER A, 1993, DIABETES CARE, V16, P902, DOI 10.2337/diacare.16.6.902; GRUBIN CE, 1994, DIABETOLOGIA, V37, P344, DOI 10.1007/BF00408469; OLSSON ML, 1987, DIABETOLOGIA, V30, P327, DOI 10.1007/BF00299026; OSTMAN J, 1989, DIABETES, V38, P88, DOI 10.2337/diab.38.1.S88; RAKOTOAMBININA B, 1995, DIABETES CARE, V18, P1487, DOI 10.2337/diacare.18.11.1487; SIBLEY RK, 1987, AM J PATHOL, V128, P151; SUTHERLAND DER, 1989, DIABETES, V38, P85, DOI 10.2337/diab.38.1.S85; TYDEN G, 1987, TRANSPLANTATION, V43, P674, DOI 10.1097/00007890-198705000-00014	11	144	146	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1996	335	12					860	863		10.1056/NEJM199609193351205	http://dx.doi.org/10.1056/NEJM199609193351205			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG869	8778604				2022-12-28	WOS:A1996VG86900005
J	Halm, EA; Browner, WS; Tubau, JF; Tateo, IM; Mangano, DT				Halm, EA; Browner, WS; Tubau, JF; Tateo, IM; Mangano, DT			Echocardiography for assessing cardiac risk in patients having noncardiac surgery	ANNALS OF INTERNAL MEDICINE			English	Article							PERIOPERATIVE MYOCARDIAL-INFARCTION; PERIPHERAL VASCULAR-SURGERY; ABDOMINAL AORTIC-ANEURYSM; DOBUTAMINE STRESS ECHOCARDIOGRAPHY; EJECTION FRACTION; DIAGNOSTIC-TEST; RADIONUCLIDE ANGIOGRAPHY; VENTRICULAR ARRHYTHMIAS; NONVASCULAR SURGERY; MEDICAL LITERATURE	Background: Cardiac complications after noncardiac surgery are a serious cause of illness and death. Echocardiography is being used before noncardiac surgery to assess risk for cardiac complications, but its role remains undefined. Objective: To examine the prognostic value and operating characteristics of transthoracic echocardiography for assessing cardiac risk before noncardiac surgery. Design: Prospective cohort study. Setting: University-affiliated Veterans Affairs medical center. Patients: 339 consecutive men who were known to have or were suspected of having coronary artery disease and were scheduled for major noncardiac surgery. Measurements: Information from detailed histories, physical examinations, and electrocardiographic and laboratory studies was routinely collected. Transthoracic echocardiography was done before surgery to assess ejection fraction, wall motion abnormalities (reported as the wall motion score [range, 5 to 25 points]), and left ventricular hypertrophy. Main Outcome Measures: Postoperative ischemic events (cardiac-related death, nonfatal myocardial infarction, and unstable angina), congestive heart failure, and ventricular tachycardia. Results: 10 patients (3%) had ischemic events; 26 (8%) had congestive heart failure; and 29 (8%) had ventricular tachycardia. No echocardiographic measurements were associated with ischemic events. In univariate analyses, an ejection fraction less than 40% was associated with all cardiac outcomes combined (odds ratio, 3.5 [95% CI, 1.8 to 6.7]), congestive heart failure (odds ratio, 3.0 [CI, 1.2 to 7.4]), and ventricular tachycardia (odds ratio, 2.6 [CI, 1.1 to 6.2]). In multivariable analyses that adjusted for known clinical risk factors, an ejection fraction less than 40% was a significant predictor of ail outcomes combined (odds ratio, 2.5 [CI, 1.2 to 5.0]) but not congestive heart failure (odds ratio, 2.1 [CI, 0.7 to 6.0]) and ventricular ejection fraction (odds ratio, 1.8 [CI, 0.7 to 4.7]). Wall motion score was a univariate predictor of all cardiac outcomes (odds ratio for each 3-unit increase, 1.6 [CI, 1.3 to 2.1]) and ventricular tachycardia (odds ratio, 1.6 [CI, 1.2 to 2.2]) but was only a multivariable risk factor for all events (odds ratio, 1.3 [CI, 1.0 to 1.7]). An ejection fraction less than 40% had a sensitivity of 0.28 to 0.31 and a specificity of 0.87 to 0.89 for all categories of adverse outcomes. Likelihood ratios for ejection fraction had poor operating characteristics. Adding echocardiographic information to predictive models that contained known clinical risk factors did not alter sensitivity, specificity, or predictive values in clinically important ways. Conclusions: The data did not support the use of transthoracic echocardiography for the assessment of cardiac risk before noncardiac surgery. Echocardiographic measurements had limited prognostic value and suboptimal operating characteristics.	VET AFFAIRS MED CTR, SAN FRANCISCO, CA 94121 USA; VET AFFAIRS MED CTR, DEPT ANESTHESIA, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Halm, EA (corresponding author), MASSACHUSETTS GEN HOSP, MED PRACTICES EVALUAT CTR, 50 STANIFORD ST, 9TH FLOOR, BOSTON, MA 02114 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36744] Funding Source: Medline; BHP HRSA HHS [PE 11001-08] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); BHP HRSA HHS		ADAMS JE, 1994, NEW ENGL J MED, V330, P670, DOI 10.1056/NEJM199403103301003; ASHBURN WL, 1980, RADIOL CLIN N AM, V18, P467; ASHTON CM, 1993, ANN INTERN MED, V118, P504, DOI 10.7326/0003-4819-118-7-199304010-00004; BARON JF, 1994, NEW ENGL J MED, V330, P663, DOI 10.1056/NEJM199403103301002; BERNING J, 1990, AM J CARDIOL, V65, P567, DOI 10.1016/0002-9149(90)91032-2; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; Bodenheimer MM, 1996, ANN INTERN MED, V124, P763, DOI 10.7326/0003-4819-124-8-199604150-00010; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; BROWNER WS, 1991, CLIN RES, V39, P7; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CHAITMAN BR, 1979, CIRCULATION, V59, P560, DOI 10.1161/01.CIR.59.3.560; COHN JN, 1993, CIRCULATION, V87, P1; COLEY CM, 1992, AM J CARDIOL, V69, P1280, DOI 10.1016/0002-9149(92)91221-O; *CRIT COMM NEW YOR, 1979, NOM CRIT DIAGN DIS H, V94; DAVILAROMAN VG, 1993, J AM COLL CARDIOL, V21, P957, DOI 10.1016/0735-1097(93)90353-3; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; Dudley JC, 1996, AM HEART J, V131, P245, DOI 10.1016/S0002-8703(96)90348-8; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; FRANCO CD, 1989, J VASC SURG, V10, P656, DOI 10.1067/mva.1989.16173; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HOLLENBERG M, 1992, JAMA-J AM MED ASSOC, V268, P205, DOI 10.1001/jama.268.2.205; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KAZMERS A, 1988, J VASC SURG, V8, P128, DOI 10.1067/mva.1988.avs0080128; Kleinbaum D.G, 1988, APPL REGRESSION ANAL; LONDON MJ, 1990, ANESTHESIOLOGY, V73, P644, DOI 10.1097/00000542-199010000-00010; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1992, JAMA-J AM MED ASSOC, V268, P233, DOI 10.1001/jama.268.2.233; MANGANO DT, 1991, CIRCULATION, V84, P493, DOI 10.1161/01.CIR.84.2.493; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; MANTHA S, 1994, ANESTH ANALG, V79, P422; MCCANN RL, 1989, J VASC SURG, V10, P240; MCENROE CS, 1990, J VASC SURG, V11, P497, DOI 10.1067/mva.1990.18756; MCPHAIL NV, 1990, CAN J SURG, V33, P224; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; OKELLY B, 1992, JAMA-J AM MED ASSOC, V268, P217, DOI 10.1001/jama.268.2.217; Ouriel K, 1995, J VASC SURG, V22, P671, DOI 10.1016/S0741-5214(95)70057-9; PASTERNACK PF, 1984, J VASC SURG, V1, P320, DOI 10.1067/mva.1984.avs0010320; PASTERNACK PF, 1985, CIRCULATION, V72, P13; POLDERMANS D, 1993, CIRCULATION, V87, P1506, DOI 10.1161/01.CIR.87.5.1506; ROMHILT DW, 1968, AM HEART J, V75, P752, DOI 10.1016/0002-8703(68)90035-5; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; TAKASE B, 1993, AM HEART J, V126, P1099, DOI 10.1016/0002-8703(93)90660-2; TISCHLER MD, 1991, AM J CARDIOL, V68, P593, DOI 10.1016/0002-9149(91)90349-P; WONG T, 1992, ANN INTERN MED, V116, P743, DOI 10.7326/0003-4819-116-9-743	50	143	146	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					433	441		10.7326/0003-4819-125-6-199609150-00001	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779454				2022-12-28	WOS:A1996VF88200003
J	Burston, SG; Weissman, JS; Farr, GW; Fenton, WA; Horwich, AL				Burston, SG; Weissman, JS; Farr, GW; Fenton, WA; Horwich, AL			Release of both native and non-native proteins from a cis-only GroEL ternary complex	NATURE			English	Article							CHAPERONIN GROEL; ESCHERICHIA-COLI; ATP HYDROLYSIS; CYCLE; BINDING; POLYPEPTIDE; MECHANISM	PROTEIN folding by the double-ring chaperonin GroEL is initiated in cts ternary complexes, in which polypeptide is sequestered in the central channel of a GroEL ring, capped by the co-chaperonin GroES(1-3), The cis ternary complex is dissociated (half-life of similar to 15 s) by trans-sided ATP hydrolysis, which triggers release of GroES(4-6). For the substrate protein rhodanese, only similar to 15% of cis-localized molecules attain their native form before hydrolysis(2,7). A major question concerning the GroEL mechanism is whether both native and non-native forms are released from the cis complex, Here we address this question using a 'cis-only' mixed-ring GroEL complex that binds polypeptide and GroES on only one of its two rings, This complex mediates refolding of rhodanese but, as with wild-type GroEL, renaturation is quenched by addition of mutant GroEL 'traps', which bind but do not release polypeptide substrate(7,8), This indicates that nonnative forms are released from the cis complex, Quenching of refolding by traps was also observed under physiological conditions, both in undiluted Xenopus oocyte extract and in intact oocytes, We conclude that release of non-native forms from GroEL in vivo allows a kinetic partitioning among various chaperones and proteolytic components, which determines both the conformation and lifetime of a protein.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,BOYER CTR,NEW HAVEN,CT 06510; YALE UNIV,DEPT GENET,BOYER CTR,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University				Burston, Steven/0000-0003-1848-1853; Weissman, Jonathan/0000-0003-2445-670X				Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCKBERGER A, IN PRESS J MOL BIOL; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KANDROR O, 1994, J BIOL CHEM, V269, P23575; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; TANDON S, 1989, J BIOL CHEM, V264, P9859; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	23	82	84	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1996	383	6595					96	99		10.1038/383096a0	http://dx.doi.org/10.1038/383096a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VF295	8779722				2022-12-28	WOS:A1996VF29500056
J	Schulz, KF				Schulz, KF			Randomised trials, human nature, and reporting guidelines	LANCET			English	Editorial Material							CLINICAL-TRIALS; QUALITY; RANDOMIZATION; PUBLICATION; OBSTETRICS; GYNECOLOGY; BIAS				Schulz, KF (corresponding author), CTR DIS CONTROL & PREVENT, DIV SEXUALLY TRANSMITTED DIS PREVENT, NATL CTR HIV STD & TB PREVENT, ATLANTA, GA 30333 USA.							ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; Chalmers I, 1989, EFFECTIVE CARE PREGN, V1, P39; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; GOTZSCHE PC, 1989, EUR J CLIN PHARMACOL, V36, P429, DOI 10.1007/BF00558064; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; GRANT JM, 1995, BRIT J OBSTET GYNAEC, V102, P849, DOI 10.1111/j.1471-0528.1995.tb10868.x; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; MOSTELLER F, 1980, CONTROL CLIN TRIALS, V1, P37, DOI 10.1016/S0197-2456(80)80006-7; POCOCK SJ, 1982, STATISTICIAN, V31, P1; RENNIE D, 1995, JAMA-J AM MED ASSOC, V273, P1054, DOI 10.1001/jama.273.13.1054; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCHULZ KF, 1995, CAN MED ASSOC J, V153, P783; Schulz KF, 1996, BRIT MED J, V312, P742; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456, DOI DOI 10.1001/JAMA.1995.03530180050029; SCHULZ KF, 1995, ONLINE J CURR CLIN T; SONIS J, 1994, J FAM PRACTICE, V39, P225; TYSON JE, 1983, J PEDIATR-US, V102, P10, DOI 10.1016/S0022-3476(83)80277-7; WILLIAMS DH, 1994, CONTROL CLIN TRIALS, V15, P294, DOI 10.1016/0197-2456(94)90045-0; 1988, CONTROLLED CLIN TRIA, V9, P287; 1996, JAMA-J AM MED ASSOC, V276, P637; 1994, JAMA-J AM MED ASSOC, V272, P1926; 1994, ANN INTERN MED, V121, P894	24	97	97	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	1996	348	9027					596	598		10.1016/S0140-6736(96)01201-9	http://dx.doi.org/10.1016/S0140-6736(96)01201-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774577				2022-12-28	WOS:A1996VF18600019
J	Ball, S				Ball, S			Antenatal screening of thyroid antibodies	LANCET			English	Editorial Material							POSTPARTUM THYROIDITIS				Ball, S (corresponding author), ROYAL VICTORIA INFIRM,DEPT MED,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							GERSTEIN HC, 1990, ARCH INTERN MED, V150, P1397, DOI 10.1001/archinte.150.7.1397; HALL R, 1995, BAILLIERE CLIN ENDOC, V9, P137, DOI 10.1016/S0950-351X(95)80883-3; HARRIS B, 1992, BMJ-BRIT MED J, V305, P152, DOI 10.1136/bmj.305.6846.152; Lazarus JH, 1996, QJM-INT J MED, V89, P429; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; OTHMAN S, 1990, CLIN ENDOCRINOL, V32, P559, DOI 10.1111/j.1365-2265.1990.tb00898.x	6	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					906	907		10.1016/S0140-6736(05)65334-2	http://dx.doi.org/10.1016/S0140-6736(05)65334-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843805				2022-12-28	WOS:A1996VL09700005
J	Glover, V; Fisk, N				Glover, V; Fisk, N			For debate - Do fetuses feel pain? We don't know; Better to err on the safe side from mid-gestation	BRITISH MEDICAL JOURNAL			English	Article							RESPONSES				Glover, V (corresponding author), QUEEN CHARLOTTES & CHELSEA HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,DEPT PAEDIAT,LONDON W6 0XG,ENGLAND.		Fisk, Nicholas M/B-2126-2009; Glover, Vivette/M-2711-2016	Fisk, Nicholas M/0000-0003-0031-7975; Glover, Vivette/0000-0001-6543-1651				ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; BENNETT P, 1994, LANCET, V344, P615; DERBYSHIRE SWG, 1994, LANCET, V344, P615, DOI 10.1016/S0140-6736(94)92001-X; FITZGERALD M, 1993, PAIN RES CLIN MANAGE, V5, P19; GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; GLOVER V, 1995, BAILLIERES CLIN PAED, P495; GREENFIELD SA, 1995, JOURNEY CENTRES MIND; Hepper P.G., 1994, J REPROD INFANT PSYC, V12, P143, DOI [10.1080/02646839408408880, DOI 10.1080/02646839408408880]; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; MEANEY MJ, 1993, CELL MOL NEUROBIOL, V13, P321, DOI 10.1007/BF00711576; ROGERS MC, 1992, NEW ENGL J MED, V326, P55, DOI 10.1056/NEJM199201023260109; TADDIO A, 1995, LANCET, V345, P291, DOI 10.1016/S0140-6736(95)90278-3; Teixeira J, 1996, LANCET, V347, P624, DOI 10.1016/S0140-6736(96)91327-6	13	27	29	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					796	796						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842075				2022-12-28	WOS:A1996VK56600029
J	Matthews, JNS; Altman, DG				Matthews, JNS; Altman, DG			Statistics notes: Interaction 2: Compare effect sizes not P values	BRITISH MEDICAL JOURNAL			English	Article									INST HLTH SCI,CTR STAT MED,ICRF MED STAT GRP,OXFORD OX3 7LF,ENGLAND	University of Oxford	Matthews, JNS (corresponding author), UNIV NEWCASTLE,DEPT MED STAT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.		Matthews, John N S/H-7502-2013	Matthews, John N S/0000-0003-2559-037X				Altman DG, 1996, BRIT MED J, V313, P486; COCKBURN F, 1980, BRIT MED J, V281, P11, DOI 10.1136/bmj.281.6232.11; 1981, AM J OBSTET GYNECOL, V141, P276	3	127	132	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 28	1996	313	7060					808	808						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VK566	8842080				2022-12-28	WOS:A1996VK56600035
J	Grewal, IS; Foellmer, HG; Grewal, KD; Xu, JC; Hardardottir, F; Baron, JL; Janeway, CA; Flavell, RA				Grewal, IS; Foellmer, HG; Grewal, KD; Xu, JC; Hardardottir, F; Baron, JL; Janeway, CA; Flavell, RA			Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis	SCIENCE			English	Article							DENDRITIC CELLS; IMMUNE-RESPONSES; TRANSGENIC MICE; ANTIGEN; EXPRESSION; RECEPTOR	The mechanism of CD40 ligand (CD40L)-mediated in vivo activation of CD4(+) T cells was examined by investigation of the development of experimental allergic encephalomyelitis (EAE) in CD40L-deficient mice that carried a transgenic T cell receptor specific for myelin basic protein. These mice failed to develop EAE after priming with antigen, and CD4(+) T cells remained quiescent and produced no inteferon-gamma (IFN-gamma). T cells were primed to make IFN-gamma and induce EAE by providing these mice with B7.1(+) antigen-presenting cells (APCs). Thus, CD40L is required to induce costimulatory activity on APCs for in vivo activation of CD4(+) T cells to produce IFN-gamma and to evoke autoimmunity.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,YALE NEUROTRANSPLANT PROGRAM,NEW HAVEN,CT 06510	Howard Hughes Medical Institute; Yale University; Yale University				Grewal, Iqbal S/0000-0002-4775-055X				Campbell KA, 1996, IMMUNITY, V4, P283, DOI 10.1016/S1074-7613(00)80436-7; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; Griggs ND, 1996, J EXP MED, V183, P801, DOI 10.1084/jem.183.3.801; HARDARDOTTIR F, 1995, P NATL ACAD SCI USA, V92, P354, DOI 10.1073/pnas.92.2.354; Heufler C, 1996, EUR J IMMUNOL, V26, P659, DOI 10.1002/eji.1830260323; INABA K, 1994, J EXP MED, V180, P1849, DOI 10.1084/jem.180.5.1849; Jaiswal AI, 1996, INT IMMUNOL, V8, P275, DOI 10.1093/intimm/8.2.275; Kamanaka M, 1996, IMMUNITY, V4, P275, DOI 10.1016/S1074-7613(00)80435-5; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KEARNEY ER, 1995, J IMMUNOL, V155, P1032; Kennedy MK, 1996, EUR J IMMUNOL, V26, P370, DOI 10.1002/eji.1830260216; KUCHROO VK, 1994, J EXP MED, V179, P1659, DOI 10.1084/jem.179.5.1659; LUDEWING B, 1995, EUR J IMMUNOL, V22, P2855; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; MOUDGIL KD, 1993, J EXP MED, V178, P2131, DOI 10.1084/jem.178.6.2131; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; PEGUETNAVARRO J, 1995, J IMMUNOL, V155, P4241; ROY M, 1995, EUR J IMMUNOL, V25, P596, DOI 10.1002/eji.1830250243; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SCHEICHER C, 1995, EUR J IMMUNOL, V25, P1566, DOI 10.1002/eji.1830250615; SETHNA MP, 1994, IMMUNITY, V1, P415, DOI 10.1016/1074-7613(94)90072-8; SHU U, 1995, EUR J IMMUNOL, V25, P1125, DOI 10.1002/eji.1830250442; Stout RD, 1996, J IMMUNOL, V156, P8; Stuber E, 1996, J EXP MED, V183, P693, DOI 10.1084/jem.183.2.693; WU Y, 1995, CURR BIOL, V5, P1303, DOI 10.1016/S0960-9822(95)00257-0; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	28	369	380	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 27	1996	273	5283					1864	1867		10.1126/science.273.5283.1864	http://dx.doi.org/10.1126/science.273.5283.1864			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VJ713	8791592				2022-12-28	WOS:A1996VJ71300046
J	Rothe, MJ; GrantKels, JM				Rothe, MJ; GrantKels, JM			Diagnostic criteria for atopic dermatitis	LANCET			English	Editorial Material							FEATURES				Rothe, MJ (corresponding author), UNIV CONNECTICUT,CTR HLTH,DIV DERMATOL,FARMINGTON,CT 06030, USA.							HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; KANWAR AJ, 1991, PEDIATR DERMATOL, V8, P114, DOI 10.1111/j.1525-1470.1991.tb00297.x; KANWAR AJN, 1996, PEDIAT DERMATOL, V13, P10; RUDZKI E, 1994, DERMATOLOGY, V189, P41, DOI 10.1159/000246781; TADA J, 1994, ACTA DERM-VENEREOL, V74, P129; Williams HC, 1996, ARCH DERMATOL, V132, P51, DOI 10.1001/archderm.132.1.51; WILLIAMS HC, 1995, DERMATOL CLIN, V13, P649, DOI 10.1016/S0733-8635(18)30070-6	7	23	23	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					769	770		10.1016/S0140-6736(05)65206-3	http://dx.doi.org/10.1016/S0140-6736(05)65206-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813980				2022-12-28	WOS:A1996VH98900006
J	Appleby, JL; Parkinson, JS; Bourret, RB				Appleby, JL; Parkinson, JS; Bourret, RB			Signal transduction via the multi-step phosphorelay: Not necessarily a road less traveled	CELL			English	Review									UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	Appleby, JL (corresponding author), UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599, USA.		Bourret, Robert/X-3606-2019	Bourret, Robert/0000-0002-6666-9220; Parkinson, John/0000-0001-8788-7844	NIGMS NIH HHS [R01 GM050860] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050860] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alex LA, 1996, P NATL ACAD SCI USA, V93, P3416, DOI 10.1073/pnas.93.8.3416; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Chang CH, 1996, J BACTERIOL, V178, P4710, DOI 10.1128/jb.178.15.4710-4716.1996; CHIANG GG, 1992, P NATL ACAD SCI USA, V89, P9415, DOI 10.1073/pnas.89.20.9415; Grossman AD, 1995, ANNU REV GENET, V29, P477, DOI 10.1146/annurev.ge.29.120195.002401; Hoch J.A., 1995, 2 COMPONENT SIGNAL T, DOI [10.1128/9781555818319, DOI 10.1128/9781555818319]; Hoch JA, 1995, 2 COMPONENT SIGNAL T; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; KEHOE DM, 1996, IN PRESS SCIENCE, V273; Li YH, 1996, J BACTERIOL, V178, P289, DOI 10.1128/jb.178.1.289-292.1996; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PLAMANN L, 1995, J BACTERIOL, V177, P2014, DOI 10.1128/jb.177.8.2014-2020.1995; Tsuzuki M, 1995, MOL MICROBIOL, V18, P953, DOI 10.1111/j.1365-2958.1995.18050953.x; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x	16	335	344	3	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 20	1996	86	6					845	848		10.1016/S0092-8674(00)80158-0	http://dx.doi.org/10.1016/S0092-8674(00)80158-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808618	Bronze			2022-12-28	WOS:A1996VJ44300001
J	Vandenberghe, R; Price, C; Wise, R; Josephs, O; Frackowiak, RSJ				Vandenberghe, R; Price, C; Wise, R; Josephs, O; Frackowiak, RSJ			Functional anatomy of a common semantic system for words and pictures	NATURE			English	Article							MEANING SYSTEMS; VISUAL AGNOSIA; OPTIC APHASIA; OBJECT; COMPREHENSION; VISION; BRAIN	THE relationship between the semantic processing of words and of pictures is a matter of debate among cognitive scientists(1,2). We studied the functional anatomy of such processing by using positron-emission tomography (PET). We contrasted activity during two semantic tasks (probing knowledge of associations between concepts, and knowledge of the visual attributes of these concepts) and a baseline task (discrimination of physical stimulus size), performed either with words or with pictures. Modality-specific activations unrelated to semantic processing occurred in the left inferior parietal lobule for words, and the right middle occipital gyrus for pictures. A semantic network common to both words and pictures extended from the left superior occipital gyrus through the middle and inferior temporal cortex to the inferior frontal gyrus. A picture-specific activation related to semantic tasks occurred in the left posterior inferior temporal sulcus, and word-specific activations related to semantic tasks were localized to the left superior temporal sulcus, left anterior middle temporal gyrus, and left inferior frontal sulcus. Thus semantic tasks activate a distributed semantic processing system shared by both words and pictures, with a few specific areas differentially active for either words or pictures.	INST NEUROL, WELLCOME DEPT COGNIT NEUROL, LONDON WC1N 3BG, ENGLAND	University of London; University College London			Vandenberghe, Rik/K-2145-2014; Vandenberghe, Rik/AAR-7485-2020; Frackowiak, Richard/H-4383-2011; Frackowiak, Richard S/I-1809-2013	Vandenberghe, Rik/0000-0001-6237-2502; Vandenberghe, Rik/0000-0001-6237-2502; Frackowiak, Richard/0000-0002-3151-822X; Price, Catherine/0000-0001-7448-4835	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERT ML, 1979, NEUROLOGY, V29, P876, DOI 10.1212/WNL.29.6.876; BEAUVOIS MF, 1982, PHILOS T R SOC B, V298, P35, DOI 10.1098/rstb.1982.0070; BUB DN, 1988, COGN NEUROPSYCHOL, V5, P27, DOI 10.1080/02643298808252926; BUTTERWORTH B, 1984, NEUROPSYCHOLOGIA, V22, P409, DOI 10.1016/0028-3932(84)90036-8; CAPTAN D, 1992, LANGUAGE STRUCTURE P, P63; CARAMAZZA A, 1990, COGNITIVE NEUROPSYCH, V7, P161, DOI 10.1080/02643299008253441; COLTHEART V, 1994, Q J EXP PSYCHOL-A, V47, P917, DOI 10.1080/14640749408401102; Damasio H, 1996, NATURE, V380, P499, DOI 10.1038/380499a0; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; Farah M.J., 1990, VISUAL AGNOSIA DISOR; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Friston KJ, 1995, HUM BRAIN MAPP, V3, P165, DOI 10.1002/hbm.460030303; GLASER WR, 1992, COGNITION, V42, P61, DOI 10.1016/0010-0277(92)90040-O; GOMORI AJ, 1984, NEUROLOGY, V34, P947, DOI 10.1212/WNL.34.7.947; Howard D., 1992, PYRAMID PALM TREES T; LINDE J, 1982, J EXP PSYCHOL LEARN, V8, P584; MACK JL, 1977, NEUROPSYCHOLOGIA, V15, P345, DOI 10.1016/0028-3932(77)90044-6; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; Martin A, 1996, NATURE, V379, P649, DOI 10.1038/379649a0; MCCARTHY RA, 1988, NATURE, V334, P428, DOI 10.1038/334428a0; MISHKIN M, 1983, TRENDS NEUROSCI, V6, P414, DOI 10.1016/0166-2236(83)90190-X; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; Price CJ, 1996, CEREB CORTEX, V6, P62, DOI 10.1093/cercor/6.1.62; Price CJ, 1996, NEUROIMAGE, V3, P40, DOI 10.1006/nimg.1996.0005; RIDDOCH MJ, 1987, COGN NEUROPSYCHOL, V4, P131, DOI 10.1080/02643298708252038; Shallice T., 1987, COGNITIVE NEUROPSYCH, P111; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; WARRINGTON EK, 1994, NEUROPSYCHOLOGIA, V32, P1465, DOI 10.1016/0028-3932(94)90118-X; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	30	962	979	4	93	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 19	1996	383	6597					254	256		10.1038/383254a0	http://dx.doi.org/10.1038/383254a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VH315	8805700	Green Accepted			2022-12-28	WOS:A1996VH31500052
J	Weinert, M; Grimes, RM; Lynch, DP				Weinert, M; Grimes, RM; Lynch, DP			Oral manifestations of HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNE-DEFICIENCY SYNDROME; HERPES-SIMPLEX VIRUS; AIDS-RELATED COMPLEX; EPSTEIN-BARR-VIRUS; KAPOSIS-SARCOMA; HAIRY LEUKOPLAKIA; BISEXUAL MEN; CLINICAL MANIFESTATIONS; PERIODONTAL-DISEASE	Objective: To provide a comprehensive, literature-based guide to the diagnosis of and the management and referral of patients with oral diseases associated with human immunodeficiency virus (HIV) infection. Data Sources: The literature was reviewed to identify common oral manifestations of HIV infection, the physical and laboratory findings associated with them, and the therapies used to treat them. The National Library of Medicine's AIDSLINE database was searched using the term ''mouth diseases.'' Additional references were identified from the bibliographies of these articles and related textbooks. Study Selection: English-language abstracts were reviewed to determine each paper's clinical relevance. To be considered clinically relevant, a paper had to describe the physical appearance of oral manifestations, methods used to diagnose oral manifestations, or treatment and referral guidelines. More than 600 abstracts were identified. Data Extraction: After the abstracts were reviewed, articles were selected and were reviewed for possible inclusion. If both of two reviewers agreed that an article was clinically relevant and dealt with conditions that occurred in more than 1% of HIV-infected patients, the article was included. Data Synthesis: 16 conditions that occur in more than 1% of HIV-infected patients were identified. Information on these conditions was collected and sorted into three categories: clinical appearance, diagnostic methods, and treatment. Conclusions: Almost all patients with HIV infection will contract oral diseases. Guidelines for recognizing, diagnosing, and managing these conditions are presented. Most conditions can be treated or alleviated through the combined efforts of the physician and the dentist.	UNIV TEXAS, HLTH SCI CTR, HOUSTON, TX USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL DENT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, COLL MED, MEMPHIS, TN USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center					BHP HRSA HHS [5D35PE00116-04] Funding Source: Medline	BHP HRSA HHS		AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; ANDRIOLO M, 1989, J AM DENT ASSOC, pS40; ANNEROTH G, 1986, J ORAL MAXIL SURG, V44, P956, DOI 10.1016/S0278-2391(86)80049-0; BARR C E, 1992, Dysphagia, V7, P126, DOI 10.1007/BF02493444; BARTLETT JG, 1994, J HOPKINS HOSPITAL G; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BOGNER JR, 1994, J ACQ IMMUN DEF SYND, V7, P463; BOTTOMLEY WK, 1990, CLIN GUIDE TREATMENT; BRAHIM J S, 1990, Ear Nose and Throat Journal, V69, P467; BRAHIM JS, 1990, ENT-EAR NOSE THROAT, V69, P4724; BRAHIM JS, 1990, ENT-EAR NOSE THROAT, V69, P467; CHAVANET P, 1994, AIDS, V8, P945, DOI 10.1097/00002030-199407000-00011; COLEBUNDERS R, 1988, ARCH OTOLARYNGOL, V114, P330; DESOUZA YG, 1990, J CLIN MICROBIOL, V28, P2775, DOI 10.1128/JCM.28.12.2775-2778.1990; DEWIT S, 1989, LANCET, V1, P746; DISMUKES WE, 1988, ANN INTERN MED, V109, P177, DOI 10.7326/0003-4819-109-3-177; DODD CL, 1991, AIDS, V5, P1339, DOI 10.1097/00002030-199111000-00009; DOVER JS, 1991, ARCH DERMATOL, V127, P1549, DOI 10.1001/archderm.127.10.1549; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; EPSTEIN JB, 1989, LANCET, V2, P1100; EPSTEIN JB, 1992, ORAL SURG ORAL MED O, V73, P193, DOI 10.1016/0030-4220(92)90194-U; ERLICH KS, 1989, NEW ENGL J MED, V320, P293, DOI 10.1056/NEJM198902023200506; EVERSOLE LR, 1992, ORAL SURG ORAL MED O, V73, P155, DOI 10.1016/0030-4220(92)90188-V; FEIGAL DW, 1991, AIDS, V5, P519, DOI 10.1097/00002030-199105000-00007; FICARRA G, 1995, ORAL MANIFESTATIONS; Flaitz C M, 1995, Compend Contin Educ Dent, V16, P136; FUNG JC, 1985, J CLIN MICROBIOL, V22, P748, DOI 10.1128/JCM.22.5.748-753.1985; GILQUIN J, 1990, LANCET, V335, P287, DOI 10.1016/0140-6736(90)90101-A; GLICK M, 1994, J PERIODONTOL, V65, P393, DOI 10.1902/jop.1994.65.5.393; GLICK M, 1994, ORAL SURG ORAL MED O, V77, P344, DOI 10.1016/0030-4220(94)90195-3; GORIN I, 1990, LANCET, V335, P1343, DOI 10.1016/0140-6736(90)91223-W; GOWDEY G, 1995, ORAL SURG ORAL MED O, V79, P64, DOI 10.1016/S1079-2104(05)80076-9; GREENSPAN D, 1987, J INFECT DIS, V155, P475, DOI 10.1093/infdis/155.3.475; GREENSPAN D, 1991, DERMATOL CLIN, V9, P517; Greenspan D, 1993, Dent Clin North Am, V37, P21; Greenspan D, 1990, AIDS MOUTH DIAGNOSIS; GREENSPAN D, 1990, AIDS MOUTH, P91; GREENSPAN J, 1994, 10 INT C AIDS YOK, P62; Greenspan J S, 1991, Dent Manage, V31, P24; Greenspan J S, 1991, Dent Manage, V31, P22; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; GREENSPAN JS, 1992, ORAL SURG ORAL MED O, V73, P142, DOI 10.1016/0030-4220(92)90185-S; HAY RJ, 1990, REV INFECT DIS, V12, pS334; HOLLANDER H, 1986, ANN INTERN MED, V104, P892, DOI 10.7326/0003-4819-104-6-892_1; KATZ MH, 1992, AIDS, V6, P95, DOI 10.1097/00002030-199201000-00013; KEENEY K, 1987, J ORAL MAXIL SURG, V45, P815, DOI 10.1016/0278-2391(87)90211-4; KIRBY AJ, 1994, J ACQ IMMUN DEF SYND, V7, P1242; KLEIN RS, 1984, NEW ENGL J MED, V311, P354, DOI 10.1056/NEJM198408093110602; KOLOKOTRONIS A, 1994, ORAL SURG ORAL MED O, V78, P41, DOI 10.1016/0030-4220(94)90115-5; KRISTAL AR, 1988, AM J EPIDEMIOL, V128, P711, DOI 10.1093/oxfordjournals.aje.a115024; LAKEBAKAAR G, 1988, ANN INTERN MED, V109, P471, DOI 10.7326/0003-4819-109-6-471; LANGFORD AA, 1988, 4 INT C AIDS STOCKH, P319; LAVASSIN F, 1995, 2 NAT C HUM RETR WAS, P55; LIANG GS, 1993, J AM ACAD DERMATOL, V29, P563, DOI 10.1016/0190-9622(93)70222-F; LIFSON AR, 1994, AIDS, V8, P73, DOI 10.1097/00002030-199401000-00011; LIN JC, 1995, LANCET, V346, P1601, DOI 10.1016/S0140-6736(95)91931-7; LUCATORTO FM, 1993, ORAL SURG ORAL MED O, V75, P192, DOI 10.1016/0030-4220(93)90093-J; MADEN C, 1994, J ACQ IMMUN DEF SYND, V7, P972; MAENZA JR, 1995, 2 NAT C HUM RETR, P55; MAHMOOD W, 1994, 10 INT C AIDS YOK, P23; MCCARTHY GM, 1992, ORAL SURG ORAL MED O, V73, P181, DOI 10.1016/0030-4220(92)90192-S; MCNEELY MC, 1989, J AM ACAD DERMATOL, V21, P1213, DOI 10.1016/S0190-9622(89)70332-7; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MURRAY HW, 1985, NEW ENGL J MED, V313, P1504, DOI 10.1056/NEJM198512123132403; MYSKOWSKI PL, 1988, ARCH DERMATOL, V124, P21, DOI 10.1001/archderm.124.1.21a; *NAT I ALL INF DIS, 1995, THAL EFF TREATM AIDS; NIELSEN H, 1994, J ORAL PATHOL MED, V23, P140, DOI 10.1111/j.1600-0714.1994.tb01102.x; NISHIO CE, 1994, 10 INT C AIDS YOK, P182; PENNEYS NS, 1985, J AM ACAD DERMATOL, V13, P845, DOI 10.1016/S0190-9622(85)70228-9; ROITHMANN S, 1990, NEW ENGL J MED, V323, P275; ROSENSTEIN DI, 1993, J AM DENT ASSOC, V124, P76, DOI 10.14219/jada.archive.1993.0258; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; ROYCE RA, 1991, AIDS, V5, P355, DOI 10.1097/00002030-199104000-00001; RUBINSTEIN A, 1986, J PEDIATR-US, V108, P498, DOI 10.1016/S0022-3476(86)80822-8; RUHNKE M, 1994, J CLIN MICROBIOL, V32, P2092, DOI 10.1128/JCM.32.9.2092-2098.1994; SAFRIN S, 1990, J INFECT DIS, V161, P1078, DOI 10.1093/infdis/161.6.1078; SANDE MA, 1992, MED MANAGEMENT AIDS; SCHIODT M, 1992, ORAL SURG ORAL MED O, V73, P164, DOI 10.1016/0030-4220(92)90189-W; SCULLY C, 1992, ORAL SURG ORAL MED O, V73, P215, DOI 10.1016/0030-4220(92)90197-X; SHUGAR JMA, 1988, LARYNGOSCOPE, V98, P772; SILVERMAN S JR, 1991, Dental Clinics of North America, V35, P259; SMITH D, 1994, 10 INT C AIDS YOK, P190; SPERLING N M, 1990, Ear Nose and Throat Journal, V69, P475; SULIS E, 1989, EUR J CANCER CLIN ON, V25, P759, DOI 10.1016/0277-5379(89)90217-4; TERADA K, 1994, LANCET, V344, P1116, DOI 10.1016/S0140-6736(94)90630-0; van der Waal I, 1991, Int Dent J, V41, P3; Volberding P A, 1989, Prog Clin Biol Res, V288, P459; WANZALA P, 1994, 10 INT C AIDS YOK, P182; WINKLER JR, 1992, ORAL SURG ORAL MED O, V73, P145, DOI 10.1016/0030-4220(92)90186-T; 1995, J AM DENT ASSOC, V126, P1	90	57	59	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1996	125	6					485	496		10.7326/0003-4819-125-6-199609150-00010	http://dx.doi.org/10.7326/0003-4819-125-6-199609150-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF882	8779462				2022-12-28	WOS:A1996VF88200011
J	Risch, N; Merikangas, K				Risch, N; Merikangas, K			The future of genetic studies of complex human diseases	SCIENCE			English	Editorial Material							TRAITS				Risch, N (corresponding author), STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305, USA.							LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; RISCH N, 1990, AM J HUM GENET, V46, P229; RISCH N, 1987, AM J HUM GENET, V40, P1; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506	4	3843	4038	15	281	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1996	273	5281					1516	1517		10.1126/science.273.5281.1516	http://dx.doi.org/10.1126/science.273.5281.1516			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG597	8801636				2022-12-28	WOS:A1996VG59700028
J	Zhang, Y; Feng, XH; Wu, RY; Derynck, R				Zhang, Y; Feng, XH; Wu, RY; Derynck, R			Receptor-associated Mad homologues synergize as effectors of the TGF-beta response	NATURE			English	Article							GROWTH-FACTOR-BETA; II RECEPTOR; PROTEIN; CLONING; COMPLEX; KINASE; CELLS; DPP	TRANSFORMING growth factor-beta TGP-Beta is the prototype for a family of extracellular proteins that affect cell proliferation and tissue differentiation(1-3). TGF-beta-related factors, including BMP-2/4, Dpp and activin, act through two types of serine/threonine kinase receptors which can form a heteromeric complex(3,4). However, the mechanism of signal transduction by these receptors is largely unknown. In Drosophila, Mad is required for signalling by Dpp(5). We have isolated complementary DNAs for four human Mad homologues, one of which, hMAD-4, is identical to DPC-4, a candidate tumour suppressor(6). hMAD-3 and -4 synergized to induce strong ligand-independent TGF-beta-like responses. When truncated at their carboxy termini, hMAD-3 and -4 act as dominant-negative inhibitors of the normal TGF-beta response. The activity of hMAD-3 and -4 was regulated by the TGF-beta receptors, and hMAD-3 but not hMAD-4 was phosphorylated and associated with the ligand-bound receptor complex. These results define hMAD-3 and -4 as effecters of the TGF-beta response and demonstrate a function for DPC-4/hMAD-4 as a tumour suppressor.	UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ARARA K, 1995, CELL, V81, P781; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1994, CYTOKINE HDB, P319; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HHOODLESS PA, 1996, CELL, V85, P489; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIKE B, 1986, J BIOL CHEM, V261, P3426; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P105, DOI 10.1016/0167-4781(92)90472-C; MATZUK MM, 1992, BIOCHIM BIOPHYS ACTA, V1130, P243; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	33	753	801	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1996	383	6596					168	172		10.1038/383168a0	http://dx.doi.org/10.1038/383168a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VG148	8774881				2022-12-28	WOS:A1996VG14800052
J	Hanes, DP; Schall, JD				Hanes, DP; Schall, JD			Neural control of voluntary movement initiation	SCIENCE			English	Article							FRONTAL EYE FIELD; NEURONS; MACAQUE; MONKEY; PONS	When humans respond to sensory stimulation, their reaction times tend to be long and variable relative to neural transduction and transmission times. The neural processes responsible for the duration and variability of reaction times are not understood. Single-cell recordings in a motor area of the cerebral cortex in behaving rhesus monkeys (Macaca mulatta) were used to evaluate two alternative mathematical models of the processes that underlie reaction times. Movements were initiated if and only ii the neural activity reached a specific and constant threshold activation level. Stochastic variability in the rate at which neural activity grew toward that threshold resulted in the distribution of reaction times. This finding elucidates a specific link between motor behavior and activation of neurons in the cerebral cortex.	VANDERBILT UNIV,DEPT PSYCHOL,NASHVILLE,TN 37240	Vanderbilt University					NEI NIH HHS [P30-EY08126] Funding Source: Medline; NIMH NIH HHS [R01-MH55806, F31-MH11178] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY008126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH055806, F31MH011178] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Brooks V.B., 1986, NEURAL BASIS MOTOR C; BRUCE CJ, 1985, J NEUROPHYSIOL, V54, P714, DOI 10.1152/jn.1985.54.3.714; BUTTNERENNEVER JA, 1988, J COMP NEUROL, V267, P307, DOI 10.1002/cne.902670302; CARPENTER RHS, 1995, NATURE, V377, P59, DOI 10.1038/377059a0; Carpenter RHS, 1988, MOVEMENTS EYES; Carpenter RHS, 1991, EYE MOVEMENTS; DEJONG R, 1990, J EXP PSYCHOL HUMAN, V16, P164, DOI 10.1037/0096-1523.16.1.164; Dias EC, 1995, J NEUROPHYSIOL, V74, P2744, DOI 10.1152/jn.1995.74.6.2744; GRATTON G, 1988, J EXP PSYCHOL HUMAN, V14, P331, DOI 10.1037/0096-1523.14.3.331; GRICE GR, 1968, PSYCHOL REV, V75, P359, DOI 10.1037/h0026287; HANES DP, 1995, VISUAL NEUROSCI, V12, P929, DOI 10.1017/S0952523800009482; HANES DP, 1995, EXP BRAIN RES, V103, P85; LEGENDY CR, 1985, J NEUROPHYSIOL, V53, P926, DOI 10.1152/jn.1985.53.4.926; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Luce RD, 1986, RESPONSE TIMES THEIR; MCCLELLAND JL, 1979, PSYCHOL REV, V86, P287, DOI 10.1037/0033-295X.86.4.287; MEYER DE, 1988, BIOL PSYCHOL, V26, P3, DOI 10.1016/0301-0511(88)90013-0; NAZIR TA, 1991, PSYCHOL RES-PSYCH FO, V53, P281, DOI 10.1007/BF00920481; PACUT A, 1977, BIOL CYBERN, V28, P63, DOI 10.1007/BF00335286; RATCLIFF R, 1978, PSYCHOL REV, V85, P59, DOI 10.1037//0033-295X.85.2.59; SAYER RJ, 1990, J NEUROSCI, V10, P826; Schall J. D., 1991, VISION VISUAL DYSFUN, V4, P388; SEGRAVES MA, 1992, J NEUROPHYSIOL, V68, P1967, DOI 10.1152/jn.1992.68.6.1967; VONHELMHOLTZ HLF, 1853, PHILOS MAG, V6, P313; Wurtz R. H, 1989, NEUROBIOLOGY SACCADI	25	857	862	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					427	430		10.1126/science.274.5286.427	http://dx.doi.org/10.1126/science.274.5286.427			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	VN173	8832893				2022-12-28	WOS:A1996VN17300056
J	Tatsuno, I; Homma, M; Oosawa, K; Kawagishi, I				Tatsuno, I; Homma, M; Oosawa, K; Kawagishi, I			Signaling by the Escherichia coli aspartate chemoreceptor tar with a single cytoplasmic domain per dimer	SCIENCE			English	Article							LIGAND-BINDING DOMAIN; BACTERIAL CHEMOTAXIS RECEPTOR; CROSS-LINKING; SALMONELLA-TYPHIMURIUM; ETHYLENE-GLYCOL; TRANSDUCTION; COMPLEX; REPELLENTS; PROTEINS; GLYCEROL	Many transmembrane receptors are oligomeric proteins. Binding oi a ligand may alter the oligomeric state of the receptor, induce structural changes within the oligomer, or both. The bacterial aspartate chemoreceptor Tar forms a homodimer in the presence or absence of ligands. Tar mediates attractant acid repellent responses by modulating the activity of the cytoplasmic kinase CheA. In vivo intersubunit suppression was used to show that certain combinations of full-length and truncated mutant Tar proteins complemented each other to restore attractant responses to aspartate. These results suggest that heterodimers with only one intact cytoplasmic domain are functional. The signaling mechanism may require interactions between dimers or conformational changes within a single cytoplasmic domain.	NAGOYA UNIV,GRAD SCH SCI,DIV BIOL SCI,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; NAGOYA UNIV,GRAD SCH POLYMATH,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN	Nagoya University; Nagoya University			Oosawa, Kenji/K-6610-2013; Tatsuno, Ichiro/GQP-8401-2022	Tatsuno, Ichiro/0000-0003-4053-9695				BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BOYD A, 1981, CELL, V26, P333, DOI 10.1016/0092-8674(81)90202-6; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; KAWAGISHI I, UNPUB; KIM SH, 1992, COLD SPRING HARB SYM, V57, P17, DOI 10.1101/SQB.1992.057.01.004; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LEE L, 1990, J BACTERIOL, V172, P377, DOI 10.1128/JB.172.1.377-382.1990; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; MADDOCK JR, 1993, SCIENCE, V259, P1717; MANSON MD, 1992, ADV MICROB PHYSIOL, V33, P277, DOI 10.1016/S0065-2911(08)60219-2; MANSON MD, UNPUB; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; OKUMURA H, UNPUB; OOSAWA K, 1983, J BACTERIOL, V154, P104, DOI 10.1128/JB.154.1.104-112.1983; OOSAWA K, 1984, J BACTERIOL, V157, P576, DOI 10.1128/JB.157.2.576-581.1984; OOSAWA K, 1986, P NATL ACAD SCI USA, V83, P6930, DOI 10.1073/pnas.83.18.6930; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SCOTT WG, 1993, J MOL BIOL, V232, P555, DOI 10.1006/jmbi.1993.1411; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; TATSUNO I, 1994, MOL MICROBIOL, V14, P755, DOI 10.1111/j.1365-2958.1994.tb01312.x; TATSUNO I, UNPUB; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WOLFE AJ, 1994, J BACTERIOL, V176, P4483, DOI 10.1128/JB.176.15.4483-4491.1994; Wu JG, 1996, BIOCHEMISTRY-US, V35, P4984, DOI 10.1021/bi9530189; YEH JI, 1993, J BIOL CHEM, V268, P9787; 1996, P NATL ACAD SCI USA, V93, P2545	36	65	65	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 18	1996	274	5286					423	425		10.1126/science.274.5286.423	http://dx.doi.org/10.1126/science.274.5286.423			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VN173	8832891				2022-12-28	WOS:A1996VN17300054
J	Calleja, M; Moreno, E; Pelaz, S; Morata, G				Calleja, M; Moreno, E; Pelaz, S; Morata, G			Visualization of gene expression in living adult Drosophila	SCIENCE			English	Article							SIGNALING MOLECULE; WING DEVELOPMENT; NERVOUS-SYSTEM; VENTRAL CELLS; PROTEIN; DORSAL; PATTERN; HEDGEHOG; BOUNDARY; ORGANS	To identify genes involved in the patterning of adult structures, Ga14-UAS (upstream activating site) technology was used to visualize patterns of gene expression directly in living flies. A large number of Ga14 insertion lines were generated and their expression patterns were studied. In addition to identifying several characterized developmental genes, the approach revealed previously unsuspected genetic subdivisions of the thorax, which may control the disposition of pattern elements. The boundary between two of these domains coincides with localized expression of the signaling molecule wingless.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOL, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Moreno, Eduardo/D-7262-2011; Pelaz, Soraya/F-3431-2015	Pelaz, Soraya/0000-0001-7699-9330; Morata, Gines/0000-0003-3274-5173; moreno, eduardo/0000-0001-5040-452X	CSR NIH HHS [RG-372/94] Funding Source: Medline	CSR NIH HHS		ARIAS AM, 1988, DEVELOPMENT, V103, P157; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND A, 1994, METHOD CELL BIOL, P435; BRAND AH, 1993, DEVELOPMENT, V118, P401; CALLEJA M, UNPUB; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CARROLL SB, 1994, SCIENCE, V265, P109, DOI 10.1126/science.7912449; Cohen Stephen M., 1993, P747; DAMBLYCHAUDIERE C, 1992, INT J DEV BIOL, V36, P85; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; Garcia-Bellido A, 1975, GENETIC CONTROL WING; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GEYER PK, 1986, EMBO J, V5, P2657, DOI 10.1002/j.1460-2075.1986.tb04548.x; GomezSkarmeta JL, 1996, CELL, V85, P95, DOI 10.1016/S0092-8674(00)81085-5; HAENLIN M, COMMUNICATION; Heitzler P, 1996, GENETICS, V143, P1271; INGHAM PW, 1985, GENETICS, V111, P463; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Lawrence P., 1992, MAKING FLY GENETICS; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MCALPINE JF, 1987, 28 RES BRANCH AGR CA, V2; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MORATA G, 1977, NATURE, V265, P211, DOI 10.1038/265211a0; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NG M, 1995, DEVELOPMENT, V121, P589; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; RODRIGUEZ I, 1990, EMBO J, V9, P3583, DOI 10.1002/j.1460-2075.1990.tb07569.x; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; STERN CURT, 1954, AMER SCI, V42, P213; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TIONG SYK, 1995, DEVELOPMENT, V121, P1649; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0	38	408	412	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	1996	274	5285					252	255		10.1126/science.274.5285.252	http://dx.doi.org/10.1126/science.274.5285.252			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VM671	8824191				2022-12-28	WOS:A1996VM67100045
J	Martikainen, PT; Valkonen, T				Martikainen, PT; Valkonen, T			Excess mortality of unemployed men and women during a period of rapidly increasing unemployment	LANCET			English	Article							EMPLOYMENT	Background Previous studies have found evidence of higher mortality rates among unemployed people than among those in employment, but the effect of changes in national unemployment rates on this association is unclear. We studied mortality in both men and women during a period of rapidly increasing unemployment in Finland. Methods In this prospective study of mortality in the Finnish population aged 25-59 years (2.5 million people), baseline sociodemographic data were obtained from the 1990 census and information on employment status in 1987-92 from Statistics Finland's labour force data files. Mortality follow-up was established by record linkage to death certificates from 1991 to 1993. Findings Individuals who experienced unemployment between 1987 and 1992 had greater mortality than those in employment after control for age, education, occupational class, and marital status. The mortality ratios for men and women unemployed for the first time in 1990, at a time of low national unemployment were 2.11 (95% CI 1.76-2.53) and 1.61 (1.09-2.36), respectively. These values were lower for those who were unemployed for the first time in 1992 when the national unemployment rate was very high (men 1.35 [1.16-1.56], women 1.30 [0.97-1.75]). The jobless who were re-employed had higher mortality than those who were continuously employed, but not as high as those who remained unemployed. Interpretation We have found that the association between unemployment and mortality weakens as the general unemployment rate increases. Studies that took place when the unemployment rate was low may thus overestimate the effect of unemployment on mortality because of unaccounted confounding.			Martikainen, PT (corresponding author), UNIV HELSINKI,DEPT SOCIOL,POPULAT RES UNIT,POB 18,FIN-00014 HELSINKI,FINLAND.			Martikainen, Pekka/0000-0001-9374-1438				BARTLEY M, 1994, J EPIDEMIOL COMMUN H, V48, P333, DOI 10.1136/jech.48.4.333; Bethune A, 1996, Popul Trends, P37; CHARLTON JRH, 1987, J EPIDEMIOL COMMUN H, V41, P107, DOI 10.1136/jech.41.2.107; IVERSEN L, 1987, BMJ-BRIT MED J, V295, P879, DOI 10.1136/bmj.295.6603.879; MARTIKAINEN P, 1995, LAMA ENNENAIKAINEN K, P11; MARTIKAINEN PT, 1990, BMJ-BRIT MED J, V301, P407, DOI 10.1136/bmj.301.6749.407; MORRIS JK, 1994, BMJ-BRIT MED J, V308, P1135, DOI 10.1136/bmj.308.6937.1135; MOSER KA, 1984, LANCET, V2, P1324; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SORLIE PD, 1990, AM J EPIDEMIOL, V132, P983, DOI 10.1093/oxfordjournals.aje.a115741; *STAT FINL, 1992, TYOSS 1989, P14; *STAT FINL, 1994, TYOV, P13; *STAT FINL, 1994, TYOV KOUL JA AMM 198, P5; VALKONEN T, 1993, SOCIOECONOMIC MORTAL, P1; VALKONEN T, 1995, ADULT MORTALITY DEV, P201	15	249	251	0	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 5	1996	348	9032					909	912		10.1016/S0140-6736(96)03291-6	http://dx.doi.org/10.1016/S0140-6736(96)03291-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VL097	8843808				2022-12-28	WOS:A1996VL09700008
J	Bland, JM; Altman, DG				Bland, JM; Altman, DG			Statistics notes .21. Measurement error (vol 312, pg 1654, 1996)	BRITISH MEDICAL JOURNAL			English	Correction, Addition									INST HLTH SCI,MED STAT GRP,IRCF,CTR STAT MED,OXFORD OX3 7LF,ENGLAND	University of Oxford	Bland, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							Altman DG, 1996, BRIT MED J, V312, P1472, DOI 10.1136/bmj.312.7044.1472; Bland JM, 1996, BRIT MED J, V312, P1654, DOI 10.1136/bmj.312.7047.1654; BLAND JM, 1974, B PHYSIO-PATHOL RESP, V10, P699	3	1060	1087	0	59	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 21	1996	313	7059					744	744						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VJ441	8819450	Green Published			2022-12-28	WOS:A1996VJ44100033
J	Gasbarrini, G; Mingrone, G; Greco, AV; Castagneto, M				Gasbarrini, G; Mingrone, G; Greco, AV; Castagneto, M			An 18-year-old woman with familial chylomicronaemia who would not stick to a diet	LANCET			English	Article							BILIOPANCREATIC DIVERSION		UNIV CATTOLICA SACRO CUORE,CATTEDRA CHIRURGI,I-00168 ROME,ITALY; UNIV CATTOLICA SACRO CUORE,CNR,CTR FISIOPATOL SHOCK,I-00168 ROME,ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR)	Gasbarrini, G (corresponding author), UNIV CATTOLICA SACRO CUORE,CATTEDRA MED INTERNA 2,LARGO A GEMELLI 8,I-00168 ROME,ITALY.		Mingrone, Geltrude/AAB-9681-2019					CASTAGNETO M, 1994, OBES SURG, V4, P161, DOI 10.1381/096089294765558755; RANDLE PJ, 1964, CIBA F COLLOQ ENDOCR, V15, P192; Scopinaro N, 1996, SURGERY, V119, P261, DOI 10.1016/S0039-6060(96)80111-5; TATARANNI PA, 1994, AM J CLIN NUTR, V60, P320, DOI 10.1093/ajcn/60.3.320	4	24	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 21	1996	348	9030					794	794		10.1016/S0140-6736(96)07328-X	http://dx.doi.org/10.1016/S0140-6736(96)07328-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH989	8813988				2022-12-28	WOS:A1996VH98900014
J	Cumano, A; DieterlenLievre, F; Godin, I				Cumano, A; DieterlenLievre, F; Godin, I			Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; IN-VITRO DIFFERENTIATION; MURINE FETAL LIVER; EMBRYONIC YOLK-SAC; B-CELL; PARAAORTIC SPLANCHNOPLEURA; BONE-MARROW; PRECURSORS; PROGENITORS; ONTOGENY	Emergence of hemopoietic stem cells in the mammalian embryo has yet to be definitively allocated. Previously, we detected multipotent hemopoietic precursors in the region surrounding the dorsal aorta (paraaortic splanchnopleura) beginning at 8.5 days postcoitum (dpc). However, as circulation is already established, it remained unclear whether hemopoietic precursors arise in situ or are blood-delivered. By adding an organotypic step to our former culture system, we now detect lymphocyte and multipotent myeloid precursors from the intraembryonic splanchnopleura as early as 7.5 dpc. Under identical conditions, yolk sacs from the same embryos are unable to generate lymphoid progeny and have a reduced potential for myeloid differentiation and maintenance. Thus, if isolated before circulation, the yolk sac does not produce multipotent precursors and therefore does not contribute to definitive hemopoiesis in the mouse.	COLL FRANCE, F-75024 PARIS, FRANCE; INST PASTEUR, INSERM, U277, UNITE BIOL MOL GENE, F-75024 PARIS, FRANCE	UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Cumano, A (corresponding author), CNRS, INST EMBRYOL CELLULAIRE & MOL, F-75024 PARIS, FRANCE.		GODIN, Isabelle/K-5769-2013	GODIN, Isabelle/0000-0001-8577-8388; Cumano, Ana/0000-0002-4578-959X				BEAUPAIN D, 1979, BLOOD, V53, P212; BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; COLLINS LS, 1987, J IMMUNOL, V138, P1082; CUMANO A, 1992, EMBO J, V11, P593, DOI 10.1002/j.1460-2075.1992.tb05091.x; CUMANO A, 1993, P NATL ACAD SCI USA, V90, P6429, DOI 10.1073/pnas.90.14.6429; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; Delassus S, 1996, IMMUNITY, V4, P97, DOI 10.1016/S1074-7613(00)80302-7; DIETERLENLIEVRE F, 1975, J EMBRYOL EXP MORPH, V33, P607; DOWNS KM, 1993, DEVELOPMENT, V118, P1255; GARCIAPORRERO JA, 1995, ANAT EMBRYOL, V192, P427; GODIN I, 1995, P NATL ACAD SCI USA, V92, P773, DOI 10.1073/pnas.92.3.773; Godin I, 1995, Semin Immunol, V7, P131, DOI 10.1016/1044-5323(95)90041-1; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; HAMILTON HL, 1952, LILLIES DEV CHICK IN; HARRISON DE, 1979, BLOOD, V54, P1152; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HUANG H, 1994, EXP HEMATOL, V22, P19; JENKINSON EJ, 1992, J EXP MED, V176, P845, DOI 10.1084/jem.176.3.845; Kanatsu M, 1996, DEVELOPMENT, V122, P823; KEE BL, 1994, INT IMMUNOL, V6, P401, DOI 10.1093/intimm/6.3.401; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LEDER A, 1992, DEVELOPMENT, V116, P1041; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LIU CP, 1991, DEVELOPMENT, V113, P1315; Medvinsky AL, 1996, BLOOD, V87, P557, DOI 10.1182/blood.V87.2.557.bloodjournal872557; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; METCALF D, 1971, FRONT BIOL, V24, P173; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; PAIGE CJ, 1979, J EXP MED, V150, P548, DOI 10.1084/jem.150.3.548; PALACIOS R, 1993, P NATL ACAD SCI USA, V90, P6581, DOI 10.1073/pnas.90.14.6581; PARAMESWARAN M, 1995, DEV GENET, V17, P16, DOI 10.1002/dvg.1020170104; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SONODA T, 1983, DEV BIOL, V97, P89, DOI 10.1016/0012-1606(83)90066-0; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; TYAN ML, 1968, J IMMUNOL, V101, P446; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WEISSMANN I, 1978, COLD SPRING HARB SYM, V5, P33; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	41	447	451	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1996	86	6					907	916		10.1016/S0092-8674(00)80166-X	http://dx.doi.org/10.1016/S0092-8674(00)80166-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808626	Bronze			2022-12-28	WOS:A1996VJ44300009
J	Pollard, VW; Michael, WM; Nakielny, S; Siomi, MC; Wang, F; Dreyfuss, G				Pollard, VW; Michael, WM; Nakielny, S; Siomi, MC; Wang, F; Dreyfuss, G			A novel receptor-mediated nuclear protein import pathway	CELL			English	Article							PORE-TARGETING COMPLEX; HNRNP PROTEINS; SACCHAROMYCES-CEREVISIAE; HUMAN HOMOLOG; T-ANTIGEN; TRANSPORT; IDENTIFICATION; LOCALIZATION; SEQUENCE; INTERACTS	Targeting of most nuclear proteins to the cell nucleus is initiated by interaction between the classical nuclear localization signals (NLSs) contained within them and the importin NLS receptor complex. We have recently delineated a novel 38 amino acid transport signal in the hnRNP A1 protein, termed M9, which confers bidirectional transport across the nuclear envelope. We show here that M9-mediated nuclear import occurs by a novel pathway that is independent of the well-characterized, importin-mediated classical NLS pathway. Additionally, we have identified a specific M9-interacting protein, termed transportin, which binds to wild-type M9 but not to transport-defective M9 mutants. Transportin is a 90 kDa protein, distantly related to importin beta, and we show that it mediates the nuclear import of M9-containing proteins. These findings demonstrate that there are at least two receptor-mediated nuclear protein import pathways. Furthermore, as hnRNP A1 likely participates in mRNA export, it raises the possibility that transportin is a mediator of this process as well.			Pollard, VW (corresponding author), UNIV PENN, SCH MED, HOWARD HUGHES MED INST, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA.		McDermott, Michael Francis/GZM-5330-2022; Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DAVIS LI, 1995, ANNU REV BIOCHEM, V64, P865, DOI 10.1146/annurev.bi.64.070195.004245; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DUVERGER E, 1995, J CELL SCI, V108, P1325; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; IMAMOTO N, 1995, FEBS LETT, V368, P415; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KILEDJIAN M, 1994, RNA PROTEIN INTERACT, P127; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Michael WM, 1995, COLD SPRING HARB SYM, V60, P663, DOI 10.1101/SQB.1995.060.01.071; MICHAEL WM, 1995, CELL, V83, P415; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; NAKIELNY S, 1996, IN PRESS J CELL BIOL; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; Pante N, 1995, INT REV CYTOL, V162B, P225; Pante N, 1996, CURR OPIN CELL BIOL, V8, P397, DOI 10.1016/S0955-0674(96)80016-0; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHAAFFGERSTENSCHLAGER I, 1995, YEAST, V11, P79, DOI 10.1002/yea.320110110; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; TOROK I, 1995, J CELL BIOL, V129, P1473, DOI 10.1083/jcb.129.6.1473; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	54	585	591	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	1996	86	6					985	994		10.1016/S0092-8674(00)80173-7	http://dx.doi.org/10.1016/S0092-8674(00)80173-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	VJ443	8808633	hybrid			2022-12-28	WOS:A1996VJ44300016
J	Benlian, P; DeGennes, JL; Foubert, L; Zhang, HF; Gagne, SE; Hayden, M				Benlian, P; DeGennes, JL; Foubert, L; Zhang, HF; Gagne, SE; Hayden, M			Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRIGLYCERIDE-RICH LIPOPROTEINS; LOW-DENSITY-LIPOPROTEIN; DIFFERENT ANCESTRIES; MISSENSE MUTATION; DEFICIENCY; METABOLISM; CHOLESTEROL; PLASMA; DISEASE; ENZYME	Background Patients with lipoprotein lipase deficiency usually present with chylomicronemia in childhood. The syndrome has been considered nonatherogenic primarily because of the low levels of low-density lipoprotein (LDL) cholesterol. We prospectively evaluated patients with lipoprotein lipase deficiency for atherosclerosis. Methods Evidence of carotid, peripheral, and coronary atherosclerosis was sought in four patients (two men and two women) with the phenotype of familial chylomicronemia by clinical examination over a period of 14 to 30 years and by Doppler ultrasonography, ultrasonography, and exercise-tolerance testing after the age of 40. Angiography was performed when indicated. Lipoprotein lipase deficiency was assessed in vivo and in vitro by functional assays and DNA-sequence analysis. Results All four patients had a profound functional deficiency of lipoprotein lipase with a reduced enzymatic mass due to missense mutations on both alleles of the lipoprotein lipase gene. In all four patients, peripheral or coronary atherosclerosis (or both) was observed before the age of 55. Despite following a low-fat diet in which fat composed 10 to 15 percent of the daily caloric intake, the patients had hypertriglyceridemia (mean [+/-SD] triglyceride level, 2621+/-1112 mg per deciliter [29.59+/-12.55 mmol per liter]), low plasma levels of high-density lipoprotein cholesterol (17+/-7 mg per deciliter [0.43+/-0.18 mmol per liter]), and very low levels of LDL cholesterol (28+/-16 mg per deciliter [0.72+/-0.41 mmol per liter]). Three patients had one risk factor for atherosclerosis, whereas in one male patient, heavy smoking and diabetes were associated with an accelerated course of the disease. Conclusions Premature atherosclerosis can occur in patients with familial chylomicronemia as a result of mutations in the lipoprotein lipase gene. Defective lipolysis may increase susceptibility to atherosclerosis in humans. (C) 1996, Massachusetts Medical Society.	GRP HOSP PITIE SALPETRIERE, SERV ENDOCRINOL & METAB, F-75634 PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Benlian, P (corresponding author), UNIV BRITISH COLUMBIA, DEPT MED GENET, 2125 E MALL, VANCOUVER, BC V6T 1Z4, CANADA.		Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419				ALLAIN CC, 1974, CLIN CHEM, V20, P470; AUSTIN MA, 1989, AM J EPIDEMIOL, V129, P249, DOI 10.1093/oxfordjournals.aje.a115130; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; Bijvoet S, 1996, J LIPID RES, V37, P640; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; BUCOLO G, 1973, CLIN CHEM, V19, P476; CHADEFAUX B, 1990, ANN BIOL CLIN-PARIS, V48, P33; CHAPMAN MJ, 1976, ATHEROSCLEROSIS, V25, P267; DEGENNES JL, 1972, NOUV PRESSE MED, V1, P1835; DEMANT T, 1993, J LIPID RES, V34, P147; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ECKEL RH, 1990, NEW ENGL J MED, V322, P477; FREDRICKSON DS, 1965, METABOLIC BASIS INHE, P429; GAGNE E, 1994, ARTERIOSCLER THROMB, V14, P1250, DOI 10.1161/01.ATV.14.8.1250; GOLDBERG IJ, 1990, J CLIN INVEST, V86, P463, DOI 10.1172/JCI114732; HAVEL RJ, 1960, J CLIN INVEST, V39, P1777, DOI 10.1172/JCI104202; Hayden M.R., 1991, CURRENT OPINION LIPI, V2, P104; HIDE WA, 1992, J LIPID RES, V33, P167; HIXSON JE, 1990, J LIPID RES, V31, P545; HODIS HN, 1995, CURR OPIN LIPIDOL, V6, P209, DOI 10.1097/00041433-199508000-00004; HOEG JM, 1983, AM J MED, V75, P889, DOI 10.1016/0002-9343(83)90423-0; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; JEMAA R, 1995, J LIPID RES, V36, P2141; LEES RS, 1973, PROG MED GENET, V9, P237; MA YH, 1992, GENOMICS, V13, P649, DOI 10.1016/0888-7543(92)90136-G; MA YH, 1992, J BIOL CHEM, V267, P1918; MA YH, 1994, HUM MUTAT, V3, P52, DOI 10.1002/humu.1380030109; MAILLY F, 1995, ARTERIOSCL THROM VAS, V15, P468, DOI 10.1161/01.ATV.15.4.468; MIESENBOCK G, 1993, J CLIN INVEST, V91, P448, DOI 10.1172/JCI116222; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; NICOLL A, 1980, EUR J CLIN INVEST, V10, P487, DOI 10.1111/j.1365-2362.1980.tb02090.x; NIKKILA EA, 1983, METABOLIC BASIS INHE, P622; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; PACY PJH, 1993, ATHEROSCLEROSIS, V103, P231, DOI 10.1016/0021-9150(93)90266-W; PATSCH JR, 1993, ATHER REV, V24, P139; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; SPRECHER DL, 1991, J CLIN INVEST, V88, P985, DOI 10.1172/JCI115402; STALENHOEF AFH, 1984, P NATL ACAD SCI-BIOL, V81, P1839, DOI 10.1073/pnas.81.6.1839; WARNICK GR, 1978, CLIN CHEM, V24, P900; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; ZAMBON A, 1993, LANCET, V341, P1119, DOI 10.1016/0140-6736(93)93129-O	41	244	255	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1996	335	12					848	854		10.1056/NEJM199609193351203	http://dx.doi.org/10.1056/NEJM199609193351203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG869	8778602	Bronze			2022-12-28	WOS:A1996VG86900003
J	Drazen, JM; Israel, E; Boushey, HA; Chinchilli, VM; Fahy, JV; Fish, JE; Lazarus, SC; Lemanske, RF; Martin, RJ; Peters, SP; Sorkness, C; Szefler, SJ				Drazen, JM; Israel, E; Boushey, HA; Chinchilli, VM; Fahy, JV; Fish, JE; Lazarus, SC; Lemanske, RF; Martin, RJ; Peters, SP; Sorkness, C; Szefler, SJ			Comparison of regularly scheduled with as-needed use of albuterol in mild asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-ADRENERGIC AGONISTS; RANDOMIZED CLINICAL-TRIALS; RESPIRATORY MEDICINE; INHALED SALBUTAMOL; BRONCHIAL-ASTHMA; INTERIM ANALYSES; CONTROVERSIES; THERAPY; HEALTH; MANAGEMENT	Background Inhaled beta-agonists are the most commonly used treatment for asthma, but data suggest that regularly scheduled use of these agents may have a deleterious effect on the control of asthma. We compared the effects of regularly scheduled use of inhaled albuterol with those of albuterol used only as needed in patients with mild chronic, stable asthma. Methods In a multicenter, double-blind study, we randomly assigned 255 patients with mild asthma to inhale albuterol either on a regular schedule (126 patients) or only as needed (129 patients). The patients were followed for 16 weeks. Results The primary outcome indicator, peak expiratory air flow measured in the morning, did not change significantly during the treatment period in the scheduled (416 liters per minute after the run-in period and 414 liters per minute after the treatment period) or the as-needed (424 liters per minute at both times) treatment groups (P = 0.71). There were no significant differences between the two groups in peak flow variability, forced expiratory volume in one second, the number of puffs of supplemental albuterol needed, asthma symptoms, asthma quality-of-life score, or airway responsiveness to methacholine. The statistically significant differences between the groups in evening peak flow and in the shortterm bronchodilator response to inhaled albuterol were small and judged to be clinically unimportant. Conclusions In patients with mild asthma, neither deleterious nor beneficial effects derived from the regular use of inhaled albuterol beyond those derived from use of the drug as needed. Inhaled albuterol should be prescribed for patients with mild asthma on an as-needed basis. (C) 1996, Massachusetts Medical Society.	HARVARD UNIV,SCH MED,BOSTON,MA; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; MILTON S HERSHEY MED CTR,HERSHEY,PA; THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107; UNIV WISCONSIN,MADISON,WI; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206; NHLBI,BETHESDA,MD 20892	Harvard University; Harvard Medical School; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Jefferson University; University of Wisconsin System; University of Wisconsin Madison; National Jewish Health; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Drazen, JM (corresponding author), BRIGHAM & WOMENS HOSP,RESP DIS DIV,75 FRANCIS ST,BOSTON,MA 02115, USA.		Drazen, Jeffrey M/E-5841-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL051831, U10HL051834, U10HL051843] Funding Source: NIH RePORTER; NHLBI NIH HHS [U10 HL 51834, U10 HL 51843, U10 HL 51831] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUERBACH I, 1993, THORAX, V48, P139, DOI 10.1136/thx.48.2.139; BARRETT TE, 1995, AM J RESP CRIT CARE, V151, P574, DOI 10.1164/ajrccm.151.2.7842223; CHAPMAN KR, 1994, LANCET, V343, P1379, DOI 10.1016/S0140-6736(94)92520-8; COCKCROFT DW, 1995, J ALLERGY CLIN IMMUN, V96, P44, DOI 10.1016/S0091-6749(95)70031-5; CRAIN EF, 1994, PEDIATRICS, V94, P356; CRANE J, 1995, THORAX, V50, pS5, DOI 10.1136/thx.50.Suppl_1.S5; DOMPELING E, 1993, ANN INTERN MED, V118, P770, DOI 10.7326/0003-4819-118-10-199305150-00003; FULLER RW, 1994, BRIT MED J, V309, P795, DOI 10.1136/bmj.309.6957.795; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; GIUNTINI CG, 1995, EUR RESPIR J, V8, P673; HARVEY JE, 1982, THORAX, V37, P280, DOI 10.1136/thx.37.4.280; HOWELL JBL, 1975, TXB MED, P825; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Laird N M, 1992, Stat Methods Med Res, V1, P225, DOI 10.1177/096228029200100302; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V95, P641, DOI 10.1016/S0091-6749(95)70166-4; *NAT ASTHM ED PROG, 1994, NIH PUBLICATION; *NAT HEART LUNG BL, 1995, NIH PUBL; NELSON HS, 1991, AM REV RESPIR DIS, V144, P249, DOI 10.1164/ajrccm/144.2.249; NELSON HS, 1995, NEW ENGL J MED, V333, P499, DOI 10.1056/NEJM199508243330807; PAGE C, 1992, RESP MED, V86, P477, DOI 10.1016/S0954-6111(96)80005-9; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; POCOCK SJ, 1982, BIOMETRICS, V38, P153, DOI 10.2307/2530298; REPSHER LH, 1984, CHEST, V85, P34, DOI 10.1378/chest.85.1.34; SEARS MR, 1995, AM J RESP CRIT CARE, V151, P600; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SHEPHERD GL, 1981, BRIT J DIS CHEST, V75, P215, DOI 10.1016/0007-0971(81)90057-7; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STAUFFER JL, 1989, CURRENT MED DIAGNOSI, P135; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301, DOI 10.1164/ajrccm/145.2_Pt_1.301; TATTERSFIELD AE, 1994, BRIT MED J, V309, P794, DOI 10.1136/bmj.309.6957.794; TAYLOR DR, 1994, CHEST, V106, P552, DOI 10.1378/chest.106.2.552; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; TWENTYMAN OP, 1992, RESP MED, V86, P471, DOI 10.1016/S0954-6111(96)80004-7; VONESH EF, 1987, BIOMETRICS, V43, P617, DOI 10.2307/2531999; WANNER A, 1995, AM J RESP CRIT CARE, V151, P597; WOOLCOCK AJ, 1988, TXB RESPIRATORY MED, P1030; ZELLWEGER JP, 1986, SCHWEIZ MED WSCHR, V116, P1260; 1987, MED LETT DRUGS THER, V29, P11; 1993, BRIT MED J, V306, P776	40	261	267	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1996	335	12					841	847		10.1056/NEJM199609193351202	http://dx.doi.org/10.1056/NEJM199609193351202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG869	8778601	Bronze			2022-12-28	WOS:A1996VG86900002
J	Kundrotas, LW; Robinson, AB				Kundrotas, LW; Robinson, AB			Gas in the portal venous system	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Kundrotas, LW (corresponding author), WILFORD HALL USAF MED CTR,LACKLAND AFB,TX 78236, USA.								0	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 19	1996	335	12					864	864		10.1056/NEJM199609193351206	http://dx.doi.org/10.1056/NEJM199609193351206			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG869	8778605				2022-12-28	WOS:A1996VG86900006
J	Kuo, MH; Brownell, JE; Sobel, RE; Ranalli, TA; Cook, RG; Edmondson, DG; Roth, SY; Allis, CD				Kuo, MH; Brownell, JE; Sobel, RE; Ranalli, TA; Cook, RG; Edmondson, DG; Roth, SY; Allis, CD			Transcription-linked acetylation by Gcn5p of histones H3 and H4 at specific lysines	NATURE			English	Article							SITE-SPECIFIC ANTIBODIES; TETRAHYMENA MACRONUCLEI; ADA2; ACETYLTRANSFERASE; FREQUENCY; ADAPTER; DOMAINS	THE yeast transcriptional adaptor(1-3), Gcn5p, is a catalytic subunit of a nuclear (type A) histone acetyltransferase linking histone acetylation to gene activation(4-6). Here we report that Gcn5p acetylates histones H3 and H4 non-randomly at specific lysines in the amino-terminal domains. Lysine 14 of H3 and lysines 8 and 16 of H4 are highly preferred acetylation sites for Gcn5p. We also demonstrate that lysine 9 is the preferred position of acetylation in newly synthesized yeast H3 in vivo. This finding, along with the fact that lysines 5 and 12 in H4 are predominant acetylation sites during chromatin assembly of many organisms(7-11), indicates that Gcn5p acetylates a distinct set of lysines that do not overlap with those sites characteristically used by type B histone acetyltransferases for histone deposition and chromatin assembly.	UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030	University of Rochester; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center				Dent, Sharon/0000-0002-4824-3269; Edmondson, Diane/0000-0003-3702-9715				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1996, J BIOL CHEM, V271, P5237; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; CLARKE DJ, 1993, BIOCHEM J, V294, P557, DOI 10.1042/bj2940557; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HORIUCHI K, 1975, ANAL BIOCHEM, V69, P491, DOI 10.1016/0003-2697(75)90151-7; MUNKS RJL, 1991, FEBS LETT, V284, P245, DOI 10.1016/0014-5793(91)80695-Y; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; VAVRA KJ, 1982, J BIOL CHEM, V257, P2591; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	23	465	476	1	29	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					269	272		10.1038/383269a0	http://dx.doi.org/10.1038/383269a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805705				2022-12-28	WOS:A1996VH31500057
J	Schumacher, A; Faust, C; Magnuson, T				Schumacher, A; Faust, C; Magnuson, T			Positional cloning of a global regulator of anterior-posterior patterning in mice	NATURE			English	Article							EXTRA-SEX-COMBS; MOUSE CHROMOSOME-7; HOX EXPRESSION; GENE; DROSOPHILA; PROTEIN; EMBRYOS; EED; TRANSFORMATION; SEQUENCES	ANTERIOR-POSTERIOR (A-P) patterning is of fundamental importance throughout vertebrate embryonic development. Murine members of the trithorax (trx) and Polycomb group (Pc-G) of genes regulate A-P patterning of segmented axial structures(1-4), demonstrating conserved upstream regulation of homeotic pathways between Drosophila and mouse. Here we report the positional cloning of a classical mouse mutation, eed (for embryonic ectoderm development), which is the highly conserved homologue of the Drosophila Pc-G gene esc (for extra sex combs), a long-term repressor of homeotic genes(5). Mutants homozygous for a null allele of eed display disrupted A-P patterning of the primitive streak during gastrulation. Mutant embryos lack a node, notochord and somites, and there is no neural induction(6). In contrast to absence of anterior structures, extra-embryonic mesoderm is abundant. Mice carrying a hypomorphic eed mutation exhibit posterior transformations along the axial skeleton. These results indicate that eed is required globally for A-P patterning throughout embryogenesis.	CASE WESTERN RESERVE UNIV,DEPT GENET,CLEVELAND,OH 44106	Case Western Reserve University								Ahringer J, 1996, GENE DEV, V10, P1120, DOI 10.1101/gad.10.9.1120; Akasaka T, 1996, DEVELOPMENT, V122, P1513; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; ALTABA ARI, 1991, DEV GROWTH DIFFER, V33, P651; ANG SL, 1994, DEVELOPMENT, V120, P2979; BARRO O, 1995, DEV GENET, V17, P117, DOI 10.1002/dvg.1020170204; DESCHAMPS J, 1993, DEV BIOL, V156, P473, DOI 10.1006/dbio.1993.1093; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUSH MK, 1992, DEV BIOL, V151, P273, DOI 10.1016/0012-1606(92)90232-6; FAUST C, 1995, DEVELOPMENT, V121, P273; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; HOLDENER BC, 1995, GENOMICS, V27, P447, DOI 10.1006/geno.1995.1076; HOLDENER BC, 1995, MAMM GENOME, V6, P474, DOI 10.1007/BF00360658; KORNFELD R, 1987, ANN REV BIOCH, V56, P615; LAWSON KA, 1991, DEVELOPMENT, V113, P891; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; RINCHIK EM, 1993, MAMM GENOME, V4, P349, DOI 10.1007/BF00360583; RINCHIK EM, 1990, P NATL ACAD SCI USA, V87, P896, DOI 10.1073/pnas.87.3.896; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SATHE SS, 1995, MECH DEVELOP, V52, P77, DOI 10.1016/0925-4773(95)00392-E; SIMON J, 1995, MECH DEVELOP, V53, P197, DOI 10.1016/0925-4773(95)00434-3; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; STITES WE, 1995, PROTEINS, V22, P132, DOI 10.1002/prot.340220206; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	30	188	191	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 19	1996	383	6597					250	253		10.1038/383250a0	http://dx.doi.org/10.1038/383250a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	VH315	8805699				2022-12-28	WOS:A1996VH31500051
J	Bosch, JLHR; Groen, J				Bosch, JLHR; Groen, J			Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients	LANCET			English	Article							ELECTRICAL-STIMULATION; BLADDER	Background Urge urinary incontinence in multiple sclerosis patients is usually due to detrusor hyperreflexia. Patients who do not respond to conservative measures such as anticholinergics, with or without clean intermittent catheterisation, are difficult to manage. Methods We applied electrical stimulation to the S3 sacral spinal nerves with the aim of activating afferent somatic nerve fibres. Stimulation of these fibres can inhibit the micturition reflex. An S3 electrode coupled to a subcutaneously placed pulse generator was implanted in four women who had shown a good response during temporary stimulation via a percutaneously placed wire electrode. All patients were followed for at least 2 years. Findings The number of leakage episodes decreased from a mean of 4 to 0.3 per 24 h. Two patients were completely dry. The hyperreflexia disappeared in one, improved in two, and got worse in one patient. The urodynamic result in the last patient may be explained by clinical progression of the multiple sclerosis. Interpretation Chronic stimulation of the S3 sacral spinal nerve by an implantable neuroprosthesis is a promising treatment option for selected multiple sclerosis patients with refractory urge incontinence.	ERASMUS UNIV ROTTERDAM,DEPT UROL,NL-3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	Bosch, JLHR (corresponding author), ACAD ZIEKENHUIS ROTTERDAM DIJKZIGT,DEPT UROL,H-1073,DR MOLEWATERPLEIN 40,NL-3015 GD ROTTERDAM,NETHERLANDS.							ABRAMS P, 1991, CLIN NEUROUROLOGY, P651; *AG HLTH CAR POL R, 1992, 920038 AG HLTH CAR P, P38; BETTS CD, 1993, J NEUROL NEUROSUR PS, V56, P245, DOI 10.1136/jnnp.56.3.245; BOSCH JLHR, 1995, J UROLOGY, V154, P504, DOI 10.1016/S0022-5347(01)67086-1; DEGROAT WC, 1990, J AUTONOM NERV SYST, V30, pS71, DOI 10.1016/0165-1838(90)90105-R; FALL M, 1991, UROL CLIN N AM, V18, P393; FOWLER CJ, 1994, J NEUROL NEUROSUR PS, V57, P169, DOI 10.1136/jnnp.57.2.169; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lindstrom S, 1989, NEUROUROL URODYNAM, V8, P392; MUNDY AR, 1985, UROL CLIN N AM, V12, P317; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; SCHMIDT RA, 1990, UROLOGY, V35, P388, DOI 10.1016/0090-4295(90)80078-2; VODUSEK DB, 1986, NEUROUROL URODYNAM, V5, P381, DOI 10.1002/nau.1930050404; VODUSEK DB, 1988, NEUROUROL URODYNAM, V6, P389	14	71	75	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					717	719		10.1016/S0140-6736(96)04437-6	http://dx.doi.org/10.1016/S0140-6736(96)04437-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806291	Green Submitted			2022-12-28	WOS:A1996VG37400011
J	Greenspan, D; Greenspan, JS				Greenspan, D; Greenspan, JS			HIV-related oral disease	LANCET			English	Article							EPSTEIN-BARR-VIRUS; AIDS-ASSOCIATED LESION; HAIRY LEUKOPLAKIA; BISEXUAL MEN; SAN-FRANCISCO; INFECTION; CANDIDIASIS; COHORTS; MANIFESTATIONS; EXPRESSION	Few people with HIV infection fail to experience oral lesions during the course of their disease. Oral mucosal and salivary gland manifestations include several that were not seen before the AIDS epidemic, while others are more severe in this population. Oral lesions reflect HIV status and the stage of immunosuppression, are important elements in HIV staging and classification schemes, raise pertinent questions about mucosal aspects of immunosuppression, and provide therapeutic challenges. Their pervasive nature and biological significance emphasise the importance of a careful oral examination as part of the general clinical evaluation.	UNIV CALIF SAN FRANCISCO,SCH DENT,CTR ORAL AIDS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Greenspan, D (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,ROOM S612,BOX 0422,513 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.		Greenspan, John/AAE-9321-2020		NIDCR NIH HHS [P01DE07946] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE007946] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGABIAN N, 1995, ORAL MANIFESTATIONS OF HIV INFECTION, P85; ANDERSEN L, 1990, J ORAL PATHOL MED, V19, P77, DOI 10.1111/j.1600-0714.1990.tb00800.x; ARAGUES M, 1990, CLIN EXP DERMATOL, V15, P335, DOI 10.1111/j.1365-2230.1990.tb02107.x; BARR CE, 1995, ORAL MANIFESTATIONS OF HIV INFECTION, P362; DANIELS TE, 1987, J INVEST DERMATOL, V89, P178, DOI 10.1111/1523-1747.ep12470556; DODD CL, 1992, ORAL SURG ORAL MED O, V73, P603, DOI 10.1016/0030-4220(92)90107-2; DODD CL, 1991, AIDS, V5, P1339, DOI 10.1097/00002030-199111000-00009; EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus, 1993, J ORAL PATHOL MED, V22, P289; FEIGAL DW, 1991, AIDS, V5, P519, DOI 10.1097/00002030-199105000-00007; FELIX DH, 1992, ORAL SURG ORAL MED O, V74, P563, DOI 10.1016/0030-4220(92)90344-P; GLICK M, 1994, J PERIODONTOL, V65, P393, DOI 10.1902/jop.1994.65.5.393; GLICK M, 1994, ORAL SURG ORAL MED O, V77, P344, DOI 10.1016/0030-4220(94)90195-3; GREENSPAN D, 1984, LANCET, V2, P831; GREENSPAN D, 1994, ORAL SURG ORAL MED O, V78, P211, DOI 10.1016/0030-4220(94)90149-X; GREENSPAN D, 1990, AIDS MOUTH; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; Greenspan JS, 1995, ORAL MANIFESTATIONS; HEINIC GS, 1993, ORAL SURG ORAL MED O, V75, P488, DOI 10.1016/0030-4220(93)90176-5; ITESCU S, 1990, RHEUM DIS CLIN N AM, V118, P683; KATZ MH, 1993, AM J DIS CHILD, V147, P45, DOI 10.1001/archpedi.1993.02160250047015; KING GN, 1994, ORAL SURG ORAL MED O, V78, P18; LIFSON AR, 1994, AIDS, V8, P73, DOI 10.1097/00002030-199401000-00011; LONING T, 1987, VIRCHOWS ARCH A, V412, P127, DOI 10.1007/BF00716184; MACPHAIL LA, 1992, ORAL SURG ORAL MED O, V73, P283, DOI 10.1016/0030-4220(92)90122-7; MACPHAIL LA, 1989, ORAL SURG ORAL MED O, V67, P427, DOI 10.1016/0030-4220(89)90386-1; MIYASAKI SH, 1992, J ACQ IMMUN DEF SYND, V5, P1039; PATERSON DL, 1995, CLIN INFECT DIS, V20, P2250; POWDERLY WG, 1993, J INFECT DIS, V168, P463, DOI 10.1093/infdis/168.2.463; RAABTRAUB N, 1995, ORAL MANIFESTATIONS OF HIV INFECTION, P159; REGEZI JA, 1994, J CUTAN PATHOL, V21, P217, DOI 10.1111/j.1600-0560.1994.tb00263.x; SHIBOSKI CH, 1994, J ACQ IMMUN DEF SYND, V7, P964; SWANGO PA, 1991, J AM DENT ASSOC, V122, P49, DOI 10.14219/jada.archive.1991.0212; THOMAS JA, 1991, AM J PATHOL, V139, P1369; TINDALL B, 1995, MED MANAGEMENT AIDS, P105; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; WINKLER JR, 1992, AIDS, V6, P1041, DOI 10.1097/00002030-199209000-00022; YOUNG LS, 1995, ORAL MANIFESTATIONS OF HIV INFECTION, P166; ZAMBON JJ, 1995, ORAL MANIFESTATIONS OF HIV INFECTION, P257	38	76	82	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 14	1996	348	9029					729	733		10.1016/S0140-6736(96)02308-2	http://dx.doi.org/10.1016/S0140-6736(96)02308-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG374	8806295				2022-12-28	WOS:A1996VG37400015
J	Law, M				Law, M			Having too much evidence (depression, suicide, and low serum cholesterol)	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HAZARDS; MEN		ROYAL LONDON HOSP, SCH MED, LONDON EC1M 6BQ, ENGLAND	Barts Health NHS Trust; Royal London Hospital	Law, M (corresponding author), ST BARTHOLOMEWS HOSP, WOLFSON INST PREVENT MED, DEPT ENVIRONM & PREVENT MED, LONDON EC1M 6BQ, ENGLAND.							DOWNS JR, 1993, JAMA-J AM MED ASSOC, V269, P3107, DOI 10.1001/jama.269.24.3107; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; GALLERANI M, 1995, BMJ-BRIT MED J, V310, P1632, DOI 10.1136/bmj.310.6995.1632; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LINES C, 1994, BRIT MED J, V309, P541, DOI 10.1136/bmj.309.6953.541; MAGNI G, 1988, NEUROPSYCHOBIOLOGY, V20, P126, DOI 10.1159/000118485; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; PEDERSEN TR, 1994, LANCET, V344, P1383; RYMAN A, 1994, BRIT MED J, V309, P421, DOI 10.1136/bmj.309.6952.421; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Steegmans PHA, 1996, BRIT MED J, V312, P221, DOI 10.1136/bmj.312.7025.221; WALD NJ, 1996, EPIDEMIOLOGICAL APPR; Wardle J, 1996, BRIT MED J, V313, P75, DOI 10.1136/bmj.313.7049.75; WYSOWSKI DK, 1990, ARCH INTERN MED, V150, P2169, DOI 10.1001/archinte.150.10.2169; Zureik M, 1996, BMJ-BRIT MED J, V313, P649, DOI 10.1136/bmj.313.7058.649	15	12	13	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 14	1996	313	7058					651	652						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VH165	8845726				2022-12-28	WOS:A1996VH16500019
J	Parving, HH; Jacobsen, P; Tarnow, L; Rossing, P; Lecerf, L; Poirier, O; Cambien, F				Parving, HH; Jacobsen, P; Tarnow, L; Rossing, P; Lecerf, L; Poirier, O; Cambien, F			Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: Observational follow up study	BRITISH MEDICAL JOURNAL			English	Article							GLOMERULAR-FILTRATION RATE; INSULIN-DEPENDENT DIABETICS; ARTERIAL BLOOD-PRESSURE; IGA NEPHROPATHY; KIDNEY-FUNCTION; IDDM PATIENTS; MICROALBUMINURIA; CAPTOPRIL; ALBUMINURIA; ENALAPRIL	Objective-To evaluate the concept that an insertion/deletion polymorphism of the angiotensin converting enzyme gene predicts the therapeutic efficacy of inhibition of angiotensin converting enzyme on progression of diabetic nephropathy. Design-Observational follow up study of patients with insulin dependent diabetes and nephropathy who had been treated with captopril for a median of 7 years (range 3-9 years). Setting-Outpatient diabetic clinic in a tertiary referral centre. Patients-35 patients with insulin dependent diabetes and nephropathy were investigated during captopril treatment (median 75 mg/day (range 12.5 to 150 mg/day)) that was in many cases combined with a loop diuretic. 11 patients were homozygous for the deletion allele and 24 were heterozygous or homozygous for the insertion allele of the angiotensin converting enzyme gene. Main outcome measures-Albuminuria, arterial blood pressure, and glomerular filtration rate according to insertion/deletion polymorphism. Results-The two groups had comparable glomerular filtration rate, albuminuria, blood pressure, and haemoglobin A,, concentration at baseline. Captopril induced nearly the same reduction in mean blood pressure in the two groups-to 103 (SD 5) mm Hg in the group with the deletion and 102 (8) mm Hg in the group with the insertion-and in geometric mean albumin excretion-573 (antilog SE 1.3) mu g/min and 470 (1.2) mu g/min, respectively. The rate of decline in glomerular filtration rate (linear regression of all glomerular filtration rate measurements during antihypertensive treatment) was significantly steeper in the group homozygous for the double deletion allele than in the other group (mean 5.7 (3.7) ml/min/year and 2.6 (2.8) ml/min/year, respectively; P = 0.01). Multiple Linear regression analysis showed that haemoglobin A(1c) concentration, albuminuria, and the double deletion genotype independently influenced the sustained rate of decline in glomerular filtration rate (R(2) (adjusted) = 0.51). Conclusion-The deletion polymorphism in the angiotensin converting enzyme gene reduces the long term beneficial effect of angiotensin converting enzyme inhibition on the progression of diabetic nephropathy in patients with insulin dependent diabetes.	INSERM,SC7,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	Parving, HH (corresponding author), STENO DIABET CTR,NIELS STEENSENS VEJ 2,DK-2820 GENTOFTE,DENMARK.		Jacobsen, Peter Karl/AAK-7609-2021; rossing, peter/AAZ-3415-2021; Cambien, Francois/AAP-9751-2020; rossing, peter/AAH-7879-2021	Jacobsen, Peter Karl/0000-0002-1520-8774; rossing, peter/0000-0002-1531-4294; Tarnow, Lise/0000-0002-8735-966X; LECERF, LAURE/0000-0001-8342-5298				BJORCK S, 1992, BMJ-BRIT MED J, V304, P339, DOI 10.1136/bmj.304.6823.339; BREYER J, 1993, J AM SOC NEPHROL, V4, P301; BROCHNERMORTENSEN J, 1976, SCAND J CLIN LAB INV, V36, P35, DOI 10.3109/00365517609068016; BROCHNERMORTENSEN J, 1985, CLIN PHYSIOL, V5, P1, DOI 10.1111/j.1475-097X.1985.tb00742.x; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; HARDEN PN, 1995, LANCET, V345, P1540, DOI 10.1016/S0140-6736(95)91088-3; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; LEVEY AS, 1991, J AM SOC NEPHROL, V1, P1087; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MILES DW, 1970, SCAND J CLIN LAB INV, V26, P5, DOI 10.3109/00365517009049206; PARVING HH, 1981, DIABETOLOGIA, V20, P457; PARVING HH, 1983, LANCET, V1, P1175; PARVING HH, 1995, AM J KIDNEY DIS, V26, P99, DOI 10.1016/0272-6386(95)90162-0; PARVING HH, 1988, BRIT MED J, V297, P1086, DOI 10.1136/bmj.297.6656.1086; PARVING HH, 1996, KIDNEY, P1864; ROSSING P, 1993, DIABETES, V42, P715, DOI 10.2337/diabetes.42.5.715; TARNOW L, 1995, DIABETES, V44, P489, DOI 10.2337/diabetes.44.5.489; UEDA S, 1995, HYPERTENSION, V25, P1266, DOI 10.1161/01.HYP.25.6.1266; vanEssen GG, 1996, LANCET, V347, P94, DOI 10.1016/S0140-6736(96)90213-5; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; YOSHIDA H, 1995, J CLIN INVEST, V96, P2162, DOI 10.1172/JCI118270	23	179	182	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					591	594						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806248				2022-12-28	WOS:A1996VG10800017
J	Weaver, T; Renton, A; Tyrer, P; Ritchie, J				Weaver, T; Renton, A; Tyrer, P; Ritchie, J			Combining qualitative studies with randomised controlled trials is often useful	BRITISH MEDICAL JOURNAL			English	Letter									SOCIAL & COMMUNITY PLANNING RES,QUALITAT RES UNIT,LONDON EC1V 0AX,ENGLAND		Weaver, T (corresponding author), IMPERIAL COLL SCH MED ST MARYS,LONDON W2 1PG,ENGLAND.			Weaver, Tim/0000-0002-3437-3556				Black N, 1996, BRIT MED J, V312, P1215	1	13	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 7	1996	313	7057					629	629						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VG108	8806277				2022-12-28	WOS:A1996VG10800068
J	Mao, XQ; Shirakawa, T; Yoshikawa, T; Yoshikawa, K; Kawai, M; Sasaki, S; Enomoto, T; Hashimoto, T; Furuyama, J; Hopkin, JM; Morimoto, K				Mao, XQ; Shirakawa, T; Yoshikawa, T; Yoshikawa, K; Kawai, M; Sasaki, S; Enomoto, T; Hashimoto, T; Furuyama, J; Hopkin, JM; Morimoto, K			Association between genetic variants of mast-cell chymase and eczema	LANCET			English	Article							BETA-SUBUNIT; ATOPY; RECEPTOR	Background Atopy is a common syndrome underlying asthma, rhinitis, and eczema, and is characterised by high immunoglobulin E (IgE) responses to common antigens. IgE and mast-cell chymase (MCC-a serine protease secreted by skin mast cells) have a key role in atopic or allergic inflammation of the skin. The gene for MCC is located within a cluster of genes for cellular proteases on chromosome 14q11.2. We aimed to identify variants of MCC and another gene within this complex, and assess whether there is a genetic association between variants of MCC and atopic disorders-particularly eczema. Methods We randomly selected 100 controls and recruited patients-100 in each group-with atopic asthma, nonatopic asthma, atopic rhinitis, and atopic eczema. PCR amplification was used to test genomic DNA for an association between allelic polymorphisms in MCC and a flanking gene (CGL1, for the cathepsin-G-like protein) on chromosome 14q11 and asthma, rhinitis, and eczema. Findings We found a significant association between a BstXI polymorphism in MCC and eczema (odds ratio 2.17 [95% CI 1.21-3.88], p=0.009), but no association with atopic asthma, rhinitis, or non-atopic asthma. There was no association between an Mboll polymorphism in CGL1 and any of the atopic disorders. Interpretation These findings suggest that variants of MCC may be one source of genetic risk for eczema.	OSAKA UNIV, SCH MED, DEPT HYG & PREVENT MED, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT DERMATOL, SUITA, OSAKA 565, JAPAN; CHURCHILL HOSP, OSLER CHEST UNIT, LUNG RES LAB, OXFORD OX3 7LJ, ENGLAND; KYOTO PREVENT MED CTR, KYOTO, JAPAN; OSAKA MED COLL, DEPT PEDIAT, TAKATSUKI, OSAKA 569, JAPAN; WAKAYAMA RED CROSS HOSP, DEPT OTORHINOLARYNGOL, WAKAYAMA, JAPAN; HYOGO MED UNIV, DEPT GENET, NISHINOMIYA, HYOGO, JAPAN	Osaka University; Osaka University; University of Oxford; Osaka Medical College; Hyogo College of Medicine; University of Hyogo								CAUGHEY GH, 1993, GENOMICS, V15, P614, DOI 10.1006/geno.1993.1115; CAUGHEY GH, 1991, J BIOL CHEM, V266, P12956; COLEMAN R, 1993, LANCET, V341, P1121, DOI 10.1016/0140-6736(93)93130-S; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; HADDAD P, 1990, GENE, V87, P265, DOI 10.1016/0378-1119(90)90311-E; HANAFIN JM, 1980, ACTA DERM-VENEREOL, V92, P44; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; UEHARA M, 1986, ACTA DERM-VENEREOL, V66, P404	11	118	122	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	1996	348	9027					581	583		10.1016/S0140-6736(95)10244-2	http://dx.doi.org/10.1016/S0140-6736(95)10244-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF186	8774571				2022-12-28	WOS:A1996VF18600012
J	Puliyel, JM; Hughes, A; Chiswick, ML; Mughal, MZ				Puliyel, JM; Hughes, A; Chiswick, ML; Mughal, MZ			Adverse local reactions from accidental BCG overdose in infants	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,DEPT PAEDIAT,MANCHESTER M13 0JH,LANCS,ENGLAND	University of Manchester			MUGHAL, Zulf/AAA-1230-2021; Hughes, Alun David/N-3781-2013	Hughes, Alun David/0000-0001-5432-5271				Farries J S, 1980, Community Med, V2, P312, DOI 10.1007/BF02549415; MILSTIEN JB, 1990, B WORLD HEALTH ORGAN, V68, P93; OBRIEN KL, 1995, PEDIATRICS, V95, P914	3	11	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 31	1996	313	7056					528	529						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	VF294	8789978	Green Published			2022-12-28	WOS:A1996VF29400018
